ID   TNR6_MOUSE              Reviewed;         327 AA.
AC   P25446; Q6GT31; Q9DCQ1;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 2.
DT   17-FEB-2016, entry version 166.
DE   RecName: Full=Tumor necrosis factor receptor superfamily member 6;
DE   AltName: Full=Apo-1 antigen;
DE   AltName: Full=Apoptosis-mediating surface antigen FAS;
DE   AltName: Full=FASLG receptor;
DE   AltName: CD_antigen=CD95;
DE   Flags: Precursor;
GN   Name=Fas; Synonyms=Apt1, Tnfrsf6;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1371136;
RA   Watanabe-Fukunaga R., Brannan C.I., Itoh N., Yonehara S.,
RA   Copeland N.G., Jenkins N.A., Nagata S.;
RT   "The cDNA structure, expression, and chromosomal assignment of the
RT   mouse Fas antigen.";
RL   J. Immunol. 148:1274-1279(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=129/Sv;
RA   Koczan D., Ibrahim S.M., Thiesen H.J.;
RT   "Role of a mutant fas receptor in a transgenic mouse.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Kidney;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=17545588; DOI=10.1158/0008-5472.CAN-06-4006;
RA   Villa-Morales M., Santos J., Perez-Gomez E., Quintanilla M.,
RA   Fernandez-Piqueras J.;
RT   "A role for the Fas/FasL system in modulating genetic susceptibility
RT   to T-cell lymphoblastic lymphomas.";
RL   Cancer Res. 67:5107-5116(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-96.
RX   PubMed=7680478; DOI=10.1073/pnas.90.5.1756;
RA   Adachi M., Watanabe-Fukunaga R., Nagata S.;
RT   "Aberrant transcription caused by the insertion of an early
RT   transposable element in an intron of the Fas antigen gene of lpr
RT   mice.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:1756-1760(1993).
RN   [8]
RP   INTERACTION WITH DAXX.
RX   PubMed=9215629; DOI=10.1016/S0092-8674(00)80294-9;
RA   Yang X., Khosravi-Far R., Chang H.Y., Baltimore D.;
RT   "Daxx, a novel Fas-binding protein that activates JNK and apoptosis.";
RL   Cell 89:1067-1076(1997).
RN   [9]
RP   INTERACTION WITH HIPK3.
RX   PubMed=11034606; DOI=10.1084/jem.192.8.1165;
RA   Rochat-Steiner V., Becker K., Micheau O., Schneider P., Burns K.,
RA   Tschopp J.;
RT   "FIST/HIPK3: a Fas/FADD-interacting serine/threonine kinase that
RT   induces FADD phosphorylation and inhibits Fas-mediated Jun NH2-
RT   terminal kinase activation.";
RL   J. Exp. Med. 192:1165-1174(2000).
RN   [10]
RP   INTERACTION WITH NOL3.
RX   PubMed=15383280; DOI=10.1016/j.molcel.2004.08.020;
RA   Nam Y.J., Mani K., Ashton A.W., Peng C.F., Krishnamurthy B.,
RA   Hayakawa Y., Lee P., Korsmeyer S.J., Kitsis R.N.;
RT   "Inhibition of both the extrinsic and intrinsic death pathways through
RT   nonhomotypic death-fold interactions.";
RL   Mol. Cell 15:901-912(2004).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-220 AND THR-314, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-206; SER-217; SER-220
RP   AND THR-314, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Kidney, Liver, Lung, Pancreas, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [14]
RP   INDUCTION.
RX   PubMed=23785138; DOI=10.1523/JNEUROSCI.2757-12.2013;
RA   Baeza-Raja B., Eckel-Mahan K., Zhang L., Vagena E., Tsigelny I.F.,
RA   Sassone-Corsi P., Ptacek L.J., Akassoglou K.;
RT   "p75 neurotrophin receptor is a clock gene that regulates oscillatory
RT   components of circadian and metabolic networks.";
RL   J. Neurosci. 33:10221-10234(2013).
RN   [15]
RP   VARIANT LPR ASN-246.
RX   PubMed=1372394; DOI=10.1038/356314a0;
RA   Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A.,
RA   Nagata S.;
RT   "Lymphoproliferation disorder in mice explained by defects in Fas
RT   antigen that mediates apoptosis.";
RL   Nature 356:314-317(1992).
CC   -!- FUNCTION: Receptor for TNFSF6/FASLG. The adapter molecule FADD
CC       recruits caspase-8 to the activated receptor. The resulting death-
CC       inducing signaling complex (DISC) performs caspase-8 proteolytic
CC       activation which initiates the subsequent cascade of caspases
CC       (aspartate-specific cysteine proteases) mediating apoptosis. FAS-
CC       mediated apoptosis may have a role in the induction of peripheral
CC       tolerance, in the antigen-stimulated suicide of mature T-cells, or
CC       both (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Binds DAXX and RIPK1. Interacts with BRE and FEM1B (By
CC       similarity). Interacts with HIPK3. Part of a complex containing
CC       HIPK3 and FADD. Interacts with FADD (By similarity). Interacts
CC       directly (via DED domain) with NOL3 (via CARD domain); inhibits
CC       death-inducing signaling complex (DISC) assembly by inhibiting the
CC       increase in FAS-FADD binding induced by FAS activation.
CC       {ECO:0000250, ECO:0000269|PubMed:15383280}.
CC   -!- INTERACTION:
CC       O89110:Casp8; NbExp=3; IntAct=EBI-296206, EBI-851690;
CC       Q9UER7:DAXX (xeno); NbExp=4; IntAct=EBI-296206, EBI-77321;
CC       O35613:Daxx; NbExp=2; IntAct=EBI-296206, EBI-77304;
CC       Q13158:FADD (xeno); NbExp=5; IntAct=EBI-296206, EBI-494804;
CC       Q61160:Fadd; NbExp=3; IntAct=EBI-296206, EBI-524415;
CC       Q9ERH7:Hipk3; NbExp=3; IntAct=EBI-296206, EBI-524356;
CC       Q60953:Pml; NbExp=6; IntAct=EBI-296206, EBI-3895605;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Detected in various tissues including thymus,
CC       liver, lung, heart, and adult ovary.
CC   -!- INDUCTION: Expression oscillates in a circadian manner in the
CC       liver with peak levels seen at CT12.
CC       {ECO:0000269|PubMed:23785138}.
CC   -!- DOMAIN: Contains a death domain involved in the binding of FADD,
CC       and maybe to other cytosolic adapter proteins.
CC   -!- DISEASE: Note=Defects in Fas are the cause of the
CC       lymphoproliferation phenotype (lpr). Lpr mice show lymphadenopathy
CC       and autoantibody production.
CC   -!- SIMILARITY: Contains 1 death domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00064}.
CC   -!- SIMILARITY: Contains 3 TNFR-Cys repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00206}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M83649; AAA37593.1; -; mRNA.
DR   EMBL; AK002590; BAB22211.1; -; mRNA.
DR   EMBL; AJ295702; CAC00638.1; -; Genomic_DNA.
DR   EMBL; AJ295703; CAC00638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ295704; CAC00638.1; JOINED; Genomic_DNA.
DR   EMBL; DQ846748; ABI24112.1; -; mRNA.
DR   EMBL; CH466534; EDL41748.1; -; Genomic_DNA.
DR   EMBL; BC061160; AAH61160.1; -; mRNA.
DR   EMBL; S56490; AAB25700.1; -; Genomic_DNA.
DR   EMBL; S56485; AAB25700.1; JOINED; Genomic_DNA.
DR   EMBL; S56486; AAB25700.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS29758.1; -.
DR   PIR; A46484; A46484.
DR   RefSeq; NP_032013.2; NM_007987.2.
DR   UniGene; Mm.1626; -.
DR   PDB; 3OQ9; X-ray; 6.80 A; A/B/C/D/E=223-308.
DR   PDBsum; 3OQ9; -.
DR   ProteinModelPortal; P25446; -.
DR   SMR; P25446; 48-159, 223-308.
DR   BioGrid; 199594; 6.
DR   DIP; DIP-31093N; -.
DR   IntAct; P25446; 11.
DR   MINT; MINT-144559; -.
DR   STRING; 10090.ENSMUSP00000025691; -.
DR   iPTMnet; P25446; -.
DR   PhosphoSite; P25446; -.
DR   SwissPalm; P25446; -.
DR   MaxQB; P25446; -.
DR   PaxDb; P25446; -.
DR   PRIDE; P25446; -.
DR   Ensembl; ENSMUST00000025691; ENSMUSP00000025691; ENSMUSG00000024778.
DR   GeneID; 14102; -.
DR   UCSC; uc008hgi.2; mouse.
DR   CTD; 355; -.
DR   MGI; MGI:95484; Fas.
DR   eggNOG; ENOG410J23A; Eukaryota.
DR   eggNOG; ENOG4112ADB; LUCA.
DR   GeneTree; ENSGT00730000111280; -.
DR   HOGENOM; HOG000139681; -.
DR   HOVERGEN; HBG004091; -.
DR   InParanoid; P25446; -.
DR   OMA; CTTCEHG; -.
DR   OrthoDB; EOG7DVDC8; -.
DR   TreeFam; TF333916; -.
DR   Reactome; R-MMU-3371378; Regulation by c-FLIP.
DR   Reactome; R-MMU-5213460; RIPK1-mediated regulated necrosis.
DR   Reactome; R-MMU-5218900; CASP8 activity is inhibited.
DR   Reactome; R-MMU-69416; Dimerization of procaspase-8.
DR   Reactome; R-MMU-75157; FasL/ CD95L signaling.
DR   EvolutionaryTrace; P25446; -.
DR   NextBio; 285130; -.
DR   PRO; PR:P25446; -.
DR   Proteomes; UP000000589; Chromosome 19.
DR   Bgee; P25446; -.
DR   CleanEx; MM_FAS; -.
DR   ExpressionAtlas; P25446; baseline and differential.
DR   Genevisible; P25446; MM.
DR   GO; GO:0097440; C:apical dendrite; IEA:Ensembl.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0031265; C:CD95 death-inducing signaling complex; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0031264; C:death-inducing signaling complex; ISO:MGI.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0005576; C:extracellular region; IDA:MGI.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0045121; C:membrane raft; ISO:MGI.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; ISO:MGI.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0042383; C:sarcolemma; IEA:Ensembl.
DR   GO; GO:0030141; C:secretory granule; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0019900; F:kinase binding; ISO:MGI.
DR   GO; GO:0005031; F:tumor necrosis factor-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0006924; P:activation-induced cell death of T cells; IDA:MGI.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IMP:MGI.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IDA:MGI.
DR   GO; GO:0019724; P:B cell mediated immunity; IMP:MGI.
DR   GO; GO:0007420; P:brain development; IBA:GO_Central.
DR   GO; GO:0071279; P:cellular response to cobalt ion; IEA:Ensembl.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071464; P:cellular response to hydrostatic pressure; IEA:Ensembl.
DR   GO; GO:0071455; P:cellular response to hyperoxia; ISO:MGI.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0071285; P:cellular response to lithium ion; IMP:MGI.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0071234; P:cellular response to phenylalanine; IEA:Ensembl.
DR   GO; GO:0043009; P:chordate embryonic development; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEP:UniProtKB.
DR   GO; GO:0031104; P:dendrite regeneration; IEA:Ensembl.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:MGI.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IMP:MGI.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0010467; P:gene expression; IMP:MGI.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IGI:MGI.
DR   GO; GO:0002377; P:immunoglobulin production; IMP:MGI.
DR   GO; GO:0006925; P:inflammatory cell apoptotic process; IDA:MGI.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IEA:Ensembl.
DR   GO; GO:0097049; P:motor neuron apoptotic process; IMP:MGI.
DR   GO; GO:0097527; P:necroptotic signaling pathway; IGI:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:MGI.
DR   GO; GO:0050869; P:negative regulation of B cell activation; IMP:MGI.
DR   GO; GO:0045060; P:negative thymic T cell selection; IMP:MGI.
DR   GO; GO:0051402; P:neuron apoptotic process; IMP:MGI.
DR   GO; GO:0001552; P:ovarian follicle atresia; IEA:Ensembl.
DR   GO; GO:0042698; P:ovulation cycle; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IDA:MGI.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:MGI.
DR   GO; GO:0070230; P:positive regulation of lymphocyte apoptotic process; IDA:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0032464; P:positive regulation of protein homooligomerization; IDA:BHF-UCL.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IC:BHF-UCL.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0043281; P:regulation of cysteine-type endopeptidase activity involved in apoptotic process; IBA:GO_Central.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0045619; P:regulation of lymphocyte differentiation; IMP:MGI.
DR   GO; GO:0045637; P:regulation of myeloid cell differentiation; IMP:MGI.
DR   GO; GO:0003014; P:renal system process; IMP:MGI.
DR   GO; GO:0046898; P:response to cycloheximide; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:1902617; P:response to fluoride; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IMP:MGI.
DR   GO; GO:0070848; P:response to growth factor; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IBA:GO_Central.
DR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IMP:MGI.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0048536; P:spleen development; IMP:MGI.
DR   GO; GO:0043029; P:T cell homeostasis; IMP:MGI.
DR   GO; GO:0021537; P:telencephalon development; IEA:Ensembl.
DR   GO; GO:0006927; P:transformed cell apoptotic process; IDA:MGI.
DR   Gene3D; 1.10.533.10; -; 1.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR008063; Fas_rcpt.
DR   InterPro; IPR001368; TNFR/NGFR_Cys_rich_reg.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00020; TNFR_c6; 2.
DR   PRINTS; PR01680; TNFACTORR6.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00208; TNFR; 3.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS00652; TNFR_NGFR_1; 2.
DR   PROSITE; PS50050; TNFR_NGFR_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Complete proteome; Disease mutation;
KW   Disulfide bond; Glycoprotein; Membrane; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22    327       Tumor necrosis factor receptor
FT                                superfamily member 6.
FT                                /FTId=PRO_0000034567.
FT   TOPO_DOM     22    169       Extracellular. {ECO:0000255}.
FT   TRANSMEM    170    186       Helical. {ECO:0000255}.
FT   TOPO_DOM    187    327       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       43     79       TNFR-Cys 1.
FT   REPEAT       80    123       TNFR-Cys 2.
FT   REPEAT      124    162       TNFR-Cys 3.
FT   DOMAIN      222    306       Death. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00064}.
FT   REGION      204    309       Interaction with HIPK3.
FT   MOD_RES     206    206       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES     217    217       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES     220    220       Phosphoserine.
FT                                {ECO:0000244|PubMed:19144319,
FT                                ECO:0000244|PubMed:21183079}.
FT   MOD_RES     314    314       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19144319,
FT                                ECO:0000244|PubMed:21183079}.
FT   CARBOHYD     43     43       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    114    114       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     44     55       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     56     69       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     59     78       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     81     97       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    100    115       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    103    123       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    125    139       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    142    153       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    145    161       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   VARIANT     246    246       I -> N (in lpr).
FT                                {ECO:0000269|PubMed:1372394}.
FT   CONFLICT     38     38       R -> H (in Ref. 1; AAA37593, 2; CAC00638
FT                                and 7; AAB25700). {ECO:0000305}.
SQ   SEQUENCE   327 AA;  37437 MW;  D8DA95CA525CED56 CRC64;
     MLWIWAVLPL VLAGSQLRVH TQGTNSISES LKLRRRVRET DKNCSEGLYQ GGPFCCQPCQ
     PGKKKVEDCK MNGGTPTCAP CTEGKEYMDK NHYADKCRRC TLCDEEHGLE VETNCTLTQN
     TKCKCKPDFY CDSPGCEHCV RCASCEHGTL EPCTATSNTN CRKQSPRNRL WLLTILVLLI
     PLVFIYRKYR KRKCWKRRQD DPESRTSSRE TIPMNASNLS LSKYIPRIAE DMTIQEAKKF
     ARENNIKEGK IDEIMHDSIQ DTAEQKVQLL LCWYQSHGKS DAYQDLIKGL KKAECRRTLD
     KFQDMVQKDL GKSTPDTGNE NEGQCLE
//
ID   CD44_HUMAN              Reviewed;         742 AA.
AC   P16070; A5YRN9; B6EAT9; D3DR12; D3DR13; O95370; P22511; Q04858;
AC   Q13419; Q13957; Q13958; Q13959; Q13960; Q13961; Q13967; Q13968;
AC   Q13980; Q15861; Q16064; Q16065; Q16066; Q16208; Q16522; Q86T72;
AC   Q86Z27; Q8N694; Q92493; Q96J24; Q9H5A5; Q9UC28; Q9UC29; Q9UC30;
AC   Q9UCB0; Q9UJ36;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 3.
DT   17-FEB-2016, entry version 198.
DE   RecName: Full=CD44 antigen;
DE   AltName: Full=CDw44;
DE   AltName: Full=Epican;
DE   AltName: Full=Extracellular matrix receptor III;
DE            Short=ECMR-III;
DE   AltName: Full=GP90 lymphocyte homing/adhesion receptor;
DE   AltName: Full=HUTCH-I;
DE   AltName: Full=Heparan sulfate proteoglycan;
DE   AltName: Full=Hermes antigen;
DE   AltName: Full=Hyaluronate receptor;
DE   AltName: Full=Phagocytic glycoprotein 1;
DE            Short=PGP-1;
DE   AltName: Full=Phagocytic glycoprotein I;
DE            Short=PGP-I;
DE   AltName: CD_antigen=CD44;
DE   Flags: Precursor;
GN   Name=CD44; Synonyms=LHR, MDU2, MDU3, MIC4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 12).
RX   PubMed=2466575; DOI=10.1016/0092-8674(89)90638-7;
RA   Stamenkovic I., Amiot M., Pesando J.M., Seed B.;
RT   "A lymphocyte molecule implicated in lymph node homing is a member of
RT   the cartilage link protein family.";
RL   Cell 56:1057-1062(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 12).
RC   TISSUE=Reticulocyte;
RX   PubMed=1840487; DOI=10.1016/0006-291X(91)91009-2;
RA   Harn H.-J., Isola N., Cooper D.L.;
RT   "The multispecific cell adhesion molecule CD44 is represented in
RT   reticulocyte cDNA.";
RL   Biochem. Biophys. Res. Commun. 178:1127-1134(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10), AND VARIANT THR-479.
RX   PubMed=1991450;
RA   Stamenkovic I., Aruffo A., Amiot M., Seed B.;
RT   "The hematopoietic and epithelial forms of CD44 are distinct
RT   polypeptides with different adhesion potentials for hyaluronate-
RT   bearing cells.";
RL   EMBO J. 10:343-348(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 10 AND 11), AND VARIANT THR-479.
RC   TISSUE=Myeloid leukemia cell;
RX   PubMed=2056274; DOI=10.1084/jem.174.1.1;
RA   Dougherty G.J., Lansdorp P.M., Cooper D.L., Humphries R.K.;
RT   "Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the
RT   human CD44 lymphocyte 'homing' receptor expressed by hemopoietic
RT   cells.";
RL   J. Exp. Med. 174:1-5(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND VARIANT THR-479.
RC   TISSUE=Keratinocyte;
RX   PubMed=1281868; DOI=10.1111/1523-1747.ep12614896;
RA   Kugelman L.C., Ganguly S., Haggerty J.G., Weissman S.M.,
RA   Milstone L.M.;
RT   "The core protein of epican, a heparan sulfate proteoglycan on
RT   keratinocytes, is an alternative form of CD44.";
RL   J. Invest. Dermatol. 99:886-891(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS
RP   ARG-417 AND THR-479.
RC   TISSUE=Lymphoblast;
RX   PubMed=1465456; DOI=10.1073/pnas.89.24.12160;
RA   Screaton G.R., Bell M.V., Jackson D.G., Cornelis F.B., Gerth U.,
RA   Bell J.I.;
RT   "Genomic structure of DNA encoding the lymphocyte homing receptor CD44
RT   reveals at least 12 alternatively spliced exons.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:12160-12164(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-417; THR-479
RP   AND HIS-494.
RX   PubMed=7508842;
RA   Gunthert U.;
RT   "CD44: a multitude of isoforms with diverse functions.";
RL   Curr. Top. Microbiol. Immunol. 184:47-63(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 13 AND 14), AND VARIANT
RP   THR-479.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=8352881; DOI=10.1002/mc.2940070403;
RA   Tanabe K.K., Nishi T., Saya H.;
RT   "Novel variants of CD44 arising from alternative splicing: changes in
RT   the CD44 alternative splicing pattern of MCF-7 breast carcinoma cells
RT   treated with hyaluronidase.";
RL   Mol. Carcinog. 7:212-220(1993).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 19).
RX   PubMed=10933060; DOI=10.1038/sj.neo.7900045;
RA   Chiu R.K., Carpenito C., Dougherty S.T., Hayes G.M., Dougherty G.J.;
RT   "Identification and characterization of CD44RC, a novel alternatively
RT   spliced soluble CD44 isoform that can potentiate the hyaluronan
RT   binding activity of cell surface CD44.";
RL   Neoplasia 1:446-452(1999).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 12).
RC   TISSUE=Articular cartilage;
RA   Bosch P.P., Stevens J.W., Buckwalter J.A., Midura R.J.;
RT   "CD44 in normal and neoplastic human cartilage.";
RL   Submitted (DEC-1995) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 10 AND 12), AND VARIANT THR-479.
RC   TISSUE=Colon adenocarcinoma, and Retinal pigment epithelium;
RA   Wiebe G.J., Freund D., Corbeil D.;
RT   "Sequence analysis of the human CD44 antigen.";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 11).
RA   Xiang Q., Wang J., Fan C., He X., Huang L., Zhu H., Qiu X., Luo W.;
RT   "Sequence analysis of a novel human CD44 variant.";
RL   Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 18).
RA   Fang X., Xu W., Zhang X.;
RT   "Construction of human CD44 eukaryotic vector and its expression in
RT   mammary carcinoma cells MCF-7.";
RL   Submitted (SEP-2008) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 12).
RC   TISSUE=Spinal cord;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4 AND 12), AND
RP   VARIANTS ARG-417 AND THR-479.
RC   TISSUE=Pancreas, and Retinal pigment epithelium;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-22.
RC   TISSUE=Lymphoblast;
RX   PubMed=1922057;
RA   Shtivelman E., Bishop J.M.;
RT   "Expression of CD44 is repressed in neuroblastoma cells.";
RL   Mol. Cell. Biol. 11:5446-5453(1991).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-742 (ISOFORM 15).
RX   PubMed=2466576; DOI=10.1016/0092-8674(89)90639-9;
RA   Goldstein L.A., Zhou D.F.H., Picker L.J., Minty C.N., Bargatze R.F.,
RA   Ding J.F., Butcher E.C.;
RT   "A human lymphocyte homing receptor, the hermes antigen, is related to
RT   cartilage proteoglycan core and link proteins.";
RL   Cell 56:1063-1072(1989).
RN   [20]
RP   PROTEIN SEQUENCE OF 55-108.
RC   TISSUE=Glial tumor;
RX   PubMed=7527301; DOI=10.1007/BF01519984;
RA   Okada H., Yoshida J., Seo H., Wakabayashi T., Sugita K., Hagiwara M.;
RT   "Anti-(glioma surface antigen) monoclonal antibody G-22 recognizes
RT   overexpressed CD44 in glioma cells.";
RL   Cancer Immunol. Immunother. 39:313-317(1994).
RN   [21]
RP   PROTEIN SEQUENCE OF 67-89.
RC   TISSUE=Peripheral blood;
RX   PubMed=7508992;
RA   Shepley M.P., Racaniello V.R.;
RT   "A monoclonal antibody that blocks poliovirus attachment recognizes
RT   the lymphocyte homing receptor CD44.";
RL   J. Virol. 68:1301-1308(1994).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 184-625 (ISOFORM 10), AND VARIANT
RP   THR-479.
RC   TISSUE=Foreskin;
RX   PubMed=2007624; DOI=10.1083/jcb.113.1.207;
RA   Brown T.A., Bouchard T., St John T., Wayner E., Carter W.G.;
RT   "Human keratinocytes express a new CD44 core protein (CD44E) as a
RT   heparan-sulfate intrinsic membrane proteoglycan with additional
RT   exons.";
RL   J. Cell Biol. 113:207-221(1991).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 221-267.
RX   PubMed=8148709; DOI=10.1136/bmj.308.6929.619;
RA   Matsumura Y., Hanbury D., Smith J., Tarin D.;
RT   "Non-invasive detection of malignancy by identification of unusual
RT   CD44 gene activity in exfoliated cancer cells.";
RL   BMJ 308:619-624(1994).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 267-603 (ISOFORM 1), AND VARIANT
RP   ARG-417.
RC   TISSUE=Lung;
RX   PubMed=1717145;
RA   Hofmann M., Rudy W., Zoeller M., Toelg C., Ponta H., Herrlich P.,
RA   Guenthert U.;
RT   "CD44 splice variants confer metastatic behavior in rats: homologous
RT   sequences are expressed in human tumor cell lines.";
RL   Cancer Res. 51:5292-5297(1991).
RN   [25]
RP   REVIEW ON FUNCTION, AND POST-TRANSLATIONAL MODIFICATIONS.
RX   PubMed=12511867; DOI=10.1038/nrm1004;
RA   Ponta H., Sherman L., Herrlich P.A.;
RT   "CD44: from adhesion molecules to signalling regulators.";
RL   Nat. Rev. Mol. Cell Biol. 4:33-45(2003).
RN   [26]
RP   PHOSPHORYLATION AT SER-706.
RX   PubMed=9580567;
RA   Peck D., Isacke C.M.;
RT   "Hyaluronan-dependent cell migration can be blocked by a CD44
RT   cytoplasmic domain peptide containing a phosphoserine at position
RT   325.";
RL   J. Cell Sci. 111:1595-1601(1998).
RN   [27]
RP   PHOSPHORYLATION AT SER-672.
RX   PubMed=12032545; DOI=10.1038/ncb797;
RA   Legg J.W., Lewis C.A., Parsons M., Ng T., Isacke C.M.;
RT   "A novel PKC-regulated mechanism controls CD44 ezrin association and
RT   directional cell motility.";
RL   Nat. Cell Biol. 4:399-407(2002).
RN   [28]
RP   GLYCOSYLATION, AND PROTEOLYTIC PROCESSING.
RX   PubMed=12883358; DOI=10.1097/00008390-200308000-00001;
RA   Bartolazzi A.;
RT   "CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage
RT   are regulated at post-translational level in cells of melanocytic
RT   lineage.";
RL   Melanoma Res. 13:325-337(2003).
RN   [29]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-57.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-686 AND SER-706, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [31]
RP   FUNCTION.
RX   PubMed=16541107; DOI=10.1038/sj.emboj.7601039;
RA   Vikesaa J., Hansen T.V., Joenson L., Borup R., Wewer U.M.,
RA   Christiansen J., Nielsen F.C.;
RT   "RNA-binding IMPs promote cell adhesion and invadopodia formation.";
RL   EMBO J. 25:1456-1468(2006).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-706, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using
RT   sequential IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-706, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [35]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-57 AND ASN-110.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [36]
RP   INTERACTION WITH UNC119.
RX   PubMed=19381274; DOI=10.1371/journal.pone.0005211;
RA   Vepachedu R., Karim Z., Patel O., Goplen N., Alam R.;
RT   "Unc119 protects from Shigella infection by inhibiting the Abl family
RT   kinases.";
RL   PLoS ONE 4:E5211-E5211(2009).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-686 AND SER-706, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [40]
RP   GLYCOSYLATION AT THR-637 AND THR-638, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-706, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [42]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 20-178, STRUCTURE BY NMR OF
RP   20-178, AND INTERACTION WITH HA.
RX   PubMed=14992719; DOI=10.1016/S1097-2765(04)00080-2;
RA   Teriete P., Banerji S., Noble M., Blundell C.D., Wright A.J.,
RA   Pickford A.R., Lowe E., Mahoney D.J., Tammi M.I., Kahmann J.D.,
RA   Campbell I.D., Day A.J., Jackson D.G.;
RT   "Structure of the regulatory hyaluronan binding domain in the
RT   inflammatory leukocyte homing receptor CD44.";
RL   Mol. Cell 13:483-496(2004).
RN   [45]
RP   STRUCTURE BY NMR OF 20-178 IN COMPLEX WITH HA.
RX   PubMed=17085435; DOI=10.1074/jbc.M608425200;
RA   Takeda M., Ogino S., Umemoto R., Sakakura M., Kajiwara M.,
RA   Sugahara K.N., Hayasaka H., Miyasaka M., Terasawa H., Shimada I.;
RT   "Ligand-induced structural changes of the CD44 hyaluronan-binding
RT   domain revealed by NMR.";
RL   J. Biol. Chem. 281:40089-40095(2006).
RN   [46]
RP   VARIANT BLOOD GROUP INDIAN PRO-46.
RX   PubMed=8636151; DOI=10.1074/jbc.271.12.7147;
RA   Telen M.J., Udani M., Washington M.K., Levesque M.C., Lloyd E.,
RA   Rao N.;
RT   "A blood group-related polymorphism of CD44 abolishes a hyaluronan-
RT   binding consensus sequence without preventing hyaluronan binding.";
RL   J. Biol. Chem. 271:7147-7153(1996).
CC   -!- FUNCTION: Receptor for hyaluronic acid (HA). Mediates cell-cell
CC       and cell-matrix interactions through its affinity for HA, and
CC       possibly also through its affinity for other ligands such as
CC       osteopontin, collagens, and matrix metalloproteinases (MMPs).
CC       Adhesion with HA plays an important role in cell migration, tumor
CC       growth and progression. In cancer cells, may play an important
CC       role in invadopodia formation. Also involved in lymphocyte
CC       activation, recirculation and homing, and in hematopoiesis.
CC       Altered expression or dysfunction causes numerous pathogenic
CC       phenotypes. Great protein heterogeneity due to numerous
CC       alternative splicing and post-translational modification events.
CC       Receptor for LGALS9; the interaction enhances binding of SMAD3 to
CC       the FOXP3 promoter, leading to up-regulation of FOXP3 expression
CC       and increased induced regulatory T (iTreg) cell stability and
CC       suppressive function (By similarity).
CC       {ECO:0000250|UniProtKB:P15379, ECO:0000269|PubMed:16541107}.
CC   -!- SUBUNIT: Interacts with PKN2 (By similarity). Interacts with TIAM1
CC       and TIAM2 (By similarity). Interacts with HA, as well as other
CC       glycosaminoglycans, collagen, laminin, and fibronectin via its N-
CC       terminal segment (PubMed:14992719, PubMed:17085435). Interacts
CC       with ANK, the ERM proteins (VIL2, RDX and MSN), and NF2 via its C-
CC       terminal segment. Interacts with UNC119 (PubMed:19381274).
CC       {ECO:0000250|UniProtKB:P15379, ECO:0000269|PubMed:14992719,
CC       ECO:0000269|PubMed:17085435, ECO:0000269|PubMed:19381274}.
CC   -!- INTERACTION:
CC       P18011:ipaB (xeno); NbExp=4; IntAct=EBI-490245, EBI-490239;
CC       P26038:MSN; NbExp=6; IntAct=EBI-490245, EBI-528768;
CC       Q9UPY5:SLC7A11; NbExp=4; IntAct=EBI-490245, EBI-3843348;
CC       P10451:SPP1; NbExp=4; IntAct=EBI-490245, EBI-723648;
CC   -!- SUBCELLULAR LOCATION: Cell membrane
CC       {ECO:0000250|UniProtKB:P15379}; Single-pass type I membrane
CC       protein {ECO:0000250|UniProtKB:P15379}. Note=Colocalizes with
CC       actin in membrane protrusions at wounding edges.
CC       {ECO:0000250|UniProtKB:P15379}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=19;
CC         Comment=Additional isoforms seem to exist. Additional isoforms
CC         are produced by alternative splicing of 10 out of 19 exons
CC         within the extracellular domain. Additional diversity is
CC         generated through the utilization of internal splice donor and
CC         acceptor sites within 2 of the exons. A variation in the
CC         cytoplasmic domain was shown to result from the alternative
CC         splicing of 2 exons. Isoform CD44 is expected to be expressed in
CC         normal cells. Splice variants have been found in many tumor cell
CC         lines. Exons 5, 6, 7, 8, 9, 10, 11, 13, 14 and 19 are
CC         alternatively spliced. Experimental confirmation may be lacking
CC         for some isoforms. {ECO:0000269|PubMed:1465456};
CC       Name=1; Synonyms=CD44;
CC         IsoId=P16070-1; Sequence=Displayed;
CC         Note=Corresponds to the largest isoform.;
CC       Name=2; Synonyms=CD44SP;
CC         IsoId=P16070-2; Sequence=VSP_005303, VSP_005304;
CC       Name=3;
CC         IsoId=P16070-3; Sequence=VSP_005305, VSP_005306;
CC         Note=Alternative splice donor/acceptor on exon 5.;
CC       Name=4; Synonyms=Epidermal;
CC         IsoId=P16070-4; Sequence=VSP_005307, VSP_005308;
CC         Note=Lacks exon 6.;
CC       Name=5;
CC         IsoId=P16070-5; Sequence=VSP_005313;
CC         Note=Alternative splice donor/acceptor on exon 7.;
CC       Name=6;
CC         IsoId=P16070-6; Sequence=VSP_005314, VSP_005315;
CC         Note=Lacks exon 10.;
CC       Name=7;
CC         IsoId=P16070-7; Sequence=VSP_005316, VSP_005317;
CC         Note=Lacks exon 13.;
CC       Name=8;
CC         IsoId=P16070-8; Sequence=VSP_005318, VSP_005319;
CC         Note=Lacks exon 14.;
CC       Name=9;
CC         IsoId=P16070-9; Sequence=VSP_005320, VSP_005321;
CC         Note=Lacks exon 19.;
CC       Name=10; Synonyms=CD44E, CD44R1, Epithelial, Keratinocyte;
CC         IsoId=P16070-10; Sequence=VSP_005309, VSP_005310;
CC         Note=Lacks exons 6-11.;
CC       Name=11; Synonyms=CD44R2;
CC         IsoId=P16070-11; Sequence=VSP_022797;
CC         Note=Lacks exons 6-13.;
CC       Name=12; Synonyms=CDw44, Reticulocyte;
CC         IsoId=P16070-12; Sequence=VSP_005311, VSP_005312;
CC         Note=Lacks exons 6-14.;
CC       Name=13; Synonyms=CD44R4;
CC         IsoId=P16070-13; Sequence=VSP_005309, VSP_005310, VSP_005318,
CC                                   VSP_005319;
CC         Note=Lacks exons 6-11 and exon 14.;
CC       Name=14; Synonyms=CD44R5;
CC         IsoId=P16070-14; Sequence=VSP_005309, VSP_005310, VSP_005316,
CC                                   VSP_005317, VSP_005318, VSP_005319;
CC         Note=Lacks exons 6-11, exon 13 and exon 14.;
CC       Name=15; Synonyms=Hermes;
CC         IsoId=P16070-15; Sequence=VSP_005311, VSP_005312, VSP_005320,
CC                                   VSP_005321;
CC         Note=Lacks exons 6-14 and exon 19.;
CC       Name=16;
CC         IsoId=P16070-16; Sequence=VSP_005305, VSP_005306, VSP_005314,
CC                                   VSP_005315;
CC         Note=Alternative splice donor/acceptor on exon 5 and lacks exon
CC         10.;
CC       Name=17;
CC         IsoId=P16070-17; Sequence=VSP_005313, VSP_005314, VSP_005315;
CC         Note=Alternative splice donor/acceptor on exon 7 and lacks exon
CC         10.;
CC       Name=18;
CC         IsoId=P16070-18; Sequence=VSP_005311, VSP_005312, VSP_043575;
CC         Note=No experimental confirmation available.;
CC       Name=19; Synonyms=CD44RC;
CC         IsoId=P16070-19; Sequence=VSP_043870, VSP_043871;
CC         Note=Soluble isoform, has enhanced hyaluronan binding.;
CC   -!- TISSUE SPECIFICITY: Isoform 10 (epithelial isoform) is expressed
CC       by cells of epithelium and highly expressed by carcinomas.
CC       Expression is repressed in neuroblastoma cells.
CC   -!- DOMAIN: The lectin-like LINK domain is responsible for hyaluronan
CC       binding. {ECO:0000250}.
CC   -!- PTM: Proteolytically cleaved in the extracellular matrix by
CC       specific proteinases (possibly MMPs) in several cell lines and
CC       tumors. {ECO:0000269|PubMed:12883358}.
CC   -!- PTM: N- and O-glycosylated. O-glycosylation contains more-or-less-
CC       sulfated chondroitin sulfate glycans, whose number may affect the
CC       accessibility of specific proteinases to their cleavage site(s).
CC       It is uncertain if O-glycosylation occurs on Thr-637 or Thr-638.
CC       {ECO:0000269|PubMed:12883358, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:22171320}.
CC   -!- PTM: Phosphorylated; activation of PKC results in the
CC       dephosphorylation of Ser-706 (constitutive phosphorylation site),
CC       and the phosphorylation of Ser-672. {ECO:0000269|PubMed:12032545,
CC       ECO:0000269|PubMed:9580567}.
CC   -!- POLYMORPHISM: CD44 is responsible for the Indian blood group
CC       system. The molecular basis of the In(A)=In1/In(B)=In2 blood group
CC       antigens is a single variation in position 46; In(B), the most
CC       frequent allele, has Arg-46. {ECO:0000269|PubMed:8636151}.
CC   -!- SIMILARITY: Contains 1 Link domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00323}.
CC   -!- WEB RESOURCE: Name=dbRBC/BGMUT; Note=Blood group antigen gene
CC       mutation database;
CC       URL="http://www.ncbi.nlm.nih.gov/gv/mhc/xslcgi.cgi?cmd=bgmut/systems_info&system=indian";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CD44 entry;
CC       URL="https://en.wikipedia.org/wiki/CD44";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CD44ID980CH11p13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M24915; AAA35674.1; -; mRNA.
DR   EMBL; M59040; AAA51950.1; -; mRNA.
DR   EMBL; X55150; CAA38951.1; -; mRNA.
DR   EMBL; X56794; CAA40133.1; -; mRNA.
DR   EMBL; X66733; CAA47271.1; -; mRNA.
DR   EMBL; L05423; AAB13622.1; -; Genomic_DNA.
DR   EMBL; L05407; AAB13622.1; JOINED; Genomic_DNA.
DR   EMBL; L05408; AAB13622.1; JOINED; Genomic_DNA.
DR   EMBL; L05409; AAB13622.1; JOINED; Genomic_DNA.
DR   EMBL; L05410; AAB13622.1; JOINED; Genomic_DNA.
DR   EMBL; L05420; AAB13622.1; JOINED; Genomic_DNA.
DR   EMBL; L05421; AAB13622.1; JOINED; Genomic_DNA.
DR   EMBL; L05422; AAB13622.1; JOINED; Genomic_DNA.
DR   EMBL; M69215; AAB13622.1; JOINED; Genomic_DNA.
DR   EMBL; L05423; AAB13623.1; -; Genomic_DNA.
DR   EMBL; L05407; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05408; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05410; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05411; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05412; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05414; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05415; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05416; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05417; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05418; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05419; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05420; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05421; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05422; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; M69215; AAB13623.1; JOINED; Genomic_DNA.
DR   EMBL; L05424; AAB13624.1; -; Genomic_DNA.
DR   EMBL; L05407; AAB13624.1; JOINED; Genomic_DNA.
DR   EMBL; L05408; AAB13624.1; JOINED; Genomic_DNA.
DR   EMBL; L05410; AAB13624.1; JOINED; Genomic_DNA.
DR   EMBL; L05420; AAB13624.1; JOINED; Genomic_DNA.
DR   EMBL; L05421; AAB13624.1; JOINED; Genomic_DNA.
DR   EMBL; L05422; AAB13624.1; JOINED; Genomic_DNA.
DR   EMBL; M69215; AAB13624.1; JOINED; Genomic_DNA.
DR   EMBL; L05424; AAB13625.1; -; Genomic_DNA.
DR   EMBL; L05407; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05408; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05410; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05411; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05412; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05414; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05416; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05417; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05418; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05419; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05420; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05421; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05422; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; M69215; AAB13625.1; JOINED; Genomic_DNA.
DR   EMBL; L05424; AAB13626.1; -; Genomic_DNA.
DR   EMBL; L05407; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05408; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05410; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05411; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05412; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05414; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05416; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05417; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05418; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05419; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05420; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05421; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05422; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; M69215; AAB13626.1; JOINED; Genomic_DNA.
DR   EMBL; L05424; AAB13627.1; -; Genomic_DNA.
DR   EMBL; L05407; AAB13627.1; JOINED; Genomic_DNA.
DR   EMBL; L05408; AAB13627.1; JOINED; Genomic_DNA.
DR   EMBL; L05410; AAB13627.1; JOINED; Genomic_DNA.
DR   EMBL; L05417; AAB13627.1; JOINED; Genomic_DNA.
DR   EMBL; L05418; AAB13627.1; JOINED; Genomic_DNA.
DR   EMBL; L05420; AAB13627.1; JOINED; Genomic_DNA.
DR   EMBL; L05421; AAB13627.1; JOINED; Genomic_DNA.
DR   EMBL; L05422; AAB13627.1; JOINED; Genomic_DNA.
DR   EMBL; M69215; AAB13627.1; JOINED; Genomic_DNA.
DR   EMBL; L05424; AAB13628.1; -; Genomic_DNA.
DR   EMBL; L05407; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05408; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05410; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05411; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05412; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05414; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05415; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05416; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05417; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05418; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05419; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05420; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05421; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; L05422; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; M69215; AAB13628.1; JOINED; Genomic_DNA.
DR   EMBL; AJ251595; CAB61878.1; -; mRNA.
DR   EMBL; S66400; AAB27917.1; -; mRNA.
DR   EMBL; S66400; AAB27918.2; -; mRNA.
DR   EMBL; S66400; AAB27919.1; -; mRNA.
DR   EMBL; AF098641; AAC70782.1; -; mRNA.
DR   EMBL; U40373; AAA82949.1; -; mRNA.
DR   EMBL; AY101192; AAM50040.1; -; mRNA.
DR   EMBL; AY101193; AAM50041.1; -; mRNA.
DR   EMBL; EF581837; ABQ59315.1; -; mRNA.
DR   EMBL; FJ216964; ACI46596.1; -; mRNA.
DR   EMBL; AL832642; CAD89965.1; -; mRNA.
DR   EMBL; AL133330; CAC10347.1; -; Genomic_DNA.
DR   EMBL; AL136989; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356215; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW68147.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68148.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68149.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68151.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68152.1; -; Genomic_DNA.
DR   EMBL; BC004372; AAH04372.1; -; mRNA.
DR   EMBL; BC067348; AAH67348.1; -; mRNA.
DR   EMBL; M25078; AAA36138.1; -; mRNA.
DR   EMBL; X55938; CAA39404.1; -; mRNA.
DR   EMBL; S72928; AAB30429.1; -; Genomic_DNA.
DR   EMBL; X62739; CAA44602.1; -; mRNA.
DR   CCDS; CCDS31455.1; -. [P16070-4]
DR   CCDS; CCDS31456.1; -. [P16070-10]
DR   CCDS; CCDS31457.1; -. [P16070-12]
DR   CCDS; CCDS31458.1; -. [P16070-19]
DR   CCDS; CCDS55754.1; -. [P16070-11]
DR   CCDS; CCDS55755.1; -. [P16070-18]
DR   CCDS; CCDS7897.1; -. [P16070-1]
DR   PIR; A47195; A47195.
DR   PIR; I37369; I37369.
DR   PIR; I77371; I77371.
DR   PIR; I77372; I77372.
DR   PIR; JH0417; JH0417.
DR   PIR; JH0518; JH0518.
DR   PIR; S13530; S13530.
DR   PIR; S24222; S24222.
DR   RefSeq; NP_000601.3; NM_000610.3. [P16070-1]
DR   RefSeq; NP_001001389.1; NM_001001389.1. [P16070-4]
DR   RefSeq; NP_001001390.1; NM_001001390.1. [P16070-10]
DR   RefSeq; NP_001001391.1; NM_001001391.1. [P16070-12]
DR   RefSeq; NP_001001392.1; NM_001001392.1. [P16070-19]
DR   RefSeq; NP_001189484.1; NM_001202555.1. [P16070-11]
DR   RefSeq; NP_001189485.1; NM_001202556.1. [P16070-18]
DR   RefSeq; NP_001189486.1; NM_001202557.1. [P16070-15]
DR   RefSeq; XP_011518790.1; XM_011520488.1. [P16070-13]
DR   UniGene; Hs.502328; -.
DR   PDB; 1POZ; NMR; -; A=20-178.
DR   PDB; 1UUH; X-ray; 2.20 A; A/B=20-178.
DR   PDB; 2I83; NMR; -; A=21-178.
DR   PDB; 4PZ3; X-ray; 1.08 A; A/B=18-170.
DR   PDB; 4PZ4; X-ray; 1.60 A; A/B=18-171.
DR   PDBsum; 1POZ; -.
DR   PDBsum; 1UUH; -.
DR   PDBsum; 2I83; -.
DR   PDBsum; 4PZ3; -.
DR   PDBsum; 4PZ4; -.
DR   ProteinModelPortal; P16070; -.
DR   SMR; P16070; 20-170.
DR   BioGrid; 107398; 81.
DR   DIP; DIP-1121N; -.
DR   IntAct; P16070; 37.
DR   MINT; MINT-5000740; -.
DR   STRING; 9606.ENSP00000398632; -.
DR   BindingDB; P16070; -.
DR   ChEMBL; CHEMBL3232692; -.
DR   DrugBank; DB08818; Hyaluronic acid.
DR   iPTMnet; P16070; -.
DR   PhosphoSite; P16070; -.
DR   SwissPalm; P16070; -.
DR   UniCarbKB; P16070; -.
DR   BioMuta; CD44; -.
DR   DMDM; 308153615; -.
DR   SWISS-2DPAGE; P16070; -.
DR   MaxQB; P16070; -.
DR   PaxDb; P16070; -.
DR   PRIDE; P16070; -.
DR   DNASU; 960; -.
DR   Ensembl; ENST00000263398; ENSP00000263398; ENSG00000026508. [P16070-12]
DR   Ensembl; ENST00000278386; ENSP00000278386; ENSG00000026508. [P16070-19]
DR   Ensembl; ENST00000352818; ENSP00000309732; ENSG00000026508. [P16070-18]
DR   Ensembl; ENST00000415148; ENSP00000389830; ENSG00000026508. [P16070-4]
DR   Ensembl; ENST00000428726; ENSP00000398632; ENSG00000026508. [P16070-1]
DR   Ensembl; ENST00000433892; ENSP00000392331; ENSG00000026508. [P16070-10]
DR   Ensembl; ENST00000434472; ENSP00000404447; ENSG00000026508. [P16070-11]
DR   GeneID; 960; -.
DR   KEGG; hsa:960; -.
DR   UCSC; uc001mvu.3; human. [P16070-1]
DR   UCSC; uc001mvv.3; human. [P16070-4]
DR   UCSC; uc001mvw.3; human. [P16070-10]
DR   UCSC; uc001mvx.3; human. [P16070-12]
DR   UCSC; uc001mvy.3; human. [P16070-19]
DR   UCSC; uc001mwc.4; human. [P16070-11]
DR   UCSC; uc010rer.2; human. [P16070-18]
DR   UCSC; uc021qfw.1; human. [P16070-15]
DR   CTD; 960; -.
DR   GeneCards; CD44; -.
DR   HGNC; HGNC:1681; CD44.
DR   HPA; CAB000112; -.
DR   HPA; CAB000316; -.
DR   HPA; HPA005785; -.
DR   MIM; 107269; gene.
DR   MIM; 172290; gene.
DR   MIM; 609027; phenotype.
DR   neXtProt; NX_P16070; -.
DR   PharmGKB; PA26221; -.
DR   eggNOG; ENOG410IZCP; Eukaryota.
DR   eggNOG; ENOG4111S6T; LUCA.
DR   GeneTree; ENSGT00530000063822; -.
DR   HOGENOM; HOG000115236; -.
DR   HOVERGEN; HBG003850; -.
DR   InParanoid; P16070; -.
DR   KO; K06256; -.
DR   OMA; SHPMGRG; -.
DR   OrthoDB; EOG77HDFT; -.
DR   PhylomeDB; P16070; -.
DR   TreeFam; TF334173; -.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-2160916; Hyaluronan uptake and degradation.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   ChiTaRS; CD44; human.
DR   EvolutionaryTrace; P16070; -.
DR   GeneWiki; CD44; -.
DR   GenomeRNAi; 960; -.
DR   NextBio; 4000; -.
DR   PRO; PR:P16070; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; P16070; -.
DR   ExpressionAtlas; P16070; baseline and differential.
DR   Genevisible; P16070; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0035692; C:macrophage migration inhibitory factor receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005518; F:collagen binding; NAS:UniProtKB.
DR   GO; GO:0005540; F:hyaluronic acid binding; IDA:UniProtKB.
DR   GO; GO:0004415; F:hyalurononglucosaminidase activity; IDA:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0060442; P:branching involved in prostate gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0051216; P:cartilage development; IEP:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; NAS:UniProtKB.
DR   GO; GO:0044344; P:cellular response to fibroblast growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0030214; P:hyaluronan catabolic process; IDA:UniProtKB.
DR   GO; GO:0030212; P:hyaluronan metabolic process; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0070487; P:monocyte aggregation; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043518; P:negative regulation of DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:1902166; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0034116; P:positive regulation of heterotypic cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:1900625; P:positive regulation of monocyte aggregation; IMP:BHF-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; NAS:UniProtKB.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0002246; P:wound healing involved in inflammatory response; IEA:Ensembl.
DR   Gene3D; 3.10.100.10; -; 1.
DR   InterPro; IPR016186; C-type_lectin-like.
DR   InterPro; IPR016187; C-type_lectin_fold.
DR   InterPro; IPR001231; CD44_antigen.
DR   InterPro; IPR000538; Link_dom.
DR   Pfam; PF00193; Xlink; 1.
DR   PRINTS; PR00658; CD44.
DR   PRINTS; PR01265; LINKMODULE.
DR   SMART; SM00445; LINK; 1.
DR   SUPFAM; SSF56436; SSF56436; 1.
DR   PROSITE; PS01241; LINK_1; 1.
DR   PROSITE; PS50963; LINK_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Blood group antigen;
KW   Cell adhesion; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Membrane;
KW   Phosphoprotein; Polymorphism; Proteoglycan;
KW   Pyrrolidone carboxylic acid; Receptor; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     20       {ECO:0000250}.
FT   CHAIN        21    742       CD44 antigen.
FT                                /FTId=PRO_0000026687.
FT   TOPO_DOM     21    649       Extracellular. {ECO:0000255}.
FT   TRANSMEM    650    670       Helical. {ECO:0000255}.
FT   TOPO_DOM    671    742       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       32    120       Link. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00323}.
FT   REGION      224    649       Stem.
FT   COMPBIAS    150    158       Arg/Lys-rich (basic).
FT   BINDING      41     41       Hyaluronan. {ECO:0000250}.
FT   BINDING      78     78       Hyaluronan. {ECO:0000250}.
FT   BINDING      79     79       Hyaluronan. {ECO:0000250}.
FT   BINDING     105    105       Hyaluronan. {ECO:0000250}.
FT   MOD_RES      21     21       Pyrrolidone carboxylic acid.
FT                                {ECO:0000305}.
FT   MOD_RES     672    672       Phosphoserine; by PKC.
FT                                {ECO:0000269|PubMed:12032545}.
FT   MOD_RES     686    686       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     697    697       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P15379}.
FT   MOD_RES     706    706       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19367720,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000269|PubMed:9580567}.
FT   CARBOHYD     25     25       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     57     57       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    100    100       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    110    110       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    120    120       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    350    350       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    548    548       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    599    599       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    636    636       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    637    637       O-linked (GalNAc...); or Thr-638.
FT                                {ECO:0000269|PubMed:22171320}.
FT   CARBOHYD    638    638       O-linked (GalNAc...); or Thr-637.
FT                                {ECO:0000269|PubMed:22171320}.
FT   DISULFID     28    129       {ECO:0000255|PROSITE-ProRule:PRU00323}.
FT   DISULFID     53    118       {ECO:0000255|PROSITE-ProRule:PRU00323}.
FT   DISULFID     77     97       {ECO:0000255|PROSITE-ProRule:PRU00323}.
FT   VAR_SEQ      23     29       DLNITCR -> GVGRRKS (in isoform 2).
FT                                {ECO:0000303|PubMed:8352881}.
FT                                /FTId=VSP_005303.
FT   VAR_SEQ      30    742       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8352881}.
FT                                /FTId=VSP_005304.
FT   VAR_SEQ      78    139       RYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYC
FT                                FNASAPPEEDCTSVTDLPNAF -> SLHCSQQSKKVWAEEK
FT                                ASDQQWQWSCGGQKAKWTQRRGQQVSGNGAFGEQGVVRNSR
FT                                PVYDS (in isoform 19).
FT                                {ECO:0000303|PubMed:10933060}.
FT                                /FTId=VSP_043870.
FT   VAR_SEQ     140    742       Missing (in isoform 19).
FT                                {ECO:0000303|PubMed:10933060}.
FT                                /FTId=VSP_043871.
FT   VAR_SEQ     192    192       G -> A (in isoform 3 and isoform 16).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_005305.
FT   VAR_SEQ     193    223       Missing (in isoform 3 and isoform 16).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_005306.
FT   VAR_SEQ     223    535       Missing (in isoform 11).
FT                                {ECO:0000303|PubMed:2056274,
FT                                ECO:0000303|Ref.12}.
FT                                /FTId=VSP_022797.
FT   VAR_SEQ     223    223       T -> N (in isoform 10, isoform 13 and
FT                                isoform 14). {ECO:0000303|PubMed:1991450,
FT                                ECO:0000303|PubMed:2007624,
FT                                ECO:0000303|PubMed:2056274,
FT                                ECO:0000303|PubMed:8352881,
FT                                ECO:0000303|Ref.11}.
FT                                /FTId=VSP_005309.
FT   VAR_SEQ     223    223       T -> R (in isoform 12, isoform 15 and
FT                                isoform 18).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|PubMed:1840487,
FT                                ECO:0000303|PubMed:2466575,
FT                                ECO:0000303|PubMed:2466576,
FT                                ECO:0000303|Ref.10, ECO:0000303|Ref.11,
FT                                ECO:0000303|Ref.13}.
FT                                /FTId=VSP_005311.
FT   VAR_SEQ     223    223       T -> S (in isoform 4).
FT                                {ECO:0000303|PubMed:1281868,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_005307.
FT   VAR_SEQ     224    604       Missing (in isoform 12, isoform 15 and
FT                                isoform 18).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|PubMed:1840487,
FT                                ECO:0000303|PubMed:2466575,
FT                                ECO:0000303|PubMed:2466576,
FT                                ECO:0000303|Ref.10, ECO:0000303|Ref.11,
FT                                ECO:0000303|Ref.13}.
FT                                /FTId=VSP_005312.
FT   VAR_SEQ     224    472       Missing (in isoform 10, isoform 13 and
FT                                isoform 14). {ECO:0000303|PubMed:1991450,
FT                                ECO:0000303|PubMed:2007624,
FT                                ECO:0000303|PubMed:2056274,
FT                                ECO:0000303|PubMed:8352881,
FT                                ECO:0000303|Ref.11}.
FT                                /FTId=VSP_005310.
FT   VAR_SEQ     224    266       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:1281868,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_005308.
FT   VAR_SEQ     266    273       Missing (in isoform 5 and isoform 17).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_005313.
FT   VAR_SEQ     385    385       I -> T (in isoform 6, isoform 16 and
FT                                isoform 17). {ECO:0000305}.
FT                                /FTId=VSP_005314.
FT   VAR_SEQ     386    428       Missing (in isoform 6, isoform 16 and
FT                                isoform 17). {ECO:0000305}.
FT                                /FTId=VSP_005315.
FT   VAR_SEQ     506    506       Q -> R (in isoform 7 and isoform 14).
FT                                {ECO:0000303|PubMed:8352881}.
FT                                /FTId=VSP_005316.
FT   VAR_SEQ     507    535       Missing (in isoform 7 and isoform 14).
FT                                {ECO:0000303|PubMed:8352881}.
FT                                /FTId=VSP_005317.
FT   VAR_SEQ     536    536       N -> R (in isoform 8, isoform 13 and
FT                                isoform 14).
FT                                {ECO:0000303|PubMed:8352881}.
FT                                /FTId=VSP_005318.
FT   VAR_SEQ     537    604       Missing (in isoform 8, isoform 13 and
FT                                isoform 14).
FT                                {ECO:0000303|PubMed:8352881}.
FT                                /FTId=VSP_005319.
FT   VAR_SEQ     605    625       Missing (in isoform 18).
FT                                {ECO:0000303|Ref.13}.
FT                                /FTId=VSP_043575.
FT   VAR_SEQ     675    675       R -> S (in isoform 9 and isoform 15).
FT                                {ECO:0000303|PubMed:2466576}.
FT                                /FTId=VSP_005320.
FT   VAR_SEQ     676    742       Missing (in isoform 9 and isoform 15).
FT                                {ECO:0000303|PubMed:2466576}.
FT                                /FTId=VSP_005321.
FT   VARIANT      46     46       R -> P (in In(A) antigen).
FT                                {ECO:0000269|PubMed:8636151}.
FT                                /FTId=VAR_006490.
FT   VARIANT     393    393       T -> M (in dbSNP:rs11607491).
FT                                /FTId=VAR_030325.
FT   VARIANT     417    417       K -> R (in dbSNP:rs9666607).
FT                                {ECO:0000269|PubMed:1465456,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:1717145,
FT                                ECO:0000269|PubMed:7508842}.
FT                                /FTId=VAR_021147.
FT   VARIANT     479    479       I -> T (in dbSNP:rs1467558).
FT                                {ECO:0000269|PubMed:1281868,
FT                                ECO:0000269|PubMed:1465456,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:1991450,
FT                                ECO:0000269|PubMed:2007624,
FT                                ECO:0000269|PubMed:2056274,
FT                                ECO:0000269|PubMed:7508842,
FT                                ECO:0000269|PubMed:8352881,
FT                                ECO:0000269|Ref.11}.
FT                                /FTId=VAR_030326.
FT   VARIANT     494    494       D -> H (in dbSNP:rs12273397).
FT                                {ECO:0000269|PubMed:7508842}.
FT                                /FTId=VAR_030327.
FT   CONFLICT     26     26       I -> M (in Ref. 10; AAA82949).
FT                                {ECO:0000305}.
FT   CONFLICT    109    109       S -> Y (in Ref. 1; AAA35674, 2; AAA51950,
FT                                3; CAA38951 and 7; CAB61878).
FT                                {ECO:0000305}.
FT   CONFLICT    221    221       A -> R (in Ref. 3; CAA38951).
FT                                {ECO:0000305}.
FT   CONFLICT    241    241       T -> A (in Ref. 7; CAB61878).
FT                                {ECO:0000305}.
FT   CONFLICT    410    410       E -> V (in Ref. 5; CAA47271).
FT                                {ECO:0000305}.
FT   CONFLICT    494    494       D -> N (in Ref. 7; CAB61878).
FT                                {ECO:0000305}.
FT   CONFLICT    555    555       T -> H (in Ref. 3; CAA38951).
FT                                {ECO:0000305}.
FT   CONFLICT    620    620       G -> E (in Ref. 1; AAA35674).
FT                                {ECO:0000305}.
FT   CONFLICT    697    697       S -> I (in Ref. 11; AAM50041 and 16;
FT                                AAH67348). {ECO:0000305}.
FT   STRAND       21     26       {ECO:0000244|PDB:4PZ3}.
FT   STRAND       33     38       {ECO:0000244|PDB:4PZ3}.
FT   HELIX        46     55       {ECO:0000244|PDB:4PZ3}.
FT   STRAND       57     59       {ECO:0000244|PDB:1POZ}.
FT   HELIX        63     71       {ECO:0000244|PDB:4PZ3}.
FT   STRAND       80     82       {ECO:0000244|PDB:4PZ3}.
FT   STRAND       85     92       {ECO:0000244|PDB:4PZ3}.
FT   HELIX        98    100       {ECO:0000244|PDB:4PZ3}.
FT   STRAND      103    106       {ECO:0000244|PDB:4PZ3}.
FT   STRAND      109    111       {ECO:0000244|PDB:1POZ}.
FT   STRAND      114    119       {ECO:0000244|PDB:4PZ3}.
FT   STRAND      121    123       {ECO:0000244|PDB:2I83}.
FT   STRAND      125    128       {ECO:0000244|PDB:4PZ3}.
FT   STRAND      130    132       {ECO:0000244|PDB:2I83}.
FT   STRAND      139    148       {ECO:0000244|PDB:4PZ3}.
FT   TURN        150    152       {ECO:0000244|PDB:1POZ}.
FT   STRAND      154    160       {ECO:0000244|PDB:4PZ3}.
FT   HELIX       165    168       {ECO:0000244|PDB:4PZ3}.
SQ   SEQUENCE   742 AA;  81538 MW;  BB9B66B19B970349 CRC64;
     MDKFWWHAAW GLCLVPLSLA QIDLNITCRF AGVFHVEKNG RYSISRTEAA DLCKAFNSTL
     PTMAQMEKAL SIGFETCRYG FIEGHVVIPR IHPNSICAAN NTGVYILTSN TSQYDTYCFN
     ASAPPEEDCT SVTDLPNAFD GPITITIVNR DGTRYVQKGE YRTNPEDIYP SNPTDDDVSS
     GSSSERSSTS GGYIFYTFST VHPIPDEDSP WITDSTDRIP ATTLMSTSAT ATETATKRQE
     TWDWFSWLFL PSESKNHLHT TTQMAGTSSN TISAGWEPNE ENEDERDRHL SFSGSGIDDD
     EDFISSTIST TPRAFDHTKQ NQDWTQWNPS HSNPEVLLQT TTRMTDVDRN GTTAYEGNWN
     PEAHPPLIHH EHHEEEETPH STSTIQATPS STTEETATQK EQWFGNRWHE GYRQTPKEDS
     HSTTGTAAAS AHTSHPMQGR TTPSPEDSSW TDFFNPISHP MGRGHQAGRR MDMDSSHSIT
     LQPTANPNTG LVEDLDRTGP LSMTTQQSNS QSFSTSHEGL EEDKDHPTTS TLTSSNRNDV
     TGGRRDPNHS EGSTTLLEGY TSHYPHTKES RTFIPVTSAK TGSFGVTAVT VGDSNSNVNR
     SLSGDQDTFH PSGGSHTTHG SESDGHSHGS QEGGANTTSG PIRTPQIPEW LIILASLLAL
     ALILAVCIAV NSRRRCGQKK KLVINSGNGA VEDRKPSGLN GEASKSQEMV HLVNKESSET
     PDQFMTADET RNLQNVDMKI GV
//
ID   IL12B_HUMAN             Reviewed;         328 AA.
AC   P29460;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   20-JAN-2016, entry version 185.
DE   RecName: Full=Interleukin-12 subunit beta;
DE            Short=IL-12B;
DE   AltName: Full=Cytotoxic lymphocyte maturation factor 40 kDa subunit;
DE            Short=CLMF p40;
DE   AltName: Full=IL-12 subunit p40;
DE   AltName: Full=NK cell stimulatory factor chain 2;
DE            Short=NKSF2;
DE   Flags: Precursor;
GN   Name=IL12B; Synonyms=NKSF2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1674604; DOI=10.1073/pnas.88.10.4143;
RA   Gubler U., Chua A.O., Schoenhaut D.S., Dwyer C.M., McComas W.,
RA   Motyka R., Nabavi N., Wolitzky A.G., Quinn P.M., Familletti P.C.,
RA   Gately M.K.;
RT   "Coexpression of two distinct genes is required to generate secreted
RT   bioactive cytotoxic lymphocyte maturation factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:4143-4147(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1673147;
RA   Wolf S.F., Temple P.A., Kobayashi M., Young D., Dicig M., Lowe L.,
RA   Dzialo R., Fitz L., Ferenz C., Hewick R.M., Kelleher K.,
RA   Herrmann S.H., Clark S.C., Azzoni L., Chan S.H., Trinchieri G.,
RA   Perussia B.;
RT   "Cloning of cDNA for natural killer cell stimulatory factor, a
RT   heterodimeric cytokine with multiple biologic effects on T and natural
RT   killer cells.";
RL   J. Immunol. 146:3074-3081(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11197695; DOI=10.1038/sj.gene.6363720;
RA   Huang D., Cancilla M.R., Morahan G.;
RT   "Complete primary structure, chromosomal localization, and definition
RT   of polymorphisms of the gene encoding the human interleukin 12 p40
RT   subunit.";
RL   Genes Immun. 1:515-520(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Hongyuan J., Meiyun Z.;
RT   "Cloning and sequence analysis of IL-12 cDNA from Chinese.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-33 AND PHE-298.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 23-45.
RX   PubMed=2204066; DOI=10.1073/pnas.87.17.6808;
RA   Stern A.S., Podlaski F.J., Hulmes J.D., Pan Y.C.E., Quinn P.M.,
RA   Wolitzky A.G., Familletti P.C., Stremlo D.L., Truitt T.,
RA   Chizzonite R., Gately M.K.;
RT   "Purification to homogeneity and partial characterization of cytotoxic
RT   lymphocyte maturation factor from human B-lymphoblastoid cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:6808-6812(1990).
RN   [8]
RP   SIMILARITY TO IL-6 RECEPTOR.
RX   PubMed=2070420; DOI=10.1016/0092-8674(91)90131-H;
RA   Gearing D.P., Cosman D.;
RT   "Homology of the p40 subunit of natural killer cell stimulatory factor
RT   (NKSF) with the extracellular domain of the interleukin-6 receptor.";
RL   Cell 66:9-10(1991).
RN   [9]
RP   SUBUNIT.
RX   PubMed=7836910; DOI=10.1084/jem.181.2.537;
RA   D'Andrea A., Ma X., Aste-Amezaga M., Paganin C., Trinchieri G.;
RT   "Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on
RT   the production of cytokines by human peripheral blood mononuclear
RT   cells: priming for IL-12 and tumor necrosis factor alpha production.";
RL   J. Exp. Med. 181:537-546(1995).
RN   [10]
RP   GLYCOSYLATION AT TRP-319.
RX   PubMed=10207176; DOI=10.1093/glycob/9.5.435;
RA   Doucey M.A., Hess D., Blommers M.J., Hofsteenge J.;
RT   "Recombinant human interleukin-12 is the second example of a C-
RT   mannosylated protein.";
RL   Glycobiology 9:435-441(1999).
RN   [11]
RP   INVOLVEMENT IN IMD29.
RX   PubMed=9854038; DOI=10.1172/JCI4950;
RA   Altare F., Lammas D., Revy P., Jouanguy E., Doeffinger R.,
RA   Lamhamedi-Cherradi S.-E., Drysdale P., Scheel-Toellner D.,
RA   Girdlestone J., Darbyshire P., Wadhwa M., Dockrell H., Salmon M.,
RA   Fischer A., Durandy A., Casanova J.-L., Kumararatne D.S.;
RT   "Inherited interleukin 12 deficiency in a child with bacille Calmette-
RT   Guerin and Salmonella enteritidis disseminated infection.";
RL   J. Clin. Invest. 102:2035-2040(1998).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH IL23A.
RX   PubMed=11114383; DOI=10.1016/S1074-7613(00)00070-4;
RA   Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., Vega F.,
RA   Yu N., Wang J., Singh K.P., Zonin F., Vaisberg E., Churakova T.,
RA   Liu M.-R., Gorman D., Wagner J., Zurawski S., Liu Y.-J., Abrams J.S.,
RA   Moore K.W., Rennick D.M., de Waal-Malefyt R., Hannum C., Bazan J.F.,
RA   Kastelein R.A.;
RT   "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with
RT   biological activities similar as well as distinct from IL-12.";
RL   Immunity 13:715-725(2000).
RN   [13]
RP   INVOLVEMENT IN IMD29.
RX   PubMed=11753820; DOI=10.1086/338625;
RA   Picard C., Fieschi C., Altare F., Al-Jumaah S., Al-Hajjar S.,
RA   Feinberg J., Dupuis S., Soudais C., Al-Mohsen I.Z., Genin E.,
RA   Lammas D., Kumararatne D.S., Leclerc T., Rafii A., Frayha H.,
RA   Murugasu B., Wah L.B., Sinniah R., Loubser M., Okamoto E.,
RA   Al-Ghonaium A., Tufenkeji H., Abel L., Casanova J.-L.;
RT   "Inherited interleukin-12 deficiency: IL12B genotype and clinical
RT   phenotype of 13 patients from six kindreds.";
RL   Am. J. Hum. Genet. 70:336-348(2002).
RN   [14]
RP   ASSOCIATION WITH PSORIASIS.
RX   PubMed=17587057; DOI=10.1007/s00439-007-0397-0;
RA   Capon F., Di Meglio P., Szaub J., Prescott N.J., Dunster C.,
RA   Baumber L., Timms K., Gutin A., Abkevic V., Burden A.D., Lanchbury J.,
RA   Barker J.N., Trembath R.C., Nestle F.O.;
RT   "Sequence variants in the genes for the interleukin-23 receptor
RT   (IL23R) and its ligand (IL12B) confer protection against psoriasis.";
RL   Hum. Genet. 122:201-206(2007).
RN   [15]
RP   ASSOCIATION WITH PSORIASIS.
RX   PubMed=18800148; DOI=10.1038/jid.2008.233;
RA   Huffmeier U., Lascorz J., Bohm B., Lohmann J., Wendler J., Mossner R.,
RA   Reich K., Traupe H., Kurrat W., Burkhardt H., Reis A.;
RT   "Genetic variants of the IL-23R pathway: association with psoriatic
RT   arthritis and psoriasis vulgaris, but no specific risk factor for
RT   arthritis.";
RL   J. Invest. Dermatol. 129:355-358(2009).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 23-328 ALONE AND IN COMPLEX
RP   WITH IL12A, GLYCOSYLATION AT ASN-222, AND DISULFIDE BONDS.
RX   PubMed=10899108; DOI=10.1093/emboj/19.14.3530;
RA   Yoon C., Johnston S.C., Tang J., Stahl M., Tobin J.F., Somers W.S.;
RT   "Charged residues dominate a unique interlocking topography in the
RT   heterodimeric cytokine interleukin-12.";
RL   EMBO J. 19:3530-3541(2000).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 23-328 IN COMPLEX WITH IL23A
RP   AND ANTIBODY.
RX   PubMed=18708069; DOI=10.1016/j.jmb.2008.08.001;
RA   Beyer B.M., Ingram R., Ramanathan L., Reichert P., Le H.V.,
RA   Madison V., Orth P.;
RT   "Crystal structures of the pro-inflammatory cytokine interleukin-23
RT   and its complex with a high-affinity neutralizing antibody.";
RL   J. Mol. Biol. 382:942-955(2008).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 23-328 IN COMPLEX WITH IL23A,
RP   AND SUBUNIT.
RX   PubMed=18680750; DOI=10.1016/j.jmb.2008.07.051;
RA   Lupardus P.J., Garcia K.C.;
RT   "The structure of interleukin-23 reveals the molecular basis of p40
RT   subunit sharing with interleukin-12.";
RL   J. Mol. Biol. 382:931-941(2008).
CC   -!- FUNCTION: Cytokine that can act as a growth factor for activated T
CC       and NK cells, enhance the lytic activity of NK/lymphokine-
CC       activated killer cells, and stimulate the production of IFN-gamma
CC       by resting PBMC. {ECO:0000269|PubMed:11114383}.
CC   -!- FUNCTION: Associates with IL23A to form the IL-23 interleukin, a
CC       heterodimeric cytokine which functions in innate and adaptive
CC       immunity. IL-23 may constitute with IL-17 an acute response to
CC       infection in peripheral tissues. IL-23 binds to a heterodimeric
CC       receptor complex composed of IL12RB1 and IL23R, activates the Jak-
CC       Stat signaling cascade, stimulates memory rather than naive T-
CC       cells and promotes production of proinflammatory cytokines. IL-23
CC       induces autoimmune inflammation and thus may be responsible for
CC       autoimmune inflammatory diseases and may be important for
CC       tumorigenesis. {ECO:0000269|PubMed:11114383}.
CC   -!- SUBUNIT: Heterodimer with IL12A; disulfide-linked. The heterodimer
CC       is known as interleukin IL-12. Heterodimer with IL23A; disulfide-
CC       linked. The heterodimer is known as interleukin IL-23. Also
CC       secreted as a monomer. {ECO:0000269|PubMed:10899108,
CC       ECO:0000269|PubMed:18680750, ECO:0000269|PubMed:18708069,
CC       ECO:0000269|PubMed:7836910}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-1029614, EBI-1029614;
CC       P29459:IL12A; NbExp=2; IntAct=EBI-1029614, EBI-1029636;
CC       Q9NPF7:IL23A; NbExp=4; IntAct=EBI-1029614, EBI-2481154;
CC       Q9EQ14:Il23a (xeno); NbExp=2; IntAct=EBI-1029614, EBI-2481329;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- PTM: Known to be C-mannosylated in the recombinant protein; it is
CC       not yet known for sure if the wild-type protein is also modified.
CC   -!- DISEASE: Immunodeficiency 29 (IMD29) [MIM:614890]: A form of
CC       Mendelian susceptibility to mycobacterial disease, a rare
CC       condition caused by impairment of interferon-gamma mediated
CC       immunity. It is characterized by predisposition to illness caused
CC       by moderately virulent mycobacterial species, such as Bacillus
CC       Calmette-Guerin (BCG) vaccine, environmental non-tuberculous
CC       mycobacteria, and by the more virulent Mycobacterium tuberculosis.
CC       Other microorganisms rarely cause severe clinical disease in
CC       individuals with susceptibility to mycobacterial infections, with
CC       the exception of Salmonella which infects less than 50% of these
CC       individuals. Clinical outcome severity depends on the degree of
CC       impairment of interferon-gamma mediated immunity. Some patients
CC       die of overwhelming mycobacterial disease with lepromatous-like
CC       lesions in early childhood, whereas others develop, later in life,
CC       disseminated but curable infections with tuberculoid granulomas.
CC       IMD29 is characterized by undetectable IL12B secretion from
CC       leukocytes. Affected individuals generally present with BCG
CC       disease after vaccination in childhood, and at least half also
CC       have Salmonella infection. Disease phenotype is relatively mild,
CC       and patients have a good prognosis. {ECO:0000269|PubMed:11753820,
CC       ECO:0000269|PubMed:9854038}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Psoriasis 11 (PSORS11) [MIM:612599]: A common, chronic
CC       inflammatory disease of the skin with multifactorial etiology. It
CC       is characterized by red, scaly plaques usually found on the scalp,
CC       elbows and knees. These lesions are caused by abnormal
CC       keratinocyte proliferation and infiltration of inflammatory cells
CC       into the dermis and epidermis. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 3
CC       subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 fibronectin type-III domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 Ig-like C2-type (immunoglobulin-like)
CC       domain. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=IL12Bbase; Note=IL12B mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/IL12Bbase/";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/il12b/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M65272; AAA35695.1; -; mRNA.
DR   EMBL; M65290; AAA59938.1; -; mRNA.
DR   EMBL; AY008847; AAG32620.1; -; Genomic_DNA.
DR   EMBL; AF180563; AAD56386.1; -; mRNA.
DR   EMBL; AF512686; AAM34792.1; -; Genomic_DNA.
DR   EMBL; BC067498; AAH67498.1; -; mRNA.
DR   EMBL; BC067499; AAH67499.1; -; mRNA.
DR   EMBL; BC067500; AAH67500.1; -; mRNA.
DR   EMBL; BC067501; AAH67501.1; -; mRNA.
DR   EMBL; BC067502; AAH67502.1; -; mRNA.
DR   EMBL; BC074723; AAH74723.1; -; mRNA.
DR   CCDS; CCDS4346.1; -.
DR   PIR; A38957; A38957.
DR   RefSeq; NP_002178.2; NM_002187.2.
DR   UniGene; Hs.674; -.
DR   PDB; 1F42; X-ray; 2.50 A; A=23-328.
DR   PDB; 1F45; X-ray; 2.80 A; A=23-328.
DR   PDB; 3D85; X-ray; 1.90 A; D=23-328.
DR   PDB; 3D87; X-ray; 2.90 A; B/D=23-328.
DR   PDB; 3DUH; X-ray; 2.30 A; A/B=23-328.
DR   PDB; 3HMX; X-ray; 3.00 A; A=23-328.
DR   PDB; 3QWR; X-ray; 3.25 A; A=23-328.
DR   PDB; 4GRW; X-ray; 2.55 A; B/D=1-328.
DR   PDB; 4OE8; X-ray; 1.74 A; A=1-328.
DR   PDB; 4OG9; X-ray; 3.39 A; A=1-328.
DR   PDBsum; 1F42; -.
DR   PDBsum; 1F45; -.
DR   PDBsum; 3D85; -.
DR   PDBsum; 3D87; -.
DR   PDBsum; 3DUH; -.
DR   PDBsum; 3HMX; -.
DR   PDBsum; 3QWR; -.
DR   PDBsum; 4GRW; -.
DR   PDBsum; 4OE8; -.
DR   PDBsum; 4OG9; -.
DR   ProteinModelPortal; P29460; -.
DR   SMR; P29460; 23-328.
DR   BioGrid; 109807; 2.
DR   DIP; DIP-3774N; -.
DR   IntAct; P29460; 5.
DR   STRING; 9606.ENSP00000231228; -.
DR   ChEMBL; CHEMBL2364153; -.
DR   DrugBank; DB05679; Ustekinumab.
DR   iPTMnet; P29460; -.
DR   PhosphoSite; P29460; -.
DR   UniCarbKB; P29460; -.
DR   BioMuta; IL12B; -.
DR   DMDM; 266320; -.
DR   PaxDb; P29460; -.
DR   PRIDE; P29460; -.
DR   DNASU; 3593; -.
DR   Ensembl; ENST00000231228; ENSP00000231228; ENSG00000113302.
DR   GeneID; 3593; -.
DR   KEGG; hsa:3593; -.
DR   UCSC; uc003lxr.1; human.
DR   CTD; 3593; -.
DR   GeneCards; IL12B; -.
DR   HGNC; HGNC:5970; IL12B.
DR   HPA; HPA040970; -.
DR   MalaCards; IL12B; -.
DR   MIM; 161561; gene.
DR   MIM; 612599; phenotype.
DR   MIM; 614890; phenotype.
DR   neXtProt; NX_P29460; -.
DR   Orphanet; 319558; Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency.
DR   Orphanet; 3287; Takayasu arteritis.
DR   PharmGKB; PA29785; -.
DR   eggNOG; ENOG410IF5K; Eukaryota.
DR   eggNOG; ENOG410YWXR; LUCA.
DR   GeneTree; ENSGT00390000012630; -.
DR   HOGENOM; HOG000113027; -.
DR   HOVERGEN; HBG052094; -.
DR   InParanoid; P29460; -.
DR   KO; K05425; -.
DR   OMA; WSTPHSY; -.
DR   OrthoDB; EOG7TBC2K; -.
DR   PhylomeDB; P29460; -.
DR   TreeFam; TF334829; -.
DR   EvolutionaryTrace; P29460; -.
DR   GeneWiki; Interleukin-12_subunit_beta; -.
DR   GenomeRNAi; 3593; -.
DR   NextBio; 14039; -.
DR   PMAP-CutDB; P29460; -.
DR   PRO; PR:P29460; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; P29460; -.
DR   CleanEx; HS_IL12B; -.
DR   Genevisible; P29460; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; TAS:UniProtKB.
DR   GO; GO:0043514; C:interleukin-12 complex; IDA:UniProtKB.
DR   GO; GO:0070743; C:interleukin-23 complex; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IEA:InterPro.
DR   GO; GO:0004896; F:cytokine receptor activity; IEA:InterPro.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042164; F:interleukin-12 alpha subunit binding; IPI:AgBase.
DR   GO; GO:0005143; F:interleukin-12 receptor binding; TAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IDA:BHF-UCL.
DR   GO; GO:0042832; P:defense response to protozoan; IEA:Ensembl.
DR   GO; GO:0051607; P:defense response to virus; IEA:Ensembl.
DR   GO; GO:0042095; P:interferon-gamma biosynthetic process; TAS:UniProtKB.
DR   GO; GO:0030101; P:natural killer cell activation; IDA:UniProtKB.
DR   GO; GO:0002323; P:natural killer cell activation involved in immune response; IEA:Ensembl.
DR   GO; GO:0044130; P:negative regulation of growth of symbiont in host; IEA:Ensembl.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0032693; P:negative regulation of interleukin-10 production; IMP:BHF-UCL.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; IDA:BHF-UCL.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0042104; P:positive regulation of activated T cell proliferation; IDA:UniProtKB.
DR   GO; GO:0010535; P:positive regulation of activation of JAK2 kinase activity; IDA:BHF-UCL.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:UniProtKB.
DR   GO; GO:0002230; P:positive regulation of defense response to virus by host; IDA:BHF-UCL.
DR   GO; GO:0032725; P:positive regulation of granulocyte macrophage colony-stimulating factor production; IDA:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0045078; P:positive regulation of interferon-gamma biosynthetic process; TAS:UniProtKB.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IDA:UniProtKB.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; IDA:BHF-UCL.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IDA:BHF-UCL.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; IDA:BHF-UCL.
DR   GO; GO:0050671; P:positive regulation of lymphocyte proliferation; IDA:UniProtKB.
DR   GO; GO:0043382; P:positive regulation of memory T cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0032946; P:positive regulation of mononuclear cell proliferation; IMP:AgBase.
DR   GO; GO:0032816; P:positive regulation of natural killer cell activation; IDA:UniProtKB.
DR   GO; GO:0002860; P:positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target; IDA:UniProtKB.
DR   GO; GO:0032819; P:positive regulation of natural killer cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0042346; P:positive regulation of NF-kappaB import into nucleus; TAS:BHF-UCL.
DR   GO; GO:0051135; P:positive regulation of NK T cell activation; IDA:BHF-UCL.
DR   GO; GO:0051142; P:positive regulation of NK T cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IDA:BHF-UCL.
DR   GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; ISS:BHF-UCL.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0002827; P:positive regulation of T-helper 1 type immune response; IDA:BHF-UCL.
DR   GO; GO:2000330; P:positive regulation of T-helper 17 cell lineage commitment; ISS:BHF-UCL.
DR   GO; GO:2000318; P:positive regulation of T-helper 17 type immune response; ISS:BHF-UCL.
DR   GO; GO:0034105; P:positive regulation of tissue remodeling; IC:BHF-UCL.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IMP:BHF-UCL.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; IDA:BHF-UCL.
DR   GO; GO:0042520; P:positive regulation of tyrosine phosphorylation of Stat4 protein; IDA:BHF-UCL.
DR   GO; GO:0042523; P:positive regulation of tyrosine phosphorylation of Stat5 protein; IDA:BHF-UCL.
DR   GO; GO:0042035; P:regulation of cytokine biosynthetic process; TAS:UniProtKB.
DR   GO; GO:0042510; P:regulation of tyrosine phosphorylation of Stat1 protein; IDA:BHF-UCL.
DR   GO; GO:0010224; P:response to UV-B; IDA:UniProtKB.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0019953; P:sexual reproduction; TAS:BHF-UCL.
DR   GO; GO:0042088; P:T-helper 1 type immune response; TAS:UniProtKB.
DR   GO; GO:0042093; P:T-helper cell differentiation; IDA:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR003530; Hematopoietin_rcpt_L_F3_CS.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR015528; IL-12_beta.
DR   InterPro; IPR019482; IL-12_beta_cen-dom.
DR   PANTHER; PTHR11321; PTHR11321; 1.
DR   Pfam; PF10420; IL12p40_C; 1.
DR   PIRSF; PIRSF038007; IL_12_beta; 1.
DR   PRINTS; PR01928; INTRLEUKN12B.
DR   SMART; SM00408; IGc2; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   PROSITE; PS50853; FN3; 1.
DR   PROSITE; PS01354; HEMATOPO_REC_L_F3; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytokine; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Immunoglobulin domain; Polymorphism;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     22       {ECO:0000269|PubMed:2204066}.
FT   CHAIN        23    328       Interleukin-12 subunit beta.
FT                                /FTId=PRO_0000010930.
FT   DOMAIN       23    106       Ig-like C2-type.
FT   DOMAIN      237    328       Fibronectin type-III.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   CARBOHYD    135    135       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    222    222       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:10899108}.
FT   CARBOHYD    319    319       C-linked (Man).
FT                                {ECO:0000269|PubMed:10207176}.
FT                                /FTId=CAR_000187.
FT   DISULFID     50     90       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:10899108}.
FT   DISULFID    131    142       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:10899108}.
FT   DISULFID    170    193       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:10899108}.
FT   DISULFID    199    199       Interchain (with C-96 in IL12A).
FT                                {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:10899108}.
FT   DISULFID    300    327       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:10899108}.
FT   VARIANT      33     33       V -> I (in dbSNP:rs3213096).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_020001.
FT   VARIANT     298    298       V -> F (in dbSNP:rs3213119).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_049170.
FT   CONFLICT    239    239       K -> N (in Ref. 2; AAA59938).
FT                                {ECO:0000305}.
FT   STRAND       24     27       {ECO:0000244|PDB:4OE8}.
FT   STRAND       30     36       {ECO:0000244|PDB:4OE8}.
FT   STRAND       44     49       {ECO:0000244|PDB:4OE8}.
FT   STRAND       51     53       {ECO:0000244|PDB:4OE8}.
FT   STRAND       59     62       {ECO:0000244|PDB:4OE8}.
FT   STRAND       70     79       {ECO:0000244|PDB:4OE8}.
FT   HELIX        82     84       {ECO:0000244|PDB:4OE8}.
FT   STRAND       86     92       {ECO:0000244|PDB:4OE8}.
FT   STRAND       95    108       {ECO:0000244|PDB:4OE8}.
FT   STRAND      116    118       {ECO:0000244|PDB:3D87}.
FT   STRAND      122    126       {ECO:0000244|PDB:4OE8}.
FT   STRAND      130    147       {ECO:0000244|PDB:4OE8}.
FT   STRAND      150    160       {ECO:0000244|PDB:4OE8}.
FT   STRAND      162    164       {ECO:0000244|PDB:4OE8}.
FT   STRAND      166    170       {ECO:0000244|PDB:4OE8}.
FT   STRAND      174    195       {ECO:0000244|PDB:4OE8}.
FT   STRAND      200    202       {ECO:0000244|PDB:3D87}.
FT   STRAND      208    216       {ECO:0000244|PDB:4OE8}.
FT   STRAND      219    227       {ECO:0000244|PDB:4OE8}.
FT   HELIX       229    232       {ECO:0000244|PDB:4OE8}.
FT   STRAND      239    245       {ECO:0000244|PDB:4OE8}.
FT   STRAND      249    257       {ECO:0000244|PDB:4OE8}.
FT   STRAND      260    262       {ECO:0000244|PDB:3HMX}.
FT   TURN        266    268       {ECO:0000244|PDB:4OE8}.
FT   STRAND      271    278       {ECO:0000244|PDB:4OE8}.
FT   STRAND      287    299       {ECO:0000244|PDB:4OE8}.
FT   STRAND      305    315       {ECO:0000244|PDB:4OE8}.
FT   STRAND      323    326       {ECO:0000244|PDB:4OE8}.
SQ   SEQUENCE   328 AA;  37169 MW;  118FA801B8F5BB2F CRC64;
     MCHQQLVISW FSLVFLASPL VAIWELKKDV YVVELDWYPD APGEMVVLTC DTPEEDGITW
     TLDQSSEVLG SGKTLTIQVK EFGDAGQYTC HKGGEVLSHS LLLLHKKEDG IWSTDILKDQ
     KEPKNKTFLR CEAKNYSGRF TCWWLTTIST DLTFSVKSSR GSSDPQGVTC GAATLSAERV
     RGDNKEYEYS VECQEDSACP AAEESLPIEV MVDAVHKLKY ENYTSSFFIR DIIKPDPPKN
     LQLKPLKNSR QVEVSWEYPD TWSTPHSYFS LTFCVQVQGK SKREKKDRVF TDKTSATVIC
     RKNASISVRA QDRYYSSSWS EWASVPCS
//
ID   ASM_HUMAN               Reviewed;         629 AA.
AC   P17405; A8K8M3; E9PKS3; P17406; Q13811; Q16837; Q16841;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   03-MAR-2009, sequence version 4.
DT   20-JAN-2016, entry version 180.
DE   RecName: Full=Sphingomyelin phosphodiesterase;
DE            EC=3.1.4.12;
DE   AltName: Full=Acid sphingomyelinase;
DE            Short=aSMase;
DE   Flags: Precursor;
GN   Name=SMPD1; Synonyms=ASM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING, AND VARIANTS ILE-322
RP   AND ARG-506.
RX   PubMed=1840600;
RA   Schuchman E.H., Suchi M., Takahashi T., Sandhoff K., Desnick R.J.;
RT   "Human acid sphingomyelinase. Isolation, nucleotide sequence and
RT   expression of the full-length and alternatively spliced cDNAs.";
RL   J. Biol. Chem. 266:8531-8539(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-506.
RX   PubMed=1292508;
RA   Newrzella D., Stoffel W.;
RT   "Molecular cloning of the acid sphingomyelinase of the mouse and the
RT   organization and complete nucleotide sequence of the gene.";
RL   Biol. Chem. Hoppe-Seyler 373:1233-1238(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-36.
RX   PubMed=1740330; DOI=10.1016/0888-7543(92)90366-Z;
RA   Schuchman E.H., Levran O., Pereira L.V., Desnick R.J.;
RT   "Structural organization and complete nucleotide sequence of the gene
RT   encoding human acid sphingomyelinase (SMPD1).";
RL   Genomics 12:197-205(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-157.
RX   PubMed=8407868;
RA   Ida H., Rennert O.M., Eto Y., Chan W.Y.;
RT   "Cloning of a human acid sphingomyelinase cDNA with a new mutation
RT   that renders the enzyme inactive.";
RL   J. Biochem. 114:15-20(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND VARIANT
RP   ARG-506.
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 128-629, PARTIAL PROTEIN
RP   SEQUENCE, ALTERNATIVE SPLICING, AND VARIANTS ILE-322 AND ARG-506.
RC   TISSUE=Fibroblast;
RX   PubMed=2555181;
RA   Quintern L.E., Schuchman E.H., Levran O., Suchi M., Ferlinz K.,
RA   Reinke H., Sandhoff K., Desnick R.J.;
RT   "Isolation of cDNA clones encoding human acid sphingomyelinase:
RT   occurrence of alternatively processed transcripts.";
RL   EMBO J. 8:2469-2473(1989).
RN   [8]
RP   GLYCOSYLATION AT ASN-86; ASN-175; ASN-335; ASN-395 AND ASN-520.
RX   PubMed=9030779; DOI=10.1111/j.1432-1033.1997.511_1a.x;
RA   Ferlinz K., Hurwitz R., Moczall H., Lansmann S., Schuchman E.H.,
RA   Sandhoff K.;
RT   "Functional characterization of the N-glycosylation sites of human
RT   acid sphingomyelinase by site-directed mutagenesis.";
RL   Eur. J. Biochem. 243:511-517(1997).
RN   [9]
RP   DISULFIDE BONDS.
RX   PubMed=12631268; DOI=10.1046/j.1432-1033.2003.03435.x;
RA   Lansmann S., Schuette C.G., Bartelsen O., Hoernschemeyer J., Linke T.,
RA   Weisgerber J., Sandhoff K.;
RT   "Human acid sphingomyelinase.";
RL   Eur. J. Biochem. 270:1076-1088(2003).
RN   [10]
RP   POLYMORPHISM.
RX   PubMed=18088425; DOI=10.1186/1471-2350-8-79;
RA   Dastani Z., Ruel I.L., Engert J.C., Genest J. Jr., Marcil M.;
RT   "Sphingomyelin phosphodiesterase-1 (SMPD1) coding variants do not
RT   contribute to low levels of high-density lipoprotein cholesterol.";
RL   BMC Med. Genet. 8:79-79(2007).
RN   [11]
RP   VARIANT NPDA SER-577.
RX   PubMed=1718266; DOI=10.1016/0006-291X(91)91697-B;
RA   Ferlinz K., Hurwitz R., Sandhoff K.;
RT   "Molecular basis of acid sphingomyelinase deficiency in a patient with
RT   Niemann-Pick disease type A.";
RL   Biochem. Biophys. Res. Commun. 179:1187-1191(1991).
RN   [12]
RP   VARIANT NPDA LEU-496.
RX   PubMed=2023926; DOI=10.1073/pnas.88.9.3748;
RA   Levran O., Desnick R.J., Schuchman E.H.;
RT   "Niemann-Pick disease: a frequent missense mutation in the acid
RT   sphingomyelinase gene of Ashkenazi Jewish type A and B patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:3748-3752(1991).
RN   [13]
RP   VARIANT NPDB ARG-608 DEL.
RX   PubMed=1885770; DOI=10.1172/JCI115380;
RA   Levran O., Desnick R.J., Schuchman E.H.;
RT   "Niemann-Pick type B disease. Identification of a single codon
RT   deletion in the acid sphingomyelinase gene and genotype/phenotype
RT   correlations in type A and B patients.";
RL   J. Clin. Invest. 88:806-810(1991).
RN   [14]
RP   VARIANT NPDA PRO-302.
RX   PubMed=1391960;
RA   Levran O., Desnick R.J., Schuchman E.H.;
RT   "Identification and expression of a common missense mutation (L302P)
RT   in the acid sphingomyelinase gene of Ashkenazi Jewish type A Niemann-
RT   Pick disease patients.";
RL   Blood 80:2081-2087(1992).
RN   [15]
RP   VARIANT NPDB ARG-436.
RX   PubMed=1301192; DOI=10.1002/humu.1380010111;
RA   Takahashi T., Desnick R.J., Takada G., Schuchman E.H.;
RT   "Identification of a missense mutation (S436R) in the acid
RT   sphingomyelinase gene from a Japanese patient with type B Niemann-Pick
RT   disease.";
RL   Hum. Mutat. 1:70-71(1992).
RN   [16]
RP   VARIANT NPDA ILE-382, AND VARIANTS NPDB ARG-242 AND SER-383.
RX   PubMed=1618760;
RA   Takahashi T., Suchi M., Desnick R.J., Takada G., Schuchman E.H.;
RT   "Identification and expression of five mutations in the human acid
RT   sphingomyelinase gene causing types A and B Niemann-Pick disease.
RT   Molecular evidence for genetic heterogeneity in the neuronopathic and
RT   non-neuronopathic forms.";
RL   J. Biol. Chem. 267:12552-12558(1992).
RN   [17]
RP   VARIANT NPDB GLY-391.
RX   PubMed=8051942; DOI=10.1007/BF00735404;
RA   Sperl W., Bart G., Vanier M.T., Christomanou H., Baldissera I.,
RA   Steichensdorf E., Paschke E.;
RT   "A family with visceral course of Niemann-Pick disease, macular halo
RT   syndrome and low sphingomyelin degradation rate.";
RL   J. Inherit. Metab. Dis. 17:93-103(1994).
RN   [18]
RP   VARIANT NPDA THR-389.
RX   PubMed=8680412; DOI=10.1002/humu.1380060412;
RA   Schuchman E.H.;
RT   "Two new mutations in the acid sphingomyelinase gene causing type A
RT   Niemann-pick disease: N389T and R441X.";
RL   Hum. Mutat. 6:352-354(1995).
RN   [19]
RP   VARIANT NPDA CYS-446.
RX   PubMed=8693491; DOI=10.1620/tjem.177.117;
RA   Takahashi T., Suchi M., Sato W., Ten S.B., Sakuragawa N.,
RA   Desnick R.J., Schuchman E.H., Takada G.;
RT   "Identification and expression of a missense mutation (Y446C) in the
RT   acid sphingomyelinase gene from a Japanese patient with type A
RT   Niemann-Pick disease.";
RL   Tohoku J. Exp. Med. 177:117-123(1995).
RN   [20]
RP   VARIANT NPDB GLN-246.
RX   PubMed=8664904;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:1<65::AID-HUMU10>3.3.CO;2-8;
RA   Ida H., Rennert O.M., Maekawa K., Eto Y.;
RT   "Identification of three novel mutations in the acid sphingomyelinase
RT   gene of Japanese patients with Niemann-Pick disease type A and B.";
RL   Hum. Mutat. 7:65-67(1996).
RN   [21]
RP   VARIANTS NPDA LYS-292 AND PRO-341.
RX   PubMed=9266408; DOI=10.1023/A:1005387932546;
RA   Pavluu H., Elleder M.;
RT   "Two novel mutations in patients with atypical phenotypes of acid
RT   sphingomyelinase deficiency.";
RL   J. Inherit. Metab. Dis. 20:615-616(1997).
RN   [22]
RP   VARIANTS NPDB VAL-49; TRP-92; PRO-137; ARG-157; PRO-196; CYS-200;
RP   MET-225; CYS-228; ASP-232; SER-245; ARG-248; HIS-289; ALA-323;
RP   ARG-330; ASP-357; HIS-376; LEU-376; PRO-379; VAL-413; TYR-421;
RP   ARG-431; PRO-432; CYS-435; VAL-452; ASP-456; TRP-474; LEU-475;
RP   LEU-480; VAL-485; ASN-488; SER-494; CYS-496; GLN-514; VAL-515;
RP   ARG-533; PRO-549; ASN-576; HIS-600 AND PRO-600.
RX   PubMed=12369017; DOI=10.1086/345074;
RA   Simonaro C.M., Desnick R.J., McGovern M.M., Wasserstein M.P.,
RA   Schuchman E.H.;
RT   "The demographics and distribution of type B Niemann-Pick disease:
RT   novel mutations lead to new genotype/phenotype correlations.";
RL   Am. J. Hum. Genet. 71:1413-1419(2002).
RN   [23]
RP   VARIANTS NPDA ARG-248; TYR-319; SER-463; LEU-475 AND HIS-537, AND
RP   VARIANTS NPDB SER-371 AND ARG-608 DEL.
RX   PubMed=12556236; DOI=10.1046/j.1469-1809.2003.00009.x;
RA   Sikora J., Pavluu-Pereira H., Elleder M., Roelofs H., Wevers R.A.;
RT   "Seven novel Acid sphingomyelinase gene mutations in Niemann-Pick type
RT   A and B patients.";
RL   Ann. Hum. Genet. 67:63-70(2003).
RN   [24]
RP   VARIANTS NPDA PRO-103; SER-245; LYS-246; GLN-294; HIS-313; PRO-450;
RP   LEU-475; LEU-496; HIS-496 AND CYS-517.
RX   PubMed=15221801; DOI=10.1002/humu.9258;
RA   Ricci V., Stroppiano M., Corsolini F., Di Rocco M., Parenti G.,
RA   Regis S., Grossi S., Biancheri R., Mazzotti R., Filocamo M.;
RT   "Screening of 25 Italian patients with Niemann-Pick A reveals fourteen
RT   new mutations, one common and thirteen private, in SMPD1.";
RL   Hum. Mutat. 24:105-105(2004).
RN   [25]
RP   VARIANTS NPDB PRO-103; PRO-225; CYS-244; THR-281; LYS-292 AND ILE-382.
RX   PubMed=15241805; DOI=10.1002/humu.9263;
RA   Pittis M.G., Ricci V., Guerci V.I., Marcais C., Ciana G., Dardis A.,
RA   Gerin F., Stroppiano M., Vanier M.T., Filocamo M., Bembi B.;
RT   "Acid sphingomyelinase: identification of nine novel mutations among
RT   Italian Niemann Pick type B patients and characterization of in vivo
RT   functional in-frame start codon.";
RL   Hum. Mutat. 24:186-187(2004).
RN   [26]
RP   VARIANTS NPDB ALA-130 AND TYR-563, AND CHARACTERIZATION OF VARIANTS
RP   NPDB PRO-103; ALA-130; PRO-225; CYS-244; THR-281; TYR-563; HIS-600 AND
RP   PRO-600.
RX   PubMed=16010684; DOI=10.1002/humu.9353;
RA   Dardis A., Zampieri S., Filocamo M., Burlina A., Bembi B.,
RA   Pittis M.G.;
RT   "Functional in vitro characterization of 14 SMPD1 mutations identified
RT   in Italian patients affected by Niemann Pick type B disease.";
RL   Hum. Mutat. 26:164-164(2005).
RN   [27]
RP   VARIANTS NPDA ARG-166; LEU-184; HIS-228; VAL-241; ARG-248; GLU-251;
RP   ALA-278; HIS-289; LYS-292; PRO-341; HIS-376; TRP-474; ARG-533 AND
RP   SER-577, AND VARIANT ARG-506.
RX   PubMed=15877209; DOI=10.1007/s10545-005-5671-5;
RA   Pavluu-Pereira H., Asfaw B., Poupctova H., Ledvinova J., Sikora J.,
RA   Vanier M.T., Sandhoff K., Zeman J., Novotna Z., Chudoba D.,
RA   Elleder M.;
RT   "Acid sphingomyelinase deficiency. Phenotype variability with
RT   prevalence of intermediate phenotype in a series of twenty-five Czech
RT   and Slovak patients. A multi-approach study.";
RL   J. Inherit. Metab. Dis. 28:203-227(2005).
RN   [28]
RP   VARIANTS NPDB ARG-166 AND ASN-176, AND VARIANT GLY-505.
RX   PubMed=16472269; DOI=10.1111/j.1445-5994.2005.01013.x;
RA   Muessig K., Harzer K., Mayrhofer H., Kraegeloh-Mann I., Haering H.-U.,
RA   Machicao F.;
RT   "Clinical findings in Niemann-Pick disease type B.";
RL   Intern. Med. J. 36:135-136(2006).
RN   [29]
RP   VARIANTS NPDB ARG-330 AND ASP-451.
RX   PubMed=19050888; DOI=10.1007/s00277-008-0648-8;
RA   Lan M.Y., Lin S.J., Chen Y.F., Peng C.H., Liu Y.F.;
RT   "A novel missense mutation of the SMPD1 gene in a Taiwanese patient
RT   with type B Niemann-Pick disease.";
RL   Ann. Hematol. 88:695-697(2009).
RN   [30]
RP   VARIANTS NPDA SER-245; CYS-367; PHE-390 DEL; ARG-421; SER-467; GLU-482
RP   AND THR-592 DEL, AND VARIANTS NPDB CYS-228; HIS-376; TRP-474; ALA-486
RP   AND ARG-608 DEL.
RX   PubMed=19405096; DOI=10.1002/humu.21018;
RA   Rodriguez-Pascau L., Gort L., Schuchman E.H., Vilageliu L.,
RA   Grinberg D., Chabas A.;
RT   "Identification and characterization of SMPD1 mutations causing
RT   Niemann-Pick types A and B in Spanish patients.";
RL   Hum. Mutat. 30:1117-1122(2009).
RN   [31]
RP   VARIANTS NPDA ARG-209 AND HIS-251, VARIANTS NPDB MET-312; ARG-425 AND
RP   HIS-523, CHARACTERIZATION OF VARIANTS NPDA ARG-209 AND HIS-251, AND
RP   CHARACTERIZATION OF VARIANTS NPDB MET-312; ARG-425 AND HIS-523.
RX   PubMed=20386867; DOI=10.2119/molmed.2010.00017;
RA   Desnick J.P., Kim J., He X., Wasserstein M.P., Simonaro C.M.,
RA   Schuchman E.H.;
RT   "Identification and characterization of eight novel SMPD1 mutations
RT   causing types A and B Niemann-Pick disease.";
RL   Mol. Med. 16:316-321(2010).
RN   [32]
RP   VARIANT NPDB SER-520.
RX   PubMed=22613662;
RA   Hua R., Wu H., Cui Z., Chen J.X., Wang Z.;
RT   "A novel SMPD1 mutation in two Chinese sibling patients with type B
RT   Niemann-Pick disease.";
RL   Chin. Med. J. 125:1511-1512(2012).
CC   -!- FUNCTION: Converts sphingomyelin to ceramide. Also has
CC       phospholipase C activities toward 1,2-diacylglycerolphosphocholine
CC       and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3
CC       have lost catalytic activity.
CC   -!- CATALYTIC ACTIVITY: Sphingomyelin + H(2)O = N-acylsphingosine +
CC       phosphocholine.
CC   -!- SUBUNIT: Monomer.
CC   -!- INTERACTION:
CC       P55210:CASP7; NbExp=6; IntAct=EBI-7095800, EBI-523958;
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=ASM-1;
CC         IsoId=P17405-1; Sequence=Displayed;
CC         Note=Most abundant (90%).;
CC       Name=2; Synonyms=ASM-2;
CC         IsoId=P17405-2; Sequence=VSP_000331, VSP_000332;
CC         Note=Intermediate abundance (10%).;
CC       Name=3; Synonyms=ASM-3;
CC         IsoId=P17405-3; Sequence=VSP_000333;
CC         Note=Low abundance (<1%).;
CC       Name=4;
CC         IsoId=P17405-4; Sequence=VSP_046964;
CC   -!- POLYMORPHISM: A common polymorphism arises from a variable number
CC       of hexanucleotide repeat sequence within the signal peptide
CC       region.
CC   -!- DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early-
CC       onset lysosomal storage disorder caused by failure to hydrolyze
CC       sphingomyelin to ceramide. It results in the accumulation of
CC       sphingomyelin and other metabolically related lipids in
CC       reticuloendothelial and other cell types throughout the body,
CC       leading to cell death. Niemann-Pick disease type A is a primarily
CC       neurodegenerative disorder characterized by onset within the first
CC       year of life, mental retardation, digestive disorders, failure to
CC       thrive, major hepatosplenomegaly, and severe neurologic symptoms.
CC       The severe neurological disorders and pulmonary infections lead to
CC       an early death, often around the age of four. Clinical features
CC       are variable. A phenotypic continuum exists between type A (basic
CC       neurovisceral) and type B (purely visceral) forms of Niemann-Pick
CC       disease, and the intermediate types encompass a cluster of
CC       variants combining clinical features of both types A and B.
CC       {ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960,
CC       ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209,
CC       ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266,
CC       ECO:0000269|PubMed:19405096, ECO:0000269|PubMed:2023926,
CC       ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:8680412,
CC       ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onset
CC       lysosomal storage disorder caused by failure to hydrolyze
CC       sphingomyelin to ceramide. It results in the accumulation of
CC       sphingomyelin and other metabolically related lipids in
CC       reticuloendothelial and other cell types throughout the body,
CC       leading to cell death. Clinical signs involve only visceral
CC       organs. The most constant sign is hepatosplenomegaly which can be
CC       associated with pulmonary symptoms. Patients remain free of
CC       neurologic manifestations. However, a phenotypic continuum exists
CC       between type A (basic neurovisceral) and type B (purely visceral)
CC       forms of Niemann-Pick disease, and the intermediate types
CC       encompass a cluster of variants combining clinical features of
CC       both types A and B. In Niemann-Pick disease type B, onset of the
CC       first symptoms occurs in early childhood and patients can survive
CC       into adulthood. {ECO:0000269|PubMed:12369017,
CC       ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192,
CC       ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684,
CC       ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269,
CC       ECO:0000269|PubMed:1885770, ECO:0000269|PubMed:19050888,
CC       ECO:0000269|PubMed:19405096, ECO:0000269|PubMed:20386867,
CC       ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:8051942,
CC       ECO:0000269|PubMed:8664904}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: There are two types of sphingomyelinases: ASM
CC       (acid), and NSM (neutral).
CC   -!- SIMILARITY: Belongs to the acid sphingomyelinase family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 saposin B-type domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00415}.
CC   -!- WEB RESOURCE: Name=Mendelian genes sphingomyelin phosphodiesterase
CC       1, acid lysosomal (SMPD1); Note=Leiden Open Variation Database
CC       (LOVD);
CC       URL="http://www.lovd.nl/SMPD1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M59916; AAA58377.1; -; mRNA.
DR   EMBL; M59917; AAA58378.1; -; Genomic_DNA.
DR   EMBL; X63600; CAA45145.1; -; Genomic_DNA.
DR   EMBL; M81780; AAA75008.1; -; Genomic_DNA.
DR   EMBL; M81780; AAA75009.1; -; Genomic_DNA.
DR   EMBL; X59960; CAA42584.1; -; mRNA.
DR   EMBL; AK292388; BAF85077.1; -; mRNA.
DR   EMBL; AC068733; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X52678; CAA36901.1; -; mRNA.
DR   EMBL; X52679; CAA36902.1; -; mRNA.
DR   PIR; S06958; S06958.
DR   PIR; S27009; A39825.
DR   RefSeq; NP_000534.3; NM_000543.4.
DR   RefSeq; NP_001007594.2; NM_001007593.2.
DR   UniGene; Hs.498173; -.
DR   ProteinModelPortal; P17405; -.
DR   BioGrid; 112493; 14.
DR   IntAct; P17405; 7.
DR   MINT; MINT-3008689; -.
DR   STRING; 9606.ENSP00000340409; -.
DR   BindingDB; P17405; -.
DR   ChEMBL; CHEMBL2760; -.
DR   DrugBank; DB00381; Amlodipine.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01151; Desipramine.
DR   iPTMnet; P17405; -.
DR   PhosphoSite; P17405; -.
DR   BioMuta; SMPD1; -.
DR   DMDM; 224471897; -.
DR   MaxQB; P17405; -.
DR   PaxDb; P17405; -.
DR   PRIDE; P17405; -.
DR   DNASU; 6609; -.
DR   Ensembl; ENST00000342245; ENSP00000340409; ENSG00000166311.
DR   Ensembl; ENST00000527275; ENSP00000435350; ENSG00000166311.
DR   GeneID; 6609; -.
DR   KEGG; hsa:6609; -.
DR   CTD; 6609; -.
DR   GeneCards; SMPD1; -.
DR   GeneReviews; SMPD1; -.
DR   HGNC; HGNC:11120; SMPD1.
DR   HPA; HPA001823; -.
DR   MalaCards; SMPD1; -.
DR   MIM; 257200; phenotype.
DR   MIM; 607608; gene.
DR   MIM; 607616; phenotype.
DR   neXtProt; NX_P17405; -.
DR   Orphanet; 77292; Niemann-Pick disease type A.
DR   Orphanet; 77293; Niemann-Pick disease type B.
DR   PharmGKB; PA35969; -.
DR   eggNOG; KOG3770; Eukaryota.
DR   eggNOG; ENOG410YYPB; LUCA.
DR   HOVERGEN; HBG004288; -.
DR   InParanoid; P17405; -.
DR   KO; K12350; -.
DR   OrthoDB; EOG79PJP3; -.
DR   PhylomeDB; P17405; -.
DR   TreeFam; TF313674; -.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   ChiTaRS; SMPD1; human.
DR   GeneWiki; Sphingomyelin_phosphodiesterase_1; -.
DR   GenomeRNAi; 6609; -.
DR   NextBio; 25729; -.
DR   PRO; PR:P17405; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; P17405; -.
DR   CleanEx; HS_SMPD1; -.
DR   ExpressionAtlas; P17405; baseline and differential.
DR   Genevisible; P17405; HS.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0042599; C:lamellar body; IEA:Ensembl.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016798; F:hydrolase activity, acting on glycosyl bonds; IEA:UniProtKB-KW.
DR   GO; GO:0004767; F:sphingomyelin phosphodiesterase activity; TAS:ProtInc.
DR   GO; GO:0046513; P:ceramide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IMP:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IMP:BHF-UCL.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006665; P:sphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0006685; P:sphingomyelin catabolic process; IEA:InterPro.
DR   GO; GO:0006684; P:sphingomyelin metabolic process; TAS:ProtInc.
DR   GO; GO:0023021; P:termination of signal transduction; IMP:BHF-UCL.
DR   Gene3D; 1.10.225.10; -; 1.
DR   Gene3D; 3.60.21.10; -; 1.
DR   InterPro; IPR004843; Calcineurin-like_PHP_apaH.
DR   InterPro; IPR029052; Metallo-depent_PP-like.
DR   InterPro; IPR011001; Saposin-like.
DR   InterPro; IPR008139; SaposinB_dom.
DR   InterPro; IPR011160; Sphingomy_PDE.
DR   Pfam; PF00149; Metallophos; 1.
DR   PIRSF; PIRSF000948; Sphingomy_PDE; 1.
DR   SMART; SM00741; SapB; 1.
DR   SUPFAM; SSF47862; SSF47862; 1.
DR   SUPFAM; SSF56300; SSF56300; 1.
DR   PROSITE; PS50015; SAP_B; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Glycosidase;
KW   Hydrolase; Lysosome; Neurodegeneration; Niemann-Pick disease;
KW   Reference proteome; Signal.
FT   SIGNAL        1     46
FT   CHAIN        47    629       Sphingomyelin phosphodiesterase.
FT                                /FTId=PRO_0000002323.
FT   DOMAIN       85    169       Saposin B-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00415}.
FT   CARBOHYD     86     86       N-linked (GlcNAc...).
FT                                {ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:9030779}.
FT   CARBOHYD    175    175       N-linked (GlcNAc...).
FT                                {ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:9030779}.
FT   CARBOHYD    335    335       N-linked (GlcNAc...).
FT                                {ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:9030779}.
FT   CARBOHYD    395    395       N-linked (GlcNAc...).
FT                                {ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:9030779}.
FT   CARBOHYD    520    520       N-linked (GlcNAc...).
FT                                {ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:9030779}.
FT   DISULFID     89    165       {ECO:0000255|PROSITE-ProRule:PRU00415}.
FT   DISULFID     92    157       {ECO:0000255|PROSITE-ProRule:PRU00415}.
FT   DISULFID    120    131       {ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268}.
FT   DISULFID    221    226       {ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268}.
FT   DISULFID    227    250       {ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268}.
FT   DISULFID    385    431       {ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268}.
FT   DISULFID    584    588       {ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268}.
FT   DISULFID    594    607       {ECO:0000255|PROSITE-ProRule:PRU00415,
FT                                ECO:0000269|PubMed:12631268}.
FT   VAR_SEQ     104    104       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046964.
FT   VAR_SEQ     363    418       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_000333.
FT   VAR_SEQ     363    374       IGGFYALSPYPG -> YLSSVETQEGKR (in isoform
FT                                2). {ECO:0000305}.
FT                                /FTId=VSP_000331.
FT   VAR_SEQ     375    418       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_000332.
FT   VARIANT      36     36       V -> A (in dbSNP:rs1050228).
FT                                {ECO:0000269|PubMed:1740330}.
FT                                /FTId=VAR_038191.
FT   VARIANT      49     49       D -> V (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060870.
FT   VARIANT      92     92       C -> W (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060871.
FT   VARIANT     103    103       L -> P (in NPDA and NPDB; expresses
FT                                protein level comparable to wild-type
FT                                SMPD1 expressing cells; retains very low
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:15221801,
FT                                ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060872.
FT   VARIANT     130    130       V -> A (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains 13% residual enzyme
FT                                activity). {ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060873.
FT   VARIANT     137    137       L -> P (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060874.
FT   VARIANT     157    157       C -> R (in NPDB; seems to be less
FT                                active). {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:8407868}.
FT                                /FTId=VAR_011387.
FT   VARIANT     166    166       G -> R (in NPDB; also in patients with an
FT                                intermediate form).
FT                                {ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:16472269}.
FT                                /FTId=VAR_060875.
FT   VARIANT     176    176       I -> N (in NPDB).
FT                                {ECO:0000269|PubMed:16472269}.
FT                                /FTId=VAR_060876.
FT   VARIANT     184    184       P -> L (in NPDA; intermediate form with
FT                                clinical features of both Niemann-Pick
FT                                disease types A and B).
FT                                {ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060877.
FT   VARIANT     196    196       A -> P (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060878.
FT   VARIANT     200    200       R -> C (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060879.
FT   VARIANT     209    209       W -> R (in NPDA; results in less than
FT                                0.5% of wild-type activity).
FT                                {ECO:0000269|PubMed:20386867}.
FT                                /FTId=VAR_068435.
FT   VARIANT     225    225       L -> M (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains no enzyme activity).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060880.
FT   VARIANT     225    225       L -> P (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains no enzyme activity).
FT                                {ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060881.
FT   VARIANT     228    228       R -> C (in NPDB).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060882.
FT   VARIANT     228    228       R -> H (in NPDA; intermediate form with
FT                                clinical features of both Niemann-Pick
FT                                disease types A and B).
FT                                {ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060883.
FT   VARIANT     232    232       G -> D (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060884.
FT   VARIANT     241    241       A -> V (in NPDA; intermediate form with
FT                                clinical features of both Niemann-Pick
FT                                disease types A and B).
FT                                {ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060885.
FT   VARIANT     242    242       G -> R (in NPDB).
FT                                {ECO:0000269|PubMed:1618760}.
FT                                /FTId=VAR_005058.
FT   VARIANT     244    244       W -> C (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains no enzyme activity).
FT                                {ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060886.
FT   VARIANT     245    245       G -> S (in NPDA and NPDB).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:15221801,
FT                                ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060887.
FT   VARIANT     246    246       E -> K (in NPDA).
FT                                {ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_060888.
FT   VARIANT     246    246       E -> Q (in NPDB; 30% residual activity).
FT                                {ECO:0000269|PubMed:8664904}.
FT                                /FTId=VAR_005059.
FT   VARIANT     248    248       S -> R (in NPDA and NPDB; also found in
FT                                patients with an intermediate form).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:12556236,
FT                                ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_015287.
FT   VARIANT     251    251       D -> E (in NPDA; intermediate form with
FT                                clinical features of both Niemann-Pick
FT                                disease types A and B).
FT                                {ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060889.
FT   VARIANT     251    251       D -> H (in NPDA; results in loss of
FT                                activity). {ECO:0000269|PubMed:20386867}.
FT                                /FTId=VAR_068436.
FT   VARIANT     278    278       D -> A (in NPDA; intermediate form with
FT                                clinical features of both Niemann-Pick
FT                                disease types A and B).
FT                                {ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060890.
FT   VARIANT     281    281       A -> T (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains no enzyme activity).
FT                                {ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060891.
FT   VARIANT     289    289       R -> H (in NPDB; also in patients with an
FT                                intermediate form).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060892.
FT   VARIANT     292    292       Q -> K (in NPDA; intermediate form with
FT                                clinical features of both Niemann-Pick
FT                                disease types A and B).
FT                                {ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:9266408}.
FT                                /FTId=VAR_060893.
FT   VARIANT     294    294       R -> Q (in NPDA).
FT                                {ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_060894.
FT   VARIANT     302    302       L -> P (in NPDA; in 23% of NPDA Ashkenazi
FT                                Jewish patients).
FT                                {ECO:0000269|PubMed:1391960}.
FT                                /FTId=VAR_005060.
FT   VARIANT     312    312       V -> M (in NPDB; results in 20% of wild-
FT                                type activity).
FT                                {ECO:0000269|PubMed:20386867}.
FT                                /FTId=VAR_068437.
FT   VARIANT     313    313       Y -> H (in NPDA).
FT                                {ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_060895.
FT   VARIANT     316    316       V -> E (in dbSNP:rs12575136).
FT                                /FTId=VAR_054642.
FT   VARIANT     319    319       H -> Y (in NPDA).
FT                                {ECO:0000269|PubMed:12556236}.
FT                                /FTId=VAR_015288.
FT   VARIANT     322    322       T -> I (in dbSNP:rs1050233).
FT                                {ECO:0000269|PubMed:1840600,
FT                                ECO:0000269|PubMed:2555181}.
FT                                /FTId=VAR_054643.
FT   VARIANT     323    323       P -> A (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060896.
FT   VARIANT     330    330       P -> R (in NPDB).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:19050888}.
FT                                /FTId=VAR_060897.
FT   VARIANT     341    341       L -> P (in NPDA; intermediate form with
FT                                clinical features of both Niemann-Pick
FT                                disease types A and B).
FT                                {ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:9266408}.
FT                                /FTId=VAR_060898.
FT   VARIANT     357    357       A -> D (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060899.
FT   VARIANT     367    367       Y -> C (in NPDA).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060900.
FT   VARIANT     371    371       P -> S (in NPDB).
FT                                {ECO:0000269|PubMed:12556236}.
FT                                /FTId=VAR_015289.
FT   VARIANT     376    376       R -> H (in NPDB; also found in a patient
FT                                with an intermediate form).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060901.
FT   VARIANT     376    376       R -> L (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060902.
FT   VARIANT     379    379       S -> P (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060903.
FT   VARIANT     382    382       M -> I (in NPDA and NPDB).
FT                                {ECO:0000269|PubMed:15241805,
FT                                ECO:0000269|PubMed:1618760}.
FT                                /FTId=VAR_005061.
FT   VARIANT     383    383       N -> S (in NPDB).
FT                                {ECO:0000269|PubMed:1618760}.
FT                                /FTId=VAR_005062.
FT   VARIANT     389    389       N -> T (in NPDA).
FT                                {ECO:0000269|PubMed:8680412}.
FT                                /FTId=VAR_005063.
FT   VARIANT     390    390       Missing (in NPDA).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060904.
FT   VARIANT     391    391       W -> G (in NPDB; low sphingomyelin
FT                                degradation rates).
FT                                {ECO:0000269|PubMed:8051942}.
FT                                /FTId=VAR_005064.
FT   VARIANT     413    413       A -> V (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060905.
FT   VARIANT     421    421       H -> R (in NPDA).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060906.
FT   VARIANT     421    421       H -> Y (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_015290.
FT   VARIANT     425    425       H -> R (in NPDB; results in loss of
FT                                activity; the patient also carries
FT                                mutation H-228 that has sufficient
FT                                activity to account for the Niemann-Pick
FT                                disease type B phenotype).
FT                                {ECO:0000269|PubMed:20386867}.
FT                                /FTId=VAR_068438.
FT   VARIANT     431    431       C -> R (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060907.
FT   VARIANT     432    432       L -> P (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060908.
FT   VARIANT     435    435       W -> C (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060909.
FT   VARIANT     436    436       S -> R (in NPDB).
FT                                {ECO:0000269|PubMed:1301192}.
FT                                /FTId=VAR_005065.
FT   VARIANT     446    446       Y -> C (in NPDA).
FT                                {ECO:0000269|PubMed:8693491}.
FT                                /FTId=VAR_011388.
FT   VARIANT     450    450       L -> P (in NPDA).
FT                                {ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_060910.
FT   VARIANT     451    451       A -> D (in NPDB).
FT                                {ECO:0000269|PubMed:19050888}.
FT                                /FTId=VAR_068439.
FT   VARIANT     452    452       A -> V (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060911.
FT   VARIANT     456    456       G -> D (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060912.
FT   VARIANT     463    463       F -> S (in NPDA).
FT                                {ECO:0000269|PubMed:12556236}.
FT                                /FTId=VAR_015291.
FT   VARIANT     467    467       Y -> S (in NPDA).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060913.
FT   VARIANT     474    474       R -> W (in NPDB; also in a patient with
FT                                an intermediate form).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060914.
FT   VARIANT     475    475       P -> L (in NPDA and NPDB).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:12556236,
FT                                ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_015292.
FT   VARIANT     480    480       F -> L (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060915.
FT   VARIANT     482    482       A -> E (in NPDA).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060916.
FT   VARIANT     485    485       A -> V (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060917.
FT   VARIANT     486    486       T -> A (in NPDB).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060918.
FT   VARIANT     488    488       Y -> N (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060919.
FT   VARIANT     494    494       G -> S (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060920.
FT   VARIANT     496    496       R -> C (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060921.
FT   VARIANT     496    496       R -> H (in NPDA).
FT                                {ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_060922.
FT   VARIANT     496    496       R -> L (in NPDA; in 32% of NPDA Ashkenazi
FT                                Jewish patients).
FT                                {ECO:0000269|PubMed:15221801,
FT                                ECO:0000269|PubMed:2023926}.
FT                                /FTId=VAR_005066.
FT   VARIANT     505    505       S -> G. {ECO:0000269|PubMed:16472269}.
FT                                /FTId=VAR_060923.
FT   VARIANT     506    506       G -> R (in dbSNP:rs1050239).
FT                                {ECO:0000269|PubMed:1292508,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:1840600,
FT                                ECO:0000269|PubMed:2555181}.
FT                                /FTId=VAR_054644.
FT   VARIANT     514    514       H -> Q (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060924.
FT   VARIANT     515    515       E -> V (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060925.
FT   VARIANT     517    517       Y -> C (in NPDA).
FT                                {ECO:0000269|PubMed:15221801}.
FT                                /FTId=VAR_060926.
FT   VARIANT     520    520       N -> S (in NPDB).
FT                                {ECO:0000269|PubMed:22613662}.
FT                                /FTId=VAR_068440.
FT   VARIANT     523    523       Q -> H (in NPDB; results in 64% of wild-
FT                                type activity).
FT                                {ECO:0000269|PubMed:20386867}.
FT                                /FTId=VAR_068441.
FT   VARIANT     533    533       W -> R (in NPDB; also in patients with an
FT                                intermediate form).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:15877209}.
FT                                /FTId=VAR_060927.
FT   VARIANT     537    537       Y -> H (in NPDA).
FT                                {ECO:0000269|PubMed:12556236}.
FT                                /FTId=VAR_015293.
FT   VARIANT     549    549       L -> P (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060928.
FT   VARIANT     563    563       D -> Y (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains 6.8% residual enzyme
FT                                activity). {ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060929.
FT   VARIANT     576    576       K -> N (in NPDB).
FT                                {ECO:0000269|PubMed:12369017}.
FT                                /FTId=VAR_060930.
FT   VARIANT     577    577       G -> S (in NPDA; also in patients with an
FT                                intermediate form).
FT                                {ECO:0000269|PubMed:15877209,
FT                                ECO:0000269|PubMed:1718266}.
FT                                /FTId=VAR_005067.
FT   VARIANT     592    592       Missing (in NPDA).
FT                                {ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_060931.
FT   VARIANT     600    600       R -> H (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains about 10% residual enzyme
FT                                activity). {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060932.
FT   VARIANT     600    600       R -> P (in NPDB; expresses protein level
FT                                comparable to wild-type SMPD1 expressing
FT                                cells; retains very low enzyme activity).
FT                                {ECO:0000269|PubMed:12369017,
FT                                ECO:0000269|PubMed:16010684}.
FT                                /FTId=VAR_060933.
FT   VARIANT     608    608       Missing (in NPDB; prevalent among NPDB
FT                                patients from the North African Maghreb
FT                                region). {ECO:0000269|PubMed:12556236,
FT                                ECO:0000269|PubMed:1885770,
FT                                ECO:0000269|PubMed:19405096}.
FT                                /FTId=VAR_005068.
FT   CONFLICT     35     36       Missing (in Ref. 4; CAA42584).
FT                                {ECO:0000305}.
FT   CONFLICT    268    268       G -> D (in Ref. 5; BAF85077).
FT                                {ECO:0000305}.
SQ   SEQUENCE   629 AA;  69752 MW;  C9888CB8359C42AC CRC64;
     MPRYGASLRQ SCPRSGREQG QDGTAGAPGL LWMGLVLALA LALALALSDS RVLWAPAEAH
     PLSPQGHPAR LHRIVPRLRD VFGWGNLTCP ICKGLFTAIN LGLKKEPNVA RVGSVAIKLC
     NLLKIAPPAV CQSIVHLFED DMVEVWRRSV LSPSEACGLL LGSTCGHWDI FSSWNISLPT
     VPKPPPKPPS PPAPGAPVSR ILFLTDLHWD HDYLEGTDPD CADPLCCRRG SGLPPASRPG
     AGYWGEYSKC DLPLRTLESL LSGLGPAGPF DMVYWTGDIP AHDVWHQTRQ DQLRALTTVT
     ALVRKFLGPV PVYPAVGNHE STPVNSFPPP FIEGNHSSRW LYEAMAKAWE PWLPAEALRT
     LRIGGFYALS PYPGLRLISL NMNFCSRENF WLLINSTDPA GQLQWLVGEL QAAEDRGDKV
     HIIGHIPPGH CLKSWSWNYY RIVARYENTL AAQFFGHTHV DEFEVFYDEE TLSRPLAVAF
     LAPSATTYIG LNPGYRVYQI DGNYSGSSHV VLDHETYILN LTQANIPGAI PHWQLLYRAR
     ETYGLPNTLP TAWHNLVYRM RGDMQLFQTF WFLYHKGHPP SEPCGTPCRL ATLCAQLSAR
     ADSPALCRHL MPDGSLPEAQ SLWPRPLFC
//
ID   NTRK2_MOUSE             Reviewed;         821 AA.
AC   P15209; Q3TUF9; Q80WU0; Q91XJ9;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   17-FEB-2016, entry version 184.
DE   RecName: Full=BDNF/NT-3 growth factors receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=GP145-TrkB/GP95-TrkB;
DE            Short=Trk-B;
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 2;
DE   AltName: Full=TrkB tyrosine kinase;
DE   Flags: Precursor;
GN   Name=Ntrk2; Synonyms=Trkb;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GP145-TRKB).
RC   TISSUE=Brain;
RX   PubMed=2555172;
RA   Klein R., Parada L.F., Coulier F., Barbacid M.;
RT   "trkB, a novel tyrosine protein kinase receptor expressed during mouse
RT   neural development.";
RL   EMBO J. 8:3701-3709(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GP145-TRKB AND GP95-TRKB).
RC   TISSUE=Brain;
RX   PubMed=2160854; DOI=10.1016/0092-8674(90)90476-U;
RA   Klein R., Conway D., Parada L.F., Barbacid M.;
RT   "The trkB tyrosine protein kinase gene codes for a second neurogenic
RT   receptor that lacks the catalytic kinase domain.";
RL   Cell 61:647-656(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS GP145-TRKB AND
RP   GP95-TRKB).
RC   STRAIN=C57BL/6J, and NOD; TISSUE=Thymus;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GP95-TRKB).
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PARTIAL NUCLEOTIDE SEQUENCE (ISOFORMS L1 AND L10).
RC   TISSUE=Trigeminal ganglion;
RX   PubMed=9148911; DOI=10.1074/jbc.272.20.13019;
RA   Ninkina N., Grashchuck M., Buchman V.L., Davies A.M.;
RT   "TrkB variants with deletions in the leucine-rich motifs of the
RT   extracellular domain.";
RL   J. Biol. Chem. 272:13019-13025(1997).
RN   [6]
RP   FUNCTION IN BDNF AND NTF3 SIGNALING.
RX   PubMed=1645620; DOI=10.1016/0092-8674(91)90396-G;
RA   Soppet D., Escandon E., Maragos J., Middlemas D.S., Reid S.W.,
RA   Blair J., Burton L.E., Stanton B.R., Kaplan D.R., Hunter T.,
RA   Nicolics K., Parada L.F.;
RT   "The neurotrophic factors brain-derived neurotrophic factor and
RT   neurotrophin-3 are ligands for the trkB tyrosine kinase receptor.";
RL   Cell 65:895-903(1991).
RN   [7]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=8402890; DOI=10.1016/S0092-8674(05)80088-1;
RA   Klein R., Smeyne R.J., Wurst W., Long L.K., Auerbach B.A.,
RA   Joyner A.L., Barbacid M.;
RT   "Targeted disruption of the trkB neurotrophin receptor gene results in
RT   nervous system lesions and neonatal death.";
RL   Cell 75:113-122(1993).
RN   [8]
RP   FUNCTION IN NTF3-MEDIATED NEURON SURVIVAL.
RX   PubMed=9728914; DOI=10.1016/S0896-6273(00)80542-5;
RA   Farinas I., Wilkinson G.A., Backus C., Reichardt L.F., Patapoutian A.;
RT   "Characterization of neurotrophin and Trk receptor functions in
RT   developing sensory ganglia: direct NT-3 activation of TrkB neurons in
RT   vivo.";
RL   Neuron 21:325-334(1998).
RN   [9]
RP   FUNCTION IN LONG-TERM POTENTIATION AND LEARNING.
RX   PubMed=10571233; DOI=10.1016/S0896-6273(00)80853-3;
RA   Minichiello L., Korte M., Wolfer D., Kuehn R., Unsicker K.,
RA   Cestari V., Rossi-Arnaud C., Lipp H.P., Bonhoeffer T., Klein R.;
RT   "Essential role for TrkB receptors in hippocampus-mediated learning.";
RL   Neuron 24:401-414(1999).
RN   [10]
RP   FUNCTION IN LONG-TERM POTENTIATION AND LEARNING, INTERACTION WITH SHC1
RP   AND PLCG1, AND MUTAGENESIS OF TYR-515 AND TYR-816.
RX   PubMed=12367511; DOI=10.1016/S0896-6273(02)00942-X;
RA   Minichiello L., Calella A.M., Medina D.L., Bonhoeffer T., Klein R.,
RA   Korte M.;
RT   "Mechanism of TrkB-mediated hippocampal long-term potentiation.";
RL   Neuron 36:121-137(2002).
RN   [11]
RP   SUBCELLULAR LOCATION, AND ENZYME REGULATION.
RX   PubMed=14581459; DOI=10.1083/jcb.200305134;
RA   Du J., Feng L., Zaitsev E., Je H.S., Liu X.W., Lu B.;
RT   "Regulation of TrkB receptor tyrosine kinase and its internalization
RT   by neuronal activity and Ca2+ influx.";
RL   J. Cell Biol. 163:385-395(2003).
RN   [12]
RP   FUNCTION IN CALCIUM SIGNALING (ISOFORM GP95-TRKB).
RX   PubMed=14603320; DOI=10.1038/nature01983;
RA   Rose C.R., Blum R., Pichler B., Lepier A., Kafitz K.W., Konnerth A.;
RT   "Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in
RT   glia cells.";
RL   Nature 426:74-78(2003).
RN   [13]
RP   FUNCTION IN NEURONAL MIGRATION AND DIFFERENTIATION.
RX   PubMed=15372074; DOI=10.1038/sj.emboj.7600399;
RA   Medina D.L., Sciarretta C., Calella A.M., Von Bohlen Und Halbach O.,
RA   Unsicker K., Minichiello L.;
RT   "TrkB regulates neocortex formation through the Shc/PLCgamma-mediated
RT   control of neuronal migration.";
RL   EMBO J. 23:3803-3814(2004).
RN   [14]
RP   FUNCTION AS A SUPPRESSOR OF ANOIKIS.
RX   PubMed=15329723; DOI=10.1038/nature02765;
RA   Douma S., Van Laar T., Zevenhoven J., Meuwissen R., Van Garderen E.,
RA   Peeper D.S.;
RT   "Suppression of anoikis and induction of metastasis by the
RT   neurotrophic receptor TrkB.";
RL   Nature 430:1034-1039(2004).
RN   [15]
RP   UBIQUITINATION, AND ENZYME REGULATION.
RX   PubMed=16113645; DOI=10.1038/sj.embor.7400503;
RA   Makkerh J.P., Ceni C., Auld D.S., Vaillancourt F., Dorval G.,
RA   Barker P.A.;
RT   "p75 neurotrophin receptor reduces ligand-induced Trk receptor
RT   ubiquitination and delays Trk receptor internalization and
RT   degradation.";
RL   EMBO Rep. 6:936-941(2005).
RN   [16]
RP   ENZYME REGULATION, AND INTERACTION WITH SH2D1A.
RX   PubMed=16223723; DOI=10.1074/jbc.M506554200;
RA   Lo K.Y., Chin W.H., Ng Y.P., Cheng A.W., Cheung Z.H., Ip N.Y.;
RT   "SLAM-associated protein as a potential negative regulator in Trk
RT   signaling.";
RL   J. Biol. Chem. 280:41744-41752(2005).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF TIAM1, FUNCTION IN CELL
RP   DIFFERENTIATION, AND INTERACTION WITH TIAM1.
RX   PubMed=16801538; DOI=10.1073/pnas.0603914103;
RA   Miyamoto Y., Yamauchi J., Tanoue A., Wu C., Mobley W.C.;
RT   "TrkB binds and tyrosine-phosphorylates Tiam1, leading to activation
RT   of Rac1 and induction of changes in cellular morphology.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10444-10449(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-515, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=18034455; DOI=10.1021/pr0701254;
RA   Ballif B.A., Carey G.R., Sunyaev S.R., Gygi S.P.;
RT   "Large-scale identification and evolution indexing of tyrosine
RT   phosphorylation sites from murine brain.";
RL   J. Proteome Res. 7:311-318(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [20]
RP   FUNCTION IN SYNAPSE FORMATION.
RX   PubMed=21414899; DOI=10.1523/JNEUROSCI.4991-10.2011;
RA   Chen A.I., Nguyen C.N., Copenhagen D.R., Badurek S., Minichiello L.,
RA   Ranscht B., Reichardt L.F.;
RT   "TrkB (tropomyosin-related kinase B) controls the assembly and
RT   maintenance of GABAergic synapses in the cerebellar cortex.";
RL   J. Neurosci. 31:2769-2780(2011).
RN   [21]
RP   INDUCTION.
RX   PubMed=23785138; DOI=10.1523/JNEUROSCI.2757-12.2013;
RA   Baeza-Raja B., Eckel-Mahan K., Zhang L., Vagena E., Tsigelny I.F.,
RA   Sassone-Corsi P., Ptacek L.J., Akassoglou K.;
RT   "p75 neurotrophin receptor is a clock gene that regulates oscillatory
RT   components of circadian and metabolic networks.";
RL   J. Neurosci. 33:10221-10234(2013).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in the development and
CC       the maturation of the central and the peripheral nervous systems
CC       through regulation of neuron survival, proliferation, migration,
CC       differentiation, and synapse formation and plasticity. Receptor
CC       for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-
CC       4. Alternatively can also bind NTF3/neurotrophin-3 which is less
CC       efficient in activating the receptor but regulates neuron survival
CC       through NTRK2. Upon ligand-binding, undergoes homodimerization,
CC       autophosphorylation and activation. Recruits, phosphorylates
CC       and/or activates several downstream effectors including SHC1,
CC       FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping
CC       signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the
CC       GRB2-Ras-MAPK cascade that regulates for instance neuronal
CC       differentiation including neurite outgrowth. Through the same
CC       effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that
CC       mainly regulates growth and survival. Through PLCG1 and the
CC       downstream protein kinase C-regulated pathways controls synaptic
CC       plasticity. Thereby, plays a role in learning and memory by
CC       regulating both short term synaptic function and long-term
CC       potentiation. PLCG1 also leads to NF-Kappa-B activation and the
CC       transcription of genes involved in cell survival. Hence, it is
CC       able to suppress anoikis, the apoptosis resulting from loss of
CC       cell-matrix interactions. Isoform GP95-TRKB may also play a role
CC       in neutrophin-dependent calcium signaling in glial cells and
CC       mediate communication between neurons and glia.
CC       {ECO:0000269|PubMed:10571233, ECO:0000269|PubMed:12367511,
CC       ECO:0000269|PubMed:15329723, ECO:0000269|PubMed:15372074,
CC       ECO:0000269|PubMed:1645620, ECO:0000269|PubMed:16801538,
CC       ECO:0000269|PubMed:21414899, ECO:0000269|PubMed:8402890,
CC       ECO:0000269|PubMed:9728914}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: The formation of active receptors dimers able
CC       to fully transduce the ligand-mediated signal, may be negatively
CC       regulated by the formation of inactive heterodimers with the non-
CC       catalytic isoforms (By similarity). The neuronal activity and the
CC       influx of calcium positively regulate the kinase activity and the
CC       internalization of the receptor which are both important for
CC       active signaling. Regulated by NGFR that may control the
CC       internalization of the receptor. NGFR may also stimulate the
CC       activation by BDNF compared to NTF3 and NTF4. SH2D1A inhibits the
CC       autophosphorylation of the receptor, and alters the recruitment
CC       and activation of downstream effectors and signaling cascades.
CC       {ECO:0000250, ECO:0000269|PubMed:14581459,
CC       ECO:0000269|PubMed:16113645, ECO:0000269|PubMed:16223723}.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures. Interacts
CC       (phosphorylated upon activation by BDNF) with SHC1; mediates SHC1
CC       phosphorylation and activation. Interacts (phosphorylated upon
CC       activation by BDNF) with PLCG1 and/or PLCG2; mediates PLCG1
CC       phosphorylation and activation. Interacts with SH2B1 and SH2B2.
CC       Interacts with NGFR; may regulate the ligand specificity of the
CC       receptor (By similarity). Interacts (phosphorylated upon ligand-
CC       binding) with SH2D1A; regulates NTRK2. Interacts with SQSTM1 and
CC       KIDINS220 (By similarity). Interacts (phosphorylated upon ligand-
CC       binding) with FRS2; activates the MAPK signaling pathway (By
CC       similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q8K4V6:Pirb; NbExp=4; IntAct=EBI-309647, EBI-8602514;
CC       P35235:Ptpn11; NbExp=2; IntAct=EBI-309647, EBI-397236;
CC       Q6PHU5:Sort1; NbExp=3; IntAct=EBI-309647, EBI-6985663;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:14581459};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:14581459}.
CC       Endosome membrane {ECO:0000269|PubMed:14581459}; Single-pass type
CC       I membrane protein {ECO:0000269|PubMed:14581459}.
CC       Note=Internalized to endosomes upon ligand-binding.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=GP145-TRKB; Synonyms=L3, TrkBTK+, TRKB-FL;
CC         IsoId=P15209-1; Sequence=Displayed;
CC       Name=GP95-TRKB; Synonyms=TRKB-T1, TrkBTK-;
CC         IsoId=P15209-2; Sequence=VSP_002908, VSP_002909;
CC         Note=Non-catalytic isoform.;
CC       Name=L1;
CC         IsoId=P15209-3; Sequence=VSP_002907;
CC       Name=L10;
CC         IsoId=P15209-4; Sequence=VSP_002905, VSP_002906;
CC   -!- TISSUE SPECIFICITY: Widely expressed in the central and peripheral
CC       nervous system. The different forms are differentially expressed
CC       in various cell types. Isoform GP95-TRKB is specifically expressed
CC       in glial cells.
CC   -!- INDUCTION: Expression oscillates in a circadian manner in the
CC       liver. {ECO:0000269|PubMed:23785138}.
CC   -!- PTM: Phosphorylated. Undergoes ligand-mediated autophosphorylation
CC       that is required for interaction with SHC1 and PLCG1 and other
CC       downstream effectors. Some isoforms are not phosphorylated (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation;
CC       regulated by NGFR. Ubiquitination regulates the internalization of
CC       the receptor. {ECO:0000269|PubMed:16113645}.
CC   -!- DISRUPTION PHENOTYPE: Mice lacking isoform GP145-TRKB, the
CC       catalytic isoform, do not display feeding activity and die at P1.
CC       This is associated neuronal deficiencies in the central and the
CC       peripheral nervous systems. {ECO:0000269|PubMed:8402890}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRCT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRNT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M33385; AAA40482.1; -; mRNA.
DR   EMBL; X17647; CAA35636.1; -; mRNA.
DR   EMBL; AK018789; BAB31412.1; -; mRNA.
DR   EMBL; AK147391; BAE27880.1; -; mRNA.
DR   EMBL; AK160789; BAE36012.1; -; mRNA.
DR   EMBL; BC052014; AAH52014.2; -; mRNA.
DR   CCDS; CCDS26573.1; -. [P15209-1]
DR   CCDS; CCDS36685.1; -. [P15209-2]
DR   PIR; A35104; A35104.
DR   PIR; S06943; S06943.
DR   RefSeq; NP_001020245.1; NM_001025074.2. [P15209-1]
DR   RefSeq; NP_001269890.1; NM_001282961.1. [P15209-1]
DR   RefSeq; NP_032771.1; NM_008745.3. [P15209-2]
DR   RefSeq; XP_006517212.1; XM_006517149.2. [P15209-1]
DR   RefSeq; XP_006517215.1; XM_006517152.2. [P15209-2]
DR   UniGene; Mm.130054; -.
DR   ProteinModelPortal; P15209; -.
DR   SMR; P15209; 31-385, 526-821.
DR   BioGrid; 201869; 5.
DR   DIP; DIP-5722N; -.
DR   IntAct; P15209; 6.
DR   MINT; MINT-240722; -.
DR   STRING; 10090.ENSMUSP00000078757; -.
DR   iPTMnet; P15209; -.
DR   PhosphoSite; P15209; -.
DR   MaxQB; P15209; -.
DR   PaxDb; P15209; -.
DR   PRIDE; P15209; -.
DR   Ensembl; ENSMUST00000079828; ENSMUSP00000078757; ENSMUSG00000055254. [P15209-1]
DR   Ensembl; ENSMUST00000109838; ENSMUSP00000105464; ENSMUSG00000055254. [P15209-2]
DR   GeneID; 18212; -.
DR   KEGG; mmu:18212; -.
DR   UCSC; uc007qui.2; mouse. [P15209-1]
DR   CTD; 4915; -.
DR   MGI; MGI:97384; Ntrk2.
DR   eggNOG; KOG1026; Eukaryota.
DR   eggNOG; ENOG410YGKQ; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000264255; -.
DR   HOVERGEN; HBG056735; -.
DR   InParanoid; P15209; -.
DR   KO; K04360; -.
DR   OMA; CSCEIMW; -.
DR   OrthoDB; EOG7QG43C; -.
DR   PhylomeDB; P15209; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   ChiTaRS; Ntrk2; mouse.
DR   NextBio; 293608; -.
DR   PRO; PR:P15209; -.
DR   Proteomes; UP000000589; Chromosome 13.
DR   Bgee; P15209; -.
DR   CleanEx; MM_NTRK2; -.
DR   ExpressionAtlas; P15209; baseline and differential.
DR   Genevisible; P15209; MM.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:MGI.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0005768; C:endosome; IDA:MGI.
DR   GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0060076; C:excitatory synapse; IEA:Ensembl.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005622; C:intracellular; IMP:GOC.
DR   GO; GO:0097481; C:neuronal postsynaptic density; IDA:MGI.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:MGI.
DR   GO; GO:0048786; C:presynaptic active zone; IEA:Ensembl.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0043195; C:terminal bouton; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0048403; F:brain-derived neurotrophic factor binding; IDA:UniProtKB.
DR   GO; GO:0060175; F:brain-derived neurotrophic factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0043121; F:neurotrophin binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0031547; P:brain-derived neurotrophic factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0035584; P:calcium-mediated signaling using intracellular calcium source; IMP:UniProtKB.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IDA:MGI.
DR   GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0021954; P:central nervous system neuron development; IMP:UniProtKB.
DR   GO; GO:0021987; P:cerebral cortex development; IMP:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IEP:UniProtKB.
DR   GO; GO:0007631; P:feeding behavior; IMP:MGI.
DR   GO; GO:0014047; P:glutamate secretion; IPI:MGI.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0007612; P:learning; IMP:UniProtKB.
DR   GO; GO:0007616; P:long-term memory; IEA:Ensembl.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IMP:UniProtKB.
DR   GO; GO:0042490; P:mechanoreceptor differentiation; IMP:MGI.
DR   GO; GO:2000811; P:negative regulation of anoikis; IDA:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0007528; P:neuromuscular junction development; IMP:MGI.
DR   GO; GO:0030182; P:neuron differentiation; IMP:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IMP:UniProtKB.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0048935; P:peripheral nervous system neuron development; IMP:UniProtKB.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:2000324; P:positive regulation of glucocorticoid receptor signaling pathway; ISO:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IMP:MGI.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IDA:MGI.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0050773; P:regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0043087; P:regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0019222; P:regulation of metabolic process; IMP:MGI.
DR   GO; GO:0046928; P:regulation of neurotransmitter secretion; IEA:Ensembl.
DR   GO; GO:0051896; P:regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0010996; P:response to auditory stimulus; IEA:Ensembl.
DR   GO; GO:0009416; P:response to light stimulus; IEA:Ensembl.
DR   GO; GO:0060041; P:retina development in camera-type eye; IMP:MGI.
DR   GO; GO:0046548; P:retinal rod cell development; IMP:MGI.
DR   GO; GO:0001570; P:vasculogenesis; IMP:MGI.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR000372; LRRNT.
DR   InterPro; IPR031635; NTRK_C2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR020455; Tyr_kin_neurotrophic_rcpt_2.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR020777; Tyr_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF16920; TPKR_C2; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01941; NTKRECEPTOR2.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00013; LRRNT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF52058; SSF52058; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Developmental protein; Differentiation; Disulfide bond; Endosome;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Leucine-rich repeat;
KW   Membrane; Neurogenesis; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     31
FT   CHAIN        32    821       BDNF/NT-3 growth factors receptor.
FT                                /FTId=PRO_0000016728.
FT   TOPO_DOM     32    429       Extracellular. {ECO:0000255}.
FT   TRANSMEM    430    453       Helical. {ECO:0000255}.
FT   TOPO_DOM    454    821       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       32     61       LRRNT.
FT   REPEAT       92    113       LRR 1.
FT   REPEAT      116    137       LRR 2.
FT   DOMAIN      148    196       LRRCT.
FT   DOMAIN      197    282       Ig-like C2-type 1.
FT   DOMAIN      301    365       Ig-like C2-type 2.
FT   DOMAIN      537    806       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     543    551       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    675    675       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     571    571       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        515    515       Interaction with SHC1.
FT   SITE        705    705       Interaction with SH2D1A. {ECO:0000250}.
FT   SITE        816    816       Interaction with PLCG1.
FT   MOD_RES     515    515       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:18034455}.
FT   MOD_RES     701    701       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     705    705       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     706    706       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     816    816       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     67     67       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD     95     95       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    178    178       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    205    205       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    241    241       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    254    254       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    280    280       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    325    325       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    338    338       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...). {ECO:0000250}.
FT   DISULFID     32     38       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID     36     45       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    152    176       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    154    194       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    218    266       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    302    345       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ      71     71       I -> M (in isoform L10). {ECO:0000305}.
FT                                /FTId=VSP_002905.
FT   VAR_SEQ      72    143       Missing (in isoform L10). {ECO:0000305}.
FT                                /FTId=VSP_002906.
FT   VAR_SEQ      72    120       Missing (in isoform L1). {ECO:0000305}.
FT                                /FTId=VSP_002907.
FT   VAR_SEQ     466    476       PASVISNDDDS -> FVLFHKIPLDG (in isoform
FT                                GP95-TRKB). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:16141072,
FT                                ECO:0000303|PubMed:2160854}.
FT                                /FTId=VSP_002908.
FT   VAR_SEQ     477    821       Missing (in isoform GP95-TRKB).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:16141072,
FT                                ECO:0000303|PubMed:2160854}.
FT                                /FTId=VSP_002909.
FT   MUTAGEN     515    515       Y->F: Loss of interaction with SHC1.
FT                                {ECO:0000269|PubMed:12367511}.
FT   MUTAGEN     816    816       Y->F: Loss of interaction with PLCG1.
FT                                {ECO:0000269|PubMed:12367511}.
SQ   SEQUENCE   821 AA;  92133 MW;  50E08D5FF86D8F30 CRC64;
     MSPWLKWHGP AMARLWGLCL LVLGFWRASL ACPTSCKCSS ARIWCTEPSP GIVAFPRLEP
     NSVDPENITE ILIANQKRLE IINEDDVEAY VGLRNLTIVD SGLKFVAYKA FLKNSNLRHI
     NFTRNKLTSL SRRHFRHLDL SDLILTGNPF TCSCDIMWLK TLQETKSSPD TQDLYCLNES
     SKNMPLANLQ IPNCGLPSAR LAAPNLTVEE GKSVTLSCSV GGDPLPTLYW DVGNLVSKHM
     NETSHTQGSL RITNISSDDS GKQISCVAEN LVGEDQDSVN LTVHFAPTIT FLESPTSDHH
     WCIPFTVRGN PKPALQWFYN GAILNESKYI CTKIHVTNHT EYHGCLQLDN PTHMNNGDYT
     LMAKNEYGKD ERQISAHFMG RPGVDYETNP NYPEVLYEDW TTPTDIGDTT NKSNEIPSTD
     VADQSNREHL SVYAVVVIAS VVGFCLLVML LLLKLARHSK FGMKGPASVI SNDDDSASPL
     HHISNGSNTP SSSEGGPDAV IIGMTKIPVI ENPQYFGITN SQLKPDTFVQ HIKRHNIVLK
     RELGEGAFGK VFLAECYNLC PEQDKILVAV KTLKDASDNA RKDFHREAEL LTNLQHEHIV
     KFYGVCVEGD PLIMVFEYMK HGDLNKFLRA HGPDAVLMAE GNPPTELTQS QMLHIAQQIA
     AGMVYLASQH FVHRDLATRN CLVGENLLVK IGDFGMSRDV YSTDYYRVGG HTMLPIRWMP
     PESIMYRKFT TESDVWSLGV VLWEIFTYGK QPWYQLSNNE VIECITQGRV LQRPRTCPQE
     VYELMLGCWQ REPHTRKNIK SIHTLLQNLA KASPVYLDIL G
//
ID   CADH1_MOUSE             Reviewed;         884 AA.
AC   P09803; Q61377;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   20-JAN-2016, entry version 180.
DE   RecName: Full=Cadherin-1;
DE   AltName: Full=ARC-1;
DE   AltName: Full=Epithelial cadherin;
DE            Short=E-cadherin;
DE   AltName: Full=Uvomorulin;
DE   AltName: CD_antigen=CD324;
DE   Contains:
DE     RecName: Full=E-Cad/CTF1;
DE   Contains:
DE     RecName: Full=E-Cad/CTF2;
DE   Contains:
DE     RecName: Full=E-Cad/CTF3;
DE   Flags: Precursor;
GN   Name=Cdh1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=ICR;
RX   PubMed=3498123; DOI=10.1038/329341a0;
RA   Nagafuchi A., Shirayoshi Y., Okazari K., Yasuda K., Takeichi M.;
RT   "Transformation of cell adhesion properties by exogenously introduced
RT   E-cadherin cDNA.";
RL   Nature 329:341-343(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=129/Sv;
RX   PubMed=1754391; DOI=10.1093/nar/19.23.6533;
RA   Ringwald M., Baribault H., Schmidt C., Kemler R.;
RT   "The structure of the gene coding for the mouse cell adhesion molecule
RT   uvomorulin.";
RL   Nucleic Acids Res. 19:6533-6539(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 174-884, AND PROTEIN SEQUENCE OF
RP   157-181.
RX   PubMed=3501370;
RA   Ringwald M., Schuh R., Vestweber D., Eistetter H., Lottspeich F.,
RA   Engel J., Doelz R., Jaehnig F., Epplen J., Mayer S., Mueller C.,
RA   Kemler R.;
RT   "The structure of cell adhesion molecule uvomorulin. Insights into the
RT   molecular mechanism of Ca2+-dependent cell adhesion.";
RL   EMBO J. 6:3647-3653(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-15.
RX   PubMed=1763063; DOI=10.1073/pnas.88.24.11495;
RA   Behrens J., Loewrick O., Klein-Hitpass L., Birchmeier W.;
RT   "The E-cadherin promoter: functional analysis of a G.C-rich region and
RT   an epithelial cell-specific palindromic regulatory element.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:11495-11499(1991).
RN   [5]
RP   IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX.
RX   PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9;
RA   Butz S., Kemler R.;
RT   "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell
RT   adhesion.";
RL   FEBS Lett. 355:195-200(1994).
RN   [6]
RP   DEVELOPMENTAL STAGE.
RC   STRAIN=C57BL/6J; TISSUE=Testis;
RX   PubMed=8879495; DOI=10.1095/biolreprod55.4.822;
RA   Munro S.B., Blaschuk O.W.;
RT   "A comprehensive survey of the cadherins expressed in the testes of
RT   fetal, immature, and adult mice utilizing the polymerase chain
RT   reaction.";
RL   Biol. Reprod. 55:822-827(1996).
RN   [7]
RP   RECONSTITUTION OF THE E-CADHERIN/CATENIN ADHESION COMPLEX, AND LACK OF
RP   ACTIN-BINDING BY THE E-CADHERIN/CATENIN ADHESION COMPLEX.
RX   PubMed=16325582; DOI=10.1016/j.cell.2005.09.020;
RA   Yamada S., Pokutta S., Drees F., Weis W.I., Nelson W.J.;
RT   "Deconstructing the cadherin-catenin-actin complex.";
RL   Cell 123:889-901(2005).
RN   [8]
RP   LACK OF ACTIN-BINDING BY THE E-CADHERIN/CATENIN ADHESION COMPLEX.
RX   PubMed=18093941; DOI=10.1073/pnas.0710504105;
RA   Abe K., Takeichi M.;
RT   "EPLIN mediates linkage of the cadherin catenin complex to F-actin and
RT   stabilizes the circumferential actin belt.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:13-19(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Kidney, Liver, Lung, and Pancreas;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [10]
RP   INTERACTION WITH TRPV4 AND CTNNB1.
RX   PubMed=20413591; DOI=10.1074/jbc.M110.103606;
RA   Sokabe T., Fukumi-Tominaga T., Yonemura S., Mizuno A., Tominaga M.;
RT   "The TRPV4 channel contributes to intercellular junction formation in
RT   keratinocytes.";
RL   J. Biol. Chem. 285:18749-18758(2010).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 157-370, AND CALCIUM-BINDING
RP   SITES.
RX   PubMed=8598933; DOI=10.1038/380360a0;
RA   Nagar B., Overduin M., Ikura M., Rini J.M.;
RT   "Structural basis of calcium-induced E-cadherin rigidification and
RT   dimerization.";
RL   Nature 380:360-364(1996).
RN   [12]
RP   STRUCTURE BY NMR OF 157-260.
RX   PubMed=8785495; DOI=10.1007/BF00202035;
RA   Overduin M., Tong K.I., Kay C.M., Ikura M.;
RT   "1H, 15N and 13C resonance assignments and monomeric structure of the
RT   amino-terminal extracellular domain of epithelial cadherin.";
RL   J. Biomol. NMR 7:173-189(1996).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 577-728 IN COMPLEX WITH
RP   CTNNB1, AND PHOSPHORYLATION.
RX   PubMed=11348595; DOI=10.1016/S0092-8674(01)00330-0;
RA   Huber A.H., Weis W.I.;
RT   "The structure of the beta-catenin/E-cadherin complex and the
RT   molecular basis of diverse ligand recognition by beta-catenin.";
RL   Cell 105:391-402(2001).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 778-884 IN COMPLEX WITH HUMAN
RP   JUP, AND PHOSPHORYLATION AT SER-840; SER-842 AND SER-848.
RX   PubMed=19759396; DOI=10.1074/jbc.M109.047928;
RA   Choi H.J., Gross J.C., Pokutta S., Weis W.I.;
RT   "Interactions of plakoglobin and beta-catenin with desmosomal
RT   cadherins: basis of selective exclusion of alpha- and beta-catenin
RT   from desmosomes.";
RL   J. Biol. Chem. 284:31776-31788(2009).
CC   -!- FUNCTION: Cadherins are calcium-dependent cell adhesion proteins.
CC       They preferentially interact with themselves in a homophilic
CC       manner in connecting cells; cadherins may thus contribute to the
CC       sorting of heterogeneous cell types. CDH1 is involved in
CC       mechanisms regulating cell-cell adhesions, mobility and
CC       proliferation of epithelial cells. Has a potent invasive
CC       suppressor role. It is a ligand for integrin alpha-E/beta-7 (By
CC       similarity). {ECO:0000250}.
CC   -!- FUNCTION: E-Cad/CTF2 promotes non-amyloidogenic degradation of
CC       Abeta precursors. Has a strong inhibitory effect on APP C99 and
CC       C83 production (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Component of an E-cadherin/
CC       catenin adhesion complex composed of at least E-cadherin/CDH1,
CC       beta-catenin/CTNNB1 or gamma-catenin/JUP, and potentially alpha-
CC       catenin/CTNNA1; the complex is located to adherens junctions. The
CC       stable association of CTNNA1 is controversial as CTNNA1 was shown
CC       not to bind to F-actin when assembled in the complex.
CC       Alternatively, the CTNNA1-containing complex may be linked to F-
CC       actin by other proteins such as LIMA1. Interaction with PSEN1,
CC       cleaves CDH1 resulting in the disassociation of cadherin-based
CC       adherens junctions (CAJs). Interacts with AJAP1, CTNND1 and DLGAP5
CC       (By similarity). Interacts with TBC1D2. Interacts with LIMA1.
CC       Interacts with CAV1 (By similarity). Interacts with the TRPV4 and
CC       CTNNB1 complex. Interacts with PIP5K1C (By similarity). Interacts
CC       with RAB8B. Interacts with DDR1; this stabilizes CDH1 at the cell
CC       surface and inhibits its internalization (By similarity).
CC       Interacts with RAPGEF2 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P61809:Cdk5r1; NbExp=2; IntAct=EBI-984420, EBI-7840438;
CC       Q02248:Ctnnb1; NbExp=14; IntAct=EBI-984420, EBI-397872;
CC       O60716-29:CTNND1 (xeno); NbExp=3; IntAct=EBI-984420, EBI-702059;
CC       P28827:PTPRM (xeno); NbExp=3; IntAct=EBI-984420, EBI-2257317;
CC       Q13309:SKP2 (xeno); NbExp=2; IntAct=EBI-984420, EBI-456291;
CC   -!- SUBCELLULAR LOCATION: Cell junction. Cell membrane; Single-pass
CC       type I membrane protein. Endosome {ECO:0000250}. Golgi apparatus,
CC       trans-Golgi network {ECO:0000250}. Note=Colocalizes with DLGAP5 at
CC       sites of cell-cell contact in intestinal epithelial cells.
CC       Anchored to actin microfilaments through association with alpha-,
CC       beta- and gamma-catenin. Sequential proteolysis induced by
CC       apoptosis or calcium influx, results in translocation from sites
CC       of cell-cell contact to the cytoplasm. Colocalizes with RAB11A
CC       endosomes during its transport from the Golgi apparatus to the
CC       plasma membrane (By similarity). {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Non-neural epithelial tissues.
CC   -!- DEVELOPMENTAL STAGE: In the testis, expression is highest in fetal
CC       gonad, then decreases 5-fold in newborn. Detectable in 7-day-old
CC       but not in 21-day-old or adult. {ECO:0000269|PubMed:8879495}.
CC   -!- DOMAIN: Three calcium ions are usually bound at the interface of
CC       each cadherin domain and rigidify the connections, imparting a
CC       strong curvature to the full-length ectodomain.
CC   -!- PTM: N-glycosylation at Asn-639 is essential for expression,
CC       folding and trafficking. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by a SCF complex containing SKP2, which
CC       requires prior phosphorylation by CK1/CSNK1A1. Ubiquitinated by
CC       CBLL1/HAKAI, requires prior phosphorylation at Tyr-756 (By
CC       similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Contains 5 cadherin domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00043}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X06115; CAA29488.1; -; mRNA.
DR   EMBL; X60961; CAA43292.1; -; Genomic_DNA.
DR   EMBL; X60962; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60963; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60964; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60965; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60966; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60967; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60968; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60969; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60970; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60971; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60972; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60973; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60974; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X60975; CAA43292.1; JOINED; Genomic_DNA.
DR   EMBL; X06339; CAA29645.1; -; mRNA.
DR   EMBL; M81449; AAA37352.1; -; Genomic_DNA.
DR   CCDS; CCDS22638.1; -.
DR   PIR; S04528; IJMSCE.
DR   PIR; S34438; S34438.
DR   RefSeq; NP_033994.1; NM_009864.3.
DR   UniGene; Mm.35605; -.
DR   PDB; 1EDH; X-ray; 2.00 A; A/B=156-380.
DR   PDB; 1FF5; X-ray; 2.93 A; A/B=157-374.
DR   PDB; 1I7W; X-ray; 2.00 A; B/D=734-884.
DR   PDB; 1I7X; X-ray; 3.00 A; B/D=734-884.
DR   PDB; 1Q1P; X-ray; 3.20 A; A=158-369.
DR   PDB; 1SUH; NMR; -; A=156-300.
DR   PDB; 2OMW; X-ray; 1.85 A; B=158-256.
DR   PDB; 2QVF; X-ray; 2.40 A; B=157-369.
DR   PDB; 3IFQ; X-ray; 2.80 A; C/D=778-884.
DR   PDB; 3LNE; X-ray; 2.00 A; A=157-369.
DR   PDB; 3LNF; X-ray; 2.50 A; A/B=157-369.
DR   PDB; 3LNG; X-ray; 2.70 A; A/B=157-369.
DR   PDB; 3LNH; X-ray; 2.60 A; A/B=157-369.
DR   PDB; 3LNI; X-ray; 2.30 A; A/B=157-369.
DR   PDB; 3Q2L; X-ray; 2.70 A; A/B=157-369.
DR   PDB; 3Q2N; X-ray; 2.73 A; A/B=157-369.
DR   PDB; 3Q2V; X-ray; 3.40 A; A/B=157-700.
DR   PDB; 3QRB; X-ray; 1.80 A; A/B=157-369.
DR   PDB; 4QD2; X-ray; 2.40 A; E/J=157-369.
DR   PDBsum; 1EDH; -.
DR   PDBsum; 1FF5; -.
DR   PDBsum; 1I7W; -.
DR   PDBsum; 1I7X; -.
DR   PDBsum; 1Q1P; -.
DR   PDBsum; 1SUH; -.
DR   PDBsum; 2OMW; -.
DR   PDBsum; 2QVF; -.
DR   PDBsum; 3IFQ; -.
DR   PDBsum; 3LNE; -.
DR   PDBsum; 3LNF; -.
DR   PDBsum; 3LNG; -.
DR   PDBsum; 3LNH; -.
DR   PDBsum; 3LNI; -.
DR   PDBsum; 3Q2L; -.
DR   PDBsum; 3Q2N; -.
DR   PDBsum; 3Q2V; -.
DR   PDBsum; 3QRB; -.
DR   PDBsum; 4QD2; -.
DR   DisProt; DP00159; -.
DR   ProteinModelPortal; P09803; -.
DR   SMR; P09803; 157-692, 784-877.
DR   BioGrid; 198631; 16.
DR   DIP; DIP-29635N; -.
DR   IntAct; P09803; 33.
DR   MINT; MINT-121804; -.
DR   STRING; 10090.ENSMUSP00000000312; -.
DR   iPTMnet; P09803; -.
DR   PhosphoSite; P09803; -.
DR   MaxQB; P09803; -.
DR   PaxDb; P09803; -.
DR   PRIDE; P09803; -.
DR   GeneID; 12550; -.
DR   KEGG; mmu:12550; -.
DR   UCSC; uc009ngi.1; mouse.
DR   CTD; 999; -.
DR   MGI; MGI:88354; Cdh1.
DR   eggNOG; KOG3594; Eukaryota.
DR   eggNOG; ENOG410XQHI; LUCA.
DR   HOGENOM; HOG000231254; -.
DR   HOVERGEN; HBG106438; -.
DR   InParanoid; P09803; -.
DR   KO; K05689; -.
DR   OrthoDB; EOG7PS1DS; -.
DR   PhylomeDB; P09803; -.
DR   TreeFam; TF316817; -.
DR   ChiTaRS; Cdh1; mouse.
DR   EvolutionaryTrace; P09803; -.
DR   NextBio; 281598; -.
DR   PRO; PR:P09803; -.
DR   Proteomes; UP000000589; Unplaced.
DR   Bgee; P09803; -.
DR   CleanEx; MM_CDH1; -.
DR   GO; GO:0015629; C:actin cytoskeleton; ISO:MGI.
DR   GO; GO:0005912; C:adherens junction; IDA:UniProtKB.
DR   GO; GO:0016235; C:aggresome; ISO:MGI.
DR   GO; GO:0043296; C:apical junction complex; IDA:MGI.
DR   GO; GO:0045177; C:apical part of cell; IDA:MGI.
DR   GO; GO:0030424; C:axon; IDA:MGI.
DR   GO; GO:0043679; C:axon terminus; IDA:MGI.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:MGI.
DR   GO; GO:0016342; C:catenin complex; ISO:MGI.
DR   GO; GO:0030054; C:cell junction; ISO:MGI.
DR   GO; GO:0071944; C:cell periphery; IDA:MGI.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0005913; C:cell-cell adherens junction; IDA:MGI.
DR   GO; GO:0005911; C:cell-cell junction; IDA:MGI.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; ISO:MGI.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0016600; C:flotillin complex; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; ISO:MGI.
DR   GO; GO:0016021; C:integral component of membrane; ISO:MGI.
DR   GO; GO:0030027; C:lamellipodium; ISO:MGI.
DR   GO; GO:0043219; C:lateral loop; IDA:BHF-UCL.
DR   GO; GO:0016328; C:lateral plasma membrane; ISO:MGI.
DR   GO; GO:0033268; C:node of Ranvier; IDA:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; IDA:BHF-UCL.
DR   GO; GO:0005802; C:trans-Golgi network; ISO:MGI.
DR   GO; GO:0030506; F:ankyrin binding; ISO:MGI.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IDA:MGI.
DR   GO; GO:0050839; F:cell adhesion molecule binding; ISO:MGI.
DR   GO; GO:0045295; F:gamma-catenin binding; ISO:MGI.
DR   GO; GO:0001948; F:glycoprotein binding; ISO:MGI.
DR   GO; GO:0032794; F:GTPase activating protein binding; ISO:MGI.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:MGI.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0034332; P:adherens junction organization; ISO:MGI.
DR   GO; GO:0070830; P:bicellular tight junction assembly; IMP:MGI.
DR   GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; IDA:MGI.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IDA:MGI.
DR   GO; GO:0071681; P:cellular response to indole-3-methanol; ISO:MGI.
DR   GO; GO:0071285; P:cellular response to lithium ion; ISO:MGI.
DR   GO; GO:0090102; P:cochlea development; IMP:MGI.
DR   GO; GO:0046697; P:decidualization; IMP:CACAO.
DR   GO; GO:0007566; P:embryo implantation; IMP:CACAO.
DR   GO; GO:0003382; P:epithelial cell morphogenesis; IMP:MGI.
DR   GO; GO:0090002; P:establishment of protein localization to plasma membrane; IDA:UniProtKB.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:InterPro.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0060576; P:intestinal epithelial cell development; IMP:MGI.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:MGI.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; ISO:MGI.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0042993; P:positive regulation of transcription factor import into nucleus; ISO:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:MGI.
DR   GO; GO:0072659; P:protein localization to plasma membrane; ISO:MGI.
DR   GO; GO:0019538; P:protein metabolic process; IDA:MGI.
DR   GO; GO:0060693; P:regulation of branching involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0043281; P:regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:MGI.
DR   GO; GO:2001222; P:regulation of neuron migration; IDA:MGI.
DR   GO; GO:0032880; P:regulation of protein localization; IMP:MGI.
DR   GO; GO:2000008; P:regulation of protein localization to cell surface; IMP:MGI.
DR   GO; GO:0033561; P:regulation of water loss via skin; IMP:MGI.
DR   GO; GO:0060662; P:salivary gland cavitation; IMP:MGI.
DR   GO; GO:0007605; P:sensory perception of sound; IMP:MGI.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IMP:MGI.
DR   GO; GO:0001829; P:trophectodermal cell differentiation; IMP:MGI.
DR   GO; GO:0035847; P:uterine epithelium development; IMP:CACAO.
DR   Gene3D; 2.60.40.60; -; 6.
DR   Gene3D; 4.10.900.10; -; 1.
DR   InterPro; IPR002126; Cadherin.
DR   InterPro; IPR015919; Cadherin-like.
DR   InterPro; IPR020894; Cadherin_CS.
DR   InterPro; IPR000233; Cadherin_cytoplasmic-dom.
DR   InterPro; IPR014868; Cadherin_pro_dom.
DR   InterPro; IPR027397; Catenin_binding_dom.
DR   Pfam; PF00028; Cadherin; 5.
DR   Pfam; PF01049; Cadherin_C; 1.
DR   Pfam; PF08758; Cadherin_pro; 1.
DR   PRINTS; PR00205; CADHERIN.
DR   SMART; SM00112; CA; 4.
DR   SMART; SM01055; Cadherin_pro; 1.
DR   SUPFAM; SSF49313; SSF49313; 6.
DR   PROSITE; PS00232; CADHERIN_1; 3.
DR   PROSITE; PS50268; CADHERIN_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell adhesion; Cell junction; Cell membrane;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Endosome; Glycoprotein;
KW   Golgi apparatus; Membrane; Metal-binding; Phosphoprotein;
KW   Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   PROPEP       24    156       {ECO:0000255}.
FT                                /FTId=PRO_0000003717.
FT   CHAIN       157    884       Cadherin-1.
FT                                /FTId=PRO_0000003718.
FT   CHAIN       703    884       E-Cad/CTF1. {ECO:0000255}.
FT                                /FTId=PRO_0000236070.
FT   CHAIN       734    884       E-Cad/CTF2. {ECO:0000255}.
FT                                /FTId=PRO_0000236071.
FT   CHAIN       753    884       E-Cad/CTF3. {ECO:0000255}.
FT                                /FTId=PRO_0000236072.
FT   TOPO_DOM    157    709       Extracellular. {ECO:0000255}.
FT   TRANSMEM    710    733       Helical. {ECO:0000255}.
FT   TOPO_DOM    734    884       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      157    264       Cadherin 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      265    377       Cadherin 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      378    488       Cadherin 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      489    595       Cadherin 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      596    699       Cadherin 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   REGION      760    771       Required for binding CTNND1 and PSEN1.
FT                                {ECO:0000250}.
FT   REGION      813    884       Required for binding alpha, beta and
FT                                gamma catenins. {ECO:0000250}.
FT   COMPBIAS    840    855       Ser-rich.
FT   METAL       259    259       Calcium 1.
FT   METAL       259    259       Calcium 2.
FT   METAL       290    290       Calcium 3.
FT   SITE        702    703       Cleavage; by a metalloproteinase.
FT                                {ECO:0000250}.
FT   SITE        733    734       Cleavage; by gamma-secretase/PS1.
FT                                {ECO:0000250}.
FT   SITE        752    753       Cleavage; by caspase-3. {ECO:0000250}.
FT   MOD_RES     755    755       Phosphotyrosine; by SRC. {ECO:0000250}.
FT   MOD_RES     756    756       Phosphotyrosine; by SRC. {ECO:0000250}.
FT   MOD_RES     757    757       Phosphotyrosine; by SRC. {ECO:0000250}.
FT   MOD_RES     772    772       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P12830}.
FT   MOD_RES     795    795       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P12830}.
FT   MOD_RES     840    840       Phosphoserine.
FT                                {ECO:0000269|PubMed:19759396}.
FT   MOD_RES     842    842       Phosphoserine.
FT                                {ECO:0000269|PubMed:19759396}.
FT   MOD_RES     848    848       Phosphoserine.
FT                                {ECO:0000269|PubMed:19759396}.
FT   CARBOHYD    560    560       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    639    639       N-linked (GlcNAc...). {ECO:0000255}.
FT   CONFLICT    267    267       E -> P (in Ref. 2; CAA43292).
FT                                {ECO:0000305}.
FT   CONFLICT    272    272       S -> F (in Ref. 2; CAA43292).
FT                                {ECO:0000305}.
FT   STRAND      160    166       {ECO:0000244|PDB:3QRB}.
FT   STRAND      171    179       {ECO:0000244|PDB:3QRB}.
FT   HELIX       183    186       {ECO:0000244|PDB:3QRB}.
FT   STRAND      190    197       {ECO:0000244|PDB:3QRB}.
FT   TURN        198    200       {ECO:0000244|PDB:3QRB}.
FT   STRAND      201    203       {ECO:0000244|PDB:3QRB}.
FT   STRAND      206    209       {ECO:0000244|PDB:3QRB}.
FT   TURN        211    213       {ECO:0000244|PDB:3QRB}.
FT   STRAND      215    218       {ECO:0000244|PDB:3QRB}.
FT   TURN        224    226       {ECO:0000244|PDB:3QRB}.
FT   STRAND      228    238       {ECO:0000244|PDB:3QRB}.
FT   TURN        239    241       {ECO:0000244|PDB:1Q1P}.
FT   STRAND      243    245       {ECO:0000244|PDB:2OMW}.
FT   STRAND      248    255       {ECO:0000244|PDB:3QRB}.
FT   STRAND      263    265       {ECO:0000244|PDB:3QRB}.
FT   STRAND      267    274       {ECO:0000244|PDB:3QRB}.
FT   STRAND      282    285       {ECO:0000244|PDB:3QRB}.
FT   TURN        294    296       {ECO:0000244|PDB:3QRB}.
FT   HELIX       298    300       {ECO:0000244|PDB:1Q1P}.
FT   STRAND      303    311       {ECO:0000244|PDB:3QRB}.
FT   STRAND      314    316       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      318    321       {ECO:0000244|PDB:3QRB}.
FT   TURN        323    325       {ECO:0000244|PDB:3QRB}.
FT   STRAND      327    330       {ECO:0000244|PDB:3QRB}.
FT   TURN        337    339       {ECO:0000244|PDB:3QRB}.
FT   STRAND      342    350       {ECO:0000244|PDB:3QRB}.
FT   HELIX       352    354       {ECO:0000244|PDB:3QRB}.
FT   STRAND      358    368       {ECO:0000244|PDB:3QRB}.
FT   STRAND      376    389       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      396    398       {ECO:0000244|PDB:3Q2V}.
FT   TURN        409    411       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      413    419       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      425    429       {ECO:0000244|PDB:3Q2V}.
FT   TURN        431    433       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      436    442       {ECO:0000244|PDB:3Q2V}.
FT   TURN        446    448       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      450    462       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      471    480       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      487    492       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      494    498       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      506    509       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      524    529       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      535    537       {ECO:0000244|PDB:3Q2V}.
FT   TURN        539    541       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      543    546       {ECO:0000244|PDB:3Q2V}.
FT   TURN        555    557       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      560    570       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      573    575       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      579    588       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      596    598       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      603    608       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      612    617       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      624    627       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      631    634       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      637    639       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      641    643       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      649    655       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      668    670       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      673    675       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      684    688       {ECO:0000244|PDB:3Q2V}.
FT   STRAND      785    789       {ECO:0000244|PDB:3IFQ}.
FT   TURN        806    808       {ECO:0000244|PDB:3IFQ}.
FT   HELIX       818    822       {ECO:0000244|PDB:1I7W}.
FT   STRAND      824    827       {ECO:0000244|PDB:1I7X}.
FT   STRAND      830    834       {ECO:0000244|PDB:3IFQ}.
FT   TURN        864    866       {ECO:0000244|PDB:1I7W}.
FT   HELIX       869    871       {ECO:0000244|PDB:1I7W}.
FT   HELIX       872    877       {ECO:0000244|PDB:1I7W}.
SQ   SEQUENCE   884 AA;  98256 MW;  7A6444148D3D5983 CRC64;
     MGARCRSFSA LLLLLQVSSW LCQELEPESC SPGFSSEVYT FPVPERHLER GHVLGRVRFE
     GCTGRPRTAF FSEDSRFKVA TDGTITVKRH LKLHKLETSF LVRARDSSHR ELSTKVTLKS
     MGHHHHRHHH RDPASESNPE LLMFPSVYPG LRRQKRDWVI PPISCPENEK GEFPKNLVQI
     KSNRDKETKV FYSITGQGAD KPPVGVFIIE RETGWLKVTQ PLDREAIAKY ILYSHAVSSN
     GEAVEDPMEI VITVTDQNDN RPEFTQEVFE GSVAEGAVPG TSVMKVSATD ADDDVNTYNA
     AIAYTIVSQD PELPHKNMFT VNRDTGVISV LTSGLDRESY PTYTLVVQAA DLQGEGLSTT
     AKAVITVKDI NDNAPVFNPS TYQGQVPENE VNARIATLKV TDDDAPNTPA WKAVYTVVND
     PDQQFVVVTD PTTNDGILKT AKGLDFEAKQ QYILHVRVEN EEPFEGSLVP STATVTVDVV
     DVNEAPIFMP AERRVEVPED FGVGQEITSY TAREPDTFMD QKITYRIWRD TANWLEINPE
     TGAIFTRAEM DREDAEHVKN STYVALIIAT DDGSPIATGT GTLLLVLLDV NDNAPIPEPR
     NMQFCQRNPQ PHIITILDPD LPPNTSPFTA ELTHGASVNW TIEYNDAAQE SLILQPRKDL
     EIGEYKIHLK LADNQNKDQV TTLDVHVCDC EGTVNNCMKA GIVAAGLQVP AILGILGGIL
     ALLILILLLL LFLRRRTVVK EPLLPPDDDT RDNVYYYDEE GGGEEDQDFD LSQLHRGLDA
     RPEVTRNDVA PTLMSVPQYR PRPANPDEIG NFIDENLKAA DSDPTAPPYD SLLVFDYEGS
     GSEAASLSSL NSSESDQDQD YDYLNEWGNR FKKLADMYGG GEDD
//
ID   NTRK1_RAT               Reviewed;         799 AA.
AC   P35739;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   20-JAN-2016, entry version 161.
DE   RecName: Full=High affinity nerve growth factor receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 1;
DE   AltName: Full=Slow nerve growth factor receptor;
DE   AltName: Full=p140-TrkA;
DE            Short=Trk-A;
DE   Flags: Precursor;
GN   Name=Ntrk1; Synonyms=Trk, Trka;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKA-II).
RX   PubMed=1312719; DOI=10.1073/pnas.89.6.2374;
RA   Meakin S.O., Suter U., Drinkwater C.C., Welcher A.A., Shooter E.M.;
RT   "The rat trk protooncogene product exhibits properties characteristic
RT   of the slow nerve growth factor receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:2374-2378(1992).
RN   [2]
RP   ALTERNATIVE SPLICING (ISOFORMS TRKA-I AND TRKA-II).
RX   PubMed=8325889;
RA   Barker P.A., Lomen-Hoerth C., Gensch E.M., Meakin S.O., Glass D.J.,
RA   Shooter E.M.;
RT   "Tissue-specific alternative splicing generates two isoforms of the
RT   trkA receptor.";
RL   J. Biol. Chem. 268:15150-15157(1993).
RN   [3]
RP   INTERACTION WITH SHC1.
RX   PubMed=8155326; DOI=10.1016/0896-6273(94)90223-2;
RA   Stephens R.M., Loeb D.M., Copeland T.D., Pawson T., Greene L.A.,
RA   Kaplan D.R.;
RT   "Trk receptors use redundant signal transduction pathways involving
RT   SHC and PLC-gamma 1 to mediate NGF responses.";
RL   Neuron 12:691-705(1994).
RN   [4]
RP   INTERACTION WITH PLCG1; SHC1; SH2B1 AND SH2B2, AND MUTAGENESIS OF
RP   VAL-527.
RX   PubMed=9856458; DOI=10.1016/S0896-6273(00)80620-0;
RA   Qian X., Riccio A., Zhang Y., Ginty D.D.;
RT   "Identification and characterization of novel substrates of Trk
RT   receptors in developing neurons.";
RL   Neuron 21:1017-1029(1998).
RN   [5]
RP   INTERACTION WITH SQSTM1.
RX   PubMed=11244088; DOI=10.1074/jbc.C000869200;
RA   Wooten M.W., Seibenhener M.L., Mamidipudi V., Diaz-Meco M.T.,
RA   Barker P.A., Moscat J.;
RT   "The atypical protein kinase C-interacting protein p62 is a scaffold
RT   for NF-kappaB activation by nerve growth factor.";
RL   J. Biol. Chem. 276:7709-7712(2001).
RN   [6]
RP   INTERACTION WITH KIDINS220.
RX   PubMed=11150334;
RA   Kong H., Boulter J., Weber J.L., Lai C., Chao M.V.;
RT   "An evolutionarily conserved transmembrane protein that is a novel
RT   downstream target of neurotrophin and ephrin receptors.";
RL   J. Neurosci. 21:176-185(2001).
RN   [7]
RP   INTERACTION WITH SQSTM1, SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=12471037; DOI=10.1074/jbc.M208468200;
RA   Geetha T., Wooten M.W.;
RT   "Association of the atypical protein kinase C-interacting protein
RT   p62/ZIP with nerve growth factor receptor TrkA regulates receptor
RT   trafficking and Erk5 signaling.";
RL   J. Biol. Chem. 278:4730-4739(2003).
RN   [8]
RP   INTERACTION WITH KIDINS220, AND DOMAIN.
RX   PubMed=15167895; DOI=10.1038/sj.emboj.7600253;
RA   Arevalo J.C., Yano H., Teng K.K., Chao M.V.;
RT   "A unique pathway for sustained neurotrophin signaling through an
RT   ankyrin-rich membrane-spanning protein.";
RL   EMBO J. 23:2358-2368(2004).
RN   [9]
RP   INTERACTION WITH NGFR AND KIDINS220, AND DOMAIN.
RX   PubMed=15378608; DOI=10.1002/jnr.20262;
RA   Chang M.-S., Arevalo J.C., Chao M.V.;
RT   "Ternary complex with Trk, p75, and an ankyrin-rich membrane spanning
RT   protein.";
RL   J. Neurosci. Res. 78:186-192(2004).
RN   [10]
RP   ENZYME REGULATION, AND INTERACTION WITH SH2D1A.
RX   PubMed=16223723; DOI=10.1074/jbc.M506554200;
RA   Lo K.Y., Chin W.H., Ng Y.P., Cheng A.W., Cheung Z.H., Ip N.Y.;
RT   "SLAM-associated protein as a potential negative regulator in Trk
RT   signaling.";
RL   J. Biol. Chem. 280:41744-41752(2005).
RN   [11]
RP   INTERACTION WITH RAB7A.
RX   PubMed=16306406; DOI=10.1523/JNEUROSCI.2029-05.2005;
RA   Saxena S., Bucci C., Weis J., Kruttgen A.;
RT   "The small GTPase Rab7 controls the endosomal trafficking and
RT   neuritogenic signaling of the nerve growth factor receptor TrkA.";
RL   J. Neurosci. 25:10930-10940(2005).
RN   [12]
RP   IDENTIFICATION IN A COMPLEX WITH KIDINS220; MAGI2 AND RAPGEF2,
RP   INTERACTION WITH RAPGEF2, AND SUBCELLULAR LOCATION.
RX   PubMed=17724123; DOI=10.1083/jcb.200610073;
RA   Hisata S., Sakisaka T., Baba T., Yamada T., Aoki K., Matsuda M.,
RA   Takai Y.;
RT   "Rap1-PDZ-GEF1 interacts with a neurotrophin receptor at late
RT   endosomes, leading to sustained activation of Rap1 and ERK and neurite
RT   outgrowth.";
RL   J. Cell Biol. 178:843-860(2007).
RN   [13]
RP   INTERACTION WITH NRADD.
RX   PubMed=18624909; DOI=10.1111/j.1471-4159.2008.05539.x;
RA   Wong A.W., Willingham M., Xiao J., Kilpatrick T.J., Murray S.S.;
RT   "Neurotrophin receptor homolog-2 regulates nerve growth factor
RT   signaling.";
RL   J. Neurochem. 106:1964-1976(2008).
RN   [14]
RP   FUNCTION IN CELL DEATH.
RX   PubMed=20811452; DOI=10.1038/nature09336;
RA   Nikoletopoulou V., Lickert H., Frade J.M., Rencurel C.,
RA   Giallonardo P., Zhang L., Bibel M., Barde Y.A.;
RT   "Neurotrophin receptors TrkA and TrkC cause neuronal death whereas
RT   TrkB does not.";
RL   Nature 467:59-63(2010).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in the development and
CC       the maturation of the central and peripheral nervous systems
CC       through regulation of proliferation, differentiation and survival
CC       of sympathetic and nervous neurons. High affinity receptor for NGF
CC       which is its primary ligand, it can also bind and be activated by
CC       NTF3/neurotrophin-3. However, NTF3 only supports axonal extension
CC       through NTRK1 but has no effect on neuron survival. Upon dimeric
CC       NGF ligand-binding, undergoes homodimerization,
CC       autophosphorylation and activation. Recruits, phosphorylates
CC       and/or activates several downstream effectors including SHC1,
CC       FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping
CC       signaling cascades driving cell survival and differentiation.
CC       Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that
CC       regulates cell differentiation and survival. Through PLCG1
CC       controls NF-Kappa-B activation and the transcription of genes
CC       involved in cell survival. Through SHC1 and SH2B1 controls a Ras-
CC       PI3 kinase-AKT1 signaling cascade that is also regulating
CC       survival. In absence of ligand and activation, may promote cell
CC       death, making the survival of neurons dependent on trophic
CC       factors. {ECO:0000269|PubMed:20811452}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: The pro-survival signaling effect of NTRK1 in
CC       neurons requires its endocytosis into signaling early endosomes
CC       and its retrograde axonal transport. This is regulated by
CC       different proteins including CFL1, RAC1 and SORT1. NTF3 is unable
CC       to induce this signaling probably due to the lability of the NTF3-
CC       NTRK1 complex in endosomes (By similarity). SH2D1A inhibits the
CC       autophosphorylation of the receptor, and alters the recruitment
CC       and activation of downstream effectors and signaling cascades.
CC       Regulated by NGFR (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures. Homodimerization
CC       is induced by binding of a NGF dimer (By similarity). Found in a
CC       complex, at least composed of KIDINS220, MAGI2, NTRK1 and RAPGEF2;
CC       the complex is mainly formed at late endosomes in a nerve growth
CC       factor (NGF)-dependent manner. Interacts with RAPGEF2; the
CC       interaction is strengthened after NGF stimulation. Interacts with
CC       SQSTM1; bridges NTRK1 to NGFR. Forms a ternary complex with NGFR
CC       and KIDINS220; this complex is affected by the expression levels
CC       of KIDINS220 and an increase in KIDINS220 expression leads to a
CC       decreased association of NGFR and NTRK1. Interacts (phosphorylated
CC       upon activation by NGF) with SHC1; mediates SHC1 phosphorylation
CC       and activation. Interacts (phosphorylated upon activation by NGF)
CC       with PLCG1; mediates PLCG1 phosphorylation and activation.
CC       Interacts (phosphorylated) with SH2B1 and SH2B2. Interacts with
CC       GRB2. Interacts with PIK3R1. Interacts with FRS2. Interacts with
CC       SORT1; may regulate NTRK1 anterograde axonal transport. Interacts
CC       with SH2D1A; regulates NTRK1. Interacts with NRADD. Interacts with
CC       RAB7A. {ECO:0000250, ECO:0000269|PubMed:11150334,
CC       ECO:0000269|PubMed:11244088, ECO:0000269|PubMed:12471037,
CC       ECO:0000269|PubMed:15167895, ECO:0000269|PubMed:15378608,
CC       ECO:0000269|PubMed:16223723, ECO:0000269|PubMed:16306406,
CC       ECO:0000269|PubMed:17724123, ECO:0000269|PubMed:18624909,
CC       ECO:0000269|PubMed:8155326, ECO:0000269|PubMed:9856458}.
CC   -!- INTERACTION:
CC       P62994:Grb2; NbExp=6; IntAct=EBI-976667, EBI-401775;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass
CC       type I membrane protein {ECO:0000250}. Early endosome membrane;
CC       Single-pass type I membrane protein. Late endosome membrane;
CC       Single-pass type I membrane protein. Note=Internalized to
CC       endosomes upon binding of NGF or NTF3 and further transported to
CC       the cell body via a retrograde axonal transport. Localized at cell
CC       membrane and early endosomes before nerve growth factor (NGF)
CC       stimulation. Recruited to late endosomes after NGF stimulation.
CC       Colocalized with RAPGEF2 at late endosomes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Both isoforms have similar biological properties.;
CC       Name=TrkA-II;
CC         IsoId=P35739-1; Sequence=Displayed;
CC       Name=TrkA-I;
CC         IsoId=P35739-2; Sequence=VSP_002900;
CC   -!- TISSUE SPECIFICITY: Isoform Trka-II is primarily expressed in
CC       neuronal cells; isoform Trka-I is found in non-neuronal tissues.
CC   -!- DOMAIN: The transmembrane domain mediates interaction with
CC       KIDINS220.
CC   -!- DOMAIN: The extracellular domain mediates interaction with NGFR.
CC   -!- PTM: Ligand-mediated autophosphorylation. Interaction with SQSTM1
CC       is phosphotyrosine-dependent. Autophosphorylation at Tyr-499
CC       mediates interaction and phosphorylation of SHC1.
CC   -!- PTM: N-glycosylated. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation;
CC       regulated by NGFR. Ubiquitination regulates the internalization of
CC       the receptor (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRCT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M85214; AAA42286.1; -; mRNA.
DR   EMBL; L12225; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   PIR; A41981; TVRTTB.
DR   RefSeq; NP_067600.1; NM_021589.1. [P35739-1]
DR   RefSeq; XP_006232808.1; XM_006232746.2. [P35739-2]
DR   UniGene; Rn.39098; -.
DR   ProteinModelPortal; P35739; -.
DR   SMR; P35739; 36-385.
DR   BioGrid; 248731; 16.
DR   DIP; DIP-5716N; -.
DR   IntAct; P35739; 2.
DR   MINT; MINT-191667; -.
DR   STRING; 10116.ENSRNOP00000018961; -.
DR   ChEMBL; CHEMBL4220; -.
DR   PhosphoSite; P35739; -.
DR   PaxDb; P35739; -.
DR   Ensembl; ENSRNOT00000018961; ENSRNOP00000018961; ENSRNOG00000013953. [P35739-1]
DR   GeneID; 59109; -.
DR   KEGG; rno:59109; -.
DR   UCSC; RGD:620144; rat. [P35739-1]
DR   CTD; 4914; -.
DR   RGD; 620144; Ntrk1.
DR   eggNOG; KOG1026; Eukaryota.
DR   eggNOG; ENOG410YGKQ; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000264255; -.
DR   HOVERGEN; HBG056735; -.
DR   InParanoid; P35739; -.
DR   KO; K03176; -.
DR   OMA; KNVTCWA; -.
DR   OrthoDB; EOG7GTT32; -.
DR   PhylomeDB; P35739; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 5301.
DR   Reactome; R-RNO-170968; Frs2-mediated activation.
DR   Reactome; R-RNO-170984; ARMS-mediated activation.
DR   Reactome; R-RNO-177504; Retrograde neurotrophin signalling.
DR   Reactome; R-RNO-187042; TRKA activation by NGF.
DR   Reactome; R-RNO-198203; PI3K/AKT activation.
DR   NextBio; 611747; -.
DR   PRO; PR:P35739; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   Genevisible; P35739; RN.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; IDA:BHF-UCL.
DR   GO; GO:0019900; F:kinase binding; IPI:RGD.
DR   GO; GO:0048406; F:nerve growth factor binding; ISS:UniProtKB.
DR   GO; GO:0010465; F:nerve growth factor receptor activity; ISS:UniProtKB.
DR   GO; GO:0005166; F:neurotrophin p75 receptor binding; IPI:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0007568; P:aging; IEP:RGD.
DR   GO; GO:0007411; P:axon guidance; IMP:RGD.
DR   GO; GO:0060385; P:axonogenesis involved in innervation; ISS:UniProtKB.
DR   GO; GO:0030183; P:B cell differentiation; IEA:Ensembl.
DR   GO; GO:0061368; P:behavioral response to formalin induced pain; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:MGI.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0071316; P:cellular response to nicotine; IDA:RGD.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IMP:RGD.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IMP:RGD.
DR   GO; GO:0010623; P:developmental programmed cell death; IDA:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:GOC.
DR   GO; GO:0007611; P:learning or memory; IMP:RGD.
DR   GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:UniProtKB.
DR   GO; GO:1901215; P:negative regulation of neuron death; IDA:RGD.
DR   GO; GO:0038180; P:nerve growth factor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0021553; P:olfactory nerve development; IEP:RGD.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:GOC.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISS:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IMP:RGD.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0014823; P:response to activity; IDA:RGD.
DR   GO; GO:0048678; P:response to axon injury; IEP:RGD.
DR   GO; GO:0042493; P:response to drug; IDA:RGD.
DR   GO; GO:0051602; P:response to electrical stimulus; IDA:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0051599; P:response to hydrostatic pressure; IEP:RGD.
DR   GO; GO:0035094; P:response to nicotine; IDA:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; IDA:RGD.
DR   GO; GO:0009314; P:response to radiation; IEP:RGD.
DR   GO; GO:0019233; P:sensory perception of pain; IMP:RGD.
DR   GO; GO:0060009; P:Sertoli cell development; IMP:RGD.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR031635; NTRK_C2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR020461; Tyr_kinase_neurotrophic_rcpt_1.
DR   InterPro; IPR020777; Tyr_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF16920; TPKR_C2; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01940; NTKRECEPTOR1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF52058; SSF52058; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Developmental protein; Differentiation; Disulfide bond; Endosome;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Leucine-rich repeat;
KW   Membrane; Neurogenesis; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     32       {ECO:0000255}.
FT   CHAIN        33    799       High affinity nerve growth factor
FT                                receptor.
FT                                /FTId=PRO_0000016725.
FT   TOPO_DOM     33    418       Extracellular. {ECO:0000255}.
FT   TRANSMEM    419    442       Helical. {ECO:0000255}.
FT   TOPO_DOM    443    799       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       90    113       LRR 1.
FT   REPEAT      116    137       LRR 2.
FT   DOMAIN      148    219       LRRCT.
FT   DOMAIN      196    285       Ig-like C2-type 1.
FT   DOMAIN      295    368       Ig-like C2-type 2.
FT   DOMAIN      513    784       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     519    527       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      472    493       Interaction with SQSTM1.
FT   ACT_SITE    653    653       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     547    547       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        499    499       Interaction with SHC1. {ECO:0000250}.
FT   SITE        794    794       Interaction with PLCG1. {ECO:0000250}.
FT   MOD_RES     499    499       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     679    679       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     683    683       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     684    684       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     794    794       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     67     67       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    190    190       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    204    204       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    255    255       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    264    264       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    320    320       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    325    325       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    341    341       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    361    361       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    404    404       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    154    193       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    217    267       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     396    401       Missing (in isoform TrkA-I).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_002900.
FT   MUTAGEN     527    527       V->D: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:9856458}.
SQ   SEQUENCE   799 AA;  87868 MW;  D564E8801E8978F8 CRC64;
     MLRGQRHGQL GWHRPAAGLG GLVTSLMLAC ACAASCRETC CPVGPSGLRC TRAGTLNTLR
     GLRGAGNLTE LYVENQRDLQ RLEFEDLQGL GELRSLTIVK SGLRFVAPDA FHFTPRLSHL
     NLSSNALESL SWKTVQGLSL QDLTLSGNPL HCSCALLWLQ RWEQEDLCGV YTQKLQGSGS
     GDQFLPLGHN NSCGVPSVKI QMPNDSVEVG DDVFLQCQVE GQALQQADWI LTELEGTATM
     KKSGDLPSLG LTLVNVTSDL NKKNVTCWAE NDVGRAEVSV QVSVSFPASV HLGKAVEQHH
     WCIPFSVDGQ PAPSLRWFFN GSVLNETSFI FTQFLESALT NETMRHGCLR LNQPTHVNNG
     NYTLLAANPY GQAAASIMAA FMDNPFEFNP EDPIPVSFSP VDTNSTSRDP VEKKDETPFG
     VSVAVGLAVS AALFLSALLL VLNKCGQRSK FGINRPAVLA PEDGLAMSLH FMTLGGSSLS
     PTEGKGSGLQ GHIMENPQYF SDTCVHHIKR QDIILKWELG EGAFGKVFLA ECYNLLNDQD
     KMLVAVKALK ETSENARQDF HREAELLTML QHQHIVRFFG VCTEGGPLLM VFEYMRHGDL
     NRFLRSHGPD AKLLAGGEDV APGPLGLGQL LAVASQVAAG MVYLASLHFV HRDLATRNCL
     VGQGLVVKIG DFGMSRDIYS TDYYRVGGRT MLPIRWMPPE SILYRKFSTE SDVWSFGVVL
     WEIFTYGKQP WYQLSNTEAI ECITQGRELE RPRACPPDVY AIMRGCWQRE PQQRLSMKDV
     HARLQALAQA PPSYLDVLG
//
ID   ITAV_HUMAN              Reviewed;        1048 AA.
AC   P06756; A0AV67; B0LPF4; B7Z883; B7ZLX0; D3DPG8; E7EWZ6; Q53SK4;
AC   Q59EB7; Q6LD15;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   20-JAN-2016, entry version 195.
DE   RecName: Full=Integrin alpha-V;
DE   AltName: Full=Vitronectin receptor subunit alpha;
DE   AltName: CD_antigen=CD51;
DE   Contains:
DE     RecName: Full=Integrin alpha-V heavy chain;
DE   Contains:
DE     RecName: Full=Integrin alpha-V light chain;
DE   Flags: Precursor;
GN   Name=ITGAV; Synonyms=MSK8, VNRA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ILE-783.
RX   PubMed=2443500;
RA   Suzuki S., Argraves W.S., Arai H., Languino L.R., Pierschbacher M.D.,
RA   Ruoslahti E.;
RT   "Amino acid sequence of the vitronectin receptor alpha subunit and
RT   comparative expression of adhesion receptor mRNAs.";
RL   J. Biol. Chem. 262:14080-14085(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10965141;
RA   Sims M.A., Field S., Barnes M.R., Shaikh N., Ellington K.,
RA   Murphy K.E., Spurr N.K., Campbell D.A.;
RT   "Cloning and characterisation of ITGAV, the genomic sequence for human
RT   cell adhesion protein (vitronectin) receptor alpha subunit, CD51.";
RL   Cytogenet. Cell Genet. 89:268-271(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT
RP   ILE-783.
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   ILE-783.
RC   TISSUE=Aortic endothelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-783.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ILE-783.
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ILE-783.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-62.
RX   PubMed=7522056; DOI=10.1016/0167-4781(94)90278-X;
RA   Donahue J.P., Sugg N., Hawiger J.;
RT   "The integrin alpha v gene: identification and characterization of the
RT   promoter region.";
RL   Biochim. Biophys. Acta 1219:228-232(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 413-1048, AND VARIANT ILE-783.
RX   PubMed=2430295; DOI=10.1073/pnas.83.22.8614;
RA   Suzuki S., Argraves W.S., Pytela R., Arai H., Krusius T.,
RA   Pierschbacher M.D., Ruoslahti E.;
RT   "cDNA and amino acid sequences of the cell adhesion protein receptor
RT   recognizing vitronectin reveal a transmembrane domain and homologies
RT   with other adhesion protein receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:8614-8618(1986).
RN   [11]
RP   PROTEIN SEQUENCE OF 31-41.
RX   PubMed=2467745; DOI=10.1016/0092-8674(89)90172-4;
RA   Cheresh D.A., Smith J.W., Cooper H.M., Quaranta V.;
RT   "A novel vitronectin receptor integrin (alpha v beta x) is responsible
RT   for distinct adhesive properties of carcinoma cells.";
RL   Cell 57:59-69(1989).
RN   [12]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH COXSACKIEVIRUS A9
RP   CAPSID PROTEINS.
RX   PubMed=7519807; DOI=10.1006/viro.1994.1494;
RA   Roivainen M., Piirainen L., Hovi T., Virtanen I., Riikonen T.,
RA   Heino J., Hyypiae T.;
RT   "Entry of coxsackievirus A9 into host cells: specific interactions
RT   with alpha v beta 3 integrin, the vitronectin receptor.";
RL   Virology 203:357-365(1994).
RN   [13]
RP   INTERACTION WITH COXSACKIEVIRUS B1 CAPSID PROTEINS.
RX   PubMed=9426447; DOI=10.1006/viro.1997.8831;
RA   Agrez M.V., Shafren D.R., Gu X., Cox K., Sheppard D., Barry R.D.;
RT   "Integrin alpha v beta 6 enhances coxsackievirus B1 lytic infection of
RT   human colon cancer cells.";
RL   Virology 239:71-77(1997).
RN   [14]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=10397733;
RA   Barillari G., Sgadari C., Fiorelli V., Samaniego F., Colombini S.,
RA   Manzari V., Modesti A., Nair B.C., Cafaro A., Stuerzl M., Ensoli B.;
RT   "The Tat protein of human immunodeficiency virus type-1 promotes
RT   vascular cell growth and locomotion by engaging the alpha5beta1 and
RT   alphavbeta3 integrins and by mobilizing sequestered basic fibroblast
RT   growth factor.";
RL   Blood 94:663-672(1999).
RN   [15]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN
RP   PARECHOVIRUS 1 CAPSID PROTEINS.
RX   PubMed=11160695; DOI=10.1128/JVI.75.4.1958-1967.2001;
RA   Joki-Korpela P., Marjomaki V., Krogerus C., Heino J., Hyypia T.;
RT   "Entry of human parechovirus 1.";
RL   J. Virol. 75:1958-1967(2001).
RN   [16]
RP   INTERACTION WITH NOV.
RX   PubMed=12695522; DOI=10.1074/jbc.M302028200;
RA   Lin C.G., Leu S.J., Chen N., Tebeau C.M., Lin S.X., Yeung C.Y.,
RA   Lau L.F.;
RT   "CCN3 (NOV) is a novel angiogenic regulator of the CCN protein
RT   family.";
RL   J. Biol. Chem. 278:24200-24208(2003).
RN   [17]
RP   GLYCOSYLATION AT ASN-615.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [18]
RP   DISULFIDE BONDS.
RX   PubMed=14596610; DOI=10.1021/bi034726u;
RA   Krokhin O.V., Cheng K., Sousa S.L., Ens W., Standing K.G.,
RA   Wilkins J.A.;
RT   "Mass spectrometric based mapping of the disulfide bonding patterns of
RT   integrin alpha chains.";
RL   Biochemistry 42:12950-12959(2003).
RN   [19]
RP   INTERACTION WITH COXSACKIEVIRUS A9 CAPSID PROTEINS.
RX   PubMed=15194773; DOI=10.1128/JVI.78.13.6967-6973.2004;
RA   Williams C.H., Kajander T., Hyypia T., Jackson T., Sheppard D.,
RA   Stanway G.;
RT   "Integrin alpha v beta 6 is an RGD-dependent receptor for
RT   coxsackievirus A9.";
RL   J. Virol. 78:6967-6973(2004).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [21]
RP   INTERACTION WITH RAB25.
RX   PubMed=17925226; DOI=10.1016/j.devcel.2007.08.012;
RA   Caswell P.T., Spence H.J., Parsons M., White D.P., Clark K.,
RA   Cheng K.W., Mills G.B., Humphries M.J., Messent A.J., Anderson K.I.,
RA   McCaffrey M.W., Ozanne B.W., Norman J.C.;
RT   "Rab25 associates with alpha5beta1 integrin to promote invasive
RT   migration in 3D microenvironments.";
RL   Dev. Cell 13:496-510(2007).
RN   [22]
RP   INTERACTION WITH HHV-8 GLYCOPROTEIN B.
RX   PubMed=18045938; DOI=10.1128/JVI.01673-07;
RA   Garrigues H.J., Rubinchikova Y.E., Dipersio C.M., Rose T.M.;
RT   "Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of
RT   Kaposi's sarcoma-associated herpesvirus and functions as an RGD-
RT   dependent entry receptor.";
RL   J. Virol. 82:1570-1580(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-74; ASN-615; ASN-704 AND
RP   ASN-874.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [25]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-74 AND ASN-874.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [26]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH ADENOVIRUS TYPE C
RP   PENTON PROTEIN.
RX   PubMed=20615244; DOI=10.1186/1743-422X-7-148;
RA   Lyle C., McCormick F.;
RT   "Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-
RT   negative cells.";
RL   Virol. J. 7:148-148(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   INTERACTION WITH CIB1.
RX   PubMed=24011356; DOI=10.1021/bi400678y;
RA   Freeman T.C. Jr., Black J.L., Bray H.G., Dagliyan O., Wu Y.I.,
RA   Tripathy A., Dokholyan N.V., Leisner T.M., Parise L.V.;
RT   "Identification of novel integrin binding partners for calcium and
RT   integrin binding protein 1 (CIB1): structural and thermodynamic basis
RT   of CIB1 promiscuity.";
RL   Biochemistry 52:7082-7090(2013).
RN   [29]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HERPES SIMPLEX
RP   VIRUS 1 ENVELOPE GLYCOPROTEIN H.
RX   PubMed=24367260; DOI=10.1371/journal.ppat.1003806;
RA   Gianni T., Salvioli S., Chesnokova L.S., Hutt-Fletcher L.M.,
RA   Campadelli-Fiume G.;
RT   "alphavbeta6- and alphavbeta8-integrins serve as interchangeable
RT   receptors for HSV gH/gL to promote endocytosis and activation of
RT   membrane fusion.";
RL   PLoS Pathog. 9:E1003806-E1003806(2013).
RN   [30]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH WEST NILE VIRUS
RP   ENVELOPE PROTEIN E.
RX   PubMed=23658209; DOI=10.1099/vir.0.052613-0;
RA   Schmidt K., Keller M., Bader B.L., Korytar T., Finke S., Ziegler U.,
RA   Groschup M.H.;
RT   "Integrins modulate the infection efficiency of West Nile virus into
RT   cells.";
RL   J. Gen. Virol. 94:1723-1733(2013).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 31-987.
RX   PubMed=11546839; DOI=10.1126/science.1064535;
RA   Xiong J.P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D.L.,
RA   Joachimiak A., Goodman S.L., Arnaout M.A.;
RT   "Crystal structure of the extracellular segment of integrin alpha
RT   Vbeta3.";
RL   Science 294:339-345(2001).
CC   -!- FUNCTION: The alpha-V (ITGAV) integrins are receptors for
CC       vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix
CC       metalloproteinase-2, osteopontin, osteomodulin, prothrombin,
CC       thrombospondin and vWF. They recognize the sequence R-G-D in a
CC       wide array of ligands.
CC   -!- FUNCTION: (Microbial infection) Integrin ITGAV:ITGB5 acts as a
CC       receptor for adenovirus type C (PubMed:20615244). Integrin
CC       ITGAV:ITGB5 and ITGAV:ITGB3 act as receptors for coxsackievirus A9
CC       and B1 (PubMed:9426447, PubMed:15194773, PubMed:7519807). Integrin
CC       ITGAV:ITGB3 acts as a receptor for herpes virus 8/HHV-8
CC       (PubMed:18045938). Integrin ITGAV:ITGB6 acts as a receptor for
CC       herpes simplex 1/HHV-1 (PubMed:24367260). Integrin ITGAV:ITGB3
CC       acts as a receptor for Human parechovirus 1 (PubMed:11160695).
CC       Integrin ITGAV:ITGB3 acts as a receptor for West nile virus
CC       (PubMed:23658209). In case of HIV-1 infection, the interaction
CC       with extracellular viral Tat protein seems to enhance angiogenesis
CC       in Kaposi's sarcoma lesions (PubMed:10397733).
CC       {ECO:0000269|PubMed:10397733, ECO:0000269|PubMed:11160695,
CC       ECO:0000269|PubMed:15194773, ECO:0000269|PubMed:18045938,
CC       ECO:0000269|PubMed:20615244, ECO:0000269|PubMed:23658209,
CC       ECO:0000269|PubMed:24367260, ECO:0000269|PubMed:7519807,
CC       ECO:0000269|PubMed:9426447}.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit. The alpha
CC       subunit is composed of a heavy and a light chain linked by a
CC       disulfide bond. Alpha-V (ITGAV) associates with either beta-1
CC       (ITGB1), beta-3 (ITGB3), beta-5 (ITGB5), beta-6 (ITGB6) or beta-8
CC       (ITGB8). Interacts with CIB1 (PubMed:24011356). Interacts with
CC       RAB25 (PubMed:17925226). Integrins ITGAV:ITGB3 and ITGAV:ITGB5
CC       interact with FBLN5 (via N-terminus) (By similarity). ITGAV:ITGB3
CC       and ITGAV:ITGB5 interact with NOV (PubMed:12695522). (Microbial
CC       infection) Integrin ITGAV:ITGB3 interacts with herpes virus 8/HHV-
CC       8 envelope glycoprotein B (PubMed:18045938). (Microbial infection)
CC       Integrin ITGAV:ITGB3 and ITGAV:ITGB6 bind to coxsackievirus A9 and
CC       coxsackievirus B1 capsid proteins (PubMed:9426447,
CC       PubMed:15194773, PubMed:7519807). (Microbial infection) Integrin
CC       ITGAV:ITGB6 interacts with herpes simplex 1/HHV-1 envelope
CC       glycoprotein H (PubMed:24367260). (Microbial infection) Integrin
CC       ITGAV:ITGB5 interacts with adenovirus type C penton protein
CC       (PubMed:20615244). (Microbial infection) Integrin ITGAV:ITGB3
CC       interacts with Human parechovirus 1 capsid proteins
CC       (PubMed:11160695). (Microbial infection) Integrin ITGAV:ITGB3
CC       interacts with West nile virus envelope protein E
CC       (PubMed:23658209). (Microbial infection) Interacts with HIV-1 Tat
CC       (PubMed:10397733). {ECO:0000250|UniProtKB:P43406,
CC       ECO:0000250|UniProtKB:P80746, ECO:0000269|PubMed:10397733,
CC       ECO:0000269|PubMed:11160695, ECO:0000269|PubMed:12695522,
CC       ECO:0000269|PubMed:15194773, ECO:0000269|PubMed:17925226,
CC       ECO:0000269|PubMed:18045938, ECO:0000269|PubMed:20615244,
CC       ECO:0000269|PubMed:23658209, ECO:0000269|PubMed:24011356,
CC       ECO:0000269|PubMed:24367260, ECO:0000269|PubMed:7519807,
CC       ECO:0000269|PubMed:9426447}.
CC   -!- INTERACTION:
CC       P05106:ITGB3; NbExp=11; IntAct=EBI-298282, EBI-702847;
CC       P18084:ITGB5; NbExp=2; IntAct=EBI-298282, EBI-1223434;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P06756-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P06756-2; Sequence=VSP_024351;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P06756-3; Sequence=VSP_044914;
CC         Note=No experimental confirmation available.;
CC   -!- SIMILARITY: Belongs to the integrin alpha chain family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 7 FG-GAP repeats. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD93131.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14648; AAA36808.1; -; mRNA.
DR   EMBL; AF251841; AAG03000.1; -; Genomic_DNA.
DR   EMBL; AF251818; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251819; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251820; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251821; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251822; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251823; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251824; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251825; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251826; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251827; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251828; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251829; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251830; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251831; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251832; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251833; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251834; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251835; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251836; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251837; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251838; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251839; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AF251840; AAG03000.1; JOINED; Genomic_DNA.
DR   EMBL; AK302990; BAH13869.1; -; mRNA.
DR   EMBL; AB209894; BAD93131.1; ALT_INIT; mRNA.
DR   EMBL; AC017101; AAY24257.1; -; Genomic_DNA.
DR   EMBL; EU332844; ABY87533.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX10934.1; -; Genomic_DNA.
DR   EMBL; BC126231; AAI26232.1; -; mRNA.
DR   EMBL; BC136442; AAI36443.1; -; mRNA.
DR   EMBL; BC144100; AAI44101.1; -; mRNA.
DR   EMBL; U07375; AAA61631.1; -; Genomic_DNA.
DR   CCDS; CCDS2292.1; -. [P06756-1]
DR   CCDS; CCDS46470.1; -. [P06756-2]
DR   CCDS; CCDS46471.1; -. [P06756-3]
DR   PIR; A27421; A27421.
DR   RefSeq; NP_001138471.1; NM_001144999.2.
DR   RefSeq; NP_001138472.1; NM_001145000.2.
DR   RefSeq; NP_002201.1; NM_002210.4.
DR   UniGene; Hs.436873; -.
DR   PDB; 1JV2; X-ray; 3.10 A; A=31-987.
DR   PDB; 1L5G; X-ray; 3.20 A; A=31-987.
DR   PDB; 1M1X; X-ray; 3.30 A; A=31-987.
DR   PDB; 1U8C; X-ray; 3.10 A; A=31-987.
DR   PDB; 3IJE; X-ray; 2.90 A; A=31-997.
DR   PDB; 4G1E; X-ray; 3.00 A; A=31-989.
DR   PDB; 4G1M; X-ray; 2.90 A; A=31-989.
DR   PDB; 4MMX; X-ray; 3.32 A; A=31-989.
DR   PDB; 4MMY; X-ray; 3.18 A; A=31-989.
DR   PDB; 4MMZ; X-ray; 3.10 A; A=31-989.
DR   PDB; 4O02; X-ray; 3.60 A; A=31-992.
DR   PDB; 4UM8; X-ray; 2.85 A; A/C=31-625.
DR   PDB; 4UM9; X-ray; 2.50 A; A/C=31-625.
DR   PDBsum; 1JV2; -.
DR   PDBsum; 1L5G; -.
DR   PDBsum; 1M1X; -.
DR   PDBsum; 1U8C; -.
DR   PDBsum; 3IJE; -.
DR   PDBsum; 4G1E; -.
DR   PDBsum; 4G1M; -.
DR   PDBsum; 4MMX; -.
DR   PDBsum; 4MMY; -.
DR   PDBsum; 4MMZ; -.
DR   PDBsum; 4O02; -.
DR   PDBsum; 4UM8; -.
DR   PDBsum; 4UM9; -.
DR   ProteinModelPortal; P06756; -.
DR   SMR; P06756; 31-989.
DR   BioGrid; 109891; 43.
DR   DIP; DIP-31785N; -.
DR   IntAct; P06756; 14.
DR   MINT; MINT-209462; -.
DR   STRING; 9606.ENSP00000261023; -.
DR   BindingDB; P06756; -.
DR   ChEMBL; CHEMBL1907598; -.
DR   DrugBank; DB00098; Anti-thymocyte Globulin (Rabbit).
DR   iPTMnet; P06756; -.
DR   PhosphoSite; P06756; -.
DR   DMDM; 143811408; -.
DR   MaxQB; P06756; -.
DR   PaxDb; P06756; -.
DR   PRIDE; P06756; -.
DR   Ensembl; ENST00000261023; ENSP00000261023; ENSG00000138448. [P06756-1]
DR   Ensembl; ENST00000374907; ENSP00000364042; ENSG00000138448. [P06756-2]
DR   Ensembl; ENST00000433736; ENSP00000404291; ENSG00000138448. [P06756-3]
DR   GeneID; 3685; -.
DR   KEGG; hsa:3685; -.
DR   UCSC; uc002upq.4; human. [P06756-1]
DR   CTD; 3685; -.
DR   GeneCards; ITGAV; -.
DR   HGNC; HGNC:6150; ITGAV.
DR   HPA; CAB002499; -.
DR   HPA; HPA004856; -.
DR   MIM; 193210; gene.
DR   neXtProt; NX_P06756; -.
DR   PharmGKB; PA37336; -.
DR   eggNOG; ENOG410IPB5; Eukaryota.
DR   eggNOG; ENOG410YR19; LUCA.
DR   GeneTree; ENSGT00760000118782; -.
DR   HOGENOM; HOG000231603; -.
DR   HOVERGEN; HBG006186; -.
DR   InParanoid; P06756; -.
DR   KO; K06487; -.
DR   OMA; SCFNVRF; -.
DR   OrthoDB; EOG7R830R; -.
DR   PhylomeDB; P06756; -.
DR   TreeFam; TF105391; -.
DR   Reactome; R-HSA-1236973; Cross-presentation of particulate exogenous antigens (phagosomes).
DR   Reactome; R-HSA-1566948; Elastic fibre formation.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000157; Laminin interactions.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   SignaLink; P06756; -.
DR   ChiTaRS; ITGAV; human.
DR   EvolutionaryTrace; P06756; -.
DR   GeneWiki; ITGAV; -.
DR   GenomeRNAi; 3685; -.
DR   NextBio; 14423; -.
DR   PMAP-CutDB; B0LPF4; -.
DR   PRO; PR:P06756; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; P06756; -.
DR   CleanEx; HS_ITGAV; -.
DR   ExpressionAtlas; P06756; baseline and differential.
DR   Genevisible; P06756; HS.
DR   GO; GO:0035867; C:alphav-beta3 integrin-IGF-1-IGF1R complex; IDA:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031527; C:filopodium membrane; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0034683; C:integrin alphav-beta3 complex; IDA:UniProtKB.
DR   GO; GO:0034684; C:integrin alphav-beta5 complex; IDA:UniProtKB.
DR   GO; GO:0034686; C:integrin alphav-beta8 complex; IDA:UniProtKB.
DR   GO; GO:0008305; C:integrin complex; NAS:UniProtKB.
DR   GO; GO:0031258; C:lamellipodium membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; ISS:BHF-UCL.
DR   GO; GO:0031528; C:microvillus membrane; IDA:UniProtKB.
DR   GO; GO:0045335; C:phagocytic vesicle; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0032587; C:ruffle membrane; IDA:UniProtKB.
DR   GO; GO:0050840; F:extracellular matrix binding; IDA:UniProtKB.
DR   GO; GO:1990430; F:extracellular matrix protein binding; IDA:UniProtKB.
DR   GO; GO:0001968; F:fibronectin binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002020; F:protease binding; IDA:UniProtKB.
DR   GO; GO:0050431; F:transforming growth factor beta binding; ISS:BHF-UCL.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEP:UniProtKB.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0038027; P:apolipoprotein A-I-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043277; P:apoptotic cell clearance; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0016049; P:cell growth; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0031589; P:cell-substrate adhesion; IMP:UniProtKB.
DR   GO; GO:0035987; P:endodermal cell differentiation; IMP:UniProtKB.
DR   GO; GO:0052066; P:entry of symbiont into host cell by promotion of host phagocytosis; NAS:BHF-UCL.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; ISS:BHF-UCL.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; ISS:BHF-UCL.
DR   GO; GO:0034113; P:heterotypic cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; NAS:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0050919; P:negative chemotaxis; IMP:UniProtKB.
DR   GO; GO:2000536; P:negative regulation of entry of bacterium into host cell; IDA:BHF-UCL.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0010888; P:negative regulation of lipid storage; IMP:BHF-UCL.
DR   GO; GO:0032369; P:negative regulation of lipid transport; IMP:BHF-UCL.
DR   GO; GO:0050748; P:negative regulation of lipoprotein metabolic process; IMP:BHF-UCL.
DR   GO; GO:0045715; P:negative regulation of low-density lipoprotein particle receptor biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0010745; P:negative regulation of macrophage derived foam cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IEA:Ensembl.
DR   GO; GO:2000425; P:regulation of apoptotic cell clearance; ISS:BHF-UCL.
DR   GO; GO:0050764; P:regulation of phagocytosis; IDA:BHF-UCL.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IDA:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0046718; P:viral entry into host cell; IMP:UniProtKB.
DR   InterPro; IPR013517; FG-GAP.
DR   InterPro; IPR013519; Int_alpha_beta-p.
DR   InterPro; IPR000413; Integrin_alpha.
DR   InterPro; IPR013649; Integrin_alpha-2.
DR   InterPro; IPR018184; Integrin_alpha_C_CS.
DR   InterPro; IPR032695; Integrin_dom.
DR   Pfam; PF01839; FG-GAP; 3.
DR   Pfam; PF00357; Integrin_alpha; 1.
DR   Pfam; PF08441; Integrin_alpha2; 1.
DR   PRINTS; PR01185; INTEGRINA.
DR   SMART; SM00191; Int_alpha; 5.
DR   SUPFAM; SSF69179; SSF69179; 3.
DR   PROSITE; PS51470; FG_GAP; 7.
DR   PROSITE; PS00242; INTEGRIN_ALPHA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell adhesion;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction; Integrin;
KW   Membrane; Metal-binding; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     30       {ECO:0000269|PubMed:2467745}.
FT   CHAIN        31   1048       Integrin alpha-V.
FT                                /FTId=PRO_0000016301.
FT   CHAIN        31    889       Integrin alpha-V heavy chain.
FT                                /FTId=PRO_0000016302.
FT   CHAIN       891   1048       Integrin alpha-V light chain.
FT                                /FTId=PRO_0000016303.
FT   TOPO_DOM     31    992       Extracellular. {ECO:0000255}.
FT   TRANSMEM    993   1016       Helical. {ECO:0000255}.
FT   TOPO_DOM   1017   1048       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       32     98       FG-GAP 1.
FT   REPEAT      109    170       FG-GAP 2.
FT   REPEAT      173    225       FG-GAP 3.
FT   REPEAT      237    295       FG-GAP 4.
FT   REPEAT      296    357       FG-GAP 5.
FT   REPEAT      358    415       FG-GAP 6.
FT   REPEAT      419    482       FG-GAP 7.
FT   CA_BIND     260    268       {ECO:0000255}.
FT   CA_BIND     314    322       {ECO:0000255}.
FT   CA_BIND     379    387       {ECO:0000255}.
FT   CA_BIND     443    451       {ECO:0000255}.
FT   MOTIF      1019   1023       GFFKR motif.
FT   CARBOHYD     74     74       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    290    290       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    296    296       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    488    488       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    554    554       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    615    615       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    704    704       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    835    835       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    851    851       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    874    874       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    945    945       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    973    973       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    980    980       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     89     97       {ECO:0000269|PubMed:14596610}.
FT   DISULFID    138    158       {ECO:0000269|PubMed:14596610}.
FT   DISULFID    172    185       {ECO:0000269|PubMed:14596610}.
FT   DISULFID    491    502       {ECO:0000269|PubMed:14596610}.
FT   DISULFID    508    565       {ECO:0000269|PubMed:14596610}.
FT   DISULFID    626    632       {ECO:0000269|PubMed:14596610}.
FT   DISULFID    698    711       {ECO:0000269|PubMed:14596610}.
FT   DISULFID    852    914       Interchain (between heavy and light
FT                                chains). {ECO:0000269|PubMed:14596610}.
FT   DISULFID    904    909       {ECO:0000269|PubMed:14596610}.
FT   VAR_SEQ       1     62       MAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEY
FT                                SGPEGSYFGFAVDFFVPSASS -> MLLGTLLLILYILMLC
FT                                (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044914.
FT   VAR_SEQ     175    211       QDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQG ->
FT                                R (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_024351.
FT   VARIANT     405    405       I -> V (in dbSNP:rs3738918).
FT                                /FTId=VAR_024289.
FT   VARIANT     548    548       S -> A (in dbSNP:rs2230615).
FT                                /FTId=VAR_055970.
FT   VARIANT     783    783       V -> I (in dbSNP:rs2230616).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2430295,
FT                                ECO:0000269|PubMed:2443500,
FT                                ECO:0000269|Ref.4, ECO:0000269|Ref.6,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_031547.
FT   CONFLICT    425    425       W -> R (in Ref. 2; AAG03000).
FT                                {ECO:0000305}.
FT   CONFLICT    700    700       F -> L (in Ref. 8; AAI44101).
FT                                {ECO:0000305}.
FT   CONFLICT   1039   1039       H -> R (in Ref. 2; AAG03000).
FT                                {ECO:0000305}.
FT   STRAND       39     42       {ECO:0000244|PDB:4UM9}.
FT   TURN         45     50       {ECO:0000244|PDB:4UM9}.
FT   STRAND       51     56       {ECO:0000244|PDB:4UM9}.
FT   STRAND       60     62       {ECO:0000244|PDB:4UM9}.
FT   STRAND       65     70       {ECO:0000244|PDB:4UM9}.
FT   STRAND       85     90       {ECO:0000244|PDB:4UM9}.
FT   STRAND       92     94       {ECO:0000244|PDB:4UM9}.
FT   STRAND       97     99       {ECO:0000244|PDB:4UM9}.
FT   STRAND      109    111       {ECO:0000244|PDB:4UM9}.
FT   STRAND      114    118       {ECO:0000244|PDB:4UM9}.
FT   STRAND      126    131       {ECO:0000244|PDB:4UM9}.
FT   STRAND      134    139       {ECO:0000244|PDB:4UM9}.
FT   STRAND      147    150       {ECO:0000244|PDB:4UM9}.
FT   STRAND      157    162       {ECO:0000244|PDB:4UM9}.
FT   STRAND      165    169       {ECO:0000244|PDB:4UM9}.
FT   STRAND      174    176       {ECO:0000244|PDB:4UM9}.
FT   TURN        178    184       {ECO:0000244|PDB:4UM9}.
FT   STRAND      189    193       {ECO:0000244|PDB:4UM9}.
FT   STRAND      197    203       {ECO:0000244|PDB:4UM9}.
FT   HELIX       206    209       {ECO:0000244|PDB:4UM9}.
FT   STRAND      211    217       {ECO:0000244|PDB:4UM9}.
FT   HELIX       218    223       {ECO:0000244|PDB:4UM9}.
FT   STRAND      235    239       {ECO:0000244|PDB:4G1E}.
FT   HELIX       245    247       {ECO:0000244|PDB:4UM9}.
FT   STRAND      254    259       {ECO:0000244|PDB:4UM9}.
FT   STRAND      261    266       {ECO:0000244|PDB:4UM9}.
FT   STRAND      268    273       {ECO:0000244|PDB:4UM9}.
FT   HELIX       276    279       {ECO:0000244|PDB:4UM9}.
FT   STRAND      282    286       {ECO:0000244|PDB:4UM9}.
FT   TURN        288    290       {ECO:0000244|PDB:4UM9}.
FT   STRAND      293    298       {ECO:0000244|PDB:4UM9}.
FT   STRAND      308    313       {ECO:0000244|PDB:4UM9}.
FT   STRAND      315    319       {ECO:0000244|PDB:4UM9}.
FT   STRAND      322    327       {ECO:0000244|PDB:4UM9}.
FT   STRAND      331    333       {ECO:0000244|PDB:4UM9}.
FT   STRAND      335    337       {ECO:0000244|PDB:4G1M}.
FT   STRAND      339    341       {ECO:0000244|PDB:4UM9}.
FT   STRAND      344    350       {ECO:0000244|PDB:4UM9}.
FT   STRAND      352    354       {ECO:0000244|PDB:3IJE}.
FT   STRAND      356    362       {ECO:0000244|PDB:4UM9}.
FT   STRAND      364    368       {ECO:0000244|PDB:1JV2}.
FT   HELIX       370    372       {ECO:0000244|PDB:1U8C}.
FT   STRAND      374    379       {ECO:0000244|PDB:4UM9}.
FT   STRAND      383    385       {ECO:0000244|PDB:4UM9}.
FT   STRAND      387    392       {ECO:0000244|PDB:4UM9}.
FT   HELIX       397    399       {ECO:0000244|PDB:4UM9}.
FT   STRAND      402    409       {ECO:0000244|PDB:4UM9}.
FT   STRAND      410    413       {ECO:0000244|PDB:4UM8}.
FT   STRAND      418    422       {ECO:0000244|PDB:4UM9}.
FT   STRAND      428    430       {ECO:0000244|PDB:4UM9}.
FT   STRAND      434    442       {ECO:0000244|PDB:4UM9}.
FT   STRAND      447    449       {ECO:0000244|PDB:4UM9}.
FT   STRAND      451    456       {ECO:0000244|PDB:4UM9}.
FT   HELIX       457    459       {ECO:0000244|PDB:4UM9}.
FT   STRAND      461    465       {ECO:0000244|PDB:4UM9}.
FT   STRAND      470    484       {ECO:0000244|PDB:4UM9}.
FT   STRAND      494    499       {ECO:0000244|PDB:3IJE}.
FT   STRAND      502    516       {ECO:0000244|PDB:4UM9}.
FT   STRAND      519    528       {ECO:0000244|PDB:4UM9}.
FT   TURN        529    532       {ECO:0000244|PDB:4UM9}.
FT   STRAND      535    537       {ECO:0000244|PDB:4G1M}.
FT   STRAND      541    543       {ECO:0000244|PDB:4UM9}.
FT   TURN        544    547       {ECO:0000244|PDB:4UM9}.
FT   STRAND      548    558       {ECO:0000244|PDB:4UM9}.
FT   STRAND      559    561       {ECO:0000244|PDB:4MMY}.
FT   STRAND      564    572       {ECO:0000244|PDB:4UM9}.
FT   HELIX       575    577       {ECO:0000244|PDB:4UM9}.
FT   STRAND      585    593       {ECO:0000244|PDB:4UM9}.
FT   TURN        595    597       {ECO:0000244|PDB:4UM9}.
FT   STRAND      601    603       {ECO:0000244|PDB:4G1E}.
FT   STRAND      610    612       {ECO:0000244|PDB:4UM9}.
FT   STRAND      614    622       {ECO:0000244|PDB:4UM9}.
FT   TURN        627    630       {ECO:0000244|PDB:3IJE}.
FT   STRAND      636    641       {ECO:0000244|PDB:3IJE}.
FT   STRAND      646    648       {ECO:0000244|PDB:3IJE}.
FT   STRAND      653    663       {ECO:0000244|PDB:3IJE}.
FT   STRAND      668    670       {ECO:0000244|PDB:3IJE}.
FT   STRAND      672    676       {ECO:0000244|PDB:3IJE}.
FT   STRAND      681    686       {ECO:0000244|PDB:3IJE}.
FT   STRAND      691    693       {ECO:0000244|PDB:4G1E}.
FT   STRAND      697    701       {ECO:0000244|PDB:3IJE}.
FT   STRAND      703    705       {ECO:0000244|PDB:3IJE}.
FT   STRAND      708    712       {ECO:0000244|PDB:3IJE}.
FT   STRAND      715    717       {ECO:0000244|PDB:3IJE}.
FT   STRAND      722    731       {ECO:0000244|PDB:3IJE}.
FT   STRAND      735    737       {ECO:0000244|PDB:4G1E}.
FT   STRAND      739    748       {ECO:0000244|PDB:3IJE}.
FT   STRAND      752    754       {ECO:0000244|PDB:3IJE}.
FT   STRAND      760    767       {ECO:0000244|PDB:3IJE}.
FT   STRAND      772    786       {ECO:0000244|PDB:3IJE}.
FT   TURN        798    802       {ECO:0000244|PDB:3IJE}.
FT   STRAND      805    814       {ECO:0000244|PDB:3IJE}.
FT   STRAND      816    818       {ECO:0000244|PDB:3IJE}.
FT   STRAND      820    833       {ECO:0000244|PDB:3IJE}.
FT   STRAND      839    856       {ECO:0000244|PDB:3IJE}.
FT   STRAND      900    902       {ECO:0000244|PDB:3IJE}.
FT   TURN        904    906       {ECO:0000244|PDB:3IJE}.
FT   STRAND      907    916       {ECO:0000244|PDB:3IJE}.
FT   STRAND      923    933       {ECO:0000244|PDB:3IJE}.
FT   HELIX       935    938       {ECO:0000244|PDB:3IJE}.
FT   STRAND      941    944       {ECO:0000244|PDB:3IJE}.
FT   STRAND      948    960       {ECO:0000244|PDB:3IJE}.
FT   STRAND      964    966       {ECO:0000244|PDB:4G1E}.
FT   STRAND      971    982       {ECO:0000244|PDB:3IJE}.
SQ   SEQUENCE   1048 AA;  116038 MW;  364EE25C5303A2D7 CRC64;
     MAFPPRRRLR LGPRGLPLLL SGLLLPLCRA FNLDVDSPAE YSGPEGSYFG FAVDFFVPSA
     SSRMFLLVGA PKANTTQPGI VEGGQVLKCD WSSTRRCQPI EFDATGNRDY AKDDPLEFKS
     HQWFGASVRS KQDKILACAP LYHWRTEMKQ EREPVGTCFL QDGTKTVEYA PCRSQDIDAD
     GQGFCQGGFS IDFTKADRVL LGGPGSFYWQ GQLISDQVAE IVSKYDPNVY SIKYNNQLAT
     RTAQAIFDDS YLGYSVAVGD FNGDGIDDFV SGVPRAARTL GMVYIYDGKN MSSLYNFTGE
     QMAAYFGFSV AATDINGDDY ADVFIGAPLF MDRGSDGKLQ EVGQVSVSLQ RASGDFQTTK
     LNGFEVFARF GSAIAPLGDL DQDGFNDIAI AAPYGGEDKK GIVYIFNGRS TGLNAVPSQI
     LEGQWAARSM PPSFGYSMKG ATDIDKNGYP DLIVGAFGVD RAILYRARPV ITVNAGLEVY
     PSILNQDNKT CSLPGTALKV SCFNVRFCLK ADGKGVLPRK LNFQVELLLD KLKQKGAIRR
     ALFLYSRSPS HSKNMTISRG GLMQCEELIA YLRDESEFRD KLTPITIFME YRLDYRTAAD
     TTGLQPILNQ FTPANISRQA HILLDCGEDN VCKPKLEVSV DSDQKKIYIG DDNPLTLIVK
     AQNQGEGAYE AELIVSIPLQ ADFIGVVRNN EALARLSCAF KTENQTRQVV CDLGNPMKAG
     TQLLAGLRFS VHQQSEMDTS VKFDLQIQSS NLFDKVSPVV SHKVDLAVLA AVEIRGVSSP
     DHVFLPIPNW EHKENPETEE DVGPVVQHIY ELRNNGPSSF SKAMLHLQWP YKYNNNTLLY
     ILHYDIDGPM NCTSDMEINP LRIKISSLQT TEKNDTVAGQ GERDHLITKR DLALSEGDIH
     TLGCGVAQCL KIVCQVGRLD RGKSAILYVK SLLWTETFMN KENQNHSYSL KSSASFNVIE
     FPYKNLPIED ITNSTLVTTN VTWGIQPAPM PVPVWVIILA VLAGLLLLAV LVFVMYRMGF
     FKRVRPPQEE QEREQLQPHE NGEGNSET
//
ID   IGF1_MOUSE              Reviewed;         153 AA.
AC   P05017; P05018; Q6LDP4; Q8C4U6;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   07-DEC-2004, sequence version 2.
DT   20-JAN-2016, entry version 161.
DE   RecName: Full=Insulin-like growth factor I;
DE            Short=IGF-I;
DE   AltName: Full=Somatomedin;
DE   Flags: Precursor;
GN   Name=Igf1; Synonyms=Igf-1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM IGF-IA).
RC   STRAIN=C57BL/6J; TISSUE=Cerebellum;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 18-153 (ISOFORM IGF-IB).
RC   STRAIN=FVB/N; TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 27-153 (ISOFORMS IGF-IA AND IGF-IB).
RC   TISSUE=Liver;
RX   PubMed=3774549; DOI=10.1093/nar/14.20.7873;
RA   Bell G.I., Stempien M.M., Fong N.M., Rall L.B.;
RT   "Sequences of liver cDNAs encoding two different mouse insulin-like
RT   growth factor I precursors.";
RL   Nucleic Acids Res. 14:7873-7882(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 75-134.
RX   PubMed=2474537;
RA   Tollefsen S.E., Lajara R., McCusker R.H., Clemmons D.R., Rotwein P.;
RT   "Insulin-like growth factors (IGF) in muscle development. Expression
RT   of IGF-I, the IGF-I receptor, and an IGF binding protein during
RT   myoblast differentiation.";
RL   J. Biol. Chem. 264:13810-13817(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 75-134.
RX   PubMed=3467309; DOI=10.1073/pnas.83.24.9343;
RA   Mathews L.S., Norstedt G., Palmiter R.D.;
RT   "Regulation of insulin-like growth factor I gene expression by growth
RT   hormone.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:9343-9347(1986).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [7]
RP   INDUCTION.
RX   PubMed=20685873; DOI=10.1210/en.2010-0407;
RA   Kawai M., Delany A.M., Green C.B., Adamo M.L., Rosen C.J.;
RT   "Nocturnin suppresses igf1 expression in bone by targeting the 3'
RT   untranslated region of igf1 mRNA.";
RL   Endocrinology 151:4861-4870(2010).
CC   -!- FUNCTION: The insulin-like growth factors, isolated from plasma,
CC       are structurally and functionally related to insulin but have a
CC       much higher growth-promoting activity. May be a physiological
CC       regulator of [1-14C]-2-deoxy-D-glucose (2DG) transport and
CC       glycogen synthesis in osteoblasts. Stimulates glucose transport in
CC       rat bone-derived osteoblastic (PyMS) cells and is effective at
CC       much lower concentrations than insulin, not only regarding
CC       glycogen and DNA synthesis but also with regard to enhancing
CC       glucose uptake. May play a role in synapse maturation (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=IGF-IA;
CC         IsoId=P05017-1; Sequence=Displayed;
CC       Name=IGF-IB;
CC         IsoId=P05017-2; Sequence=VSP_012165;
CC   -!- INDUCTION: Expression in the bone oscillates in a circadian manner
CC       and its expression is negatively regulated by CCRN4L/NOC.
CC       {ECO:0000269|PubMed:20685873}.
CC   -!- SIMILARITY: Belongs to the insulin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH12409.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK081019; BAC38117.1; -; mRNA.
DR   EMBL; BC012409; AAH12409.1; ALT_INIT; mRNA.
DR   EMBL; X04480; CAA28168.1; -; mRNA.
DR   EMBL; X04482; CAA28170.1; -; mRNA.
DR   EMBL; M28139; AAA74553.1; -; Genomic_DNA.
DR   EMBL; M14983; AAA37925.1; -; Genomic_DNA.
DR   CCDS; CCDS48661.1; -. [P05017-1]
DR   PIR; A25540; A25540.
DR   RefSeq; NP_001104745.1; NM_001111275.2. [P05017-1]
DR   RefSeq; NP_001300939.1; NM_001314010.1. [P05017-1]
DR   RefSeq; NP_034642.2; NM_010512.5.
DR   RefSeq; XP_006513329.1; XM_006513266.2.
DR   UniGene; Mm.268521; -.
DR   ProteinModelPortal; P05017; -.
DR   SMR; P05017; 50-111.
DR   MINT; MINT-266530; -.
DR   iPTMnet; P05017; -.
DR   PhosphoSite; P05017; -.
DR   MaxQB; P05017; -.
DR   PRIDE; P05017; -.
DR   Ensembl; ENSMUST00000095360; ENSMUSP00000093005; ENSMUSG00000020053. [P05017-1]
DR   Ensembl; ENSMUST00000122386; ENSMUSP00000113905; ENSMUSG00000020053. [P05017-1]
DR   GeneID; 16000; -.
DR   UCSC; uc007gqw.2; mouse. [P05017-1]
DR   CTD; 3479; -.
DR   MGI; MGI:96432; Igf1.
DR   HOGENOM; HOG000233362; -.
DR   HOVERGEN; HBG006137; -.
DR   InParanoid; P05017; -.
DR   OrthoDB; EOG7TF7CG; -.
DR   Reactome; R-MMU-114608; Platelet degranulation.
DR   Reactome; R-MMU-2404192; Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R).
DR   Reactome; R-MMU-2428928; IRS-related events triggered by IGF1R.
DR   Reactome; R-MMU-2428933; SHC-related events triggered by IGF1R.
DR   Reactome; R-MMU-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-MMU-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   ChiTaRS; Igf1; mouse.
DR   NextBio; 288784; -.
DR   PRO; PR:P05017; -.
DR   Proteomes; UP000000589; Chromosome 10.
DR   Bgee; P05017; -.
DR   CleanEx; MM_IGF1; -.
DR   ExpressionAtlas; P05017; baseline and differential.
DR   Genevisible; P05017; MM.
DR   GO; GO:0005623; C:cell; IDA:GOC.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0042567; C:insulin-like growth factor ternary complex; ISS:BHF-UCL.
DR   GO; GO:0005622; C:intracellular; ISO:GOC.
DR   GO; GO:0005179; F:hormone activity; ISO:MGI.
DR   GO; GO:0005158; F:insulin receptor binding; IDA:MGI.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; IPI:MGI.
DR   GO; GO:0005178; F:integrin binding; ISO:MGI.
DR   GO; GO:0001974; P:blood vessel remodeling; IMP:MGI.
DR   GO; GO:0035630; P:bone mineralization involved in bone maturation; ISO:MGI.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IMP:MGI.
DR   GO; GO:0001775; P:cell activation; ISO:MGI.
DR   GO; GO:0048468; P:cell development; IMP:MGI.
DR   GO; GO:0008283; P:cell proliferation; ISO:MGI.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IDA:MGI.
DR   GO; GO:1990314; P:cellular response to insulin-like growth factor stimulus; IMP:MGI.
DR   GO; GO:0050650; P:chondroitin sulfate proteoglycan biosynthetic process; IDA:MGI.
DR   GO; GO:0007623; P:circadian rhythm; IEP:UniProtKB.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; ISO:MGI.
DR   GO; GO:0031017; P:exocrine pancreas development; IMP:MGI.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IDA:MGI.
DR   GO; GO:0010001; P:glial cell differentiation; IMP:MGI.
DR   GO; GO:0048839; P:inner ear development; IDA:MGI.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IDA:MGI.
DR   GO; GO:0048286; P:lung alveolus development; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IGI:MGI.
DR   GO; GO:0060463; P:lung lobe morphogenesis; IMP:MGI.
DR   GO; GO:0060426; P:lung vasculature development; IMP:MGI.
DR   GO; GO:0030879; P:mammary gland development; IMP:MGI.
DR   GO; GO:0035264; P:multicellular organism growth; IDA:MGI.
DR   GO; GO:0014896; P:muscle hypertrophy; ISO:MGI.
DR   GO; GO:0045445; P:myoblast differentiation; ISO:MGI.
DR   GO; GO:0051450; P:myoblast proliferation; ISO:MGI.
DR   GO; GO:0014904; P:myotube cell development; ISO:MGI.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; IMP:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:MGI.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IGI:MGI.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; ISO:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0060283; P:negative regulation of oocyte development; ISO:MGI.
DR   GO; GO:0050732; P:negative regulation of peptidyl-tyrosine phosphorylation; IMP:MGI.
DR   GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; IDA:UniProtKB.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; ISO:MGI.
DR   GO; GO:0007399; P:nervous system development; IMP:MGI.
DR   GO; GO:0001649; P:osteoblast differentiation; IEP:BHF-UCL.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; ISO:MGI.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; ISO:MGI.
DR   GO; GO:0042104; P:positive regulation of activated T cell proliferation; ISO:MGI.
DR   GO; GO:0070886; P:positive regulation of calcineurin-NFAT signaling cascade; ISO:MGI.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISO:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IGI:MGI.
DR   GO; GO:0021940; P:positive regulation of cerebellar granule cell precursor proliferation; IDA:MGI.
DR   GO; GO:0043388; P:positive regulation of DNA binding; ISO:MGI.
DR   GO; GO:0045740; P:positive regulation of DNA replication; ISO:MGI.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISO:MGI.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; ISO:MGI.
DR   GO; GO:0046326; P:positive regulation of glucose import; ISS:UniProtKB.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; ISO:MGI.
DR   GO; GO:0010560; P:positive regulation of glycoprotein biosynthetic process; ISO:MGI.
DR   GO; GO:0043568; P:positive regulation of insulin-like growth factor receptor signaling pathway; ISO:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:MGI.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISO:MGI.
DR   GO; GO:2000288; P:positive regulation of myoblast proliferation; IMP:MGI.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISO:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:MGI.
DR   GO; GO:0033160; P:positive regulation of protein import into nucleus, translocation; ISO:MGI.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:MGI.
DR   GO; GO:0050714; P:positive regulation of protein secretion; ISO:MGI.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; ISO:MGI.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; ISO:MGI.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; ISO:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; ISO:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:1904075; P:positive regulation of trophectodermal cell proliferation; ISO:MGI.
DR   GO; GO:0042523; P:positive regulation of tyrosine phosphorylation of Stat5 protein; ISO:MGI.
DR   GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; IMP:MGI.
DR   GO; GO:0060740; P:prostate gland epithelium morphogenesis; IMP:MGI.
DR   GO; GO:0060736; P:prostate gland growth; IDA:MGI.
DR   GO; GO:0060741; P:prostate gland stromal morphogenesis; IMP:MGI.
DR   GO; GO:0043491; P:protein kinase B signaling; ISO:MGI.
DR   GO; GO:0050821; P:protein stabilization; ISO:MGI.
DR   GO; GO:0030166; P:proteoglycan biosynthetic process; ISO:MGI.
DR   GO; GO:0032878; P:regulation of establishment or maintenance of cell polarity; IDA:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:MGI.
DR   GO; GO:0045428; P:regulation of nitric oxide biosynthetic process; IMP:MGI.
DR   GO; GO:0051246; P:regulation of protein metabolic process; IGI:MGI.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IDA:MGI.
DR   GO; GO:0009408; P:response to heat; ISO:MGI.
DR   GO; GO:0014834; P:skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration; ISO:MGI.
DR   GO; GO:0060509; P:Type I pneumocyte differentiation; IMP:MGI.
DR   GO; GO:0060510; P:Type II pneumocyte differentiation; IMP:MGI.
DR   GO; GO:0030104; P:water homeostasis; IGI:MGI.
DR   Gene3D; 1.10.100.10; -; 1.
DR   InterPro; IPR022341; IGF-I.
DR   InterPro; IPR016179; Insulin-like.
DR   InterPro; IPR022350; Insulin-like_growth_factor.
DR   InterPro; IPR022353; Insulin_CS.
DR   InterPro; IPR022352; Insulin_family.
DR   Pfam; PF00049; Insulin; 2.
DR   PRINTS; PR02002; INSLNLIKEGF.
DR   PRINTS; PR02005; INSLNLIKEGF1.
DR   PRINTS; PR00276; INSULINFAMLY.
DR   SMART; SM00078; IlGF; 1.
DR   SUPFAM; SSF56994; SSF56994; 1.
DR   PROSITE; PS00262; INSULIN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disulfide bond;
KW   Growth factor; Reference proteome; Secreted; Signal.
FT   SIGNAL        1      ?       {ECO:0000255}.
FT   PROPEP        ?     48       {ECO:0000250}.
FT                                /FTId=PRO_0000015666.
FT   CHAIN        49    118       Insulin-like growth factor I.
FT                                /FTId=PRO_0000015667.
FT   PROPEP      119    153       E peptide.
FT                                /FTId=PRO_0000015668.
FT   REGION       49     77       B.
FT   REGION       78     89       C.
FT   REGION       90    110       A.
FT   REGION      111    118       D.
FT   DISULFID     54     96       {ECO:0000250}.
FT   DISULFID     66    109       {ECO:0000250}.
FT   DISULFID     95    100       {ECO:0000250}.
FT   VAR_SEQ     135    153       EVHLKNTSRGSAGNKTYRM -> SPSLSTNKKTKLQRRRKG
FT                                STFEE (in isoform IGF-IB).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:3774549}.
FT                                /FTId=VSP_012165.
SQ   SEQUENCE   153 AA;  17093 MW;  967596AEAC0CA387 CRC64;
     MGKISSLPTQ LFKICLCDFL KIKIHIMSSS HLFYLALCLL TFTSSTTAGP ETLCGAELVD
     ALQFVCGPRG FYFNKPTGYG SSIRRAPQTG IVDECCFRSC DLRRLEMYCA PLKPTKAARS
     IRAQRHTDMP KTQKEVHLKN TSRGSAGNKT YRM
//
ID   ATL4_HUMAN              Reviewed;        1074 AA.
AC   Q6UY14; B2RTT0; F8WAD0; Q5T5F7; Q6IPM6; Q8N643; Q9HBS6;
DT   31-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2006, sequence version 2.
DT   20-JAN-2016, entry version 114.
DE   RecName: Full=ADAMTS-like protein 4;
DE            Short=ADAMTSL-4;
DE   AltName: Full=Thrombospondin repeat-containing protein 1;
DE   Flags: Precursor;
GN   Name=ADAMTSL4; Synonyms=TSRC1 {ECO:0000312|EMBL:CAI15499.1};
GN   ORFNames=PP1396, UNQ2803/PRO34012;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAQ88489.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [2] {ECO:0000312|EMBL:CAI15499.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [3] {ECO:0000305, ECO:0000312|EMBL:AAH71852.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 425-1074 (ISOFORM 1), AND VARIANT
RP   PRO-193.
RC   TISSUE=Lung {ECO:0000312|EMBL:AAH71852.1}, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 638-1074.
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H.,
RA   Qiu X., Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y.,
RA   Shu H., Chen X., Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S.,
RA   Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [5] {ECO:0000305}
RP   IDENTIFICATION (ISOFORM 1).
RX   PubMed=12706885; DOI=10.1016/S0378-1119(03)00423-2;
RA   Buchner D.A., Meisler M.H.;
RT   "TSRC1, a widely expressed gene containing seven thrombospondin type I
RT   repeats.";
RL   Gene 307:23-30(2003).
RN   [6]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-490.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [7] {ECO:0000305}
RP   FUNCTION, AND INTERACTION WITH CTSB.
RX   PubMed=16364318; DOI=10.1016/j.febslet.2005.12.005;
RA   Liu J., Guo Q., Chen B., Yu Y., Lu H., Li Y.-Y.;
RT   "Cathepsin B and its interacting proteins, bikunin and TSRC1,
RT   correlate with TNF-induced apoptosis of ovarian cancer cells OV-90.";
RL   FEBS Lett. 580:245-250(2006).
RN   [8]
RP   TISSUE SPECIFICITY, AND INVOLVEMENT IN ECTOL2.
RX   PubMed=19200529; DOI=10.1016/j.ajhg.2009.01.007;
RA   Ahram D., Sato T.S., Kohilan A., Tayeh M., Chen S., Leal S.,
RA   Al-Salem M., El-Shanti H.;
RT   "A homozygous mutation in ADAMTSL4 causes autosomal-recessive isolated
RT   ectopia lentis.";
RL   Am. J. Hum. Genet. 84:274-278(2009).
RN   [9]
RP   GLYCOSYLATION AT ASN-490.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [10]
RP   INVOLVEMENT IN ECTOLP.
RX   PubMed=20702823; DOI=10.1167/iovs.10-5597;
RA   Christensen A.E., Fiskerstrand T., Knappskog P.M., Boman H.,
RA   Roedahl E.;
RT   "A novel ADAMTSL4 mutation in autosomal recessive ectopia lentis et
RT   pupillae.";
RL   Invest. Ophthalmol. Vis. Sci. 51:6369-6373(2010).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH FBN1, AND
RP   GLYCOSYLATION.
RX   PubMed=21989719; DOI=10.1167/iovs.10-5955;
RA   Gabriel L.A., Wang L.W., Bader H., Ho J.C., Majors A.K.,
RA   Hollyfield J.G., Traboulsi E.I., Apte S.S.;
RT   "ADAMTSL4, a secreted glycoprotein widely distributed in the eye,
RT   binds Fibrillin-1 microfibrils and accelerates microfibril
RT   biogenesis.";
RL   Invest. Ophthalmol. Vis. Sci. 53:461-469(2012).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Positive regulation of apoptosis. May facilitate FBN1
CC       microfibril biogenesis. {ECO:0000269|PubMed:16364318,
CC       ECO:0000269|PubMed:21989719}.
CC   -!- SUBUNIT: Interacts with CTSB. Interacts with FBN1.
CC       {ECO:0000269|PubMed:16364318, ECO:0000269|PubMed:21989719}.
CC   -!- INTERACTION:
CC       Q53FW8:-; NbExp=3; IntAct=EBI-10173507, EBI-10242473;
CC       Q6ZMM2-2:ADAMTSL5; NbExp=3; IntAct=EBI-10173507, EBI-10254938;
CC       Q9Y4X0:AMMECR1; NbExp=3; IntAct=EBI-10173507, EBI-8583355;
CC       B3KTP4:ApoL6; NbExp=3; IntAct=EBI-10173507, EBI-10175904;
CC       Q9BZE9:ASPSCR1; NbExp=3; IntAct=EBI-10173507, EBI-1993677;
CC       Q9NUL5:C19orf66; NbExp=3; IntAct=EBI-10173507, EBI-10313866;
CC       Q8IYR0:C6orf165; NbExp=3; IntAct=EBI-10173507, EBI-749051;
CC       Q8TAB7:CCDC26; NbExp=3; IntAct=EBI-10173507, EBI-10271580;
CC       Q9Y6H1:CHCHD2; NbExp=3; IntAct=EBI-10173507, EBI-2321769;
CC       A5D8T8:CLEC18A; NbExp=3; IntAct=EBI-10173507, EBI-10173491;
CC       Q9UBL6:CPNE7; NbExp=3; IntAct=EBI-10173507, EBI-744841;
CC       Q02930-3:CREB5; NbExp=3; IntAct=EBI-10173507, EBI-10192698;
CC       P09228:CST2; NbExp=3; IntAct=EBI-10173507, EBI-8832659;
CC       P07858:CTSB; NbExp=3; IntAct=EBI-742002, EBI-715062;
CC       Q96SQ9:CYP2S1; NbExp=3; IntAct=EBI-10173507, EBI-8633740;
CC       Q14689-6:DIP2A; NbExp=3; IntAct=EBI-10173507, EBI-10233719;
CC       Q96T75:DSCR8; NbExp=3; IntAct=EBI-10173507, EBI-10294182;
CC       O60573:EIF4E2; NbExp=3; IntAct=EBI-10173507, EBI-398610;
CC       P16930:FAH; NbExp=3; IntAct=EBI-10173507, EBI-4397076;
CC       Q9H5Z6:FAM124B; NbExp=3; IntAct=EBI-10173507, EBI-741626;
CC       O95363:FARS2; NbExp=3; IntAct=EBI-10173507, EBI-2513774;
CC       Q969U6:FBXW5; NbExp=3; IntAct=EBI-10173507, EBI-741068;
CC       P68106:FKBP1B; NbExp=3; IntAct=EBI-10173507, EBI-6693977;
CC       P21333-2:FLNA; NbExp=3; IntAct=EBI-10173507, EBI-9641086;
CC       O43559:FRS3; NbExp=3; IntAct=EBI-10173507, EBI-725515;
CC       P23769:GATA2; NbExp=3; IntAct=EBI-10173507, EBI-2806671;
CC       P09681:GIP; NbExp=3; IntAct=EBI-10173507, EBI-8588553;
CC       Q8NEA9:GMCL1P1; NbExp=3; IntAct=EBI-10173507, EBI-745707;
CC       Q9Y223:GNE; NbExp=3; IntAct=EBI-10173507, EBI-4291090;
CC       Q0D2H9:GOLGA8DP; NbExp=3; IntAct=EBI-10173507, EBI-10181276;
CC       V9HW60:HEL-S-182mP; NbExp=3; IntAct=EBI-10173507, EBI-10180762;
CC       P14210:HGF; NbExp=3; IntAct=EBI-10173507, EBI-1039104;
CC       P49639:HOXA1; NbExp=3; IntAct=EBI-10173507, EBI-740785;
CC       P09022:Hoxa1 (xeno); NbExp=3; IntAct=EBI-742002, EBI-3957603;
CC       P60412:KRTAP10-11; NbExp=3; IntAct=EBI-10173507, EBI-10217483;
CC       P60370:KRTAP10-5; NbExp=3; IntAct=EBI-10173507, EBI-10172150;
CC       P60410:KRTAP10-8; NbExp=3; IntAct=EBI-10173507, EBI-10171774;
CC       P60411:KRTAP10-9; NbExp=3; IntAct=EBI-10173507, EBI-10172052;
CC       Q9BYQ6:KRTAP4-11; NbExp=3; IntAct=EBI-10173507, EBI-10302392;
CC       Q9BQ66:KRTAP4-12; NbExp=3; IntAct=EBI-10173507, EBI-739863;
CC       Q9BYR5:KRTAP4-2; NbExp=3; IntAct=EBI-10173507, EBI-10172511;
CC       Q6L8G9:KRTAP5-6; NbExp=3; IntAct=EBI-10173507, EBI-10250562;
CC       P26371:KRTAP5-9; NbExp=5; IntAct=EBI-10173507, EBI-3958099;
CC       Q9BYQ4:KRTAP9-2; NbExp=3; IntAct=EBI-10173507, EBI-1044640;
CC       Q9BYQ2:KRTAP9-4; NbExp=3; IntAct=EBI-10173507, EBI-10185730;
CC       Q5T7P3:LCE1B; NbExp=3; IntAct=EBI-10173507, EBI-10245913;
CC       Q5TA82:LCE2D; NbExp=3; IntAct=EBI-10173507, EBI-10246750;
CC       Q5T5A8:LCE3C; NbExp=3; IntAct=EBI-10173507, EBI-10245291;
CC       Q5T5B0:LCE3E; NbExp=3; IntAct=EBI-10173507, EBI-10245456;
CC       Q5TA78:LCE4A; NbExp=3; IntAct=EBI-10173507, EBI-10246358;
CC       Q8TCE9:LGALS14; NbExp=3; IntAct=EBI-10173507, EBI-10274069;
CC       P25800:LMO1; NbExp=3; IntAct=EBI-10173507, EBI-8639312;
CC       P25791:LMO2; NbExp=3; IntAct=EBI-10173507, EBI-739696;
CC       Q17RB8:LONRF1; NbExp=3; IntAct=EBI-10173507, EBI-2341787;
CC       Q8WV35:LRRC29; NbExp=3; IntAct=EBI-10173507, EBI-10276755;
CC       O60336:MAPKBP1; NbExp=3; IntAct=EBI-10173507, EBI-947402;
CC       Q9UJV3-2:MID2; NbExp=3; IntAct=EBI-10173507, EBI-10172526;
CC       Q6PF18:MORN3; NbExp=3; IntAct=EBI-10173507, EBI-9675802;
CC       Q8N6N6:NATD1; NbExp=3; IntAct=EBI-10173507, EBI-8656665;
CC       Q9GZQ4:NMUR2; NbExp=3; IntAct=EBI-10173507, EBI-10303844;
CC       P34130:NTF4; NbExp=3; IntAct=EBI-10173507, EBI-3907456;
CC       Q96PB7:OLFM3; NbExp=3; IntAct=EBI-10173507, EBI-10292253;
CC       Q7Z2X4:PID1; NbExp=3; IntAct=EBI-10173507, EBI-10256685;
CC       Q13526:PIN1; NbExp=3; IntAct=EBI-10173507, EBI-714158;
CC       Q147X8:PTGER3; NbExp=3; IntAct=EBI-10173507, EBI-10234038;
CC       Q8WUD1:RAB2B; NbExp=3; IntAct=EBI-10173507, EBI-5542466;
CC       Q96PM5:RCHY1; NbExp=3; IntAct=EBI-10173507, EBI-947779;
CC       Q9H4E5:RHOJ; NbExp=3; IntAct=EBI-10173507, EBI-6285694;
CC       Q9UHI7:SLC23A1; NbExp=3; IntAct=EBI-10173507, EBI-1759386;
CC       Q9NP91:SLC6A20; NbExp=3; IntAct=EBI-10173507, EBI-10311198;
CC       Q92922:SMARCC1; NbExp=3; IntAct=EBI-10173507, EBI-355653;
CC       Q6RVD6:SPATA8; NbExp=3; IntAct=EBI-10173507, EBI-8635958;
CC       P20155:SPINK2; NbExp=3; IntAct=EBI-10173507, EBI-10200479;
CC       O75716:STK16; NbExp=3; IntAct=EBI-742002, EBI-749295;
CC       Q92537:SUSD6; NbExp=3; IntAct=EBI-10173507, EBI-2866213;
CC       Q15560:TCEA2; NbExp=3; IntAct=EBI-10173507, EBI-710310;
CC       Q86TG1:TMEM150A; NbExp=3; IntAct=EBI-10173507, EBI-2799342;
CC       O95985:TOP3B; NbExp=3; IntAct=EBI-10173507, EBI-373403;
CC       Q8IWZ5:TRIM42; NbExp=3; IntAct=EBI-10173507, EBI-5235829;
CC       Q15654:TRIP6; NbExp=3; IntAct=EBI-10173507, EBI-742327;
CC       Q96PN8:TSSK3; NbExp=3; IntAct=EBI-10173507, EBI-3918381;
CC       Q8TAU3:ZNF417; NbExp=3; IntAct=EBI-10173507, EBI-740727;
CC       Q96SQ5:ZNF587; NbExp=3; IntAct=EBI-10173507, EBI-6427977;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000269|PubMed:21989719}. Note=Colocalizes with FMN1
CC       microfibrils in the eye ECM.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1 {ECO:0000269|PubMed:12706885};
CC         IsoId=Q6UY14-1; Sequence=Displayed;
CC         Note=Gene prediction confirmed by EST data. {ECO:0000305};
CC       Name=2 {ECO:0000269|PubMed:12975309};
CC         IsoId=Q6UY14-2; Sequence=VSP_052183, VSP_052184;
CC         Note=No experimental confirmation available. {ECO:0000305};
CC       Name=3;
CC         IsoId=Q6UY14-3; Sequence=VSP_055759;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in colon, heart, leukocyte, liver,
CC       lung, skeletal muscle, spleen, testis and placenta. Weaker
CC       expression in bone marrow, brain tissue, kidney and pancreas.
CC       Expression studies in fetal tissues reveal strong expression in
CC       heart, kidney, liver, lung and skeletal muscle, but weaker
CC       expression in fetal brain and skin. {ECO:0000269|PubMed:19200529}.
CC   -!- PTM: N-glycosylated. Can be O-fucosylated by POFUT2 on a serine or
CC       a threonine residue found within the consensus sequence C1-X(2)-
CC       (S/T)-C2-G of the TSP type-1 repeat domains where C1 and C2 are
CC       the first and second cysteine residue of the repeat, respectively.
CC       Fucosylated repeats can then be further glycosylated by the
CC       addition of a beta-1,3-glucose residue by the glucosyltransferase,
CC       B3GALTL. Fucosylation mediates the efficient secretion of ADAMTS
CC       family members. Also can be C-glycosylated with one or two mannose
CC       molecules on tryptophan residues within the consensus sequence W-
CC       X-X-W of the TPRs. N- and C-glycosylations can also facilitate
CC       secretion (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Ectopia lentis 2, isolated, autosomal recessive (ECTOL2)
CC       [MIM:225100]: An ocular abnormality characterized by partial or
CC       complete displacement of the lens from its space resulting from
CC       defective zonule formation. {ECO:0000269|PubMed:19200529}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Ectopia lentis et pupillae (ECTOLP) [MIM:225200]: An
CC       ocular abnormality characterized by displacement of the lenses and
CC       the pupils, associated with other ocular anomalies, but without
CC       systemic manifestations. The condition is usually bilateral, with
CC       the lenses and pupils displaced in opposite directions. Additional
CC       signs include enlarged corneal diameter, increased corneal
CC       astigmatism, increased anterior chamber depth, thinning and
CC       flattening of the iris with loss of crypts, angle malformation
CC       caused by enlarged iris processes, persistent pupillary membrane,
CC       loss of zonular fibers, tilted disk, and increased axial length.
CC       Secondary manifestations include refractive errors, glaucoma,
CC       early cataract development, and retinal detachment. Membrane
CC       formation on the posterior aspect of the iris has been observed
CC       both in histologic sections and on ultrasound biomicroscopy.
CC       {ECO:0000269|PubMed:20702823}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 1 PLAC domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00233}.
CC   -!- SIMILARITY: Contains 6 TSP type-1 domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00210}.
CC   -!- CAUTION: Although similar to members of the ADAMTS family, it
CC       lacks the metalloprotease and disintegrin-like domains which are
CC       typical of that family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAG17217.1; Type=Frameshift; Positions=719; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY358122; AAQ88489.1; -; mRNA.
DR   EMBL; AL356356; CAI15499.1; -; Genomic_DNA.
DR   EMBL; AL356356; CAI15500.2; -; Genomic_DNA.
DR   EMBL; BC027478; AAH27478.2; -; mRNA.
DR   EMBL; BC071852; AAH71852.1; -; mRNA.
DR   EMBL; BC094811; AAH94811.1; -; mRNA.
DR   EMBL; BC140800; AAI40801.1; -; mRNA.
DR   EMBL; AF217974; AAG17217.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS30852.1; -. [Q6UY14-2]
DR   CCDS; CCDS72908.1; -. [Q6UY14-3]
DR   CCDS; CCDS955.1; -. [Q6UY14-1]
DR   RefSeq; NP_001275536.1; NM_001288607.1.
DR   RefSeq; NP_001275537.1; NM_001288608.1. [Q6UY14-3]
DR   RefSeq; NP_061905.2; NM_019032.5. [Q6UY14-1]
DR   RefSeq; NP_079284.2; NM_025008.4. [Q6UY14-2]
DR   RefSeq; XP_011507948.1; XM_011509646.1. [Q6UY14-3]
DR   RefSeq; XP_011507949.1; XM_011509647.1. [Q6UY14-3]
DR   RefSeq; XP_011507950.1; XM_011509648.1. [Q6UY14-3]
DR   UniGene; Hs.516243; -.
DR   ProteinModelPortal; Q6UY14; -.
DR   SMR; Q6UY14; 364-548.
DR   BioGrid; 120002; 107.
DR   IntAct; Q6UY14; 99.
DR   MINT; MINT-1445070; -.
DR   STRING; 9606.ENSP00000271643; -.
DR   iPTMnet; Q6UY14; -.
DR   PhosphoSite; Q6UY14; -.
DR   BioMuta; ADAMTSL4; -.
DR   DMDM; 118573317; -.
DR   PaxDb; Q6UY14; -.
DR   PRIDE; Q6UY14; -.
DR   DNASU; 54507; -.
DR   Ensembl; ENST00000271643; ENSP00000271643; ENSG00000143382. [Q6UY14-1]
DR   Ensembl; ENST00000369038; ENSP00000358034; ENSG00000143382. [Q6UY14-1]
DR   Ensembl; ENST00000369039; ENSP00000358035; ENSG00000143382. [Q6UY14-3]
DR   Ensembl; ENST00000369041; ENSP00000358037; ENSG00000143382. [Q6UY14-2]
DR   GeneID; 54507; -.
DR   KEGG; hsa:54507; -.
DR   UCSC; uc001euw.3; human. [Q6UY14-2]
DR   UCSC; uc001eux.3; human. [Q6UY14-1]
DR   CTD; 54507; -.
DR   GeneCards; ADAMTSL4; -.
DR   GeneReviews; ADAMTSL4; -.
DR   HGNC; HGNC:19706; ADAMTSL4.
DR   HPA; HPA006279; -.
DR   MalaCards; ADAMTSL4; -.
DR   MIM; 225100; phenotype.
DR   MIM; 225200; phenotype.
DR   MIM; 610113; gene.
DR   neXtProt; NX_Q6UY14; -.
DR   Orphanet; 1885; Isolated ectopia lentis.
DR   PharmGKB; PA134879921; -.
DR   eggNOG; KOG3538; Eukaryota.
DR   eggNOG; KOG4597; Eukaryota.
DR   eggNOG; ENOG41102GD; LUCA.
DR   GeneTree; ENSGT00760000118885; -.
DR   HOGENOM; HOG000034174; -.
DR   HOVERGEN; HBG080879; -.
DR   InParanoid; Q6UY14; -.
DR   OMA; RCGRGQR; -.
DR   OrthoDB; EOG73FQKT; -.
DR   PhylomeDB; Q6UY14; -.
DR   TreeFam; TF316874; -.
DR   Reactome; R-HSA-5173214; O-glycosylation of TSR domain-containing proteins.
DR   ChiTaRS; ADAMTSL4; human.
DR   GeneWiki; ADAMTSL4; -.
DR   GenomeRNAi; 54507; -.
DR   NextBio; 35468390; -.
DR   PRO; PR:Q6UY14; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; Q6UY14; -.
DR   CleanEx; HS_ADAMTSL4; -.
DR   ExpressionAtlas; Q6UY14; baseline and differential.
DR   Genevisible; Q6UY14; HS.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005614; C:interstitial matrix; IEA:Ensembl.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IEA:InterPro.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0036066; P:protein O-linked fucosylation; TAS:Reactome.
DR   GO; GO:0006493; P:protein O-linked glycosylation; TAS:Reactome.
DR   InterPro; IPR010294; ADAM_spacer1.
DR   InterPro; IPR010909; PLAC.
DR   InterPro; IPR000884; TSP1_rpt.
DR   Pfam; PF05986; ADAM_spacer1; 1.
DR   Pfam; PF08686; PLAC; 1.
DR   Pfam; PF00090; TSP_1; 5.
DR   SMART; SM00209; TSP1; 6.
DR   SUPFAM; SSF82895; SSF82895; 6.
DR   PROSITE; PS50900; PLAC; 1.
DR   PROSITE; PS50092; TSP1; 6.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; Complete proteome;
KW   Extracellular matrix; Glycoprotein; Polymorphism; Reference proteome;
KW   Repeat; Secreted; Signal.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25   1074       ADAMTS-like protein 4. {ECO:0000255}.
FT                                /FTId=PRO_0000257966.
FT   DOMAIN       48     93       TSP type-1 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      723    782       TSP type-1 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      783    842       TSP type-1 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      845    909       TSP type-1 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      910    969       TSP type-1 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      970   1026       TSP type-1 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN     1029   1066       PLAC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00233}.
FT   COMPBIAS    602    664       Pro-rich. {ECO:0000255}.
FT   CARBOHYD      3      3       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    490    490       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19139490}.
FT   CARBOHYD    773    773       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     411    411       E -> EAPLLPLRHAFFLLPGAGSGDSTG (in isoform
FT                                3). {ECO:0000305}.
FT                                /FTId=VSP_055759.
FT   VAR_SEQ     854    877       CSAECGTGIQRRSVVCLGSGAALG -> VSPEPPAISCILG
FT                                NHAQDTSAFPA (in isoform 2).
FT                                {ECO:0000303|PubMed:12975309,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_052183.
FT   VAR_SEQ     878   1074       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12975309,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_052184.
FT   VARIANT     193    193       A -> P (in dbSNP:rs41317515).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_061918.
FT   VARIANT    1028   1028       R -> H (in dbSNP:rs56411234).
FT                                /FTId=VAR_061919.
SQ   SEQUENCE   1074 AA;  116545 MW;  79AE0E5DF5488CA1 CRC64;
     MENWTGRPWL YLLLLLSLPQ LCLDQEVLSG HSLQTPTEEG QGPEGVWGPW VQWASCSQPC
     GVGVQRRSRT CQLPTVQLHP SLPLPPRPPR HPEALLPRGQ GPRPQTSPET LPLYRTQSRG
     RGGPLRGPAS HLGREETQEI RAARRSRLRD PIKPGMFGYG RVPFALPLHR NRRHPRSPPR
     SELSLISSRG EEAIPSPTPR AEPFSANGSP QTELPPTELS VHTPSPQAEP LSPETAQTEV
     APRTRPAPLR HHPRAQASGT EPPSPTHSLG EGGFFRASPQ PRRPSSQGWA SPQVAGRRPD
     PFPSVPRGRG QQGQGPWGTG GTPHGPRLEP DPQHPGAWLP LLSNGPHASS LWSLFAPSSP
     IPRCSGESEQ LRACSQAPCP PEQPDPRALQ CAAFNSQEFM GQLYQWEPFT EVQGSQRCEL
     NCRPRGFRFY VRHTEKVQDG TLCQPGAPDI CVAGRCLSPG CDGILGSGRR PDGCGVCGGD
     DSTCRLVSGN LTDRGGPLGY QKILWIPAGA LRLQIAQLRP SSNYLALRGP GGRSIINGNW
     AVDPPGSYRA GGTVFRYNRP PREEGKGESL SAEGPTTQPV DVYMIFQEEN PGVFYQYVIS
     SPPPILENPT PEPPVPQLQP EILRVEPPLA PAPRPARTPG TLQRQVRIPQ MPAPPHPRTP
     LGSPAAYWKR VGHSACSASC GKGVWRPIFL CISRESGEEL DERSCAAGAR PPASPEPCHG
     TPCPPYWEAG EWTSCSRSCG PGTQHRQLQC RQEFGGGGSS VPPERCGHLP RPNITQSCQL
     RLCGHWEVGS PWSQCSVRCG RGQRSRQVRC VGNNGDEVSE QECASGPPQP PSREACDMGP
     CTTAWFHSDW SSKCSAECGT GIQRRSVVCL GSGAALGPGQ GEAGAGTGQS CPTGSRPPDM
     RACSLGPCER TWRWYTGPWG ECSSECGSGT QRRDIICVSK LGTEFNVTSP SNCSHLPRPP
     ALQPCQGQAC QDRWFSTPWS PCSRSCQGGT QTREVQCLST NQTLSTRCPP QLRPSRKRPC
     NSQPCSQRPD DQCKDSSPHC PLVVQARLCV YPYYTATCCR SCAHVLERSP QDPS
//
ID   UD11_HUMAN              Reviewed;         533 AA.
AC   P22309; A6NJC3; B8K286;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   17-FEB-2016, entry version 178.
DE   RecName: Full=UDP-glucuronosyltransferase 1-1;
DE            Short=UDPGT 1-1;
DE            Short=UGT1*1;
DE            Short=UGT1-01;
DE            Short=UGT1.1;
DE            EC=2.4.1.17;
DE   AltName: Full=Bilirubin-specific UDPGT isozyme 1;
DE            Short=hUG-BR1;
DE   AltName: Full=UDP-glucuronosyltransferase 1-A;
DE            Short=UGT-1A;
DE            Short=UGT1A;
DE   AltName: Full=UDP-glucuronosyltransferase 1A1;
DE   Flags: Precursor;
GN   Name=UGT1A1; Synonyms=GNT1, UGT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=1898728;
RA   Ritter J.K., Crawford J.M., Owens I.S.;
RT   "Cloning of two human liver bilirubin UDP-glucuronosyltransferase
RT   cDNAs with expression in COS-1 cells.";
RL   J. Biol. Chem. 266:1043-1047(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=1339448;
RA   Ritter J.K., Chen F., Sheen Y.Y., Tran H.M., Kimura S., Yeatman M.T.,
RA   Owens I.S.;
RT   "A novel complex locus UGT1 encodes human bilirubin, phenol, and other
RT   UDP-glucuronosyltransferase isozymes with identical carboxyl
RT   termini.";
RL   J. Biol. Chem. 267:3257-3261(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11434514; DOI=10.1097/00008571-200106000-00011;
RA   Gong Q.H., Cho J.W., Huang T., Potter C., Gholami N., Basu N.K.,
RA   Kubota S., Carvalho S., Pennington M.W., Owens I.S., Popescu N.C.;
RT   "Thirteen UDP-glucuronosyltransferase genes are encoded at the human
RT   UGT1 gene complex locus.";
RL   Pharmacogenetics 11:357-368(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Guillemette C., Levesque E., Girard H., Bernard O.;
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-50.
RA   Ueyama H., Koiwai O., Soeda Y., Sato H., Satoh Y., Ohkubo I.,
RA   Doida Y.;
RT   "Analysis of the promoter of human bilirubin UDP-
RT   glucuronosyltransferase gene (UGT1*1) in relevance to Gilbert's
RT   syndrome.";
RL   Hepatol. Res. 9:152-163(1997).
RN   [7]
RP   COMPONENT OF A CHAPERONE COMPLEX.
RX   PubMed=12475965; DOI=10.1091/mbc.E02-05-0311;
RA   Meunier L., Usherwood Y.-K., Chung K.T., Hendershot L.M.;
RT   "A subset of chaperones and folding enzymes form multiprotein
RT   complexes in endoplasmic reticulum to bind nascent proteins.";
RL   Mol. Biol. Cell 13:4456-4469(2002).
RN   [8]
RP   ALTERNATIVE SPLICING, FUNCTION (ISOFORM 2), SUBCELLULAR LOCATION,
RP   SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=17187418; DOI=10.1002/hep.21464;
RA   Levesque E., Girard H., Journault K., Lepine J., Guillemette C.;
RT   "Regulation of the UGT1A1 bilirubin-conjugating pathway: role of a new
RT   splicing event at the UGT1A locus.";
RL   Hepatology 45:128-138(2007).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, KINETIC PARAMETERS, SUBSTRATE
RP   SPECIFICITY, AND CHARACTERIZATION OF VARIANTS CN2 ARG-71; LEU-83;
RP   GLN-229 AND ASP-486.
RX   PubMed=18004206; DOI=10.1097/FPC.0b013e328256b1b6;
RA   Udomuksorn W., Elliot D.J., Lewis B.C., Mackenzie P.I.,
RA   Yoovathaworn K., Miners J.O.;
RT   "Influence of mutations associated with Gilbert and Crigler-Najjar
RT   type II syndromes on the glucuronidation kinetics of bilirubin and
RT   other UDP-glucuronosyltransferase 1A substrates.";
RL   Pharmacogenet. Genomics 17:1017-1029(2007).
RN   [10]
RP   ALTERNATIVE SPLICING, CATALYTIC ACTIVITY, FUNCTION (ISOFORM 2), AND
RP   TISSUE SPECIFICITY.
RX   PubMed=18004212; DOI=10.1097/FPC.0b013e3282f1f118;
RA   Girard H., Levesque E., Bellemare J., Journault K., Caillier B.,
RA   Guillemette C.;
RT   "Genetic diversity at the UGT1 locus is amplified by a novel 3'
RT   alternative splicing mechanism leading to nine additional UGT1A
RT   proteins that act as regulators of glucuronidation activity.";
RL   Pharmacogenet. Genomics 17:1077-1089(2007).
RN   [11]
RP   FUNCTION.
RX   PubMed=19545173; DOI=10.1021/mp8002557;
RA   Tang L., Singh R., Liu Z., Hu M.;
RT   "Structure and concentration changes affect characterization of UGT
RT   isoform-specific metabolism of isoflavones.";
RL   Mol. Pharm. 6:1466-1482(2009).
RN   [12]
RP   FUNCTION, SUBSTRATE SPECIFICITY, VARIANT CN1 THR-402, VARIANTS CN2
RP   ARG-15; ARG-71; PHE-191; TRP-209; TRP-336; HIS-387; PRO-443 AND
RP   ASP-486, CHARACTERIZATION OF VARIANT CN1 THR-402, AND CHARACTERIZATION
RP   OF VARIANTS CN2 ARG-71; GLN-175; PHE-191; TRP-209; ARG-331; TRP-336;
RP   HIS-387; VAL-395 AND PRO-443.
RX   PubMed=19830808; DOI=10.1002/humu.21133;
RA   Sneitz N., Bakker C.T., de Knegt R.J., Halley D.J., Finel M.,
RA   Bosma P.J.;
RT   "Crigler-Najjar syndrome in The Netherlands: identification of four
RT   novel UGT1A1 alleles, genotype-phenotype correlation, and functional
RT   analysis of 10 missense mutants.";
RL   Hum. Mutat. 31:52-59(2010).
RN   [13]
RP   INVOLVEMENT IN BILIQTL1.
RX   PubMed=19414484; DOI=10.1093/hmg/ddp202;
RA   Johnson A.D., Kavousi M., Smith A.V., Chen M.H., Dehghan A.,
RA   Aspelund T., Lin J.P., van Duijn C.M., Harris T.B., Cupples L.A.,
RA   Uitterlinden A.G., Launer L., Hofman A., Rivadeneira F., Stricker B.,
RA   Yang Q., O'Donnell C.J., Gudnason V., Witteman J.C.;
RT   "Genome-wide association meta-analysis for total serum bilirubin
RT   levels.";
RL   Hum. Mol. Genet. 18:2700-2710(2009).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-102.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [15]
RP   SUBUNIT.
RX   PubMed=20610558; DOI=10.1124/dmd.110.034835;
RA   Bellemare J., Rouleau M., Girard H., Harvey M., Guillemette C.;
RT   "Alternatively spliced products of the UGT1A gene interact with the
RT   enzymatically active proteins to inhibit glucuronosyltransferase
RT   activity in vitro.";
RL   Drug Metab. Dispos. 38:1785-1789(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   VARIANT CN1 PHE-375.
RX   PubMed=1634050;
RA   Bosma P.J., Chowdhury J.R., Huang T.-J., Lahiri P., Elferink R.P.J.O.,
RA   van Es H.H.G., Lederstein M., Whitington P.F., Jansen P.L.M.,
RA   Chowdhury N.R.;
RT   "Mechanisms of inherited deficiencies of multiple UDP-
RT   glucuronosyltransferase isoforms in two patients with Crigler-Najjar
RT   syndrome, type I.";
RL   FASEB J. 6:2859-2863(1992).
RN   [18]
RP   VARIANTS CN2 ARG-71 AND ASP-486.
RX   PubMed=8280139; DOI=10.1006/bbrc.1993.2610;
RA   Aono S., Yamada Y., Keino H., Hanada N., Nakagawa T., Sasaoka Y.,
RA   Yazawa T., Sato H., Koiwai O.;
RT   "Identification of defect in the genes for bilirubin UDP-glucuronosyl-
RT   transferase in a patient with Crigler-Najjar syndrome type II.";
RL   Biochem. Biophys. Res. Commun. 197:1239-1244(1993).
RN   [19]
RP   VARIANT CN2 ARG-331.
RX   PubMed=8276413; DOI=10.1006/geno.1993.1451;
RA   Moghrabi N., Clarke D.J., Boxer M., Burchell B.;
RT   "Identification of an A-to-G missense mutation in exon 2 of the UGT1
RT   gene complex that causes Crigler-Najjar syndrome type 2.";
RL   Genomics 18:171-173(1993).
RN   [20]
RP   VARIANT CN1 PHE-170 DEL.
RX   PubMed=8226884;
RA   Ritter J.K., Yeatman M.T., Kaiser C., Gridelli B., Owens I.S.;
RT   "A phenylalanine codon deletion at the UGT1 gene complex locus of a
RT   Crigler-Najjar type I patient generates a pH-sensitive bilirubin UDP-
RT   glucuronosyltransferase.";
RL   J. Biol. Chem. 268:23573-23579(1993).
RN   [21]
RP   VARIANTS CN1 VAL-292; GLU-308; ARG-357; THR-368; ARG-381; PRO-401 AND
RP   GLU-428.
RX   PubMed=7989045; DOI=10.1007/BF00206965;
RA   Labrune P., Myara A., Hadchouel M., Ronchi F., Bernard O., Trivin F.,
RA   Roy Chowdhury N., Roy Chowdhury J., Munnich A., Odievre M.;
RT   "Genetic heterogeneity of Crigler-Najjar syndrome type I: a study of
RT   14 cases.";
RL   Hum. Genet. 94:693-697(1994).
RN   [22]
RP   VARIANTS CN1 GLU-308 AND PHE-375, AND CHARACTERIZATION OF VARIANTS CN1
RP   GLU-308 AND PHE-375.
RX   PubMed=7906695; DOI=10.1172/JCI117008;
RA   Erps L.T., Ritter J.K., Hersh J.H., Blossom D., Martin N.C.,
RA   Owens I.S.;
RT   "Identification of two single base substitutions in the UGT1 gene
RT   locus which abolish bilirubin uridine diphosphate
RT   glucuronosyltransferase activity in vitro.";
RL   J. Clin. Invest. 93:564-570(1994).
RN   [23]
RP   VARIANTS CN1 PHE-170 DEL; ARG-177; ARG-276 AND PHE-375, AND VARIANTS
RP   CN2 GLN-175 AND TRP-209.
RX   PubMed=7989595; DOI=10.1172/JCI117604;
RA   Seppen J., Bosma P.J., Goldhoorn B.G., Bakker C.T.M.,
RA   Roy Chowdhury J., Roy Chowdhury N., Jansen P.L.M.,
RA   Oude Elferink R.P.J.;
RT   "Discrimination between Crigler-Najjar type I and II by expression of
RT   mutant bilirubin uridine diphosphate-glucuronosyltransferase.";
RL   J. Clin. Invest. 94:2385-2391(1994).
RN   [24]
RP   VARIANTS GILBS ARG-71; GLN-229 AND GLY-367.
RC   TISSUE=Liver, and Peripheral blood leukocyte;
RX   PubMed=7715297; DOI=10.1016/S0140-6736(95)90702-5;
RA   Aono S., Adachi Y., Uyama E., Yamada Y., Keino H., Nanno T.,
RA   Koiwai O., Sato H.;
RT   "Analysis of genes for bilirubin UDP-glucuronosyltransferase in
RT   Gilbert's syndrome.";
RL   Lancet 345:958-959(1995).
RN   [25]
RP   VARIANT CN2 ARG-15, AND CHARACTERIZATION OF VARIANT CN2 ARG-15.
RX   PubMed=8706880; DOI=10.1016/0014-5793(96)00677-1;
RA   Seppen J., Steenken E., Lindhout D., Bosma P.J., Oude Elferink R.P.J.;
RT   "A mutation which disrupts the hydrophobic core of the signal peptide
RT   of bilirubin UDP-glucuronosyltransferase, an endoplasmic reticulum
RT   membrane protein, causes Crigler-Najjar type II.";
RL   FEBS Lett. 390:294-298(1996).
RN   [26]
RP   VARIANT CN2 THR-294, AND CHARACTERIZATION OF VARIANT CN2 THR-294.
RX   PubMed=9639672; DOI=10.1016/S0925-4439(98)00030-1;
RA   Ciotti M., Chen F., Rubaltelli F.F., Owens I.S.;
RT   "Coding defect and a TATA box mutation at the bilirubin UDP-
RT   glucuronosyltransferase gene cause Crigler-Najjar type I disease.";
RL   Biochim. Biophys. Acta 1407:40-50(1998).
RN   [27]
RP   VARIANTS CN2 ARG-71; TRP-209; GLN-229 AND ASP-486.
RX   PubMed=9621515; DOI=10.1007/s100380050050;
RA   Yamamoto K., Soeda Y., Kamisako T., Hosaka H., Fukano M., Sato H.,
RA   Fujiyama Y., Dachi Y., Satoh Y., Bamba T.;
RT   "Analysis of bilirubin uridine 5'-diphosphate (UDP)-
RT   glucuronosyltransferase gene mutations in seven patients with Crigler-
RT   Najjar syndrome type II.";
RL   J. Hum. Genet. 43:111-114(1998).
RN   [28]
RP   VARIANT GILBS ASP-486.
RX   PubMed=9627603; DOI=10.1016/S0022-3476(98)70408-1;
RA   Maruo Y., Sato H., Yamano T., Doida Y., Shimada M.;
RT   "Gilbert syndrome caused by a homozygous missense mutation (Tyr486Asp)
RT   of bilirubin UDP-glucuronosyltransferase gene.";
RL   J. Pediatr. 132:1045-1047(1998).
RN   [29]
RP   VARIANTS CN1 ASP-39; PHE-170 DEL; ARG-177; ARG-276; VAL-291; GLU-308;
RP   TRP-336; ARG-357; THR-368; PHE-375; ARG-381; SER-387; PRO-401 AND
RP   GLU-428, VARIANTS CN2 ARG-15; GLN-175; TRP-209; GLY-225 AND ARG-331,
RP   AND VARIANTS GILBS ARG-71; GLN-229; THR-294; GLY-367 AND ASP-486.
RX   PubMed=11013440;
RX   DOI=10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z;
RA   Kadakol A., Ghosh S.S., Sappal B.S., Sharma G., Chowdhury J.R.,
RA   Chowdhury N.R.;
RT   "Genetic lesions of bilirubin uridine-diphosphoglucuronate
RT   glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert
RT   syndromes: correlation of genotype to phenotype.";
RL   Hum. Mutat. 16:297-306(2000).
RN   [30]
RP   VARIANTS HBLRTFN ARG-71 AND ASP-486.
RX   PubMed=11061796; DOI=10.1542/peds.106.5.e59;
RA   Maruo Y., Nishizawa K., Sato H., Sawa H., Shimada M.;
RT   "Prolonged unconjugated hyperbilirubinemia associated with breast milk
RT   and mutations of the bilirubin uridine diphosphate-
RT   glucuronosyltransferase gene.";
RL   Pediatrics 106:E59-E59(2000).
RN   [31]
RP   VARIANT CN2 GLN-175.
RX   PubMed=11370628; DOI=10.1136/jmg.38.4.244;
RA   Kadakol A., Sappal B.S., Ghosh S.S., Lowenheim M., Chowdhury A.,
RA   Chowdhury S., Santra A., Arias I.M., Chowdhury J.R., Chowdhury N.R.;
RT   "Interaction of coding region mutations and the Gilbert-type promoter
RT   abnormality of the UGT1A1 gene causes moderate degrees of unconjugated
RT   hyperbilirubinaemia and may lead to neonatal kernicterus.";
RL   J. Med. Genet. 38:244-249(2001).
RN   [32]
RP   VARIANT CN2 ASP-400.
RX   PubMed=12402338; DOI=10.1002/humu.10122;
RA   Labrune P., Myara A., Chalas J., Le Bihan B., Capel L., Francoual J.;
RT   "Association of a homozygous (TA)8 promoter polymorphism and a N400D
RT   mutation of UGT1A1 in a child with Crigler-Najjar type II syndrome.";
RL   Hum. Mutat. 20:399-401(2002).
RN   [33]
RP   VARIANT GILBS LEU-83.
RX   PubMed=12139570; DOI=10.1046/j.1442-200X.2002.t01-1-01577.x;
RA   Sutomo R., Laosombat V., Sadewa A.H., Yokoyama N., Nakamura H.,
RA   Matsuo M., Nishio H.;
RT   "Novel missense mutation of the UGT1A1 gene in Thai siblings with
RT   Gilbert's syndrome.";
RL   Pediatr. Int. 44:427-432(2002).
RN   [34]
RP   CHARACTERIZATION OF VARIANT CN2 ARG-15.
RX   PubMed=14550264; DOI=10.1016/j.bbrc.2003.09.072;
RA   Ohnishi A., Emi Y.;
RT   "Rapid proteasomal degradation of translocation-deficient UDP-
RT   glucuronosyltransferase 1A1 proteins in patients with Crigler-Najjar
RT   type II.";
RL   Biochem. Biophys. Res. Commun. 310:735-741(2003).
RN   [35]
RP   VARIANTS CN1 GLN-336; ARG-357; PHE-375; SER-387 AND VAL-395, VARIANTS
RP   CN2 GLN-34; PHE-170 DEL; TRP-209; GLY-225; LEU-336; TRP-336; ARG-354;
RP   CYS-403 AND ASP-478, AND VARIANTS CN1/CN2 VAL-377 AND ARG-461.
RX   PubMed=15712364; DOI=10.1002/humu.9322;
RA   Servedio V., d'Apolito M., Maiorano N., Minuti B., Torricelli F.,
RA   Ronchi F., Zancan L., Perrotta S., Vajro P., Boschetto L.,
RA   Iolascon A.;
RT   "Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome
RT   patients: identification of twelve novel alleles and genotype-
RT   phenotype correlation.";
RL   Hum. Mutat. 25:325-325(2005).
RN   [36]
RP   VARIANT CN1 PHE-171 DEL, AND VARIANTS CN2 TYR-279; ARG-354; VAL-370;
RP   VAL-395; PRO-443 AND ARG-461.
RX   PubMed=17229650; DOI=10.3324/haematol.10585;
RA   D'Apolito M., Marrone A., Servedio V., Vajro P., De Falco L.,
RA   Iolascon A.;
RT   "Seven novel mutations of the UGT1A1 gene in patients with
RT   unconjugated hyperbilirubinemia.";
RL   Haematologica 92:133-134(2007).
RN   [37]
RP   VARIANT CN1 ASN-36, AND VARIANT CN2 CYS-230.
RX   PubMed=23992562; DOI=10.1111/ahg.12039;
RA   Khan S., Irfan M., Sher G., Zubaida B., Alvi M.A., Yasinzai M.,
RA   Naeem M.;
RT   "UGT1A1 gene mutations in Pakistani children suffering from inherited
RT   nonhemolytic unconjugated hyperbilirubinemias.";
RL   Ann. Hum. Genet. 77:482-487(2013).
RN   [38]
RP   VARIANTS CN2 PHE-170 DEL AND CYS-367.
RX   PubMed=23099197; DOI=10.1016/j.clinbiochem.2012.10.007;
RA   Minucci A., Canu G., Gentile L., Cimino V., Giardina B., Zuppi C.,
RA   Capoluongo E.;
RT   "Identification of a novel mutation in UDP-glucuronosyltransferase
RT   (UGT1A1) gene in a child with neonatal unconjugated
RT   hyperbilirubinemia.";
RL   Clin. Biochem. 46:170-172(2013).
CC   -!- FUNCTION: UDPGT is of major importance in the conjugation and
CC       subsequent elimination of potentially toxic xenobiotics and
CC       endogenous compounds. This isoform glucuronidates bilirubin IX-
CC       alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates
CC       and diconjugate. Is also able to catalyze the glucuronidation of
CC       17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-
CC       methylumbelliferone, 1-naphthol, paranitrophenol, scopoletin, and
CC       umbelliferone. Isoform 2 lacks transferase activity but acts as a
CC       negative regulator of isoform 1. {ECO:0000269|PubMed:18004206,
CC       ECO:0000269|PubMed:19545173, ECO:0000269|PubMed:19830808}.
CC   -!- CATALYTIC ACTIVITY: UDP-glucuronate + acceptor = UDP + acceptor
CC       beta-D-glucuronoside. {ECO:0000269|PubMed:18004206,
CC       ECO:0000269|PubMed:18004212}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.26 uM for bilirubin {ECO:0000269|PubMed:18004206};
CC         Vmax=1080 pmol/min/mg enzyme with bilirubin as substrate
CC         {ECO:0000269|PubMed:18004206};
CC   -!- SUBUNIT: Isoform 1 interacts with isoform 2/i2 suggesting that
CC       oligomerization is involved in negative regulation of transferase
CC       activity by isoform 2. Isoform 1 also interacts with respective i2
CC       isoforms of UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9 and
CC       UGT1A10. Part of a large chaperone multiprotein complex comprising
CC       DNAJB11, HSP90B1, HSPA5, HYOU, PDIA2, PDIA4, PDIA6, PPIB, SDF2L1,
CC       UGT1A1 and very small amounts of ERP29, but not, or at very low
CC       levels, CALR nor CANX. {ECO:0000269|PubMed:17187418,
CC       ECO:0000269|PubMed:20610558}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Microsome
CC       {ECO:0000269|PubMed:17187418}. Endoplasmic reticulum membrane
CC       {ECO:0000305|PubMed:17187418}; Single-pass membrane protein
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Microsome
CC       {ECO:0000269|PubMed:17187418}. Endoplasmic reticulum
CC       {ECO:0000305|PubMed:17187418}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=i1;
CC         IsoId=P22309-1; Sequence=Displayed;
CC       Name=2; Synonyms=i2, UGT1A1s;
CC         IsoId=P22309-2; Sequence=VSP_053958;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are expressed in
CC       liver, colon and small intestine. Isoform 2 but not isoform 1 is
CC       expressed in kidney. Isoform 1 and isoform 2 are not expressed in
CC       esophagus. Not expressed in skin. {ECO:0000269|PubMed:1339448,
CC       ECO:0000269|PubMed:17187418, ECO:0000269|PubMed:18004212}.
CC   -!- POLYMORPHISM: Genetic variation in UGT1A1 defines the bilirubin
CC       serum levels quantitative trait locus 1 (BILIQTL1) [MIM:601816].
CC       Variation in serum bilirubin is associated with altered
CC       cardiovascular disease risk and drug metabolism.
CC       {ECO:0000269|PubMed:19414484}.
CC   -!- DISEASE: Gilbert syndrome (GILBS) [MIM:143500]: Occurs as a
CC       consequence of reduced bilirubin transferase activity and is often
CC       detected in young adults with vague non-specific complaints.
CC       {ECO:0000269|PubMed:11013440, ECO:0000269|PubMed:12139570,
CC       ECO:0000269|PubMed:7715297, ECO:0000269|PubMed:9627603}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Transient familial neonatal hyperbilirubinemia (HBLRTFN)
CC       [MIM:237900]: A condition characterized by excessive concentration
CC       of bilirubin in the blood, which may lead to jaundice. Breast milk
CC       jaundice is a common problem in nursing infants.
CC       {ECO:0000269|PubMed:11061796}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry. The defect
CC       has been ascribed to various breast milk substances, but the
CC       component or combination of components that is responsible remains
CC       unclear. Defects of UGT1A1 are an underlying cause of the
CC       prolonged unconjugated hyperbilirubinemia associated with breast
CC       milk. One or more components in the milk may trigger the jaundice
CC       in infants who have such mutations. Mutations are identical to
CC       those detected in patients with Gilbert syndrome, a risk factor of
CC       neonatal non-physiologic hyperbilirubinemia and a genetic factor
CC       in fasting hyperbilirubinemia.
CC   -!- DISEASE: Crigler-Najjar syndrome 1 (CN1) [MIM:218800]: Patients
CC       have severe hyperbilirubinemia and usually die of kernicterus
CC       (bilirubin accumulation in the basal ganglia and brainstem nuclei)
CC       within the first year of life. CN1 inheritance is autosomal
CC       recessive. {ECO:0000269|PubMed:11013440,
CC       ECO:0000269|PubMed:15712364, ECO:0000269|PubMed:1634050,
CC       ECO:0000269|PubMed:17229650, ECO:0000269|PubMed:19830808,
CC       ECO:0000269|PubMed:23992562, ECO:0000269|PubMed:7906695,
CC       ECO:0000269|PubMed:7989045, ECO:0000269|PubMed:7989595,
CC       ECO:0000269|PubMed:8226884}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Crigler-Najjar syndrome 2 (CN2) [MIM:606785]: Patients
CC       have less severe hyperbilirubinemia and usually survive into
CC       adulthood without neurologic damage. Phenobarbital, which induces
CC       the partially deficient glucuronyl transferase, can diminish the
CC       jaundice. CN2 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:11013440, ECO:0000269|PubMed:11370628,
CC       ECO:0000269|PubMed:12402338, ECO:0000269|PubMed:15712364,
CC       ECO:0000269|PubMed:17229650, ECO:0000269|PubMed:19830808,
CC       ECO:0000269|PubMed:23099197, ECO:0000269|PubMed:23992562,
CC       ECO:0000269|PubMed:7989595, ECO:0000269|PubMed:8276413,
CC       ECO:0000269|PubMed:8280139, ECO:0000269|PubMed:8706880,
CC       ECO:0000269|PubMed:9621515, ECO:0000269|PubMed:9639672}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: The gene is part of the UGT1A complex locus which
CC       displays alternative use of promoters, first exons and terminal
CC       exons. The locus is defined by 13 first exons, which are
CC       alternatively spliced to 3 other common exons and 2 alternative
CC       terminal exons 5. From the 27 possible mRNA isoforms, 9 produce
CC       functionally active polypeptides (UGT1A1, 1A3, 1A4, 1A5, 1A6, 1A7,
CC       1A8, 1A9 and 1A10) called isoforms 1 (i1). Use of an alternative
CC       exon 5 (5b) as terminal exon is leading to 9 additional
CC       alternatively spliced products termed isoforms i2 and which lack
CC       transferase activity.
CC   -!- SIMILARITY: Belongs to the UDP-glycosyltransferase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA61247.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAF03522.2; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Glucuronosyltransferase entry;
CC       URL="https://en.wikipedia.org/wiki/Glucuronosyltransferase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M57899; AAA63195.1; -; mRNA.
DR   EMBL; M84124; AAA61247.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M84122; AAA61247.1; JOINED; Genomic_DNA.
DR   EMBL; M84123; AAA61247.1; JOINED; Genomic_DNA.
DR   EMBL; M84125; AAA61248.1; -; Genomic_DNA.
DR   EMBL; DQ364247; ABC96771.1; -; mRNA.
DR   EMBL; AF297093; AAG30424.1; -; Genomic_DNA.
DR   EMBL; AC006985; AAF03522.2; ALT_SEQ; Genomic_DNA.
DR   EMBL; D87674; BAA25600.1; -; Genomic_DNA.
DR   CCDS; CCDS2510.1; -. [P22309-1]
DR   PIR; A39092; A39092.
DR   RefSeq; NP_000454.1; NM_000463.2. [P22309-1]
DR   UniGene; Hs.554822; -.
DR   ProteinModelPortal; P22309; -.
DR   SMR; P22309; 116-444.
DR   BioGrid; 120087; 3.
DR   IntAct; P22309; 9.
DR   STRING; 9606.ENSP00000304845; -.
DR   BindingDB; P22309; -.
DR   ChEMBL; CHEMBL1287617; -.
DR   DrugBank; DB01048; Abacavir.
DR   DrugBank; DB00316; Acetaminophen.
DR   DrugBank; DB00173; Adenine.
DR   DrugBank; DB01076; Atorvastatin.
DR   DrugBank; DB06626; Axitinib.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB08930; Dolutegravir.
DR   DrugBank; DB06210; Eltrombopag.
DR   DrugBank; DB00530; Erlotinib.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB00773; Etoposide.
DR   DrugBank; DB00973; Ezetimibe.
DR   DrugBank; DB04953; Ezogabine.
DR   DrugBank; DB01544; Flunitrazepam.
DR   DrugBank; DB00712; Flurbiprofen.
DR   DrugBank; DB01095; Fluvastatin.
DR   DrugBank; DB01050; Ibuprofen.
DR   DrugBank; DB05039; Indacaterol.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugBank; DB00762; Irinotecan.
DR   DrugBank; DB00678; Losartan.
DR   DrugBank; DB00227; Lovastatin.
DR   DrugBank; DB00295; Morphine.
DR   DrugBank; DB00688; Mycophenolate mofetil.
DR   DrugBank; DB01024; Mycophenolic acid.
DR   DrugBank; DB00704; Naltrexone.
DR   DrugBank; DB00788; Naproxen.
DR   DrugBank; DB04868; Nilotinib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB06817; Raltegravir.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB01045; Rifampicin.
DR   DrugBank; DB00641; Simvastatin.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB00870; Suprofen.
DR   DrugBank; DB01420; Testosterone Propionate.
DR   CAZy; GT1; Glycosyltransferase Family 1.
DR   iPTMnet; P22309; -.
DR   PhosphoSite; P22309; -.
DR   BioMuta; UGT1A1; -.
DR   DMDM; 136729; -.
DR   PaxDb; P22309; -.
DR   PeptideAtlas; P22309; -.
DR   PRIDE; P22309; -.
DR   DNASU; 54658; -.
DR   Ensembl; ENST00000305208; ENSP00000304845; ENSG00000241635. [P22309-1]
DR   Ensembl; ENST00000360418; ENSP00000353593; ENSG00000241635. [P22309-2]
DR   GeneID; 54658; -.
DR   KEGG; hsa:54658; -.
DR   UCSC; uc002vvb.3; human. [P22309-1]
DR   UCSC; uc010znc.1; human.
DR   CTD; 54658; -.
DR   GeneCards; UGT1A1; -.
DR   HGNC; HGNC:12530; UGT1A1.
DR   MalaCards; UGT1A1; -.
DR   MIM; 143500; phenotype.
DR   MIM; 191740; gene.
DR   MIM; 218800; phenotype.
DR   MIM; 237900; phenotype.
DR   MIM; 601816; phenotype.
DR   MIM; 606785; phenotype.
DR   neXtProt; NX_P22309; -.
DR   Orphanet; 79234; Crigler-Najjar syndrome type 1.
DR   Orphanet; 79235; Crigler-Najjar syndrome type 2.
DR   Orphanet; 357; Gilbert syndrome.
DR   Orphanet; 240885; Irinotecan toxicity.
DR   Orphanet; 240905; Raltegravir toxicity.
DR   Orphanet; 2312; Transient familial neonatal hyperbilirubinemia.
DR   PharmGKB; PA37181; -.
DR   PharmGKB; PA420; -.
DR   eggNOG; KOG1192; Eukaryota.
DR   eggNOG; COG1819; LUCA.
DR   GeneTree; ENSGT00760000118949; -.
DR   HOGENOM; HOG000220832; -.
DR   HOVERGEN; HBG004033; -.
DR   InParanoid; P22309; -.
DR   KO; K00699; -.
DR   OMA; LEESHFD; -.
DR   OrthoDB; EOG7GBFWS; -.
DR   PhylomeDB; P22309; -.
DR   TreeFam; TF315472; -.
DR   BRENDA; 2.4.1.17; 2681.
DR   BRENDA; 2.4.1.95; 2681.
DR   Reactome; R-HSA-156588; Glucuronidation.
DR   Reactome; R-HSA-189483; Heme degradation.
DR   Reactome; R-HSA-5579002; Defective UGT1A1 causes hyperbilirubinemia.
DR   SABIO-RK; P22309; -.
DR   GenomeRNAi; 54658; -.
DR   NextBio; 27033972; -.
DR   PRO; PR:P22309; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; P22309; -.
DR   CleanEx; HS_UGT1A1; -.
DR   ExpressionAtlas; P22309; baseline and differential.
DR   Genevisible; P22309; HS.
DR   GO; GO:0070069; C:cytochrome complex; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0034663; C:endoplasmic reticulum chaperone complex; IEA:Ensembl.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; NAS:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0004857; F:enzyme inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0015020; F:glucuronosyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0001972; F:retinoic acid binding; IDA:BHF-UCL.
DR   GO; GO:0005496; F:steroid binding; IDA:BHF-UCL.
DR   GO; GO:0006953; P:acute-phase response; IEA:Ensembl.
DR   GO; GO:0006789; P:bilirubin conjugation; TAS:ProtInc.
DR   GO; GO:0070980; P:biphenyl catabolic process; IEA:Ensembl.
DR   GO; GO:0052695; P:cellular glucuronidation; IDA:UniProtKB.
DR   GO; GO:0071361; P:cellular response to ethanol; IEA:Ensembl.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; IEA:Ensembl.
DR   GO; GO:0007586; P:digestion; NAS:ProtInc.
DR   GO; GO:0017144; P:drug metabolic process; IC:BHF-UCL.
DR   GO; GO:0008210; P:estrogen metabolic process; TAS:ProtInc.
DR   GO; GO:0051552; P:flavone metabolic process; IDA:BHF-UCL.
DR   GO; GO:0009813; P:flavonoid biosynthetic process; IBA:GO_Central.
DR   GO; GO:0052696; P:flavonoid glucuronidation; IDA:BHF-UCL.
DR   GO; GO:0042167; P:heme catabolic process; TAS:Reactome.
DR   GO; GO:0046483; P:heterocycle metabolic process; IC:BHF-UCL.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0043086; P:negative regulation of catalytic activity; IDA:GOC.
DR   GO; GO:2001030; P:negative regulation of cellular glucuronidation; IDA:UniProtKB.
DR   GO; GO:0045922; P:negative regulation of fatty acid metabolic process; ISS:BHF-UCL.
DR   GO; GO:1904224; P:negative regulation of glucuronosyltransferase activity; ISS:BHF-UCL.
DR   GO; GO:0045939; P:negative regulation of steroid metabolic process; IC:BHF-UCL.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0006778; P:porphyrin-containing compound metabolic process; TAS:Reactome.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; IEA:Ensembl.
DR   GO; GO:0042573; P:retinoic acid metabolic process; IC:BHF-UCL.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0008202; P:steroid metabolic process; IC:BHF-UCL.
DR   GO; GO:0052697; P:xenobiotic glucuronidation; IDA:BHF-UCL.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   InterPro; IPR002213; UDP_glucos_trans.
DR   PANTHER; PTHR11926; PTHR11926; 1.
DR   Pfam; PF00201; UDPGT; 1.
DR   PROSITE; PS00375; UDPGT; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation;
KW   Endoplasmic reticulum; Glycoprotein; Glycosyltransferase; Membrane;
KW   Microsome; Reference proteome; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26    533       UDP-glucuronosyltransferase 1-1.
FT                                /FTId=PRO_0000036000.
FT   TRANSMEM    491    507       Helical. {ECO:0000255}.
FT   CARBOHYD    102    102       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    295    295       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    347    347       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     435    533       SYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLR
FT                                PAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRK
FT                                CLGKKGRVKKAHKSKTH -> RKKQQSGRQM (in
FT                                isoform 2). {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_053958.
FT   VARIANT      15     15       L -> R (in CN2; mutant protein rapidly
FT                                degraded by the proteasome owing to its
FT                                mislocalization in the cell).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:14550264,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:8706880}.
FT                                /FTId=VAR_019410.
FT   VARIANT      34     34       P -> Q (in CN2).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026134.
FT   VARIANT      36     36       D -> N (in CN1).
FT                                {ECO:0000269|PubMed:23992562}.
FT                                /FTId=VAR_071402.
FT   VARIANT      39     39       H -> D (in CN1).
FT                                {ECO:0000269|PubMed:11013440}.
FT                                /FTId=VAR_026135.
FT   VARIANT      71     71       G -> R (in CN2, GILBS and HBLRTFN; has
FT                                significant residual bilirubin
FT                                glucuronidation activity of about 25% to
FT                                50% of that of the wild-type protein;
FT                                displays no change in biluribin affinity;
FT                                dbSNP:rs4148323).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:11061796,
FT                                ECO:0000269|PubMed:18004206,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:7715297,
FT                                ECO:0000269|PubMed:8280139,
FT                                ECO:0000269|PubMed:9621515}.
FT                                /FTId=VAR_009504.
FT   VARIANT      83     83       F -> L (in GILBS; displays less than 10%
FT                                of wild-type bilirubin glucuronidation
FT                                activity; dbSNP:rs56059937).
FT                                {ECO:0000269|PubMed:12139570,
FT                                ECO:0000269|PubMed:18004206}.
FT                                /FTId=VAR_026136.
FT   VARIANT     170    170       Missing (in CN1 and CN2; has nearly
FT                                normal activity at pH 7.6 and is inactive
FT                                at pH 6.4). {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:23099197,
FT                                ECO:0000269|PubMed:7989595,
FT                                ECO:0000269|PubMed:8226884}.
FT                                /FTId=VAR_007695.
FT   VARIANT     171    171       Missing (in CN2).
FT                                {ECO:0000269|PubMed:17229650}.
FT                                /FTId=VAR_064955.
FT   VARIANT     175    175       L -> Q (in CN2; has low residual
FT                                bilirubin glucuronidation activity of
FT                                about 4.6% of that of the wild-type
FT                                protein). {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:11370628,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:7989595}.
FT                                /FTId=VAR_019411.
FT   VARIANT     177    177       C -> R (in CN1).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989595}.
FT                                /FTId=VAR_007697.
FT   VARIANT     191    191       S -> F (in CN2; has low residual
FT                                bilirubin glucuronidation activity of
FT                                about 5.3% of that of the wild-type
FT                                protein). {ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_064956.
FT   VARIANT     209    209       R -> W (in CN2; has low residual
FT                                bilirubin glucuronidation activity of
FT                                about 2.9% of that of the wild-type
FT                                protein). {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:7989595,
FT                                ECO:0000269|PubMed:9621515}.
FT                                /FTId=VAR_007698.
FT   VARIANT     225    225       V -> G (in CN2; dbSNP:rs35003977).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026137.
FT   VARIANT     229    229       P -> Q (in CN2 and GILBS; displays 2-fold
FT                                decrease in biluribin affinity and 61% of
FT                                wild-type bilirubin glucuronidation
FT                                activity; dbSNP:rs35350960).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:18004206,
FT                                ECO:0000269|PubMed:7715297,
FT                                ECO:0000269|PubMed:9621515}.
FT                                /FTId=VAR_009505.
FT   VARIANT     230    230       Y -> C (in CN2).
FT                                {ECO:0000269|PubMed:23992562}.
FT                                /FTId=VAR_071403.
FT   VARIANT     276    276       G -> R (in CN1).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989595}.
FT                                /FTId=VAR_007699.
FT   VARIANT     279    279       N -> Y (in CN2).
FT                                {ECO:0000269|PubMed:17229650}.
FT                                /FTId=VAR_064957.
FT   VARIANT     291    291       E -> V (in CN1).
FT                                {ECO:0000269|PubMed:11013440}.
FT                                /FTId=VAR_026138.
FT   VARIANT     292    292       A -> V (in CN1).
FT                                {ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007700.
FT   VARIANT     294    294       I -> T (in GILBS and CN2; 40-55% normal
FT                                activity; normal Km for bilirubin; when
FT                                homozygous far less repressive and
FT                                generates the mild Gilbert phenotype).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:9639672}.
FT                                /FTId=VAR_026139.
FT   VARIANT     308    308       G -> E (in CN1; no enzyme activity).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7906695,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007701.
FT   VARIANT     331    331       Q -> R (in CN2; has no residual bilirubin
FT                                glucuronidation activity).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:8276413}.
FT                                /FTId=VAR_007702.
FT   VARIANT     336    336       R -> L (in CN1 and CN2).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026140.
FT   VARIANT     336    336       R -> Q (in CN1).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026141.
FT   VARIANT     336    336       R -> W (in CN2; has very low residual
FT                                bilirubin glucuronidation activity of
FT                                about 0.4% of that of the wild-type
FT                                protein). {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_026142.
FT   VARIANT     354    354       W -> R (in CN2).
FT                                {ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:17229650}.
FT                                /FTId=VAR_026143.
FT   VARIANT     357    357       Q -> R (in CN1).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007703.
FT   VARIANT     367    367       R -> C (in CN2).
FT                                {ECO:0000269|PubMed:23099197}.
FT                                /FTId=VAR_071404.
FT   VARIANT     367    367       R -> G (in GILBS; dbSNP:rs55750087).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7715297}.
FT                                /FTId=VAR_012283.
FT   VARIANT     368    368       A -> T (in CN1).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007704.
FT   VARIANT     370    370       I -> V (in CN2).
FT                                {ECO:0000269|PubMed:17229650}.
FT                                /FTId=VAR_064958.
FT   VARIANT     375    375       S -> F (in CN1; no enzyme activity).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:1634050,
FT                                ECO:0000269|PubMed:7906695,
FT                                ECO:0000269|PubMed:7989595}.
FT                                /FTId=VAR_007705.
FT   VARIANT     376    376       H -> R (in CN1 and CN2).
FT                                /FTId=VAR_026144.
FT   VARIANT     377    377       G -> V (in CN1 and CN2).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026145.
FT   VARIANT     381    381       S -> R (in CN1).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007706.
FT   VARIANT     387    387       P -> H (in CN2; has no residual bilirubin
FT                                glucuronidation activity).
FT                                {ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_064959.
FT   VARIANT     387    387       P -> S (in CN1).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026146.
FT   VARIANT     395    395       G -> V (in CN1; has no residual bilirubin
FT                                glucuronidation activity).
FT                                {ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:17229650,
FT                                ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_026147.
FT   VARIANT     400    400       N -> D (in CN2; dbSNP:rs28934877).
FT                                {ECO:0000269|PubMed:12402338}.
FT                                /FTId=VAR_019412.
FT   VARIANT     401    401       A -> P (in CN1).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007707.
FT   VARIANT     402    402       K -> T (in CN1; has no residual bilirubin
FT                                glucuronidation activity; N-glycosylation
FT                                does take place at this new additional
FT                                site). {ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_064960.
FT   VARIANT     403    403       R -> C (in CN2).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026148.
FT   VARIANT     428    428       K -> E (in CN1).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:7989045}.
FT                                /FTId=VAR_007708.
FT   VARIANT     443    443       L -> P (in CN2; has no residual bilirubin
FT                                glucuronidation activity).
FT                                {ECO:0000269|PubMed:17229650,
FT                                ECO:0000269|PubMed:19830808}.
FT                                /FTId=VAR_064961.
FT   VARIANT     461    461       W -> R (in CN1 and CN2).
FT                                {ECO:0000269|PubMed:15712364,
FT                                ECO:0000269|PubMed:17229650}.
FT                                /FTId=VAR_026149.
FT   VARIANT     478    478       A -> D (in CN2).
FT                                {ECO:0000269|PubMed:15712364}.
FT                                /FTId=VAR_026150.
FT   VARIANT     486    486       Y -> D (in CN2, GILBS and HBLRTFN;
FT                                displays less than 10% of wild-type
FT                                bilirubin glucuronidation activity).
FT                                {ECO:0000269|PubMed:11013440,
FT                                ECO:0000269|PubMed:11061796,
FT                                ECO:0000269|PubMed:18004206,
FT                                ECO:0000269|PubMed:19830808,
FT                                ECO:0000269|PubMed:8280139,
FT                                ECO:0000269|PubMed:9621515,
FT                                ECO:0000269|PubMed:9627603}.
FT                                /FTId=VAR_007709.
FT   VARIANT     511    511       A -> P (in dbSNP:rs1042709).
FT                                /FTId=VAR_025355.
SQ   SEQUENCE   533 AA;  59591 MW;  19C90231AD0EB547 CRC64;
     MAVESQGGRP LVLGLLLCVL GPVVSHAGKI LLIPVDGSHW LSMLGAIQQL QQRGHEIVVL
     APDASLYIRD GAFYTLKTYP VPFQREDVKE SFVSLGHNVF ENDSFLQRVI KTYKKIKKDS
     AMLLSGCSHL LHNKELMASL AESSFDVMLT DPFLPCSPIV AQYLSLPTVF FLHALPCSLE
     FEATQCPNPF SYVPRPLSSH SDHMTFLQRV KNMLIAFSQN FLCDVVYSPY ATLASEFLQR
     EVTVQDLLSS ASVWLFRSDF VKDYPRPIMP NMVFVGGINC LHQNPLSQEF EAYINASGEH
     GIVVFSLGSM VSEIPEKKAM AIADALGKIP QTVLWRYTGT RPSNLANNTI LVKWLPQNDL
     LGHPMTRAFI THAGSHGVYE SICNGVPMVM MPLFGDQMDN AKRMETKGAG VTLNVLEMTS
     EDLENALKAV INDKSYKENI MRLSSLHKDR PVEPLDLAVF WVEFVMRHKG APHLRPAAHD
     LTWYQYHSLD VIGFLLAVVL TVAFITFKCC AYGYRKCLGK KGRVKKAHKS KTH
//
ID   CCL2_RAT                Reviewed;         148 AA.
AC   P14844; Q549R5;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   17-FEB-2016, entry version 128.
DE   RecName: Full=C-C motif chemokine 2;
DE   AltName: Full=Immediate-early serum-responsive protein JE;
DE   AltName: Full=Monocyte chemoattractant protein 1;
DE   AltName: Full=Monocyte chemotactic protein 1;
DE            Short=MCP-1;
DE   AltName: Full=Small-inducible cytokine A2;
DE   Flags: Precursor;
GN   Name=Ccl2; Synonyms=Je, Mcp1, Scya2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=WAG/RIJ; TISSUE=Kidney;
RX   PubMed=2106664; DOI=10.1093/nar/18.1.23;
RA   Timmers H.T.M., Pronk G.J., Bos J.L., van der Eb A.J.;
RT   "Analysis of the rat JE gene promoter identifies an AP-1 binding site
RT   essential for basal expression but not for TPA induction.";
RL   Nucleic Acids Res. 18:23-34(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1704226; DOI=10.1016/0006-291X(91)91445-I;
RA   Yoshimura T., Takeya M., Takahashi K.;
RT   "Molecular cloning of rat monocyte chemoattractant protein-1 (MCP-1)
RT   and its expression in rat spleen cells and tumor cell lines.";
RL   Biochem. Biophys. Res. Commun. 174:504-509(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Aortic smooth muscle;
RA   Poon M., Taubman M.B.;
RT   "Cloning of the full-length rat JE/MCP-1 cDNA.";
RL   Submitted (APR-1998) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Chemotactic factor that attracts monocytes, but not
CC       neutrophils.
CC   -!- SUBUNIT: Monomer or homodimer; in equilibrium. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SIMILARITY: Belongs to the intercrine beta (chemokine CC) family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X17053; CAA34901.1; -; Genomic_DNA.
DR   EMBL; M57441; AAA63496.1; -; mRNA.
DR   EMBL; AF058786; AAC15187.1; -; mRNA.
DR   PIR; S07723; S07723.
DR   RefSeq; NP_113718.1; NM_031530.1.
DR   UniGene; Rn.4772; -.
DR   ProteinModelPortal; P14844; -.
DR   STRING; 10116.ENSRNOP00000009448; -.
DR   PhosphoSite; P14844; -.
DR   PaxDb; P14844; -.
DR   PRIDE; P14844; -.
DR   Ensembl; ENSRNOT00000009448; ENSRNOP00000009448; ENSRNOG00000007159.
DR   GeneID; 24770; -.
DR   KEGG; rno:24770; -.
DR   CTD; 6347; -.
DR   RGD; 3645; Ccl2.
DR   eggNOG; ENOG410J1ST; Eukaryota.
DR   eggNOG; ENOG410YXJU; LUCA.
DR   GeneTree; ENSGT00730000110714; -.
DR   HOGENOM; HOG000036686; -.
DR   HOVERGEN; HBG017871; -.
DR   InParanoid; P14844; -.
DR   KO; K14624; -.
DR   OMA; NAPLTCC; -.
DR   OrthoDB; EOG7673DP; -.
DR   PhylomeDB; P14844; -.
DR   TreeFam; TF339372; -.
DR   Reactome; R-RNO-380108; Chemokine receptors bind chemokines.
DR   NextBio; 604340; -.
DR   PRO; PR:P14844; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   Genevisible; P14844; RN.
DR   GO; GO:0043679; C:axon terminus; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:RGD.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0043204; C:perikaryon; IDA:RGD.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:RGD.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IDA:RGD.
DR   GO; GO:0045202; C:synapse; IDA:RGD.
DR   GO; GO:0031727; F:CCR2 chemokine receptor binding; IMP:RGD.
DR   GO; GO:0008009; F:chemokine activity; IDA:RGD.
DR   GO; GO:0008201; F:heparin binding; IPI:RGD.
DR   GO; GO:0007568; P:aging; IEP:RGD.
DR   GO; GO:0043615; P:astrocyte cell migration; IEA:Ensembl.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:RGD.
DR   GO; GO:0071318; P:cellular response to ATP; IEP:RGD.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEP:RGD.
DR   GO; GO:0035690; P:cellular response to drug; IEP:RGD.
DR   GO; GO:0044344; P:cellular response to fibroblast growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071403; P:cellular response to high density lipoprotein particle stimulus; IEP:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEP:RGD.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEP:RGD.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:RGD.
DR   GO; GO:0071354; P:cellular response to interleukin-6; IEP:RGD.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0071402; P:cellular response to lipoprotein particle stimulus; IEP:RGD.
DR   GO; GO:0036006; P:cellular response to macrophage colony-stimulating factor stimulus; IEP:RGD.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEP:RGD.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEP:RGD.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:RGD.
DR   GO; GO:0070098; P:chemokine-mediated signaling pathway; IMP:RGD.
DR   GO; GO:0042466; P:chemokinesis; TAS:RGD.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IMP:RGD.
DR   GO; GO:0007010; P:cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0008347; P:glial cell migration; IMP:RGD.
DR   GO; GO:0035684; P:helper T cell extravasation; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEP:RGD.
DR   GO; GO:0002523; P:leukocyte migration involved in inflammatory response; IMP:RGD.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0048247; P:lymphocyte chemotaxis; IDA:RGD.
DR   GO; GO:0048246; P:macrophage chemotaxis; IDA:RGD.
DR   GO; GO:0000165; P:MAPK cascade; IEA:Ensembl.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IEP:RGD.
DR   GO; GO:0060137; P:maternal process involved in parturition; IEP:RGD.
DR   GO; GO:0002548; P:monocyte chemotaxis; IBA:GO_Central.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:2000502; P:negative regulation of natural killer cell chemotaxis; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IMP:RGD.
DR   GO; GO:0031100; P:organ regeneration; IEP:RGD.
DR   GO; GO:2000427; P:positive regulation of apoptotic cell clearance; IEA:Ensembl.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; IEA:Ensembl.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:RGD.
DR   GO; GO:0022409; P:positive regulation of cell-cell adhesion; IDA:RGD.
DR   GO; GO:0002693; P:positive regulation of cellular extravasation; IDA:RGD.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IDA:RGD.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:RGD.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IBA:GO_Central.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IBA:GO_Central.
DR   GO; GO:0090265; P:positive regulation of immune complex clearance by monocytes and macrophages; IEA:Ensembl.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IBA:GO_Central.
DR   GO; GO:0001912; P:positive regulation of leukocyte mediated cytotoxicity; IMP:RGD.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; IDA:RGD.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; IDA:RGD.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IDA:RGD.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IEA:Ensembl.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:RGD.
DR   GO; GO:0050806; P:positive regulation of synaptic transmission; IDA:RGD.
DR   GO; GO:0050870; P:positive regulation of T cell activation; IEA:Ensembl.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IMP:RGD.
DR   GO; GO:0043491; P:protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl.
DR   GO; GO:0010574; P:regulation of vascular endothelial growth factor production; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:0043200; P:response to amino acid; IEP:RGD.
DR   GO; GO:0046677; P:response to antibiotic; IEP:RGD.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0010332; P:response to gamma radiation; IEP:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IEP:RGD.
DR   GO; GO:0009408; P:response to heat; IDA:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0032570; P:response to progesterone; IEP:RGD.
DR   GO; GO:0033552; P:response to vitamin B3; IEP:RGD.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IMP:RGD.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:RGD.
DR   InterPro; IPR000827; Chemokine_CC_CS.
DR   InterPro; IPR001811; Chemokine_IL8-like_dom.
DR   Pfam; PF00048; IL8; 1.
DR   SMART; SM00199; SCY; 1.
DR   SUPFAM; SSF54117; SSF54117; 1.
DR   PROSITE; PS00472; SMALL_CYTOKINES_CC; 1.
PE   2: Evidence at transcript level;
KW   Chemotaxis; Complete proteome; Cytokine; Disulfide bond; Glycoprotein;
KW   Inflammatory response; Pyrrolidone carboxylic acid;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     23       {ECO:0000250}.
FT   CHAIN        24    148       C-C motif chemokine 2.
FT                                /FTId=PRO_0000005151.
FT   MOD_RES      24     24       Pyrrolidone carboxylic acid.
FT                                {ECO:0000250|UniProtKB:P13500}.
FT   CARBOHYD    126    126       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     34     59       {ECO:0000250}.
FT   DISULFID     35     75       {ECO:0000250}.
SQ   SEQUENCE   148 AA;  16460 MW;  62D4C42BF4B11C9D CRC64;
     MQVSVTLLGL LFTVAACSIH VLSQPDAVNA PLTCCYSFTG KMIPMSRLEN YKRITSSRCP
     KEAVVFVTKL KREICADPNK EWVQKYIRKL DQNQVRSETT VFYKIASTLR TSAPLNVNLT
     HKSEANASTL FSTTTSSTSV EVTSMTEN
//
ID   GHR_HUMAN               Reviewed;         638 AA.
AC   P10912; Q9HCX2;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   20-JAN-2016, entry version 190.
DE   RecName: Full=Growth hormone receptor;
DE            Short=GH receptor;
DE   AltName: Full=Somatotropin receptor;
DE   Contains:
DE     RecName: Full=Growth hormone-binding protein;
DE              Short=GH-binding protein;
DE              Short=GHBP;
DE     AltName: Full=Serum-binding protein;
DE   Flags: Precursor;
GN   Name=GHR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Liver;
RX   PubMed=2825030; DOI=10.1038/330537a0;
RA   Leung D.W., Spencer S.A., Cachianes G., Hammonds R.G., Collins C.,
RA   Henzel W.J., Barnard R., Waters M.J., Wood W.I.;
RT   "Growth hormone receptor and serum binding protein: purification,
RT   cloning and expression.";
RL   Nature 330:537-543(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT LEU-544.
RX   PubMed=2813379; DOI=10.1073/pnas.86.20.8083;
RA   Godowski P.J., Leung D.W., Meacham L.R., Galgani J.P., Hellmiss R.,
RA   Keret R., Rotwein P.S., Parks J.S., Laron Z., Wood W.I.;
RT   "Characterization of the human growth hormone receptor gene and
RT   demonstration of a partial gene deletion in two patients with Laron-
RT   type dwarfism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:8083-8087(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Placenta;
RX   PubMed=1569971; DOI=10.1210/mend.6.2.1569971;
RA   Urbanek M., MacLeod J.N., Cooke N.E., Liebhaber S.A.;
RT   "Expression of a human growth hormone (hGH) receptor isoform is
RT   predicted by tissue-specific alternative splicing of exon 3 of the hGH
RT   receptor gene transcript.";
RL   Mol. Endocrinol. 6:279-287(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Liver;
RX   PubMed=8855247; DOI=10.1073/pnas.93.20.10723;
RA   Dastot F., Sobrier M.-L., Duquesnoy P., Duriez B., Goossens M.,
RA   Amselem S.;
RT   "Alternatively spliced forms in the cytoplasmic domain of the human
RT   growth hormone (GH) receptor regulate its ability to generate a
RT   soluble GH-binding protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:10723-10728(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=9360546; DOI=10.1210/jc.82.11.3813;
RA   Amit T., Bergman T., Dastot F., Youdim M.B.H., Amselem S.,
RA   Hochberg Z.;
RT   "A membrane-fixed, truncated isoform of the human growth hormone
RT   receptor.";
RL   J. Clin. Endocrinol. Metab. 82:3813-3817(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Liver;
RX   PubMed=9058373; DOI=10.1210/me.11.3.265;
RA   Ross R.J., Esposito N., Shen X.Y., Von Laue S., Chew S.L.,
RA   Dobson P.R., Postel-Vinay M.-C., Finidori J.;
RT   "A short isoform of the human growth hormone receptor functions as a
RT   dominant negative inhibitor of the full-length receptor and generates
RT   large amounts of binding protein.";
RL   Mol. Endocrinol. 11:265-273(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 263-336.
RA   Orlovsky I.V., Borovikova I.E., Rubtsov P.M.;
RT   "Comparing of nucleotide sequences of alternatively spliced region of
RT   mammalian growth hormone receptor genes.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   CHARACTERIZATION (ISOFORM 4).
RX   PubMed=8360189;
RA   Urbanek M., Russell J.E., Cooke N.E., Liebhaber S.A.;
RT   "Functional characterization of the alternatively spliced, placental
RT   human growth hormone receptor.";
RL   J. Biol. Chem. 268:19025-19032(1993).
RN   [9]
RP   MOLECULAR MECHANISM OF PRODUCTION (ISOFORM 4).
RX   PubMed=10764769; DOI=10.1074/jbc.M001615200;
RA   Pantel J., Machinis K., Sobrier M.-L., Duquesnoy P., Goossens M.,
RA   Amselem S.;
RT   "Species-specific alternative splice mimicry at the growth hormone
RT   receptor locus revealed by the lineage of retroelements during primate
RT   evolution.";
RL   J. Biol. Chem. 275:18664-18669(2000).
RN   [10]
RP   DISULFIDE BONDS.
RX   PubMed=2406245;
RA   Fuh G., Mulkerrin M.G., Bass S., McFarland N., Brochier M.,
RA   Bourrel J.H., Light D.R., Wells J.A.;
RT   "The human growth hormone receptor. Secretion from Escherichia coli
RT   and disulfide bonding pattern of the extracellular binding domain.";
RL   J. Biol. Chem. 265:3111-3115(1990).
RN   [11]
RP   SITE CRITICAL TO PROTEOLYSIS, AND MUTAGENESIS OF GLU-260; GLU-261 AND
RP   ASP-262.
RX   PubMed=11785980; DOI=10.1006/bbrc.2001.6261;
RA   Conte F., Salles J.P., Raynal P., Fernandez L., Molinas C., Tauber M.,
RA   Bieth E.;
RT   "Identification of a region critical for proteolysis of the human
RT   growth hormone receptor.";
RL   Biochem. Biophys. Res. Commun. 290:851-857(2002).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-341, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 19-254 IN COMPLEX WITH GROWTH
RP   HORMONE.
RX   PubMed=1549776; DOI=10.1126/science.1549776;
RA   de Vos A.M., Ultsch M., Kossiakoff A.A.;
RT   "Human growth hormone and extracellular domain of its receptor:
RT   crystal structure of the complex.";
RL   Science 255:306-312(1992).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 19-256 IN COMPLEX WITH GROWTH
RP   HORMONE.
RX   PubMed=8943276; DOI=10.1074/jbc.271.50.32197;
RA   Sundstroem M., Lundqvist T., Roedin J., Giebel L.B., Milligan D.,
RA   Norstedt G.;
RT   "Crystal structure of an antagonist mutant of human growth hormone,
RT   G120R, in complex with its receptor at 2.9-A resolution.";
RL   J. Biol. Chem. 271:32197-32203(1996).
RN   [15]
RP   VARIANT LARS SER-114.
RX   PubMed=2779634; DOI=10.1056/NEJM198910123211501;
RA   Amselem S., Duquesnoy P., Attree O., Novelli G., Bousnina S.,
RA   Postel-Vinay M.-C., Goossens M.;
RT   "Laron dwarfism and mutations of the growth hormone-receptor gene.";
RL   N. Engl. J. Med. 321:989-995(1989).
RN   [16]
RP   VARIANT LARS PHE-440.
RX   PubMed=8421103; DOI=10.1210/jc.76.1.54;
RA   Kou K., Lajara R., Rotwein P.;
RT   "Amino acid substitutions in the intracellular part of the growth
RT   hormone receptor in a patient with the Laron syndrome.";
RL   J. Clin. Endocrinol. Metab. 76:54-59(1993).
RN   [17]
RP   VARIANTS LARS LYS-89; GLN-149; ASP-162; CYS-179 AND GLY-229.
RX   PubMed=8504296; DOI=10.1093/hmg/2.4.355;
RA   Amselem S., Duquesnoy P., Duriez B., Dastot F., Sobrier M.-L.,
RA   Valleix S., Goossens M.;
RT   "Spectrum of growth hormone receptor mutations and associated
RT   haplotypes in Laron syndrome.";
RL   Hum. Mol. Genet. 2:355-359(1993).
RN   [18]
RP   CHARACTERIZATION OF VARIANT LARS SER-114.
RX   PubMed=8450064; DOI=10.1172/JCI116304;
RA   Edery M., Rozakis-Adcock M., Goujon L., Finidori J., Levi-Meyrueis C.,
RA   Paly J., Djiane J., Postel-Vinay M.-C., Kelly P.A.;
RT   "Lack of hormone binding in COS-7 cells expressing a mutated growth
RT   hormone receptor found in Laron dwarfism.";
RL   J. Clin. Invest. 91:838-844(1993).
RN   [19]
RP   VARIANT LARS HIS-170.
RX   PubMed=8137822;
RA   Duquesnoy P., Sobrier M.-L., Duriez B., Dastot F., Buchanan C.R.,
RA   Savage M.O., Preece M.A., Craescu C.T., Blouquit Y., Goossens M.,
RA   Amselem S.;
RT   "A single amino acid substitution in the exoplasmic domain of the
RT   human growth hormone (GH) receptor confers familial GH resistance
RT   (Laron syndrome) with positive GH-binding activity by abolishing
RT   receptor homodimerization.";
RL   EMBO J. 13:1386-1395(1994).
RN   [20]
RP   VARIANTS GHIP LYS-62 AND CYS-179, AND VARIANTS HIS-229 AND ASP-242.
RX   PubMed=7565946; DOI=10.1056/NEJM199510263331701;
RA   Goddard A.D., Covello R., Luoh S.-M., Clackson T., Attie K.M.,
RA   Gesundheit N., Rundle A.C., Wells J.A., Carlsson L.M.S.;
RT   "Mutations of the growth hormone receptor in children with idiopathic
RT   short stature.";
RL   N. Engl. J. Med. 333:1093-1098(1995).
RN   [21]
RP   VARIANTS LARS SER-56; LEU-58 AND ARG-68.
RX   PubMed=9024232; DOI=10.1210/jc.82.2.435;
RA   Sobrier M.-L., Dastot F., Duquesnoy P., Kandemir N., Yordam N.,
RA   Goossens M., Amselem S.;
RT   "Nine novel growth hormone receptor gene mutations in patients with
RT   Laron syndrome.";
RL   J. Clin. Endocrinol. Metab. 82:435-437(1997).
RN   [22]
RP   VARIANT LARS GLN-149, AND CHARACTERIZATION OF VARIANT LARS GLN-149.
RX   PubMed=9661642; DOI=10.1210/jcem.83.7.4954;
RA   Walker J.L., Crock P.A., Behncken S.N., Rowlinson S.W.,
RA   Nicholson L.M., Boulton T.J.C., Waters M.J.;
RT   "A novel mutation affecting the interdomain link region of the growth
RT   hormone receptor in a Vietnamese girl, and response to long-term
RT   treatment with recombinant human insulin-like growth factor-I and
RT   luteinizing hormone-releasing hormone analogue.";
RL   J. Clin. Endocrinol. Metab. 83:2554-2561(1998).
RN   [23]
RP   VARIANT ILE-162.
RX   PubMed=9814495; DOI=10.1210/jc.83.11.4079;
RA   Sanchez J.E., Perera E., Baumbach L., Cleveland W.W.;
RT   "Growth hormone receptor mutations in children with idiopathic short
RT   stature.";
RL   J. Clin. Endocrinol. Metab. 83:4079-4083(1998).
RN   [24]
RP   VARIANTS LARS HIS-170; THR-171; PRO-172 AND GLY-173, AND
RP   CHARACTERIZATION OF VARIANTS LARS THR-171; PRO-172 AND GLY-173.
RX   PubMed=9851797; DOI=10.1210/jc.83.12.4481;
RA   Wojcik J., Berg M.A., Esposito N., Geffner M.E., Sakati N.,
RA   Reiter E.O., Dower S., Francke U., Postel-Vinay M.-C., Finidori J.;
RT   "Four contiguous amino acid substitutions, identified in patients with
RT   Laron syndrome, differently affect the binding affinity and
RT   intracellular trafficking of the growth hormone receptor.";
RL   J. Clin. Endocrinol. Metab. 83:4481-4489(1998).
RN   [25]
RP   VARIANTS HIS-179; HIS-229; PHE-440; THR-495; LEU-544 AND THR-579.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [26]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [27]
RP   VARIANTS LARS CYS-226 AND ASN-262.
RX   PubMed=10870033; DOI=10.1530/eje.0.1430071;
RA   Enberg B., Luthman H., Segnestam K., Ritzen E.M., Sundstroem M.,
RA   Norstedt G.;
RT   "Characterisation of novel missense mutations in the GH receptor gene
RT   causing severe growth retardation.";
RL   Eur. J. Endocrinol. 143:71-76(2000).
RN   [28]
RP   VARIANT LEU-544.
RX   PubMed=12910492; DOI=10.1002/ajmg.a.20172;
RA   Takada D., Ezura Y., Ono S., Iino Y., Katayama Y., Xin Y., Wu L.L.,
RA   Larringa-Shum S., Stephenson S.H., Hunt S.C., Hopkins P.N., Emi M.;
RT   "Growth hormone receptor variant (L526I) modifies plasma HDL
RT   cholesterol phenotype in familial hypercholesterolemia: intra-familial
RT   association study in an eight-generation hyperlipidemic kindred.";
RL   Am. J. Med. Genet. A 121:136-140(2003).
RN   [29]
RP   VARIANT LARS ILE-244.
RX   PubMed=14678285; DOI=10.1111/j.1365-2265.2004.01930.x;
RA   Jorge A.A.L., Souza S.C.A.L., Arnhold I.J.P., Mendonca B.B.;
RT   "The first homozygous mutation (S226I) in the highly-conserved WSXWS-
RT   like motif of the GH receptor causing Laron syndrome: suppression of
RT   GH secretion by GnRH analogue therapy not restored by
RT   dihydrotestosterone administration.";
RL   Clin. Endocrinol. (Oxf.) 60:36-40(2004).
CC   -!- FUNCTION: Receptor for pituitary gland growth hormone involved in
CC       regulating postnatal body growth. On ligand binding, couples to
CC       the JAK2/STAT5 pathway (By similarity). {ECO:0000250}.
CC   -!- FUNCTION: The soluble form (GHBP) acts as a reservoir of growth
CC       hormone in plasma and may be a modulator/inhibitor of GH
CC       signaling.
CC   -!- FUNCTION: Isoform 2 up-regulates the production of GHBP and acts
CC       as a negative inhibitor of GH signaling.
CC   -!- SUBUNIT: On growth hormone (GH) binding, forms homodimers and
CC       binds JAK2 via a box 1-containing domain. Binding to SOCS3
CC       inhibits JAK2 activation, binding to CIS and SOCS2 inhibits STAT5
CC       activation. Interacts with ADAM17. {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q16829:DUSP7; NbExp=2; IntAct=EBI-286316, EBI-1265847;
CC       P01241:GH1; NbExp=3; IntAct=EBI-286316, EBI-1026046;
CC       P16333:NCK1; NbExp=3; IntAct=EBI-286316, EBI-389883;
CC       Q9JLI4:Ncoa6 (xeno); NbExp=2; IntAct=EBI-286316, EBI-286271;
CC       P18031:PTPN1; NbExp=5; IntAct=EBI-286316, EBI-968788;
CC       P17706:PTPN2; NbExp=8; IntAct=EBI-286316, EBI-984930;
CC       P26045:PTPN3; NbExp=4; IntAct=EBI-286316, EBI-1047946;
CC       P43378:PTPN9; NbExp=2; IntAct=EBI-286316, EBI-742898;
CC       P23467:PTPRB; NbExp=3; IntAct=EBI-286316, EBI-1265766;
CC       Q9HD43:PTPRH; NbExp=4; IntAct=EBI-286316, EBI-1267176;
CC       Q12913:PTPRJ; NbExp=2; IntAct=EBI-286316, EBI-2264500;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Note=On growth hormone binding, GHR is ubiquitinated,
CC       internalized, down-regulated and transported into a degradative or
CC       non-degradative pathway. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane; Single-pass type I
CC       membrane protein. Note=Remains fixed to the cell membrane and is
CC       not internalized.
CC   -!- SUBCELLULAR LOCATION: Growth hormone-binding protein: Secreted.
CC       Note=Complexed to a substantial fraction of circulating GH.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=GHRfl;
CC         IsoId=P10912-1; Sequence=Displayed;
CC       Name=2; Synonyms=GHRtr, GHR1-279;
CC         IsoId=P10912-2; Sequence=VSP_010227, VSP_010228;
CC       Name=3; Synonyms=GHR1-277;
CC         IsoId=P10912-3; Sequence=VSP_010229, VSP_010230;
CC       Name=4; Synonyms=GHRd3;
CC         IsoId=P10912-4; Sequence=VSP_010225, VSP_010226;
CC         Note=Arises by species-specific retrovirus-mediated alternative
CC         splice mimicry.;
CC   -!- TISSUE SPECIFICITY: Expressed in various tissues with high
CC       expression in liver and skeletal muscle. Isoform 4 is
CC       predominantly expressed in kidney, bladder, adrenal gland and
CC       brain stem. Isoform 1 expression in placenta is predominant in
CC       chorion and decidua. Isoform 4 is highly expressed in placental
CC       villi. Isoform 2 is expressed in lung, stomach and muscle. Low
CC       levels in liver.
CC   -!- DOMAIN: The WSXWS motif appears to be necessary for proper protein
CC       folding and thereby efficient intracellular transport and cell-
CC       surface receptor binding.
CC   -!- DOMAIN: The box 1 motif is required for JAK interaction and/or
CC       activation.
CC   -!- DOMAIN: The extracellular domain is the ligand-binding domain
CC       representing the growth hormone-binding protein (GHBP).
CC   -!- DOMAIN: The ubiquitination-dependent endocytosis motif (UbE) is
CC       required for recruitment of the ubiquitin conjugation system on to
CC       the receptor and for its internalization.
CC   -!- PTM: The soluble form (GHBP) is produced by phorbol ester-promoted
CC       proteolytic cleavage at the cell surface (shedding) by
CC       ADAM17/TACE. Shedding is inhibited by growth hormone (GH) binding
CC       to the receptor probably due to a conformational change in GHR
CC       rendering the receptor inaccessible to ADAM17 (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: On GH binding, phosphorylated on tyrosine residues in the
CC       cytoplasmic domain by JAK2. {ECO:0000250}.
CC   -!- PTM: On ligand binding, ubiquitinated on lysine residues in the
CC       cytoplasmic domain. This ubiquitination is not sufficient for GHR
CC       internalization (By similarity). {ECO:0000250}.
CC   -!- POLYMORPHISM: Genetic variation in GHR may act as phenotype
CC       modifier in familial hypercholesterolemia [MIM:143890] patients
CC       carrying a mutation in the LDLR gene.
CC   -!- DISEASE: Laron syndrome (LARS) [MIM:262500]: A severe form of
CC       growth hormone insensitivity characterized by growth impairment,
CC       short stature, dysfunctional growth hormone receptor, and failure
CC       to generate insulin-like growth factor I in response to growth
CC       hormone. {ECO:0000269|PubMed:10870033,
CC       ECO:0000269|PubMed:14678285, ECO:0000269|PubMed:2779634,
CC       ECO:0000269|PubMed:8137822, ECO:0000269|PubMed:8421103,
CC       ECO:0000269|PubMed:8504296, ECO:0000269|PubMed:9024232,
CC       ECO:0000269|PubMed:9661642, ECO:0000269|PubMed:9851797}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Growth hormone insensitivity, partial (GHIP)
CC       [MIM:604271]: A disease characterized by partial resistance to
CC       growth hormone resulting in short stature. Short stature is
CC       defined by a standing height more than 2 standard deviations below
CC       the mean (or below the 2.5 percentile) for sex and chronological
CC       age, compared with a well-nourished, healthy, genetically relevant
CC       population. {ECO:0000269|PubMed:7565946}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 1
CC       subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 fibronectin type-III domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X06562; CAA29808.1; -; mRNA.
DR   EMBL; M28466; AAA52555.1; -; Genomic_DNA.
DR   EMBL; M28458; AAA52555.1; JOINED; Genomic_DNA.
DR   EMBL; M28459; AAA52555.1; JOINED; Genomic_DNA.
DR   EMBL; M28460; AAA52555.1; JOINED; Genomic_DNA.
DR   EMBL; M28461; AAA52555.1; JOINED; Genomic_DNA.
DR   EMBL; M28462; AAA52555.1; JOINED; Genomic_DNA.
DR   EMBL; M28463; AAA52555.1; JOINED; Genomic_DNA.
DR   EMBL; M28464; AAA52555.1; JOINED; Genomic_DNA.
DR   EMBL; M28465; AAA52555.1; JOINED; Genomic_DNA.
DR   EMBL; AJ278681; CAC06613.1; -; Genomic_DNA.
DR   CCDS; CCDS3940.1; -. [P10912-1]
DR   CCDS; CCDS56364.1; -. [P10912-4]
DR   PIR; A33991; A33991.
DR   RefSeq; NP_000154.1; NM_000163.4. [P10912-1]
DR   RefSeq; NP_001229328.1; NM_001242399.2.
DR   RefSeq; NP_001229329.1; NM_001242400.2. [P10912-1]
DR   RefSeq; NP_001229330.1; NM_001242401.3. [P10912-1]
DR   RefSeq; NP_001229331.1; NM_001242402.2. [P10912-1]
DR   RefSeq; NP_001229332.1; NM_001242403.2. [P10912-1]
DR   RefSeq; NP_001229333.1; NM_001242404.2. [P10912-1]
DR   RefSeq; NP_001229334.1; NM_001242405.2. [P10912-1]
DR   RefSeq; NP_001229335.1; NM_001242406.2. [P10912-1]
DR   RefSeq; NP_001229389.1; NM_001242460.1. [P10912-4]
DR   RefSeq; NP_001229391.1; NM_001242462.1.
DR   UniGene; Hs.125180; -.
DR   UniGene; Hs.684632; -.
DR   UniGene; Hs.688223; -.
DR   PDB; 1A22; X-ray; 2.60 A; B=19-256.
DR   PDB; 1AXI; X-ray; 2.10 A; B=19-254.
DR   PDB; 1HWG; X-ray; 2.50 A; B/C=19-255.
DR   PDB; 1HWH; X-ray; 2.90 A; B=19-255.
DR   PDB; 1KF9; X-ray; 2.60 A; B/C/E/F=19-256.
DR   PDB; 2AEW; X-ray; 2.70 A; A/B=47-251.
DR   PDB; 3HHR; X-ray; 2.80 A; B/C=50-254.
DR   PDBsum; 1A22; -.
DR   PDBsum; 1AXI; -.
DR   PDBsum; 1HWG; -.
DR   PDBsum; 1HWH; -.
DR   PDBsum; 1KF9; -.
DR   PDBsum; 2AEW; -.
DR   PDBsum; 3HHR; -.
DR   DisProt; DP00033; -.
DR   ProteinModelPortal; P10912; -.
DR   SMR; P10912; 50-252.
DR   BioGrid; 108957; 30.
DR   DIP; DIP-630N; -.
DR   IntAct; P10912; 23.
DR   MINT; MINT-1528703; -.
DR   STRING; 9606.ENSP00000230882; -.
DR   ChEMBL; CHEMBL1976; -.
DR   DrugBank; DB00082; Pegvisomant.
DR   DrugBank; DB00052; Somatropin recombinant.
DR   iPTMnet; P10912; -.
DR   PhosphoSite; P10912; -.
DR   BioMuta; GHR; -.
DR   DMDM; 121180; -.
DR   PaxDb; P10912; -.
DR   PRIDE; P10912; -.
DR   Ensembl; ENST00000230882; ENSP00000230882; ENSG00000112964. [P10912-1]
DR   Ensembl; ENST00000357703; ENSP00000350335; ENSG00000112964. [P10912-4]
DR   Ensembl; ENST00000537449; ENSP00000442206; ENSG00000112964. [P10912-1]
DR   Ensembl; ENST00000612382; ENSP00000478332; ENSG00000112964. [P10912-1]
DR   Ensembl; ENST00000612626; ENSP00000479846; ENSG00000112964. [P10912-1]
DR   Ensembl; ENST00000615111; ENSP00000478291; ENSG00000112964. [P10912-1]
DR   Ensembl; ENST00000618088; ENSP00000482373; ENSG00000112964. [P10912-1]
DR   GeneID; 2690; -.
DR   KEGG; hsa:2690; -.
DR   UCSC; uc003jmt.3; human. [P10912-1]
DR   UCSC; uc021xyb.1; human. [P10912-2]
DR   UCSC; uc021xyc.1; human. [P10912-3]
DR   UCSC; uc021xyd.1; human. [P10912-4]
DR   CTD; 2690; -.
DR   GeneCards; GHR; -.
DR   HGNC; HGNC:4263; GHR.
DR   MalaCards; GHR; -.
DR   MIM; 143890; phenotype.
DR   MIM; 262500; phenotype.
DR   MIM; 600946; gene.
DR   MIM; 604271; phenotype.
DR   neXtProt; NX_P10912; -.
DR   Orphanet; 633; Laron syndrome.
DR   Orphanet; 314802; Short stature due to partial GHR deficiency.
DR   PharmGKB; PA28674; -.
DR   eggNOG; ENOG410IFQI; Eukaryota.
DR   eggNOG; ENOG410XTHJ; LUCA.
DR   GeneTree; ENSGT00530000063112; -.
DR   HOGENOM; HOG000015773; -.
DR   HOVERGEN; HBG005836; -.
DR   InParanoid; P10912; -.
DR   KO; K05080; -.
DR   OrthoDB; EOG79W94T; -.
DR   PhylomeDB; P10912; -.
DR   TreeFam; TF330851; -.
DR   Reactome; R-HSA-1170546; Prolactin receptor signaling.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   SignaLink; P10912; -.
DR   ChiTaRS; GHR; human.
DR   EvolutionaryTrace; P10912; -.
DR   GeneWiki; Growth_hormone_receptor; -.
DR   GenomeRNAi; 2690; -.
DR   NextBio; 10636; -.
DR   PMAP-CutDB; P10912; -.
DR   PRO; PR:P10912; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; P10912; -.
DR   CleanEx; HS_GHR; -.
DR   ExpressionAtlas; P10912; baseline and differential.
DR   Genevisible; P10912; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0070195; C:growth hormone receptor complex; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005622; C:intracellular; ISS:GOC.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0004896; F:cytokine receptor activity; IEA:InterPro.
DR   GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0017046; F:peptide hormone binding; IPI:BHF-UCL.
DR   GO; GO:0070064; F:proline-rich region binding; ISS:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; ISS:BHF-UCL.
DR   GO; GO:0006103; P:2-oxoglutarate metabolic process; ISS:BHF-UCL.
DR   GO; GO:0042977; P:activation of JAK2 kinase activity; ISS:BHF-UCL.
DR   GO; GO:0000187; P:activation of MAPK activity; ISS:BHF-UCL.
DR   GO; GO:0000255; P:allantoin metabolic process; ISS:BHF-UCL.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IMP:BHF-UCL.
DR   GO; GO:0006101; P:citrate metabolic process; ISS:BHF-UCL.
DR   GO; GO:0006600; P:creatine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0046449; P:creatinine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0006631; P:fatty acid metabolic process; ISS:BHF-UCL.
DR   GO; GO:0060396; P:growth hormone receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0006549; P:isoleucine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0007259; P:JAK-STAT cascade; ISS:BHF-UCL.
DR   GO; GO:0060397; P:JAK-STAT cascade involved in growth hormone signaling pathway; TAS:Reactome.
DR   GO; GO:0044236; P:multicellular organismal metabolic process; IMP:BHF-UCL.
DR   GO; GO:0006107; P:oxaloacetate metabolic process; ISS:BHF-UCL.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IMP:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; ISS:BHF-UCL.
DR   GO; GO:0042523; P:positive regulation of tyrosine phosphorylation of Stat5 protein; ISS:BHF-UCL.
DR   GO; GO:0031623; P:receptor internalization; IDA:BHF-UCL.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; ISS:BHF-UCL.
DR   GO; GO:0046898; P:response to cycloheximide; IDA:BHF-UCL.
DR   GO; GO:0032355; P:response to estradiol; IDA:BHF-UCL.
DR   GO; GO:0006105; P:succinate metabolic process; ISS:BHF-UCL.
DR   GO; GO:0019530; P:taurine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0006573; P:valine metabolic process; ISS:BHF-UCL.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR025871; GHBP.
DR   InterPro; IPR015152; Growth/epo_recpt_lig-bind.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003528; Long_hematopoietin_rcpt_CS.
DR   Pfam; PF09067; EpoR_lig-bind; 1.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF12772; GHBP; 1.
DR   SMART; SM00060; FN3; 1.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   PROSITE; PS50853; FN3; 1.
DR   PROSITE; PS01352; HEMATOPO_REC_L_F1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond; Dwarfism;
KW   Endocytosis; Glycoprotein; Membrane; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Secreted; Signal; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    638       Growth hormone receptor.
FT                                /FTId=PRO_0000010957.
FT   CHAIN        19    256       Growth hormone-binding protein.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000010958.
FT   TOPO_DOM     19    264       Extracellular. {ECO:0000255}.
FT   TRANSMEM    265    288       Helical. {ECO:0000255}.
FT   TOPO_DOM    289    638       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      151    254       Fibronectin type-III.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   REGION      260    262       Required for ADAM17-mediated proteolysis.
FT                                {ECO:0000250}.
FT   MOTIF       240    244       WSXWS motif.
FT   MOTIF       297    305       Box 1 motif.
FT   MOTIF       340    349       UbE motif.
FT   SITE        345    345       Required for endocytosis and down-
FT                                regulation. {ECO:0000250}.
FT   MOD_RES     341    341       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     46     46       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    115    115       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    156    156       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    161    161       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    200    200       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     56     66       {ECO:0000269|PubMed:2406245}.
FT   DISULFID    101    112       {ECO:0000269|PubMed:2406245}.
FT   DISULFID    126    140       {ECO:0000269|PubMed:2406245}.
FT   VAR_SEQ      24     24       A -> D (in isoform 4).
FT                                {ECO:0000303|PubMed:1569971}.
FT                                /FTId=VSP_010225.
FT   VAR_SEQ      25     46       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:1569971}.
FT                                /FTId=VSP_010226.
FT   VAR_SEQ     292    297       RIKMLI -> SSSSKD (in isoform 2).
FT                                {ECO:0000303|PubMed:8855247,
FT                                ECO:0000303|PubMed:9058373,
FT                                ECO:0000303|PubMed:9360546}.
FT                                /FTId=VSP_010227.
FT   VAR_SEQ     292    294       RIK -> KEN (in isoform 3).
FT                                {ECO:0000303|PubMed:9058373}.
FT                                /FTId=VSP_010229.
FT   VAR_SEQ     295    638       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:9058373}.
FT                                /FTId=VSP_010230.
FT   VAR_SEQ     298    638       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8855247,
FT                                ECO:0000303|PubMed:9058373,
FT                                ECO:0000303|PubMed:9360546}.
FT                                /FTId=VSP_010228.
FT   VARIANT      56     56       C -> S (in LARS).
FT                                {ECO:0000269|PubMed:9024232}.
FT                                /FTId=VAR_018426.
FT   VARIANT      58     58       S -> L (in LARS).
FT                                {ECO:0000269|PubMed:9024232}.
FT                                /FTId=VAR_018427.
FT   VARIANT      62     62       E -> K (in GHIP).
FT                                {ECO:0000269|PubMed:7565946}.
FT                                /FTId=VAR_002708.
FT   VARIANT      68     68       W -> R (in LARS).
FT                                {ECO:0000269|PubMed:9024232}.
FT                                /FTId=VAR_018428.
FT   VARIANT      89     89       R -> K (in LARS).
FT                                {ECO:0000269|PubMed:8504296}.
FT                                /FTId=VAR_002709.
FT   VARIANT     114    114       F -> S (in LARS; loss of ability to bind
FT                                ligand). {ECO:0000269|PubMed:2779634,
FT                                ECO:0000269|PubMed:8450064}.
FT                                /FTId=VAR_002710.
FT   VARIANT     143    143       V -> A (in LARS).
FT                                /FTId=VAR_002711.
FT   VARIANT     149    149       P -> Q (in LARS; disrupts GH binding).
FT                                {ECO:0000269|PubMed:8504296,
FT                                ECO:0000269|PubMed:9661642}.
FT                                /FTId=VAR_018429.
FT   VARIANT     162    162       V -> D (in LARS).
FT                                {ECO:0000269|PubMed:8504296}.
FT                                /FTId=VAR_002712.
FT   VARIANT     162    162       V -> F (in dbSNP:rs6413484).
FT                                /FTId=VAR_020002.
FT   VARIANT     162    162       V -> I (found in a patient with
FT                                idiopathic short stature; unknown
FT                                pathological significance;
FT                                dbSNP:rs6413484).
FT                                {ECO:0000269|PubMed:9814495}.
FT                                /FTId=VAR_018430.
FT   VARIANT     170    170       D -> H (in LARS; abolishes receptor
FT                                homodimerization).
FT                                {ECO:0000269|PubMed:8137822,
FT                                ECO:0000269|PubMed:9851797}.
FT                                /FTId=VAR_002713.
FT   VARIANT     171    171       I -> T (in LARS; almost completely
FT                                abolishes GH-binding at cell surface: 53%
FT                                binding to membrane fractions).
FT                                {ECO:0000269|PubMed:9851797}.
FT                                /FTId=VAR_018431.
FT   VARIANT     172    172       Q -> P (in LARS; almost completely
FT                                abolishes GH-binding at cell surface and
FT                                in membrane fractions).
FT                                {ECO:0000269|PubMed:9851797}.
FT                                /FTId=VAR_018432.
FT   VARIANT     173    173       V -> G (in LARS; almost completely
FT                                abolishes GH-binding at cell surface: 26%
FT                                binding to membrane fractions).
FT                                {ECO:0000269|PubMed:9851797}.
FT                                /FTId=VAR_018433.
FT   VARIANT     179    179       R -> C (in LARS and GHIP;
FT                                dbSNP:rs121909362).
FT                                {ECO:0000269|PubMed:7565946,
FT                                ECO:0000269|PubMed:8504296}.
FT                                /FTId=VAR_002714.
FT   VARIANT     179    179       R -> H (in dbSNP:rs6181).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_013937.
FT   VARIANT     226    226       Y -> C (in LARS).
FT                                {ECO:0000269|PubMed:10870033}.
FT                                /FTId=VAR_018434.
FT   VARIANT     229    229       R -> G (in LARS).
FT                                {ECO:0000269|PubMed:8504296}.
FT                                /FTId=VAR_002715.
FT   VARIANT     229    229       R -> H (found in a patient with
FT                                idiopathic short stature; unknown
FT                                pathological significance; dbSNP:rs6177).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:7565946}.
FT                                /FTId=VAR_013938.
FT   VARIANT     242    242       E -> D (found in a patient with
FT                                idiopathic short stature; unknown
FT                                pathological significance;
FT                                dbSNP:rs45588036).
FT                                {ECO:0000269|PubMed:7565946}.
FT                                /FTId=VAR_002716.
FT   VARIANT     244    244       S -> I (in LARS).
FT                                {ECO:0000269|PubMed:14678285}.
FT                                /FTId=VAR_018435.
FT   VARIANT     262    262       D -> N (in LARS).
FT                                {ECO:0000269|PubMed:10870033}.
FT                                /FTId=VAR_018436.
FT   VARIANT     440    440       C -> F (in LARS; dbSNP:rs6182).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:8421103}.
FT                                /FTId=VAR_013939.
FT   VARIANT     465    465       E -> K (in dbSNP:rs34283856).
FT                                /FTId=VAR_032704.
FT   VARIANT     495    495       P -> T (in dbSNP:rs6183).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_013940.
FT   VARIANT     544    544       I -> L (polymorphism with a modifier
FT                                effect on plasma HDL cholesterol levels
FT                                in familial hypercholesterolemia
FT                                patients; dbSNP:rs6180).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:12910492,
FT                                ECO:0000269|PubMed:2813379}.
FT                                /FTId=VAR_013941.
FT   VARIANT     579    579       P -> T (in dbSNP:rs6184).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_013942.
FT   MUTAGEN     260    260       E->A: No change in shedding activity: No
FT                                change in hormone binding.
FT                                {ECO:0000269|PubMed:11785980}.
FT   MUTAGEN     261    261       E->A: No change in shedding activity: No
FT                                change in hormone binding.
FT                                {ECO:0000269|PubMed:11785980}.
FT   MUTAGEN     262    262       D->A: No change in shedding activity: No
FT                                change in hormone binding.
FT                                {ECO:0000269|PubMed:11785980}.
FT   STRAND       53     62       {ECO:0000244|PDB:1AXI}.
FT   STRAND       64     68       {ECO:0000244|PDB:1AXI}.
FT   STRAND       83     88       {ECO:0000244|PDB:1AXI}.
FT   TURN         93     96       {ECO:0000244|PDB:1HWG}.
FT   TURN        104    107       {ECO:0000244|PDB:3HHR}.
FT   STRAND      111    114       {ECO:0000244|PDB:1AXI}.
FT   HELIX       116    118       {ECO:0000244|PDB:1AXI}.
FT   STRAND      121    131       {ECO:0000244|PDB:1AXI}.
FT   STRAND      134    142       {ECO:0000244|PDB:1AXI}.
FT   HELIX       143    146       {ECO:0000244|PDB:1AXI}.
FT   STRAND      153    159       {ECO:0000244|PDB:1AXI}.
FT   STRAND      167    176       {ECO:0000244|PDB:1AXI}.
FT   TURN        183    186       {ECO:0000244|PDB:1AXI}.
FT   STRAND      190    198       {ECO:0000244|PDB:1AXI}.
FT   STRAND      210    221       {ECO:0000244|PDB:1AXI}.
FT   STRAND      226    234       {ECO:0000244|PDB:1AXI}.
FT   STRAND      240    243       {ECO:0000244|PDB:2AEW}.
FT   STRAND      247    249       {ECO:0000244|PDB:1AXI}.
SQ   SEQUENCE   638 AA;  71500 MW;  EAF77EADE4787822 CRC64;
     MDLWQLLLTL ALAGSSDAFS GSEATAAILS RAPWSLQSVN PGLKTNSSKE PKFTKCRSPE
     RETFSCHWTD EVHHGTKNLG PIQLFYTRRN TQEWTQEWKE CPDYVSAGEN SCYFNSSFTS
     IWIPYCIKLT SNGGTVDEKC FSVDEIVQPD PPIALNWTLL NVSLTGIHAD IQVRWEAPRN
     ADIQKGWMVL EYELQYKEVN ETKWKMMDPI LTTSVPVYSL KVDKEYEVRV RSKQRNSGNY
     GEFSEVLYVT LPQMSQFTCE EDFYFPWLLI IIFGIFGLTV MLFVFLFSKQ QRIKMLILPP
     VPVPKIKGID PDLLKEGKLE EVNTILAIHD SYKPEFHSDD SWVEFIELDI DEPDEKTEES
     DTDRLLSSDH EKSHSNLGVK DGDSGRTSCC EPDILETDFN ANDIHEGTSE VAQPQRLKGE
     ADLLCLDQKN QNNSPYHDAC PATQQPSVIQ AEKNKPQPLP TEGAESTHQA AHIQLSNPSS
     LSNIDFYAQV SDITPAGSVV LSPGQKNKAG MSQCDMHPEM VSLCQENFLM DNAYFCEADA
     KKCIPVAPHI KVESHIQPSL NQEDIYITTE SLTTAAGRPG TGEHVPGSEM PVPDYTSIHI
     VQSPQGLILN ATALPLPDKE FLSSCGYVST DQLNKIMP
//
ID   E2AK3_MOUSE             Reviewed;        1114 AA.
AC   Q9Z2B5; Q9CTK8; Q9CWT5;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   17-FEB-2016, entry version 151.
DE   RecName: Full=Eukaryotic translation initiation factor 2-alpha kinase 3;
DE            EC=2.7.11.1;
DE   AltName: Full=PRKR-like endoplasmic reticulum kinase;
DE   AltName: Full=Pancreatic eIF2-alpha kinase;
DE   Flags: Precursor;
GN   Name=Eif2ak3; Synonyms=Pek, Perk;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF LYS-618.
RC   STRAIN=NIH Swiss; TISSUE=Fibroblast;
RX   PubMed=9930704; DOI=10.1038/16729;
RA   Harding H.P., Zhang Y., Ron D.;
RT   "Protein translation and folding are coupled by an endoplasmic-
RT   reticulum-resident kinase.";
RL   Nature 397:271-274(1999).
RN   [2]
RP   ERRATUM.
RA   Harding H.P., Zhang Y., Ron D.;
RL   Nature 398:90-90(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-152 AND 769-1114.
RC   STRAIN=C57BL/6J;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   FUNCTION.
RX   PubMed=11106749; DOI=10.1016/S1097-2765(00)00108-8;
RA   Harding H.P., Novoa I., Zhang Y., Zeng H., Wek R., Schapira M.,
RA   Ron D.;
RT   "Regulated translation initiation controls stress-induced gene
RT   expression in mammalian cells.";
RL   Mol. Cell 6:1099-1108(2000).
RN   [5]
RP   SUBUNIT.
RX   PubMed=10854322; DOI=10.1038/35014014;
RA   Bertolotti A., Zhang Y., Hendershot L.M., Harding H.P., Ron D.;
RT   "Dynamic interaction of BiP and ER stress transducers in the unfolded-
RT   protein response.";
RL   Nat. Cell Biol. 2:326-332(2000).
RN   [6]
RP   FUNCTION.
RX   PubMed=11035797; DOI=10.1073/pnas.220247197;
RA   Brewer J.W., Diehl J.A.;
RT   "PERK mediates cell-cycle exit during the mammalian unfolded protein
RT   response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:12625-12630(2000).
RN   [7]
RP   INTERACTION WITH DNAJC3.
RX   PubMed=12446838; DOI=10.1073/pnas.252341799;
RA   Yan W., Frank C.L., Korth M.J., Sopher B.L., Novoa I., Ron D.,
RA   Katze M.G.;
RT   "Control of PERK eIF2alpha kinase activity by the endoplasmic
RT   reticulum stress-induced molecular chaperone P58IPK.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:15920-15925(2002).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Lung, and Pancreas;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH MFN2.
RX   PubMed=23921556; DOI=10.1038/emboj.2013.168;
RA   Munoz J.P., Ivanova S., Sanchez-Wandelmer J., Martinez-Cristobal P.,
RA   Noguera E., Sancho A., Diaz-Ramos A., Hernandez-Alvarez M.I.,
RA   Sebastian D., Mauvezin C., Palacin M., Zorzano A.;
RT   "Mfn2 modulates the UPR and mitochondrial function via repression of
RT   PERK.";
RL   EMBO J. 32:2348-2361(2013).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.81 ANGSTROMS) OF 583-701 AND 867-1078,
RP   SUBUNIT, AND PHOSPHORYLATION AT THR-980.
RX   PubMed=21543844; DOI=10.1107/S0907444911006445;
RA   Cui W., Li J., Ron D., Sha B.;
RT   "The structure of the PERK kinase domain suggests the mechanism for
RT   its activation.";
RL   Acta Crystallogr. D 67:423-428(2011).
CC   -!- FUNCTION: Metabolic-stress sensing protein kinase that
CC       phosphorylates the alpha subunit of eukaryotic translation
CC       initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' during the
CC       unfolded protein response (UPR) and in response to low amino acid
CC       availability (PubMed:11106749). Converts phosphorylated eIF-2-
CC       alpha/EIF2S1 either in a global protein synthesis inhibitor,
CC       leading to a reduced overall utilization of amino acids, or to a
CC       translation initiation activator of specific mRNAs, such as the
CC       transcriptional activator ATF4, and hence allowing ATF4-mediated
CC       reprogramming of amino acid biosynthetic gene expression to
CC       alleviate nutrient depletion (PubMed:23921556). Serves as a
CC       critical effector of unfolded protein response (UPR)-induced G1
CC       growth arrest due to the loss of cyclin-D1 (CCND1)
CC       (PubMed:11035797). Involved in control of mitochondrial morphology
CC       and function (PubMed:23921556). {ECO:0000269|PubMed:11035797,
CC       ECO:0000269|PubMed:11106749, ECO:0000269|PubMed:23921556}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Perturbation in protein folding in the
CC       endoplasmic reticulum (ER) promotes reversible dissociation from
CC       HSPA5/BIP and oligomerization, resulting in
CC       transautophosphorylation and kinase activity induction.
CC   -!- SUBUNIT: Forms dimers with HSPA5/BIP in resting cells.
CC       Oligomerizes in ER-stressed cells. Interacts with DNAJC3 and MFN2.
CC       {ECO:0000269|PubMed:10854322, ECO:0000269|PubMed:12446838,
CC       ECO:0000269|PubMed:21543844, ECO:0000269|PubMed:23921556}.
CC   -!- INTERACTION:
CC       P27958:- (xeno); NbExp=5; IntAct=EBI-1226344, EBI-6904269;
CC       P05198:EIF2S1 (xeno); NbExp=4; IntAct=EBI-1226344, EBI-1056162;
CC       Q80U63:Mfn2; NbExp=2; IntAct=EBI-1226344, EBI-8437663;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Single-pass
CC       type I membrane protein.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- INDUCTION: By ER stress.
CC   -!- DOMAIN: The lumenal domain senses perturbations in protein folding
CC       in the ER, probably through reversible interaction with HSPA5/BIP.
CC   -!- PTM: Autophosphorylated. Phosphorylated at Tyr-615 following
CC       endoplasmic reticulum stress, leading to activate its tyrosine-
CC       protein kinase activity. Dephosphorylated by PTPN1/TP1B, leading
CC       to inactivate its enzyme activity (By similarity). Oligomerization
CC       of the N-terminal ER luminal domain by ER stress promotes PERK
CC       trans-autophosphorylation of the C-terminal cytoplasmic kinase
CC       domain at multiple residues including Thr-980 on the kinase
CC       activation loop. {ECO:0000250, ECO:0000269|PubMed:21543844}.
CC   -!- PTM: N-glycosylated.
CC   -!- PTM: ADP-ribosylated by PARP16 upon ER stress, which increases
CC       kinase activity. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF076681; AAD03337.1; -; mRNA.
DR   EMBL; AK010397; BAB26908.1; -; mRNA.
DR   EMBL; AK003226; BAB22655.1; -; mRNA.
DR   CCDS; CCDS20223.1; -.
DR   PIR; T14351; T14351.
DR   RefSeq; NP_001300847.1; NM_001313918.1.
DR   UniGene; Mm.247167; -.
DR   PDB; 3QD2; X-ray; 2.81 A; B=583-1078.
DR   PDB; 4YZY; X-ray; 3.20 A; A=100-399.
DR   PDBsum; 3QD2; -.
DR   PDBsum; 4YZY; -.
DR   ProteinModelPortal; Q9Z2B5; -.
DR   SMR; Q9Z2B5; 100-396, 583-668, 872-1078.
DR   DIP; DIP-39494N; -.
DR   IntAct; Q9Z2B5; 3.
DR   STRING; 10090.ENSMUSP00000034093; -.
DR   iPTMnet; Q9Z2B5; -.
DR   PhosphoSite; Q9Z2B5; -.
DR   MaxQB; Q9Z2B5; -.
DR   PaxDb; Q9Z2B5; -.
DR   PRIDE; Q9Z2B5; -.
DR   GeneID; 13666; -.
DR   UCSC; uc009cgc.1; mouse.
DR   MGI; MGI:1341830; Eif2ak3.
DR   eggNOG; KOG1033; Eukaryota.
DR   eggNOG; ENOG410XS0B; LUCA.
DR   HOGENOM; HOG000112308; -.
DR   HOVERGEN; HBG051431; -.
DR   InParanoid; Q9Z2B5; -.
DR   PhylomeDB; Q9Z2B5; -.
DR   PRO; PR:Q9Z2B5; -.
DR   Proteomes; UP000000589; Unplaced.
DR   Bgee; Q9Z2B5; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:MGI.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; ISO:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; ISO:MGI.
DR   GO; GO:0071074; F:eukaryotic initiation factor eIF2 binding; IC:ParkinsonsUK-UCL.
DR   GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0004672; F:protein kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0019903; F:protein phosphatase binding; ISO:MGI.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:MGI.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:MGI.
DR   GO; GO:0001525; P:angiogenesis; ISO:MGI.
DR   GO; GO:0030282; P:bone mineralization; IMP:MGI.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:MGI.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; ISS:UniProtKB.
DR   GO; GO:0070417; P:cellular response to cold; ISS:UniProtKB.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0002063; P:chondrocyte development; IMP:MGI.
DR   GO; GO:0036492; P:eiF2alpha phosphorylation in response to endoplasmic reticulum stress; ISS:UniProtKB.
DR   GO; GO:0031018; P:endocrine pancreas development; ISS:UniProtKB.
DR   GO; GO:0007029; P:endoplasmic reticulum organization; IMP:MGI.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; ISS:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; ISS:UniProtKB.
DR   GO; GO:0045444; P:fat cell differentiation; IDA:MGI.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IMP:MGI.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IMP:MGI.
DR   GO; GO:0007595; P:lactation; IMP:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:MGI.
DR   GO; GO:0031642; P:negative regulation of myelination; IMP:MGI.
DR   GO; GO:0017148; P:negative regulation of translation; IMP:AgBase.
DR   GO; GO:1902010; P:negative regulation of translation in response to endoplasmic reticulum stress; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0001503; P:ossification; ISS:UniProtKB.
DR   GO; GO:0031016; P:pancreas development; IMP:MGI.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0036499; P:PERK-mediated unfolded protein response; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1902237; P:positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; IGI:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1903788; P:positive regulation of glutathione biosynthetic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IMP:MGI.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0009967; P:positive regulation of signal transduction; IDA:MGI.
DR   GO; GO:0045943; P:positive regulation of transcription from RNA polymerase I promoter; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1990440; P:positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0060734; P:regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation; IMP:UniProtKB.
DR   GO; GO:1902235; P:regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; ISO:MGI.
DR   GO; GO:0019217; P:regulation of fatty acid metabolic process; IMP:MGI.
DR   GO; GO:0010998; P:regulation of translational initiation by eIF2 alpha phosphorylation; IMP:UniProtKB.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IMP:MGI.
DR   GO; GO:0032933; P:SREBP signaling pathway; IDA:MGI.
DR   GO; GO:0006412; P:translation; IDA:MGI.
DR   Gene3D; 2.140.10.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR027295; Quinoprotein_ADH-like_fam.
DR   InterPro; IPR011047; Quinoprotein_ADH-like_supfam.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   SUPFAM; SSF50998; SSF50998; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; ATP-binding; Complete proteome;
KW   Endoplasmic reticulum; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Signal; Stress response; Transferase;
KW   Translation regulation; Transmembrane; Transmembrane helix;
KW   Unfolded protein response.
FT   SIGNAL        1     28       {ECO:0000255}.
FT   CHAIN        29   1114       Eukaryotic translation initiation factor
FT                                2-alpha kinase 3.
FT                                /FTId=PRO_0000024323.
FT   TOPO_DOM     29    510       Lumenal. {ECO:0000255}.
FT   TRANSMEM    511    531       Helical. {ECO:0000255}.
FT   TOPO_DOM    532   1114       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      589   1075       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     595    603       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS     48     51       Poly-Ala.
FT   COMPBIAS    224    229       Poly-Glu.
FT   ACT_SITE    935    935       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     618    618       ATP.
FT   MOD_RES     615    615       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9NZJ5}.
FT   MOD_RES     711    711       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9NZJ5}.
FT   MOD_RES     980    980       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21543844}.
FT   MOD_RES    1092   1092       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9NZJ5}.
FT   CARBOHYD    254    254       N-linked (GlcNAc...).
FT   MUTAGEN     618    618       K->A: Loss of activity and
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:9930704}.
FT   CONFLICT    143    152       VFGNKMIIPS -> GTHKTSSKEC (in Ref. 3;
FT                                BAB26908). {ECO:0000305}.
FT   CONFLICT    826    826       Missing (in Ref. 3; BAB22655).
FT                                {ECO:0000305}.
FT   STRAND      101    106       {ECO:0000244|PDB:4YZY}.
FT   STRAND      109    114       {ECO:0000244|PDB:4YZY}.
FT   STRAND      123    127       {ECO:0000244|PDB:4YZY}.
FT   STRAND      133    136       {ECO:0000244|PDB:4YZY}.
FT   STRAND      189    192       {ECO:0000244|PDB:4YZY}.
FT   STRAND      195    201       {ECO:0000244|PDB:4YZY}.
FT   STRAND      209    212       {ECO:0000244|PDB:4YZY}.
FT   STRAND      217    219       {ECO:0000244|PDB:4YZY}.
FT   STRAND      232    244       {ECO:0000244|PDB:4YZY}.
FT   STRAND      252    264       {ECO:0000244|PDB:4YZY}.
FT   STRAND      306    309       {ECO:0000244|PDB:4YZY}.
FT   TURN        310    313       {ECO:0000244|PDB:4YZY}.
FT   STRAND      314    317       {ECO:0000244|PDB:4YZY}.
FT   STRAND      320    322       {ECO:0000244|PDB:4YZY}.
FT   STRAND      327    330       {ECO:0000244|PDB:4YZY}.
FT   STRAND      335    345       {ECO:0000244|PDB:4YZY}.
FT   HELIX       584    588       {ECO:0000244|PDB:3QD2}.
FT   STRAND      589    596       {ECO:0000244|PDB:3QD2}.
FT   STRAND      601    608       {ECO:0000244|PDB:3QD2}.
FT   TURN        609    611       {ECO:0000244|PDB:3QD2}.
FT   STRAND      614    621       {ECO:0000244|PDB:3QD2}.
FT   TURN        625    627       {ECO:0000244|PDB:3QD2}.
FT   HELIX       628    639       {ECO:0000244|PDB:3QD2}.
FT   STRAND      650    656       {ECO:0000244|PDB:3QD2}.
FT   HELIX       661    667       {ECO:0000244|PDB:3QD2}.
FT   STRAND      881    887       {ECO:0000244|PDB:3QD2}.
FT   HELIX       894    899       {ECO:0000244|PDB:3QD2}.
FT   HELIX       904    906       {ECO:0000244|PDB:3QD2}.
FT   HELIX       909    928       {ECO:0000244|PDB:3QD2}.
FT   HELIX       938    940       {ECO:0000244|PDB:3QD2}.
FT   STRAND      941    943       {ECO:0000244|PDB:3QD2}.
FT   STRAND      949    951       {ECO:0000244|PDB:3QD2}.
FT   HELIX       986    988       {ECO:0000244|PDB:3QD2}.
FT   HELIX       991    995       {ECO:0000244|PDB:3QD2}.
FT   HELIX      1002   1016       {ECO:0000244|PDB:3QD2}.
FT   HELIX      1022   1033       {ECO:0000244|PDB:3QD2}.
FT   HELIX      1039   1044       {ECO:0000244|PDB:3QD2}.
FT   HELIX      1046   1056       {ECO:0000244|PDB:3QD2}.
FT   HELIX      1060   1062       {ECO:0000244|PDB:3QD2}.
FT   HELIX      1066   1071       {ECO:0000244|PDB:3QD2}.
SQ   SEQUENCE   1114 AA;  124682 MW;  65A47D6C0DD2E046 CRC64;
     MERATRPGPR ALLLLLFLLL GCAAGISAVA PARSLLAPAS ETVFGLGAAA APTSAARVPA
     VATAEVTVED AEALPAAAGE PESRATEPDD DVELRPRGRS LVIISTLDGR IAALDAENDG
     KKQWDLDVGS GSLVSSSLSK PEVFGNKMII PSLDGDLFQW DRDRESMEAV PFTVESLLES
     SYKFGDDVVL VGGKSLITYG LSAYSGKLRY ICSALGCRRW DSDEMEEEED ILLLQRTQKT
     VRAVGPRSGS EKWNFSVGHF ELRYIPDMET RAGFIESTFK PGGNKEDSKI ISDVEEQEAT
     MLDTVIKVSV ADWKVMAFSR KGGRLEWEYQ FCTPIASAWL VRDGKVIPIS LFDDTSYTAS
     EEALGDEEDI VEAARGATEN SVYLGMYRGQ LYLQSSVRVS EKFPTSPKAL ESVNGENAII
     PLPTIKWKPL IHSPSRTPVL VGSDEFDKCL SNDKYSHEEY SNGALSILQY PYDNGYYLPY
     YKRERNKRST QITVRFLDSP HYSKNIRKKD PILLLHWWKE IFGTILLCIV ATTFIVRRLF
     HPQPHRQRKE SETQCQTESK YDSVSADVSD NSWNDMKYSG YVSRYLTDFE PIQCMGRGGF
     GVVFEAKNKV DDCNYAIKRI RLPNRELARE KVMREVKALA KLEHPGIVRY FNAWLETPPE
     KWQEEMDEIW LKDESTDWPL SSPSPMDAPS VKIRRMDPFS TKEQIEVIAP SPERSRSFSV
     GISCGQTSSS ESQFSPLEFS GTDCGDNSDS ADAAYNLQDS CLTDCEDVED GTVDGNDEGH
     SFELCPSEAS PYTRSREGTS SSIVFEDSGC GNASSKEEPR GNRLHDGNHY VNKLTDLKCS
     SSRSSSEATT LSTSPTRPTT LSLDFTKNTV GQLQPSSPKV YLYIQMQLCR KENLKDWMNR
     RCSLEDREHG VCLHIFLQIA EAVEFLHSKG LMHRDLKPSN IFFTMDDVVK VGDFGLVTAM
     DQDEEEQTVL TPMPAYATHT GQVGTKLYMS PEQIHGNNYS HKVDIFSLGL ILFELLYPFS
     TQMERVRILT DVRNLKFPLL FTQKYPQEHM MVQDMLSPSP TERPEATDII ENAIFENLEF
     PGKTVLRQRS RSMSSSGTKH SRQPSCSYSP LPGN
//
ID   NMDE2_RAT               Reviewed;        1482 AA.
AC   Q00960; Q62684;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   17-FEB-2016, entry version 154.
DE   RecName: Full=Glutamate receptor ionotropic, NMDA 2B;
DE            Short=GluN2B;
DE   AltName: Full=Glutamate [NMDA] receptor subunit epsilon-2;
DE   AltName: Full=N-methyl D-aspartate receptor subtype 2B;
DE            Short=NMDAR2B;
DE            Short=NR2B;
DE   Flags: Precursor;
GN   Name=Grin2b;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=1350383; DOI=10.1126/science.256.5060.1217;
RA   Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H.,
RA   Burnashev N., Sakmann B., Seeburg P.H.;
RT   "Heteromeric NMDA receptors: molecular and functional distinction of
RT   subtypes.";
RL   Science 256:1217-1221(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7524561; DOI=10.1016/0896-6273(94)90258-5;
RA   Sullivan J.M., Traynelis S.F., Chen H.S., Escobar W., Heinemann S.F.,
RA   Lipton S.A.;
RT   "Identification of two cysteine residues that are required for redox
RT   modulation of the NMDA subtype of glutamate receptor.";
RL   Neuron 13:929-936(1994).
RN   [3]
RP   INTERACTION WITH DLG4.
RX   PubMed=7569905; DOI=10.1126/science.7569905;
RA   Kornau H.C., Schenker L.T., Kennedy M.B., Seeburg P.H.;
RT   "Domain interaction between NMDA receptor subunits and the
RT   postsynaptic density protein PSD-95.";
RL   Science 269:1737-1740(1995).
RN   [4]
RP   INTERACTION WITH INADL.
RX   PubMed=9647694; DOI=10.1006/mcne.1998.0679;
RA   Kurschner C., Mermelstein P.G., Holden W.T., Surmeier D.J.;
RT   "CIPP, a novel multivalent PDZ domain protein, selectively interacts
RT   with Kir4.0 family members, NMDA receptor subunits, neurexins, and
RT   neuroligins.";
RL   Mol. Cell. Neurosci. 11:161-172(1998).
RN   [5]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN1; GRIN3A AND PPP2CB.
RX   PubMed=11588171;
RA   Chan S.F., Sucher N.J.;
RT   "An NMDA receptor signaling complex with protein phosphatase 2A.";
RL   J. Neurosci. 21:7985-7992(2001).
RN   [6]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN1 AND GRIN3A.
RX   PubMed=11160393;
RA   Perez-Otano I., Schulteis C.T., Contractor A., Lipton S.A.,
RA   Trimmer J.S., Sucher N.J., Heinemann S.F.;
RT   "Assembly with the NR1 subunit is required for surface expression of
RT   NR3A-containing NMDA receptors.";
RL   J. Neurosci. 21:1228-1237(2001).
RN   [7]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN1 AND GRIN3A.
RX   PubMed=12391275; DOI=10.1124/mol.62.5.1119;
RA   Al-Hallaq R.A., Jarabek B.R., Fu Z., Vicini S., Wolfe B.B.,
RA   Yasuda R.P.;
RT   "Association of NR3A with the N-methyl-D-aspartate receptor NR1 and
RT   NR2 subunits.";
RL   Mol. Pharmacol. 62:1119-1127(2002).
RN   [8]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN1 AND GRIN3A.
RX   PubMed=11929923; DOI=10.1152/jn.00531.2001;
RA   Sasaki Y.F., Rothe T., Premkumar L.S., Das S., Cui J., Talantova M.V.,
RA   Wong H.-K., Gong X., Chan S.F., Zhang D., Nakanishi N., Sucher N.J.,
RA   Lipton S.A.;
RT   "Characterization and comparison of the NR3A subunit of the NMDA
RT   receptor in recombinant systems and primary cortical neurons.";
RL   J. Neurophysiol. 87:2052-2063(2002).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-886; SER-917; SER-920;
RP   TYR-1039; SER-1255; SER-1259 AND SER-1303, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A.,
RA   Lundby C., Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14
RT   different rat organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 32-394 IN COMPLEX WITH ZINC
RP   ION, GLYCOSYLATION AT ASN-74; HIS-127; ASP-283; GLU-284 AND ASN-341,
RP   MUTAGENESIS OF HIS-60; HIS-311 AND HIS-359, AND DISULFIDE BOND.
RX   PubMed=19910922; DOI=10.1038/emboj.2009.338;
RA   Karakas E., Simorowski N., Furukawa H.;
RT   "Structure of the zinc-bound amino-terminal domain of the NMDA
RT   receptor NR2B subunit.";
RL   EMBO J. 28:3910-3920(2009).
CC   -!- FUNCTION: NMDA receptor subtype of glutamate-gated ion channels
CC       with high calcium permeability and voltage-dependent sensitivity
CC       to magnesium. Mediated by glycine. In concert with DAPK1 at
CC       extrasynaptic sites, acts as a central mediator for stroke damage.
CC       Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA
CC       receptor channel activity inducing injurious Ca2+ influx through
CC       them, resulting in an irreversible neuronal death (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Forms heteromeric channel of a zeta subunit (GRIN1), a
CC       epsilon subunit (GRIN2A, GRIN2B, GRIN2C or GRIN2D) and a third
CC       subunit (GRIN3A or GRIN3B). Found in a complex with GRIN1, GRIN3A
CC       and PPP2CB. Found in a complex with GRIN1 and GRIN3B. Interacts
CC       with MAGI3. Interacts with HIP1 and Neto1 (By similarity).
CC       Interacts with PDZ domains of INADL and DLG4. Interacts with DAPK1
CC       (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P11275:Camk2a; NbExp=2; IntAct=EBI-396905, EBI-2640645;
CC       P11798:Camk2a (xeno); NbExp=3; IntAct=EBI-396905, EBI-400384;
CC       Q62936:Dlg3; NbExp=6; IntAct=EBI-396905, EBI-349596;
CC       P31016:Dlg4; NbExp=8; IntAct=EBI-396905, EBI-375655;
CC       Q63ZW7:Inadl (xeno); NbExp=4; IntAct=EBI-396905, EBI-8366894;
CC       Q460M5:Lrfn2; NbExp=2; IntAct=EBI-396905, EBI-877185;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cell junction, synapse, postsynaptic cell membrane; Multi-pass
CC       membrane protein.
CC   -!- PTM: Phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA
CC       receptor channel activity. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the glutamate-gated ion channel
CC       (TC 1.A.10.1) family. NR2B/GRIN2B subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M91562; AAA41714.1; -; mRNA.
DR   EMBL; U11419; AAA50554.1; -; mRNA.
DR   PIR; B43274; B43274.
DR   RefSeq; NP_036706.1; NM_012574.1.
DR   UniGene; Rn.9711; -.
DR   PDB; 3JPW; X-ray; 2.80 A; A=32-394.
DR   PDB; 3JPY; X-ray; 3.21 A; A=32-394.
DR   PDB; 3QEL; X-ray; 2.60 A; B/D=31-394.
DR   PDB; 3QEM; X-ray; 3.00 A; B/D=31-394.
DR   PDB; 4PE5; X-ray; 3.96 A; B/D=27-852.
DR   PDBsum; 3JPW; -.
DR   PDBsum; 3JPY; -.
DR   PDBsum; 3QEL; -.
DR   PDBsum; 3QEM; -.
DR   PDBsum; 4PE5; -.
DR   ProteinModelPortal; Q00960; -.
DR   SMR; Q00960; 404-802.
DR   BioGrid; 246575; 11.
DR   DIP; DIP-33702N; -.
DR   IntAct; Q00960; 16.
DR   MINT; MINT-104014; -.
DR   STRING; 10116.ENSRNOP00000011697; -.
DR   BindingDB; Q00960; -.
DR   ChEMBL; CHEMBL2096669; -.
DR   GuidetoPHARMACOLOGY; 457; -.
DR   TCDB; 1.A.10.1.6; the glutamate-gated ion channel (gic) family of neurotransmitter receptors.
DR   iPTMnet; Q00960; -.
DR   PhosphoSite; Q00960; -.
DR   SwissPalm; Q00960; -.
DR   UniCarbKB; Q00960; -.
DR   PaxDb; Q00960; -.
DR   PRIDE; Q00960; -.
DR   GeneID; 24410; -.
DR   KEGG; rno:24410; -.
DR   UCSC; RGD:2738; rat.
DR   CTD; 2904; -.
DR   RGD; 2738; Grin2b.
DR   eggNOG; KOG1053; Eukaryota.
DR   eggNOG; ENOG410XNUR; LUCA.
DR   HOGENOM; HOG000113802; -.
DR   HOVERGEN; HBG052635; -.
DR   InParanoid; Q00960; -.
DR   KO; K05210; -.
DR   PhylomeDB; Q00960; -.
DR   EvolutionaryTrace; Q00960; -.
DR   NextBio; 603231; -.
DR   PRO; PR:Q00960; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0043197; C:dendritic spine; IDA:RGD.
DR   GO; GO:0043005; C:neuron projection; IDA:UniProtKB.
DR   GO; GO:0017146; C:NMDA selective glutamate receptor complex; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IDA:RGD.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; IDA:UniProtKB.
DR   GO; GO:0043083; C:synaptic cleft; IDA:RGD.
DR   GO; GO:0043195; C:terminal bouton; IDA:RGD.
DR   GO; GO:0030018; C:Z disc; IDA:RGD.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:RGD.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:RGD.
DR   GO; GO:0031749; F:D2 dopamine receptor binding; IPI:RGD.
DR   GO; GO:0008144; F:drug binding; IPI:RGD.
DR   GO; GO:0005234; F:extracellular-glutamate-gated ion channel activity; IDA:RGD.
DR   GO; GO:0005149; F:interleukin-1 receptor binding; IPI:RGD.
DR   GO; GO:0004970; F:ionotropic glutamate receptor activity; IDA:RGD.
DR   GO; GO:0035255; F:ionotropic glutamate receptor binding; IPI:RGD.
DR   GO; GO:0042165; F:neurotransmitter binding; IDA:RGD.
DR   GO; GO:0004972; F:NMDA glutamate receptor activity; IDA:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:RGD.
DR   GO; GO:0005102; F:receptor binding; IPI:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0001508; P:action potential; IMP:RGD.
DR   GO; GO:0008306; P:associative learning; IMP:RGD.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEP:RGD.
DR   GO; GO:0071359; P:cellular response to dsRNA; IEP:RGD.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEP:RGD.
DR   GO; GO:0071396; P:cellular response to lipid; IEP:RGD.
DR   GO; GO:0010350; P:cellular response to magnesium starvation; IEP:RGD.
DR   GO; GO:0071287; P:cellular response to manganese ion; IEP:RGD.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0021987; P:cerebral cortex development; IEP:RGD.
DR   GO; GO:0021766; P:hippocampus development; IEP:RGD.
DR   GO; GO:0034220; P:ion transmembrane transport; IDA:GOC.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; IDA:RGD.
DR   GO; GO:0007611; P:learning or memory; TAS:RGD.
DR   GO; GO:0007616; P:long-term memory; IEP:RGD.
DR   GO; GO:0007613; P:memory; IDA:UniProtKB.
DR   GO; GO:0033555; P:multicellular organismal response to stress; IEP:RGD.
DR   GO; GO:0010942; P:positive regulation of cell death; IDA:RGD.
DR   GO; GO:0014049; P:positive regulation of glutamate secretion; IDA:UniProtKB.
DR   GO; GO:0050806; P:positive regulation of synaptic transmission; IMP:RGD.
DR   GO; GO:0043113; P:receptor clustering; IDA:RGD.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IMP:RGD.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0014075; P:response to amine; IEP:RGD.
DR   GO; GO:0001975; P:response to amphetamine; IEP:RGD.
DR   GO; GO:0051592; P:response to calcium ion; IEP:RGD.
DR   GO; GO:0009743; P:response to carbohydrate; IEP:RGD.
DR   GO; GO:0042220; P:response to cocaine; IEP:RGD.
DR   GO; GO:0034097; P:response to cytokine; IEP:RGD.
DR   GO; GO:0051602; P:response to electrical stimulus; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0060992; P:response to fungicide; IEP:RGD.
DR   GO; GO:0060416; P:response to growth hormone; IEP:RGD.
DR   GO; GO:0032026; P:response to magnesium ion; IEP:RGD.
DR   GO; GO:0010042; P:response to manganese ion; IEP:RGD.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0051597; P:response to methylmercury; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0051707; P:response to other organism; IEP:RGD.
DR   GO; GO:0009636; P:response to toxic substance; IEP:RGD.
DR   GO; GO:0048511; P:rhythmic process; IDA:RGD.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR019594; Glu/Gly-bd.
DR   InterPro; IPR001508; Iono_rcpt_met.
DR   InterPro; IPR001320; Iontro_rcpt.
DR   InterPro; IPR018884; NMDAR2_C.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00060; Lig_chan; 1.
DR   Pfam; PF10613; Lig_chan-Glu_bd; 1.
DR   Pfam; PF10565; NMDAR2_C; 1.
DR   PRINTS; PR00177; NMDARECEPTOR.
DR   SMART; SM00918; Lig_chan-Glu_bd; 1.
DR   SMART; SM00079; PBPe; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell junction; Cell membrane;
KW   Complete proteome; Disulfide bond; Glycoprotein; Ion channel;
KW   Ion transport; Ligand-gated ion channel; Magnesium; Membrane;
KW   Metal-binding; Phosphoprotein; Postsynaptic cell membrane; Receptor;
KW   Reference proteome; Signal; Synapse; Transmembrane;
KW   Transmembrane helix; Transport; Zinc.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   CHAIN        27   1482       Glutamate receptor ionotropic, NMDA 2B.
FT                                /FTId=PRO_0000011579.
FT   TOPO_DOM     27    557       Extracellular. {ECO:0000255}.
FT   TRANSMEM    558    578       Helical. {ECO:0000255}.
FT   TOPO_DOM    579    634       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    635    655       Helical. {ECO:0000255}.
FT   TOPO_DOM    656    817       Extracellular. {ECO:0000255}.
FT   TRANSMEM    818    838       Helical. {ECO:0000255}.
FT   TOPO_DOM    839   1482       Cytoplasmic. {ECO:0000255}.
FT   REGION     1292   1304       Interaction with DAPK1. {ECO:0000250}.
FT   MOTIF      1480   1482       PDZ-binding.
FT   COMPBIAS    984    989       Poly-His.
FT   METAL       127    127       Zinc.
FT   METAL       284    284       Zinc.
FT   SITE        615    615       Functional determinant of NMDA receptors.
FT                                {ECO:0000250}.
FT   MOD_RES     882    882       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q01097}.
FT   MOD_RES     886    886       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES     917    917       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES     920    920       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES     962    962       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q01097}.
FT   MOD_RES    1039   1039       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES    1058   1058       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q01097}.
FT   MOD_RES    1061   1061       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q01097}.
FT   MOD_RES    1064   1064       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q01097}.
FT   MOD_RES    1109   1109       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q01097}.
FT   MOD_RES    1133   1133       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q01097}.
FT   MOD_RES    1143   1143       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q01097}.
FT   MOD_RES    1155   1155       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q01097}.
FT   MOD_RES    1255   1255       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES    1259   1259       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES    1303   1303       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES    1472   1472       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q01097}.
FT   CARBOHYD     74     74       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19910922}.
FT   CARBOHYD    341    341       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19910922}.
FT   CARBOHYD    348    348       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    444    444       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    491    491       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    542    542       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    688    688       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     86    321       {ECO:0000269|PubMed:19910922}.
FT   MUTAGEN      60     60       H->A: Normal zinc binding.
FT                                {ECO:0000269|PubMed:19910922}.
FT   MUTAGEN     127    127       H->A: Reduced zinc binding.
FT   MUTAGEN     283    283       D->A: Slightly reduced zinc binding.
FT   MUTAGEN     284    284       E->A: Reduced zinc binding.
FT   MUTAGEN     311    311       H->A: Normal zinc binding.
FT                                {ECO:0000269|PubMed:19910922}.
FT   MUTAGEN     359    359       H->A: Normal zinc binding.
FT                                {ECO:0000269|PubMed:19910922}.
FT   CONFLICT   1256   1256       E -> K (in Ref. 2; AAA50554).
FT                                {ECO:0000305}.
FT   CONFLICT   1430   1431       VT -> SA (in Ref. 2; AAA50554).
FT                                {ECO:0000305}.
FT   STRAND       34     44       {ECO:0000244|PDB:3QEL}.
FT   HELIX        47     50       {ECO:0000244|PDB:3QEL}.
FT   HELIX        53     55       {ECO:0000244|PDB:3JPW}.
FT   STRAND       64     73       {ECO:0000244|PDB:3QEL}.
FT   HELIX        78     91       {ECO:0000244|PDB:3QEL}.
FT   STRAND       94    103       {ECO:0000244|PDB:3QEL}.
FT   HELIX       107    119       {ECO:0000244|PDB:3QEL}.
FT   STRAND      123    127       {ECO:0000244|PDB:3QEL}.
FT   HELIX       128    131       {ECO:0000244|PDB:3QEL}.
FT   STRAND      143    147       {ECO:0000244|PDB:3QEL}.
FT   HELIX       150    163       {ECO:0000244|PDB:3QEL}.
FT   STRAND      168    175       {ECO:0000244|PDB:3QEL}.
FT   HELIX       179    191       {ECO:0000244|PDB:3QEL}.
FT   STRAND      198    205       {ECO:0000244|PDB:3QEL}.
FT   STRAND      211    213       {ECO:0000244|PDB:3QEL}.
FT   HELIX       215    220       {ECO:0000244|PDB:3QEL}.
FT   STRAND      226    232       {ECO:0000244|PDB:3QEL}.
FT   HELIX       234    245       {ECO:0000244|PDB:3QEL}.
FT   TURN        246    248       {ECO:0000244|PDB:3QEL}.
FT   STRAND      250    253       {ECO:0000244|PDB:3QEM}.
FT   STRAND      255    258       {ECO:0000244|PDB:3QEL}.
FT   HELIX       260    263       {ECO:0000244|PDB:3QEL}.
FT   STRAND      275    281       {ECO:0000244|PDB:3JPW}.
FT   TURN        284    286       {ECO:0000244|PDB:3QEL}.
FT   HELIX       289    308       {ECO:0000244|PDB:3QEL}.
FT   TURN        309    311       {ECO:0000244|PDB:3QEL}.
FT   TURN        322    326       {ECO:0000244|PDB:3QEL}.
FT   HELIX       327    330       {ECO:0000244|PDB:3QEL}.
FT   HELIX       336    339       {ECO:0000244|PDB:3QEL}.
FT   STRAND      355    359       {ECO:0000244|PDB:3QEL}.
FT   STRAND      362    367       {ECO:0000244|PDB:3QEL}.
FT   STRAND      369    371       {ECO:0000244|PDB:3JPY}.
FT   STRAND      373    379       {ECO:0000244|PDB:3QEL}.
FT   STRAND      384    387       {ECO:0000244|PDB:3QEL}.
SQ   SEQUENCE   1482 AA;  166071 MW;  AEF8B9DF3C1B0D5D CRC64;
     MKPSAECCSP KFWLVLAVLA VSGSKARSQK SPPSIGIAVI LVGTSDEVAI KDAHEKDDFH
     HLSVVPRVEL VAMNETDPKS IITRICDLMS DRKIQGVVFA DDTDQEAIAQ ILDFISAQTL
     TPILGIHGGS SMIMADKDES SMFFQFGPSI EQQASVMLNI MEEYDWYIFS IVTTYFPGYQ
     DFVNKIRSTI ENSFVGWELE EVLLLDMSLD DGDSKIQNQL KKLQSPIILL YCTKEEATYI
     FEVANSVGLT GYGYTWIVPS LVAGDTDTVP SEFPTGLISV SYDEWDYGLP ARVRDGIAII
     TTAASDMLSE HSFIPEPKSS CYNTHEKRIY QSNMLNRYLI NVTFEGRNLS FSEDGYQMHP
     KLVIILLNKE RKWERVGKWK DKSLQMKYYV WPRMCPETEE QEDDHLSIVT LEEAPFVIVE
     SVDPLSGTCM RNTVPCQKRI ISENKTDEEP GYIKKCCKGF CIDILKKISK SVKFTYDLYL
     VTNGKHGKKI NGTWNGMIGE VVMKRAYMAV GSLTINEERS EVVDFSVPFI ETGISVMVSR
     SNGTVSPSAF LEPFSADVWV MMFVMLLIVS AVAVFVFEYF SPVGYNRCLA DGREPGGPSF
     TIGKAIWLLW GLVFNNSVPV QNPKGTTSKI MVSVWAFFAV IFLASYTANL AAFMIQEEYV
     DQVSGLSDKK FQRPNDFSPP FRFGTVPNGS TERNIRNNYA EMHAYMGKFN QRGVDDALLS
     LKTGKLDAFI YDAAVLNYMA GRDEGCKLVT IGSGKVFAST GYGIAIQKDS GWKRQVDLAI
     LQLFGDGEME ELEALWLTGI CHNEKNEVMS SQLDIDNMAG VFYMLGAAMA LSLITFICEH
     LFYWQFRHCF MGVCSGKPGM VFSISRGIYS CIHGVAIEER QSVMNSPTAT MNNTHSNILR
     LLRTAKNMAN LSGVNGSPQS ALDFIRRESS VYDISEHRRS FTHSDCKSYN NPPCEENLFS
     DYISEVERTF GNLQLKDSNV YQDHYHHHHR PHSIGSTSSI DGLYDCDNPP FTTQPRSISK
     KPLDIGLPSS KHSQLSDLYG KFSFKSDRYS GHDDLIRSDV SDISTHTVTY GNIEGNAAKR
     RKQQYKDSLK KRPASAKSRR EFDEIELAYR RRPPRSPDHK RYFRDKEGLR DFYLDQFRTK
     ENSPHWEHVD LTDIYKERSD DFKRDSVSGG GPCTNRSHLK HGTGEKHGVV GGVPAPWEKN
     LTNVDWEDRS GGNFCRSCPS KLHNYSSTVA GQNSGRQACI RCEACKKAGN LYDISEDNSL
     QELDQPAAPV AVTSNASSTK YPQSPTNSKA QKKNRNKLRR QHSYDTFVDL QKEEAALAPR
     SVSLKDKGRF MDGSPYAHMF EMPAGESSFA NKSSVPTAGH HHNNPGSGYM LSKSLYPDRV
     TQNPFIPTFG DDQCLLHGSK SYFFRQPTVA GASKTRPDFR ALVTNKPVVV TLHGAVPGRF
     QKDICIGNQS NPCVPNNKNP RAFNGSSNGH VYEKLSSIES DV
//
ID   NRP1_HUMAN              Reviewed;         923 AA.
AC   O14786; B0LPG9; O60461; Q5T7F1; Q5T7F2; Q5T7F3; Q86T59; Q96I90;
AC   Q96IH5;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 3.
DT   17-FEB-2016, entry version 172.
DE   RecName: Full=Neuropilin-1;
DE   AltName: Full=Vascular endothelial cell growth factor 165 receptor;
DE   AltName: CD_antigen=CD304;
DE   Flags: Precursor;
GN   Name=NRP1; Synonyms=NRP, VEGF165R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-179.
RX   PubMed=9288753; DOI=10.1016/S0092-8674(00)80534-6;
RA   He Z., Tessier-Lavigne M.;
RT   "Neuropilin is a receptor for the axonal chemorepellent semaphorin
RT   III.";
RL   Cell 90:739-751(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 22-39, AND
RP   VARIANT ALA-179.
RC   TISSUE=Mammary gland;
RX   PubMed=9529250; DOI=10.1016/S0092-8674(00)81402-6;
RA   Soker S., Takashima S., Miao H.-Q., Neufeld G., Klagsbrun M.;
RT   "Neuropilin-1 is expressed by endothelial and tumor cells as an
RT   isoform-specific receptor for vascular endothelial growth factor.";
RL   Cell 92:735-745(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PROTEIN SEQUENCE OF 22-31, AND
RP   VARIANT ALA-179.
RC   TISSUE=Prostatic adenocarcinoma;
RX   PubMed=10688880; DOI=10.1073/pnas.040337597;
RA   Gagnon M.L., Bielenberg D.R., Gechtman Z., Miao H.-Q., Takashima S.,
RA   Soker S., Klagsbrun M.;
RT   "Identification of a natural soluble neuropilin-1 that binds vascular
RT   endothelial growth factor: in vivo expression and antitumor
RT   activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:2573-2578(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   ALA-179.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-179.
RC   TISSUE=Skeletal muscle;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-179.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ALA-179.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND VARIANT
RP   ALA-179.
RC   TISSUE=Kidney, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH PLXNB1.
RX   PubMed=10520995; DOI=10.1016/S0092-8674(00)80063-X;
RA   Tamagnone L., Artigiani S., Chen H., He Z., Ming G.-L., Song H.-L.,
RA   Chedotal A., Winberg M.L., Goodman C.S., Poo M.-M.,
RA   Tessier-Lavigne M., Comoglio P.M.;
RT   "Plexins are a large family of receptors for transmembrane, secreted
RT   and GPI-anchored semaphorins in vertebrates.";
RL   Cell 99:71-80(1999).
RN   [11]
RP   CHARACTERIZATION.
RX   PubMed=10748121; DOI=10.1074/jbc.M909259199;
RA   Gluzman-Poltorak Z., Cohen T., Herzog Y., Neufeld G.;
RT   "Neuropilin-2 is a receptor for the vascular endothelial growth factor
RT   (VEGF) forms VEGF-145 and VEGF-165.";
RL   J. Biol. Chem. 275:18040-18045(2000).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-150.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [13]
RP   GLYCOSYLATION AT SER-612.
RX   PubMed=16763549; DOI=10.1038/sj.emboj.7601188;
RA   Shintani Y., Takashima S., Asano Y., Kato H., Liao Y., Yamazaki S.,
RA   Tsukamoto O., Seguchi O., Yamamoto H., Fukushima T., Sugahara K.,
RA   Kitakaze M., Hori M.;
RT   "Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2
RT   signaling.";
RL   EMBO J. 25:3045-3055(2006).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-150; ASN-261 AND ASN-522.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 273-427.
RX   PubMed=12517344; DOI=10.1016/S0969-2126(02)00941-3;
RA   Lee C.C., Kreusch A., McMullan D., Ng K., Spraggon G.;
RT   "Crystal structure of the human neuropilin-1 b1 domain.";
RL   Structure 11:99-108(2003).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 141-586 ALONE AND IN COMPLEX
RP   WITH ANTIBODY, GLYCOSYLATION AT ASN-150 AND ASN-261, SUBUNIT,
RP   CALCIUM-BINDING SITES, HEPARIN-BINDING, AND DISULFIDE BONDS.
RX   PubMed=17989695; DOI=10.1038/sj.emboj.7601906;
RA   Appleton B.A., Wu P., Maloney J., Yin J., Liang W.C., Stawicki S.,
RA   Mortara K., Bowman K.K., Elliott J.M., Desmarais W., Bazan J.F.,
RA   Bagri A., Tessier-Lavigne M., Koch A.W., Wu Y., Watts R.J.,
RA   Wiesmann C.;
RT   "Structural studies of neuropilin/antibody complexes provide insights
RT   into semaphorin and VEGF binding.";
RL   EMBO J. 26:4902-4912(2007).
CC   -!- FUNCTION: The membrane-bound isoform 1 is a receptor involved in
CC       the development of the cardiovascular system, in angiogenesis, in
CC       the formation of certain neuronal circuits and in organogenesis
CC       outside the nervous system. It mediates the chemorepulsant
CC       activity of semaphorins. It binds to semaphorin 3A, The PLGF-2
CC       isoform of PGF, The VEGF-165 isoform of VEGF and VEGF-B.
CC       Coexpression with KDR results in increased VEGF-165 binding to KDR
CC       as well as increased chemotaxis. It may regulate VEGF-induced
CC       angiogenesis.
CC   -!- FUNCTION: The soluble isoform 2 binds VEGF-165 and appears to
CC       inhibit its binding to cells. It may also induce apoptosis by
CC       sequestering VEGF-165. May bind as well various members of the
CC       semaphorin family. Its expression has an averse effect on blood
CC       vessel number and integrity.
CC   -!- SUBUNIT: Homodimer, and heterodimer with NRP2. Interacts with FER
CC       (By similarity). Binds PLXNB1. {ECO:0000250,
CC       ECO:0000269|PubMed:10520995, ECO:0000269|PubMed:17989695}.
CC   -!- INTERACTION:
CC       P21333:FLNA; NbExp=2; IntAct=EBI-1187100, EBI-350432;
CC       P35968:KDR; NbExp=2; IntAct=EBI-1187100, EBI-1005487;
CC       P15692:VEGFA; NbExp=4; IntAct=EBI-1187100, EBI-1026643;
CC       P15692-4:VEGFA; NbExp=4; IntAct=EBI-6285281, EBI-1026691;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Membrane-bound;
CC         IsoId=O14786-1; Sequence=Displayed;
CC       Name=2; Synonyms=Soluble, SNRP1;
CC         IsoId=O14786-2; Sequence=VSP_004339, VSP_004340;
CC       Name=3;
CC         IsoId=O14786-3; Sequence=VSP_053498, VSP_004339, VSP_004340;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: The expression of isoforms 1 and 2 does not
CC       seem to overlap. Isoform 1 is expressed by the blood vessels of
CC       different tissues. In the developing embryo it is found
CC       predominantly in the nervous system. In adult tissues, it is
CC       highly expressed in heart and placenta; moderately in lung, liver,
CC       skeletal muscle, kidney and pancreas; and low in adult brain.
CC       Isoform 2 is found in liver hepatocytes, kidney distal and
CC       proximal tubules.
CC   -!- DOMAIN: The tandem CUB domains mediate binding to semaphorin,
CC       while the tandem F5/8 domains are responsible for heparin and VEGF
CC       binding.
CC   -!- SIMILARITY: Belongs to the neuropilin family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 CUB domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00059}.
CC   -!- SIMILARITY: Contains 2 F5/8 type C domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00081}.
CC   -!- SIMILARITY: Contains 1 MAM domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00128}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF018956; AAC51759.1; -; mRNA.
DR   EMBL; AF016050; AAC12921.1; -; mRNA.
DR   EMBL; AF145712; AAF44344.1; -; mRNA.
DR   EMBL; BT006995; AAP35641.1; -; mRNA.
DR   EMBL; BX510902; CAD91133.1; -; mRNA.
DR   EMBL; EU332859; ABY87548.1; -; Genomic_DNA.
DR   EMBL; AL353600; CAI16997.1; -; Genomic_DNA.
DR   EMBL; AL121748; CAI16997.1; JOINED; Genomic_DNA.
DR   EMBL; AL353600; CAI16998.1; -; Genomic_DNA.
DR   EMBL; AL121748; CAI16998.1; JOINED; Genomic_DNA.
DR   EMBL; AL121748; CAI40248.1; -; Genomic_DNA.
DR   EMBL; AL353600; CAI40248.1; JOINED; Genomic_DNA.
DR   EMBL; AL121748; CAI40250.1; -; Genomic_DNA.
DR   EMBL; AL353600; CAI40250.1; JOINED; Genomic_DNA.
DR   EMBL; CH471072; EAW85942.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85944.1; -; Genomic_DNA.
DR   EMBL; BC007533; AAH07533.1; -; mRNA.
DR   EMBL; BC007737; AAH07737.1; -; mRNA.
DR   CCDS; CCDS31179.1; -. [O14786-3]
DR   CCDS; CCDS31180.1; -. [O14786-2]
DR   CCDS; CCDS7177.1; -. [O14786-1]
DR   RefSeq; NP_001019799.1; NM_001024628.2.
DR   RefSeq; NP_001019800.1; NM_001024629.2.
DR   RefSeq; NP_003864.4; NM_003873.5.
DR   UniGene; Hs.131704; -.
DR   UniGene; Hs.653996; -.
DR   PDB; 1KEX; X-ray; 1.90 A; A=273-427.
DR   PDB; 2QQI; X-ray; 1.80 A; A=273-586.
DR   PDB; 2QQM; X-ray; 2.00 A; A=141-586.
DR   PDB; 2QQN; X-ray; 2.20 A; A=273-427.
DR   PDB; 3I97; X-ray; 2.90 A; A/B=273-427.
DR   PDB; 4DEQ; X-ray; 2.65 A; A/B=274-429.
DR   PDB; 4RN5; X-ray; 1.73 A; A=273-427.
DR   PDBsum; 1KEX; -.
DR   PDBsum; 2QQI; -.
DR   PDBsum; 2QQM; -.
DR   PDBsum; 2QQN; -.
DR   PDBsum; 3I97; -.
DR   PDBsum; 4DEQ; -.
DR   PDBsum; 4RN5; -.
DR   ProteinModelPortal; O14786; -.
DR   SMR; O14786; 25-612, 681-801.
DR   BioGrid; 114356; 40.
DR   DIP; DIP-5743N; -.
DR   IntAct; O14786; 7.
DR   MINT; MINT-2834207; -.
DR   STRING; 9606.ENSP00000265371; -.
DR   BindingDB; O14786; -.
DR   ChEMBL; CHEMBL5174; -.
DR   DrugBank; DB00039; Palifermin.
DR   DrugBank; DB04895; Pegaptanib.
DR   iPTMnet; O14786; -.
DR   PhosphoSite; O14786; -.
DR   SwissPalm; O14786; -.
DR   BioMuta; NRP1; -.
DR   MaxQB; O14786; -.
DR   PaxDb; O14786; -.
DR   PRIDE; O14786; -.
DR   DNASU; 8829; -.
DR   Ensembl; ENST00000265371; ENSP00000265371; ENSG00000099250. [O14786-1]
DR   Ensembl; ENST00000374821; ENSP00000363954; ENSG00000099250. [O14786-3]
DR   Ensembl; ENST00000374822; ENSP00000363955; ENSG00000099250. [O14786-2]
DR   Ensembl; ENST00000374867; ENSP00000364001; ENSG00000099250. [O14786-1]
DR   GeneID; 8829; -.
DR   KEGG; hsa:8829; -.
DR   UCSC; uc001iwx.4; human. [O14786-1]
DR   UCSC; uc001ixa.2; human.
DR   CTD; 8829; -.
DR   GeneCards; NRP1; -.
DR   HGNC; HGNC:8004; NRP1.
DR   HPA; CAB004511; -.
DR   HPA; HPA030278; -.
DR   MIM; 602069; gene.
DR   neXtProt; NX_O14786; -.
DR   PharmGKB; PA31783; -.
DR   eggNOG; ENOG410IE8T; Eukaryota.
DR   eggNOG; ENOG410YRBE; LUCA.
DR   GeneTree; ENSGT00760000119073; -.
DR   HOGENOM; HOG000039978; -.
DR   HOVERGEN; HBG000502; -.
DR   InParanoid; O14786; -.
DR   KO; K06724; -.
DR   OMA; CWHNGMS; -.
DR   PhylomeDB; O14786; -.
DR   TreeFam; TF316506; -.
DR   Reactome; R-HSA-194306; Neurophilin interactions with VEGF and VEGFR.
DR   Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-HSA-399955; SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion.
DR   Reactome; R-HSA-399956; CRMPs in Sema3A signaling.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-447041; CHL1 interactions.
DR   ChiTaRS; NRP1; human.
DR   EvolutionaryTrace; O14786; -.
DR   GeneWiki; Neuropilin_1; -.
DR   GenomeRNAi; 8829; -.
DR   NextBio; 33134; -.
DR   PMAP-CutDB; B0LPG9; -.
DR   PRO; PR:O14786; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; O14786; -.
DR   CleanEx; HS_NRP1; -.
DR   ExpressionAtlas; O14786; baseline and differential.
DR   Genevisible; O14786; HS.
DR   GO; GO:0030424; C:axon; ISS:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0031410; C:cytoplasmic vesicle; TAS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0005769; C:early endosome; ISS:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005883; C:neurofilament; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; TAS:BHF-UCL.
DR   GO; GO:0002116; C:semaphorin receptor complex; NAS:BHF-UCL.
DR   GO; GO:0097443; C:sorting endosome; ISS:BHF-UCL.
DR   GO; GO:0015026; F:coreceptor activity; TAS:BHF-UCL.
DR   GO; GO:0019955; F:cytokine binding; NAS:BHF-UCL.
DR   GO; GO:0019838; F:growth factor binding; IPI:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0017154; F:semaphorin receptor activity; NAS:BHF-UCL.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; ISS:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0060978; P:angiogenesis involved in coronary vascular morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048844; P:artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048846; P:axon extension involved in axon guidance; ISS:BHF-UCL.
DR   GO; GO:0007411; P:axon guidance; NAS:BHF-UCL.
DR   GO; GO:0007413; P:axonal fasciculation; IEA:Ensembl.
DR   GO; GO:0060385; P:axonogenesis involved in innervation; ISS:BHF-UCL.
DR   GO; GO:0021785; P:branchiomotor neuron axon guidance; IEA:Ensembl.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; ISS:BHF-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0035729; P:cellular response to hepatocyte growth factor stimulus; IMP:BHF-UCL.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; ISS:BHF-UCL.
DR   GO; GO:0071679; P:commissural neuron axon guidance; ISS:BHF-UCL.
DR   GO; GO:0060982; P:coronary artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0016358; P:dendrite development; IEA:Ensembl.
DR   GO; GO:0060666; P:dichotomous subdivision of terminal units involved in salivary gland branching; IEA:Ensembl.
DR   GO; GO:0035767; P:endothelial cell chemotaxis; IMP:BHF-UCL.
DR   GO; GO:0097102; P:endothelial tip cell fate specification; ISS:BHF-UCL.
DR   GO; GO:0021612; P:facial nerve structural organization; IEA:Ensembl.
DR   GO; GO:1903375; P:facioacoustic ganglion development; IEA:Ensembl.
DR   GO; GO:0061552; P:ganglion morphogenesis; IEA:Ensembl.
DR   GO; GO:0021828; P:gonadotrophin-releasing hormone neuronal migration to the hypothalamus; IEA:Ensembl.
DR   GO; GO:0048012; P:hepatocyte growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0048843; P:negative regulation of axon extension involved in axon guidance; IEA:Ensembl.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0021675; P:nerve development; ISS:BHF-UCL.
DR   GO; GO:1901166; P:neural crest cell migration involved in autonomic nervous system development; ISS:BHF-UCL.
DR   GO; GO:0001764; P:neuron migration; ISS:BHF-UCL.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:ProtInc.
DR   GO; GO:0043049; P:otic placode formation; IEA:Ensembl.
DR   GO; GO:0001569; P:patterning of blood vessels; ISS:BHF-UCL.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0050918; P:positive chemotaxis; ISS:BHF-UCL.
DR   GO; GO:0048842; P:positive regulation of axon extension involved in axon guidance; ISS:BHF-UCL.
DR   GO; GO:0060301; P:positive regulation of cytokine activity; TAS:BHF-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; TAS:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; TAS:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:1902336; P:positive regulation of retinal ganglion cell axon guidance; ISS:BHF-UCL.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; TAS:BHF-UCL.
DR   GO; GO:1902946; P:protein localization to early endosome; ISS:BHF-UCL.
DR   GO; GO:0090259; P:regulation of retinal ganglion cell axon guidance; ISS:BHF-UCL.
DR   GO; GO:0060627; P:regulation of vesicle-mediated transport; TAS:BHF-UCL.
DR   GO; GO:0061441; P:renal artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0061299; P:retina vasculature morphogenesis in camera-type eye; ISS:BHF-UCL.
DR   GO; GO:0031290; P:retinal ganglion cell axon guidance; ISS:BHF-UCL.
DR   GO; GO:0071526; P:semaphorin-plexin signaling pathway; NAS:BHF-UCL.
DR   GO; GO:1902287; P:semaphorin-plexin signaling pathway involved in axon guidance; IEA:Ensembl.
DR   GO; GO:1902285; P:semaphorin-plexin signaling pathway involved in neuron projection guidance; ISS:BHF-UCL.
DR   GO; GO:0097374; P:sensory neuron axon guidance; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002040; P:sprouting angiogenesis; ISS:BHF-UCL.
DR   GO; GO:0061549; P:sympathetic ganglion development; ISS:BHF-UCL.
DR   GO; GO:0097490; P:sympathetic neuron projection extension; ISS:BHF-UCL.
DR   GO; GO:0097491; P:sympathetic neuron projection guidance; ISS:BHF-UCL.
DR   GO; GO:1901998; P:toxin transport; IEA:Ensembl.
DR   GO; GO:0061551; P:trigeminal ganglion development; IEA:Ensembl.
DR   GO; GO:0021637; P:trigeminal nerve structural organization; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0038190; P:VEGF-activated neuropilin signaling pathway; ISS:BHF-UCL.
DR   GO; GO:1902378; P:VEGF-activated neuropilin signaling pathway involved in axon guidance; IEA:Ensembl.
DR   GO; GO:0036486; P:ventral trunk neural crest cell migration; IEA:Ensembl.
DR   GO; GO:0021649; P:vestibulocochlear nerve structural organization; IEA:Ensembl.
DR   Gene3D; 2.60.120.260; -; 2.
DR   Gene3D; 2.60.120.290; -; 2.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR000859; CUB_dom.
DR   InterPro; IPR000421; FA58C.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR000998; MAM_dom.
DR   InterPro; IPR014648; Neuropilin.
DR   InterPro; IPR022579; Neuropilin1_C.
DR   InterPro; IPR027146; NRP1.
DR   PANTHER; PTHR10127:SF654; PTHR10127:SF654; 1.
DR   Pfam; PF00431; CUB; 2.
DR   Pfam; PF11980; DUF3481; 1.
DR   Pfam; PF00754; F5_F8_type_C; 2.
DR   Pfam; PF00629; MAM; 1.
DR   PIRSF; PIRSF036960; Neuropilin; 1.
DR   PRINTS; PR00020; MAMDOMAIN.
DR   SMART; SM00042; CUB; 2.
DR   SMART; SM00231; FA58C; 2.
DR   SMART; SM00137; MAM; 1.
DR   SUPFAM; SSF49785; SSF49785; 2.
DR   SUPFAM; SSF49854; SSF49854; 2.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   PROSITE; PS01180; CUB; 2.
DR   PROSITE; PS01285; FA58C_1; 2.
DR   PROSITE; PS01286; FA58C_2; 2.
DR   PROSITE; PS50022; FA58C_3; 2.
DR   PROSITE; PS00740; MAM_1; 1.
DR   PROSITE; PS50060; MAM_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; Calcium;
KW   Cell membrane; Complete proteome; Developmental protein;
KW   Differentiation; Direct protein sequencing; Disulfide bond;
KW   Glycoprotein; Heparan sulfate; Heparin-binding; Membrane;
KW   Metal-binding; Neurogenesis; Phosphoprotein; Polymorphism;
KW   Proteoglycan; Receptor; Reference proteome; Repeat; Secreted; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     21       {ECO:0000269|PubMed:10688880,
FT                                ECO:0000269|PubMed:9529250}.
FT   CHAIN        22    923       Neuropilin-1.
FT                                /FTId=PRO_0000021859.
FT   TOPO_DOM     22    856       Extracellular. {ECO:0000255}.
FT   TRANSMEM    857    879       Helical. {ECO:0000255}.
FT   TOPO_DOM    880    923       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       27    141       CUB 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00059}.
FT   DOMAIN      147    265       CUB 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00059}.
FT   DOMAIN      275    424       F5/8 type C 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00081}.
FT   DOMAIN      431    583       F5/8 type C 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00081}.
FT   DOMAIN      645    811       MAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00128}.
FT   METAL       195    195       Calcium. {ECO:0000244|PDB:2QQM,
FT                                ECO:0000269|PubMed:17989695}.
FT   METAL       209    209       Calcium. {ECO:0000244|PDB:2QQM,
FT                                ECO:0000269|PubMed:17989695}.
FT   METAL       250    250       Calcium. {ECO:0000244|PDB:2QQM,
FT                                ECO:0000269|PubMed:17989695}.
FT   MOD_RES     894    894       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97333}.
FT   CARBOHYD    150    150       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:17989695,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    261    261       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17989695,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    300    300       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    522    522       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    612    612       O-linked (Xyl...) (chondroitin sulfate);
FT                                alternate. {ECO:0000269|PubMed:16763549}.
FT   CARBOHYD    612    612       O-linked (Xyl...) (heparan sulfate);
FT                                alternate. {ECO:0000269|PubMed:16763549}.
FT   CARBOHYD    842    842       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     27     54       {ECO:0000305|PubMed:17989695}.
FT   DISULFID     82    104       {ECO:0000305|PubMed:17989695}.
FT   DISULFID    147    173       {ECO:0000269|PubMed:17989695}.
FT   DISULFID    206    228       {ECO:0000269|PubMed:17989695}.
FT   DISULFID    275    424       {ECO:0000269|PubMed:17989695}.
FT   DISULFID    431    583       {ECO:0000269|PubMed:17989695}.
FT   VAR_SEQ     587    621       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_053498.
FT   VAR_SEQ     642    644       EFP -> GIK (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:10688880,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_004339.
FT   VAR_SEQ     645    923       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:10688880,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_004340.
FT   VARIANT     179    179       V -> A (in dbSNP:rs7079053).
FT                                {ECO:0000269|PubMed:10688880,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:9288753,
FT                                ECO:0000269|PubMed:9529250,
FT                                ECO:0000269|Ref.4, ECO:0000269|Ref.6,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_046536.
FT   VARIANT     561    561       F -> L (in dbSNP:rs2228637).
FT                                /FTId=VAR_046537.
FT   VARIANT     733    733       V -> I (in dbSNP:rs2228638).
FT                                /FTId=VAR_056957.
FT   CONFLICT     26     26       K -> E (in Ref. 1; AAC51759).
FT                                {ECO:0000305}.
FT   CONFLICT    219    219       D -> G (in Ref. 5; CAD91133).
FT                                {ECO:0000305}.
FT   CONFLICT    749    749       D -> H (in Ref. 2; AAC12921).
FT                                {ECO:0000305}.
FT   CONFLICT    855    855       D -> E (in Ref. 1; AAC51759).
FT                                {ECO:0000305}.
FT   STRAND      149    151       {ECO:0000244|PDB:2QQM}.
FT   STRAND      153    159       {ECO:0000244|PDB:2QQM}.
FT   TURN        161    164       {ECO:0000244|PDB:2QQM}.
FT   STRAND      172    178       {ECO:0000244|PDB:2QQM}.
FT   HELIX       180    182       {ECO:0000244|PDB:2QQM}.
FT   STRAND      185    193       {ECO:0000244|PDB:2QQM}.
FT   STRAND      208    217       {ECO:0000244|PDB:2QQM}.
FT   TURN        218    220       {ECO:0000244|PDB:2QQM}.
FT   STRAND      223    227       {ECO:0000244|PDB:2QQM}.
FT   STRAND      235    238       {ECO:0000244|PDB:2QQM}.
FT   STRAND      240    248       {ECO:0000244|PDB:2QQM}.
FT   STRAND      257    264       {ECO:0000244|PDB:2QQM}.
FT   TURN        273    275       {ECO:0000244|PDB:4RN5}.
FT   TURN        281    283       {ECO:0000244|PDB:4RN5}.
FT   STRAND      284    286       {ECO:0000244|PDB:4RN5}.
FT   HELIX       288    290       {ECO:0000244|PDB:4RN5}.
FT   STRAND      291    294       {ECO:0000244|PDB:4RN5}.
FT   HELIX       299    301       {ECO:0000244|PDB:4RN5}.
FT   HELIX       303    306       {ECO:0000244|PDB:4RN5}.
FT   STRAND      318    323       {ECO:0000244|PDB:3I97}.
FT   STRAND      326    342       {ECO:0000244|PDB:4RN5}.
FT   TURN        347    349       {ECO:0000244|PDB:4RN5}.
FT   STRAND      352    371       {ECO:0000244|PDB:4RN5}.
FT   STRAND      373    378       {ECO:0000244|PDB:2QQM}.
FT   STRAND      385    389       {ECO:0000244|PDB:4RN5}.
FT   STRAND      391    414       {ECO:0000244|PDB:4RN5}.
FT   STRAND      417    424       {ECO:0000244|PDB:4RN5}.
FT   HELIX       426    428       {ECO:0000244|PDB:2QQI}.
FT   TURN        437    439       {ECO:0000244|PDB:2QQI}.
FT   HELIX       444    446       {ECO:0000244|PDB:2QQI}.
FT   STRAND      447    449       {ECO:0000244|PDB:2QQI}.
FT   TURN        450    453       {ECO:0000244|PDB:2QQI}.
FT   HELIX       459    462       {ECO:0000244|PDB:2QQI}.
FT   TURN        464    466       {ECO:0000244|PDB:2QQM}.
FT   STRAND      471    473       {ECO:0000244|PDB:2QQM}.
FT   STRAND      485    502       {ECO:0000244|PDB:2QQI}.
FT   TURN        506    508       {ECO:0000244|PDB:2QQM}.
FT   STRAND      515    525       {ECO:0000244|PDB:2QQI}.
FT   STRAND      534    537       {ECO:0000244|PDB:2QQI}.
FT   STRAND      544    547       {ECO:0000244|PDB:2QQI}.
FT   STRAND      550    566       {ECO:0000244|PDB:2QQI}.
FT   STRAND      570    572       {ECO:0000244|PDB:2QQI}.
FT   STRAND      576    584       {ECO:0000244|PDB:2QQI}.
SQ   SEQUENCE   923 AA;  103134 MW;  1EAC2FA6C8FD6A0B CRC64;
     MERGLPLLCA VLALVLAPAG AFRNDKCGDT IKIESPGYLT SPGYPHSYHP SEKCEWLIQA
     PDPYQRIMIN FNPHFDLEDR DCKYDYVEVF DGENENGHFR GKFCGKIAPP PVVSSGPFLF
     IKFVSDYETH GAGFSIRYEI FKRGPECSQN YTTPSGVIKS PGFPEKYPNS LECTYIVFVP
     KMSEIILEFE SFDLEPDSNP PGGMFCRYDR LEIWDGFPDV GPHIGRYCGQ KTPGRIRSSS
     GILSMVFYTD SAIAKEGFSA NYSVLQSSVS EDFKCMEALG MESGEIHSDQ ITASSQYSTN
     WSAERSRLNY PENGWTPGED SYREWIQVDL GLLRFVTAVG TQGAISKETK KKYYVKTYKI
     DVSSNGEDWI TIKEGNKPVL FQGNTNPTDV VVAVFPKPLI TRFVRIKPAT WETGISMRFE
     VYGCKITDYP CSGMLGMVSG LISDSQITSS NQGDRNWMPE NIRLVTSRSG WALPPAPHSY
     INEWLQIDLG EEKIVRGIII QGGKHRENKV FMRKFKIGYS NNGSDWKMIM DDSKRKAKSF
     EGNNNYDTPE LRTFPALSTR FIRIYPERAT HGGLGLRMEL LGCEVEAPTA GPTTPNGNLV
     DECDDDQANC HSGTGDDFQL TGGTTVLATE KPTVIDSTIQ SEFPTYGFNC EFGWGSHKTF
     CHWEHDNHVQ LKWSVLTSKT GPIQDHTGDG NFIYSQADEN QKGKVARLVS PVVYSQNSAH
     CMTFWYHMSG SHVGTLRVKL RYQKPEEYDQ LVWMAIGHQG DHWKEGRVLL HKSLKLYQVI
     FEGEIGKGNL GGIAVDDISI NNHISQEDCA KPADLDKKNP EIKIDETGST PGYEGEGEGD
     KNISRKPGNV LKTLDPILIT IIAMSALGVL LGAVCGVVLY CACWHNGMSE RNLSALENYN
     FELVDGVKLK KDKLNTQSTY SEA
//
ID   SFRP1_MOUSE             Reviewed;         314 AA.
AC   Q8C4U3; O08861; Q505A2; Q8R1J4;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 3.
DT   17-FEB-2016, entry version 119.
DE   RecName: Full=Secreted frizzled-related protein 1;
DE            Short=sFRP-1;
DE   Flags: Precursor;
GN   Name=Sfrp1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   STRAIN=C57BL/6J; TISSUE=Embryonic eye;
RX   PubMed=9096311; DOI=10.1073/pnas.94.7.2859;
RA   Rattner A., Hsieh J.-C., Smallwood P.M., Gilbert D.J., Copeland N.G.,
RA   Jenkins N.A., Nathans J.;
RT   "A family of secreted proteins contains homology to the cysteine-rich
RT   ligand-binding domain of frizzled receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:2859-2863(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and FVB/N; TISSUE=Brain, and Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 43-314.
RC   STRAIN=C57BL/6J; TISSUE=Cerebellum;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=9739103; DOI=10.1016/S0925-4773(98)00072-0;
RA   Leimeister C., Bach A., Gessler M.;
RT   "Developmental expression patterns of mouse sFRP genes encoding
RT   members of the secreted frizzled related protein family.";
RL   Mech. Dev. 75:29-42(1998).
RN   [5]
RP   INTERACTION WITH WNT8, AND DEVELOPMENTAL STAGE.
RX   PubMed=10640709; DOI=10.1016/S0925-4773(99)00236-1;
RA   Jaspard B., Couffinhal T., Dufourcq P., Moreau C., Duplaa C.;
RT   "Expression pattern of mouse sFRP-1 and mWnt-8 gene during heart
RT   morphogenesis.";
RL   Mech. Dev. 90:263-267(2000).
RN   [6]
RP   FUNCTION AS AN ANGIOGENIC FACTOR.
RX   PubMed=15306229; DOI=10.1016/j.cardiores.2004.05.006;
RA   Ezan J., Leroux L., Barandon L., Dufourcq P., Jaspard B., Moreau C.,
RA   Allieres C., Daret D., Couffinhal T., Duplaa C.;
RT   "FrzA/sFRP-1, a secreted antagonist of the Wnt-Frizzled pathway,
RT   controls vascular cell proliferation in vitro and in vivo.";
RL   Cardiovasc. Res. 63:731-738(2004).
RN   [7]
RP   INTERACTION WITH MYOC.
RX   PubMed=19188438; DOI=10.1128/MCB.01274-08;
RA   Kwon H.S., Lee H.S., Ji Y., Rubin J.S., Tomarev S.I.;
RT   "Myocilin is a modulator of Wnt signaling.";
RL   Mol. Cell. Biol. 29:2139-2154(2009).
CC   -!- FUNCTION: Soluble frizzled-related proteins (sFRPS) function as
CC       modulators of Wnt signaling through direct interaction with Wnts.
CC       They have a role in regulating cell growth and differentiation in
CC       specific cell types. SFRP1 decreases intracellular beta-catenin
CC       levels (By similarity). Has antiproliferative effects on vascular
CC       cells, in vitro and in vivo, and can induce, in vivo, an
CC       angiogenic response. In vascular cell cycle, delays the G1 phase
CC       and entry into the S phase. In kidney development, inhibits tubule
CC       formation and bud growth in metanephroi (By similarity). Inhibits
CC       WNT1/WNT4-mediated TCF-dependent transcription (By similarity).
CC       {ECO:0000250, ECO:0000269|PubMed:15306229}.
CC   -!- SUBUNIT: Interacts with WNT8, WNT1, WNT2, WNT4 and FRZD6 (By
CC       similarity). Interacts with MYOC. {ECO:0000250,
CC       ECO:0000269|PubMed:10640709, ECO:0000269|PubMed:19188438}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250}. Note=Cell membrane
CC       or extracellular matrix-associated. Released by heparin-binding
CC       (By similarity). {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in kidney and embryonic
CC       heart. Also highly expressed in the eye, where it is principally
CC       localized to the ciliary body and the lens epithelium. Weaker
CC       expression in heart, lung and brain. In the brain, is expressed
CC       exclusively in the choroid plexus. {ECO:0000269|PubMed:9096311}.
CC   -!- DEVELOPMENTAL STAGE: In the developing kidney expressed at 13.5
CC       dpc in the periphery of the metanophros and surrounding the uretic
CC       and nephrogenic tubules. At 14.5 dpc, expression decreases in the
CC       outer cortical cells and becomes visible in the tubular parts of
CC       the nephron. From 15.5 dpc, highly expressed in the future loops
CC       of Henle. In the developing CNS, expression located to the
CC       forebrain and hindbrain. At 8.0 dpc, expressed in the future
CC       forebrain and in the ventral portion of the presumptive hindbrain.
CC       At 8.5 dpc, expression is maintained in these tissues with a
CC       strong signal in rhombomere 4. Until 11.5 dpc, expression
CC       continues in the hindbrain with additional expression at 9.5 dpc
CC       and 10.5 dpc, in the nasal and epibranchial placodes. In the
CC       forbrain, initial expression is found in the proencephalon of the
CC       forebrain, and then strong expression in the telencephalic vesicle
CC       up to 15.5 dpc. Expression is then found in specific cell
CC       populations throughout the brain. In the developing eye,
CC       expression, by 10.5 dpc, is confined to ectodermal cells overlying
CC       the dorsal part of the optic cup. In later stages, expression
CC       limited to the lens fiber cells and the future pigmented retina.
CC       By 15.5 dpc, expression is confined to the anterior part of the
CC       lens. During limb development, barely expressed until later
CC       stages, when it is found in the distal part of the separating
CC       phalanges. In other developing structures, expressed in nasal
CC       placodes at 9.5 dpc, in medial nasal processes at E10.5 and then
CC       in the anterior portion of the invaginating olfactory epithelium.
CC       At 15.5 dpc, expressed on the basal side of the nasal epithelium.
CC       Also expressed in developing teeth, with the highest levels at
CC       15.5 dpc and 16.5 dpc in the mesenchyme and the dental epithelium
CC       of the developing molars. As well, expressed in the ventral body
CC       wall, in the mesenchyme derived adrenal cortex, the cochlear
CC       epithelium and the branching epithelium of the salivary gland. In
CC       the developing heart, weakly expressed from 8.5 dpc in the tubular
CC       heart endocardium and myocardium. From 8.5 dpc to 12.5 dpc
CC       expressed in cardiomyocytes. At 9.5 dpc, expression found in the
CC       common ventricular and atrial chamber of the developing heart, in
CC       the aortic sac and in the sinus venosus. High expression found
CC       from 11.5 dpc-12.5 dpc, in the trabeculated wall of the
CC       ventricular chamber together with the wall of the atrial chamber.
CC       Expression also found in the muscular part of the interventricular
CC       septum. From 9.5 dpc-11.5 dpc expression in the visceral yolk sac
CC       confined to the inner lining endothelial cell layer. Expression in
CC       the developing heart decreases after 14.5 dpc.
CC       {ECO:0000269|PubMed:10640709, ECO:0000269|PubMed:9739103}.
CC   -!- DOMAIN: The FZ domain is involved in binding with Wnt ligands.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the secreted frizzled-related protein
CC       (sFRP) family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 FZ (frizzled) domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00090}.
CC   -!- SIMILARITY: Contains 1 NTR domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00295}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U88566; AAC53145.1; -; mRNA.
DR   EMBL; BC024495; AAH24495.1; -; mRNA.
DR   EMBL; BC094662; AAH94662.1; -; mRNA.
DR   EMBL; AK081052; BAC38123.1; -; mRNA.
DR   CCDS; CCDS22191.1; -.
DR   RefSeq; NP_038862.2; NM_013834.3.
DR   RefSeq; XP_011240430.1; XM_011242128.1.
DR   UniGene; Mm.281691; -.
DR   ProteinModelPortal; Q8C4U3; -.
DR   SMR; Q8C4U3; 62-161.
DR   BioGrid; 203185; 7.
DR   STRING; 10090.ENSMUSP00000033952; -.
DR   ChEMBL; CHEMBL1075304; -.
DR   MEROPS; I93.002; -.
DR   PhosphoSite; Q8C4U3; -.
DR   MaxQB; Q8C4U3; -.
DR   PaxDb; Q8C4U3; -.
DR   PRIDE; Q8C4U3; -.
DR   Ensembl; ENSMUST00000033952; ENSMUSP00000033952; ENSMUSG00000031548.
DR   GeneID; 20377; -.
DR   KEGG; mmu:20377; -.
DR   UCSC; uc009lev.2; mouse.
DR   CTD; 6422; -.
DR   MGI; MGI:892014; Sfrp1.
DR   eggNOG; KOG3577; Eukaryota.
DR   eggNOG; ENOG410XRC8; LUCA.
DR   GeneTree; ENSGT00760000118864; -.
DR   HOGENOM; HOG000231058; -.
DR   HOVERGEN; HBG052928; -.
DR   InParanoid; Q8C4U3; -.
DR   KO; K02166; -.
DR   OMA; DDVCIAM; -.
DR   OrthoDB; EOG789CBZ; -.
DR   TreeFam; TF350133; -.
DR   ChiTaRS; Sfrp1; mouse.
DR   NextBio; 298286; -.
DR   PRO; PR:Q8C4U3; -.
DR   Proteomes; UP000000589; Chromosome 8.
DR   Bgee; Q8C4U3; -.
DR   CleanEx; MM_SFRP1; -.
DR   Genevisible; Q8C4U3; MM.
DR   GO; GO:0009986; C:cell surface; ISO:MGI.
DR   GO; GO:0005829; C:cytosol; ISO:MGI.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0031012; C:extracellular matrix; ISO:MGI.
DR   GO; GO:0005615; C:extracellular space; ISO:MGI.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0005622; C:intracellular; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; ISO:MGI.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; ISO:MGI.
DR   GO; GO:0008144; F:drug binding; ISO:MGI.
DR   GO; GO:0005109; F:frizzled binding; ISO:MGI.
DR   GO; GO:0004930; F:G-protein coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0008201; F:heparin binding; ISO:MGI.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0017147; F:Wnt-protein binding; ISO:MGI.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISO:MGI.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IGI:MGI.
DR   GO; GO:0060346; P:bone trabecula formation; IMP:MGI.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; ISO:MGI.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IEA:Ensembl.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IEA:Ensembl.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IDA:UniProtKB.
DR   GO; GO:0044344; P:cellular response to fibroblast growth factor stimulus; ISO:MGI.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; ISO:MGI.
DR   GO; GO:0071504; P:cellular response to heparin; ISO:MGI.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl.
DR   GO; GO:0009267; P:cellular response to starvation; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; ISO:MGI.
DR   GO; GO:0071305; P:cellular response to vitamin D; IEA:Ensembl.
DR   GO; GO:0071481; P:cellular response to X-ray; IDA:UniProtKB.
DR   GO; GO:0090246; P:convergent extension involved in somitogenesis; IGI:MGI.
DR   GO; GO:0046546; P:development of primary male sexual characteristics; IGI:MGI.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IGI:MGI.
DR   GO; GO:0071542; P:dopaminergic neuron differentiation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; ISO:MGI.
DR   GO; GO:0008585; P:female gonad development; IGI:MGI.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IBA:GOC.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; ISO:MGI.
DR   GO; GO:0060218; P:hematopoietic stem cell differentiation; ISO:MGI.
DR   GO; GO:0030097; P:hemopoiesis; IMP:MGI.
DR   GO; GO:0008584; P:male gonad development; IGI:MGI.
DR   GO; GO:1904693; P:midbrain morphogenesis; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; ISO:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0045578; P:negative regulation of B cell differentiation; IMP:UniProtKB.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IGI:MGI.
DR   GO; GO:0046851; P:negative regulation of bone remodeling; ISO:MGI.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:2000080; P:negative regulation of canonical Wnt signaling pathway involved in controlling type B pancreatic cell proliferation; ISO:MGI.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISO:MGI.
DR   GO; GO:0030336; P:negative regulation of cell migration; ISO:MGI.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISO:MGI.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; ISO:MGI.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; ISO:MGI.
DR   GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; ISO:MGI.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; ISO:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:MGI.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; ISO:MGI.
DR   GO; GO:0043508; P:negative regulation of JUN kinase activity; IGI:MGI.
DR   GO; GO:0030279; P:negative regulation of ossification; IMP:MGI.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; IMP:MGI.
DR   GO; GO:0033689; P:negative regulation of osteoblast proliferation; IMP:MGI.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; IMP:MGI.
DR   GO; GO:0050732; P:negative regulation of peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:2000041; P:negative regulation of planar cell polarity pathway involved in axis elongation; IGI:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IGI:MGI.
DR   GO; GO:2000054; P:negative regulation of Wnt signaling pathway involved in dorsal/ventral axis specification; ISO:MGI.
DR   GO; GO:0014034; P:neural crest cell fate commitment; IMP:MGI.
DR   GO; GO:0001843; P:neural tube closure; IGI:MGI.
DR   GO; GO:0021915; P:neural tube development; IGI:MGI.
DR   GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0090179; P:planar cell polarity pathway involved in neural tube closure; IGI:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISO:MGI.
DR   GO; GO:0030307; P:positive regulation of cell growth; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISO:MGI.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISO:MGI.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:MGI.
DR   GO; GO:1902043; P:positive regulation of extrinsic apoptotic signaling pathway via death domain receptors; ISO:MGI.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; ISO:MGI.
DR   GO; GO:2000271; P:positive regulation of fibroblast apoptotic process; ISO:MGI.
DR   GO; GO:2000052; P:positive regulation of non-canonical Wnt signaling pathway; ISO:MGI.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; ISO:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; ISO:MGI.
DR   GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; IMP:MGI.
DR   GO; GO:0006508; P:proteolysis; ISO:MGI.
DR   GO; GO:0060687; P:regulation of branching involved in prostate gland morphogenesis; IMP:MGI.
DR   GO; GO:0010564; P:regulation of cell cycle process; ISO:MGI.
DR   GO; GO:1904338; P:regulation of dopaminergic neuron differentiation; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0090175; P:regulation of establishment of planar polarity; IGI:MGI.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0014070; P:response to organic cyclic compound; ISO:MGI.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IMP:MGI.
DR   GO; GO:0001756; P:somitogenesis; IEP:BHF-UCL.
DR   GO; GO:0044345; P:stromal-epithelial cell signaling involved in prostate gland development; IEP:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; ISO:MGI.
DR   GO; GO:0001657; P:ureteric bud development; IEP:UniProtKB.
DR   GO; GO:0090244; P:Wnt signaling pathway involved in somitogenesis; IGI:MGI.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; IDA:MGI.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   InterPro; IPR015526; Frizzled/SFRP.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR001134; Netrin_domain.
DR   InterPro; IPR018933; Netrin_module_non-TIMP.
DR   InterPro; IPR026559; SFRP1.
DR   InterPro; IPR008993; TIMP-like_OB-fold.
DR   PANTHER; PTHR11309; PTHR11309; 1.
DR   PANTHER; PTHR11309:SF87; PTHR11309:SF87; 1.
DR   Pfam; PF01392; Fz; 1.
DR   Pfam; PF01759; NTR; 1.
DR   SMART; SM00643; C345C; 1.
DR   SMART; SM00063; FRI; 1.
DR   SUPFAM; SSF50242; SSF50242; 1.
DR   SUPFAM; SSF63501; SSF63501; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50189; NTR; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Developmental protein; Differentiation;
KW   Disulfide bond; Glycoprotein; Reference proteome; Secreted; Signal;
KW   Wnt signaling pathway.
FT   SIGNAL        1     31       {ECO:0000255}.
FT   CHAIN        32    314       Secreted frizzled-related protein 1.
FT                                /FTId=PRO_0000032539.
FT   DOMAIN       53    169       FZ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00090}.
FT   DOMAIN      186    306       NTR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00295}.
FT   CARBOHYD    173    173       N-linked (GlcNAc...). {ECO:0000250}.
FT   DISULFID     58    121       {ECO:0000250}.
FT   DISULFID     68    114       {ECO:0000250}.
FT   DISULFID    105    140       {ECO:0000250}.
FT   DISULFID    129    166       {ECO:0000250}.
FT   DISULFID    133    157       {ECO:0000250}.
FT   DISULFID    186    256       {ECO:0000250}.
FT   DISULFID    189    258       {ECO:0000250}.
FT   DISULFID    203    306       {ECO:0000250}.
FT   CONFLICT     28     28       A -> S (in Ref. 2; AAH24495).
FT                                {ECO:0000305}.
FT   CONFLICT    245    245       R -> A (in Ref. 1; AAC53145).
FT                                {ECO:0000305}.
SQ   SEQUENCE   314 AA;  35413 MW;  3D98A15127DFA421 CRC64;
     MGVGRSARGR GGAASGVLLA LAAALLAAGS ASEYDYVSFQ SDIGSYQSGR FYTKPPQCVD
     IPVDLRLCHN VGYKKMVLPN LLEHETMAEV KQQASSWVPL LNKNCHMGTQ VFLCSLFAPV
     CLDRPIYPCR WLCEAVRDSC EPVMQFFGFY WPEMLKCDKF PEGDVCIAMT PPNTTEASKP
     QGTTVCPPCD NELKSEAIIE HLCASEFALR MKIKEVKKEN GDKKIVPKKK KPLKLGPIKK
     KELKRLVLFL KNGADCPCHQ LDNLSHNFLI MGRKVKSQYL LTAIHKWDKK NKEFKNFMKR
     MKNHECPTFQ SVFK
//
ID   WNT4_MOUSE              Reviewed;         351 AA.
AC   P22724;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   09-DEC-2015, entry version 143.
DE   RecName: Full=Protein Wnt-4;
DE   Flags: Precursor;
GN   Name=Wnt4; Synonyms=Wnt-4;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2279700; DOI=10.1101/gad.4.12b.2319;
RA   Gavin B.J., McMahon J.A., McMahon A.P.;
RT   "Expression of multiple novel Wnt-1/int-1-related genes during fetal
RT   and adult mouse development.";
RL   Genes Dev. 4:2319-2332(1990).
RN   [2]
RP   INTERACTION WITH PORCN.
RX   PubMed=10866835; DOI=10.1046/j.1432-1033.2000.01478.x;
RA   Tanaka K., Okabayashi H., Asashima M., Perrimon N., Kadowaki T.;
RT   "The evolutionarily conserved porcupine gene family is involved in the
RT   processing of the Wnt family.";
RL   Eur. J. Biochem. 267:4300-4311(2000).
CC   -!- FUNCTION: Ligand for members of the frizzled family of seven
CC       transmembrane receptors. May be an intracellular signaling
CC       molecule involved in segmentation of the forebrain. Is likely to
CC       signal over only few cell diameters (By similarity). Seems to be
CC       involved in kidney development. {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with PORCN. {ECO:0000269|PubMed:10866835}.
CC   -!- INTERACTION:
CC       O35082:Kl; NbExp=2; IntAct=EBI-1570945, EBI-1570828;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- TISSUE SPECIFICITY: In adults in lung and brain.
CC   -!- PTM: Palmitoleylation is required for efficient binding to
CC       frizzled receptors. Depalmitoleylation leads to Wnt signaling
CC       pathway inhibition. {ECO:0000250|UniProtKB:P27467,
CC       ECO:0000250|UniProtKB:P56704}.
CC   -!- SIMILARITY: Belongs to the Wnt family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M89797; AAA40566.1; -; mRNA.
DR   CCDS; CCDS18815.1; -.
DR   PIR; C36470; C36470.
DR   RefSeq; NP_033549.1; NM_009523.2.
DR   UniGene; Mm.20355; -.
DR   ProteinModelPortal; P22724; -.
DR   SMR; P22724; 66-350.
DR   BioGrid; 204576; 4.
DR   IntAct; P22724; 2.
DR   STRING; 10090.ENSMUSP00000036580; -.
DR   PhosphoSite; P22724; -.
DR   MaxQB; P22724; -.
DR   PaxDb; P22724; -.
DR   PRIDE; P22724; -.
DR   Ensembl; ENSMUST00000045747; ENSMUSP00000036580; ENSMUSG00000036856.
DR   GeneID; 22417; -.
DR   KEGG; mmu:22417; -.
DR   UCSC; uc008viv.2; mouse.
DR   CTD; 54361; -.
DR   MGI; MGI:98957; Wnt4.
DR   eggNOG; KOG3913; Eukaryota.
DR   eggNOG; ENOG410XQZ1; LUCA.
DR   HOGENOM; HOG000039529; -.
DR   HOVERGEN; HBG001595; -.
DR   InParanoid; P22724; -.
DR   KO; K00408; -.
DR   OMA; YVIAISW; -.
DR   OrthoDB; EOG7C8GJ8; -.
DR   PhylomeDB; P22724; -.
DR   TreeFam; TF105310; -.
DR   Reactome; R-MMU-3238698; WNT ligand biogenesis and trafficking.
DR   NextBio; 302837; -.
DR   PRO; PR:P22724; -.
DR   Proteomes; UP000000589; Chromosome 4.
DR   Bgee; P22724; -.
DR   CleanEx; MM_WNT4; -.
DR   ExpressionAtlas; P22724; baseline and differential.
DR   Genevisible; P22724; MM.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; ISS:UniProtKB.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IDA:MGI.
DR   GO; GO:0005109; F:frizzled binding; IPI:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; TAS:MGI.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0030325; P:adrenal gland development; IEA:Ensembl.
DR   GO; GO:0048856; P:anatomical structure development; IGI:MGI.
DR   GO; GO:0006702; P:androgen biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IMP:MGI.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IGI:MGI.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IMP:MGI.
DR   GO; GO:0045165; P:cell fate commitment; IMP:MGI.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:MGI.
DR   GO; GO:0009267; P:cellular response to starvation; IEP:MGI.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0001838; P:embryonic epithelial tube formation; IDA:MGI.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IEA:Ensembl.
DR   GO; GO:0090002; P:establishment of protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0008585; P:female gonad development; IMP:UniProtKB.
DR   GO; GO:0030237; P:female sex determination; ISS:UniProtKB.
DR   GO; GO:0007276; P:gamete generation; IGI:MGI.
DR   GO; GO:0042445; P:hormone metabolic process; IMP:MGI.
DR   GO; GO:0033080; P:immature T cell proliferation in thymus; IMP:MGI.
DR   GO; GO:0060993; P:kidney morphogenesis; IGI:MGI.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; ISS:UniProtKB.
DR   GO; GO:0060231; P:mesenchymal to epithelial transition; IMP:MGI.
DR   GO; GO:0072164; P:mesonephric tubule development; IGI:MGI.
DR   GO; GO:0001823; P:mesonephros development; IMP:UniProtKB.
DR   GO; GO:0072162; P:metanephric mesenchymal cell differentiation; NAS:UniProtKB.
DR   GO; GO:0072210; P:metanephric nephron development; IMP:MGI.
DR   GO; GO:0072273; P:metanephric nephron morphogenesis; IMP:MGI.
DR   GO; GO:0072174; P:metanephric tubule formation; IMP:MGI.
DR   GO; GO:0001656; P:metanephros development; IMP:MGI.
DR   GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IGI:MGI.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IMP:MGI.
DR   GO; GO:0030336; P:negative regulation of cell migration; IGI:BHF-UCL.
DR   GO; GO:0040037; P:negative regulation of fibroblast growth factor receptor signaling pathway; IGI:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:2000019; P:negative regulation of male gonad development; ISS:UniProtKB.
DR   GO; GO:0010894; P:negative regulation of steroid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0061369; P:negative regulation of testicular blood vessel morphogenesis; ISO:MGI.
DR   GO; GO:2000225; P:negative regulation of testosterone biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0061045; P:negative regulation of wound healing; IGI:BHF-UCL.
DR   GO; GO:0072006; P:nephron development; IMP:MGI.
DR   GO; GO:0030182; P:neuron differentiation; IBA:GO_Central.
DR   GO; GO:0035567; P:non-canonical Wnt signaling pathway; IDA:MGI.
DR   GO; GO:0038030; P:non-canonical Wnt signaling pathway via MAPK cascade; ISO:MGI.
DR   GO; GO:0048599; P:oocyte development; IMP:MGI.
DR   GO; GO:0061205; P:paramesonephric duct development; IMP:UniProtKB.
DR   GO; GO:0032349; P:positive regulation of aldosterone biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; ISS:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; ISS:UniProtKB.
DR   GO; GO:2000066; P:positive regulation of cortisol biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0061184; P:positive regulation of dermatome development; ISS:BHF-UCL.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IGI:BHF-UCL.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IGI:BHF-UCL.
DR   GO; GO:0045836; P:positive regulation of meiotic nuclear division; IGI:MGI.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IGI:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0022407; P:regulation of cell-cell adhesion; IMP:MGI.
DR   GO; GO:0072033; P:renal vesicle formation; IMP:MGI.
DR   GO; GO:0072034; P:renal vesicle induction; IDA:MGI.
DR   GO; GO:0007548; P:sex differentiation; IMP:MGI.
DR   GO; GO:0007165; P:signal transduction; TAS:MGI.
DR   GO; GO:0051145; P:smooth muscle cell differentiation; IDA:MGI.
DR   GO; GO:0060126; P:somatotropin secreting cell differentiation; IMP:MGI.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IDA:MGI.
DR   GO; GO:0060748; P:tertiary branching involved in mammary gland duct morphogenesis; IMP:MGI.
DR   GO; GO:0060129; P:thyroid-stimulating hormone-secreting cell differentiation; IMP:MGI.
DR   GO; GO:0035239; P:tube morphogenesis; IMP:MGI.
DR   InterPro; IPR005817; Wnt.
DR   InterPro; IPR009142; Wnt4.
DR   InterPro; IPR018161; Wnt_CS.
DR   PANTHER; PTHR12027; PTHR12027; 1.
DR   Pfam; PF00110; wnt; 1.
DR   PRINTS; PR01844; WNT4PROTEIN.
DR   PRINTS; PR01349; WNTPROTEIN.
DR   SMART; SM00097; WNT1; 1.
DR   PROSITE; PS00246; WNT1; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Developmental protein; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Lipoprotein; Reference proteome;
KW   Secreted; Signal; Wnt signaling pathway.
FT   SIGNAL        1     22       {ECO:0000255}.
FT   CHAIN        23    351       Protein Wnt-4.
FT                                /FTId=PRO_0000041422.
FT   LIPID       212    212       O-palmitoleyl serine; by PORCN.
FT                                {ECO:0000250|UniProtKB:P56704}.
FT   CARBOHYD     88     88       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    297    297       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     78     89       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    128    136       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    138    155       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    206    220       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    208    215       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    296    311       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    326    341       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    328    338       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    333    334       {ECO:0000250|UniProtKB:P28026}.
SQ   SEQUENCE   351 AA;  39050 MW;  7E1C5C739BE939D9 CRC64;
     MSPRSCLRSL RLLVFAVFSA AASNWLYLAK LSSVGSISEE ETCEKLKGLI QRQVQMCKRN
     LEVMDSVRRG AQLAIEECQY QFRNRRWNCS TLDSLPVFGK VVTQGTREAA FVYAISSAGV
     AFAVTRACSS GELEKCGCDR TVHGVSPQGF QWSGCSDNIA YGVAFSQSFV DVRERSKGAS
     SSRALMNLHN NEAGRKAILT HMRVECKCHG VSGSCEVKTC WRAVPPFRQV GHALKEKFDG
     ATEVEPRRVG SSRALVPRNA QFKPHTDEDL VYLEPSPDFC EQDIRSGVLG TRGRTCNKTS
     KAIDGCELLC CGRGFHTAQV ELAERCGCRF HWCCFVKCRQ CQRLVEMHTC R
//
ID   FGF8_MOUSE              Reviewed;         268 AA.
AC   P37237;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 1.
DT   20-JAN-2016, entry version 144.
DE   RecName: Full=Fibroblast growth factor 8;
DE            Short=FGF-8;
DE   AltName: Full=Androgen-induced growth factor;
DE            Short=AIGF;
DE   AltName: Full=Heparin-binding growth factor 8;
DE            Short=HBGF-8;
DE   Flags: Precursor;
GN   Name=Fgf8; Synonyms=Aigf;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=1409588; DOI=10.1073/pnas.89.19.8928;
RA   Tanaka A., Miyamoto K., Minamino N., Takeda M., Sato B., Matsuo H.,
RA   Matsumoto K.;
RT   "Cloning and characterization of an androgen-induced growth factor
RT   essential for the androgen-dependent growth of mouse mammary carcinoma
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:8928-8932(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=7884899;
RA   Macarthur C.A., Shankar D.B., Shackleford G.M.;
RT   "Fgf-8, activated by proviral insertion, cooperates with the Wnt-1
RT   transgene in murine mammary tumorigenesis.";
RL   J. Virol. 69:2501-2507(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7583127; DOI=10.1016/S0960-9822(95)00157-6;
RA   Mahmood R., Bresnick J., Hornbruch A., Mahony C., Morton N.,
RA   Colquhoun K., Martin P., Lumsden A., Dickson C., Mason I.;
RT   "A role for FGF-8 in the initiation and maintenance of vertebrate limb
RT   bud outgrowth.";
RL   Curr. Biol. 5:797-806(1995).
CC   -!- FUNCTION: Plays an important role in the regulation of embryonic
CC       development, cell proliferation, cell differentiation and cell
CC       migration. Required for normal brain, eye, ear and limb
CC       development during embryogenesis. Required for normal development
CC       of the gonadotropin-releasing hormone (GnRH) neuronal system.
CC       Plays a role in neurite outgrowth in hippocampal cells (By
CC       similarity). Cooperates with Wnt-1 in mouse mammary tumor virus-
CC       induced murine mammary tumorigenesis (PubMed:7884899).
CC       {ECO:0000250|UniProtKB:P55075, ECO:0000269|PubMed:7884899}.
CC   -!- SUBUNIT: Monomer. Homodimer. Interacts with FGFR1, FGFR2, FGFR3
CC       and FGFR4. Affinity between fibroblast growth factors (FGFs) and
CC       their receptors is increased by heparan sulfate glycosaminoglycans
CC       that function as coreceptors (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=FGF-8C;
CC         IsoId=P37237-1; Sequence=Displayed;
CC       Name=FGF-8B;
CC         IsoId=P37237-2; Sequence=VSP_001527;
CC       Name=FGF-8A;
CC         IsoId=P37237-3; Sequence=VSP_001528;
CC   -!- TISSUE SPECIFICITY: Absent in normal mammary glands and detected
CC       only in adult testis and ovary and in midgestational embryos.
CC   -!- INDUCTION: By androgens.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- SIMILARITY: Belongs to the heparin-binding growth factors family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D12483; BAA02051.1; -; mRNA.
DR   EMBL; D12482; BAA02050.1; -; mRNA.
DR   EMBL; U18673; AAA65387.1; -; mRNA.
DR   EMBL; Z48746; CAA88637.1; -; mRNA.
DR   CCDS; CCDS29864.1; -. [P37237-1]
DR   CCDS; CCDS50450.1; -. [P37237-3]
DR   CCDS; CCDS50451.1; -. [P37237-2]
DR   PIR; A46245; A46245.
DR   PIR; B46245; B46245.
DR   RefSeq; NP_001159834.1; NM_001166362.1. [P37237-2]
DR   RefSeq; NP_001159835.1; NM_001166363.1. [P37237-3]
DR   RefSeq; NP_034335.1; NM_010205.2. [P37237-1]
DR   UniGene; Mm.4012; -.
DR   ProteinModelPortal; P37237; -.
DR   SMR; P37237; 87-233.
DR   DIP; DIP-6030N; -.
DR   IntAct; P37237; 1.
DR   STRING; 10090.ENSMUSP00000026241; -.
DR   PhosphoSite; P37237; -.
DR   PaxDb; P37237; -.
DR   PRIDE; P37237; -.
DR   Ensembl; ENSMUST00000026241; ENSMUSP00000026241; ENSMUSG00000025219. [P37237-1]
DR   Ensembl; ENSMUST00000111927; ENSMUSP00000107558; ENSMUSG00000025219. [P37237-3]
DR   Ensembl; ENSMUST00000111928; ENSMUSP00000107559; ENSMUSG00000025219. [P37237-2]
DR   GeneID; 14179; -.
DR   UCSC; uc008hrh.2; mouse. [P37237-3]
DR   UCSC; uc012bmo.1; mouse. [P37237-1]
DR   CTD; 2253; -.
DR   MGI; MGI:99604; Fgf8.
DR   eggNOG; KOG3885; Eukaryota.
DR   eggNOG; ENOG4111IPH; LUCA.
DR   GeneTree; ENSGT00730000110785; -.
DR   HOGENOM; HOG000115986; -.
DR   HOVERGEN; HBG005659; -.
DR   InParanoid; P37237; -.
DR   PhylomeDB; P37237; -.
DR   TreeFam; TF331233; -.
DR   Reactome; R-MMU-109704; PI3K Cascade.
DR   Reactome; R-MMU-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-MMU-190322; FGFR4 ligand binding and activation.
DR   Reactome; R-MMU-190371; FGFR3b ligand binding and activation.
DR   Reactome; R-MMU-190372; FGFR3c ligand binding and activation.
DR   Reactome; R-MMU-190373; FGFR1c ligand binding and activation.
DR   Reactome; R-MMU-190375; FGFR2c ligand binding and activation.
DR   Reactome; R-MMU-5654219; Phospholipase C-mediated cascade: FGFR1.
DR   Reactome; R-MMU-5654221; Phospholipase C-mediated cascade, FGFR2.
DR   Reactome; R-MMU-5654227; Phospholipase C-mediated cascade, FGFR3.
DR   Reactome; R-MMU-5654228; Phospholipase C-mediated cascade, FGFR4.
DR   Reactome; R-MMU-5654688; SHC-mediated cascade:FGFR1.
DR   Reactome; R-MMU-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-MMU-5654693; FRS-mediated FGFR1 signaling.
DR   Reactome; R-MMU-5654695; PI-3K cascade:FGFR2.
DR   Reactome; R-MMU-5654699; SHC-mediated cascade:FGFR2.
DR   Reactome; R-MMU-5654700; FRS-mediated FGFR2 signaling.
DR   Reactome; R-MMU-5654704; SHC-mediated cascade:FGFR3.
DR   Reactome; R-MMU-5654706; FRS-mediated FGFR3 signaling.
DR   Reactome; R-MMU-5654710; PI-3K cascade:FGFR3.
DR   Reactome; R-MMU-5654712; FRS-mediated FGFR4 signaling.
DR   Reactome; R-MMU-5654719; SHC-mediated cascade:FGFR4.
DR   Reactome; R-MMU-5654720; PI-3K cascade:FGFR4.
DR   Reactome; R-MMU-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-MMU-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-MMU-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-MMU-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-MMU-5673001; RAF/MAP kinase cascade.
DR   NextBio; 285366; -.
DR   PRO; PR:P37237; -.
DR   Proteomes; UP000000589; Chromosome 19.
DR   Bgee; P37237; -.
DR   CleanEx; MM_FGF8; -.
DR   ExpressionAtlas; P37237; baseline and differential.
DR   Genevisible; P37237; MM.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; ISO:MGI.
DR   GO; GO:0005622; C:intracellular; IMP:GOC.
DR   GO; GO:0042056; F:chemoattractant activity; IEA:Ensembl.
DR   GO; GO:0008083; F:growth factor activity; ISO:MGI.
DR   GO; GO:0005105; F:type 1 fibroblast growth factor receptor binding; ISO:MGI.
DR   GO; GO:0005111; F:type 2 fibroblast growth factor receptor binding; ISO:MGI.
DR   GO; GO:0035909; P:aorta morphogenesis; IGI:MGI.
DR   GO; GO:0006915; P:apoptotic process; IMP:MGI.
DR   GO; GO:0001974; P:blood vessel remodeling; IGI:MGI.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:MGI.
DR   GO; GO:0060348; P:bone development; ISO:MGI.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IMP:MGI.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:MGI.
DR   GO; GO:0045165; P:cell fate commitment; IGI:MGI.
DR   GO; GO:0090134; P:cell migration involved in mesendoderm migration; IMP:MGI.
DR   GO; GO:0021846; P:cell proliferation in forebrain; IMP:MGI.
DR   GO; GO:0060128; P:corticotropin hormone secreting cell differentiation; IDA:MGI.
DR   GO; GO:0007368; P:determination of left/right symmetry; IMP:MGI.
DR   GO; GO:0071542; P:dopaminergic neuron differentiation; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0033563; P:dorsal/ventral axon guidance; IEA:Ensembl.
DR   GO; GO:0009792; P:embryo development ending in birth or egg hatching; IMP:MGI.
DR   GO; GO:0035050; P:embryonic heart tube development; IMP:MGI.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IGI:MGI.
DR   GO; GO:0003198; P:epithelial to mesenchymal transition involved in endocardial cushion formation; IMP:BHF-UCL.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:MGI.
DR   GO; GO:0021798; P:forebrain dorsal/ventral pattern formation; IMP:MGI.
DR   GO; GO:0048853; P:forebrain morphogenesis; IMP:MGI.
DR   GO; GO:0021884; P:forebrain neuron development; IEA:Ensembl.
DR   GO; GO:0048699; P:generation of neurons; IMP:MGI.
DR   GO; GO:0008406; P:gonad development; ISO:MGI.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0001947; P:heart looping; IMP:MGI.
DR   GO; GO:0003007; P:heart morphogenesis; IMP:MGI.
DR   GO; GO:0042472; P:inner ear morphogenesis; IGI:MGI.
DR   GO; GO:0001822; P:kidney development; IMP:MGI.
DR   GO; GO:0035108; P:limb morphogenesis; IGI:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0060425; P:lung morphogenesis; IMP:MGI.
DR   GO; GO:0030539; P:male genitalia development; IDA:MGI.
DR   GO; GO:0000165; P:MAPK cascade; IMP:MGI.
DR   GO; GO:0008078; P:mesodermal cell migration; IMP:MGI.
DR   GO; GO:0001656; P:metanephros development; IEA:Ensembl.
DR   GO; GO:0030917; P:midbrain-hindbrain boundary development; IMP:MGI.
DR   GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0055026; P:negative regulation of cardiac muscle tissue development; ISO:MGI.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:MGI.
DR   GO; GO:0001839; P:neural plate morphogenesis; IMP:MGI.
DR   GO; GO:0060563; P:neuroepithelial cell differentiation; ISO:MGI.
DR   GO; GO:0042476; P:odontogenesis; IEA:Ensembl.
DR   GO; GO:0001759; P:organ induction; IGI:MGI.
DR   GO; GO:0030916; P:otic vesicle formation; IGI:MGI.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IGI:MGI.
DR   GO; GO:0003148; P:outflow tract septum morphogenesis; IGI:UniProtKB.
DR   GO; GO:0021543; P:pallium development; IMP:MGI.
DR   GO; GO:0001569; P:patterning of blood vessels; IGI:MGI.
DR   GO; GO:0060037; P:pharyngeal system development; IGI:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IGI:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:MGI.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IDA:MGI.
DR   GO; GO:0046622; P:positive regulation of organ growth; IMP:MGI.
DR   GO; GO:0042487; P:regulation of odontogenesis of dentin-containing tooth; IGI:MGI.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IDA:MGI.
DR   GO; GO:0021544; P:subpallium development; IMP:MGI.
DR   GO; GO:0021537; P:telencephalon development; IMP:MGI.
DR   GO; GO:0030878; P:thyroid gland development; IMP:MGI.
DR   GO; GO:0060129; P:thyroid-stimulating hormone-secreting cell differentiation; IDA:MGI.
DR   InterPro; IPR008996; Cytokine_IL1-like.
DR   InterPro; IPR028249; FGF8.
DR   InterPro; IPR002209; Fibroblast_GF_fam.
DR   InterPro; IPR028142; IL-1_fam/FGF_fam.
DR   PANTHER; PTHR11486; PTHR11486; 1.
DR   PANTHER; PTHR11486:SF3; PTHR11486:SF3; 1.
DR   Pfam; PF00167; FGF; 1.
DR   PRINTS; PR00262; IL1HBGF.
DR   SMART; SM00442; FGF; 1.
DR   SUPFAM; SSF50353; SSF50353; 1.
DR   PROSITE; PS00247; HBGF_FGF; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Developmental protein;
KW   Differentiation; Direct protein sequencing; Glycoprotein;
KW   Growth factor; Mitogen; Pyrrolidone carboxylic acid;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     22       {ECO:0000255}.
FT   CHAIN        23    268       Fibroblast growth factor 8.
FT                                /FTId=PRO_0000008971.
FT   MOD_RES      23     23       Pyrrolidone carboxylic acid.
FT                                {ECO:0000255}.
FT   CARBOHYD     60     60       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    190    190       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ      24     87       Missing (in isoform FGF-8A).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_001528.
FT   VAR_SEQ      24     87       VRSAAQKRGPGAGNPADTLGQGHEDRPFGQRSRAGKNFTNP
FT                                APNYPEEGSKEQRDSVLPKVTQR -> VTVQSSPNFTQ
FT                                (in isoform FGF-8B). {ECO:0000305}.
FT                                /FTId=VSP_001527.
SQ   SEQUENCE   268 AA;  30420 MW;  3330A9F342AD7109 CRC64;
     MGSPRSALSC LLLHLLVLCL QAQVRSAAQK RGPGAGNPAD TLGQGHEDRP FGQRSRAGKN
     FTNPAPNYPE EGSKEQRDSV LPKVTQRHVR EQSLVTDQLS RRLIRTYQLY SRTSGKHVQV
     LANKRINAMA EDGDPFAKLI VETDTFGSRV RVRGAETGLY ICMNKKGKLI AKSNGKGKDC
     VFTEIVLENN YTALQNAKYE GWYMAFTRKG RPRKGSKTRQ HQREVHFMKR LPRGHHTTEQ
     SLRFEFLNYP PFTRSLRGSQ RTWAPEPR
//
ID   ANT3_HUMAN              Reviewed;         464 AA.
AC   P01008; B2R6P0; P78439; P78447; Q13815; Q5TC78; Q7KZ43; Q7KZ97;
AC   Q9UC78;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   17-FEB-2016, entry version 210.
DE   RecName: Full=Antithrombin-III;
DE            Short=ATIII;
DE   AltName: Full=Serpin C1;
DE   Flags: Precursor;
GN   Name=SERPINC1; Synonyms=AT3; ORFNames=PRO0309;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6298709; DOI=10.1093/nar/10.24.8113;
RA   Bock S.C., Wion K.L., Vehar G.A., Lawn R.M.;
RT   "Cloning and expression of the cDNA for human antithrombin III.";
RL   Nucleic Acids Res. 10:8113-8125(1982).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6572945; DOI=10.1073/pnas.80.7.1845;
RA   Chandra T., Stackhouse R., Kidd V.J., Woo S.L.C.;
RT   "Isolation and sequence characterization of a cDNA clone of human
RT   antithrombin III.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:1845-1848(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT AT3D MET-438.
RA   Tsuji H., Takada O., Nakagawa M., Tanaka S., Hashimoto-Gotoh T.;
RT   "Hereditary antithrombin III deficiency: identification of an
RT   arginine-406 to methionine point mutation near protease reactive
RT   site.";
RL   (In) Yoshida T.O., Wilson J.M. (eds.);
RL   Molecular approaches to the study and treatment of Human diseases,
RL   pp.51-55, Elsevier, Amsterdam (1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8476848; DOI=10.1021/bi00067a008;
RA   Olds R.J., Lane D.A., Chowdhury V., de Stefano V., Leone G.,
RA   Thein S.L.;
RT   "Complete nucleotide sequence of the antithrombin gene: evidence for
RT   homologous recombination causing thrombophilia.";
RL   Biochemistry 32:4216-4224(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Fetal liver;
RA   Zhang C., Yu Y., Zhang S., Wei H., Bi J., Zhou G., Dong C., Zai Y.,
RA   Xu W., Gao F., Liu M., He F.;
RT   "Functional prediction of the coding sequences of 75 new genes deduced
RT   by analysis of cDNA clones from human fetal liver.";
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLU-30 AND ALA-147.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   PROTEIN SEQUENCE OF 33-464, GLYCOSYLATION AT ASN-128; ASN-167; ASN-187
RP   AND ASN-224, AND DISULFIDE BONDS.
RA   Petersen T.E., Dudek-Wojciechowska G., Sottrup-Jensen L.,
RA   Magnusson S.;
RT   "Primary structure of antithrombin-III (heparin cofactor). Partial
RT   homology between alpha-1-antitrypsin and antithrombin-III.";
RL   (In) Collen D., Wiman B., Verstraete M. (eds.);
RL   The physiological inhibitors of blood coagulation and fibrinolysis,
RL   pp.43-54, Elsevier, Amsterdam (1979).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 42-464.
RX   PubMed=6305982;
RA   Prochownik E.V., Markham A.F., Orkin S.H.;
RT   "Isolation of a cDNA clone for human antithrombin III.";
RL   J. Biol. Chem. 258:8389-8394(1983).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 137-208, AND VARIANT AT3D
RP   LEU-439.
RX   PubMed=3191114; DOI=10.1021/bi00416a052;
RA   Bock S.C., Marrinan J.A., Radziejewska E.;
RT   "Antithrombin III Utah: proline-407 to leucine mutation in a highly
RT   conserved region near the inhibitor reactive site.";
RL   Biochemistry 27:6171-6178(1988).
RN   [13]
RP   PROTEIN SEQUENCE OF 371-425, MASS SPECTROMETRY, AND VARIANT AT3D
RP   THR-414.
RC   TISSUE=Plasma;
RX   PubMed=7734359; DOI=10.1111/j.1365-2141.1995.tb08368.x;
RA   Lindo V.S., Kakkar V.V., Learmonth M., Melissari E., Zappacosta F.,
RA   Panico M., Morris H.R.;
RT   "Antithrombin-TRI (Ala382 to Thr) causing severe thromboembolic
RT   tendency undergoes the S-to-R transition and is associated with a
RT   plasma-inactive high-molecular-weight complex of aggregated
RT   antithrombin.";
RL   Br. J. Haematol. 89:589-601(1995).
RN   [14]
RP   REACTIVE SITE.
RX   PubMed=7238875; DOI=10.1016/0014-5793(81)80255-4;
RA   Bjoerk I., Danielsson A., Fenton J.W. II, Joernvall H.;
RT   "The site in human antithrombin for functional proteolytic cleavage by
RT   human thrombin.";
RL   FEBS Lett. 126:257-260(1981).
RN   [15]
RP   HEPARIN-BINDING SITE.
RX   PubMed=6693405;
RA   Blackburn M.N., Smith R.L., Carson J., Sibley C.C.;
RT   "The heparin-binding site of antithrombin III. Identification of a
RT   critical tryptophan in the amino acid sequence.";
RL   J. Biol. Chem. 259:939-941(1984).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-187.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.M400015-MCP200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H.,
RA   Thuluvath P.J., Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-128 AND ASN-187.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [18]
RP   FUNCTION IN MEMBRANE-ANCHORED SERINE PROTEASE TMPRSS7 INHIBITION, AND
RP   HETERODIMER WITH TMPRSS7.
RX   PubMed=15853774; DOI=10.1042/BJ20050299;
RA   Szabo R., Netzel-Arnett S., Hobson J.P., Antalis T.M., Bugge T.H.;
RT   "Matriptase-3 is a novel phylogenetically preserved membrane-anchored
RT   serine protease with broad serpin reactivity.";
RL   Biochem. J. 390:231-242(2005).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-128; ASN-187 AND ASN-224.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-224.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-128 AND ASN-187.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-187, AND STRUCTURE OF
RP   CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-68, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   PHOSPHORYLATION AT THR-63 AND SER-68.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   PubMed=8087553; DOI=10.1016/S0969-2126(00)00028-9;
RA   Carrell R.W., Stein P.E., Fermi G., Wardell M.R.;
RT   "Biological implications of a 3 A structure of dimeric antithrombin.";
RL   Structure 2:257-270(1994).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS).
RX   PubMed=7656006; DOI=10.1038/nsb0194-48;
RA   Schreuder H.A., de Boer B., Dijkema R., Mulders J., Theunissen H.J.M.,
RA   Grootenhuis P.D.J., Hol W.G.J.;
RT   "The intact and cleaved human antithrombin III complex as a model for
RT   serpin-proteinase interactions.";
RL   Nat. Struct. Biol. 1:48-54(1994).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS).
RX   PubMed=9067613; DOI=10.1006/jmbi.1996.0798;
RA   Skinner R., Abrahams J.P., Whisstock J.C., Lesk A.M., Carrel R.W.,
RA   Wardell M.R.;
RT   "The 2.6 A structure of antithrombin indicates a conformational change
RT   at the heparin binding site.";
RL   J. Mol. Biol. 266:601-609(1997).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS).
RX   PubMed=9761669; DOI=10.1006/jmbi.1998.2083;
RA   Skinner R., Chang W.-S.W., Jin L., Pei X.Y., Huntington J.A.,
RA   Abrahams J.P., Carrell R.W., Lomas D.A.;
RT   "Implications for function and therapy of a 2.9 A structure of binary-
RT   complexed antithrombin.";
RL   J. Mol. Biol. 283:9-14(1998).
RN   [30]
RP   REVIEW.
RX   PubMed=2126464; DOI=10.1016/0300-9084(90)90123-X;
RA   Mourey L., Samama J.-P., Delarue M., Choay J., Lormeau J.C.,
RA   Petitou M., Moras D.;
RT   "Antithrombin III: structural and functional aspects.";
RL   Biochimie 72:599-608(1990).
RN   [31]
RP   REVIEW ON VARIANTS.
RX   PubMed=8236149;
RA   Lane D.A., Olds R.J., Boisclair M., Chowdhury V., Thein S.L.,
RA   Cooper D.N., Blajchman M., Perry D., Emmerich J., Aiach M.;
RT   "Antithrombin III mutation database: first update. For the Thrombin
RT   and its Inhibitors Subcommittee of the Scientific and Standardization
RT   Committee of the International Society on Thrombosis and
RT   Haemostasis.";
RL   Thromb. Haemost. 70:361-369(1993).
RN   [32]
RP   REVIEW ON VARIANTS.
RX   PubMed=7749926; DOI=10.1038/nsb0295-96;
RA   Stein P.E., Carrell R.W.;
RT   "What do dysfunctional serpins tell us about molecular mobility and
RT   disease?";
RL   Nat. Struct. Biol. 2:96-113(1995).
RN   [33]
RP   REVIEW ON VARIANTS.
RX   PubMed=8664906;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:1<7::AID-HUMU2>3.3.CO;2-A;
RA   Perry D.J., Carrell R.W.;
RT   "Molecular genetics of human antithrombin deficiency.";
RL   Hum. Mutat. 7:7-22(1996).
RN   [34]
RP   VARIANTS AT3D SER-17; PRO-23; ASN-39; CYS-56; LEU-73; CYS-79; HIS-79;
RP   SER-79; ASN-87 DEL; CYS-89; LEU-90; CYS-95; SER-95; PRO-98; THR-112;
RP   PHE-131; VAL-131; LYS-133; PHE-138-139-LYS DEL; PRO-148; PRO-150;
RP   PRO-158; TYR-160; GLN-161; CYS-198; HIS-198; ILE-218 DEL; ASP-219;
RP   LYS-219; ARG-257; LYS-269; ILE-283; ASN-316; LYS-334; ARG-412;
RP   THR-414; PRO-416; SER-416; VAL-419; ASP-424; CYS-425; HIS-425;
RP   PRO-425; LEU-426; CYS-434; LEU-434; SER-434; THR-436; LYS-437;
RP   GLY-438; MET-438; LEU-439; THR-439; THR-453; ARG-456; THR-457;
RP   ASP-459; LEU-461 AND PHE-462, AND VARIANTS GLU-30; THR-52 AND CYS-190.
RX   PubMed=9031473;
RG   The plasma coagulation inhibitors subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis;
RA   Lane D.A., Bayston T., Olds R.J., Fitches A.C., Cooper D.N.,
RA   Millar D.S., Jochmans K., Perry D.J., Okajima K., Thein S.L.,
RA   Emmerich J.;
RT   "Antithrombin mutation database: 2nd (1997) update.";
RL   Thromb. Haemost. 77:197-211(1997).
RN   [35]
RP   VARIANT AT3D CYS-79.
RX   PubMed=6582486; DOI=10.1073/pnas.81.2.289;
RA   Koide T., Odani S., Takahashi K., Ono T., Sakuragawa N.;
RT   "Antithrombin III Toyama: replacement of arginine-47 by cysteine in
RT   hereditary abnormal antithrombin III that lacks heparin-binding
RT   ability.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:289-293(1984).
RN   [36]
RP   VARIANT AT3D LEU-73, AND CHARACTERIZATION OF VARIANT AT3D LEU-73.
RX   PubMed=3080419;
RA   Chang J.Y., Tran T.H.;
RT   "Antithrombin III Basel. Identification of a Pro-Leu substitution in a
RT   hereditary abnormal antithrombin with impaired heparin cofactor
RT   activity.";
RL   J. Biol. Chem. 261:1174-1176(1986).
RN   [37]
RP   VARIANT AT3D LEU-426.
RX   PubMed=3805013;
RA   Stephens A.W., Thalley B.S., Hirs C.H.W.;
RT   "Antithrombin-III Denver, a reactive site variant.";
RL   J. Biol. Chem. 262:1044-1048(1987).
RN   [38]
RP   VARIANT AT3D THR-414.
RX   PubMed=3179438;
RA   Devrak-Kizuk R., Chui D.H.K., Prochownik E.V., Carter C.J.,
RA   Ofosu F.A., Blajchman M.A.;
RT   "Antithrombin-III-Hamilton: a gene with a point mutation (guanine to
RT   adenine) in codon 382 causing impaired serine protease reactivity.";
RL   Blood 72:1518-1523(1988).
RN   [39]
RP   VARIANTS AT3D CYS-425 AND HIS-425.
RX   PubMed=3162733;
RA   Erdjument H., Laned D.A., Panico M., di Marzo V., Morris H.R.;
RT   "Single amino acid substitutions in the reactive site of antithrombin
RT   leading to thrombosis. Congenital substitution of arginine 393 to
RT   cysteine in antithrombin Northwick Park and to histidine in
RT   antithrombin Glasgow.";
RL   J. Biol. Chem. 263:5589-5593(1988).
RN   [40]
RP   VARIANT AT3D HIS-425.
RX   PubMed=2781509; DOI=10.1016/0049-3848(89)90127-8;
RA   Erdjument H., Lane D.A., Panico M., di Marzo V., Morris H.R.,
RA   Bauer K., Rosenberg R.D.;
RT   "Antithrombin Chicago, amino acid substitution of arginine 393 to
RT   histidine.";
RL   Thromb. Res. 54:613-619(1989).
RN   [41]
RP   VARIANT AT3D CYS-56.
RX   PubMed=2365065; DOI=10.1016/0014-5793(90)81530-2;
RA   Borg J.Y., Brennan S.O., Carrell R.W., George P., Perry D.J., Shaw J.;
RT   "Antithrombin Rouen-IV 24 Arg-->Cys. The amino-terminal contribution
RT   to heparin binding.";
RL   FEBS Lett. 266:163-166(1990).
RN   [42]
RP   VARIANT GLU-30.
RX   PubMed=1977621; DOI=10.1016/0014-5793(90)81057-U;
RA   Daly M., Bruce D., Perry D.J., Price J., Harper P.L., O'Meara A.,
RA   Carrell R.W.;
RT   "Antithrombin Dublin (-3 Val-->Glu): an N-terminal variant which has
RT   an aberrant signal peptidase cleavage site.";
RL   FEBS Lett. 273:87-90(1990).
RN   [43]
RP   VARIANT AT3D GLN-161.
RX   PubMed=2229057;
RA   Gandrille S., Aiach M., Lane D.A., Vidaud D., Molho-Sabatier P.,
RA   Caso R., de Moerloose P., Fiessinger J.-N., Clauser E.;
RT   "Important role of arginine 129 in heparin-binding site of
RT   antithrombin III. Identification of a novel mutation arginine 129 to
RT   glutamine.";
RL   J. Biol. Chem. 265:18997-19001(1990).
RN   [44]
RP   CHARACTERIZATION OF VARIANT AT3D THR-414, AND MUTAGENESIS OF ALA-414.
RX   PubMed=2013320; DOI=10.1016/0014-5793(91)80305-M;
RA   Austin R.C., Rachubinski R.A., Blachjman M.A.;
RT   "Site-directed mutagenesis of alanine-382 of human antithrombin III.";
RL   FEBS Lett. 280:254-258(1991).
RN   [45]
RP   VARIANT AT3D SER-416.
RX   PubMed=1906811; DOI=10.1016/0014-5793(91)80809-H;
RA   Perry D.J., Daly M., Harper P.L., Tait R.C., Price J., Walker I.D.,
RA   Carrell R.W.;
RT   "Antithrombin Cambridge II, 384 Ala to Ser. Further evidence of the
RT   role of the reactive centre loop in the inhibitory function of the
RT   serpins.";
RL   FEBS Lett. 285:248-250(1991).
RN   [46]
RP   VARIANT AT3D PHE-131.
RX   PubMed=1555650; DOI=10.1016/0014-5793(92)80854-A;
RA   Olds R.J., Lane D.A., Boisclair M., Sas G., Bock S.C., Thein S.L.;
RT   "Antithrombin Budapest 3. An antithrombin variant with reduced heparin
RT   affinity resulting from the substitution L99F.";
RL   FEBS Lett. 300:241-246(1992).
RN   [47]
RP   VARIANT AT3D ASP-424.
RX   PubMed=1547341;
RA   Blajchman M.A., Fernandez-Rachubinski F., Sheffield W.P., Austin R.C.,
RA   Schulman S.;
RT   "Antithrombin-III Stockholm: a codon 392 (Gly-->Asp) mutation with
RT   normal heparin binding and impaired serine protease reactivity.";
RL   Blood 79:1428-1434(1992).
RN   [48]
RP   VARIANT AT3D PRO-148.
RX   PubMed=8443391;
RA   Okajima K., Abe H., Maeda S., Motomura M., Tsujihata M., Nagataki S.,
RA   Okabe H., Takatsuki K.;
RT   "Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with
RT   defective heparin binding associated with thrombosis.";
RL   Blood 81:1300-1305(1993).
RN   [49]
RP   VARIANT AT3D 138-PHE-LYS-139 DEL.
RX   PubMed=8486379; DOI=10.1006/geno.1993.1184;
RA   Olds R.J., Lane D.A., Beresford C.H., Abildgaard U., Hughes P.M.,
RA   Thein S.L.;
RT   "A recurrent deletion in the antithrombin gene, AT106-108(-6 bp),
RT   identified by DNA heteroduplex detection.";
RL   Genomics 16:298-299(1993).
RN   [50]
RP   VARIANTS AT3D HIS-79 AND TYR-160.
RX   PubMed=7981186;
RA   Emmerich J., Vidaud D., Alhenc-Gelas M., Chadeuf G.,
RA   Gouault-Heilmann M., Aillaud M.-F., Aiach M.;
RT   "Three novel mutations of antithrombin inducing high-molecular-mass
RT   compounds.";
RL   Arterioscler. Thromb. 14:1958-1965(1994).
RN   [51]
RP   VARIANTS AT3D THR-112; TYR-152 AND ILE-283, AND VARIANT CYS-190.
RX   PubMed=7959685; DOI=10.1007/BF00211016;
RA   Millar D.S., Wacey A.I., Ribando J., Melissari E., Laursen B.,
RA   Woods P., Kakkar V.V., Cooper D.N.;
RT   "Three novel missense mutations in the antithrombin III (AT3) gene
RT   causing recurrent venous thrombosis.";
RL   Hum. Genet. 94:509-512(1994).
RN   [52]
RP   VARIANT AT3D ARG-456.
RX   PubMed=8274732;
RA   Jochmans K., Lissens W., Vervoort R., Peeters S., de Waelwe M.,
RA   Liebaers I.;
RT   "Antithrombin-Gly 424 Arg: a novel point mutation responsible for type
RT   1 antithrombin deficiency and neonatal thrombosis.";
RL   Blood 83:146-151(1994).
RN   [53]
RP   VARIANTS AT3D SER-95; THR-453 AND PHE-462.
RX   PubMed=7994035;
RA   van Boven H.H., Olds R.J., Thein S.L., Reitsma P.H., Lane D.A.,
RA   Briet E., Vandenbroucke J.P., Rosendaal F.R.;
RT   "Hereditary antithrombin deficiency: heterogeneity of the molecular
RT   basis and mortality in Dutch families.";
RL   Blood 84:4209-4213(1994).
RN   [54]
RP   VARIANT AT3D ASP-219.
RX   PubMed=7989582; DOI=10.1172/JCI117589;
RA   Bruce D., Perry D.J., Borg J.-Y., Carrell R.W., Wardell M.R.;
RT   "Thromboembolic disease due to thermolabile conformational changes of
RT   antithrombin Rouen-VI (187 Asn-->Asp).";
RL   J. Clin. Invest. 94:2265-2274(1994).
RN   [55]
RP   VARIANTS AT3D VAL-131 AND PRO-150.
RA   Chowdhury V., Olds R.J., Lane D.A., Mille B., Pabinger I., Thein S.L.;
RT   "Two novel antithrombin variants (L99V and Q118P) which alter the
RT   heparin binding domain.";
RL   Nouv. Rev. Fr. Hematol. 86:268-268(1994).
RN   [56]
RP   VARIANT AT3D 273-LYS--LYS-307 DEL.
RX   PubMed=7878627;
RA   Emmerich J., Chadeuf G., Alhenc-Gelas M., Gouault-Heilman M.,
RA   Toulon P., Fiessinger J.-N., Aiach M.;
RT   "Molecular basis of antithrombin type I deficiency: the first large
RT   in-frame deletion and two novel mutations in exon 6.";
RL   Thromb. Haemost. 72:534-539(1994).
RN   [57]
RP   VARIANT AT3D HIS-425.
RX   PubMed=7832187; DOI=10.1002/ajh.2830480104;
RA   Okajima K., Abe H., Wagatsuma M., Okabe H., Takatsuki K.;
RT   "Antithrombin III Kumamoto II; a single mutation at Arg393-His
RT   increased the affinity of antithrombin III for heparin.";
RL   Am. J. Hematol. 48:12-18(1995).
RN   [58]
RP   VARIANT AT3D ARG-127.
RX   PubMed=9157604;
RA   Ozawa T., Takikawa Y., Niiya K., Fujiwara T., Suzuki K., Sato S.,
RA   Sakuragawa N.;
RT   "Antithrombin Morioka (Cys 95-Arg): a novel missense mutation causing
RT   type I antithrombin deficiency.";
RL   Thromb. Haemost. 77:403-403(1997).
RN   [59]
RP   VARIANT AT3D PRO-23.
RX   PubMed=9845533;
RA   Fitches A.C., Appleby R., Lane D.A., De Stefano V., Leone G.,
RA   Olds R.J.;
RT   "Impaired cotranslational processing as a mechanism for type I
RT   antithrombin deficiency.";
RL   Blood 92:4671-4676(1998).
RN   [60]
RP   VARIANTS AT3D ARG-32; LEU-73; CYS-79; HIS-198; ARG-257 AND ARG-412.
RX   PubMed=9759613;
RA   Jochmans K., Lissens W., Seneca S., Capel P., Chatelain B., Meeus P.,
RA   Osselaer J.C., Peerlinck K., Seghers J., Slacmeulder M., Stibbe J.,
RA   van de Loo J., Vermylen J., Liebaers I., De Waele M.;
RT   "The molecular basis of antithrombin deficiency in Belgian and Dutch
RT   families.";
RL   Thromb. Haemost. 80:376-381(1998).
RN   [61]
RP   VARIANT THR-167.
RX   PubMed=10361121;
RA   Bayston T.A., Tripodi A., Mannucci P.M., Thompson E., Ireland H.,
RA   Fitches A.C., Hananeia L., Olds R.J., Lane D.A.;
RT   "Familial overexpression of beta-antithrombin caused by an Asn135-to-
RT   Thr substitution.";
RL   Blood 93:4242-4247(1999).
RN   [62]
RP   VARIANTS AT3D PHE-214; PRO-223; ILE-243; THR-251; VAL-283 AND PRO-397.
RX   PubMed=10997988; DOI=10.1046/j.1365-2141.2000.02245.x;
RA   Picard V., Bura A., Emmerich J., Alhenc-Gelas M., Biron C.,
RA   Houbouyan-Reveillard L.L., Molho P., Labatide-Alanore A., Sie P.,
RA   Toulon P., Verdy E., Aiach M.;
RT   "Molecular bases of antithrombin deficiency in French families:
RT   identification of seven novel mutations in the antithrombin gene.";
RL   Br. J. Haematol. 110:731-734(2000).
RN   [63]
RP   VARIANT AT3D 152-HIS--PHE-154 DEL.
RX   PubMed=11794707; DOI=10.1007/BF02982095;
RA   Niiya K., Kiguchi T., Dansako H., Fujimura K., Fujimoto T., Iijima K.,
RA   Tanimoto M., Harada M.;
RT   "Two novel gene mutations in type I antithrombin deficiency.";
RL   Int. J. Hematol. 74:469-472(2001).
RN   [64]
RP   VARIANT AT3D PRO-223.
RX   PubMed=11713457; DOI=10.1067/mpd.2001.118191;
RA   Baud O., Picard V., Durand P., Duchemin J., Proulle V.,
RA   Alhenc-Gelas M., Devictor D., Dreyfus M.;
RT   "Intracerebral hemorrhage associated with a novel antithrombin gene
RT   mutation in a neonate.";
RL   J. Pediatr. 139:741-743(2001).
RN   [65]
RP   VARIANT AT3D GLU-146.
RX   PubMed=12353073; DOI=10.1267/THRO88030436;
RA   Mushunje A., Zhou A., Huntington J.A., Conard J., Carrell R.W.;
RT   "Antithrombin 'DREUX' (Lys 114Glu): a variant with complete loss of
RT   heparin affinity.";
RL   Thromb. Haemost. 88:436-443(2002).
RN   [66]
RP   VARIANT AT3D LEU-261.
RX   PubMed=12595305; DOI=10.1182/blood-2002-11-3391;
RA   Picard V., Dautzenberg M.-D., Villoutreix B.O., Orliaguet G.,
RA   Alhenc-Gelas M., Aiach M.;
RT   "Antithrombin Phe229Leu: a new homozygous variant leading to
RT   spontaneous antithrombin polymerization in vivo associated with severe
RT   childhood thrombosis.";
RL   Blood 102:919-925(2003).
RN   [67]
RP   VARIANTS AT3D LYS-121; HIS-178; CYS-425; HIS-425 AND PRO-441.
RX   PubMed=12894857; DOI=10.1007/BF02983246;
RA   Nagaizumi K., Inaba H., Amano K., Suzuki M., Arai M., Fukutake K.;
RT   "Five novel and four recurrent point mutations in the antithrombin
RT   gene causing venous thrombosis.";
RL   Int. J. Hematol. 78:79-83(2003).
RN   [68]
RP   VARIANTS AT3D LEU-179; CYS-425 AND LEU-426.
RX   PubMed=15164384; DOI=10.1002/ajh.20067;
RA   David D., Ribeiro S., Ferrao L., Gago T., Crespo F.;
RT   "Molecular basis of inherited antithrombin deficiency in Portuguese
RT   families: identification of genetic alterations and screening for
RT   additional thrombotic risk factors.";
RL   Am. J. Hematol. 76:163-171(2004).
RN   [69]
RP   VARIANT AT3D HIS-398.
RX   PubMed=16908819; DOI=10.1001/archopht.124.8.1165;
RA   Kuhli C., Jochmans K., Scharrer I., Luechtenberg M., Hattenbach L.-O.;
RT   "Retinal vein occlusion associated with antithrombin deficiency
RT   secondary to a novel G9840C missense mutation.";
RL   Arch. Ophthalmol. 124:1165-1169(2006).
RN   [70]
RP   VARIANTS AT3D PHE-53; LEU-73; ASP-125; PRO-170; ASN-218; GLY-248;
RP   PRO-293; ARG-401; CYS-425; GLY-438 AND ALA-439, AND VARIANT GLU-30.
RX   PubMed=23910795; DOI=10.1111/jth.12364;
RA   Puurunen M., Salo P., Engelbarth S., Javela K., Perola M.;
RT   "Type II antithrombin deficiency caused by a founder mutation Pro73Leu
RT   in the Finnish population: clinical picture.";
RL   J. Thromb. Haemost. 11:1844-1849(2013).
CC   -!- FUNCTION: Most important serine protease inhibitor in plasma that
CC       regulates the blood coagulation cascade. AT-III inhibits thrombin,
CC       matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its
CC       inhibitory activity is greatly enhanced in the presence of
CC       heparin. {ECO:0000269|PubMed:15853774}.
CC   -!- SUBUNIT: Forms protease inhibiting heterodimer with TMPRSS7.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space.
CC   -!- TISSUE SPECIFICITY: Found in plasma.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- MASS SPECTROMETRY: Mass=57863; Method=Electrospray; Range=33-464;
CC       Evidence={ECO:0000269|PubMed:7734359};
CC   -!- MASS SPECTROMETRY: Mass=57911; Method=Electrospray; Range=33-464;
CC       Note=Variant Thr-414.; Evidence={ECO:0000269|PubMed:7734359};
CC   -!- DISEASE: Antithrombin III deficiency (AT3D) [MIM:613118]: An
CC       important risk factor for hereditary thrombophilia, a hemostatic
CC       disorder characterized by a tendency to recurrent thrombosis.
CC       Antithrombin-III deficiency is classified into 4 types. Type I:
CC       characterized by a 50% decrease in antigenic and functional
CC       levels. Type II: has defects affecting the thrombin-binding
CC       domain. Type III: alteration of the heparin-binding domain. Plasma
CC       AT-III antigen levels are normal in type II and III. Type IV:
CC       consists of miscellaneous group of unclassifiable mutations.
CC       {ECO:0000269|PubMed:10997988, ECO:0000269|PubMed:11713457,
CC       ECO:0000269|PubMed:11794707, ECO:0000269|PubMed:12353073,
CC       ECO:0000269|PubMed:12595305, ECO:0000269|PubMed:12894857,
CC       ECO:0000269|PubMed:15164384, ECO:0000269|PubMed:1547341,
CC       ECO:0000269|PubMed:1555650, ECO:0000269|PubMed:16908819,
CC       ECO:0000269|PubMed:1906811, ECO:0000269|PubMed:2229057,
CC       ECO:0000269|PubMed:2365065, ECO:0000269|PubMed:23910795,
CC       ECO:0000269|PubMed:2781509, ECO:0000269|PubMed:3080419,
CC       ECO:0000269|PubMed:3162733, ECO:0000269|PubMed:3179438,
CC       ECO:0000269|PubMed:3191114, ECO:0000269|PubMed:3805013,
CC       ECO:0000269|PubMed:6582486, ECO:0000269|PubMed:7734359,
CC       ECO:0000269|PubMed:7832187, ECO:0000269|PubMed:7878627,
CC       ECO:0000269|PubMed:7959685, ECO:0000269|PubMed:7981186,
CC       ECO:0000269|PubMed:7989582, ECO:0000269|PubMed:7994035,
CC       ECO:0000269|PubMed:8274732, ECO:0000269|PubMed:8443391,
CC       ECO:0000269|PubMed:8486379, ECO:0000269|PubMed:9031473,
CC       ECO:0000269|PubMed:9157604, ECO:0000269|PubMed:9759613,
CC       ECO:0000269|PubMed:9845533, ECO:0000269|Ref.3,
CC       ECO:0000269|Ref.55}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the serpin family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Antithrombin entry;
CC       URL="https://en.wikipedia.org/wiki/Antithrombin";
CC   -!- WEB RESOURCE: Name=Antithrombin mutation database;
CC       URL="http://www1.imperial.ac.uk/medicine/about/divisions/is/haemo/coag/antithrombin/";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/serpinc1/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=SERPINC1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L00185; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L00186; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L00190; AAB40025.1; -; Genomic_DNA.
DR   EMBL; D29832; BAA06212.1; -; mRNA.
DR   EMBL; X68793; CAA48690.1; -; Genomic_DNA.
DR   EMBL; AF130100; AAG35525.1; -; mRNA.
DR   EMBL; AK312654; BAG35537.1; -; mRNA.
DR   EMBL; AF386078; AAK60337.1; -; Genomic_DNA.
DR   EMBL; AL136170; CAI19423.1; -; Genomic_DNA.
DR   EMBL; CH471067; EAW90969.1; -; Genomic_DNA.
DR   EMBL; M21643; AAA51793.1; -; Genomic_DNA.
DR   EMBL; M21644; AAA51794.1; -; Genomic_DNA.
DR   EMBL; M21643; AAA51794.1; JOINED; Genomic_DNA.
DR   EMBL; M21642; AAA51796.1; -; Genomic_DNA.
DR   EMBL; M21636; AAA51796.1; JOINED; Genomic_DNA.
DR   EMBL; M21637; AAA51796.1; JOINED; Genomic_DNA.
DR   EMBL; M21638; AAA51796.1; JOINED; Genomic_DNA.
DR   EMBL; M21640; AAA51796.1; JOINED; Genomic_DNA.
DR   EMBL; M21641; AAA51796.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS1313.1; -.
DR   PIR; A49494; XHHU3.
DR   RefSeq; NP_000479.1; NM_000488.3.
DR   UniGene; Hs.75599; -.
DR   PDB; 1ANT; X-ray; 3.00 A; I/L=33-464.
DR   PDB; 1ATH; X-ray; 3.20 A; A/B=33-464.
DR   PDB; 1AZX; X-ray; 2.90 A; I/L=33-464.
DR   PDB; 1BR8; X-ray; 2.90 A; I/L=33-464.
DR   PDB; 1DZG; X-ray; 2.80 A; I/L=33-464.
DR   PDB; 1DZH; X-ray; 2.85 A; I/L=33-464.
DR   PDB; 1E03; X-ray; 2.90 A; I/L=33-464.
DR   PDB; 1E04; X-ray; 2.60 A; I/L=33-464.
DR   PDB; 1E05; X-ray; 2.62 A; I/L=33-464.
DR   PDB; 1JVQ; X-ray; 2.60 A; I/L=33-464.
DR   PDB; 1LK6; X-ray; 2.80 A; I/L=33-464.
DR   PDB; 1NQ9; X-ray; 2.60 A; I/L=33-464.
DR   PDB; 1OYH; X-ray; 2.62 A; I/L=33-464.
DR   PDB; 1R1L; X-ray; 2.70 A; I/L=33-464.
DR   PDB; 1SR5; X-ray; 3.10 A; A=33-464.
DR   PDB; 1T1F; X-ray; 2.75 A; A/B/C=33-464.
DR   PDB; 1TB6; X-ray; 2.50 A; I=33-464.
DR   PDB; 2ANT; X-ray; 2.60 A; I/L=33-464.
DR   PDB; 2B4X; X-ray; 2.80 A; I/L=37-463.
DR   PDB; 2B5T; X-ray; 2.10 A; I=33-464.
DR   PDB; 2BEH; X-ray; 2.70 A; I/L=33-464.
DR   PDB; 2GD4; X-ray; 3.30 A; C/I=22-464.
DR   PDB; 2HIJ; X-ray; 2.90 A; I/L=33-464.
DR   PDB; 2ZNH; X-ray; 2.80 A; A/B=33-464.
DR   PDB; 3EVJ; X-ray; 3.00 A; I/L=33-464.
DR   PDB; 3KCG; X-ray; 1.70 A; I=33-464.
DR   PDB; 4EB1; X-ray; 2.80 A; I/L=33-464.
DR   PDBsum; 1ANT; -.
DR   PDBsum; 1ATH; -.
DR   PDBsum; 1AZX; -.
DR   PDBsum; 1BR8; -.
DR   PDBsum; 1DZG; -.
DR   PDBsum; 1DZH; -.
DR   PDBsum; 1E03; -.
DR   PDBsum; 1E04; -.
DR   PDBsum; 1E05; -.
DR   PDBsum; 1JVQ; -.
DR   PDBsum; 1LK6; -.
DR   PDBsum; 1NQ9; -.
DR   PDBsum; 1OYH; -.
DR   PDBsum; 1R1L; -.
DR   PDBsum; 1SR5; -.
DR   PDBsum; 1T1F; -.
DR   PDBsum; 1TB6; -.
DR   PDBsum; 2ANT; -.
DR   PDBsum; 2B4X; -.
DR   PDBsum; 2B5T; -.
DR   PDBsum; 2BEH; -.
DR   PDBsum; 2GD4; -.
DR   PDBsum; 2HIJ; -.
DR   PDBsum; 2ZNH; -.
DR   PDBsum; 3EVJ; -.
DR   PDBsum; 3KCG; -.
DR   PDBsum; 4EB1; -.
DR   ProteinModelPortal; P01008; -.
DR   SMR; P01008; 37-463.
DR   BioGrid; 106953; 11.
DR   DIP; DIP-38009N; -.
DR   IntAct; P01008; 3.
DR   STRING; 9606.ENSP00000356671; -.
DR   BindingDB; P01008; -.
DR   ChEMBL; CHEMBL2111449; -.
DR   DrugBank; DB00407; Ardeparin.
DR   DrugBank; DB06779; Dalteparin.
DR   DrugBank; DB01225; Enoxaparin.
DR   DrugBank; DB00569; Fondaparinux sodium.
DR   DrugBank; DB01109; Heparin.
DR   DrugBank; DB08813; Nadroparin.
DR   DrugBank; DB06271; Sulodexide.
DR   DrugBank; DB06822; Tinzaparin.
DR   GuidetoPHARMACOLOGY; 2632; -.
DR   MEROPS; I04.018; -.
DR   iPTMnet; P01008; -.
DR   PhosphoSite; P01008; -.
DR   UniCarbKB; P01008; -.
DR   BioMuta; SERPINC1; -.
DR   DMDM; 113936; -.
DR   DOSAC-COBS-2DPAGE; P01008; -.
DR   REPRODUCTION-2DPAGE; P01008; -.
DR   SWISS-2DPAGE; P01008; -.
DR   MaxQB; P01008; -.
DR   PaxDb; P01008; -.
DR   PRIDE; P01008; -.
DR   Ensembl; ENST00000367698; ENSP00000356671; ENSG00000117601.
DR   GeneID; 462; -.
DR   KEGG; hsa:462; -.
DR   UCSC; uc001gjt.3; human.
DR   CTD; 462; -.
DR   GeneCards; SERPINC1; -.
DR   HGNC; HGNC:775; SERPINC1.
DR   HPA; CAB016790; -.
DR   HPA; HPA001816; -.
DR   HPA; HPA024007; -.
DR   MalaCards; SERPINC1; -.
DR   MIM; 107300; gene.
DR   MIM; 613118; phenotype.
DR   neXtProt; NX_P01008; -.
DR   Orphanet; 82; Hereditary thrombophilia due to congenital antithrombin deficiency.
DR   PharmGKB; PA35026; -.
DR   eggNOG; KOG2392; Eukaryota.
DR   eggNOG; COG4826; LUCA.
DR   GeneTree; ENSGT00760000118789; -.
DR   HOVERGEN; HBG005957; -.
DR   InParanoid; P01008; -.
DR   KO; K03911; -.
DR   OMA; ACDNTLK; -.
DR   OrthoDB; EOG7327PB; -.
DR   PhylomeDB; P01008; -.
DR   TreeFam; TF343094; -.
DR   Reactome; R-HSA-140837; Intrinsic Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   ChiTaRS; SERPINC1; human.
DR   EvolutionaryTrace; P01008; -.
DR   GeneWiki; Antithrombin; -.
DR   GenomeRNAi; 462; -.
DR   NextBio; 1911; -.
DR   PMAP-CutDB; P01008; -.
DR   PRO; PR:P01008; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P01008; -.
DR   CleanEx; HS_SERPINC1; -.
DR   ExpressionAtlas; P01008; baseline and differential.
DR   Genevisible; P01008; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; NAS:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IBA:GOC.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:2000266; P:regulation of blood coagulation, intrinsic pathway; IEA:InterPro.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   InterPro; IPR015555; AT-III.
DR   InterPro; IPR023795; Serpin_CS.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   PANTHER; PTHR11461; PTHR11461; 1.
DR   PANTHER; PTHR11461:SF53; PTHR11461:SF53; 1.
DR   Pfam; PF00079; Serpin; 1.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; SSF56574; 1.
DR   PROSITE; PS00284; SERPIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Blood coagulation; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Hemostasis; Heparin-binding; Phosphoprotein;
KW   Polymorphism; Protease inhibitor; Reference proteome; Secreted;
KW   Serine protease inhibitor; Signal; Thrombophilia.
FT   SIGNAL        1     32       {ECO:0000269|Ref.10}.
FT   CHAIN        33    464       Antithrombin-III.
FT                                /FTId=PRO_0000032489.
FT   BINDING      81     81       Heparin.
FT   BINDING     161    161       Heparin.
FT   BINDING     177    177       Heparin.
FT   SITE        425    426       Reactive bond.
FT   MOD_RES      63     63       Phosphothreonine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES      68     68       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   CARBOHYD    128    128       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|Ref.10}.
FT   CARBOHYD    167    167       N-linked (GlcNAc...).
FT                                {ECO:0000269|Ref.10}.
FT   CARBOHYD    187    187       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:15084671,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19838169,
FT                                ECO:0000269|Ref.10}.
FT   CARBOHYD    224    224       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|Ref.10}.
FT   DISULFID     40    160       {ECO:0000269|Ref.10}.
FT   DISULFID     53    127       {ECO:0000269|Ref.10}.
FT   DISULFID    279    462       {ECO:0000269|Ref.10}.
FT   VARIANT      17     17       Y -> S (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_027450.
FT   VARIANT      23     23       L -> P (in AT3D; type-I; does not undergo
FT                                post-translational glycosylation).
FT                                {ECO:0000269|PubMed:9031473,
FT                                ECO:0000269|PubMed:9845533}.
FT                                /FTId=VAR_012748.
FT   VARIANT      30     30       V -> E (in Dublin; dbSNP:rs2227624).
FT                                {ECO:0000269|PubMed:1977621,
FT                                ECO:0000269|PubMed:23910795,
FT                                ECO:0000269|PubMed:9031473,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_007032.
FT   VARIANT      32     32       C -> R (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9759613}.
FT                                /FTId=VAR_027451.
FT   VARIANT      39     39       I -> N (in AT3D; type-II; Rouen-3; lack
FT                                of heparin-binding properties;
FT                                dbSNP:rs28929468).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007033.
FT   VARIANT      52     52       M -> T (previously Whitechapel).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007034.
FT   VARIANT      53     53       C -> F (in AT3D).
FT                                {ECO:0000269|PubMed:23910795}.
FT                                /FTId=VAR_071199.
FT   VARIANT      56     56       R -> C (in AT3D; type-II; Rouen-4; lack
FT                                of heparin-binding properties;
FT                                dbSNP:rs28929469).
FT                                {ECO:0000269|PubMed:2365065,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007035.
FT   VARIANT      73     73       P -> L (in AT3D; type-II; lacks heparin-
FT                                binding ability; dbSNP:rs121909551).
FT                                {ECO:0000269|PubMed:23910795,
FT                                ECO:0000269|PubMed:3080419,
FT                                ECO:0000269|PubMed:9031473,
FT                                ECO:0000269|PubMed:9759613}.
FT                                /FTId=VAR_007036.
FT   VARIANT      79     79       R -> C (in AT3D; Tours/Alger/Amiens/
FT                                Toyama/Paris-1/Paris-2/Padua-2/Barcelona-
FT                                2/Kumamoto/Omura/Sasebo; lacks heparin-
FT                                binding ability).
FT                                {ECO:0000269|PubMed:6582486,
FT                                ECO:0000269|PubMed:9031473,
FT                                ECO:0000269|PubMed:9759613}.
FT                                /FTId=VAR_007037.
FT   VARIANT      79     79       R -> H (in AT3D; type-II; Rouen-1/Padua-
FT                                1/Bligny/Budapest-2; lack of heparin-
FT                                binding properties; dbSNP:rs121909552).
FT                                {ECO:0000269|PubMed:7981186,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007038.
FT   VARIANT      79     79       R -> S (in AT3D; type-II; Rouen-2; lack
FT                                of heparin-binding properties).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007039.
FT   VARIANT      87     87       Missing (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007040.
FT   VARIANT      89     89       R -> C (in AT3D; type-I;
FT                                dbSNP:rs147266200).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007041.
FT   VARIANT      90     90       F -> L (in AT3D; type-I; Budapest-6).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007042.
FT   VARIANT      95     95       Y -> C (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_027452.
FT   VARIANT      95     95       Y -> S (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:7994035,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_012316.
FT   VARIANT      98     98       L -> P (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_027453.
FT   VARIANT     108    109       Missing (in AT3D; type-I).
FT                                /FTId=VAR_007043.
FT   VARIANT     112    112       P -> T (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:7959685,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007044.
FT   VARIANT     121    121       M -> K (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:12894857}.
FT                                /FTId=VAR_027454.
FT   VARIANT     125    125       G -> D (in AT3D).
FT                                {ECO:0000269|PubMed:23910795}.
FT                                /FTId=VAR_071200.
FT   VARIANT     127    127       C -> R (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9157604}.
FT                                /FTId=VAR_027455.
FT   VARIANT     131    131       L -> F (in AT3D; type-II; Budapest-3/
FT                                Budapest-7). {ECO:0000269|PubMed:1555650,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007045.
FT   VARIANT     131    131       L -> V (in AT3D; type-II; Southport).
FT                                {ECO:0000269|PubMed:9031473,
FT                                ECO:0000269|Ref.55}.
FT                                /FTId=VAR_007046.
FT   VARIANT     133    133       Q -> K (in AT3D; type I).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007047.
FT   VARIANT     138    139       Missing (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:8486379}.
FT                                /FTId=VAR_007048.
FT   VARIANT     146    146       K -> E (in AT3D; Dreux; complete loss af
FT                                heparin binding).
FT                                {ECO:0000269|PubMed:12353073}.
FT                                /FTId=VAR_027456.
FT   VARIANT     147    147       T -> A (in dbSNP:rs2227606).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_013085.
FT   VARIANT     148    148       S -> P (in AT3D; type-II; Nagasaki;
FT                                defective heparin binding associated with
FT                                thrombosis). {ECO:0000269|PubMed:8443391,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007049.
FT   VARIANT     150    150       Q -> P (in AT3D; type-II; Vienna).
FT                                {ECO:0000269|PubMed:9031473,
FT                                ECO:0000269|Ref.55}.
FT                                /FTId=VAR_007050.
FT   VARIANT     152    154       Missing (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:11794707}.
FT                                /FTId=VAR_012749.
FT   VARIANT     152    152       H -> Y (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:7959685}.
FT                                /FTId=VAR_007051.
FT   VARIANT     153    153       Missing (in AT3D; type-I).
FT                                /FTId=VAR_007052.
FT   VARIANT     158    158       L -> P (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007053.
FT   VARIANT     160    160       C -> Y (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:7981186,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_027457.
FT   VARIANT     161    161       R -> Q (in AT3D; type-II; Geneva).
FT                                {ECO:0000269|PubMed:2229057,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007054.
FT   VARIANT     167    167       N -> T. {ECO:0000269|PubMed:10361121}.
FT                                /FTId=VAR_012750.
FT   VARIANT     170    170       S -> P (in AT3D).
FT                                {ECO:0000269|PubMed:23910795}.
FT                                /FTId=VAR_071201.
FT   VARIANT     178    178       L -> H (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:12894857}.
FT                                /FTId=VAR_027458.
FT   VARIANT     179    179       F -> L (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:15164384}.
FT                                /FTId=VAR_027459.
FT   VARIANT     190    190       Y -> C (polymorphism in population of
FT                                Scandinavian origin).
FT                                {ECO:0000269|PubMed:7959685,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007055.
FT   VARIANT     198    198       Y -> C (in AT3D; type-I and -II;
FT                                Whitechapel).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007056.
FT   VARIANT     198    198       Y -> H (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9031473,
FT                                ECO:0000269|PubMed:9759613}.
FT                                /FTId=VAR_027460.
FT   VARIANT     214    214       S -> F (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:10997988}.
FT                                /FTId=VAR_027461.
FT   VARIANT     214    214       S -> Y (in AT3D; type-I).
FT                                /FTId=VAR_007057.
FT   VARIANT     218    218       I -> N (in AT3D).
FT                                {ECO:0000269|PubMed:23910795}.
FT                                /FTId=VAR_071202.
FT   VARIANT     218    218       Missing (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_027462.
FT   VARIANT     219    219       N -> D (in AT3D; type-II; Rouen-6;
FT                                increases affinity for heparin).
FT                                {ECO:0000269|PubMed:7989582,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007059.
FT   VARIANT     219    219       N -> K (in AT3D; type-II; Glasgow-3).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007058.
FT   VARIANT     223    223       S -> P (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:10997988,
FT                                ECO:0000269|PubMed:11713457}.
FT                                /FTId=VAR_027463.
FT   VARIANT     243    243       T -> I (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:10997988}.
FT                                /FTId=VAR_027464.
FT   VARIANT     248    248       V -> G (in AT3D).
FT                                {ECO:0000269|PubMed:23910795}.
FT                                /FTId=VAR_071203.
FT   VARIANT     251    251       I -> T (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:10997988}.
FT                                /FTId=VAR_027465.
FT   VARIANT     257    257       W -> R (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9031473,
FT                                ECO:0000269|PubMed:9759613}.
FT                                /FTId=VAR_027466.
FT   VARIANT     261    261       F -> L (in AT3D).
FT                                {ECO:0000269|PubMed:12595305}.
FT                                /FTId=VAR_027467.
FT   VARIANT     269    269       E -> K (in AT3D; type-II; Truro;
FT                                increases affinity for heparin).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007060.
FT   VARIANT     273    307       Missing (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:7878627}.
FT                                /FTId=VAR_007061.
FT   VARIANT     283    283       M -> I (in AT3D; type-II).
FT                                {ECO:0000269|PubMed:7959685,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007062.
FT   VARIANT     283    283       M -> V (in AT3D; type-II).
FT                                {ECO:0000269|PubMed:10997988}.
FT                                /FTId=VAR_027468.
FT   VARIANT     293    293       R -> P (in AT3D).
FT                                {ECO:0000269|PubMed:23910795}.
FT                                /FTId=VAR_071204.
FT   VARIANT     302    302       L -> P (in AT3D; type-I).
FT                                /FTId=VAR_007063.
FT   VARIANT     316    316       I -> N (in AT3D; type-II; Haslar/
FT                                Whitechapel).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007064.
FT   VARIANT     323    323       S -> P (in AT3D).
FT                                /FTId=VAR_027469.
FT   VARIANT     334    334       E -> K (in AT3D; type-II).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007065.
FT   VARIANT     344    344       Missing (in AT3D; type-I).
FT                                /FTId=VAR_007066.
FT   VARIANT     381    381       S -> P (in AT3D; type-I).
FT                                /FTId=VAR_007067.
FT   VARIANT     391    391       R -> Q.
FT                                /FTId=VAR_007068.
FT   VARIANT     397    397       S -> P (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:10997988}.
FT                                /FTId=VAR_027470.
FT   VARIANT     398    398       D -> H (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:16908819}.
FT                                /FTId=VAR_027471.
FT   VARIANT     401    401       H -> R (in AT3D).
FT                                {ECO:0000269|PubMed:23910795}.
FT                                /FTId=VAR_071205.
FT   VARIANT     412    412       S -> R (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9031473,
FT                                ECO:0000269|PubMed:9759613}.
FT                                /FTId=VAR_027472.
FT   VARIANT     414    414       A -> T (in AT3D; type-II; Hamilton/
FT                                Glasgow-2; reduces interaction with
FT                                thrombin by 90%).
FT                                {ECO:0000269|PubMed:2013320,
FT                                ECO:0000269|PubMed:3179438,
FT                                ECO:0000269|PubMed:7734359,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007069.
FT   VARIANT     416    416       A -> P (in AT3D; type-II; Charleville/
FT                                Sudbury/Vicenza/Cambridge-1;
FT                                dbSNP:rs28930978).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007070.
FT   VARIANT     416    416       A -> S (in AT3D; type-II; Cambridge-2;
FT                                dbSNP:rs121909548).
FT                                {ECO:0000269|PubMed:1906811,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007071.
FT   VARIANT     419    419       A -> V (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007072.
FT   VARIANT     424    424       G -> D (in AT3D; type-II; Stockholm).
FT                                {ECO:0000269|PubMed:1547341,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007073.
FT   VARIANT     425    425       R -> C (in AT3D; type-II;
FT                                dbSNP:rs121909554).
FT                                {ECO:0000269|PubMed:12894857,
FT                                ECO:0000269|PubMed:15164384,
FT                                ECO:0000269|PubMed:23910795,
FT                                ECO:0000269|PubMed:3162733,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007075.
FT   VARIANT     425    425       R -> H (in AT3D; type-II; Glasgow/
FT                                Sheffield/Chicago/Avranches/Kumamoto-2;
FT                                increases affinity for heparin; deprived
FT                                of inhibitory activity).
FT                                {ECO:0000269|PubMed:12894857,
FT                                ECO:0000269|PubMed:2781509,
FT                                ECO:0000269|PubMed:3162733,
FT                                ECO:0000269|PubMed:7832187,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007074.
FT   VARIANT     425    425       R -> P (in AT3D; type-II; Pescara;
FT                                deprived of inhibitory of activity).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007076.
FT   VARIANT     426    426       S -> L (in AT3D; type-II; Denver/Milano-
FT                                2; deprived of inhibitory activity).
FT                                {ECO:0000269|PubMed:15164384,
FT                                ECO:0000269|PubMed:3805013,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007077.
FT   VARIANT     434    434       F -> C (in AT3D; type-II; Rosny).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007078.
FT   VARIANT     434    434       F -> L (in AT3D; type-II; Maisons-
FT                                Laffite). {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007080.
FT   VARIANT     434    434       F -> S (in AT3D; type-II; Torino).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007079.
FT   VARIANT     436    436       A -> T (in AT3D; type-II; Oslo/Paris-3).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007081.
FT   VARIANT     437    437       N -> K (in AT3D; type-II; La Rochelle).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007082.
FT   VARIANT     438    438       R -> G (in AT3D; type I and type-II).
FT                                {ECO:0000269|PubMed:23910795,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_009258.
FT   VARIANT     438    438       R -> M (in AT3D; type-II; Kyoto).
FT                                {ECO:0000269|PubMed:9031473,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_007083.
FT   VARIANT     439    439       P -> A (in AT3D).
FT                                {ECO:0000269|PubMed:23910795}.
FT                                /FTId=VAR_071206.
FT   VARIANT     439    439       P -> L (in AT3D; type-II; Utah; deprived
FT                                of inhibitory activity).
FT                                {ECO:0000269|PubMed:3191114,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007084.
FT   VARIANT     439    439       P -> T (in AT3D; type-II; Budapest-5).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007085.
FT   VARIANT     441    441       L -> P (in AT3D; type-II).
FT                                {ECO:0000269|PubMed:12894857}.
FT                                /FTId=VAR_027473.
FT   VARIANT     453    453       I -> T (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:7994035,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007086.
FT   VARIANT     456    456       G -> R (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:8274732,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007087.
FT   VARIANT     457    457       R -> T (in AT3D; type-II).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007088.
FT   VARIANT     459    461       Missing (in AT3D; type-I).
FT                                /FTId=VAR_007089.
FT   VARIANT     459    459       A -> D (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007090.
FT   VARIANT     461    461       P -> L (in AT3D; type-II; Budapest).
FT                                {ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007091.
FT   VARIANT     462    462       C -> F (in AT3D; type-I).
FT                                {ECO:0000269|PubMed:7994035,
FT                                ECO:0000269|PubMed:9031473}.
FT                                /FTId=VAR_007092.
FT   MUTAGEN     414    414       A->K: Reduces interaction with thrombin
FT                                by 99%. {ECO:0000269|PubMed:2013320}.
FT   MUTAGEN     414    414       A->Q: Reduces interaction with thrombin
FT                                by 80%. {ECO:0000269|PubMed:2013320}.
FT   CONFLICT     69     70       EQ -> QE (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     77     77       N -> NN (in Ref. 3; BAA06212).
FT                                {ECO:0000305}.
FT   CONFLICT     97     97       H -> R (in Ref. 5; AAG35525).
FT                                {ECO:0000305}.
FT   CONFLICT    120    120       A -> T (in Ref. 6; BAG35537).
FT                                {ECO:0000305}.
FT   CONFLICT    226    226       T -> A (in Ref. 6; BAG35537).
FT                                {ECO:0000305}.
FT   CONFLICT    247    249       Missing (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    388    388       Missing (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    395    395       Y -> YA (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        39     41       {ECO:0000244|PDB:3KCG}.
FT   TURN         44     46       {ECO:0000244|PDB:3KCG}.
FT   STRAND       51     53       {ECO:0000244|PDB:1OYH}.
FT   HELIX        78    101       {ECO:0000244|PDB:3KCG}.
FT   STRAND      104    106       {ECO:0000244|PDB:1DZG}.
FT   STRAND      108    110       {ECO:0000244|PDB:3KCG}.
FT   HELIX       112    123       {ECO:0000244|PDB:3KCG}.
FT   HELIX       128    137       {ECO:0000244|PDB:3KCG}.
FT   HELIX       140    142       {ECO:0000244|PDB:2B5T}.
FT   HELIX       145    149       {ECO:0000244|PDB:3KCG}.
FT   HELIX       151    166       {ECO:0000244|PDB:3KCG}.
FT   TURN        167    169       {ECO:0000244|PDB:3KCG}.
FT   STRAND      170    181       {ECO:0000244|PDB:3KCG}.
FT   STRAND      184    186       {ECO:0000244|PDB:1E04}.
FT   HELIX       188    198       {ECO:0000244|PDB:3KCG}.
FT   STRAND      203    205       {ECO:0000244|PDB:3KCG}.
FT   HELIX       207    225       {ECO:0000244|PDB:3KCG}.
FT   TURN        226    228       {ECO:0000244|PDB:3KCG}.
FT   STRAND      236    239       {ECO:0000244|PDB:2B4X}.
FT   STRAND      240    242       {ECO:0000244|PDB:1DZG}.
FT   STRAND      245    255       {ECO:0000244|PDB:3KCG}.
FT   STRAND      257    259       {ECO:0000244|PDB:3KCG}.
FT   HELIX       263    265       {ECO:0000244|PDB:3KCG}.
FT   STRAND      267    272       {ECO:0000244|PDB:3KCG}.
FT   STRAND      274    276       {ECO:0000244|PDB:2B5T}.
FT   STRAND      278    294       {ECO:0000244|PDB:3KCG}.
FT   HELIX       296    298       {ECO:0000244|PDB:3KCG}.
FT   STRAND      300    306       {ECO:0000244|PDB:3KCG}.
FT   STRAND      309    317       {ECO:0000244|PDB:3KCG}.
FT   STRAND      320    322       {ECO:0000244|PDB:2B5T}.
FT   HELIX       324    329       {ECO:0000244|PDB:3KCG}.
FT   HELIX       333    342       {ECO:0000244|PDB:3KCG}.
FT   STRAND      344    353       {ECO:0000244|PDB:3KCG}.
FT   STRAND      355    362       {ECO:0000244|PDB:3KCG}.
FT   HELIX       364    369       {ECO:0000244|PDB:3KCG}.
FT   HELIX       374    376       {ECO:0000244|PDB:3KCG}.
FT   TURN        378    380       {ECO:0000244|PDB:3KCG}.
FT   TURN        384    386       {ECO:0000244|PDB:3KCG}.
FT   STRAND      389    392       {ECO:0000244|PDB:3KCG}.
FT   STRAND      398    407       {ECO:0000244|PDB:3KCG}.
FT   STRAND      409    413       {ECO:0000244|PDB:2B5T}.
FT   STRAND      419    422       {ECO:0000244|PDB:1E04}.
FT   STRAND      423    426       {ECO:0000244|PDB:3KCG}.
FT   STRAND      432    435       {ECO:0000244|PDB:3KCG}.
FT   STRAND      440    446       {ECO:0000244|PDB:3KCG}.
FT   TURN        447    450       {ECO:0000244|PDB:3KCG}.
FT   STRAND      451    459       {ECO:0000244|PDB:3KCG}.
SQ   SEQUENCE   464 AA;  52602 MW;  9A4E324F00683D9D CRC64;
     MYSNVIGTVT SGKRKVYLLS LLLIGFWDCV TCHGSPVDIC TAKPRDIPMN PMCIYRSPEK
     KATEDEGSEQ KIPEATNRRV WELSKANSRF ATTFYQHLAD SKNDNDNIFL SPLSISTAFA
     MTKLGACNDT LQQLMEVFKF DTISEKTSDQ IHFFFAKLNC RLYRKANKSS KLVSANRLFG
     DKSLTFNETY QDISELVYGA KLQPLDFKEN AEQSRAAINK WVSNKTEGRI TDVIPSEAIN
     ELTVLVLVNT IYFKGLWKSK FSPENTRKEL FYKADGESCS ASMMYQEGKF RYRRVAEGTQ
     VLELPFKGDD ITMVLILPKP EKSLAKVEKE LTPEVLQEWL DELEEMMLVV HMPRFRIEDG
     FSLKEQLQDM GLVDLFSPEK SKLPGIVAEG RDDLYVSDAF HKAFLEVNEE GSEAAASTAV
     VIAGRSLNPN RVTFKANRPF LVFIREVPLN TIIFMGRVAN PCVK
//
ID   LIRB1_HUMAN             Reviewed;         650 AA.
AC   Q8NHL6; A2IXV4; A8MXT0; O75024; O75025; Q8NHJ9; Q8NHK0;
DT   03-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   17-FEB-2016, entry version 137.
DE   RecName: Full=Leukocyte immunoglobulin-like receptor subfamily B member 1;
DE            Short=LIR-1;
DE            Short=Leukocyte immunoglobulin-like receptor 1;
DE   AltName: Full=CD85 antigen-like family member J;
DE   AltName: Full=Immunoglobulin-like transcript 2;
DE            Short=ILT-2;
DE   AltName: Full=Monocyte/macrophage immunoglobulin-like receptor 7;
DE            Short=MIR-7;
DE   AltName: CD_antigen=CD85j;
DE   Flags: Precursor;
GN   Name=LILRB1; Synonyms=ILT2, LIR1, MIR7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RX   PubMed=9259559; DOI=10.1016/S0960-9822(06)00263-6;
RA   Wagtmann N., Rojo S., Eichler E., Mohrenweiser H., Long E.O.;
RT   "A new human gene complex encoding the killer cell inhibitory
RT   receptors and related monocyte/macrophage receptors.";
RL   Curr. Biol. 7:615-618(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), VARIANTS PRO-68;
RP   THR-142; ILE-155 AND LYS-625, INTERACTION WITH H301 AND PTPN6,
RP   PHOSPHORYLATION, TISSUE SPECIFICITY, AND FUNCTION.
RC   TISSUE=Lymphoblast;
RX   PubMed=9285411; DOI=10.1016/S1074-7613(00)80529-4;
RA   Cosman D., Fanger N., Borges L., Kubin M., Chin W., Peterson L.,
RA   Hsu M.-L.;
RT   "A novel immunoglobulin superfamily receptor for cellular and viral
RT   MHC class I molecules.";
RL   Immunity 7:273-282(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=10941837; DOI=10.1007/s002510000183;
RA   Liu W.R., Kim J., Nwankwo C., Ashworth L.K., Arm J.P.;
RT   "Genomic organization of the human leukocyte immunoglobulin-like
RT   receptors within the leukocyte receptor complex on chromosome
RT   19q13.4.";
RL   Immunogenetics 51:659-669(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), ALTERNATIVE SPLICING,
RP   SUBCELLULAR LOCATION (ISOFORM 5), AND VARIANTS PRO-68; THR-93; THR-142
RP   AND ILE-155.
RX   PubMed=19658091; DOI=10.1002/eji.200839080;
RA   Jones D.C., Roghanian A., Brown D.P., Chang C., Allen R.L.,
RA   Trowsdale J., Young N.T.;
RT   "Alternative mRNA splicing creates transcripts encoding soluble
RT   proteins from most LILR genes.";
RL   Eur. J. Immunol. 39:3195-3206(2009).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-68; THR-93;
RP   THR-142; ILE-155 AND LYS-625.
RX   PubMed=20600445; DOI=10.1016/j.humimm.2010.06.015;
RA   Davidson C.L., Li N.L., Burshtyn D.N.;
RT   "LILRB1 polymorphism and surface phenotypes of natural killer cells.";
RL   Hum. Immunol. 71:942-949(2010).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Canavez F.C.;
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   PRO-68; THR-142; ILE-155 AND LYS-625.
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH PTPN6 AND FCGR1A, PHOSPHORYLATION, TISSUE
RP   SPECIFICITY, AND FUNCTION.
RX   PubMed=9842885;
RX   DOI=10.1002/(SICI)1521-4141(199811)28:11<3423::AID-IMMU3423>3.0.CO;2-2;
RA   Fanger N.A., Cosman D., Peterson L., Braddy S.C., Maliszewski C.R.,
RA   Borges L.;
RT   "The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-
RT   mediated signaling in monocytes.";
RL   Eur. J. Immunol. 28:3423-3434(1998).
RN   [10]
RP   INTERACTION WITH HHV-5 PROTEIN UL18.
RX   PubMed=10591185; DOI=10.1016/S1074-7613(00)80135-1;
RA   Chapman T.L., Heikeman A.P., Bjorkman P.J.;
RT   "The inhibitory receptor LIR-1 uses a common binding interaction to
RT   recognize class I MHC molecules and the viral homolog UL18.";
RL   Immunity 11:603-613(1999).
RN   [11]
RP   PHOSPHORYLATION AT TYR-533; TYR-614 AND TYR-644, MUTAGENESIS OF
RP   TYR-533; TYR-562; TYR-614 AND TYR-644, INTERACTION WITH FCER1A, AND
RP   FUNCTION.
RX   PubMed=11907092; DOI=10.4049/jimmunol.168.7.3351;
RA   Bellon T., Kitzig F., Sayos J., Lopez-Botet M.;
RT   "Mutational analysis of immunoreceptor tyrosine-based inhibition
RT   motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor.";
RL   J. Immunol. 168:3351-3359(2002).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 25-221, AND DISULFIDE BONDS.
RX   PubMed=11114384; DOI=10.1016/S1074-7613(00)00071-6;
RA   Chapman T.L., Heikema A.P., West A.P. Jr., Bjorkman P.J.;
RT   "Crystal structure and ligand binding properties of the D1D2 region of
RT   the inhibitory receptor LIR-1 (ILT2).";
RL   Immunity 13:727-736(2000).
CC   -!- FUNCTION: Receptor for class I MHC antigens. Recognizes a broad
CC       spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Receptor for
CC       H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand
CC       binding results in inhibitory signals and down-regulation of the
CC       immune response. Engagement of LILRB1 present on natural killer
CC       cells or T-cells by class I MHC molecules protects the target
CC       cells from lysis. Interaction with HLA-B or HLA-E leads to
CC       inhibition of the signal triggered by FCER1A and inhibits
CC       serotonin release. Inhibits FCGR1A-mediated phosphorylation of
CC       cellular proteins and mobilization of intracellular calcium ions.
CC       {ECO:0000269|PubMed:11907092, ECO:0000269|PubMed:9285411,
CC       ECO:0000269|PubMed:9842885}.
CC   -!- SUBUNIT: Binds PTPN6 when phosphorylated. Binds FCER1A and FCGR1A.
CC       Interacts with human cytomegalovirus/HHV-5 protein UL18.
CC       {ECO:0000269|PubMed:10591185, ECO:0000269|PubMed:11907092,
CC       ECO:0000269|PubMed:9285411, ECO:0000269|PubMed:9842885}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305|PubMed:19658091};
CC       Single-pass type I membrane protein {ECO:0000255}.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Secreted
CC       {ECO:0000269|PubMed:19658091}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q8NHL6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NHL6-2; Sequence=VSP_008456;
CC       Name=3;
CC         IsoId=Q8NHL6-3; Sequence=VSP_008456, VSP_008457;
CC       Name=4;
CC         IsoId=Q8NHL6-4; Sequence=VSP_008457;
CC       Name=5; Synonyms=65 Kda, sLILRB1;
CC         IsoId=Q8NHL6-5; Sequence=VSP_008456, VSP_057087, VSP_057088;
CC         Note=May act as dominant negative regulator and block the
CC         interaction between membrane-associated isoforms and HLA-class
CC         I. {ECO:0000269|PubMed:19658091};
CC   -!- TISSUE SPECIFICITY: Expressed predominantly on B-cells and
CC       monocytes, and at lower levels on dendritic cells. Detected on a
CC       low percentage of T-cells and natural killer (NK) cells.
CC       {ECO:0000269|PubMed:9285411, ECO:0000269|PubMed:9842885}.
CC   -!- DOMAIN: Contains 4 copies of a cytoplasmic motif that is referred
CC       to as the immunoreceptor tyrosine-based inhibitor motif (ITIM).
CC       This motif is involved in modulation of cellular responses. The
CC       phosphorylated ITIM motif can bind the SH2 domain of several SH2-
CC       containing phosphatases.
CC   -!- PTM: Phosphorylated on tyrosine residues. Dephosphorylated by
CC       PTPN6. {ECO:0000269|PubMed:11907092, ECO:0000269|PubMed:9285411,
CC       ECO:0000269|PubMed:9842885}.
CC   -!- SIMILARITY: Contains 4 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF004230; AAB67710.1; -; mRNA.
DR   EMBL; AF009220; AAB63521.1; -; mRNA.
DR   EMBL; AF009221; AAB63522.1; -; mRNA.
DR   EMBL; AF189277; AAG08984.1; -; Genomic_DNA.
DR   EMBL; EU915608; ACK56074.1; -; mRNA.
DR   EMBL; HM135394; ADJ55944.1; -; Genomic_DNA.
DR   EMBL; HM135401; ADJ55951.1; -; Genomic_DNA.
DR   EMBL; AF283984; AAL36988.1; -; mRNA.
DR   EMBL; AF283985; AAL36989.1; -; mRNA.
DR   EMBL; AC009892; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015731; AAH15731.1; -; mRNA.
DR   CCDS; CCDS42614.1; -. [Q8NHL6-3]
DR   CCDS; CCDS42615.1; -. [Q8NHL6-2]
DR   CCDS; CCDS42616.1; -. [Q8NHL6-4]
DR   CCDS; CCDS42617.1; -. [Q8NHL6-1]
DR   RefSeq; NP_001075106.2; NM_001081637.2.
DR   RefSeq; NP_001075107.2; NM_001081638.3.
DR   RefSeq; NP_001075108.2; NM_001081639.3.
DR   RefSeq; NP_001265327.2; NM_001278398.2.
DR   RefSeq; NP_001265328.2; NM_001278399.2.
DR   RefSeq; NP_006660.4; NM_006669.6.
DR   UniGene; Hs.667388; -.
DR   PDB; 1G0X; X-ray; 2.10 A; A=25-221.
DR   PDB; 1P7Q; X-ray; 3.40 A; D=25-221.
DR   PDB; 1UFU; X-ray; 3.00 A; A=25-221.
DR   PDB; 1UGN; X-ray; 1.80 A; A=24-221.
DR   PDB; 1VDG; X-ray; 2.80 A; A/B=24-220.
DR   PDB; 3D2U; X-ray; 2.21 A; D/H=24-221.
DR   PDB; 4LL9; X-ray; 2.69 A; A/B/C=222-417.
DR   PDB; 4NO0; X-ray; 2.70 A; D=27-221.
DR   PDBsum; 1G0X; -.
DR   PDBsum; 1P7Q; -.
DR   PDBsum; 1UFU; -.
DR   PDBsum; 1UGN; -.
DR   PDBsum; 1VDG; -.
DR   PDBsum; 3D2U; -.
DR   PDBsum; 4LL9; -.
DR   PDBsum; 4NO0; -.
DR   ProteinModelPortal; Q8NHL6; -.
DR   SMR; Q8NHL6; 27-417.
DR   BioGrid; 116070; 7.
DR   IntAct; Q8NHL6; 4.
DR   MINT; MINT-7144935; -.
DR   STRING; 9606.ENSP00000315997; -.
DR   MEROPS; I43.951; -.
DR   iPTMnet; Q8NHL6; -.
DR   PhosphoSite; Q8NHL6; -.
DR   BioMuta; LILRB1; -.
DR   DMDM; 37537910; -.
DR   PaxDb; Q8NHL6; -.
DR   PRIDE; Q8NHL6; -.
DR   DNASU; 10859; -.
DR   Ensembl; ENST00000448689; ENSP00000409968; ENSG00000104972.
DR   Ensembl; ENST00000612636; ENSP00000479887; ENSG00000277807. [Q8NHL6-3]
DR   Ensembl; ENST00000616408; ENSP00000481700; ENSG00000274669.
DR   Ensembl; ENST00000617686; ENSP00000478282; ENSG00000277807. [Q8NHL6-4]
DR   Ensembl; ENST00000618055; ENSP00000480365; ENSG00000277807. [Q8NHL6-1]
DR   Ensembl; ENST00000618681; ENSP00000479753; ENSG00000277807. [Q8NHL6-2]
DR   GeneID; 10859; -.
DR   KEGG; hsa:10859; -.
DR   UCSC; uc002qgj.3; human. [Q8NHL6-1]
DR   UCSC; uc002qgk.3; human. [Q8NHL6-2]
DR   UCSC; uc002qgl.3; human. [Q8NHL6-4]
DR   UCSC; uc002qgm.3; human. [Q8NHL6-3]
DR   CTD; 10859; -.
DR   GeneCards; LILRB1; -.
DR   H-InvDB; HIX0137208; -.
DR   HGNC; HGNC:6605; LILRB1.
DR   MIM; 604811; gene.
DR   neXtProt; NX_Q8NHL6; -.
DR   PharmGKB; PA30379; -.
DR   eggNOG; ENOG410IKJD; Eukaryota.
DR   eggNOG; ENOG41116BR; LUCA.
DR   HOGENOM; HOG000234395; -.
DR   HOVERGEN; HBG074353; -.
DR   InParanoid; Q8NHL6; -.
DR   KO; K06512; -.
DR   OMA; SWITWIR; -.
DR   PhylomeDB; Q8NHL6; -.
DR   TreeFam; TF336644; -.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   ChiTaRS; LILRB1; human.
DR   EvolutionaryTrace; Q8NHL6; -.
DR   GeneWiki; LILRB1; -.
DR   GenomeRNAi; 10859; -.
DR   NextBio; 41223; -.
DR   PRO; PR:Q8NHL6; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Proteomes; UP000005640; Unplaced.
DR   Bgee; Q8NHL6; -.
DR   CleanEx; HS_LILRB1; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030107; F:HLA-A specific inhibitory MHC class I receptor activity; IDA:UniProtKB.
DR   GO; GO:0030109; F:HLA-B specific inhibitory MHC class I receptor activity; IDA:UniProtKB.
DR   GO; GO:0042288; F:MHC class I protein binding; IDA:UniProtKB.
DR   GO; GO:0032393; F:MHC class I receptor activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0008157; F:protein phosphatase 1 binding; IPI:UniProtKB.
DR   GO; GO:0042169; F:SH2 domain binding; IDA:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEP:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0097028; P:dendritic cell differentiation; IEP:UniProtKB.
DR   GO; GO:0002774; P:Fc receptor mediated inhibitory signaling pathway; IDA:UniProtKB.
DR   GO; GO:0002767; P:immune response-inhibiting cell surface receptor signaling pathway; NAS:BHF-UCL.
DR   GO; GO:0032609; P:interferon-gamma production; IDA:UniProtKB.
DR   GO; GO:0072643; P:interferon-gamma secretion; IDA:UniProtKB.
DR   GO; GO:0046636; P:negative regulation of alpha-beta T cell activation; IDA:UniProtKB.
DR   GO; GO:0051926; P:negative regulation of calcium ion transport; IDA:UniProtKB.
DR   GO; GO:2001186; P:negative regulation of CD8-positive, alpha-beta T cell activation; IDA:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0002740; P:negative regulation of cytokine secretion involved in immune response; IDA:UniProtKB.
DR   GO; GO:2000669; P:negative regulation of dendritic cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:2001199; P:negative regulation of dendritic cell differentiation; IMP:UniProtKB.
DR   GO; GO:0045806; P:negative regulation of endocytosis; IDA:UniProtKB.
DR   GO; GO:0035548; P:negative regulation of interferon-beta secretion; IDA:UniProtKB.
DR   GO; GO:0045077; P:negative regulation of interferon-gamma biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IDA:UniProtKB.
DR   GO; GO:2001180; P:negative regulation of interleukin-10 secretion; IDA:UniProtKB.
DR   GO; GO:2001183; P:negative regulation of interleukin-12 secretion; IDA:UniProtKB.
DR   GO; GO:0032945; P:negative regulation of mononuclear cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045953; P:negative regulation of natural killer cell mediated cytotoxicity; IDA:UniProtKB.
DR   GO; GO:2001205; P:negative regulation of osteoclast development; IDA:UniProtKB.
DR   GO; GO:0014063; P:negative regulation of serotonin secretion; IDA:UniProtKB.
DR   GO; GO:2001189; P:negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell; IDA:UniProtKB.
DR   GO; GO:0001915; P:negative regulation of T cell mediated cytotoxicity; IDA:UniProtKB.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IDA:UniProtKB.
DR   GO; GO:2001202; P:negative regulation of transforming growth factor-beta secretion; IDA:UniProtKB.
DR   GO; GO:0042536; P:negative regulation of tumor necrosis factor biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045919; P:positive regulation of cytolysis; IDA:UniProtKB.
DR   GO; GO:0002230; P:positive regulation of defense response to virus by host; IDA:UniProtKB.
DR   GO; GO:2001193; P:positive regulation of gamma-delta T cell activation involved in immune response; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; NAS:BHF-UCL.
DR   GO; GO:0031623; P:receptor internalization; TAS:UniProtKB.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0009615; P:response to virus; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0002309; P:T cell proliferation involved in immune response; IDA:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   Pfam; PF13895; Ig_2; 1.
DR   SMART; SM00409; IG; 3.
DR   SUPFAM; SSF48726; SSF48726; 4.
DR   PROSITE; PS50835; IG_LIKE; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Cell membrane;
KW   Complete proteome; Disulfide bond; Glycoprotein; Immunity;
KW   Immunoglobulin domain; Membrane; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Repeat; Secreted; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    650       Leukocyte immunoglobulin-like receptor
FT                                subfamily B member 1.
FT                                /FTId=PRO_0000014820.
FT   TOPO_DOM     24    461       Extracellular. {ECO:0000255}.
FT   TRANSMEM    462    482       Helical. {ECO:0000255}.
FT   TOPO_DOM    483    650       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       27    115       Ig-like C2-type 1.
FT   DOMAIN      116    221       Ig-like C2-type 2.
FT   DOMAIN      222    312       Ig-like C2-type 3.
FT   DOMAIN      313    409       Ig-like C2-type 4.
FT   MOTIF       531    536       ITIM motif 1.
FT   MOTIF       560    565       ITIM motif 2.
FT   MOTIF       612    617       ITIM motif 3.
FT   MOTIF       642    647       ITIM motif 4.
FT   MOD_RES     522    522       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O75023}.
FT   MOD_RES     533    533       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:11907092}.
FT   MOD_RES     614    614       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:11907092}.
FT   MOD_RES     644    644       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:11907092}.
FT   CARBOHYD    281    281       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    302    302       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    341    341       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     49     98       {ECO:0000244|PDB:1G0X,
FT                                ECO:0000269|PubMed:11114384}.
FT   DISULFID    145    197       {ECO:0000244|PDB:1G0X,
FT                                ECO:0000269|PubMed:11114384}.
FT   DISULFID    157    167       {ECO:0000244|PDB:1G0X,
FT                                ECO:0000269|PubMed:11114384}.
FT   DISULFID    246    297       {ECO:0000244|PDB:1G0X,
FT                                ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:11114384}.
FT   DISULFID    346    397       {ECO:0000244|PDB:1G0X,
FT                                ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:11114384}.
FT   VAR_SEQ     437    437       S -> SA (in isoform 2, isoform 3 and
FT                                isoform 5). {ECO:0000303|PubMed:19658091,
FT                                ECO:0000303|PubMed:9285411}.
FT                                /FTId=VSP_008456.
FT   VAR_SEQ     455    455       L -> E (in isoform 5).
FT                                {ECO:0000303|PubMed:19658091}.
FT                                /FTId=VSP_057087.
FT   VAR_SEQ     456    650       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:19658091}.
FT                                /FTId=VSP_057088.
FT   VAR_SEQ     550    550       R -> RQ (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:20600445,
FT                                ECO:0000303|PubMed:9259559,
FT                                ECO:0000303|PubMed:9285411}.
FT                                /FTId=VSP_008457.
FT   VARIANT      68     68       L -> P (in dbSNP:rs1061679).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:19658091,
FT                                ECO:0000269|PubMed:20600445,
FT                                ECO:0000269|PubMed:9285411}.
FT                                /FTId=VAR_016993.
FT   VARIANT      93     93       A -> T (in dbSNP:rs12460501).
FT                                {ECO:0000269|PubMed:19658091,
FT                                ECO:0000269|PubMed:20600445}.
FT                                /FTId=VAR_049888.
FT   VARIANT     142    142       I -> T (in dbSNP:rs1061680).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:19658091,
FT                                ECO:0000269|PubMed:20600445,
FT                                ECO:0000269|PubMed:9285411}.
FT                                /FTId=VAR_016994.
FT   VARIANT     155    155       S -> I (in dbSNP:rs1061681).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:19658091,
FT                                ECO:0000269|PubMed:20600445,
FT                                ECO:0000269|PubMed:9285411}.
FT                                /FTId=VAR_016995.
FT   VARIANT     301    301       H -> Y (in dbSNP:rs1045818).
FT                                /FTId=VAR_059398.
FT   VARIANT     459    459       L -> V (in dbSNP:rs45511398).
FT                                /FTId=VAR_067316.
FT   VARIANT     620    620       L -> F (in dbSNP:rs634222).
FT                                /FTId=VAR_016996.
FT   VARIANT     625    625       E -> K (in dbSNP:rs16985478).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:20600445,
FT                                ECO:0000269|PubMed:9285411}.
FT                                /FTId=VAR_067317.
FT   MUTAGEN     533    533       Y->F: Impairs receptor phosphorylation
FT                                and abolishes inhibition of serotonin
FT                                release. No effect on PTPN6 binding; when
FT                                associated with F-562.
FT                                {ECO:0000269|PubMed:11907092}.
FT   MUTAGEN     562    562       Y->F: No effect on PTPN6 binding; when
FT                                associated with F-533.
FT                                {ECO:0000269|PubMed:11907092}.
FT   MUTAGEN     614    614       Y->F: No effect on PTPN6 binding.
FT                                Abolishes PTPN6 binding; when associated
FT                                with F-644.
FT                                {ECO:0000269|PubMed:11907092}.
FT   MUTAGEN     644    644       Y->F: Reduces PTPN6 binding. Abolishes
FT                                PTPN6 binding; when associated with F-
FT                                614. {ECO:0000269|PubMed:11907092}.
FT   CONFLICT    557    557       P -> L (in Ref. 6; AAL36989).
FT                                {ECO:0000305}.
FT   STRAND       30     35       {ECO:0000244|PDB:1UGN}.
FT   STRAND       37     40       {ECO:0000244|PDB:1UGN}.
FT   STRAND       45     50       {ECO:0000244|PDB:1UGN}.
FT   STRAND       52     54       {ECO:0000244|PDB:1VDG}.
FT   STRAND       58     65       {ECO:0000244|PDB:1UGN}.
FT   HELIX        68     71       {ECO:0000244|PDB:1UGN}.
FT   HELIX        75     78       {ECO:0000244|PDB:1UGN}.
FT   TURN         79     81       {ECO:0000244|PDB:1UGN}.
FT   STRAND       82     87       {ECO:0000244|PDB:1UGN}.
FT   HELIX        90     92       {ECO:0000244|PDB:1UGN}.
FT   STRAND       94    102       {ECO:0000244|PDB:1UGN}.
FT   TURN        103    105       {ECO:0000244|PDB:1UGN}.
FT   STRAND      114    119       {ECO:0000244|PDB:1UGN}.
FT   STRAND      126    131       {ECO:0000244|PDB:1UGN}.
FT   STRAND      133    136       {ECO:0000244|PDB:1UGN}.
FT   STRAND      141    146       {ECO:0000244|PDB:1UGN}.
FT   STRAND      152    159       {ECO:0000244|PDB:1UGN}.
FT   STRAND      167    169       {ECO:0000244|PDB:1UGN}.
FT   HELIX       172    174       {ECO:0000244|PDB:1G0X}.
FT   STRAND      179    184       {ECO:0000244|PDB:1UGN}.
FT   STRAND      193    200       {ECO:0000244|PDB:1UGN}.
FT   STRAND      204    208       {ECO:0000244|PDB:3D2U}.
FT   STRAND      215    220       {ECO:0000244|PDB:1UGN}.
FT   STRAND      227    232       {ECO:0000244|PDB:4LL9}.
FT   STRAND      234    236       {ECO:0000244|PDB:4LL9}.
FT   STRAND      242    250       {ECO:0000244|PDB:4LL9}.
FT   STRAND      253    259       {ECO:0000244|PDB:4LL9}.
FT   STRAND      266    270       {ECO:0000244|PDB:4LL9}.
FT   STRAND      278    284       {ECO:0000244|PDB:4LL9}.
FT   HELIX       289    291       {ECO:0000244|PDB:4LL9}.
FT   STRAND      293    300       {ECO:0000244|PDB:4LL9}.
FT   STRAND      314    320       {ECO:0000244|PDB:4LL9}.
FT   STRAND      322    329       {ECO:0000244|PDB:4LL9}.
FT   STRAND      341    350       {ECO:0000244|PDB:4LL9}.
FT   STRAND      353    364       {ECO:0000244|PDB:4LL9}.
FT   STRAND      367    370       {ECO:0000244|PDB:4LL9}.
FT   STRAND      375    386       {ECO:0000244|PDB:4LL9}.
FT   HELIX       389    391       {ECO:0000244|PDB:4LL9}.
FT   STRAND      393    401       {ECO:0000244|PDB:4LL9}.
FT   STRAND      404    408       {ECO:0000244|PDB:4LL9}.
SQ   SEQUENCE   650 AA;  70819 MW;  549196EA4ED2767C CRC64;
     MTPILTVLIC LGLSLGPRTH VQAGHLPKPT LWAEPGSVIT QGSPVTLRCQ GGQETQEYRL
     YREKKTALWI TRIPQELVKK GQFPIPSITW EHAGRYRCYY GSDTAGRSES SDPLELVVTG
     AYIKPTLSAQ PSPVVNSGGN VILQCDSQVA FDGFSLCKEG EDEHPQCLNS QPHARGSSRA
     IFSVGPVSPS RRWWYRCYAY DSNSPYEWSL PSDLLELLVL GVSKKPSLSV QPGPIVAPEE
     TLTLQCGSDA GYNRFVLYKD GERDFLQLAG AQPQAGLSQA NFTLGPVSRS YGGQYRCYGA
     HNLSSEWSAP SDPLDILIAG QFYDRVSLSV QPGPTVASGE NVTLLCQSQG WMQTFLLTKE
     GAADDPWRLR STYQSQKYQA EFPMGPVTSA HAGTYRCYGS QSSKPYLLTH PSDPLELVVS
     GPSGGPSSPT TGPTSTSGPE DQPLTPTGSD PQSGLGRHLG VVIGILVAVI LLLLLLLLLF
     LILRHRRQGK HWTSTQRKAD FQHPAGAVGP EPTDRGLQWR SSPAADAQEE NLYAAVKHTQ
     PEDGVEMDTR SPHDEDPQAV TYAEVKHSRP RREMASPPSP LSGEFLDTKD RQAEEDRQMD
     TEAAASEAPQ DVTYAQLHSL TLRREATEPP PSQEGPSPAV PSIYATLAIH
//
ID   NTRK2_RAT               Reviewed;         821 AA.
AC   Q63604; Q63605; Q63606;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   17-FEB-2016, entry version 153.
DE   RecName: Full=BDNF/NT-3 growth factors receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 2;
DE   AltName: Full=TrkB tyrosine kinase;
DE            Short=Trk-B;
DE   Flags: Precursor;
GN   Name=Ntrk2; Synonyms=Trkb;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Cerebellum;
RX   PubMed=1846020;
RA   Middlemas D.S., Lindberg R.A., Hunter T.;
RT   "trkB, a neural receptor protein-tyrosine kinase: evidence for a full-
RT   length and two truncated receptors.";
RL   Mol. Cell. Biol. 11:143-153(1991).
RN   [2]
RP   FUNCTION IN BDNF AND NTF3 SIGNALING, PHOSPHORYLATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=1645620; DOI=10.1016/0092-8674(91)90396-G;
RA   Soppet D., Escandon E., Maragos J., Middlemas D.S., Reid S.W.,
RA   Blair J., Burton L.E., Stanton B.R., Kaplan D.R., Hunter T.,
RA   Nicolics K., Parada L.F.;
RT   "The neurotrophic factors brain-derived neurotrophic factor and
RT   neurotrophin-3 are ligands for the trkB tyrosine kinase receptor.";
RL   Cell 65:895-903(1991).
RN   [3]
RP   PHOSPHORYLATION AT TYR-701; TYR-705; TYR-706 AND TYR-816.
RX   PubMed=8106527;
RA   Middlemas D.S., Meisenhelder J., Hunter T.;
RT   "Identification of TrkB autophosphorylation sites and evidence that
RT   phospholipase C-gamma 1 is a substrate of the TrkB receptor.";
RL   J. Biol. Chem. 269:5458-5466(1994).
RN   [4]
RP   ALTERNATIVE SPLICING, HOMODIMERIZATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=8627351;
RA   Eide F.F., Vining E.R., Eide B.L., Zang K., Wang X.Y., Reichardt L.F.;
RT   "Naturally occurring truncated trkB receptors have dominant inhibitory
RT   effects on brain-derived neurotrophic factor signaling.";
RL   J. Neurosci. 16:3123-3129(1996).
RN   [5]
RP   INTERACTION WITH SH2B1 AND SH2B2.
RX   PubMed=9856458; DOI=10.1016/S0896-6273(00)80620-0;
RA   Qian X., Riccio A., Zhang Y., Ginty D.D.;
RT   "Identification and characterization of novel substrates of Trk
RT   receptors in developing neurons.";
RL   Neuron 21:1017-1029(1998).
RN   [6]
RP   FUNCTION IN CELL PROLIFERATION, FUNCTION IN PHOSPHORYLATION OF SHC1
RP   AND PLCG1, AUTOPHOSPHORYLATION, INTERACTION WITH SHC1; PLCG1 AND
RP   PLCG2, AND MUTAGENESIS OF LYS-571; TYR-701; TYR-705 AND TYR-706.
RX   PubMed=9582017; DOI=10.1038/sj.onc.1201688;
RA   McCarty J.H., Feinstein S.C.;
RT   "Activation loop tyrosines contribute varying roles to TrkB
RT   autophosphorylation and signal transduction.";
RL   Oncogene 16:1691-1700(1998).
RN   [7]
RP   INTERACTION WITH NGFR.
RX   PubMed=9927421; DOI=10.1093/emboj/18.3.616;
RA   Bibel M., Hoppe E., Barde Y.A.;
RT   "Biochemical and functional interactions between the neurotrophin
RT   receptors trk and p75NTR.";
RL   EMBO J. 18:616-622(1999).
RN   [8]
RP   INTERACTION WITH FRS2.
RX   PubMed=10092678; DOI=10.1074/jbc.274.14.9861;
RA   Meakin S.O., MacDonald J.I.S., Gryz E.A., Kubu C.J., Verdi J.M.;
RT   "The signaling adapter FRS-2 competes with Shc for binding to the
RT   nerve growth factor receptor TrkA. A model for discriminating
RT   proliferation and differentiation.";
RL   J. Biol. Chem. 274:9861-9870(1999).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF FRS2, INTERACTION WITH SHC1, AND
RP   MUTAGENESIS OF TYR-515.
RX   PubMed=10196222; DOI=10.1074/jbc.274.16.11321;
RA   Easton J.B., Moody N.M., Zhu X., Middlemas D.S.;
RT   "Brain-derived neurotrophic factor induces phosphorylation of
RT   fibroblast growth factor receptor substrate 2.";
RL   J. Biol. Chem. 274:11321-11327(1999).
RN   [10]
RP   FUNCTION IN AXONOGENESIS AND NEURON SURVIVAL.
RX   PubMed=10985347; DOI=10.1016/S0896-6273(00)00035-0;
RA   Atwal J.K., Massie B., Miller F.D., Kaplan D.R.;
RT   "The TrkB-Shc site signals neuronal survival and local axon growth via
RT   MEK and P13-kinase.";
RL   Neuron 27:265-277(2000).
RN   [11]
RP   INTERACTION WITH SQSTM1.
RX   PubMed=12471037; DOI=10.1074/jbc.M208468200;
RA   Geetha T., Wooten M.W.;
RT   "Association of the atypical protein kinase C-interacting protein
RT   p62/ZIP with nerve growth factor receptor TrkA regulates receptor
RT   trafficking and Erk5 signaling.";
RL   J. Biol. Chem. 278:4730-4739(2003).
RN   [12]
RP   INTERACTION WITH KIDINS220.
RX   PubMed=15167895; DOI=10.1038/sj.emboj.7600253;
RA   Arevalo J.C., Yano H., Teng K.K., Chao M.V.;
RT   "A unique pathway for sustained neurotrophin signaling through an
RT   ankyrin-rich membrane-spanning protein.";
RL   EMBO J. 23:2358-2368(2004).
RN   [13]
RP   ENZYME REGULATION, INTERACTION WITH SH2D1A, AND MUTAGENESIS OF
RP   TYR-705.
RX   PubMed=16223723; DOI=10.1074/jbc.M506554200;
RA   Lo K.Y., Chin W.H., Ng Y.P., Cheng A.W., Cheung Z.H., Ip N.Y.;
RT   "SLAM-associated protein as a potential negative regulator in Trk
RT   signaling.";
RL   J. Biol. Chem. 280:41744-41752(2005).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in the development and
CC       the maturation of the central and the peripheral nervous systems
CC       through regulation of neuron survival, proliferation, migration,
CC       differentiation, and synapse formation and plasticity. Receptor
CC       for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-
CC       4. Alternatively can also bind NTF3/neurotrophin-3 which is less
CC       efficient in activating the receptor but regulates neuron survival
CC       through NTRK2. Upon ligand-binding, undergoes homodimerization,
CC       autophosphorylation and activation. Recruits, phosphorylates
CC       and/or activates several downstream effectors including SHC1,
CC       FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping
CC       signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the
CC       GRB2-Ras-MAPK cascade that regulates for instance neuronal
CC       differentiation including neurite outgrowth. Through the same
CC       effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that
CC       mainly regulates growth and survival. Through PLCG1 and the
CC       downstream protein kinase C-regulated pathways controls synaptic
CC       plasticity. Thereby, plays a role in learning and memory by
CC       regulating both short term synaptic function and long-term
CC       potentiation. PLCG1 also leads to NF-Kappa-B activation and the
CC       transcription of genes involved in cell survival. Hence, it is
CC       able to suppress anoikis, the apoptosis resulting from loss of
CC       cell-matrix interactions. May also play a role in neutrophin-
CC       dependent calcium signaling in glial cells.
CC       {ECO:0000269|PubMed:10196222, ECO:0000269|PubMed:10985347,
CC       ECO:0000269|PubMed:1645620, ECO:0000269|PubMed:9582017}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: The neuronal activity and the influx of calcium
CC       positively regulate the kinase activity and the internalization of
CC       the receptor which are both important for active signaling.
CC       Regulated by NGFR that may control the internalization of the
CC       receptor. NGFR may also stimulate the activation by BDNF compared
CC       to NTF3 and NTF4. SH2D1A inhibits the autophosphorylation of the
CC       receptor, and alters the recruitment and activation of downstream
CC       effectors and signaling cascades. The formation of active
CC       receptors dimers able to fully transduce the ligand-mediated
CC       signal, may be negatively regulated by the formation of inactive
CC       heterodimers with the non-catalytic isoforms.
CC       {ECO:0000269|PubMed:16223723}.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures. Interacts
CC       (phosphorylated upon activation by BDNF) with SHC1; mediates SHC1
CC       phosphorylation and activation. Interacts (phosphorylated upon
CC       activation by BDNF) with PLCG1 and/or PLCG2; mediates PLCG1
CC       phosphorylation and activation. Interacts with SH2B1 and SH2B2.
CC       Interacts with NGFR; may regulate the ligand specificity of the
CC       receptor. Interacts (phosphorylated upon ligand-binding) with
CC       SH2D1A; regulates NTRK2. Interacts with SQSTM1 and KIDINS220.
CC       Interacts (phosphorylated upon ligand-binding) with FRS2;
CC       activates the MAPK signaling pathway.
CC       {ECO:0000269|PubMed:10092678, ECO:0000269|PubMed:10196222,
CC       ECO:0000269|PubMed:12471037, ECO:0000269|PubMed:15167895,
CC       ECO:0000269|PubMed:16223723, ECO:0000269|PubMed:9582017,
CC       ECO:0000269|PubMed:9856458, ECO:0000269|PubMed:9927421}.
CC   -!- INTERACTION:
CC       Q8K4V6:Pirb (xeno); NbExp=3; IntAct=EBI-7287667, EBI-8602514;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1645620};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:1645620}.
CC       Endosome membrane {ECO:0000250}; Single-pass type I membrane
CC       protein {ECO:0000250}. Note=Internalized to endosomes upon ligand-
CC       binding. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=GP145-TrkB;
CC         IsoId=Q63604-1; Sequence=Displayed;
CC       Name=T1; Synonyms=GP95-TrkB;
CC         IsoId=Q63604-2; Sequence=VSP_002910, VSP_002911;
CC         Note=Non-catalytic isoform.;
CC       Name=T2;
CC         IsoId=Q63604-3; Sequence=VSP_002912, VSP_002913;
CC         Note=Non-catalytic isoform.;
CC   -!- TISSUE SPECIFICITY: Widely expressed in the central and peripheral
CC       nervous system. The different forms are differentially expressed
CC       in various cell types. Isoform T2 is primarily expressed in
CC       neurons.
CC   -!- PTM: Phosphorylated. Undergoes ligand-mediated autophosphorylation
CC       that is required for interaction with SHC1 and PLCG1 and other
CC       downstream effectors. Some isoforms are not phosphorylated.
CC       {ECO:0000269|PubMed:1645620, ECO:0000269|PubMed:8106527}.
CC   -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation;
CC       regulated by NGFR. Ubiquitination regulates the internalization of
CC       the receptor (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRCT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRNT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M55291; AAA42279.1; -; mRNA.
DR   EMBL; M55292; AAA42280.1; -; mRNA.
DR   EMBL; M55293; AAA42281.1; -; mRNA.
DR   PIR; A39667; A39667.
DR   PIR; B39667; B39667.
DR   PIR; C39667; C39667.
DR   RefSeq; NP_001156640.1; NM_001163168.2. [Q63604-2]
DR   RefSeq; NP_036863.1; NM_012731.2. [Q63604-1]
DR   UniGene; Rn.11246; -.
DR   ProteinModelPortal; Q63604; -.
DR   SMR; Q63604; 283-385.
DR   BioGrid; 247131; 6.
DR   DIP; DIP-5717N; -.
DR   IntAct; Q63604; 4.
DR   MINT; MINT-1204365; -.
DR   STRING; 10116.ENSRNOP00000045635; -.
DR   ChEMBL; CHEMBL1795111; -.
DR   iPTMnet; Q63604; -.
DR   PhosphoSite; Q63604; -.
DR   UniCarbKB; Q63604; -.
DR   PaxDb; Q63604; -.
DR   PRIDE; Q63604; -.
DR   Ensembl; ENSRNOT00000042145; ENSRNOP00000045635; ENSRNOG00000018839. [Q63604-1]
DR   Ensembl; ENSRNOT00000090914; ENSRNOP00000070128; ENSRNOG00000018839. [Q63604-2]
DR   GeneID; 25054; -.
DR   KEGG; rno:25054; -.
DR   UCSC; RGD:3213; rat. [Q63604-1]
DR   CTD; 4915; -.
DR   RGD; 3213; Ntrk2.
DR   eggNOG; KOG1026; Eukaryota.
DR   eggNOG; ENOG410YGKQ; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000264255; -.
DR   HOVERGEN; HBG056735; -.
DR   InParanoid; Q63604; -.
DR   KO; K04360; -.
DR   OMA; CSCEIMW; -.
DR   OrthoDB; EOG7QG43C; -.
DR   PhylomeDB; Q63604; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 5301.
DR   NextBio; 605258; -.
DR   PRO; PR:Q63604; -.
DR   Proteomes; UP000002494; Chromosome 17.
DR   ExpressionAtlas; Q63604; baseline and differential.
DR   Genevisible; Q63604; RN.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0043679; C:axon terminus; IDA:RGD.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0043197; C:dendritic spine; IDA:RGD.
DR   GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0060076; C:excitatory synapse; IDA:RGD.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0030426; C:growth cone; IDA:RGD.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0043204; C:perikaryon; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:RGD.
DR   GO; GO:0014069; C:postsynaptic density; IDA:RGD.
DR   GO; GO:0048786; C:presynaptic active zone; IDA:RGD.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0048403; F:brain-derived neurotrophic factor binding; IDA:UniProtKB.
DR   GO; GO:0060175; F:brain-derived neurotrophic factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0043121; F:neurotrophin binding; IDA:UniProtKB.
DR   GO; GO:0005030; F:neurotrophin receptor activity; IDA:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:RGD.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IMP:RGD.
DR   GO; GO:0007568; P:aging; IEP:RGD.
DR   GO; GO:0031547; P:brain-derived neurotrophic factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; IEP:RGD.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEP:RGD.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:RGD.
DR   GO; GO:0021954; P:central nervous system neuron development; ISS:UniProtKB.
DR   GO; GO:0021987; P:cerebral cortex development; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEP:RGD.
DR   GO; GO:0007612; P:learning; ISS:UniProtKB.
DR   GO; GO:0007616; P:long-term memory; IDA:RGD.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:UniProtKB.
DR   GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; ISS:UniProtKB.
DR   GO; GO:0038179; P:neurotrophin signaling pathway; IDA:GOC.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IMP:GOC.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:2000324; P:positive regulation of glucocorticoid receptor signaling pathway; IGI:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IMP:RGD.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0050773; P:regulation of dendrite development; IMP:RGD.
DR   GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0046928; P:regulation of neurotransmitter secretion; IDA:RGD.
DR   GO; GO:0010996; P:response to auditory stimulus; IEP:RGD.
DR   GO; GO:0009416; P:response to light stimulus; IEP:RGD.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR000372; LRRNT.
DR   InterPro; IPR031635; NTRK_C2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR020455; Tyr_kin_neurotrophic_rcpt_2.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR020777; Tyr_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF16920; TPKR_C2; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01941; NTKRECEPTOR2.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00013; LRRNT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF52058; SSF52058; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Developmental protein; Differentiation; Disulfide bond; Endosome;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Leucine-rich repeat;
KW   Membrane; Neurogenesis; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     31       {ECO:0000250}.
FT   CHAIN        32    821       BDNF/NT-3 growth factors receptor.
FT                                /FTId=PRO_0000016729.
FT   TOPO_DOM     32    429       Extracellular. {ECO:0000255}.
FT   TRANSMEM    430    453       Helical. {ECO:0000255}.
FT   TOPO_DOM    454    821       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       32     61       LRRNT.
FT   REPEAT       92    113       LRR 1.
FT   REPEAT      116    137       LRR 2.
FT   DOMAIN      148    196       LRRCT.
FT   DOMAIN      197    282       Ig-like C2-type 1.
FT   DOMAIN      295    365       Ig-like C2-type 2.
FT   DOMAIN      537    806       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     543    551       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    675    675       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     571    571       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        515    515       Interaction with SHC1.
FT   SITE        705    705       Interaction with SH2D1A.
FT   SITE        816    816       Interaction with PLCG1. {ECO:0000250}.
FT   MOD_RES     515    515       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     701    701       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8106527}.
FT   MOD_RES     705    705       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8106527}.
FT   MOD_RES     706    706       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8106527}.
FT   MOD_RES     816    816       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8106527}.
FT   CARBOHYD     67     67       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD     95     95       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    178    178       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    205    205       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    241    241       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    254    254       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    280    280       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    325    325       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    338    338       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...). {ECO:0000250}.
FT   DISULFID     32     38       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID     36     45       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    152    176       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    154    194       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    218    266       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    302    345       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     466    476       PASVISNDDDS -> FVLFHKIPLDG (in isoform
FT                                T1). {ECO:0000305}.
FT                                /FTId=VSP_002910.
FT   VAR_SEQ     466    474       PASVISNDD -> KQKCAYFAS (in isoform T2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_002912.
FT   VAR_SEQ     475    821       Missing (in isoform T2). {ECO:0000305}.
FT                                /FTId=VSP_002913.
FT   VAR_SEQ     477    821       Missing (in isoform T1). {ECO:0000305}.
FT                                /FTId=VSP_002911.
FT   MUTAGEN     515    515       Y->F: Loss of interaction with SHC1.
FT                                {ECO:0000269|PubMed:10196222}.
FT   MUTAGEN     571    571       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:9582017}.
FT   MUTAGEN     701    701       Y->F: Loss of autophosphorylation and
FT                                altered interaction with SHC1 and PLCG1;
FT                                when associated with F-705 and F-706.
FT                                {ECO:0000269|PubMed:9582017}.
FT   MUTAGEN     705    705       Y->F: Loss of autophosphorylation; when
FT                                associated with F-701 and F-706.
FT                                {ECO:0000269|PubMed:16223723,
FT                                ECO:0000269|PubMed:9582017}.
FT   MUTAGEN     706    706       Y->F: Loss of autophosphorylation; when
FT                                associated with F-701 and F-705.
FT                                {ECO:0000269|PubMed:9582017}.
SQ   SEQUENCE   821 AA;  92186 MW;  0DDACDA212CDAA0E CRC64;
     MSPWPRWHGP AMARLWGLCL LVLGFWRASL ACPMSCKCST TRIWCTEPSP GIVAFPRLEP
     NSIDPENITE ILIANQKRLE IINEDDVEAY VGLKNLTIVD SGLKFVAYKA FLKNGNLRHI
     NFTRNKLTSL SRRHFRHLDL SDLILTGNPF TCSCDIMWLK TLQETKSSPD TQDLYCLNES
     SKNTPLANLQ IPNCGLPSAR LAAPNLTVEE GKSVTISCSV GGDPLPTLYW DVGNLVSKHM
     NETSHTQGSL RITNISSDDS GKQISCVAEN LVGEDQDSVN LTVHFAPTIT FLESPTSDHH
     WCIPFTVRGN PKPALQWFYN GAILNESKYI CTKIHVTNHT EYHGCLQLDN PTHMNNGDYT
     LMAKNEYGKD ERQISAHFMG RPGVDYETNP NYPEVLYEDW TTPTDIGDTT NKSNEIPSTD
     VADQTNREHL SVYAVVVIAS VVGFCLLVML LLLKLARHSK FGMKGPASVI SNDDDSASPL
     HHISNGSNTP SSSEGGPDAV IIGMTKIPVI ENPQYFGITN SQLKPDTFVQ HIKRHNIVLK
     RELGEGAFGK VFLAECYNLC PEQDKILVAV KTLKDASDNA RKDFHREAEL LTNLQHEHIV
     KFYGVCVEGD PLIMVFEYMK HGDLNKFLRA HGPDAVLMAE GNPPTELTQS QMLHIAQQIA
     AGMVYLASQH FVHRDLATRN CLVGENLLVK IGDFGMSRDV YSTDYYRVGG HTMLPIRWMP
     PESIMYRKFT TESDVWSLGV VLWEIFTYGK QPWYQLSNNE VIECITQGRV LQRPRTCPQE
     VYELMLGCWQ REPHTRKNIK NIHTLLQNLA KASPVYLDIL G
//
ID   ERN1_HUMAN              Reviewed;         977 AA.
AC   O75460; A1L457; A8K8N8; A8MXS7; Q59EE2;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-2008, sequence version 2.
DT   17-FEB-2016, entry version 156.
DE   RecName: Full=Serine/threonine-protein kinase/endoribonuclease IRE1;
DE   AltName: Full=Endoplasmic reticulum-to-nucleus signaling 1;
DE   AltName: Full=Inositol-requiring protein 1;
DE            Short=hIRE1p;
DE   AltName: Full=Ire1-alpha;
DE            Short=IRE1a;
DE   Includes:
DE     RecName: Full=Serine/threonine-protein kinase;
DE              EC=2.7.11.1;
DE   Includes:
DE     RecName: Full=Endoribonuclease;
DE              EC=3.1.26.-;
DE   Flags: Precursor;
GN   Name=ERN1 {ECO:0000312|HGNC:HGNC:3449};
GN   Synonyms=IRE1 {ECO:0000312|EMBL:AAC25991.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAC25991.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ENZYME REGULATION,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AUTOPHOSPHORYLATION,
RP   GLYCOSYLATION, AND MUTAGENESIS OF LYS-599.
RC   TISSUE=Liver {ECO:0000312|EMBL:AAC25991.1};
RX   PubMed=9637683; DOI=10.1101/gad.12.12.1812;
RA   Tirasophon W., Welihinda A.A., Kaufman R.J.;
RT   "A stress response pathway from the endoplasmic reticulum to the
RT   nucleus requires a novel bifunctional protein kinase/endoribonuclease
RT   (Ire1p) in mammalian cells.";
RL   Genes Dev. 12:1812-1824(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Endothelial cell;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 2-977 (ISOFORM 2).
RC   TISSUE=Brain, and Leukocyte;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH TAOK3 AND TRAF2.
RX   PubMed=11278723; DOI=10.1074/jbc.M010677200;
RA   Yoneda T., Imaizumi K., Oono K., Yui D., Gomi F., Katayama T.,
RA   Tohyama M.;
RT   "Activation of caspase-12, an endoplastic reticulum (ER) resident
RT   caspase, through tumor necrosis factor receptor-associated factor 2-
RT   dependent mechanism in response to the ER stress.";
RL   J. Biol. Chem. 276:13935-13940(2001).
RN   [8] {ECO:0000305}
RP   FUNCTION, AND MUTAGENESIS OF LYS-599.
RX   PubMed=11175748; DOI=10.1038/35055065;
RA   Iwawaki T., Hosoda A., Okuda T., Kamigori Y., Nomura-Furuwatari C.,
RA   Kimata Y., Tsuru A., Kohno K.;
RT   "Translational control by the ER transmembrane kinase/ribonuclease
RT   IRE1 under ER stress.";
RL   Nat. Cell Biol. 3:158-164(2001).
RN   [9] {ECO:0000305}
RP   FUNCTION, HOMODIMERIZATION, ENZYME REGULATION, INTERACTION WITH HSPA5,
RP   AND MUTAGENESIS OF CYS-109; CYS-148 AND CYS-332.
RX   PubMed=12637535; DOI=10.1074/jbc.M300418200;
RA   Liu C.Y., Xu Z., Kaufman R.J.;
RT   "Structure and intermolecular interactions of the luminal dimerization
RT   domain of human IRE1alpha.";
RL   J. Biol. Chem. 278:17680-17687(2003).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-973, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   ADP-RIBOSYLATION BY PARP16.
RX   PubMed=23103912; DOI=10.1038/ncb2593;
RA   Jwa M., Chang P.;
RT   "PARP16 is a tail-anchored endoplasmic reticulum protein required for
RT   the PERK-and IRE1alpha-mediated unfolded protein response.";
RL   Nat. Cell Biol. 14:1223-1230(2012).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 24-390.
RX   PubMed=16973740; DOI=10.1073/pnas.0606480103;
RA   Zhou J., Liu C.Y., Back S.H., Clark R.L., Peisach D., Xu Z.,
RA   Kaufman R.J.;
RT   "The crystal structure of human IRE1 luminal domain reveals a
RT   conserved dimerization interface required for activation of the
RT   unfolded protein response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:14343-14348(2006).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-244; MET-418; ARG-474; TRP-635;
RP   SER-700; PHE-769 AND LEU-830.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Senses unfolded proteins in the lumen of the endoplasmic
CC       reticulum via its N-terminal domain which leads to enzyme auto-
CC       activation. The active endoribonuclease domain splices XBP1 mRNA
CC       to generate a new C-terminus, converting it into a potent
CC       unfolded-protein response transcriptional activator and triggering
CC       growth arrest and apoptosis. {ECO:0000250|UniProtKB:Q9EQY0,
CC       ECO:0000269|PubMed:11175748, ECO:0000269|PubMed:12637535,
CC       ECO:0000269|PubMed:9637683}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:9637683}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: The kinase domain is activated by trans-
CC       autophosphorylation. Kinase activity is required for activation of
CC       the endoribonuclease domain. {ECO:0000269|PubMed:12637535,
CC       ECO:0000269|PubMed:9637683}.
CC   -!- SUBUNIT: Interacts with DAB2IP (via PH domain); the interaction
CC       occurs in a ER stress-induced dependent manner and is required for
CC       subsequent recruitment of TRAF2 to ERN1 (By similarity).
CC       Homodimer; disulfide-linked. Dimer formation is driven by
CC       hydrophobic interactions within the N-terminal luminal domains and
CC       stabilized by disulfide bridges. Also binds HSPA5, a negative
CC       regulator of the unfolded protein response. This interaction may
CC       disrupt homodimerization and prevent activation of ERN1. Interacts
CC       with TAOK3 and TRAF2. {ECO:0000250, ECO:0000269|PubMed:11278723,
CC       ECO:0000269|PubMed:12637535}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-371750, EBI-371750;
CC       O08734:Bak1 (xeno); NbExp=2; IntAct=EBI-371750, EBI-822441;
CC       Q07812:BAX; NbExp=2; IntAct=EBI-371750, EBI-516580;
CC       Q07813:Bax (xeno); NbExp=2; IntAct=EBI-371750, EBI-700711;
CC       P20029:Hspa5 (xeno); NbExp=2; IntAct=EBI-371750, EBI-772325;
CC       Q86TM6:SYVN1; NbExp=2; IntAct=EBI-371750, EBI-947849;
CC       Q9H2K8:TAOK3; NbExp=3; IntAct=EBI-371750, EBI-1384100;
CC       Q12933:TRAF2; NbExp=3; IntAct=EBI-371750, EBI-355744;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:9637683}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:9637683}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O75460-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75460-2; Sequence=VSP_034582, VSP_034583;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. High levels observed
CC       in pancreatic tissue. {ECO:0000269|PubMed:9637683}.
CC   -!- PTM: Autophosphorylated. {ECO:0000269|PubMed:9637683}.
CC   -!- PTM: ADP-ribosylated by PARP16 upon ER stress, which increases
CC       both kinase and endonuclease activities.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 KEN domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00725}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF059198; AAC25991.1; -; mRNA.
DR   EMBL; AK292403; BAF85092.1; -; mRNA.
DR   EMBL; DA254477; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AB209869; BAD93106.1; -; mRNA.
DR   EMBL; AC005803; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025362; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471109; EAW94214.1; -; Genomic_DNA.
DR   EMBL; BC130405; AAI30406.1; -; mRNA.
DR   EMBL; BC130407; AAI30408.1; -; mRNA.
DR   EMBL; BI912495; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS45762.1; -. [O75460-1]
DR   RefSeq; NP_001424.3; NM_001433.3. [O75460-1]
DR   UniGene; Hs.133982; -.
DR   UniGene; Hs.700027; -.
DR   UniGene; Hs.744953; -.
DR   PDB; 2HZ6; X-ray; 3.10 A; A=24-390.
DR   PDB; 3P23; X-ray; 2.70 A; A/B/C/D=547-977.
DR   PDB; 4U6R; X-ray; 2.50 A; A=547-977.
DR   PDB; 4YZ9; X-ray; 2.46 A; A/B/C=562-966.
DR   PDB; 4YZC; X-ray; 2.49 A; A/B=562-966.
DR   PDB; 4YZD; X-ray; 3.10 A; A/B/C=562-966.
DR   PDB; 4Z7G; X-ray; 2.60 A; A/B=562-977.
DR   PDB; 4Z7H; X-ray; 2.90 A; A/B=562-977.
DR   PDBsum; 2HZ6; -.
DR   PDBsum; 3P23; -.
DR   PDBsum; 4U6R; -.
DR   PDBsum; 4YZ9; -.
DR   PDBsum; 4YZC; -.
DR   PDBsum; 4YZD; -.
DR   PDBsum; 4Z7G; -.
DR   PDBsum; 4Z7H; -.
DR   ProteinModelPortal; O75460; -.
DR   SMR; O75460; 29-368, 561-963.
DR   BioGrid; 108391; 26.
DR   DIP; DIP-31711N; -.
DR   IntAct; O75460; 11.
DR   MINT; MINT-3001268; -.
DR   STRING; 9606.ENSP00000401445; -.
DR   BindingDB; O75460; -.
DR   ChEMBL; CHEMBL1163101; -.
DR   GuidetoPHARMACOLOGY; 2020; -.
DR   iPTMnet; O75460; -.
DR   PhosphoSite; O75460; -.
DR   BioMuta; ERN1; -.
DR   MaxQB; O75460; -.
DR   PaxDb; O75460; -.
DR   PRIDE; O75460; -.
DR   DNASU; 2081; -.
DR   Ensembl; ENST00000433197; ENSP00000401445; ENSG00000178607. [O75460-1]
DR   Ensembl; ENST00000606895; ENSP00000475519; ENSG00000178607. [O75460-2]
DR   GeneID; 2081; -.
DR   KEGG; hsa:2081; -.
DR   UCSC; uc002jdz.2; human. [O75460-1]
DR   CTD; 2081; -.
DR   GeneCards; ERN1; -.
DR   H-InvDB; HIX0014084; -.
DR   HGNC; HGNC:3449; ERN1.
DR   HPA; CAB009495; -.
DR   HPA; HPA027730; -.
DR   MIM; 604033; gene.
DR   neXtProt; NX_O75460; -.
DR   PharmGKB; PA27861; -.
DR   eggNOG; KOG1027; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00390000015684; -.
DR   HOGENOM; HOG000012929; -.
DR   HOVERGEN; HBG051506; -.
DR   InParanoid; O75460; -.
DR   KO; K08852; -.
DR   OMA; SEDCKDN; -.
DR   OrthoDB; EOG7C2R0H; -.
DR   PhylomeDB; O75460; -.
DR   TreeFam; TF313986; -.
DR   Reactome; R-HSA-381070; IRE1alpha activates chaperones.
DR   SignaLink; O75460; -.
DR   ChiTaRS; ERN1; human.
DR   EvolutionaryTrace; O75460; -.
DR   GeneWiki; ERN1; -.
DR   GenomeRNAi; 2081; -.
DR   NextBio; 8459; -.
DR   PRO; PR:O75460; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; O75460; -.
DR   CleanEx; HS_ERN1; -.
DR   Genevisible; O75460; HS.
DR   GO; GO:1990597; C:AIP1-IRE1 complex; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:1990332; C:Ire1 complex; NAS:ParkinsonsUK-UCL.
DR   GO; GO:1990630; C:IRE1-RACK1-PP2A complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1990604; C:IRE1-TRAF2-ASK1 complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005637; C:nuclear inner membrane; IEA:Ensembl.
DR   GO; GO:0043531; F:ADP binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0004521; F:endoribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0030544; F:Hsp70 protein binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0051879; F:Hsp90 protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007257; P:activation of JUN kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006987; P:activation of signaling protein activity involved in unfolded protein response; IDA:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; ISS:UniProtKB.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; TAS:Reactome.
DR   GO; GO:0001935; P:endothelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:1901142; P:insulin metabolic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:0036498; P:IRE1-mediated unfolded protein response; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006402; P:mRNA catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0006379; P:mRNA cleavage; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070055; P:mRNA endonucleolytic cleavage involved in unfolded protein response; IDA:WormBase.
DR   GO; GO:0070054; P:mRNA splicing, via endonucleolytic cleavage and ligation; IDA:UniProtKB.
DR   GO; GO:0036289; P:peptidyl-serine autophosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1990579; P:peptidyl-serine trans-autophosphorylation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1900103; P:positive regulation of endoplasmic reticulum unfolded protein response; IMP:UniProtKB.
DR   GO; GO:0033120; P:positive regulation of RNA splicing; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0016241; P:regulation of macroautophagy; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0090502; P:RNA phosphodiester bond hydrolysis, endonucleolytic; IDA:GOC.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 2.140.10.10; -; 1.
DR   InterPro; IPR010513; KEN_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR018391; PQQ_beta_propeller_repeat.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR006567; PUG-dom.
DR   InterPro; IPR027295; Quinoprotein_ADH-like_fam.
DR   InterPro; IPR011047; Quinoprotein_ADH-like_supfam.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF06479; Ribonuc_2-5A; 1.
DR   SMART; SM00564; PQQ; 5.
DR   SMART; SM00580; PUG; 1.
DR   SUPFAM; SSF50998; SSF50998; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51392; KEN; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Complete proteome; Disulfide bond; Endoplasmic reticulum;
KW   Glycoprotein; Hydrolase; Kinase; Magnesium; Membrane; Metal-binding;
KW   Multifunctional enzyme; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Signal; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Transmembrane helix; Unfolded protein response.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    977       Serine/threonine-protein
FT                                kinase/endoribonuclease IRE1.
FT                                /FTId=PRO_0000024327.
FT   TOPO_DOM     19    443       Lumenal. {ECO:0000255}.
FT   TRANSMEM    444    464       Helical. {ECO:0000255}.
FT   TOPO_DOM    465    977       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      571    832       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      835    963       KEN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00725}.
FT   NP_BIND     577    585       ATP. {ECO:0000250|UniProtKB:P32361,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   ACT_SITE    688    688       Proton acceptor.
FT                                {ECO:0000250|UniProtKB:P32361,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159,
FT                                ECO:0000255|PROSITE-ProRule:PRU10027}.
FT   BINDING     599    599       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:9637683}.
FT   MOD_RES     973    973       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   CARBOHYD    176    176       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ      19     70       IFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKED
FT                                PVLQVPTHVEE -> VSDRGAWGGGQLATAGSGPGQRRGAG
FT                                AGVRAGSATAAARCPVSPAVGGSGRA (in isoform
FT                                2). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_034582.
FT   VAR_SEQ      71    977       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_034583.
FT   VARIANT     244    244       N -> S (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040488.
FT   VARIANT     418    418       V -> M (in dbSNP:rs55869215).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040489.
FT   VARIANT     474    474       L -> R (in a lung adenocarcinoma sample;
FT                                somatic mutation; dbSNP:rs186305118).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040490.
FT   VARIANT     635    635       R -> W (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040491.
FT   VARIANT     700    700       N -> S. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040492.
FT   VARIANT     769    769       S -> F (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040493.
FT   VARIANT     830    830       P -> L (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040494.
FT   MUTAGEN     109    109       C->S: No effect on dimerization.
FT                                {ECO:0000269|PubMed:12637535}.
FT   MUTAGEN     148    148       C->S: No effect on dimerization. Weakens
FT                                dimer; when associated with S-148.
FT                                {ECO:0000269|PubMed:12637535}.
FT   MUTAGEN     332    332       C->S: No effect on dimerization. Weakens
FT                                dimer; when associated with S-332.
FT                                {ECO:0000269|PubMed:12637535}.
FT   MUTAGEN     599    599       K->A: Loss of autophosphorylation and of
FT                                endoribonuclease activity. Inhibition of
FT                                growth arrest.
FT                                {ECO:0000269|PubMed:11175748,
FT                                ECO:0000269|PubMed:9637683}.
FT   CONFLICT    190    191       DV -> EG (in Ref. 1; AAC25991).
FT                                {ECO:0000305}.
FT   CONFLICT    768    768       I -> V (in Ref. 1; AAC25991).
FT                                {ECO:0000305}.
FT   CONFLICT    816    816       D -> G (in Ref. 2; BAF85092).
FT                                {ECO:0000305}.
FT   CONFLICT    824    825       KH -> ND (in Ref. 1; AAC25991).
FT                                {ECO:0000305}.
FT   CONFLICT    880    880       V -> D (in Ref. 1; AAC25991).
FT                                {ECO:0000305}.
FT   CONFLICT    904    904       M -> T (in Ref. 2; BAF85092).
FT                                {ECO:0000305}.
FT   CONFLICT    924    924       S -> T (in Ref. 1; AAC25991).
FT                                {ECO:0000305}.
FT   STRAND       32     37       {ECO:0000244|PDB:2HZ6}.
FT   STRAND       40     46       {ECO:0000244|PDB:2HZ6}.
FT   TURN         47     49       {ECO:0000244|PDB:2HZ6}.
FT   STRAND       52     57       {ECO:0000244|PDB:2HZ6}.
FT   STRAND       73     75       {ECO:0000244|PDB:2HZ6}.
FT   TURN         77     79       {ECO:0000244|PDB:2HZ6}.
FT   STRAND       82     84       {ECO:0000244|PDB:2HZ6}.
FT   STRAND       93     95       {ECO:0000244|PDB:2HZ6}.
FT   HELIX       100    104       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      120    128       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      154    164       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      168    172       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      176    182       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      197    201       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      205    209       {ECO:0000244|PDB:2HZ6}.
FT   TURN        211    213       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      216    221       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      226    231       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      238    240       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      243    246       {ECO:0000244|PDB:2HZ6}.
FT   HELIX       247    264       {ECO:0000244|PDB:2HZ6}.
FT   HELIX       273    279       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      280    284       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      286    288       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      297    300       {ECO:0000244|PDB:2HZ6}.
FT   TURN        359    361       {ECO:0000244|PDB:2HZ6}.
FT   STRAND      564    566       {ECO:0000244|PDB:4YZC}.
FT   STRAND      567    580       {ECO:0000244|PDB:4YZ9}.
FT   TURN        581    583       {ECO:0000244|PDB:4YZ9}.
FT   STRAND      584    591       {ECO:0000244|PDB:4YZ9}.
FT   STRAND      594    601       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       603    605       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       606    617       {ECO:0000244|PDB:4YZ9}.
FT   STRAND      628    633       {ECO:0000244|PDB:4YZ9}.
FT   STRAND      638    642       {ECO:0000244|PDB:4YZ9}.
FT   STRAND      645    648       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       649    655       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       657    661       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       665    681       {ECO:0000244|PDB:4YZ9}.
FT   TURN        691    693       {ECO:0000244|PDB:4YZ9}.
FT   STRAND      694    697       {ECO:0000244|PDB:4YZ9}.
FT   TURN        701    703       {ECO:0000244|PDB:4YZD}.
FT   STRAND      707    709       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       712    714       {ECO:0000244|PDB:4YZC}.
FT   HELIX       740    743       {ECO:0000244|PDB:4YZC}.
FT   HELIX       754    768       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       778    780       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       781    787       {ECO:0000244|PDB:4YZ9}.
FT   STRAND      793    795       {ECO:0000244|PDB:4YZC}.
FT   HELIX       800    812       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       817    819       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       823    827       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       830    832       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       835    849       {ECO:0000244|PDB:4YZ9}.
FT   STRAND      854    856       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       857    865       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       867    870       {ECO:0000244|PDB:4YZ9}.
FT   STRAND      874    878       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       880    887       {ECO:0000244|PDB:4YZ9}.
FT   STRAND      888    890       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       897    909       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       911    913       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       916    922       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       927    936       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       940    947       {ECO:0000244|PDB:4YZ9}.
FT   HELIX       948    951       {ECO:0000244|PDB:4YZ9}.
FT   STRAND      952    954       {ECO:0000244|PDB:3P23}.
FT   HELIX       955    957       {ECO:0000244|PDB:4YZ9}.
FT   TURN        958    960       {ECO:0000244|PDB:4YZ9}.
SQ   SEQUENCE   977 AA;  109735 MW;  A2DF808CCE015536 CRC64;
     MPARRLLLLL TLLLPGLGIF GSTSTVTLPE TLLFVSTLDG SLHAVSKRTG SIKWTLKEDP
     VLQVPTHVEE PAFLPDPNDG SLYTLGSKNN EGLTKLPFTI PELVQASPCR SSDGILYMGK
     KQDIWYVIDL LTGEKQQTLS SAFADSLCPS TSLLYLGRTE YTITMYDTKT RELRWNATYF
     DYAASLPEDD VDYKMSHFVS NGDGLVVTVD SESGDVLWIQ NYASPVVAFY VWQREGLRKV
     MHINVAVETL RYLTFMSGEV GRITKWKYPF PKETEAKSKL TPTLYVGKYS TSLYASPSMV
     HEGVAVVPRG STLPLLEGPQ TDGVTIGDKG ECVITPSTDV KFDPGLKSKN KLNYLRNYWL
     LIGHHETPLS ASTKMLERFP NNLPKHRENV IPADSEKKSF EEVINLVDQT SENAPTTVSR
     DVEEKPAHAP ARPEAPVDSM LKDMATIILS TFLLIGWVAF IITYPLSMHQ QQQLQHQQFQ
     KELEKIQLLQ QQQQQLPFHP PGDTAQDGEL LDTSGPYSES SGTSSPSTSP RASNHSLCSG
     SSASKAGSSP SLEQDDGDEE TSVVIVGKIS FCPKDVLGHG AEGTIVYRGM FDNRDVAVKR
     ILPECFSFAD REVQLLRESD EHPNVIRYFC TEKDRQFQYI AIELCAATLQ EYVEQKDFAH
     LGLEPITLLQ QTTSGLAHLH SLNIVHRDLK PHNILISMPN AHGKIKAMIS DFGLCKKLAV
     GRHSFSRRSG VPGTEGWIAP EMLSEDCKEN PTYTVDIFSA GCVFYYVISE GSHPFGKSLQ
     RQANILLGAC SLDCLHPEKH EDVIARELIE KMIAMDPQKR PSAKHVLKHP FFWSLEKQLQ
     FFQDVSDRIE KESLDGPIVK QLERGGRAVV KMDWRENITV PLQTDLRKFR TYKGGSVRDL
     LRAMRNKKHH YRELPAEVRE TLGSLPDDFV CYFTSRFPHL LAHTYRAMEL CSHERLFQPY
     YFHEPPEPQP PVTPDAL
//
ID   EGFR_MOUSE              Reviewed;        1210 AA.
AC   Q01279;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   17-FEB-2016, entry version 181.
DE   RecName: Full=Epidermal growth factor receptor;
DE            EC=2.7.10.1;
DE   Flags: Precursor;
GN   Name=Egfr;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/cJ; TISSUE=Liver;
RX   PubMed=1408137;
RA   Avivi A., Skorecki K., Yayon A., Givol D.;
RT   "Promoter region of the murine fibroblast growth factor receptor 2
RT   (bek/KGFR) gene.";
RL   Oncogene 7:1957-1962(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/cJ, and CD-1; TISSUE=Decidua, and Liver;
RX   PubMed=7678348; DOI=10.1073/pnas.90.1.55;
RA   Paria B.C., Das S.K., Andrews G.K., Dey S.K.;
RT   "Expression of the epidermal growth factor receptor gene is regulated
RT   in mouse blastocysts during delayed implantation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:55-59(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/cJ; TISSUE=Liver;
RA   Hibbs M.L.;
RL   Submitted (APR-1994) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=B6/C3; TISSUE=Liver;
RX   PubMed=8125255; DOI=10.1101/gad.8.4.399;
RA   Luetteke N.C., Phillips H.K., Qiu T.H., Copeland N.G., Earp H.S.,
RA   Jenkins N.A., Lee D.C.;
RT   "The mouse waved-2 phenotype results from a point mutation in the EGF
RT   receptor tyrosine kinase.";
RL   Genes Dev. 8:399-413(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-714.
RC   TISSUE=Brain;
RX   PubMed=2030916;
RA   Avivi A., Lax I., Ullrich A., Schlessinger J., Givol D., Morse B.;
RT   "Comparison of EGF receptor sequences as a guide to study the ligand
RT   binding site.";
RL   Oncogene 6:673-676(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 969-1117.
RC   STRAIN=C3H/HeJ;
RA   Eisinger D.P., Serrero G.;
RL   Submitted (JUN-1992) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   FUNCTION IN CELL GROWTH, FUNCTION IN PHOSPHORYLATION OF EPS8, AND
RP   INTERACTION WITH EPS8.
RX   PubMed=8404850;
RA   Fazioli F., Minichiello L., Matoska V., Castagnino P., Miki T.,
RA   Wong W.T., di Fiore P.P.;
RT   "Eps8, a substrate for the epidermal growth factor receptor kinase,
RT   enhances EGF-dependent mitogenic signals.";
RL   EMBO J. 12:3799-3808(1993).
RN   [8]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=7630400; DOI=10.1038/376337a0;
RA   Miettinen P.J., Berger J.E., Meneses J., Phung Y., Pedersen R.A.,
RA   Werb Z., Derynck R.;
RT   "Epithelial immaturity and multiorgan failure in mice lacking
RT   epidermal growth factor receptor.";
RL   Nature 376:337-341(1995).
RN   [9]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=7618084; DOI=10.1126/science.7618084;
RA   Threadgill D.W., Dlugosz A.A., Hansen L.A., Tennenbaum T., Lichti U.,
RA   Yee D., LaMantia C., Mourton T., Herrup K., Harris R.C.;
RT   "Targeted disruption of mouse EGF receptor: effect of genetic
RT   background on mutant phenotype.";
RL   Science 269:230-234(1995).
RN   [10]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=7618085; DOI=10.1126/science.7618085;
RA   Sibilia M., Wagner E.F.;
RT   "Strain-dependent epithelial defects in mice lacking the EGF
RT   receptor.";
RL   Science 269:234-238(1995).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF EPS15, ENZYME REGULATION, AND
RP   ENDOCYTOSIS.
RX   PubMed=10953014; DOI=10.1083/jcb.150.4.905;
RA   Confalonieri S., Salcini A.E., Puri C., Tacchetti C., Di Fiore P.P.;
RT   "Tyrosine phosphorylation of Eps15 is required for ligand-regulated,
RT   but not constitutive, endocytosis.";
RL   J. Cell Biol. 150:905-912(2000).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-352 AND ASN-444.
RC   STRAIN=C57BL/6J; TISSUE=Plasma;
RX   PubMed=16944957; DOI=10.1021/pr060186m;
RA   Ghesquiere B., Van Damme J., Martens L., Vandekerckhove J.,
RA   Gevaert K.;
RT   "Proteome-wide characterization of N-glycosylation events by diagonal
RT   chromatography.";
RL   J. Proteome Res. 5:2438-2447(2006).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-175.
RC   STRAIN=C57BL/6J; TISSUE=Plasma;
RX   PubMed=17330941; DOI=10.1021/pr0604559;
RA   Bernhard O.K., Kapp E.A., Simpson R.J.;
RT   "Enhanced analysis of the mouse plasma proteome using cysteine-
RT   containing tryptic glycopeptides.";
RL   J. Proteome Res. 6:987-995(2007).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1197, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung,
RC   Pancreas, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [16]
RP   UBQUITINATION BY RNF115 AND RNF126, AND INTERACTION WITH RNF115 AND
RP   RNF126.
RX   PubMed=23418353; DOI=10.1242/jcs.116129;
RA   Smith C.J., Berry D.M., McGlade C.J.;
RT   "The E3 ubiquitin ligases RNF126 and Rabring7 regulate endosomal
RT   sorting of the epidermal growth factor receptor.";
RL   J. Cell Sci. 126:1366-1380(2013).
RN   [17]
RP   INTERACTION WITH GPRC5A.
RX   PubMed=25744720; DOI=10.1158/0008-5472.CAN-14-2005;
RA   Zhong S., Yin H., Liao Y., Yao F., Li Q., Zhang J., Jiao H., Zhao Y.,
RA   Xu D., Liu S., Song H., Gao Y., Liu J., Ma L., Pang Z., Yang R.,
RA   Ding C., Sun B., Lin X., Ye X., Guo W., Han B., Zhou B.P., Chin Y.E.,
RA   Deng J.;
RT   "Lung tumor suppressor GPRC5A binds EGFR and restrains its effector
RT   signaling.";
RL   Cancer Res. 75:1801-1814(2015).
CC   -!- FUNCTION: Receptor tyrosine kinase binding ligands of the EGF
CC       family and activating several signaling cascades to convert
CC       extracellular cues into appropriate cellular responses. Known
CC       ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN,
CC       BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF.
CC       Ligand binding triggers receptor homo- and/or heterodimerization
CC       and autophosphorylation on key cytoplasmic residues. The
CC       phosphorylated receptor recruits adapter proteins like GRB2 which
CC       in turn activates complex downstream signaling cascades. Activates
CC       at least 4 major downstream signaling cascades including the RAS-
CC       RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May
CC       also activate the NF-kappa-B signaling cascade. Also directly
CC       phosphorylates other proteins like RGS16, activating its GTPase
CC       activity and probably coupling the EGF receptor signaling to the G
CC       protein-coupled receptor signaling. Also phosphorylates MUC1 and
CC       increases its interaction with SRC and CTNNB1/beta-catenin.
CC       {ECO:0000269|PubMed:10953014, ECO:0000269|PubMed:8404850}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Endocytosis and inhibition of the activated
CC       EGFR by phosphatases like PTPRJ and PTPRK constitute immediate
CC       regulatory mechanisms. Upon EGF-binding phosphorylates EPS15 that
CC       regulates EGFR endocytosis and activity. Moreover, inducible
CC       feedback inhibitors including LRIG1, SOCS4, SOCS5 and ERRFI1
CC       constitute alternative regulatory mechanisms for the EGFR
CC       signaling. {ECO:0000269|PubMed:10953014}.
CC   -!- SUBUNIT: Binding of the ligand triggers homo- and/or
CC       heterodimerization of the receptor triggering its
CC       autophosphorylation. Heterodimer with ERBB2. Interacts with
CC       ERRFI1; inhibits dimerization of the kinase domain and
CC       autophosphorylation. Part of a complex with ERBB2 and either
CC       PIK3C2A or PIK3C2B. Interacts with GRB2; an adapter protein
CC       coupling the receptor to downstream signaling pathways. Interacts
CC       with GAB2; involved in signaling downstream of EGFR. Interacts
CC       with STAT3; mediates EGFR downstream signaling in cell
CC       proliferation. Interacts with RIPK1; involved in NF-kappa-B
CC       activation. Interacts (autophosphorylated) with CBL, CBLB and
CC       CBLC; involved in EGFR ubiquitination and regulation. Interacts
CC       with SOCS5; regulates EGFR degradation through TCEB1- and TCEB2-
CC       mediated ubiquitination and proteasomal degradation. Interacts
CC       with PRMT5; methylates EGFR and enhances interaction with PTPN6.
CC       Interacts (phosphorylated) with PTPN6; inhibits EGFR-dependent
CC       activation of MAPK/ERK. Interacts with COPG1; essential for
CC       regulation of EGF-dependent nuclear transport of EGFR by
CC       retrograde trafficking from the Golgi to the ER. Interacts with
CC       TNK2; this interaction is dependent on EGF stimulation and kinase
CC       activity of EGFR. Interacts with PCNA; positively regulates PCNA.
CC       Interacts with PELP1. Interacts with MUC1. Interacts with AP2M1.
CC       Interacts with FER. Interacts (via SH2 domains) with GRB2, NCK1
CC       and NCK2. Interacts with EPS8; mediates EPS8 phosphorylation.
CC       Interacts with ATX2. Interacts with GAREM1. Interacts
CC       (ubiquitinated) with ANKRD13A/B/D; the interaction is direct and
CC       may regulate EGFR internalization after EGF stimulation. Interacts
CC       with GPER1; the interaction occurs in an estrogen-dependent
CC       manner. Interacts (via C-terminal cytoplasmic kinase domain) with
CC       ZPR1 (via zinc fingers). Interacts with RNF115 and RNF126.
CC       Interacts with GPRC5A (via its transmembrane domain)
CC       (PubMed:25744720). Interacts with FAM83B; positively regulates
CC       EGFR inducing its autophospharylation in absence of stimulation by
CC       EGF (By similarity). {ECO:0000250|UniProtKB:P00533,
CC       ECO:0000269|PubMed:23418353, ECO:0000269|PubMed:25744720,
CC       ECO:0000269|PubMed:8404850}.
CC   -!- INTERACTION:
CC       P22682:Cbl; NbExp=2; IntAct=EBI-6296235, EBI-640919;
CC       P01133:EGF (xeno); NbExp=3; IntAct=EBI-6296235, EBI-640857;
CC       P32883:Kras; NbExp=3; IntAct=EBI-6296235, EBI-644267;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane {ECO:0000250}; Single-pass
CC       type I membrane protein {ECO:0000250}. Golgi apparatus membrane
CC       {ECO:0000250}; Single-pass type I membrane protein {ECO:0000250}.
CC       Nucleus membrane {ECO:0000250}; Single-pass type I membrane
CC       protein {ECO:0000250}. Endosome. Endosome membrane. Nucleus
CC       {ECO:0000250}. Note=In response to EGF, translocated from the cell
CC       membrane to the nucleus via Golgi and ER. Endocytosed upon
CC       activation by ligand. Colocalized with GPER1 in the nucleus of
CC       estrogen agonist-induced cancer-associated fibroblasts (CAF) (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Monoubiquitinated and polyubiquitinated upon EGF stimulation;
CC       which does not affect tyrosine kinase activity or signaling
CC       capacity but may play a role in lysosomal targeting. Polyubiquitin
CC       linkage is mainly through 'Lys-63', but linkage through 'Lys-48',
CC       'Lys-11' and 'Lys-29' also occurs. Deubiquitinated by OTUD7B,
CC       preventing degradation (By similarity). Ubiquitinated by RNF115
CC       and RNF126. {ECO:0000250|UniProtKB:P00533,
CC       ECO:0000269|PubMed:23418353}.
CC   -!- PTM: Phosphorylated. Phosphorylation of Ser-697 is partial and
CC       occurs only if Thr-695 is phosphorylated. Phosphorylation at Thr-
CC       680 and Thr-695 by PRKD1 inhibits EGF-induced MAPK8/JNK1
CC       activation. Dephosphorylation by PTPRJ prevents endocytosis and
CC       stabilizes the receptor at the plasma membrane.
CC       Autophosphorylation at Tyr-1197 is stimulated by methylation at
CC       Arg-1199 and enhances interaction with PTPN6. Autophosphorylation
CC       at Tyr-1092 and/or Tyr-1110 recruits STAT3. Dephosphorylated by
CC       PTPN1 and PTPN2 (By similarity). {ECO:0000250}.
CC   -!- PTM: Methylated. Methylation at Arg-1199 by PRMT5 positively
CC       stimulates phosphorylation at Tyr-1197 (By similarity).
CC       {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Mice are growth retarded and die at
CC       different stages of development depending on their genetic
CC       background. Embryonic death is due to placental defects. Mice
CC       surviving until birth or later display brain, bone, heart and
CC       various epithelial development defects in several organs,
CC       including skin, lung and gastrointestinal tract.
CC       {ECO:0000269|PubMed:7618084, ECO:0000269|PubMed:7618085,
CC       ECO:0000269|PubMed:7630400}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X78987; CAA55587.1; -; mRNA.
DR   EMBL; U03425; AAA17899.1; -; mRNA.
DR   EMBL; X59698; CAA42219.1; -; mRNA.
DR   EMBL; L06864; AAA53029.1; -; mRNA.
DR   EMBL; Z12608; CAA78249.1; -; mRNA.
DR   CCDS; CCDS24443.1; -.
DR   PIR; A53183; A53183.
DR   RefSeq; NP_997538.1; NM_207655.2.
DR   UniGene; Mm.420648; -.
DR   UniGene; Mm.439882; -.
DR   UniGene; Mm.8534; -.
DR   ProteinModelPortal; Q01279; -.
DR   SMR; Q01279; 26-636, 644-1020.
DR   BioGrid; 199402; 20.
DR   DIP; DIP-5763N; -.
DR   IntAct; Q01279; 9.
DR   MINT; MINT-143143; -.
DR   STRING; 10090.ENSMUSP00000020329; -.
DR   BindingDB; Q01279; -.
DR   ChEMBL; CHEMBL3608; -.
DR   iPTMnet; Q01279; -.
DR   PhosphoSite; Q01279; -.
DR   SwissPalm; Q01279; -.
DR   MaxQB; Q01279; -.
DR   PaxDb; Q01279; -.
DR   PRIDE; Q01279; -.
DR   Ensembl; ENSMUST00000020329; ENSMUSP00000020329; ENSMUSG00000020122.
DR   GeneID; 13649; -.
DR   UCSC; uc007ibo.1; mouse.
DR   CTD; 1956; -.
DR   MGI; MGI:95294; Egfr.
DR   eggNOG; KOG1025; Eukaryota.
DR   eggNOG; ENOG410XNSR; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000230982; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; Q01279; -.
DR   OMA; ANLDVNM; -.
DR   PhylomeDB; Q01279; -.
DR   TreeFam; TF106002; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   Reactome; R-MMU-1227986; Signaling by ERBB2.
DR   Reactome; R-MMU-1236394; Signaling by ERBB4.
DR   Reactome; R-MMU-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-MMU-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-MMU-177929; Signaling by EGFR.
DR   Reactome; R-MMU-179812; GRB2 events in EGFR signaling.
DR   Reactome; R-MMU-180292; GAB1 signalosome.
DR   Reactome; R-MMU-180336; SHC1 events in EGFR signaling.
DR   Reactome; R-MMU-182971; EGFR downregulation.
DR   Reactome; R-MMU-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-MMU-212718; EGFR interacts with phospholipase C-gamma.
DR   Reactome; R-MMU-2179392; EGFR Transactivation by Gastrin.
DR   Reactome; R-MMU-445144; Signal transduction by L1.
DR   Reactome; R-MMU-5673001; RAF/MAP kinase cascade.
DR   ChiTaRS; Egfr; mouse.
DR   NextBio; 284374; -.
DR   PRO; PR:Q01279; -.
DR   Proteomes; UP000000589; Chromosome 11.
DR   Bgee; Q01279; -.
DR   CleanEx; MM_EGFR; -.
DR   ExpressionAtlas; Q01279; baseline and differential.
DR   Genevisible; Q01279; MM.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:MGI.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0031901; C:early endosome membrane; ISO:MGI.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:MGI.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; ISS:UniProtKB.
DR   GO; GO:0010008; C:endosome membrane; ISO:MGI.
DR   GO; GO:0005925; C:focal adhesion; ISO:MGI.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005622; C:intracellular; IDA:MGI.
DR   GO; GO:0016020; C:membrane; ISO:MGI.
DR   GO; GO:0045121; C:membrane raft; ISO:MGI.
DR   GO; GO:0097489; C:multivesicular body, internal vesicle lumen; ISO:MGI.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0051015; F:actin filament binding; ISO:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISO:MGI.
DR   GO; GO:0005006; F:epidermal growth factor-activated receptor activity; IDA:MGI.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0016301; F:kinase activity; IDA:MGI.
DR   GO; GO:0030235; F:nitric-oxide synthase regulator activity; IEA:Ensembl.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:MGI.
DR   GO; GO:0019903; F:protein phosphatase binding; ISO:MGI.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase activity; IEA:InterPro.
DR   GO; GO:0004871; F:signal transducer activity; IDA:MGI.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; ISO:MGI.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:MGI.
DR   GO; GO:0000902; P:cell morphogenesis; IGI:MGI.
DR   GO; GO:0008283; P:cell proliferation; ISO:MGI.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; ISO:MGI.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IDA:UniProtKB.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; ISS:UniProtKB.
DR   GO; GO:0021795; P:cerebral cortex cell migration; IMP:MGI.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IMP:MGI.
DR   GO; GO:0001892; P:embryonic placenta development; IMP:MGI.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:MGI.
DR   GO; GO:0008544; P:epidermis development; IMP:MGI.
DR   GO; GO:0061029; P:eyelid development in camera-type eye; IGI:MGI.
DR   GO; GO:0001942; P:hair follicle development; IMP:MGI.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0060571; P:morphogenesis of an epithelial fold; IMP:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; ISO:MGI.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:0035413; P:positive regulation of catenin import into nucleus; ISO:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0031659; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle; ISO:MGI.
DR   GO; GO:0045739; P:positive regulation of DNA repair; ISO:MGI.
DR   GO; GO:0045740; P:positive regulation of DNA replication; ISO:MGI.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IMP:BHF-UCL.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISO:MGI.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; ISO:MGI.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; ISO:MGI.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; ISO:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IGI:MGI.
DR   GO; GO:0050999; P:regulation of nitric-oxide synthase activity; ISO:MGI.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IMP:MGI.
DR   GO; GO:0070141; P:response to UV-A; ISO:MGI.
DR   GO; GO:0007435; P:salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0007165; P:signal transduction; IDA:MGI.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; ISO:MGI.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 4.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell membrane; Complete proteome; Developmental protein;
KW   Disulfide bond; Endoplasmic reticulum; Endosome; Glycoprotein;
KW   Golgi apparatus; Isopeptide bond; Kinase; Membrane; Methylation;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25   1210       Epidermal growth factor receptor.
FT                                /FTId=PRO_0000016666.
FT   TOPO_DOM     25    647       Extracellular. {ECO:0000255}.
FT   TRANSMEM    648    670       Helical. {ECO:0000255}.
FT   TOPO_DOM    671   1210       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       75    300       Approximate.
FT   REPEAT      390    600       Approximate.
FT   DOMAIN      714    981       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     720    728       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     792    793       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      690    706       Important for dimerization,
FT                                phosphorylation and activation.
FT                                {ECO:0000250}.
FT   ACT_SITE    839    839       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     747    747       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     857    857       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE       1018   1018       Important for interaction with PIK3C2B.
FT                                {ECO:0000250}.
FT   MOD_RES     229    229       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES     680    680       Phosphothreonine; by PKC and PKD/PRKD1.
FT                                {ECO:0000250}.
FT   MOD_RES     695    695       Phosphothreonine; by PKD/PRKD1.
FT                                {ECO:0000250}.
FT   MOD_RES     697    697       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES     993    993       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES     997    997       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES    1000   1000       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1018   1018       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1028   1028       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES    1041   1041       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES    1043   1043       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES    1044   1044       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES    1070   1070       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES    1071   1071       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES    1092   1092       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1110   1110       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1166   1166       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES    1172   1172       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1197   1197       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:17242355}.
FT   MOD_RES    1199   1199       Omega-N-methylarginine; alternate.
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   MOD_RES    1199   1199       Omega-N-methylated arginine; alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD    128    128       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    175    175       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17330941}.
FT   CARBOHYD    196    196       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    352    352       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16944957}.
FT   CARBOHYD    413    413       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    444    444       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16944957}.
FT   CARBOHYD    528    528       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    568    568       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    603    603       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    623    623       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    190    199       {ECO:0000250}.
FT   DISULFID    194    207       {ECO:0000250}.
FT   DISULFID    215    223       {ECO:0000250}.
FT   DISULFID    219    231       {ECO:0000250}.
FT   DISULFID    232    240       {ECO:0000250}.
FT   DISULFID    236    248       {ECO:0000250}.
FT   DISULFID    251    260       {ECO:0000250}.
FT   DISULFID    264    291       {ECO:0000250}.
FT   DISULFID    295    307       {ECO:0000250}.
FT   DISULFID    311    326       {ECO:0000250}.
FT   DISULFID    329    333       {ECO:0000250}.
FT   DISULFID    506    515       {ECO:0000250}.
FT   DISULFID    510    523       {ECO:0000250}.
FT   DISULFID    526    535       {ECO:0000250}.
FT   DISULFID    539    555       {ECO:0000250}.
FT   DISULFID    558    571       {ECO:0000250}.
FT   DISULFID    562    579       {ECO:0000250}.
FT   DISULFID    582    591       {ECO:0000250}.
FT   DISULFID    595    617       {ECO:0000250}.
FT   DISULFID    620    628       {ECO:0000250}.
FT   DISULFID    624    636       {ECO:0000250}.
FT   CROSSLNK    718    718       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   CROSSLNK    739    739       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   CROSSLNK    756    756       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   CROSSLNK    869    869       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   CROSSLNK    931    931       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   CROSSLNK    972    972       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P00533}.
FT   CONFLICT    539    539       C -> W (in Ref. 5; CAA42219).
FT                                {ECO:0000305}.
FT   CONFLICT    991    991       L -> F (in Ref. 4; AAA17899).
FT                                {ECO:0000305}.
FT   CONFLICT   1116   1117       HP -> DR (in Ref. 6; CAA78249).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1210 AA;  134853 MW;  690E20D46DF2D2F5 CRC64;
     MRPSGTARTT LLVLLTALCA AGGALEEKKV CQGTSNRLTQ LGTFEDHFLS LQRMYNNCEV
     VLGNLEITYV QRNYDLSFLK TIQEVAGYVL IALNTVERIP LENLQIIRGN ALYENTYALA
     ILSNYGTNRT GLRELPMRNL QEILIGAVRF SNNPILCNMD TIQWRDIVQN VFMSNMSMDL
     QSHPSSCPKC DPSCPNGSCW GGGEENCQKL TKIICAQQCS HRCRGRSPSD CCHNQCAAGC
     TGPRESDCLV CQKFQDEATC KDTCPPLMLY NPTTYQMDVN PEGKYSFGAT CVKKCPRNYV
     VTDHGSCVRA CGPDYYEVEE DGIRKCKKCD GPCRKVCNGI GIGEFKDTLS INATNIKHFK
     YCTAISGDLH ILPVAFKGDS FTRTPPLDPR ELEILKTVKE ITGFLLIQAW PDNWTDLHAF
     ENLEIIRGRT KQHGQFSLAV VGLNITSLGL RSLKEISDGD VIISGNRNLC YANTINWKKL
     FGTPNQKTKI MNNRAEKDCK AVNHVCNPLC SSEGCWGPEP RDCVSCQNVS RGRECVEKCN
     ILEGEPREFV ENSECIQCHP ECLPQAMNIT CTGRGPDNCI QCAHYIDGPH CVKTCPAGIM
     GENNTLVWKY ADANNVCHLC HANCTYGCAG PGLQGCEVWP SGPKIPSIAT GIVGGLLFIV
     VVALGIGLFM RRRHIVRKRT LRRLLQEREL VEPLTPSGEA PNQAHLRILK ETEFKKIKVL
     GSGAFGTVYK GLWIPEGEKV KIPVAIKELR EATSPKANKE ILDEAYVMAS VDNPHVCRLL
     GICLTSTVQL ITQLMPYGCL LDYVREHKDN IGSQYLLNWC VQIAKGMNYL EDRRLVHRDL
     AARNVLVKTP QHVKITDFGL AKLLGAEEKE YHAEGGKVPI KWMALESILH RIYTHQSDVW
     SYGVTVWELM TFGSKPYDGI PASDISSILE KGERLPQPPI CTIDVYMIMV KCWMIDADSR
     PKFRELILEF SKMARDPQRY LVIQGDERMH LPSPTDSNFY RALMDEEDME DVVDADEYLI
     PQQGFFNSPS TSRTPLLSSL SATSNNSTVA CINRNGSCRV KEDAFLQRYS SDPTGAVTED
     NIDDAFLPVP EYVNQSVPKR PAGSVQNPVY HNQPLHPAPG RDLHYQNPHS NAVGNPEYLN
     TAQPTCLSSG FNSPALWIQK GSHQMSLDNP DYQQDFFPKE TKPNGIFKGP TAENAEYLRV
     APPSSEFIGA
//
ID   IL6RA_HUMAN             Reviewed;         468 AA.
AC   P08887; A8KAE8; B2R6V4; Q16202; Q53EQ7; Q5FWG2; Q5VZ23;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1988, sequence version 1.
DT   17-FEB-2016, entry version 187.
DE   RecName: Full=Interleukin-6 receptor subunit alpha;
DE            Short=IL-6 receptor subunit alpha;
DE            Short=IL-6R subunit alpha;
DE            Short=IL-6R-alpha;
DE            Short=IL-6RA;
DE   AltName: Full=IL-6R 1;
DE   AltName: Full=Membrane glycoprotein 80;
DE            Short=gp80;
DE   AltName: CD_antigen=CD126;
DE   Flags: Precursor;
GN   Name=IL6R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3136546; DOI=10.1126/science.3136546;
RA   Yamasaki K., Taga T., Hirata Y., Yawata H., Kawanishi Y., Seed B.,
RA   Taniguchi T., Hirano T., Kishimoto T.;
RT   "Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2)
RT   receptor.";
RL   Science 241:825-828(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Yamasaki K., Taga T., Hirata Y., Yawata H., Kawanishi Y., Seed B.,
RA   Taniguchi T., Hirano T., Kishimoto T.;
RT   "Molecular structure of interleukin 6 receptor.";
RL   Proc. Jpn. Acad., B, Phys. Biol. Sci. 64:209-211(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1872801;
RA   Schooltink H., Stoyan T., Lenz D., Schmitz H., Hirano T.,
RA   Kishimoto T., Heinrich P.C., Rose-John S.;
RT   "Structural and functional studies on the human hepatic interleukin-6
RT   receptor. Molecular cloning and overexpression in HepG2 cells.";
RL   Biochem. J. 277:659-664(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ALA-358.
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 313-365 (ISOFORM 2).
RX   PubMed=8056053; DOI=10.1002/eji.1830240837;
RA   Horiuchi S., Koyanagi Y., Zhou Y., Miyamoto H., Tanaka Y., Waki M.,
RA   Matsumoto A., Yamamoto M., Yamamoto N.;
RT   "Soluble interleukin-6 receptors released from T cell or
RT   granulocyte/macrophage cell lines and human peripheral blood
RT   mononuclear cells are generated through an alternative splicing
RT   mechanism.";
RL   Eur. J. Immunol. 24:1945-1948(1994).
RN   [10]
RP   PARTIAL PROTEIN SEQUENCE, GLYCOSYLATION AT ASN-55; ASN-93 AND ASN-221,
RP   LACK OF GLYCOSYLATION AT ASN-245, AND DISULFIDE BONDS.
RX   PubMed=10066782; DOI=10.1074/jbc.274.11.7207;
RA   Cole A.R., Hall N.E., Treutlein H.R., Eddes J.S., Reid G.E.,
RA   Moritz R.L., Simpson R.J.;
RT   "Disulfide bond structure and N-glycosylation sites of the
RT   extracellular domain of the human interleukin-6 receptor.";
RL   J. Biol. Chem. 274:7207-7215(1999).
RN   [11]
RP   PROTEIN SEQUENCE OF 20-49, AND SUBCELLULAR LOCATION.
RX   PubMed=2529343; DOI=10.1084/jem.170.4.1409;
RA   Novick D., Engelmann H., Wallach D., Rubinstein M.;
RT   "Soluble cytokine receptors are present in normal human urine.";
RL   J. Exp. Med. 170:1409-1414(1989).
RN   [12]
RP   MUTAGENESIS.
RX   PubMed=8467812;
RA   Yawata H., Yasukawa K., Natsuka S., Murakami M., Yamasaki K., Hibi M.,
RA   Taga T., Kishimoto T.;
RT   "Structure-function analysis of human IL-6 receptor: dissociation of
RT   amino acid residues required for IL-6-binding and for IL-6 signal
RT   transduction through gp130.";
RL   EMBO J. 12:1705-1712(1993).
RN   [13]
RP   FUNCTION.
RX   PubMed=11017875;
RA   Martens A.S., Bode J.G., Heinrich P.C., Graeve L.;
RT   "The cytoplasmic domain of the interleukin-6 receptor gp80 mediates
RT   its basolateral sorting in polarized Madin-Darby canine kidney
RT   cells.";
RL   J. Cell Sci. 113:3593-3602(2000).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16270750; DOI=10.1016/j.ejcb.2005.06.001;
RA   Buk D.M., Renner O., Graeve L.;
RT   "Increased association with detergent-resistant membranes/lipid rafts
RT   of apically targeted mutants of the interleukin-6 receptor gp80.";
RL   Eur. J. Cell Biol. 84:819-831(2005).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 20-344.
RX   PubMed=12461182; DOI=10.1073/pnas.232432399;
RA   Varghese J.N., Moritz R.L., Lou M.-Z., Van Donkelaar A., Ji H.,
RA   Ivancic N., Branson K.M., Hall N.E., Simpson R.J.;
RT   "Structure of the extracellular domains of the human interleukin-6
RT   receptor alpha-chain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:15959-15964(2002).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (3.65 ANGSTROMS) OF 115-315.
RX   PubMed=12829785; DOI=10.1126/science.1083901;
RA   Boulanger M.J., Chow D.-C., Brevnova E.E., Garcia K.C.;
RT   "Hexameric structure and assembly of the interleukin-6/IL-6 alpha-
RT   receptor/gp130 complex.";
RL   Science 300:2101-2104(2003).
RN   [17]
RP   POLYMORPHISM, VARIANT ALA-358, AND ASSOCIATION OF VARIANT ALA-358 WITH
RP   IL6 AND SOLUBLE IL6R SERUM LEVELS.
RX   PubMed=17357077; DOI=10.1086/513206;
RG   Health, Aging and Body Composition (Health ABC) Study;
RA   Reich D., Patterson N., Ramesh V., De Jager P.L., McDonald G.J.,
RA   Tandon A., Choy E., Hu D., Tamraz B., Pawlikowska L., Wassel-Fyr C.,
RA   Huntsman S., Waliszewska A., Rossin E., Li R., Garcia M., Reiner A.,
RA   Ferrell R., Cummings S., Kwok P.Y., Harris T., Zmuda J.M., Ziv E.;
RT   "Admixture mapping of an allele affecting interleukin 6 soluble
RT   receptor and interleukin 6 levels.";
RL   Am. J. Hum. Genet. 80:716-726(2007).
CC   -!- FUNCTION: Part of the receptor for interleukin 6. Binds to IL6
CC       with low affinity, but does not transduce a signal. Signal
CC       activation necessitate an association with IL6ST. Activation may
CC       lead to the regulation of the immune response, acute-phase
CC       reactions and hematopoiesis.
CC   -!- FUNCTION: Low concentration of a soluble form of IL6 receptor acts
CC       as an agonist of IL6 activity.
CC   -!- SUBUNIT: Hexamer of two molecules each of IL6, IL6R and IL6ST.
CC   -!- INTERACTION:
CC       P05231:IL6; NbExp=5; IntAct=EBI-299383, EBI-720533;
CC       Q2HRC7:K2 (xeno); NbExp=3; IntAct=EBI-299383, EBI-9007403;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Basolateral cell membrane;
CC       Single-pass type I membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Long;
CC         IsoId=P08887-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P08887-2; Sequence=VSP_001682, VSP_001683;
CC   -!- TISSUE SPECIFICITY: Isoform 2 is expressed in peripheral blood
CC       mononuclear cells and weakly found in urine and serum.
CC   -!- DOMAIN: The two fibronectin type-III-like domains, contained in
CC       the N-terminal part, form together a cytokine-binding domain.
CC   -!- DOMAIN: The WSXWS motif appears to be necessary for proper protein
CC       folding and thereby efficient intracellular transport and cell-
CC       surface receptor binding.
CC   -!- PTM: A short soluble form may also be released from the membrane
CC       by proteolysis.
CC   -!- POLYMORPHISM: Genetic variations in IL6R determine soluble IL6R
CC       serum levels [MIM:614689].
CC   -!- POLYMORPHISM: Genetic variations in IL6R define the IL6 serum
CC       level quantitative trait locus [MIM:614752].
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 3
CC       subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 Ig-like C2-type (immunoglobulin-like)
CC       domain. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X12830; CAA31312.1; -; mRNA.
DR   EMBL; X58298; CAA41231.1; -; mRNA.
DR   EMBL; AK293013; BAF85702.1; -; mRNA.
DR   EMBL; AK312730; BAG35601.1; -; mRNA.
DR   EMBL; AK223582; BAD97302.1; -; mRNA.
DR   EMBL; AL162591; CAH72853.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53200.1; -; Genomic_DNA.
DR   EMBL; BC089410; AAH89410.1; -; mRNA.
DR   EMBL; S72848; AAC60635.1; -; mRNA.
DR   CCDS; CCDS1067.1; -. [P08887-1]
DR   CCDS; CCDS1068.1; -. [P08887-2]
DR   PIR; A41242; A41242.
DR   RefSeq; NP_000556.1; NM_000565.3. [P08887-1]
DR   RefSeq; NP_001193795.1; NM_001206866.1.
DR   RefSeq; NP_852004.1; NM_181359.2. [P08887-2]
DR   UniGene; Hs.135087; -.
DR   PDB; 1N26; X-ray; 2.40 A; A=20-344.
DR   PDB; 1N2Q; Model; -; C/D=20-344.
DR   PDB; 1P9M; X-ray; 3.65 A; C=115-315.
DR   PDB; 2ARW; NMR; -; A=212-336.
DR   PDBsum; 1N26; -.
DR   PDBsum; 1N2Q; -.
DR   PDBsum; 1P9M; -.
DR   PDBsum; 2ARW; -.
DR   ProteinModelPortal; P08887; -.
DR   SMR; P08887; 20-318.
DR   BioGrid; 109784; 15.
DR   DIP; DIP-162N; -.
DR   DIP; DIP-3777N; -.
DR   IntAct; P08887; 5.
DR   MINT; MINT-190110; -.
DR   STRING; 9606.ENSP00000357470; -.
DR   ChEMBL; CHEMBL2364155; -.
DR   DrugBank; DB06273; Tocilizumab.
DR   GuidetoPHARMACOLOGY; 1708; -.
DR   PhosphoSite; P08887; -.
DR   BioMuta; IL6R; -.
DR   DMDM; 124343; -.
DR   MaxQB; P08887; -.
DR   PaxDb; P08887; -.
DR   PRIDE; P08887; -.
DR   DNASU; 3570; -.
DR   Ensembl; ENST00000344086; ENSP00000340589; ENSG00000160712. [P08887-2]
DR   Ensembl; ENST00000368485; ENSP00000357470; ENSG00000160712. [P08887-1]
DR   GeneID; 3570; -.
DR   KEGG; hsa:3570; -.
DR   UCSC; uc001fez.2; human. [P08887-1]
DR   UCSC; uc001ffa.2; human. [P08887-2]
DR   CTD; 3570; -.
DR   GeneCards; IL6R; -.
DR   HGNC; HGNC:6019; IL6R.
DR   MIM; 147880; gene.
DR   MIM; 614689; phenotype.
DR   MIM; 614752; phenotype.
DR   neXtProt; NX_P08887; -.
DR   PharmGKB; PA29835; -.
DR   eggNOG; ENOG410II5K; Eukaryota.
DR   eggNOG; ENOG4111XGC; LUCA.
DR   GeneTree; ENSGT00530000063103; -.
DR   HOVERGEN; HBG052118; -.
DR   InParanoid; P08887; -.
DR   KO; K05055; -.
DR   OrthoDB; EOG71CFM2; -.
DR   PhylomeDB; P08887; -.
DR   TreeFam; TF331210; -.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
DR   SignaLink; P08887; -.
DR   ChiTaRS; IL6R; human.
DR   EvolutionaryTrace; P08887; -.
DR   GeneWiki; Interleukin-6_receptor; -.
DR   GenomeRNAi; 3570; -.
DR   NextBio; 13954; -.
DR   PMAP-CutDB; P08887; -.
DR   PRO; PR:P08887; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P08887; -.
DR   CleanEx; HS_IL6R; -.
DR   ExpressionAtlas; P08887; baseline and differential.
DR   Genevisible; P08887; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070110; C:ciliary neurotrophic factor receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005896; C:interleukin-6 receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0070119; F:ciliary neurotrophic factor binding; IPI:BHF-UCL.
DR   GO; GO:0004896; F:cytokine receptor activity; IEA:InterPro.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0019981; F:interleukin-6 binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0006953; P:acute-phase response; TAS:BHF-UCL.
DR   GO; GO:0070120; P:ciliary neurotrophic factor-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; TAS:BHF-UCL.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; NAS:BHF-UCL.
DR   GO; GO:0031018; P:endocrine pancreas development; IMP:BHF-UCL.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0002384; P:hepatic immune response; TAS:BHF-UCL.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0002548; P:monocyte chemotaxis; IC:BHF-UCL.
DR   GO; GO:0032966; P:negative regulation of collagen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0032717; P:negative regulation of interleukin-8 production; NAS:BHF-UCL.
DR   GO; GO:0002446; P:neutrophil mediated immunity; TAS:BHF-UCL.
DR   GO; GO:0010536; P:positive regulation of activation of Janus kinase activity; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IDA:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0002690; P:positive regulation of leukocyte chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; TAS:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; IMP:BHF-UCL.
DR   GO; GO:0034097; P:response to cytokine; IDA:BHF-UCL.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR003530; Hematopoietin_rcpt_L_F3_CS.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR015321; TypeI_recpt_CBD.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF09240; IL6Ra-bind; 1.
DR   SMART; SM00060; FN3; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS01354; HEMATOPO_REC_L_F3; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Immunoglobulin domain; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Secreted; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     19       {ECO:0000269|PubMed:2529343}.
FT   CHAIN        20    468       Interleukin-6 receptor subunit alpha.
FT                                /FTId=PRO_0000010895.
FT   TOPO_DOM     20    365       Extracellular. {ECO:0000255}.
FT   TRANSMEM    366    386       Helical. {ECO:0000255}.
FT   TOPO_DOM    387    468       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       26    112       Ig-like C2-type.
FT   DOMAIN      113    217       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      218    316       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   MOTIF       303    307       WSXWS motif.
FT   SITE        245    245       Not glycosylated.
FT   CARBOHYD     55     55       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:10066782}.
FT   CARBOHYD     93     93       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:10066782}.
FT   CARBOHYD    221    221       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:10066782}.
FT   DISULFID     25    193       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:10066782}.
FT   DISULFID     47     96       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:10066782}.
FT   DISULFID    121    132       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:10066782}.
FT   DISULFID    165    176       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:10066782}.
FT   VAR_SEQ     356    365       VQDSSSVPLP -> GSRRRGSCGL (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8056053}.
FT                                /FTId=VSP_001682.
FT   VAR_SEQ     366    468       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8056053}.
FT                                /FTId=VSP_001683.
FT   VARIANT     358    358       D -> A (significantly associated with
FT                                circulating levels of IL6 and soluble
FT                                IL6R; dbSNP:rs2228145).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:17357077}.
FT                                /FTId=VAR_021995.
FT   VARIANT     385    385       V -> I (in dbSNP:rs28730736).
FT                                /FTId=VAR_049166.
FT   MUTAGEN     121    121       C->S: Complete loss of ligand-binding.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     122    122       F->A: No change of ligand-binding and IL6
FT                                signaling. {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     132    132       C->A: Complete loss of ligand-binding.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     134    134       W->L: Complete loss of ligand-binding.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     140    140       P->G: No change of ligand-binding and IL6
FT                                signaling. {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     153    153       F->L: No change of ligand-binding and IL6
FT                                signaling. {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     165    165       C->L: Complete loss of ligand-binding.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     174    174       F->L: No change of ligand-binding and IL6
FT                                signaling. {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     176    176       C->A: Complete loss of ligand-binding.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     184    184       D->T: 30% decrease of ligand-binding and
FT                                IL6 signaling.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     190    190       V->G: 80% decrease of ligand-binding and
FT                                no IL6 signaling.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     193    193       C->D: Complete loss of ligand-binding.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     211    211       C->A: No change of ligand-binding and IL6
FT                                signaling. {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     217    217       D->V: Complete loss of ligand-binding.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     232    232       R->S: 30% decrease of ligand-binding and
FT                                IL6 signaling.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     233    233       W->Q: 30% decrease of ligand-binding and
FT                                increase of IL6 signaling.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     254    254       E->A: 50% decrease of ligand-binding and
FT                                IL6 signaling.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     277    277       C->D: 30% increase of ligand-binding and
FT                                100% increase in IL6 signaling.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     278    278       V->N: 50% Decrease of ligand-binding and
FT                                50% increase in IL6 signaling.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     279    279       I->D: Complete loss of ligand-binding.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     280    280       H->I: No change of ligand-binding and no
FT                                IL6 signaling.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     281    281       D->G: 70% decrease of ligand-binding and
FT                                no IL6 signaling.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     285    285       G->D: 80% decrease of ligand-binding and
FT                                no IL6 signaling.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     291    291       Q->K: Complete loss of ligand-binding.
FT                                {ECO:0000269|PubMed:8467812}.
FT   MUTAGEN     293    293       R->G: Complete loss of ligand-binding.
FT                                {ECO:0000269|PubMed:8467812}.
FT   CONFLICT    210    210       G -> D (in Ref. 5; BAD97302).
FT                                {ECO:0000305}.
FT   STRAND       34     37       {ECO:0000244|PDB:1N26}.
FT   STRAND       43     46       {ECO:0000244|PDB:1N26}.
FT   STRAND       56     63       {ECO:0000244|PDB:1N26}.
FT   STRAND       65     68       {ECO:0000244|PDB:1N26}.
FT   STRAND       72     83       {ECO:0000244|PDB:1N26}.
FT   HELIX        88     90       {ECO:0000244|PDB:1N26}.
FT   STRAND       92    101       {ECO:0000244|PDB:1N26}.
FT   STRAND      105    110       {ECO:0000244|PDB:1N26}.
FT   STRAND      120    125       {ECO:0000244|PDB:1N26}.
FT   STRAND      130    134       {ECO:0000244|PDB:1N26}.
FT   STRAND      145    157       {ECO:0000244|PDB:1N26}.
FT   STRAND      159    168       {ECO:0000244|PDB:1N26}.
FT   TURN        169    172       {ECO:0000244|PDB:1N26}.
FT   STRAND      173    178       {ECO:0000244|PDB:1N26}.
FT   STRAND      187    196       {ECO:0000244|PDB:1N26}.
FT   STRAND      199    202       {ECO:0000244|PDB:1N26}.
FT   STRAND      206    209       {ECO:0000244|PDB:1N26}.
FT   TURN        210    212       {ECO:0000244|PDB:1N26}.
FT   STRAND      220    226       {ECO:0000244|PDB:1N26}.
FT   STRAND      234    239       {ECO:0000244|PDB:1N26}.
FT   STRAND      247    249       {ECO:0000244|PDB:1N26}.
FT   STRAND      251    259       {ECO:0000244|PDB:1N26}.
FT   STRAND      266    269       {ECO:0000244|PDB:1N26}.
FT   HELIX       271    273       {ECO:0000244|PDB:1N26}.
FT   STRAND      275    281       {ECO:0000244|PDB:1N26}.
FT   STRAND      288    296       {ECO:0000244|PDB:1N26}.
FT   TURN        297    299       {ECO:0000244|PDB:1N26}.
FT   STRAND      310    312       {ECO:0000244|PDB:1N26}.
SQ   SEQUENCE   468 AA;  51548 MW;  62AA239FA14F1B8B CRC64;
     MLAVGCALLA ALLAAPGAAL APRRCPAQEV ARGVLTSLPG DSVTLTCPGV EPEDNATVHW
     VLRKPAAGSH PSRWAGMGRR LLLRSVQLHD SGNYSCYRAG RPAGTVHLLV DVPPEEPQLS
     CFRKSPLSNV VCEWGPRSTP SLTTKAVLLV RKFQNSPAED FQEPCQYSQE SQKFSCQLAV
     PEGDSSFYIV SMCVASSVGS KFSKTQTFQG CGILQPDPPA NITVTAVARN PRWLSVTWQD
     PHSWNSSFYR LRFELRYRAE RSKTFTTWMV KDLQHHCVIH DAWSGLRHVV QLRAQEEFGQ
     GEWSEWSPEA MGTPWTESRS PPAENEVSTP MQALTTNKDD DNILFRDSAN ATSLPVQDSS
     SVPLPTFLVA GGSLAFGTLL CIAIVLRFKK TWKLRALKEG KTSMHPPYSL GQLVPERPRP
     TPVLVPLISP PVSPSSLGSD NTSSHNRPDA RDPRSPYDIS NTDYFFPR
//
ID   GELS_HUMAN              Reviewed;         782 AA.
AC   P06396; A2A418; A8MUD1; A8MYN7; B7Z373; B7Z5V1; F5H1A8; Q5T0I2;
AC   Q8WVV7;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   17-FEB-2016, entry version 195.
DE   RecName: Full=Gelsolin;
DE   AltName: Full=AGEL;
DE   AltName: Full=Actin-depolymerizing factor;
DE            Short=ADF;
DE   AltName: Full=Brevin;
DE   Flags: Precursor;
GN   Name=GSN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND ALTERNATIVE
RP   INITIATION.
RX   PubMed=3020431; DOI=10.1038/323455a0;
RA   Kwiatkowski D.J., Stossel T.P., Orkin S.H., Mole J.E., Colten H.R.,
RA   Yin H.L.;
RT   "Plasma and cytoplasmic gelsolins are encoded by a single gene and
RT   contain a duplicated actin-binding domain.";
RL   Nature 323:455-458(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4).
RC   TISSUE=Hippocampus, Testis, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 53-72 (ISOFORM 2).
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [7]
RP   INTERACTION WITH FIBRONECTIN.
RX   PubMed=6092370;
RA   Lind S.E., Janmey P.A.;
RT   "Human plasma gelsolin binds to fibronectin.";
RL   J. Biol. Chem. 259:13262-13266(1984).
RN   [8]
RP   IDENTITY OF AMYL5 AMYLOID PROTEIN WITH GELSOLIN.
RX   PubMed=2157434; DOI=10.1016/0006-291X(90)90612-Q;
RA   Haltia M., Prelli F., Ghiso J., Kiuru S., Sommer H., Palo J.,
RA   Frangione B.;
RT   "Amyloid protein in familial amyloidosis (Finnish type) is homologous
RT   to gelsolin, an actin-binding protein.";
RL   Biochem. Biophys. Res. Commun. 167:927-932(1990).
RN   [9]
RP   IDENTITY OF AMYL5 AMYLOID PROTEIN WITH GELSOLIN.
RX   PubMed=2153578; DOI=10.1016/0014-5793(90)80072-Q;
RA   Maury C.P.J., Alli K., Baumann M.;
RT   "Finnish hereditary amyloidosis. Amino acid sequence homology between
RT   the amyloid fibril protein and human plasma gelsoline.";
RL   FEBS Lett. 260:85-87(1990).
RN   [10]
RP   DISULFIDE BOND.
RX   PubMed=8703941; DOI=10.1021/bi960920n;
RA   Wen D., Corina K., Chow E.P., Miller S., Janmey P.A., Pepinsky R.B.;
RT   "The plasma and cytoplasmic forms of human gelsolin differ in
RT   disulfide structure.";
RL   Biochemistry 35:9700-9709(1996).
RN   [11]
RP   DISULFIDE BOND.
RX   PubMed=9003812; DOI=10.1016/S0014-5793(96)01439-1;
RA   Allen P.G.;
RT   "Functional consequences of disulfide bond formation in gelsolin.";
RL   FEBS Lett. 401:89-94(1997).
RN   [12]
RP   PHOSPHORYLATION AT TYR-86; TYR-409; TYR-465; TYR-603 AND TYR-651.
RX   PubMed=10210201; DOI=10.1110/ps.8.1.234;
RA   De Corte V., Demol H., Goethals M., Van Damme J., Gettemans J.,
RA   Vandekerckhove J.;
RT   "Identification of Tyr438 as the major in vitro c-Src phosphorylation
RT   site in human gelsolin: a mass spectrometric approach.";
RL   Protein Sci. 8:234-241(1999).
RN   [13]
RP   FUNCTION.
RX   PubMed=20393563; DOI=10.1038/nature08895;
RA   Kim J., Lee J.E., Heynen-Genel S., Suyama E., Ono K., Lee K.,
RA   Ideker T., Aza-Blanc P., Gleeson J.G.;
RT   "Functional genomic screen for modulators of ciliogenesis and cilium
RT   length.";
RL   Nature 464:1048-1051(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 28-503.
RX   PubMed=8395021; DOI=10.1038/364685a0;
RA   McLaughlin P.J., Gooch J.T., Mannherz H.-G., Weeds A.G.;
RT   "Structure of gelsolin segment 1-actin complex and the mechanism of
RT   filament severing.";
RL   Nature 364:685-692(1993).
RN   [17]
RP   STRUCTURE BY NMR OF 177-196.
RX   PubMed=8599675; DOI=10.1016/S0006-3495(95)80140-2;
RA   Xian W., Vegners R., Janmey P.A., Braunlin W.H.;
RT   "Spectroscopic studies of a phosphoinositide-binding peptide from
RT   gelsolin: behavior in solutions of mixed solvent and anionic
RT   micelles.";
RL   Biophys. J. 69:2695-2702(1995).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 439-782, AND CALCIUM-BINDING
RP   SITES.
RX   PubMed=16466744; DOI=10.1016/j.jmb.2006.01.026;
RA   Chumnarnsilpa S., Loonchanta A., Xue B., Choe H., Urosev D., Wang H.,
RA   Lindberg U., Burtnick L.D., Robinson R.C.;
RT   "Calcium ion exchange in crystalline gelsolin.";
RL   J. Mol. Biol. 357:773-782(2006).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 53-174 IN COMPLEX WITH ACTA1;
RP   COBL AND TMSB4X, AND SUBUNIT.
RX   PubMed=23009842; DOI=10.1016/j.bpj.2012.07.030;
RA   Durer Z.A., Kudryashov D.S., Sawaya M.R., Altenbach C., Hubbell W.,
RA   Reisler E.;
RT   "Structural states and dynamics of the D-loop in actin.";
RL   Biophys. J. 103:930-939(2012).
RN   [20]
RP   VARIANT AMYL5 ASN-214.
RX   PubMed=2176481;
RA   Ghiso J., Haltia M., Prelli F., Novello J., Frangione B.;
RT   "Gelsolin variant (Asn-187) in familial amyloidosis, Finnish type.";
RL   Biochem. J. 272:827-830(1990).
RN   [21]
RP   VARIANTS AMYL5 ASN-214 AND TYR-214.
RX   PubMed=1338910; DOI=10.1038/ng1092-157;
RA   de la Chapelle A., Tolvanen R., Boysen G., Santavy J.,
RA   Bleeker-Wagemakers L., Maury C.P.J., Kere J.;
RT   "Gelsolin-derived familial amyloidosis caused by asparagine or
RT   tyrosine substitution for aspartic acid at residue 187.";
RL   Nat. Genet. 2:157-160(1992).
RN   [22]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-22; ILE-201 AND ASN-611.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Calcium-regulated, actin-modulating protein that binds
CC       to the plus (or barbed) ends of actin monomers or filaments,
CC       preventing monomer exchange (end-blocking or capping). It can
CC       promote the assembly of monomers into filaments (nucleation) as
CC       well as sever filaments already formed. Plays a role in
CC       ciliogenesis. {ECO:0000269|PubMed:20393563}.
CC   -!- SUBUNIT: Binds to actin and to fibronectin. Identified in a
CC       complex composed of ACTA1, COBL, GSN AND TMSB4X. Interacts with
CC       the inactive form of EIF2AK2/PKR (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P49407:ARRB1; NbExp=3; IntAct=EBI-351506, EBI-743313;
CC       P32121:ARRB2; NbExp=3; IntAct=EBI-351506, EBI-714559;
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm, cytoskeleton.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=4;
CC       Name=1; Synonyms=Secreted, Plasma;
CC         IsoId=P06396-1; Sequence=Displayed;
CC       Name=2; Synonyms=Cytoplasmic;
CC         IsoId=P06396-2; Sequence=VSP_018959;
CC       Name=3;
CC         IsoId=P06396-3; Sequence=VSP_042879;
CC       Name=4;
CC         IsoId=P06396-4; Sequence=VSP_054791;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Phagocytic cells, platelets, fibroblasts,
CC       nonmuscle cells, smooth and skeletal muscle cells.
CC   -!- PTM: Phosphorylation on Tyr-86, Tyr-409, Tyr-465, Tyr-603 and Tyr-
CC       651 in vitro is induced in presence of phospholipids.
CC       {ECO:0000269|PubMed:10210201}.
CC   -!- DISEASE: Amyloidosis 5 (AMYL5) [MIM:105120]: A hereditary
CC       generalized amyloidosis due to gelsolin amyloid deposition. It is
CC       typically characterized by cranial neuropathy and lattice corneal
CC       dystrophy. Most patients have modest involvement of internal
CC       organs, but severe systemic disease can develop in some
CC       individuals causing peripheral polyneuropathy, amyloid
CC       cardiomyopathy, and nephrotic syndrome leading to renal failure.
CC       {ECO:0000269|PubMed:1338910, ECO:0000269|PubMed:2176481}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the villin/gelsolin family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 6 gelsolin-like repeats. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Gelsolin entry;
CC       URL="https://en.wikipedia.org/wiki/Gelsolin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04412; CAA28000.1; -; mRNA.
DR   EMBL; AK096280; BAG53247.1; -; mRNA.
DR   EMBL; AK125819; BAG54252.1; -; mRNA.
DR   EMBL; AK295572; BAH12109.1; -; mRNA.
DR   EMBL; AK299453; BAH13037.1; -; mRNA.
DR   EMBL; AK315494; BAG37878.1; -; mRNA.
DR   EMBL; AL137068; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL513122; CAI14413.1; -; Genomic_DNA.
DR   EMBL; AL513122; CAM20459.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW87489.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW87490.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW87491.1; -; Genomic_DNA.
DR   EMBL; BC017491; AAH17491.1; -; mRNA.
DR   EMBL; BC026033; AAH26033.1; -; mRNA.
DR   CCDS; CCDS48011.1; -. [P06396-3]
DR   CCDS; CCDS65118.1; -. [P06396-4]
DR   CCDS; CCDS6828.1; -. [P06396-1]
DR   CCDS; CCDS6829.1; -. [P06396-2]
DR   PIR; A03011; FAHUP.
DR   RefSeq; NP_000168.1; NM_000177.4. [P06396-1]
DR   RefSeq; NP_001121134.1; NM_001127662.1. [P06396-2]
DR   RefSeq; NP_001121135.2; NM_001127663.1.
DR   RefSeq; NP_001121136.1; NM_001127664.1. [P06396-2]
DR   RefSeq; NP_001121137.1; NM_001127665.1. [P06396-2]
DR   RefSeq; NP_001121138.1; NM_001127666.1. [P06396-3]
DR   RefSeq; NP_001121139.1; NM_001127667.1. [P06396-3]
DR   RefSeq; NP_001244958.1; NM_001258029.1.
DR   RefSeq; NP_001244959.1; NM_001258030.1. [P06396-4]
DR   RefSeq; NP_937895.1; NM_198252.2. [P06396-2]
DR   RefSeq; XP_005252000.1; XM_005251943.1. [P06396-3]
DR   RefSeq; XP_005252001.1; XM_005251944.1. [P06396-3]
DR   RefSeq; XP_005252002.1; XM_005251945.3. [P06396-2]
DR   RefSeq; XP_006717142.1; XM_006717079.1. [P06396-3]
DR   RefSeq; XP_011516888.1; XM_011518586.1. [P06396-3]
DR   RefSeq; XP_011516889.1; XM_011518587.1. [P06396-3]
DR   RefSeq; XP_011516890.1; XM_011518588.1. [P06396-3]
DR   RefSeq; XP_011516891.1; XM_011518589.1. [P06396-3]
DR   RefSeq; XP_011516892.1; XM_011518590.1. [P06396-3]
DR   RefSeq; XP_011516893.1; XM_011518591.1. [P06396-2]
DR   RefSeq; XP_011516894.1; XM_011518592.1. [P06396-2]
DR   RefSeq; XP_011516895.1; XM_011518593.1. [P06396-2]
DR   UniGene; Hs.522373; -.
DR   PDB; 1C0F; X-ray; 2.40 A; S=53-176.
DR   PDB; 1C0G; X-ray; 2.00 A; S=53-176.
DR   PDB; 1D4X; X-ray; 1.75 A; G=52-177.
DR   PDB; 1DEJ; X-ray; 2.40 A; S=53-176.
DR   PDB; 1EQY; X-ray; 2.30 A; S=52-176.
DR   PDB; 1ESV; X-ray; 2.00 A; S=52-176.
DR   PDB; 1H1V; X-ray; 3.00 A; G=439-769.
DR   PDB; 1KCQ; X-ray; 1.65 A; A=185-288.
DR   PDB; 1MDU; X-ray; 2.20 A; A/D=52-176.
DR   PDB; 1NLV; X-ray; 1.80 A; G=52-176.
DR   PDB; 1NM1; X-ray; 1.80 A; G=52-176.
DR   PDB; 1NMD; X-ray; 1.90 A; G=52-176.
DR   PDB; 1P8X; X-ray; 2.00 A; A/B/C=439-782.
DR   PDB; 1P8Z; X-ray; 2.60 A; G=52-187.
DR   PDB; 1SOL; NMR; -; A=177-196.
DR   PDB; 1T44; X-ray; 2.00 A; G=55-179.
DR   PDB; 1YAG; X-ray; 1.90 A; G=52-176.
DR   PDB; 1YVN; X-ray; 2.10 A; G=52-176.
DR   PDB; 2FF3; X-ray; 2.00 A; A=52-179.
DR   PDB; 2FF6; X-ray; 2.05 A; G=52-179.
DR   PDB; 2FH1; X-ray; 1.55 A; A/B/C=439-782.
DR   PDB; 2FH2; X-ray; 2.50 A; A/B/C=439-782.
DR   PDB; 2FH3; X-ray; 2.87 A; A/B/C=439-782.
DR   PDB; 2FH4; X-ray; 3.00 A; A/B/C=439-782.
DR   PDB; 3A5L; X-ray; 2.40 A; S=53-176.
DR   PDB; 3A5M; X-ray; 2.40 A; S=53-176.
DR   PDB; 3A5N; X-ray; 2.36 A; S=53-176.
DR   PDB; 3A5O; X-ray; 2.40 A; S=53-176.
DR   PDB; 3CI5; X-ray; 1.70 A; G=52-176.
DR   PDB; 3CIP; X-ray; 1.60 A; G=52-176.
DR   PDB; 3CJB; X-ray; 3.21 A; G=52-176.
DR   PDB; 3CJC; X-ray; 3.90 A; G=52-176.
DR   PDB; 3FFK; X-ray; 3.00 A; A/D=52-426.
DR   PDB; 3FFN; X-ray; 3.00 A; A/B=1-782.
DR   PDB; 3TU5; X-ray; 3.00 A; B=53-174.
DR   PDB; 4PKG; X-ray; 1.80 A; G=52-176.
DR   PDB; 4PKH; X-ray; 2.15 A; B/E/G/J=52-176, B/E/G/J=196-260.
DR   PDB; 4PKI; X-ray; 2.30 A; G=52-176.
DR   PDB; 4S10; X-ray; 2.61 A; C/D=186-288.
DR   PDB; 4Z94; X-ray; 2.40 A; G=52-176.
DR   PDBsum; 1C0F; -.
DR   PDBsum; 1C0G; -.
DR   PDBsum; 1D4X; -.
DR   PDBsum; 1DEJ; -.
DR   PDBsum; 1EQY; -.
DR   PDBsum; 1ESV; -.
DR   PDBsum; 1H1V; -.
DR   PDBsum; 1KCQ; -.
DR   PDBsum; 1MDU; -.
DR   PDBsum; 1NLV; -.
DR   PDBsum; 1NM1; -.
DR   PDBsum; 1NMD; -.
DR   PDBsum; 1P8X; -.
DR   PDBsum; 1P8Z; -.
DR   PDBsum; 1SOL; -.
DR   PDBsum; 1T44; -.
DR   PDBsum; 1YAG; -.
DR   PDBsum; 1YVN; -.
DR   PDBsum; 2FF3; -.
DR   PDBsum; 2FF6; -.
DR   PDBsum; 2FH1; -.
DR   PDBsum; 2FH2; -.
DR   PDBsum; 2FH3; -.
DR   PDBsum; 2FH4; -.
DR   PDBsum; 3A5L; -.
DR   PDBsum; 3A5M; -.
DR   PDBsum; 3A5N; -.
DR   PDBsum; 3A5O; -.
DR   PDBsum; 3CI5; -.
DR   PDBsum; 3CIP; -.
DR   PDBsum; 3CJB; -.
DR   PDBsum; 3CJC; -.
DR   PDBsum; 3FFK; -.
DR   PDBsum; 3FFN; -.
DR   PDBsum; 3TU5; -.
DR   PDBsum; 4PKG; -.
DR   PDBsum; 4PKH; -.
DR   PDBsum; 4PKI; -.
DR   PDBsum; 4S10; -.
DR   PDBsum; 4Z94; -.
DR   ProteinModelPortal; P06396; -.
DR   SMR; P06396; 50-782.
DR   BioGrid; 109189; 56.
DR   DIP; DIP-2196N; -.
DR   IntAct; P06396; 43.
DR   MINT; MINT-5000481; -.
DR   STRING; 9606.ENSP00000362924; -.
DR   iPTMnet; P06396; -.
DR   PhosphoSite; P06396; -.
DR   BioMuta; GSN; -.
DR   DMDM; 121116; -.
DR   OGP; P06396; -.
DR   MaxQB; P06396; -.
DR   PaxDb; P06396; -.
DR   PeptideAtlas; P06396; -.
DR   PRIDE; P06396; -.
DR   DNASU; 2934; -.
DR   Ensembl; ENST00000341272; ENSP00000340888; ENSG00000148180. [P06396-2]
DR   Ensembl; ENST00000373808; ENSP00000362914; ENSG00000148180. [P06396-2]
DR   Ensembl; ENST00000373818; ENSP00000362924; ENSG00000148180. [P06396-1]
DR   Ensembl; ENST00000373823; ENSP00000362929; ENSG00000148180. [P06396-2]
DR   Ensembl; ENST00000412819; ENSP00000416586; ENSG00000148180. [P06396-2]
DR   Ensembl; ENST00000436847; ENSP00000411293; ENSG00000148180. [P06396-3]
DR   Ensembl; ENST00000545652; ENSP00000445823; ENSG00000148180. [P06396-4]
DR   GeneID; 2934; -.
DR   KEGG; hsa:2934; -.
DR   UCSC; uc004bld.1; human. [P06396-1]
DR   UCSC; uc010mvq.1; human. [P06396-3]
DR   CTD; 2934; -.
DR   GeneCards; GSN; -.
DR   HGNC; HGNC:4620; GSN.
DR   HPA; CAB010823; -.
DR   HPA; CAB016728; -.
DR   HPA; CAB036009; -.
DR   MalaCards; GSN; -.
DR   MIM; 105120; phenotype.
DR   MIM; 137350; gene.
DR   neXtProt; NX_P06396; -.
DR   Orphanet; 85448; Familial amyloidosis, Finnish type.
DR   PharmGKB; PA29011; -.
DR   eggNOG; KOG0443; Eukaryota.
DR   eggNOG; ENOG410XR0A; LUCA.
DR   GeneTree; ENSGT00760000119111; -.
DR   HOGENOM; HOG000233630; -.
DR   HOVERGEN; HBG004183; -.
DR   InParanoid; P06396; -.
DR   KO; K05768; -.
DR   OMA; ANMEERK; -.
DR   OrthoDB; EOG7288RJ; -.
DR   PhylomeDB; P06396; -.
DR   TreeFam; TF313468; -.
DR   Reactome; R-HSA-264870; Caspase-mediated cleavage of cytoskeletal proteins.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   ChiTaRS; GSN; human.
DR   EvolutionaryTrace; P06396; -.
DR   GeneWiki; Gelsolin; -.
DR   GenomeRNAi; 2934; -.
DR   NextBio; 11625; -.
DR   PMAP-CutDB; P06396; -.
DR   PRO; PR:P06396; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; P06396; -.
DR   CleanEx; HS_GSN; -.
DR   ExpressionAtlas; P06396; baseline and differential.
DR   Genevisible; P06396; HS.
DR   GO; GO:0030478; C:actin cap; IDA:UniProtKB.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:ProtInc.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0030864; C:cortical actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IEA:Ensembl.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0002102; C:podosome; IDA:UniProtKB.
DR   GO; GO:0001726; C:ruffle; IEA:Ensembl.
DR   GO; GO:0016528; C:sarcoplasm; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IMP:UniProtKB.
DR   GO; GO:0045159; F:myosin II binding; IPI:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0051693; P:actin filament capping; IMP:UniProtKB.
DR   GO; GO:0030041; P:actin filament polymerization; IDA:UniProtKB.
DR   GO; GO:0090527; P:actin filament reorganization; IGI:UniProtKB.
DR   GO; GO:0051014; P:actin filament severing; IDA:UniProtKB.
DR   GO; GO:0045010; P:actin nucleation; IEA:InterPro.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:1990000; P:amyloid fibril formation; IMP:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0051016; P:barbed-end actin filament capping; TAS:ProtInc.
DR   GO; GO:0006921; P:cellular component disassembly involved in execution phase of apoptosis; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0060271; P:cilium morphogenesis; IMP:UniProtKB.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IMP:UniProtKB.
DR   GO; GO:0046597; P:negative regulation of viral entry into host cell; IMP:UniProtKB.
DR   GO; GO:0014003; P:oligodendrocyte development; IEA:Ensembl.
DR   GO; GO:0006911; P:phagocytosis, engulfment; ISS:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IEA:Ensembl.
DR   GO; GO:0051127; P:positive regulation of actin nucleation; IMP:UniProtKB.
DR   GO; GO:2001269; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:1902174; P:positive regulation of keratinocyte apoptotic process; IMP:UniProtKB.
DR   GO; GO:1903923; P:positive regulation of protein processing in phagocytic vesicle; ISS:UniProtKB.
DR   GO; GO:0012501; P:programmed cell death; TAS:Reactome.
DR   GO; GO:0031648; P:protein destabilization; IMP:UniProtKB.
DR   GO; GO:1903903; P:regulation of establishment of T cell polarity; IMP:UniProtKB.
DR   GO; GO:1903906; P:regulation of plasma membrane raft polarization; IMP:UniProtKB.
DR   GO; GO:0071801; P:regulation of podosome assembly; IMP:UniProtKB.
DR   GO; GO:1903909; P:regulation of receptor clustering; IMP:UniProtKB.
DR   GO; GO:1903689; P:regulation of wound healing, spreading of epidermal cells; IMP:UniProtKB.
DR   GO; GO:0097017; P:renal protein absorption; IMP:UniProtKB.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051593; P:response to folic acid; IEA:Ensembl.
DR   GO; GO:0042989; P:sequestering of actin monomers; IMP:UniProtKB.
DR   GO; GO:0014891; P:striated muscle atrophy; IMP:UniProtKB.
DR   GO; GO:0042246; P:tissue regeneration; IEA:Ensembl.
DR   Gene3D; 3.40.20.10; -; 6.
DR   InterPro; IPR029006; ADF-H/Gelsolin-like_dom.
DR   InterPro; IPR030004; Gelsolin.
DR   InterPro; IPR007123; Gelsolin-like_dom.
DR   InterPro; IPR007122; Villin/Gelsolin.
DR   PANTHER; PTHR11977; PTHR11977; 1.
DR   PANTHER; PTHR11977:SF29; PTHR11977:SF29; 1.
DR   Pfam; PF00626; Gelsolin; 6.
DR   PRINTS; PR00597; GELSOLIN.
DR   SMART; SM00262; GEL; 6.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Actin capping; Actin-binding;
KW   Alternative initiation; Alternative splicing; Amyloid; Amyloidosis;
KW   Calcium; Cilium biogenesis/degradation; Complete proteome;
KW   Corneal dystrophy; Cytoplasm; Cytoskeleton; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL        1     27
FT   CHAIN        28    782       Gelsolin.
FT                                /FTId=PRO_0000036385.
FT   REPEAT       76    126       Gelsolin-like 1.
FT   REPEAT      198    238       Gelsolin-like 2.
FT   REPEAT      314    356       Gelsolin-like 3.
FT   REPEAT      453    504       Gelsolin-like 4.
FT   REPEAT      576    616       Gelsolin-like 5.
FT   REPEAT      679    721       Gelsolin-like 6.
FT   REGION       53    176       Actin-severing. {ECO:0000255}.
FT   REGION      123    126       Actin-actin interfilament contact point.
FT   REGION      162    169       Polyphosphoinositide binding.
FT                                {ECO:0000250}.
FT   REGION      188    196       Polyphosphoinositide binding.
FT                                {ECO:0000250}.
FT   REGION      434    782       Actin-binding, Ca-sensitive.
FT                                {ECO:0000255}.
FT   METAL       471    471       Calcium 1; via carbonyl oxygen.
FT   METAL       472    472       Calcium 1.
FT   METAL       502    502       Calcium 1.
FT   METAL       551    551       Calcium 1; via carbonyl oxygen.
FT   METAL       591    591       Calcium 2.
FT   METAL       591    591       Calcium 2; via carbonyl oxygen.
FT   METAL       592    592       Calcium 2.
FT   METAL       614    614       Calcium 2.
FT   METAL       696    696       Calcium 3; via carbonyl oxygen.
FT   METAL       697    697       Calcium 3.
FT   METAL       719    719       Calcium 3.
FT   MOD_RES      86     86       Phosphotyrosine; by SRC; in vitro.
FT                                {ECO:0000269|PubMed:10210201}.
FT   MOD_RES     409    409       Phosphotyrosine; by SRC; in vitro.
FT                                {ECO:0000269|PubMed:10210201}.
FT   MOD_RES     465    465       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:10210201}.
FT   MOD_RES     584    584       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P13020}.
FT   MOD_RES     603    603       Phosphotyrosine; by SRC; in vitro.
FT                                {ECO:0000269|PubMed:10210201}.
FT   MOD_RES     651    651       Phosphotyrosine; by SRC; in vitro.
FT                                {ECO:0000269|PubMed:10210201}.
FT   DISULFID    215    228       In isoform 1.
FT                                {ECO:0000269|PubMed:8703941,
FT                                ECO:0000269|PubMed:9003812}.
FT   VAR_SEQ       1     51       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:3020431}.
FT                                /FTId=VSP_018959.
FT   VAR_SEQ       1     48       MAPHRPAPALLCALSLALCALSLPVRAATASRGASQAGAPQ
FT                                GRVPEAR -> MEKLFCCF (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042879.
FT   VAR_SEQ       1     48       MAPHRPAPALLCALSLALCALSLPVRAATASRGASQAGAPQ
FT                                GRVPEAR -> MPLCT (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054791.
FT   VARIANT      22     22       S -> L (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036337.
FT   VARIANT     129    129       A -> T (in dbSNP:rs2230287).
FT                                /FTId=VAR_024690.
FT   VARIANT     201    201       T -> I (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036338.
FT   VARIANT     214    214       D -> N (in AMYL5).
FT                                {ECO:0000269|PubMed:1338910,
FT                                ECO:0000269|PubMed:2176481}.
FT                                /FTId=VAR_007718.
FT   VARIANT     214    214       D -> Y (in AMYL5).
FT                                {ECO:0000269|PubMed:1338910}.
FT                                /FTId=VAR_007719.
FT   VARIANT     231    231       N -> D (in dbSNP:rs11550199).
FT                                /FTId=VAR_061982.
FT   VARIANT     611    611       S -> N (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036339.
FT   VARIANT     668    668       R -> L (in dbSNP:rs9696578).
FT                                /FTId=VAR_033958.
FT   CONFLICT    294    294       N -> D (in Ref. 2; BAH13037).
FT                                {ECO:0000305}.
FT   CONFLICT    419    419       R -> W (in Ref. 2; BAH13037).
FT                                {ECO:0000305}.
FT   CONFLICT    603    603       Y -> H (in Ref. 2; BAH13037).
FT                                {ECO:0000305}.
FT   STRAND       52     55       {ECO:0000244|PDB:3FFN}.
FT   HELIX        57     61       {ECO:0000244|PDB:3CIP}.
FT   STRAND       64     74       {ECO:0000244|PDB:3CIP}.
FT   STRAND       77     80       {ECO:0000244|PDB:3CIP}.
FT   HELIX        83     85       {ECO:0000244|PDB:3CIP}.
FT   STRAND       88     90       {ECO:0000244|PDB:3CIP}.
FT   STRAND       94    102       {ECO:0000244|PDB:3CIP}.
FT   TURN        104    106       {ECO:0000244|PDB:1P8Z}.
FT   STRAND      108    116       {ECO:0000244|PDB:3CIP}.
FT   HELIX       122    138       {ECO:0000244|PDB:3CIP}.
FT   TURN        139    141       {ECO:0000244|PDB:3CIP}.
FT   STRAND      143    149       {ECO:0000244|PDB:3CIP}.
FT   HELIX       155    158       {ECO:0000244|PDB:3CIP}.
FT   STRAND      166    169       {ECO:0000244|PDB:3CIP}.
FT   HELIX       172    174       {ECO:0000244|PDB:3FFN}.
FT   STRAND      179    181       {ECO:0000244|PDB:1SOL}.
FT   STRAND      188    203       {ECO:0000244|PDB:1KCQ}.
FT   HELIX       207    209       {ECO:0000244|PDB:1KCQ}.
FT   STRAND      214    219       {ECO:0000244|PDB:1KCQ}.
FT   STRAND      221    228       {ECO:0000244|PDB:1KCQ}.
FT   HELIX       234    250       {ECO:0000244|PDB:1KCQ}.
FT   STRAND      256    262       {ECO:0000244|PDB:1KCQ}.
FT   TURN        263    265       {ECO:0000244|PDB:3FFK}.
FT   HELIX       268    274       {ECO:0000244|PDB:1KCQ}.
FT   HELIX       288    294       {ECO:0000244|PDB:3FFK}.
FT   STRAND      299    304       {ECO:0000244|PDB:3FFK}.
FT   STRAND      306    309       {ECO:0000244|PDB:3FFN}.
FT   STRAND      311    321       {ECO:0000244|PDB:3FFK}.
FT   HELIX       323    325       {ECO:0000244|PDB:3FFK}.
FT   STRAND      330    336       {ECO:0000244|PDB:3FFK}.
FT   HELIX       337    339       {ECO:0000244|PDB:3FFK}.
FT   STRAND      341    346       {ECO:0000244|PDB:3FFK}.
FT   HELIX       352    368       {ECO:0000244|PDB:3FFK}.
FT   STRAND      376    381       {ECO:0000244|PDB:3FFK}.
FT   HELIX       387    390       {ECO:0000244|PDB:3FFK}.
FT   STRAND      393    395       {ECO:0000244|PDB:3FFK}.
FT   STRAND      402    406       {ECO:0000244|PDB:3FFN}.
FT   HELIX       412    414       {ECO:0000244|PDB:3FFN}.
FT   TURN        424    426       {ECO:0000244|PDB:3FFN}.
FT   HELIX       427    429       {ECO:0000244|PDB:3FFN}.
FT   HELIX       431    437       {ECO:0000244|PDB:3FFN}.
FT   STRAND      445    453       {ECO:0000244|PDB:2FH1}.
FT   STRAND      456    459       {ECO:0000244|PDB:2FH1}.
FT   HELIX       462    464       {ECO:0000244|PDB:2FH1}.
FT   STRAND      467    469       {ECO:0000244|PDB:2FH1}.
FT   STRAND      472    482       {ECO:0000244|PDB:2FH1}.
FT   STRAND      485    494       {ECO:0000244|PDB:2FH1}.
FT   HELIX       500    516       {ECO:0000244|PDB:2FH1}.
FT   TURN        517    519       {ECO:0000244|PDB:1P8X}.
FT   STRAND      521    527       {ECO:0000244|PDB:2FH1}.
FT   HELIX       533    536       {ECO:0000244|PDB:2FH1}.
FT   HELIX       537    539       {ECO:0000244|PDB:2FH1}.
FT   STRAND      544    548       {ECO:0000244|PDB:2FH1}.
FT   TURN        553    555       {ECO:0000244|PDB:2FH1}.
FT   STRAND      562    570       {ECO:0000244|PDB:2FH1}.
FT   STRAND      576    581       {ECO:0000244|PDB:2FH1}.
FT   HELIX       585    587       {ECO:0000244|PDB:2FH1}.
FT   STRAND      592    597       {ECO:0000244|PDB:2FH1}.
FT   STRAND      602    606       {ECO:0000244|PDB:2FH1}.
FT   HELIX       612    624       {ECO:0000244|PDB:2FH1}.
FT   STRAND      630    633       {ECO:0000244|PDB:2FH1}.
FT   HELIX       639    644       {ECO:0000244|PDB:2FH1}.
FT   STRAND      645    647       {ECO:0000244|PDB:2FH4}.
FT   HELIX       655    658       {ECO:0000244|PDB:2FH1}.
FT   HELIX       661    664       {ECO:0000244|PDB:3FFN}.
FT   STRAND      668    673       {ECO:0000244|PDB:2FH1}.
FT   TURN        675    677       {ECO:0000244|PDB:3FFN}.
FT   STRAND      680    684       {ECO:0000244|PDB:2FH1}.
FT   HELIX       690    692       {ECO:0000244|PDB:2FH1}.
FT   STRAND      697    702       {ECO:0000244|PDB:2FH1}.
FT   STRAND      707    711       {ECO:0000244|PDB:2FH1}.
FT   HELIX       717    732       {ECO:0000244|PDB:2FH1}.
FT   TURN        735    737       {ECO:0000244|PDB:2FH1}.
FT   STRAND      744    748       {ECO:0000244|PDB:2FH1}.
FT   HELIX       754    757       {ECO:0000244|PDB:2FH1}.
FT   STRAND      760    762       {ECO:0000244|PDB:2FH1}.
FT   STRAND      765    767       {ECO:0000244|PDB:1H1V}.
FT   HELIX       772    778       {ECO:0000244|PDB:3FFN}.
SQ   SEQUENCE   782 AA;  85698 MW;  8CEBC52257A160F7 CRC64;
     MAPHRPAPAL LCALSLALCA LSLPVRAATA SRGASQAGAP QGRVPEARPN SMVVEHPEFL
     KAGKEPGLQI WRVEKFDLVP VPTNLYGDFF TGDAYVILKT VQLRNGNLQY DLHYWLGNEC
     SQDESGAAAI FTVQLDDYLN GRAVQHREVQ GFESATFLGY FKSGLKYKKG GVASGFKHVV
     PNEVVVQRLF QVKGRRVVRA TEVPVSWESF NNGDCFILDL GNNIHQWCGS NSNRYERLKA
     TQVSKGIRDN ERSGRARVHV SEEGTEPEAM LQVLGPKPAL PAGTEDTAKE DAANRKLAKL
     YKVSNGAGTM SVSLVADENP FAQGALKSED CFILDHGKDG KIFVWKGKQA NTEERKAALK
     TASDFITKMD YPKQTQVSVL PEGGETPLFK QFFKNWRDPD QTDGLGLSYL SSHIANVERV
     PFDAATLHTS TAMAAQHGMD DDGTGQKQIW RIEGSNKVPV DPATYGQFYG GDSYIILYNY
     RHGGRQGQII YNWQGAQSTQ DEVAASAILT AQLDEELGGT PVQSRVVQGK EPAHLMSLFG
     GKPMIIYKGG TSREGGQTAP ASTRLFQVRA NSAGATRAVE VLPKAGALNS NDAFVLKTPS
     AAYLWVGTGA SEAEKTGAQE LLRVLRAQPV QVAEGSEPDG FWEALGGKAA YRTSPRLKDK
     KMDAHPPRLF ACSNKIGRFV IEEVPGELMQ EDLATDDVML LDTWDQVFVW VGKDSQEEEK
     TEALTSAKRY IETDPANRDR RTPITVVKQG FEPPSFVGWF LGWDDDYWSV DPLDRAMAEL
     AA
//
ID   LIPL_HUMAN              Reviewed;         475 AA.
AC   P06858; B2R5T9; Q16282; Q16283; Q96FC4;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   20-JAN-2016, entry version 197.
DE   RecName: Full=Lipoprotein lipase;
DE            Short=LPL;
DE            EC=3.1.1.34;
DE   Flags: Precursor;
GN   Name=LPL; Synonyms=LIPD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3823907; DOI=10.1126/science.3823907;
RA   Wion K.L., Kirchgessner T.G., Lusis A.J., Schotz M.C., Lawn R.M.;
RT   "Human lipoprotein lipase complementary DNA sequence.";
RL   Science 235:1638-1641(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=2701938; DOI=10.1093/nar/17.6.2351;
RA   Gotoda T., Senda M., Gamou T., Furuichi Y., Oka K.;
RT   "Nucleotide sequence of human cDNA coding for a lipoprotein lipase
RT   (LPL) cloned from placental cDNA library.";
RL   Nucleic Acids Res. 17:2351-2352(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2243796; DOI=10.1093/nar/18.21.6436;
RA   Takagi A., Ikeda Y., Yamamoto A.;
RT   "DNA sequence of lipoprotein lipase cDNA cloned from human monocytic
RT   leukemia THP-1 cells.";
RL   Nucleic Acids Res. 18:6436-6436(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1537564; DOI=10.1016/0378-1119(92)90658-C;
RA   Chuat J.-C., Raisonnier A., Etienne J., Galibert F.;
RT   "The lipoprotein lipase-encoding human gene: sequence from intron-6 to
RT   intron-9 and presence in intron-7 of a 40-million-year-old Alu
RT   sequence.";
RL   Gene 110:257-261(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-318.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-318.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-5.
RX   PubMed=1406652;
RA   Enerbaeck S., Ohlsson B.G., Samuelsson L., Bjursell G.;
RT   "Characterization of the human lipoprotein lipase (LPL) promoter:
RT   evidence of two cis-regulatory regions, LP-alpha and LP-beta, of
RT   importance for the differentiation-linked induction of the LPL gene
RT   during adipogenesis.";
RL   Mol. Cell. Biol. 12:4622-4633(1992).
RN   [10]
RP   PROTEIN SEQUENCE OF 28-44.
RC   TISSUE=Milk;
RX   PubMed=2340307; DOI=10.1016/0005-2760(90)90213-H;
RA   Zechner R.;
RT   "Rapid and simple isolation procedure for lipoprotein lipase from
RT   human milk.";
RL   Biochim. Biophys. Acta 1044:20-25(1990).
RN   [11]
RP   HEPARIN-BINDING, AND CATALYTIC ACTIVITY.
RX   PubMed=11342582; DOI=10.1172/JCI11774;
RA   Lutz E.P., Merkel M., Kako Y., Melford K., Radner H., Breslow J.L.,
RA   Bensadoun A., Goldberg I.J.;
RT   "Heparin-binding defective lipoprotein lipase is unstable and causes
RT   abnormalities in lipid delivery to tissues.";
RL   J. Clin. Invest. 107:1183-1192(2001).
RN   [12]
RP   INTERACTION WITH GPIHBP1.
RX   PubMed=17997385; DOI=10.1016/j.bbalip.2007.10.005;
RA   Gin P., Beigneux A.P., Davies B., Young M.F., Ryan R.O., Bensadoun A.,
RA   Fong L.G., Young S.G.;
RT   "Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to
RT   GPIHBP1 containing a G56R amino acid substitution.";
RL   Biochim. Biophys. Acta 1771:1464-1468(2007).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-70.
RC   TISSUE=Milk;
RX   PubMed=18780401; DOI=10.1002/pmic.200701057;
RA   Picariello G., Ferranti P., Mamone G., Roepstorff P., Addeo F.;
RT   "Identification of N-linked glycoproteins in human milk by hydrophilic
RT   interaction liquid chromatography and mass spectrometry.";
RL   Proteomics 8:3833-3847(2008).
RN   [14]
RP   3D-STRUCTURE MODELING.
RX   PubMed=8308035;
RA   van Tilbeurgh H., Roussel A., Lalouel J.-M., Cambillau C.;
RT   "Lipoprotein lipase. Molecular model based on the pancreatic lipase X-
RT   ray structure: consequences for heparin binding and catalysis.";
RL   J. Biol. Chem. 269:4626-4633(1994).
RN   [15]
RP   REVIEW ON VARIANTS.
RA   Hayden M.R., Ma Y., Brunzell J., Henderson H.E.;
RT   "Genetic variants affecting human lipoprotein and hepatic lipases.";
RL   Curr. Opin. Lipidol. 2:104-109(1991).
RN   [16]
RP   VARIANT LPL DEFICIENCY THR-271.
RX   PubMed=2121025;
RA   Hata A., Emi M., Luc G., Basdevant A., Gambert P., Iverius P.-H.,
RA   Lalouel J.-M.;
RT   "Compound heterozygote for lipoprotein lipase deficiency: Ser-->Thr244
RT   and transition in 3' splice site of intron 2 (AG-->AA) in the
RT   lipoprotein lipase gene.";
RL   Am. J. Hum. Genet. 47:721-726(1990).
RN   [17]
RP   VARIANT LPL DEFICIENCY GLU-215.
RX   PubMed=1969408;
RA   Emi M., Wilson D.E., Iverius P.H., Wiu L., Hata A., Hegele R.,
RA   Williams R.R., Lalouel J.-M.;
RT   "Missense mutation (Gly-->Glu188) of human lipoprotein lipase
RT   imparting functional deficiency.";
RL   J. Biol. Chem. 265:5910-5916(1990).
RN   [18]
RP   VARIANT LPL DEFICIENCY GLU-215.
RX   PubMed=1975597; DOI=10.1172/JCI114769;
RA   Monsalve M.V., Henderson H., Roederer G., Julien P., Deeb S.,
RA   Kastelein J.J.P., Peritz L., Devlin R., Bruin T., Murthy M.R.V.,
RA   Gagne C., Davignon J., Lupien P.J., Brunzell J.D., Hayden M.R.;
RT   "A missense mutation at codon 188 of the human lipoprotein lipase gene
RT   is a frequent cause of lipoprotein lipase deficiency in persons of
RT   different ancestries.";
RL   J. Clin. Invest. 86:728-734(1990).
RN   [19]
RP   VARIANT LPL DEFICIENCY THR-203.
RX   PubMed=2110364; DOI=10.1073/pnas.87.9.3474;
RA   Beg O.U., Meng M.S., Skarlatos S.I., Previato L., Brunzell J.D.,
RA   Brewer H.B. Jr., Fojo S.S.;
RT   "Lipoprotein lipase Bethesda: a single amino acid substitution (Ala-
RT   176-->Thr) leads to abnormal heparin binding and loss of enzymic
RT   activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:3474-3478(1990).
RN   [20]
RP   VARIANTS LPL DEFICIENCY THR-221 AND HIS-270.
RX   PubMed=1702428;
RA   Dichek H.L., Fojo S.S., Beg O.U., Skarlatos S.I., Brunzell J.D.,
RA   Cutler G.B. Jr., Brewer H.B. Jr.;
RT   "Identification of two separate allelic mutations in the lipoprotein
RT   lipase gene of a patient with the familial hyperchylomicronemia
RT   syndrome.";
RL   J. Biol. Chem. 266:473-477(1991).
RN   [21]
RP   VARIANT LPL DEFICIENCY GLY-183.
RX   PubMed=1907278;
RA   Faustinella F., Chang A., van Biervliet J.P., Rosseneu M.,
RA   Vinaimont N., Smith L.C., Chen S.-H., Chan L.;
RT   "Catalytic triad residue mutation (Asp156-->Gly) causing familial
RT   lipoprotein lipase deficiency. Co-inheritance with a nonsense mutation
RT   (Ser447-->Ter) in a Turkish family.";
RL   J. Biol. Chem. 266:14418-14424(1991).
RN   [22]
RP   VARIANT LPL DEFICIENCY GLU-169.
RX   PubMed=2010533; DOI=10.1172/JCI115114;
RA   Ameis D., Kobayashi J., Davis R.C., Ben-Zeev O., Malloy M.J.,
RA   Kane J.P., Lee G., Wong H., Havel R.J., Schotz M.C.;
RT   "Familial chylomicronemia (type I hyperlipoproteinemia) due to a
RT   single missense mutation in the lipoprotein lipase gene.";
RL   J. Clin. Invest. 87:1165-1170(1991).
RN   [23]
RP   VARIANT LPL DEFICIENCY THR-221.
RX   PubMed=1674945; DOI=10.1172/JCI115229;
RA   Henderson H.E., Ma Y., Hassan F., Monsalve M.V., Marais A.D.,
RA   Winkler F., Gubernator K., Peterson J., Brunzell J.D., Hayden M.R.;
RT   "Amino acid substitution (Ile194-->Thr) in exon 5 of the lipoprotein
RT   lipase gene causes lipoprotein lipase deficiency in three unrelated
RT   probands. Support for a multicentric origin.";
RL   J. Clin. Invest. 87:2005-2011(1991).
RN   [24]
RP   VARIANTS LPL DEFICIENCY GLU-231 AND HIS-270, AND CHARACTERIZATION OF
RP   VARIANTS LPL DEFICIENCY GLU-231 AND HIS-270.
RX   PubMed=1752947; DOI=10.1172/JCI115507;
RA   Gotoda T., Yamada N., Kawamura M., Kozaki K., Mori N., Ishibashi S.,
RA   Shimano H., Takaku F., Yazaki Y., Furuichi Y., Murase T.;
RT   "Heterogeneous mutations in the human lipoprotein lipase gene in
RT   patients with familial lipoprotein lipase deficiency.";
RL   J. Clin. Invest. 88:1856-1864(1991).
RN   [25]
RP   VARIANT LPL DEFICIENCY LEU-234.
RX   PubMed=2038366; DOI=10.1056/NEJM199106203242502;
RA   Ma Y., Henderson H.E., Ven Murthy M.R., Roederer G., Monsalve M.V.,
RA   Clarke L.A., Normand T., Julien P., Gagne C., Lambert M., Davignon J.,
RA   Lupien P.J., Brunzell J., Hayden M.R.;
RT   "A mutation in the human lipoprotein lipase gene as the most common
RT   cause of familial chylomicronemia in French Canadians.";
RL   N. Engl. J. Med. 324:1761-1766(1991).
RN   [26]
RP   VARIANT LPL DEFICIENCY ARG-113.
RX   PubMed=1598907;
RA   Ishimura-Oka K., Faustinella F., Kihara S., Smith L.C., Oka K.,
RA   Chan L.;
RT   "A missense mutation (Trp86-->Arg) in exon 3 of the lipoprotein lipase
RT   gene: a cause of familial chylomicronemia.";
RL   Am. J. Hum. Genet. 50:1275-1280(1992).
RN   [27]
RP   VARIANT LPL DEFICIENCY ARG-184.
RX   PubMed=1521525; DOI=10.1111/j.1432-1033.1992.tb17182.x;
RA   Bruin T., Kastelein J.J., van Diermen D.E., Ma Y., Henderson H.E.,
RA   Stuyt P.M., Stalenhoef A.F.H., Sturk A., Brunzell J.D., Hayden M.R.;
RT   "A missense mutation Pro157Arg in lipoprotein lipase (LPLNijmegen)
RT   resulting in loss of catalytic activity.";
RL   Eur. J. Biochem. 208:267-272(1992).
RN   [28]
RP   VARIANT LPL DEFICIENCY ASN-277.
RX   PubMed=1639392; DOI=10.1016/0888-7543(92)90136-G;
RA   Ma Y., Wilson B.I., Bijvoet S., Henderson H.E., Cramb E., Roederer G.,
RA   Ven Murthy M.R., Julien P., Bakker H.D., Kastelein J.J.,
RA   Brunzell J.D., Hayden M.R.;
RT   "A missense mutation (Asp250-->Asn) in exon 6 of the human lipoprotein
RT   lipase gene causes chylomicronemia in patients of different
RT   ancestries.";
RL   Genomics 13:649-653(1992).
RN   [29]
RP   VARIANTS LPL DEFICIENCY ASN-183; GLY-183 AND SER-243.
RX   PubMed=1730727;
RA   Ma Y.H., Bruin T., Tuzgol S., Wilson B.I., Roederer G., Liu M.S.,
RA   Davignon J., Kastelein J.J., Brunzell J.D., Hayden M.R.;
RT   "Two naturally occurring mutations at the first and second bases of
RT   codon aspartic acid 156 in the proposed catalytic triad of human
RT   lipoprotein lipase. In vivo evidence that aspartic acid 156 is
RT   essential for catalysis.";
RL   J. Biol. Chem. 267:1918-1923(1992).
RN   [30]
RP   CHARACTERIZATION OF VARIANTS LPL DEFICIENCY ASN-183 AND GLY-183, AND
RP   MUTAGENESIS OF SER-159 AND HIS-268.
RX   PubMed=1371284;
RA   Emmerich J., Beg O.U., Peterson J., Previato L., Brunzell J.D.,
RA   Brewer H.B. Jr., Santamarina-Fojo S.;
RT   "Human lipoprotein lipase. Analysis of the catalytic triad by site-
RT   directed mutagenesis of Ser-132, Asp-156, and His-241.";
RL   J. Biol. Chem. 267:4161-4165(1992).
RN   [31]
RP   VARIANT LPL DEFICIENCY GLU-222.
RX   PubMed=1400331;
RA   Hata A., Ridinger D.N., Sutherland S.D., Emi M., Kwong L.K.,
RA   Shuhua J., Lubbers A., Guy-Grand B., Basdevant A., Iverius P.H.,
RA   Wilson D.E., Lalouel J.-M.;
RT   "Missense mutations in exon 5 of the human lipoprotein lipase gene.
RT   Inactivation correlates with loss of dimerization.";
RL   J. Biol. Chem. 267:20132-20139(1992).
RN   [32]
RP   VARIANTS LPL DEFICIENCY GLU-215; HIS-270 AND ASN-277.
RX   PubMed=1619366;
RA   Ishimura-Oka K., Semenkovich C.F., Faustinella F., Goldberg I.J.,
RA   Shachter N., Smith L.C., Coleman T., Hide W.A., Brown W.V., Oka K.;
RT   "A missense (Asp250-->Asn) mutation in the lipoprotein lipase gene in
RT   two unrelated families with familial lipoprotein lipase deficiency.";
RL   J. Lipid Res. 33:745-754(1992).
RN   [33]
RP   VARIANTS LPL DEFICIENCY ARG-113; ARG-163; GLU-215; THR-221 AND
RP   SER-232.
RX   PubMed=1479292;
RA   Reina M., Brunzell J.D., Deeb S.S.;
RT   "Molecular basis of familial chylomicronemia: mutations in the
RT   lipoprotein lipase and apolipoprotein C-II genes.";
RL   J. Lipid Res. 33:1823-1832(1992).
RN   [34]
RP   VARIANT LPL DEFICIENCY THR-361.
RX   PubMed=8096693; DOI=10.1006/bbrc.1993.1323;
RA   Kobayashi J., Sasaki N., Tashiro J., Inadera H., Saito Y., Yoshida S.;
RT   "A missense mutation (Ala334-->Thr) in exon 7 of the lipoprotein
RT   lipase gene in a case with type I hyperlipidemia.";
RL   Biochem. Biophys. Res. Commun. 191:1046-1054(1993).
RN   [35]
RP   VARIANT LPL DEFICIENCY GLU-207.
RX   PubMed=8288243; DOI=10.1006/geno.1993.1481;
RA   Haubenwallner S., Horl G., Shachter N.S., Presta E., Fried S.K.,
RA   Hofler G., Kostner G.M., Breslow J.L., Zechner R.;
RT   "A novel missense mutation in the gene for lipoprotein lipase
RT   resulting in a highly conservative amino acid substitution
RT   (Asp180-->Glu) causes familial chylomicronemia (type I
RT   hyperlipoproteinemia).";
RL   Genomics 18:392-396(1993).
RN   [36]
RP   VARIANT LPL DEFICIENCY CYS-199.
RX   PubMed=8486765; DOI=10.1172/JCI116414;
RA   Ma Y., Liu M.-S., Ginzinger D., Frohlich J., Brunzell J.D.,
RA   Hayden M.R.;
RT   "Gene-environment interaction in the conversion of a mild-to-severe
RT   phenotype in a patient homozygous for a Ser172-->Cys mutation in the
RT   lipoprotein lipase gene.";
RL   J. Clin. Invest. 91:1953-1958(1993).
RN   [37]
RP   VARIANT LPL DEFICIENCY SER-102.
RX   PubMed=8325986; DOI=10.1172/JCI116551;
RA   Wilson D.E., Hata A., Kwong L.K., Lingam A., Shuhua J., Ridinger D.N.,
RA   Yeager C., Kaltenborn K.C., Iverius P.-H., Lalouel J.-M.;
RT   "Mutations in exon 3 of the lipoprotein lipase gene segregating in a
RT   family with hypertriglyceridemia, pancreatitis, and non-insulin-
RT   dependent diabetes.";
RL   J. Clin. Invest. 92:203-211(1993).
RN   [38]
RP   VARIANT LPL DEFICIENCY SER-181.
RX   PubMed=8301230;
RA   Bruin T., Tuzgol S., van Diermen D.E., Hoogerbrugge-Van der Linden N.,
RA   Brunzell J.D., Hayden M.R., Kastelein J.J.;
RT   "Recurrent pancreatitis and chylomicronemia in an extended Dutch
RT   kindred is caused by a Gly154-->Ser substitution in lipoprotein
RT   lipase.";
RL   J. Lipid Res. 34:2109-2119(1993).
RN   [39]
RP   VARIANT LPL DEFICIENCY VAL-392.
RX   PubMed=8135797; DOI=10.1006/bbrc.1994.1266;
RA   Chimienti G.P.G., Resta F., di Perma V., Tarricone C., Lovecchio M.,
RA   Collacicco A.M., Capurso A.;
RT   "A new Italian case of lipoprotein lipase deficiency: a Leu365-> Val
RT   change resulting in loss of enzyme activity.";
RL   Biochem. Biophys. Res. Commun. 199:570-576(1994).
RN   [40]
RP   VARIANT LPL DEFICIENCY SER-70, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY SER-70.
RX   PubMed=7999071; DOI=10.1006/bbrc.1994.2694;
RA   Kobayashi J., Inadera H., Fujita Y., Talley G., Morisaki N.,
RA   Yoshida S., Saito Y., Fojo S.S., Brewer H.B. Jr.;
RT   "A naturally occurring mutation at the second base of codon asparagine
RT   43 in the proposed N-linked glycosylation site of human lipoprotein
RT   lipase: in vivo evidence that asparagine 43 is essential for catalysis
RT   and secretion.";
RL   Biochem. Biophys. Res. Commun. 205:506-515(1994).
RN   [41]
RP   VARIANTS LPL DEFICIENCY HIS-270 AND CYS-270.
RX   PubMed=7906986; DOI=10.1002/humu.1380030109;
RA   Ma Y., Liu M.-S., Chitayat D., Bruin T., Beisiegel U., Benlian P.,
RA   Foubert L., De Gennes J.L., Funke H., Forsythe I., Blaichman S.,
RA   Papanikolaou M., Erkelens D.W., Kastelein J., Brunzell J.D.,
RA   Hayden M.R.;
RT   "Recurrent missense mutations at the first and second base of codon
RT   Arg243 in human lipoprotein lipase in patients of different
RT   ancestries.";
RL   Hum. Mutat. 3:52-58(1994).
RN   [42]
RP   VARIANTS LPL DEFICIENCY LEU-96 AND GLU-215, AND CHARACTERIZATION OF
RP   VARIANT LPL DEFICIENCY LEU-96.
RX   PubMed=7912254;
RA   Bruin T., Tuzgoel S., Mulder W.J., van den Ende A.E., Jansen H.,
RA   Hayden M.R., Kastelein J.J.P.;
RT   "A compound heterozygote for lipoprotein lipase deficiency,
RT   Val69-->Leu and Gly188-->Glu: correlation between in vitro LPL
RT   activity and clinical expression.";
RL   J. Lipid Res. 35:438-445(1994).
RN   [43]
RP   VARIANTS LPL DEFICIENCY CYS-199; ARG-279; THR-288 AND SER-318, AND
RP   CHARACTERIZATION OF VARIANTS LPL DEFICIENCY ARG-279 AND THR-288.
RX   PubMed=8077845;
RA   Ma Y., Ooi T.C., Liu M.-S., Zhang H., McPherson R., Edwards A.L.,
RA   Forsythe I.J., Frohlich J., Brunzell J.D., Hayden M.R.;
RT   "High frequency of mutations in the human lipoprotein lipase gene in
RT   pregnancy-induced chylomicronemia: possible association with
RT   apolipoprotein E2 isoform.";
RL   J. Lipid Res. 35:1066-1075(1994).
RN   [44]
RP   VARIANT LPL DEFICIENCY VAL-437.
RX   PubMed=7806969;
RA   Previato L., Guardamagna O., Dugi K.A., Ronan R., Talley G.D.,
RA   Santamarina-Fojo S., Brewer H.B. Jr.;
RT   "A novel missense mutation in the C-terminal domain of lipoprotein
RT   lipase (Glu410-->Val) leads to enzyme inactivation and familial
RT   chylomicronemia.";
RL   J. Lipid Res. 35:1552-1560(1994).
RN   [45]
RP   VARIANT LPL DEFICIENCY SER-318.
RX   PubMed=7647785; DOI=10.1038/ng0595-28;
RA   Reymer P.W.A., Gagne E., Groenemeyer B.E., Zhang H., Forsyth I.,
RA   Jansen H., Seidell J.C., Kromhout D., Lie K.E., Kastelein J.J.,
RA   Hayden M.R.;
RT   "A lipoprotein lipase mutation (Asn291Ser) is associated with reduced
RT   HDL cholesterol levels in premature atherosclerosis.";
RL   Nat. Genet. 10:28-34(1995).
RN   [46]
RP   VARIANT LPL DEFICIENCY TYR-445, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY TYR-445.
RX   PubMed=8858123; DOI=10.1006/bbrc.1996.1487;
RA   Henderson H.E., Hassan F., Marais D., Hayden M.R.;
RT   "A new mutation destroying disulphide bridging in the C-terminal
RT   domain of lipoprotein lipase.";
RL   Biochem. Biophys. Res. Commun. 227:189-194(1996).
RN   [47]
RP   VARIANT LPL DEFICIENCY SER-318, AND VARIANT ASN-36.
RX   PubMed=8872057; DOI=10.1111/j.1365-2362.1996.tb02146.x;
RA   de Bruin T.W.A., Mailly F., van Barlingen H.H.J.J., Fisher R.,
RA   Castro Cabezas M., Talmud P., Dallinga-Thie G.M., Humphries S.E.;
RT   "Lipoprotein lipase gene mutations D9N and N291S in four pedigrees
RT   with familial combined hyperlipidaemia.";
RL   Eur. J. Clin. Invest. 26:631-639(1996).
RN   [48]
RP   VARIANTS LPL DEFICIENCY ASN-277 AND LYS-437.
RX   PubMed=8956048;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:4<381::AID-HUMU16>3.0.CO;2-Z;
RA   Wiebusch H., Funke H., Bruin T., Bucher H., von Eckardstein A.,
RA   Kastelein J.J.P., Assmann G.;
RT   "Compound heterozygosity for a known (D250N) and a novel (E410K)
RT   missense mutation in the C-terminal domain of lipoprotein lipase
RT   causes familial chylomicronemia.";
RL   Hum. Mutat. 8:381-383(1996).
RN   [49]
RP   VARIANTS LPL DEFICIENCY GLY-190 AND GLU-215.
RX   PubMed=8956052;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:4<392::AID-HUMU20>3.0.CO;2-X;
RA   Wiebusch H., Funke H., Santer R., Richter W., Assmann G.;
RT   "A novel missense (E163G) mutation in the catalytic subunit of
RT   lipoprotein lipase causes familial chylomicronemia.";
RL   Hum. Mutat. 8:392-392(1996).
RN   [50]
RP   VARIANT LPL DEFICIENCY HIS-289, VARIANT ASN-36, CHARACTERIZATION OF
RP   VARIANT LPL DEFICIENCY HIS-289, AND CHARACTERIZATION OF VARIANT
RP   ASN-36.
RX   PubMed=8728326;
RA   Rouis M., Lohse P., Dugi K.A., Lohse P., Beg O.U., Ronan R.,
RA   Talley G.D., Brunzell J.D., Santamarina-Fojo S.;
RT   "Homozygosity for two point mutations in the lipoprotein lipase (LPL)
RT   gene in a patient with familial LPL deficiency: LPL(Asp9-->Asn,
RT   Tyr262-->His).";
RL   J. Lipid Res. 37:651-661(1996).
RN   [51]
RP   VARIANTS LPL DEFICIENCY ALA-128; GLU-215; ARG-215; CYS-270; ASN-277
RP   AND PRO-313.
RX   PubMed=8778602; DOI=10.1056/NEJM199609193351203;
RA   Benlian P., De Gennes J.L., Foubert L., Zhang H., Gagne S.E.,
RA   Hayden M.;
RT   "Premature atherosclerosis in patients with familial chylomicronemia
RT   caused by mutations in the lipoprotein lipase gene.";
RL   N. Engl. J. Med. 335:848-854(1996).
RN   [52]
RP   VARIANT LPL DEFICIENCY ARG-286.
RX   PubMed=9298816;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:3<179::AID-HUMU1>3.3.CO;2-N;
RA   Foubert L., Bruin T., de Gennes J.-L., Ehrenborg E., Furioli J.,
RA   Kastelein J.J., Benlian P., Hayden M.R.;
RT   "A single Ser259Arg mutation in the gene for lipoprotein lipase causes
RT   chylomicronemia in Moroccans of Berber ancestry.";
RL   Hum. Mutat. 10:179-185(1997).
RN   [53]
RP   VARIANTS.
RX   PubMed=9401010;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:6<465::AID-HUMU8>3.3.CO;2-3;
RA   Mailly F., Palmen J., Muller D.P.R., Gibbs T., Lloyd J., Brunzell J.,
RA   Durrington P., Mitropoulos K., Betteridge J., Watts G., Lithell H.,
RA   Angelico F., Humphries S.E., Talmud P.J.;
RT   "Familial lipoprotein lipase (LPL) deficiency: a catalogue of LPL gene
RT   mutations identified in 20 patients from the UK, Sweden, and Italy.";
RL   Hum. Mutat. 10:465-473(1997).
RN   [54]
RP   VARIANTS LPL DEFICIENCY ALA-128; HIS-183; GLU-215; ARG-215; LEU-234;
RP   CYS-270 AND ASN-277.
RX   PubMed=9279761; DOI=10.1136/jmg.34.8.672;
RA   Foubert L., De Gennes J.L., Lagarde J.P., Ehrenborg E., Raisonnier A.,
RA   Girardet J.P., Hayden M.R., Benlian P.;
RT   "Assessment of French patients with LPL deficiency for French Canadian
RT   mutations.";
RL   J. Med. Genet. 34:672-675(1997).
RN   [55]
RP   VARIANTS LPL DEFICIENCY THR-252 AND HIS-270.
RX   PubMed=9714430;
RX   DOI=10.1002/(SICI)1096-8628(19980724)78:4<313::AID-AJMG1>3.0.CO;2-M;
RA   Henderson H.E., Bijvoet S.M., Mannens M.A.M.M., Bruin T.,
RA   Erkelens D.W., Hayden M.R., Kastelein J.J.P.;
RT   "Ile225Thr loop mutation in the lipoprotein lipase (LPL) gene is a de
RT   novo event.";
RL   Am. J. Med. Genet. 78:313-316(1998).
RN   [56]
RP   VARIANT LPL DEFICIENCY LYS-448, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY LYS-448.
RX   PubMed=9498099; DOI=10.1016/S0009-8981(97)00144-7;
RA   Henderson H., Leisegang F., Hassan F., Hayden M., Marais D.;
RT   "A novel Glu421Lys substitution in the lipoprotein lipase gene in
RT   pregnancy-induced hypertriglyceridemic pancreatitis.";
RL   Clin. Chim. Acta 269:1-12(1998).
RN   [57]
RP   VARIANTS LPL DEFICIENCY GLU-215 AND GLY-286.
RX   PubMed=10660334;
RA   Evans D., Wendt D., Ahle S., Guerra A., Beisiegel U.;
RT   "Compound heterozygosity for a new (S259G) and a previously described
RT   (G188E) mutation in lipoprotein lipase (LPL) as a cause of
RT   chylomicronemia.";
RL   Hum. Mutat. 12:217-217(1998).
RN   [58]
RP   VARIANTS LPL DEFICIENCY THR-288 AND SER-318, AND VARIANT ASN-36.
RX   PubMed=9719626; DOI=10.1006/mgme.1998.2712;
RA   Zhang Q., Liu Y., Liu B.W., Fan P., Cavanna J., Galton D.J.;
RT   "Common genetic variants of lipoprotein lipase and apolipoproteins AI-
RT   CIII that relate to coronary artery disease: a study in Chinese and
RT   European subjects.";
RL   Mol. Genet. Metab. 64:177-183(1998).
RN   [59]
RP   VARIANT LPL DEFICIENCY SER-318, AND VARIANTS MET-370 AND ALA-379.
RX   PubMed=9662394; DOI=10.1038/907;
RA   Nickerson D.A., Taylor S.L., Weiss K.M., Clark A.G., Hutchinson R.G.,
RA   Stengaerd J., Salomaa V., Vartiainen E., Boerwinkle E., Sing C.F.;
RT   "DNA sequence diversity in a 9.7-kb region of the human lipoprotein
RT   lipase gene.";
RL   Nat. Genet. 19:233-240(1998).
RN   [60]
RP   VARIANT THR-427.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [61]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [62]
RP   VARIANT LPL DEFICIENCY LEU-297, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY LEU-297.
RX   PubMed=11068186; DOI=10.1016/S0925-4439(00)00067-3;
RA   Takagi A., Ikeda Y., Takeda E., Yamamoto A.;
RT   "A newly identified lipoprotein lipase (LPL) gene mutation (F270L) in
RT   a Japanese patient with familial LPL deficiency.";
RL   Biochim. Biophys. Acta 1502:433-446(2000).
RN   [63]
RP   VARIANTS LPL DEFICIENCY ARG-132 AND GLU-231, AND CHARACTERIZATION OF
RP   VARIANTS LPL DEFICIENCY ARG-132 AND GLU-231.
RX   PubMed=11099402; DOI=10.1042/CS20000134;
RA   Ikeda Y., Goji K., Takagi A.;
RT   "A compound heterozygote for a novel missense mutation (G105R) in exon
RT   3 and a missense mutation (D204E) in exon 5 of the lipoprotein lipase
RT   gene in a Japanese infant with hyperchylomicronaemia.";
RL   Clin. Sci. 99:569-578(2000).
RN   [64]
RP   VARIANT LPL DEFICIENCY TRP-266.
RX   PubMed=11134145; DOI=10.1210/jc.85.12.4795;
RA   Hoffmann M.M., Jacob S., Luft D., Schmuelling R.-M., Rett K.,
RA   Maerz W., Haering H.-U., Matthaei S.;
RT   "Type I hyperlipoproteinemia due to a novel loss of function mutation
RT   of lipoprotein lipase, Cys(239)-->Trp, associated with recurrent
RT   severe pancreatitis.";
RL   J. Clin. Endocrinol. Metab. 85:4795-4798(2000).
RN   [65]
RP   VARIANT LPL DEFICIENCY ASP-210, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY ASP-210.
RX   PubMed=10787434;
RA   Hoelzl B., Kraft H.G., Wiebusch H., Sandhofer A., Patsch J.,
RA   Sandhofer F., Paulweber B.;
RT   "Two novel mutations in the lipoprotein lipase gene in a family with
RT   marked hypertriglyceridemia in heterozygous carriers. Potential
RT   interaction with the polymorphic marker D1S104 on chromosome 1q21-
RT   q23.";
RL   J. Lipid Res. 41:734-741(2000).
RN   [66]
RP   VARIANT LPL DEFICIENCY VAL-181, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY VAL-181.
RX   PubMed=11441134;
RA   Ikeda Y., Takagi A., Nakata Y., Sera Y., Hyoudou S., Hamamoto K.,
RA   Nishi Y., Yamamoto A.;
RT   "Novel compound heterozygous mutations for lipoprotein lipase
RT   deficiency. A G-to-T transversion at the first position of exon 5
RT   causing G154V missense mutation and a 5' splice site mutation of
RT   intron 8.";
RL   J. Lipid Res. 42:1072-1081(2001).
RN   [67]
RP   VARIANTS LPL DEFICIENCY THR-98; ILE-208; VAL-279; ARG-279; TYR-310;
RP   ARG-325 AND PHE-365, AND CHARACTERIZATION OF VARIANTS LPL DEFICIENCY
RP   THR-98; ILE-208; VAL-279; ARG-279; TYR-310; ARG-325 AND PHE-365.
RX   PubMed=12204001; DOI=10.1002/humu.9054;
RA   Chan L.Y.S., Lam C.-W., Mak Y.-T., Tomlinson B., Tsang M.-W., Baum L.,
RA   Masarei J.R.L., Pang C.-P.;
RT   "Genotype-phenotype studies of six novel LPL mutations in Chinese
RT   patients with hypertriglyceridemia.";
RL   Hum. Mutat. 20:232-233(2002).
RN   [68]
RP   VARIANT LPL DEFICIENCY PHE-303, AND CHARACTERIZATION OF VARIANT LPL
RP   DEFICIENCY PHE-303.
RX   PubMed=12641539; DOI=10.1046/j.1365-2362.2003.01129.x;
RA   Saika Y., Sakai N., Takahashi M., Maruyama T., Kihara S., Ouchi N.,
RA   Ishigami M., Hiraoka H., Nakamura T., Yamashita S., Matsuzawa Y.;
RT   "Novel LPL mutation (L303F) found in a patient associated with
RT   coronary artery disease and severe systemic atherosclerosis.";
RL   Eur. J. Clin. Invest. 33:216-222(2003).
RN   [69]
RP   VARIANT LPL DEFICIENCY SER-318, AND VARIANT ASN-36.
RX   PubMed=12966036; DOI=10.1093/hmg/ddg314;
RA   Morabia A., Cayanis E., Costanza M.C., Ross B.M., Flaherty M.S.,
RA   Alvin G.B., Das K., Gilliam T.C.;
RT   "Association of extreme blood lipid profile phenotypic variation with
RT   11 reverse cholesterol transport genes and 10 non-genetic
RT   cardiovascular disease risk factors.";
RL   Hum. Mol. Genet. 12:2733-2743(2003).
RN   [70]
RP   VARIANT LPL DEFICIENCY VAL-201.
RX   PubMed=14984478; DOI=10.1111/j.0009-9163.2004.00205.x;
RA   Abifadel M., Jambart S., Allard D., Rabes J.-P., Varret M., Derre A.,
RA   Chouery E., Salem N., Junien C., Aydenian H., Boileau C.;
RT   "Identification of the first Lebanese mutation in the LPL gene and
RT   description of a rapid detection method.";
RL   Clin. Genet. 65:158-161(2004).
RN   [71]
RP   VARIANTS LPL DEFICIENCY GLU-215 AND ARG-328.
RX   PubMed=15185149; DOI=10.1007/s00431-004-1474-1;
RA   Kavazarakis E., Stabouli S., Gourgiotis D., Roumeliotou K.,
RA   Traeger-Synodinos J., Bossios A., Fretzayas A., Kanavakis E.;
RT   "Severe hypertriglyceridaemia in a Greek infant: a clinical,
RT   biochemical and genetic study.";
RL   Eur. J. Pediatr. 163:462-466(2004).
RN   [72]
RP   VARIANTS LPL DEFICIENCY SER-70; ARG-132; VAL-181; GLU-215; THR-221;
RP   ARG-225; ALA-227; GLU-231; CYS-270; HIS-270; THR-288; LEU-297;
RP   ARG-305; PHE-330 AND THR-361.
RX   PubMed=15256764; DOI=10.5551/jat.11.131;
RG   The research committee on primary hyperlipidemia of the ministry of health and welfare of Japan;
RA   Maruyama T., Yamashita S., Matsuzawa Y., Bujo H., Takahashi K.,
RA   Saito Y., Ishibashi S., Ohashi K., Shionoiri F., Gotoda T., Yamada N.,
RA   Kita T.;
RT   "Mutations in Japanese subjects with primary hyperlipidemia -- results
RT   from the Research Committee of the Ministry of Health and Welfare of
RT   Japan since 1996.";
RL   J. Atheroscler. Thromb. 11:131-145(2004).
RN   [73]
RP   VARIANTS LPL DEFICIENCY GLU-186; GLU-215 AND THR-221.
RX   PubMed=15877202; DOI=10.1007/s10545-005-7060-5;
RA   Santer R., Gokcay G., Demirkol M., Gal A., Lukacs Z.;
RT   "Hyperchylomicronaemia due to lipoprotein lipase deficiency as a cause
RT   of false-positive newborn screening for biotinidase deficiency.";
RL   J. Inherit. Metab. Dis. 28:137-140(2005).
CC   -!- FUNCTION: The primary function of this lipase is the hydrolysis of
CC       triglycerides of circulating chylomicrons and very low density
CC       lipoproteins (VLDL). Binding to heparin sulfate proteogylcans at
CC       the cell surface is vital to the function. The apolipoprotein,
CC       APOC2, acts as a coactivator of LPL activity in the presence of
CC       lipids on the luminal surface of vascular endothelium (By
CC       similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: Triacylglycerol + H(2)O = diacylglycerol + a
CC       carboxylate. {ECO:0000269|PubMed:11342582}.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with APOC2; the
CC       interaction activates LPL activity in the presence of lipids.
CC       Interacts with GPIHBP1. {ECO:0000250,
CC       ECO:0000269|PubMed:17997385}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Lipid-anchor,
CC       GPI-anchor {ECO:0000250}. Secreted {ECO:0000250}. Note=Locates to
CC       the plasma membrane of microvilli of hepatocytes with triacyl-
CC       glycerol-rich lipoproteins (TRL). Some of the bound LPL is then
CC       internalized and located inside non-coated endocytic vesicles (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Tyrosine nitration after lipopolysaccharide (LPS) challenge
CC       down-regulates the lipase activity. {ECO:0000250}.
CC   -!- DISEASE: Lipoprotein lipase deficiency (LPL deficiency)
CC       [MIM:238600]: Recessive disorder usually manifesting in childhood.
CC       On a normal diet, patients often present with abdominal pain,
CC       hepatosplenomegaly, lipemia retinalis, eruptive xanthomata, and
CC       massive hypertriglyceridemia, sometimes complicated with acute
CC       pancreatitis. {ECO:0000269|PubMed:10660334,
CC       ECO:0000269|PubMed:10787434, ECO:0000269|PubMed:11068186,
CC       ECO:0000269|PubMed:11099402, ECO:0000269|PubMed:11134145,
CC       ECO:0000269|PubMed:11441134, ECO:0000269|PubMed:12204001,
CC       ECO:0000269|PubMed:12641539, ECO:0000269|PubMed:12966036,
CC       ECO:0000269|PubMed:1400331, ECO:0000269|PubMed:1479292,
CC       ECO:0000269|PubMed:14984478, ECO:0000269|PubMed:15185149,
CC       ECO:0000269|PubMed:1521525, ECO:0000269|PubMed:15256764,
CC       ECO:0000269|PubMed:15877202, ECO:0000269|PubMed:1598907,
CC       ECO:0000269|PubMed:1619366, ECO:0000269|PubMed:1639392,
CC       ECO:0000269|PubMed:1674945, ECO:0000269|PubMed:1702428,
CC       ECO:0000269|PubMed:1730727, ECO:0000269|PubMed:1752947,
CC       ECO:0000269|PubMed:1907278, ECO:0000269|PubMed:1969408,
CC       ECO:0000269|PubMed:1975597, ECO:0000269|PubMed:2010533,
CC       ECO:0000269|PubMed:2038366, ECO:0000269|PubMed:2110364,
CC       ECO:0000269|PubMed:2121025, ECO:0000269|PubMed:7647785,
CC       ECO:0000269|PubMed:7806969, ECO:0000269|PubMed:7906986,
CC       ECO:0000269|PubMed:7912254, ECO:0000269|PubMed:7999071,
CC       ECO:0000269|PubMed:8077845, ECO:0000269|PubMed:8096693,
CC       ECO:0000269|PubMed:8135797, ECO:0000269|PubMed:8288243,
CC       ECO:0000269|PubMed:8301230, ECO:0000269|PubMed:8325986,
CC       ECO:0000269|PubMed:8486765, ECO:0000269|PubMed:8728326,
CC       ECO:0000269|PubMed:8778602, ECO:0000269|PubMed:8858123,
CC       ECO:0000269|PubMed:8872057, ECO:0000269|PubMed:8956048,
CC       ECO:0000269|PubMed:8956052, ECO:0000269|PubMed:9279761,
CC       ECO:0000269|PubMed:9298816, ECO:0000269|PubMed:9498099,
CC       ECO:0000269|PubMed:9662394, ECO:0000269|PubMed:9714430,
CC       ECO:0000269|PubMed:9719626}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the AB hydrolase superfamily. Lipase
CC       family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 PLAT domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00152}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=LPL";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Lipoprotein lipase entry;
CC       URL="https://en.wikipedia.org/wiki/Lipoprotein_lipase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M15856; AAB59536.1; -; mRNA.
DR   EMBL; X14390; CAA32564.1; -; mRNA.
DR   EMBL; X54516; CAA38372.1; -; mRNA.
DR   EMBL; M76722; AAA59528.1; -; Genomic_DNA.
DR   EMBL; S76076; AAB21000.1; -; Genomic_DNA.
DR   EMBL; S76077; AAB20999.1; -; Genomic_DNA.
DR   EMBL; BT006726; AAP35372.1; -; mRNA.
DR   EMBL; AK312311; BAG35236.1; -; mRNA.
DR   EMBL; CH471080; EAW63764.1; -; Genomic_DNA.
DR   EMBL; BC011353; AAH11353.1; -; mRNA.
DR   EMBL; X68111; CAA48230.1; -; Genomic_DNA.
DR   CCDS; CCDS6012.1; -.
DR   PIR; A26082; LIHUL.
DR   RefSeq; NP_000228.1; NM_000237.2.
DR   UniGene; Hs.180878; -.
DR   ProteinModelPortal; P06858; -.
DR   SMR; P06858; 36-450.
DR   BioGrid; 110205; 18.
DR   IntAct; P06858; 12.
DR   MINT; MINT-1369348; -.
DR   STRING; 9606.ENSP00000309757; -.
DR   BindingDB; P06858; -.
DR   ChEMBL; CHEMBL2060; -.
DR   DrugBank; DB05269; AST-120.
DR   DrugBank; DB06439; Tyloxapol.
DR   SwissLipids; SLP:000000568; -.
DR   ESTHER; human-LPL; Lipoprotein_Lipase.
DR   iPTMnet; P06858; -.
DR   PhosphoSite; P06858; -.
DR   BioMuta; LPL; -.
DR   DMDM; 126314; -.
DR   MaxQB; P06858; -.
DR   PaxDb; P06858; -.
DR   PRIDE; P06858; -.
DR   DNASU; 4023; -.
DR   Ensembl; ENST00000311322; ENSP00000309757; ENSG00000175445.
DR   GeneID; 4023; -.
DR   KEGG; hsa:4023; -.
DR   UCSC; uc003wzk.4; human.
DR   CTD; 4023; -.
DR   GeneCards; LPL; -.
DR   GeneReviews; LPL; -.
DR   HGNC; HGNC:6677; LPL.
DR   MalaCards; LPL; -.
DR   MIM; 238600; phenotype.
DR   MIM; 609708; gene.
DR   neXtProt; NX_P06858; -.
DR   Orphanet; 309015; Familial lipoprotein lipase deficiency.
DR   Orphanet; 70470; Hyperlipoproteinemia type 5.
DR   PharmGKB; PA232; -.
DR   eggNOG; ENOG410IJUA; Eukaryota.
DR   eggNOG; ENOG4111GMM; LUCA.
DR   GeneTree; ENSGT00760000119069; -.
DR   HOGENOM; HOG000038553; -.
DR   HOVERGEN; HBG002259; -.
DR   InParanoid; P06858; -.
DR   KO; K01059; -.
DR   OMA; ESVANCH; -.
DR   PhylomeDB; P06858; -.
DR   TreeFam; TF324997; -.
DR   BRENDA; 3.1.1.34; 2681.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   GeneWiki; Lipoprotein_lipase; -.
DR   GenomeRNAi; 4023; -.
DR   NextBio; 15776; -.
DR   PRO; PR:P06858; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; P06858; -.
DR   CleanEx; HS_LPL; -.
DR   ExpressionAtlas; P06858; baseline and differential.
DR   Genevisible; P06858; HS.
DR   GO; GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0042627; C:chylomicron; IEA:UniProtKB-KW.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IEA:UniProtKB-KW.
DR   GO; GO:0034185; F:apolipoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0008201; F:heparin binding; IDA:BHF-UCL.
DR   GO; GO:0004465; F:lipoprotein lipase activity; IDA:BHF-UCL.
DR   GO; GO:0004620; F:phospholipase activity; ISS:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.
DR   GO; GO:0017129; F:triglyceride binding; IEA:Ensembl.
DR   GO; GO:0004806; F:triglyceride lipase activity; IDA:BHF-UCL.
DR   GO; GO:0034371; P:chylomicron remodeling; IC:BHF-UCL.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0006644; P:phospholipid metabolic process; ISS:BHF-UCL.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0010886; P:positive regulation of cholesterol storage; IMP:BHF-UCL.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IC:BHF-UCL.
DR   GO; GO:0010890; P:positive regulation of sequestering of triglyceride; IMP:BHF-UCL.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; ISS:AgBase.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0019432; P:triglyceride biosynthetic process; IEA:Ensembl.
DR   GO; GO:0019433; P:triglyceride catabolic process; IDA:BHF-UCL.
DR   GO; GO:0070328; P:triglyceride homeostasis; IGI:BHF-UCL.
DR   GO; GO:0006641; P:triglyceride metabolic process; ISS:BHF-UCL.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   Gene3D; 2.60.60.20; -; 1.
DR   Gene3D; 3.40.50.1820; -; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR016272; Lipase_LIPH.
DR   InterPro; IPR013818; Lipase_N.
DR   InterPro; IPR002330; Lipo_Lipase.
DR   InterPro; IPR001024; PLAT/LH2_dom.
DR   InterPro; IPR000734; TAG_lipase.
DR   PANTHER; PTHR11610; PTHR11610; 1.
DR   PANTHER; PTHR11610:SF3; PTHR11610:SF3; 1.
DR   Pfam; PF00151; Lipase; 1.
DR   Pfam; PF01477; PLAT; 1.
DR   PIRSF; PIRSF000865; Lipoprotein_lipase_LIPH; 1.
DR   PRINTS; PR00822; LIPOLIPASE.
DR   PRINTS; PR00821; TAGLIPASE.
DR   SMART; SM00308; LH2; 1.
DR   SUPFAM; SSF49723; SSF49723; 1.
DR   SUPFAM; SSF53474; SSF53474; 1.
DR   TIGRFAMs; TIGR03230; lipo_lipase; 1.
DR   PROSITE; PS00120; LIPASE_SER; 1.
DR   PROSITE; PS50095; PLAT; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Chylomicron; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; GPI-anchor; Heparin-binding; Hydrolase; Hyperlipidemia;
KW   Lipid degradation; Lipid metabolism; Lipoprotein; Membrane; Nitration;
KW   Polymorphism; Reference proteome; Secreted; Signal; VLDL.
FT   SIGNAL        1     27       {ECO:0000269|PubMed:2340307}.
FT   CHAIN        28    475       Lipoprotein lipase.
FT                                /FTId=PRO_0000017775.
FT   DOMAIN      341    464       PLAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00152}.
FT   REGION      346    441       Heparin-binding. {ECO:0000250}.
FT   ACT_SITE    159    159       Nucleophile.
FT   ACT_SITE    183    183       Charge relay system.
FT   ACT_SITE    268    268       Charge relay system.
FT   MOD_RES     121    121       Nitrated tyrosine.
FT                                {ECO:0000250|UniProtKB:Q06000}.
FT   MOD_RES     191    191       Nitrated tyrosine.
FT                                {ECO:0000250|UniProtKB:Q06000}.
FT   MOD_RES     343    343       Nitrated tyrosine.
FT                                {ECO:0000250|UniProtKB:Q06000}.
FT   CARBOHYD     70     70       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:18780401}.
FT   CARBOHYD    386    386       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     54     67       {ECO:0000255|PROSITE-ProRule:PRU00152}.
FT   DISULFID    243    266       {ECO:0000255|PROSITE-ProRule:PRU00152}.
FT   DISULFID    291    310       {ECO:0000255|PROSITE-ProRule:PRU00152}.
FT   DISULFID    302    305       {ECO:0000255|PROSITE-ProRule:PRU00152}.
FT   DISULFID    445    465       {ECO:0000255|PROSITE-ProRule:PRU00152}.
FT   VARIANT      36     36       D -> N (in LPL deficiency; has
FT                                approximately 80% of the specific
FT                                activity of wild-type enzyme;
FT                                dbSNP:rs1801177).
FT                                {ECO:0000269|PubMed:12966036,
FT                                ECO:0000269|PubMed:8728326,
FT                                ECO:0000269|PubMed:8872057,
FT                                ECO:0000269|PubMed:9719626}.
FT                                /FTId=VAR_011948.
FT   VARIANT      70     70       N -> S (in LPL deficiency; produces an
FT                                inactive protein which is not secreted
FT                                into the media).
FT                                {ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:7999071}.
FT                                /FTId=VAR_057914.
FT   VARIANT      71     71       H -> Q (in dbSNP:rs11542065).
FT                                /FTId=VAR_049819.
FT   VARIANT      96     96       V -> L (in LPL deficiency; gives rise to
FT                                a 80% decrease in specific catalytic
FT                                activity). {ECO:0000269|PubMed:7912254}.
FT                                /FTId=VAR_057915.
FT   VARIANT      98     98       A -> T (in LPL deficiency; decreases the
FT                                specific activity of the enzyme; reduces
FT                                the secretion of the mutant protein
FT                                significantly; the total LPL mass is
FT                                reduced compared to that of the wild-type
FT                                construct).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057916.
FT   VARIANT     102    102       R -> S (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8325986}.
FT                                /FTId=VAR_004211.
FT   VARIANT     113    113       W -> G (in LPL deficiency).
FT                                /FTId=VAR_004212.
FT   VARIANT     113    113       W -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:1479292,
FT                                ECO:0000269|PubMed:1598907}.
FT                                /FTId=VAR_004213.
FT   VARIANT     128    128       T -> A (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8778602,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_057917.
FT   VARIANT     132    132       G -> R (in LPL deficiency; synthesized as
FT                                a catalytically inactive form).
FT                                {ECO:0000269|PubMed:11099402,
FT                                ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057918.
FT   VARIANT     163    163       H -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:1479292}.
FT                                /FTId=VAR_004214.
FT   VARIANT     169    169       G -> E (in LPL deficiency; loss of
FT                                activity). {ECO:0000269|PubMed:2010533}.
FT                                /FTId=VAR_004215.
FT   VARIANT     181    181       G -> S (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8301230}.
FT                                /FTId=VAR_004216.
FT   VARIANT     181    181       G -> V (in LPL deficiency; synthesized as
FT                                a catalytically inactive form).
FT                                {ECO:0000269|PubMed:11441134,
FT                                ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057919.
FT   VARIANT     183    183       D -> G (in LPL deficiency; lacks both
FT                                triolein and tributyrin esterase
FT                                activities). {ECO:0000269|PubMed:1371284,
FT                                ECO:0000269|PubMed:1730727,
FT                                ECO:0000269|PubMed:1907278}.
FT                                /FTId=VAR_004217.
FT   VARIANT     183    183       D -> H (in LPL deficiency).
FT                                {ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_057920.
FT   VARIANT     183    183       D -> N (in LPL deficiency; lacks both
FT                                triolein and tributyrin esterase
FT                                activities). {ECO:0000269|PubMed:1371284,
FT                                ECO:0000269|PubMed:1730727}.
FT                                /FTId=VAR_004218.
FT   VARIANT     184    184       P -> R (in LPL deficiency; Nijmegen; loss
FT                                of activity).
FT                                {ECO:0000269|PubMed:1521525}.
FT                                /FTId=VAR_004219.
FT   VARIANT     185    185       A -> T (in LPL deficiency; 3.2% of
FT                                activity).
FT                                /FTId=VAR_004220.
FT   VARIANT     186    186       G -> E (in LPL deficiency).
FT                                {ECO:0000269|PubMed:15877202}.
FT                                /FTId=VAR_057921.
FT   VARIANT     190    190       E -> G (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8956052}.
FT                                /FTId=VAR_057922.
FT   VARIANT     199    199       S -> C (in LPL deficiency; mild
FT                                hypertriglyceridemia; partial activity).
FT                                {ECO:0000269|PubMed:8077845,
FT                                ECO:0000269|PubMed:8486765}.
FT                                /FTId=VAR_004221.
FT   VARIANT     201    201       D -> V (in LPL deficiency).
FT                                {ECO:0000269|PubMed:14984478}.
FT                                /FTId=VAR_057923.
FT   VARIANT     203    203       A -> T (in LPL deficiency; Bethesda; loss
FT                                of activity and abnormal heparin
FT                                binding). {ECO:0000269|PubMed:2110364}.
FT                                /FTId=VAR_004222.
FT   VARIANT     207    207       D -> E (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8288243}.
FT                                /FTId=VAR_004223.
FT   VARIANT     208    208       V -> I (in LPL deficiency; decreases the
FT                                specific activity of the enzyme; has a
FT                                mild effect on the secretion of the
FT                                mutant enzyme; the total LPL mass is
FT                                reduced compared to that of the wild-type
FT                                construct).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057924.
FT   VARIANT     210    210       H -> D (in LPL deficiency; complete loss
FT                                of enzyme activity).
FT                                {ECO:0000269|PubMed:10787434}.
FT                                /FTId=VAR_057925.
FT   VARIANT     210    210       H -> Q (in LPL deficiency; loss of
FT                                activity).
FT                                /FTId=VAR_004224.
FT   VARIANT     215    215       G -> E (in LPL deficiency; loss of
FT                                activity; dbSNP:rs118204057).
FT                                {ECO:0000269|PubMed:10660334,
FT                                ECO:0000269|PubMed:1479292,
FT                                ECO:0000269|PubMed:15185149,
FT                                ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:15877202,
FT                                ECO:0000269|PubMed:1619366,
FT                                ECO:0000269|PubMed:1969408,
FT                                ECO:0000269|PubMed:1975597,
FT                                ECO:0000269|PubMed:7912254,
FT                                ECO:0000269|PubMed:8778602,
FT                                ECO:0000269|PubMed:8956052,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_004225.
FT   VARIANT     215    215       G -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8778602,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_057926.
FT   VARIANT     220    220       S -> R (in LPL deficiency; 2.0% of
FT                                activity).
FT                                /FTId=VAR_004226.
FT   VARIANT     221    221       I -> T (in LPL deficiency; loss of
FT                                activity). {ECO:0000269|PubMed:1479292,
FT                                ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:15877202,
FT                                ECO:0000269|PubMed:1674945,
FT                                ECO:0000269|PubMed:1702428}.
FT                                /FTId=VAR_004227.
FT   VARIANT     222    222       G -> E (in LPL deficiency).
FT                                {ECO:0000269|PubMed:1400331}.
FT                                /FTId=VAR_004228.
FT   VARIANT     225    225       K -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057927.
FT   VARIANT     227    227       V -> A (in LPL deficiency;
FT                                dbSNP:rs528243561).
FT                                {ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057928.
FT   VARIANT     231    231       D -> E (in LPL deficiency; loss of
FT                                activity). {ECO:0000269|PubMed:11099402,
FT                                ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:1752947}.
FT                                /FTId=VAR_004229.
FT   VARIANT     232    232       I -> S (in LPL deficiency).
FT                                {ECO:0000269|PubMed:1479292}.
FT                                /FTId=VAR_004230.
FT   VARIANT     234    234       P -> L (in LPL deficiency; loss of
FT                                activity). {ECO:0000269|PubMed:2038366,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_004231.
FT   VARIANT     243    243       C -> S (in LPL deficiency; loss of
FT                                activity). {ECO:0000269|PubMed:1730727}.
FT                                /FTId=VAR_004232.
FT   VARIANT     252    252       I -> T (in LPL deficiency).
FT                                {ECO:0000269|PubMed:9714430}.
FT                                /FTId=VAR_057929.
FT   VARIANT     266    266       C -> W (in LPL deficiency).
FT                                {ECO:0000269|PubMed:11134145}.
FT                                /FTId=VAR_057930.
FT   VARIANT     270    270       R -> C (in LPL deficiency).
FT                                {ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:7906986,
FT                                ECO:0000269|PubMed:8778602,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_057931.
FT   VARIANT     270    270       R -> H (in LPL deficiency; loss of
FT                                activity). {ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:1619366,
FT                                ECO:0000269|PubMed:1702428,
FT                                ECO:0000269|PubMed:1752947,
FT                                ECO:0000269|PubMed:7906986,
FT                                ECO:0000269|PubMed:9714430}.
FT                                /FTId=VAR_004233.
FT   VARIANT     271    271       S -> T (in LPL deficiency;
FT                                dbSNP:rs28934893).
FT                                {ECO:0000269|PubMed:2121025}.
FT                                /FTId=VAR_004234.
FT   VARIANT     277    277       D -> N (in LPL deficiency; 5% of full
FT                                activity). {ECO:0000269|PubMed:1619366,
FT                                ECO:0000269|PubMed:1639392,
FT                                ECO:0000269|PubMed:8778602,
FT                                ECO:0000269|PubMed:8956048,
FT                                ECO:0000269|PubMed:9279761}.
FT                                /FTId=VAR_004235.
FT   VARIANT     278    278       S -> C (in LPL deficiency).
FT                                /FTId=VAR_004236.
FT   VARIANT     279    279       L -> R (in LPL deficiency; decreases the
FT                                specific activity of the enzyme; the
FT                                total LPL mass is reduced compared to
FT                                that of the wild-type construct;
FT                                dbSNP:rs35414700).
FT                                {ECO:0000269|PubMed:12204001,
FT                                ECO:0000269|PubMed:8077845}.
FT                                /FTId=VAR_057932.
FT   VARIANT     279    279       L -> V (in LPL deficiency; decreases the
FT                                specific activity of the enzyme; the
FT                                total LPL mass is reduced compared to
FT                                that of the wild-type construct).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057933.
FT   VARIANT     286    286       S -> G (in LPL deficiency).
FT                                {ECO:0000269|PubMed:10660334}.
FT                                /FTId=VAR_004237.
FT   VARIANT     286    286       S -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:9298816}.
FT                                /FTId=VAR_004238.
FT   VARIANT     288    288       A -> T (in LPL deficiency; the LPL mass
FT                                level is approximately 67% of the normal;
FT                                the activity is 32% of the nornal;
FT                                dbSNP:rs1800011).
FT                                {ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:8077845,
FT                                ECO:0000269|PubMed:9719626}.
FT                                /FTId=VAR_011949.
FT   VARIANT     289    289       Y -> H (in LPL deficiency; no enzyme
FT                                activity). {ECO:0000269|PubMed:8728326}.
FT                                /FTId=VAR_057934.
FT   VARIANT     297    297       F -> L (in LPL deficiency and
FT                                hyperlipidemia; synthesized as a
FT                                catalytically inactive form; total amount
FT                                is almost equal to that of the normal
FT                                enzyme; non-releasable by heparin due to
FT                                the abnormal structure of the mutant
FT                                protein). {ECO:0000269|PubMed:11068186,
FT                                ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057935.
FT   VARIANT     303    303       L -> F (in LPL deficiency; approximately
FT                                6% of normal LPL activity and 40% of LPL
FT                                mass are detected in the patient's
FT                                postheparin plasma; results in the
FT                                production of a functionally inactive
FT                                enzyme). {ECO:0000269|PubMed:12641539}.
FT                                /FTId=VAR_057936.
FT   VARIANT     305    305       C -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057937.
FT   VARIANT     310    310       C -> Y (in LPL deficiency; decreases the
FT                                specific activity of the enzyme; reduces
FT                                the secretion of the mutant protein
FT                                significantly; the total LPL mass is
FT                                reduced compared to that of the wild-type
FT                                construct).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057938.
FT   VARIANT     313    313       L -> P (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8778602}.
FT                                /FTId=VAR_057939.
FT   VARIANT     318    318       N -> S (in LPL deficiency; loss of
FT                                activity; frequent mutation;
FT                                dbSNP:rs268).
FT                                {ECO:0000269|PubMed:12966036,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:7647785,
FT                                ECO:0000269|PubMed:8077845,
FT                                ECO:0000269|PubMed:8872057,
FT                                ECO:0000269|PubMed:9662394,
FT                                ECO:0000269|PubMed:9719626,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_004239.
FT   VARIANT     325    325       S -> R (in LPL deficiency; has no effect
FT                                on the specific activity of the enzyme;
FT                                has a mild effect on the secretion of the
FT                                mutant enzyme; the total LPL mass is
FT                                reduced compared to that of the wild-type
FT                                construct).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057940.
FT   VARIANT     328    328       M -> R (in LPL deficiency).
FT                                {ECO:0000269|PubMed:15185149}.
FT                                /FTId=VAR_057941.
FT   VARIANT     328    328       M -> T (in LPL deficiency).
FT                                /FTId=VAR_004240.
FT   VARIANT     330    330       L -> F (in LPL deficiency).
FT                                {ECO:0000269|PubMed:15256764}.
FT                                /FTId=VAR_057942.
FT   VARIANT     330    330       L -> P (in LPL deficiency).
FT                                /FTId=VAR_004241.
FT   VARIANT     361    361       A -> T (in LPL deficiency).
FT                                {ECO:0000269|PubMed:15256764,
FT                                ECO:0000269|PubMed:8096693}.
FT                                /FTId=VAR_004242.
FT   VARIANT     365    365       S -> F (in LPL deficiency; increases the
FT                                specific activity of the enzyme; has a
FT                                mild effect on the secretion of the
FT                                mutant enzyme; the total LPL mass is
FT                                reduced compared to that of the wild-type
FT                                construct; dbSNP:rs546542623).
FT                                {ECO:0000269|PubMed:12204001}.
FT                                /FTId=VAR_057943.
FT   VARIANT     370    370       V -> M (in dbSNP:rs298).
FT                                {ECO:0000269|PubMed:9662394}.
FT                                /FTId=VAR_011950.
FT   VARIANT     379    379       T -> A (in dbSNP:rs300).
FT                                {ECO:0000269|PubMed:9662394}.
FT                                /FTId=VAR_011951.
FT   VARIANT     392    392       L -> V (in LPL deficiency; loss of
FT                                activity). {ECO:0000269|PubMed:8135797}.
FT                                /FTId=VAR_004243.
FT   VARIANT     423    424       Missing (in LPL deficiency; affects the
FT                                protein folding).
FT                                /FTId=VAR_004244.
FT   VARIANT     427    427       A -> T (in dbSNP:rs5934).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_011952.
FT   VARIANT     437    437       E -> K (in LPL deficiency).
FT                                {ECO:0000269|PubMed:8956048}.
FT                                /FTId=VAR_004245.
FT   VARIANT     437    437       E -> V (in LPL deficiency).
FT                                {ECO:0000269|PubMed:7806969}.
FT                                /FTId=VAR_004246.
FT   VARIANT     445    445       C -> Y (in LPL deficiency; has 48% of
FT                                normal activity in vitro; decreased
FT                                levels of activity account for by the
FT                                lower protein mass levels of the mutants
FT                                rather than by decreased enzymatic
FT                                activities).
FT                                {ECO:0000269|PubMed:8858123}.
FT                                /FTId=VAR_057944.
FT   VARIANT     448    448       E -> K (in LPL deficiency; results in a
FT                                moderate reduction in catalytic activity;
FT                                dbSNP:rs149089920).
FT                                {ECO:0000269|PubMed:9498099}.
FT                                /FTId=VAR_057945.
FT   MUTAGEN     159    159       S->G: Lacks both triolein and tributyrin
FT                                esterase activities.
FT                                {ECO:0000269|PubMed:1371284}.
FT   MUTAGEN     159    159       S->T: Lacks both triolein and tributyrin
FT                                esterase activities.
FT                                {ECO:0000269|PubMed:1371284}.
FT   MUTAGEN     268    268       H->G: Lacks both triolein and tributyrin
FT                                esterase activities.
FT                                {ECO:0000269|PubMed:1371284}.
FT   MUTAGEN     268    268       H->Q: Lacks both triolein and tributyrin
FT                                esterase activities.
FT                                {ECO:0000269|PubMed:1371284}.
SQ   SEQUENCE   475 AA;  53162 MW;  FBD00FCD334FB8AA CRC64;
     MESKALLVLT LAVWLQSLTA SRGGVAAADQ RRDFIDIESK FALRTPEDTA EDTCHLIPGV
     AESVATCHFN HSSKTFMVIH GWTVTGMYES WVPKLVAALY KREPDSNVIV VDWLSRAQEH
     YPVSAGYTKL VGQDVARFIN WMEEEFNYPL DNVHLLGYSL GAHAAGIAGS LTNKKVNRIT
     GLDPAGPNFE YAEAPSRLSP DDADFVDVLH TFTRGSPGRS IGIQKPVGHV DIYPNGGTFQ
     PGCNIGEAIR VIAERGLGDV DQLVKCSHER SIHLFIDSLL NEENPSKAYR CSSKEAFEKG
     LCLSCRKNRC NNLGYEINKV RAKRSSKMYL KTRSQMPYKV FHYQVKIHFS GTESETHTNQ
     AFEISLYGTV AESENIPFTL PEVSTNKTYS FLIYTEVDIG ELLMLKLKWK SDSYFSWSDW
     WSSPGFAIQK IRVKAGETQK KVIFCSREKV SHLQKGKAPA VFVKCHDKSL NKKSG
//
ID   JAG1_HUMAN              Reviewed;        1218 AA.
AC   P78504; A0AV43; B4DYR1; E9PCF9; O14902; O15122; Q15816;
DT   02-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2002, sequence version 3.
DT   17-FEB-2016, entry version 174.
DE   RecName: Full=Protein jagged-1;
DE            Short=Jagged1;
DE            Short=hJ1;
DE   AltName: CD_antigen=CD339;
DE   Flags: Precursor;
GN   Name=JAG1; Synonyms=JAGL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9268641; DOI=10.1006/geno.1997.4820;
RA   Oda T., Elkahloun A.G., Meltzer P.S., Chandrasekharappa S.C.;
RT   "Identification and cloning of the human homolog (JAG1) of the rat
RT   Jagged1 gene from the Alagille syndrome critical region at 20p12.";
RL   Genomics 43:376-379(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INVOLVEMENT IN ALGS1, AND
RP   VARIANT ALGS1 CYS-184.
RC   TISSUE=Bone marrow;
RX   PubMed=9207788; DOI=10.1038/ng0797-243;
RA   Li L., Krantz I.D., Deng Y., Genin A., Banta A.B., Collins C.C.,
RA   Qi M., Trask B.J., Kuo W.L., Cochran J., Costa T., Pierpont M.E.M.,
RA   Rand E.B., Piccoli D.A., Hood L., Spinner N.B.;
RT   "Alagille syndrome is caused by mutations in human Jagged1, which
RT   encodes a ligand for Notch1.";
RL   Nat. Genet. 16:243-251(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=9462510; DOI=10.1016/S1074-7613(00)80457-4;
RA   Li L., Milner L.A., Deng Y., Iwata M., Banta A.B., Graf L.,
RA   Marcovina S., Friedman C., Trask B.J., Hood L., Torok-Storb B.;
RT   "The human homolog of rat Jagged1 expressed by marrow stroma inhibits
RT   differentiation of 32D cells through interaction with Notch1.";
RL   Immunity 8:43-55(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Cervix carcinoma;
RX   PubMed=10329626; DOI=10.1093/emboj/18.10.2803;
RA   Bash J., Zong W.-X., Banga S., Rivera A., Ballard D.W., Ron Y.,
RA   Gelinas C.;
RT   "Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the
RT   expression of Jagged1, a ligand for Notch receptors.";
RL   EMBO J. 18:2803-2811(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10079256; DOI=10.1016/S0002-9440(10)65325-4;
RA   Gray G.E., Mann R.S., Mitsiadis E., Henrique D., Carcangiu M.-L.,
RA   Banks A., Leiman J., Ward D., Ish-Horowitz D., Artavanis-Tsakonas S.;
RT   "Human ligands of the Notch receptor.";
RL   Am. J. Pathol. 154:785-794(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 14-1218 (ISOFORM 1).
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=8955070; DOI=10.1074/jbc.271.51.32499;
RA   Zimrin A.B., Pepper M.S., McMahon G.A., Nguyen F., Montesano R.,
RA   Maciag T.;
RT   "An antisense oligonucleotide to the notch ligand Jagged enhances
RT   fibroblast growth factor-induced angiogenesis in vitro.";
RL   J. Biol. Chem. 271:32499-32502(1996).
RN   [10]
RP   DISEASE.
RX   PubMed=9207787; DOI=10.1038/ng0797-235;
RA   Oda T., Elkahloun A.G., Pike B.L., Okajima K., Krantz I.D., Genin A.,
RA   Piccoli D.A., Meltzer P.S., Spinner N.B., Collins F.S.,
RA   Chandrasekharappa S.C.;
RT   "Mutations in the human Jagged1 gene are responsible for Alagille
RT   syndrome.";
RL   Nat. Genet. 16:235-242(1997).
RN   [11]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=10978356; DOI=10.1136/jmg.37.9.658;
RA   Jones E.A., Clement-Jones M., Wilson D.I.;
RT   "JAGGED1 expression in human embryos: correlation with the Alagille
RT   syndrome phenotype.";
RL   J. Med. Genet. 37:658-662(2000).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 185-335, FUNCTION,
RP   INTERACTION WITH NOTCH1, DOMAIN, MUTAGENESIS OF PHE-207, AND DISULFIDE
RP   BONDS.
RX   PubMed=18660822; DOI=10.1038/nsmb.1457;
RA   Cordle J., Johnson S., Tay J.Z., Roversi P., Wilkin M.B.,
RA   de Madrid B.H., Shimizu H., Jensen S., Whiteman P., Jin B.,
RA   Redfield C., Baron M., Lea S.M., Handford P.A.;
RT   "A conserved face of the Jagged/Serrate DSL domain is involved in
RT   Notch trans-activation and cis-inhibition.";
RL   Nat. Struct. Mol. Biol. 15:849-857(2008).
RN   [14]
RP   STRUCTURE BY NMR OF 252-295, DOMAIN, AND DISULFIDE BONDS.
RX   PubMed=19586525; DOI=10.1186/1472-6807-9-43;
RA   Pintar A., Guarnaccia C., Dhir S., Pongor S.;
RT   "Exon 6 of human JAG1 encodes a conserved structural unit.";
RL   BMC Struct. Biol. 9:43-43(2009).
RN   [15]
RP   VARIANTS ALGS1 CYS-184 AND HIS-184.
RX   PubMed=9585603; DOI=10.1086/301875;
RA   Krantz I.D., Colliton R.P., Genin A., Rand E.B., Li L., Piccoli D.A.,
RA   Spinner N.B.;
RT   "Spectrum and frequency of Jagged1 (JAG1) mutations in Alagille
RT   syndrome patients and their families.";
RL   Am. J. Hum. Genet. 62:1361-1369(1998).
RN   [16]
RP   VARIANTS ALGS1 HIS-79; THR-127; ARG-129; LEU-163; GLY-184; SER-187;
RP   GLY-229; PHE-284; CYS-288; PHE-438; SER-731 AND ARG-740.
RX   PubMed=10220506; DOI=10.1016/S0016-5085(99)70017-X;
RA   Crosnier C., Driancourt C., Raynaud N., Dhorne-Pollet S., Pollet N.,
RA   Bernard O., Hadchouel M., Meunier-Rotival M.;
RT   "Mutations in JAGGED1 gene are predominantly sporadic in Alagille
RT   syndrome.";
RL   Gastroenterology 116:1141-1148(1999).
RN   [17]
RP   VARIANTS ALGS1 THR-152 AND LEU-184.
RX   PubMed=10533065;
RX   DOI=10.1002/(SICI)1098-1004(199911)14:5<394::AID-HUMU5>3.0.CO;2-1;
RA   Pilia G., Uda M., Macis D., Frau F., Crisponi L., Balli F.,
RA   Barbera C., Colombo C., Frediani T., Gatti R., Iorio R., Marazzi M.G.,
RA   Marcellini M., Musumeci S., Nebbia G., Vajro P., Ruffa G., Zancan L.,
RA   Cao A., DeVirgilis S.;
RT   "Jagged-1 mutation analysis in Italian Alagille syndrome patients.";
RL   Hum. Mutat. 14:394-400(1999).
RN   [18]
RP   VARIANTS ALGS1 TYR-229 AND ARG-386.
RX   PubMed=11058898;
RX   DOI=10.1002/1098-1004(200011)16:5<408::AID-HUMU5>3.0.CO;2-9;
RA   Heritage M.L., MacMillan J.C., Colliton R.P., Genin A., Spinner N.B.,
RA   Anderson G.J.;
RT   "Jagged1 (JAG1) mutation detection in an Australian Alagille syndrome
RT   population.";
RL   Hum. Mutat. 16:408-416(2000).
RN   [19]
RP   VARIANT TOF ASP-274.
RX   PubMed=11152664; DOI=10.1093/hmg/10.2.163;
RA   Eldadah Z.A., Hamosh A., Biery N.J., Montgomery R.A., Duke M.,
RA   Elkins R., Dietz H.C.;
RT   "Familial tetralogy of Fallot caused by mutation in the Jagged1
RT   gene.";
RL   Hum. Mol. Genet. 10:163-169(2001).
RN   [20]
RP   VARIANT ALGS1 SER-37.
RX   PubMed=11157803; DOI=10.1093/hmg/10.4.405;
RA   Morrissette J.J.D., Colliton R.P., Spinner N.B.;
RT   "Defective intracellular transport and processing of JAG1 missense
RT   mutations in Alagille syndrome.";
RL   Hum. Mol. Genet. 10:405-413(2001).
RN   [21]
RP   VARIANTS ALGS1 PHE-220 AND ARG-753.
RX   PubMed=11139247;
RX   DOI=10.1002/1098-1004(2001)17:1<72::AID-HUMU11>3.0.CO;2-U;
RA   Crosnier C., Driancourt C., Raynaud N., Hadchouel M.,
RA   Meunier-Rotival M.;
RT   "Fifteen novel mutations in the JAGGED1 gene of patients with Alagille
RT   syndrome.";
RL   Hum. Mutat. 17:72-73(2001).
RN   [22]
RP   VARIANTS ALGS1 ASP-33; SER-37; SER-78; ASN-181; TYR-714 AND SER-902.
RX   PubMed=11180599;
RX   DOI=10.1002/1098-1004(200102)17:2<151::AID-HUMU8>3.3.CO;2-K;
RA   Colliton R.P., Bason L., Lu F.-M., Piccoli D.A., Krantz I.D.,
RA   Spinner N.B.;
RT   "Mutation analysis of Jagged1 (JAG1) in Alagille syndrome patients.";
RL   Hum. Mutat. 17:151-152(2001).
RN   [23]
RP   VARIANT DEAFNESS TYR-234.
RX   PubMed=12022040; DOI=10.1086/341327;
RA   Le Caignec C., Lefevre M., Schott J.J., Chaventre A., Gayet M.,
RA   Calais C., Moisan J.P.;
RT   "Familial deafness, congenital heart defects, and posterior
RT   embryotoxon caused by cysteine substitution in the first epidermal-
RT   growth-factor-like domain of Jagged 1.";
RL   Am. J. Hum. Genet. 71:180-186(2002).
RN   [24]
RP   VARIANTS BILIARY ATRESIA LEU-45; ASP-53; MET-65; LYS-203; ASP-690;
RP   ARG-871; GLN-908; PRO-921 AND GLN-1213.
RX   PubMed=12297837; DOI=10.1053/jhep.2002.35820;
RA   Kohsaka T., Yuan Z.-R., Guo S.-X., Tagawa M., Nakamura A., Nakano M.,
RA   Kawasasaki H., Inomata Y., Tanaka K., Miyauchi J.;
RT   "The significance of human Jagged 1 mutations detected in severe cases
RT   of extrahepatic biliary atresia.";
RL   Hepatology 36:904-912(2002).
RN   [25]
RP   VARIANTS ALGS1 SER-39; HIS-184 AND ARG-913.
RX   PubMed=12442286; DOI=10.1002/humu.9095;
RA   Heritage M.L., MacMillan J.C., Anderson G.J.;
RT   "DHPLC mutation analysis of Jagged1 (JAG1) reveals six novel mutations
RT   in Australian Alagille syndrome patients.";
RL   Hum. Mutat. 20:481-481(2002).
RN   [26]
RP   CHARACTERIZATION OF VARIANT ASP-274.
RX   PubMed=12649809; DOI=10.1086/374386;
RA   Lu F., Morrissette J.J.D., Spinner N.B.;
RT   "Conditional JAG1 mutation shows the developing heart is more
RT   sensitive than developing liver to JAG1 dosage.";
RL   Am. J. Hum. Genet. 72:1065-1070(2003).
RN   [27]
RP   VARIANTS ALGS1 VAL-31; PRO-40; SER-75; SER-123; ARG-163; CYS-224;
RP   LEU-269 AND GLN-937.
RX   PubMed=12497640; DOI=10.1002/humu.9102;
RA   Roepke A., Kujat A., Graeber M., Giannakudis J., Hansmann I.;
RT   "Identification of 36 novel Jagged1 (JAG1) mutations in patients with
RT   Alagille syndrome.";
RL   Hum. Mutat. 21:100-100(2003).
RN   [28]
RP   VARIANTS ALGS1 ASN-120 AND TYR-187.
RX   PubMed=15712272; DOI=10.1002/humu.9313;
RA   Jurkiewicz D., Popowska E., Glaeser C., Hansmann I.,
RA   Krajewska-Walasek M.;
RT   "Twelve novel JAG1 gene mutations in Polish Alagille syndrome
RT   patients.";
RL   Hum. Mutat. 25:321-321(2005).
RN   [29]
RP   VARIANTS ALGS1 22-CYS--ARG-25 DEL; SER-33; VAL-33; ARG-92; TYR-92;
RP   PRO-155; GLY-252; SER-256; ARG-271; SER-504; TYR-693; GLN-889; TYR-911
RP   AND 1055-VAL-ARG-1056 GLY DELINS, AND VARIANT LYS-818.
RX   PubMed=16575836; DOI=10.1002/humu.20310;
RA   Warthen D.M., Moore E.C., Kamath B.M., Morrissette J.J.D., Sanchez P.,
RA   Piccoli D.A., Krantz I.D., Spinner N.B.;
RT   "Jagged1 (JAG1) mutations in Alagille syndrome: increasing the
RT   mutation detection rate.";
RL   Hum. Mutat. 27:436-443(2006).
RN   [30]
RP   VARIANT ALGS1 TRP-436.
RX   PubMed=23801938; DOI=10.1159/000347231;
RA   Vozzi D., Licastro D., Martelossi S., Athanasakis E., Gasparini P.,
RA   Fabretto A.;
RT   "Alagille Syndrome: A new missense mutation detected by whole-exome
RT   sequencing in a case previously found to be negative by DHPLC and
RT   MLPA.";
RL   Mol. Syndromol. 4:207-210(2013).
CC   -!- FUNCTION: Ligand for multiple Notch receptors and involved in the
CC       mediation of Notch signaling. May be involved in cell-fate
CC       decisions during hematopoiesis. Seems to be involved in early and
CC       late stages of mammalian cardiovascular development. Inhibits
CC       myoblast differentiation (By similarity). Enhances fibroblast
CC       growth factor-induced angiogenesis (in vitro). {ECO:0000250,
CC       ECO:0000269|PubMed:18660822, ECO:0000269|PubMed:9462510}.
CC   -!- SUBUNIT: Interacts with NOTCH2 and NOTCH3 (By similarity).
CC       Interacts with NOTCH1 (in the presence of calcium ions).
CC       {ECO:0000250, ECO:0000269|PubMed:18660822}.
CC   -!- INTERACTION:
CC       P15529:CD46; NbExp=5; IntAct=EBI-2847071, EBI-2623451;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P78504-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P78504-2; Sequence=VSP_056532;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed in adult and fetal tissues.
CC       In cervix epithelium expressed in undifferentiated subcolumnar
CC       reserve cells and squamous metaplasia. Expression is up-regulated
CC       in cervical squamous cell carcinoma. Expressed in bone marrow cell
CC       line HS-27a which supports the long-term maintenance of immature
CC       progenitor cells.
CC   -!- DEVELOPMENTAL STAGE: Expressed in 32-52 days embryos in the distal
CC       cardiac outflow tract and pulmonary artery, major arteries, portal
CC       vein, optic vesicle, otocyst, branchial arches, metanephros,
CC       pancreas, mesocardium, around the major bronchial branches, and in
CC       the neural tube. {ECO:0000269|PubMed:10978356}.
CC   -!- DOMAIN: The second EGF-like domain is atypical.
CC       {ECO:0000269|PubMed:18660822, ECO:0000269|PubMed:19586525}.
CC   -!- DISEASE: Alagille syndrome 1 (ALGS1) [MIM:118450]: A form of
CC       Alagille syndrome, an autosomal dominant multisystem disorder. It
CC       is clinically defined by hepatic bile duct paucity and cholestasis
CC       in association with cardiac, skeletal, and ophthalmologic
CC       manifestations. There are characteristic facial features and less
CC       frequent clinical involvement of the renal and vascular systems.
CC       {ECO:0000269|PubMed:10220506, ECO:0000269|PubMed:10533065,
CC       ECO:0000269|PubMed:11058898, ECO:0000269|PubMed:11139247,
CC       ECO:0000269|PubMed:11157803, ECO:0000269|PubMed:11180599,
CC       ECO:0000269|PubMed:12442286, ECO:0000269|PubMed:12497640,
CC       ECO:0000269|PubMed:15712272, ECO:0000269|PubMed:16575836,
CC       ECO:0000269|PubMed:23801938, ECO:0000269|PubMed:9207788,
CC       ECO:0000269|PubMed:9585603}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Tetralogy of Fallot (TOF) [MIM:187500]: A congenital
CC       heart anomaly which consists of pulmonary stenosis, ventricular
CC       septal defect, dextroposition of the aorta (aorta is on the right
CC       side instead of the left) and hypertrophy of the right ventricle.
CC       In this condition, blood from both ventricles (oxygen-rich and
CC       oxygen-poor) is pumped into the body often causing cyanosis.
CC       {ECO:0000269|PubMed:11152664}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 1 DSL domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00377}.
CC   -!- SIMILARITY: Contains 16 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC51323.1; Type=Frameshift; Positions=1187; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JAG1ID41029ch20p12.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF003837; AAC51731.1; -; mRNA.
DR   EMBL; U73936; AAC52020.1; -; mRNA.
DR   EMBL; AF028593; AAB84053.1; -; mRNA.
DR   EMBL; U61276; AAB39007.1; -; mRNA.
DR   EMBL; AK302554; BAG63823.1; -; mRNA.
DR   EMBL; AL035456; CAC07198.1; -; Genomic_DNA.
DR   EMBL; BC126205; AAI26206.1; -; mRNA.
DR   EMBL; BC126207; AAI26208.1; -; mRNA.
DR   EMBL; U77720; AAC51323.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS13112.1; -. [P78504-1]
DR   RefSeq; NP_000205.1; NM_000214.2. [P78504-1]
DR   UniGene; Hs.224012; -.
DR   UniGene; Hs.626544; -.
DR   PDB; 2KB9; NMR; -; A=252-295.
DR   PDB; 2VJ2; X-ray; 2.50 A; A/B=185-335.
DR   PDB; 4CBZ; X-ray; 2.50 A; A/B=32-335.
DR   PDB; 4CC0; X-ray; 2.32 A; A/B=32-335.
DR   PDB; 4CC1; X-ray; 2.84 A; A/B=32-335.
DR   PDB; 4XI7; X-ray; 2.05 A; C=1120-1130.
DR   PDB; 5BO1; X-ray; 2.56 A; A/B=186-335.
DR   PDBsum; 2KB9; -.
DR   PDBsum; 2VJ2; -.
DR   PDBsum; 4CBZ; -.
DR   PDBsum; 4CC0; -.
DR   PDBsum; 4CC1; -.
DR   PDBsum; 4XI7; -.
DR   PDBsum; 5BO1; -.
DR   DisProt; DP00418; -.
DR   ProteinModelPortal; P78504; -.
DR   SMR; P78504; 32-337.
DR   BioGrid; 106689; 8.
DR   DIP; DIP-46371N; -.
DR   IntAct; P78504; 10.
DR   MINT; MINT-2804836; -.
DR   STRING; 9606.ENSP00000254958; -.
DR   ChEMBL; CHEMBL3217396; -.
DR   iPTMnet; P78504; -.
DR   PhosphoSite; P78504; -.
DR   SwissPalm; P78504; -.
DR   BioMuta; JAG1; -.
DR   DMDM; 20455033; -.
DR   MaxQB; P78504; -.
DR   PaxDb; P78504; -.
DR   PeptideAtlas; P78504; -.
DR   PRIDE; P78504; -.
DR   DNASU; 182; -.
DR   Ensembl; ENST00000254958; ENSP00000254958; ENSG00000101384. [P78504-1]
DR   GeneID; 182; -.
DR   KEGG; hsa:182; -.
DR   UCSC; uc002wnw.2; human. [P78504-1]
DR   CTD; 182; -.
DR   GeneCards; JAG1; -.
DR   GeneReviews; JAG1; -.
DR   HGNC; HGNC:6188; JAG1.
DR   HPA; CAB010343; -.
DR   HPA; HPA021555; -.
DR   MalaCards; JAG1; -.
DR   MIM; 118450; phenotype.
DR   MIM; 187500; phenotype.
DR   MIM; 601920; gene+phenotype.
DR   neXtProt; NX_P78504; -.
DR   Orphanet; 261600; Alagille syndrome due to 20p12 microdeletion.
DR   Orphanet; 261619; Alagille syndrome due to a JAG1 point mutation.
DR   Orphanet; 3303; Tetralogy of Fallot.
DR   PharmGKB; PA29986; -.
DR   eggNOG; KOG1217; Eukaryota.
DR   eggNOG; ENOG410XP6K; LUCA.
DR   GeneTree; ENSGT00810000125346; -.
DR   HOGENOM; HOG000113124; -.
DR   HOVERGEN; HBG031645; -.
DR   InParanoid; P78504; -.
DR   KO; K06052; -.
DR   OMA; MPGAPDK; -.
DR   OrthoDB; EOG7BKCSS; -.
DR   PhylomeDB; P78504; -.
DR   TreeFam; TF351835; -.
DR   Reactome; R-HSA-1980148; Signaling by NOTCH3.
DR   Reactome; R-HSA-1980150; Signaling by NOTCH4.
DR   Reactome; R-HSA-2122948; Activated NOTCH1 Transmits Signal to the Nucleus.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2660826; Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant.
DR   Reactome; R-HSA-2691232; Constitutive Signaling by NOTCH1 HD Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-2979096; NOTCH2 Activation and Transmission of Signal to the Nucleus.
DR   SignaLink; P78504; -.
DR   ChiTaRS; JAG1; human.
DR   EvolutionaryTrace; P78504; -.
DR   GeneWiki; JAG1; -.
DR   GenomeRNAi; 182; -.
DR   NextBio; 35476290; -.
DR   PRO; PR:P78504; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; P78504; -.
DR   CleanEx; HS_JAG1; -.
DR   ExpressionAtlas; P78504; baseline and differential.
DR   Genevisible; P78504; HS.
DR   GO; GO:0005912; C:adherens junction; ISS:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; TAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0008083; F:growth factor activity; NAS:UniProtKB.
DR   GO; GO:0005112; F:Notch binding; IPI:UniProtKB.
DR   GO; GO:0005198; F:structural molecule activity; NAS:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; NAS:UniProtKB.
DR   GO; GO:0035909; P:aorta morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0042491; P:auditory receptor cell differentiation; IEA:Ensembl.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0061309; P:cardiac neural crest cell development involved in outflow tract morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003215; P:cardiac right ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001709; P:cell fate determination; NAS:UniProtKB.
DR   GO; GO:0061073; P:ciliary body morphogenesis; IEA:Ensembl.
DR   GO; GO:0072017; P:distal tubule development; IEA:Ensembl.
DR   GO; GO:0061444; P:endocardial cushion cell development; ISS:BHF-UCL.
DR   GO; GO:0045446; P:endothelial cell differentiation; NAS:UniProtKB.
DR   GO; GO:0072015; P:glomerular visceral epithelial cell development; ISS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; NAS:UniProtKB.
DR   GO; GO:0030216; P:keratinocyte differentiation; NAS:UniProtKB.
DR   GO; GO:0072070; P:loop of Henle development; IEA:Ensembl.
DR   GO; GO:0002011; P:morphogenesis of an epithelial sheet; IEA:Ensembl.
DR   GO; GO:0045445; P:myoblast differentiation; NAS:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:2000737; P:negative regulation of stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0072006; P:nephron development; ISS:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; NAS:UniProtKB.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEP:UniProtKB.
DR   GO; GO:0007220; P:Notch receptor processing; TAS:Reactome.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; IMP:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045639; P:positive regulation of myeloid cell differentiation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0061156; P:pulmonary artery morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003184; P:pulmonary valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0030334; P:regulation of cell migration; NAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; NAS:UniProtKB.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IEA:Ensembl.
DR   GO; GO:0002456; P:T cell mediated immunity; IMP:UniProtKB.
DR   InterPro; IPR001774; DSL.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR026219; Jagged/Serrate.
DR   InterPro; IPR011651; Notch_ligand_N.
DR   InterPro; IPR001007; VWF_dom.
DR   Pfam; PF01414; DSL; 1.
DR   Pfam; PF00008; EGF; 11.
DR   Pfam; PF07645; EGF_CA; 1.
DR   Pfam; PF07657; MNNL; 1.
DR   PRINTS; PR02059; JAGGEDFAMILY.
DR   SMART; SM00051; DSL; 1.
DR   SMART; SM00181; EGF; 6.
DR   SMART; SM00179; EGF_CA; 10.
DR   SMART; SM00214; VWC; 1.
DR   SUPFAM; SSF57184; SSF57184; 3.
DR   PROSITE; PS00010; ASX_HYDROXYL; 10.
DR   PROSITE; PS51051; DSL; 1.
DR   PROSITE; PS00022; EGF_1; 16.
DR   PROSITE; PS01186; EGF_2; 12.
DR   PROSITE; PS50026; EGF_3; 15.
DR   PROSITE; PS01187; EGF_CA; 8.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Complete proteome;
KW   Developmental protein; Disease mutation; Disulfide bond;
KW   EGF-like domain; Glycoprotein; Membrane; Notch signaling pathway;
KW   Polymorphism; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     33       {ECO:0000255}.
FT   CHAIN        34   1218       Protein jagged-1.
FT                                /FTId=PRO_0000007625.
FT   TOPO_DOM     34   1067       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1068   1093       Helical. {ECO:0000255}.
FT   TOPO_DOM   1094   1218       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      185    229       DSL. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00377}.
FT   DOMAIN      230    263       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      264    294       EGF-like 2; atypical.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      296    334       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      336    372       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      374    410       EGF-like 5; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      412    448       EGF-like 6; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      450    485       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      487    523       EGF-like 8; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      525    561       EGF-like 9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      586    627       EGF-like 10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      629    665       EGF-like 11; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      667    703       EGF-like 12; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      705    741       EGF-like 13. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      744    780       EGF-like 14. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      782    818       EGF-like 15; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      820    856       EGF-like 16; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   REGION      199    207       Important for interaction with NOTCH1.
FT   CARBOHYD    143    143       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    217    217       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    382    382       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    559    559       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    745    745       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    960    960       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    991    991       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1045   1045       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1064   1064       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    187    196
FT   DISULFID    200    212
FT   DISULFID    220    229
FT   DISULFID    234    245
FT   DISULFID    238    251
FT   DISULFID    253    262
FT   DISULFID    265    276
FT   DISULFID    271    282
FT   DISULFID    284    293
FT   DISULFID    300    312
FT   DISULFID    306    322
FT   DISULFID    324    333
FT   DISULFID    340    351       {ECO:0000250}.
FT   DISULFID    345    360       {ECO:0000250}.
FT   DISULFID    362    371       {ECO:0000250}.
FT   DISULFID    378    389       {ECO:0000250}.
FT   DISULFID    383    398       {ECO:0000250}.
FT   DISULFID    400    409       {ECO:0000250}.
FT   DISULFID    416    427       {ECO:0000250}.
FT   DISULFID    421    436       {ECO:0000250}.
FT   DISULFID    438    447       {ECO:0000250}.
FT   DISULFID    454    464       {ECO:0000250}.
FT   DISULFID    458    473       {ECO:0000250}.
FT   DISULFID    475    484       {ECO:0000250}.
FT   DISULFID    491    502       {ECO:0000250}.
FT   DISULFID    496    511       {ECO:0000250}.
FT   DISULFID    513    522       {ECO:0000250}.
FT   DISULFID    529    540       {ECO:0000250}.
FT   DISULFID    534    549       {ECO:0000250}.
FT   DISULFID    551    560       {ECO:0000250}.
FT   DISULFID    578    605       {ECO:0000250}.
FT   DISULFID    599    615       {ECO:0000250}.
FT   DISULFID    617    626       {ECO:0000250}.
FT   DISULFID    633    644       {ECO:0000250}.
FT   DISULFID    638    653       {ECO:0000250}.
FT   DISULFID    655    664       {ECO:0000250}.
FT   DISULFID    671    682       {ECO:0000250}.
FT   DISULFID    676    691       {ECO:0000250}.
FT   DISULFID    693    702       {ECO:0000250}.
FT   DISULFID    709    720       {ECO:0000250}.
FT   DISULFID    714    729       {ECO:0000250}.
FT   DISULFID    731    740       {ECO:0000250}.
FT   DISULFID    748    759       {ECO:0000250}.
FT   DISULFID    753    768       {ECO:0000250}.
FT   DISULFID    770    779       {ECO:0000250}.
FT   DISULFID    786    797       {ECO:0000250}.
FT   DISULFID    791    806       {ECO:0000250}.
FT   DISULFID    808    817       {ECO:0000250}.
FT   DISULFID    824    835       {ECO:0000250}.
FT   DISULFID    829    844       {ECO:0000250}.
FT   DISULFID    846    855       {ECO:0000250}.
FT   VAR_SEQ       1    159       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056532.
FT   VARIANT      22     25       Missing (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026296.
FT   VARIANT      31     31       A -> V (in ALGS1).
FT                                {ECO:0000269|PubMed:12497640}.
FT                                /FTId=VAR_026297.
FT   VARIANT      33     33       G -> D (in ALGS1).
FT                                {ECO:0000269|PubMed:11180599}.
FT                                /FTId=VAR_026298.
FT   VARIANT      33     33       G -> S (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026299.
FT   VARIANT      33     33       G -> V (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026300.
FT   VARIANT      37     37       L -> S (in ALGS1).
FT                                {ECO:0000269|PubMed:11157803,
FT                                ECO:0000269|PubMed:11180599}.
FT                                /FTId=VAR_013186.
FT   VARIANT      39     39       I -> S (in ALGS1).
FT                                {ECO:0000269|PubMed:12442286}.
FT                                /FTId=VAR_026301.
FT   VARIANT      40     40       L -> P (in ALGS1).
FT                                {ECO:0000269|PubMed:12497640}.
FT                                /FTId=VAR_026302.
FT   VARIANT      45     45       V -> L (in biliary atresia; extrahepatic;
FT                                dbSNP:rs183974372).
FT                                {ECO:0000269|PubMed:12297837}.
FT                                /FTId=VAR_026303.
FT   VARIANT      53     53       N -> D (in biliary atresia;
FT                                extrahepatic).
FT                                {ECO:0000269|PubMed:12297837}.
FT                                /FTId=VAR_026304.
FT   VARIANT      65     65       K -> M (in biliary atresia;
FT                                extrahepatic).
FT                                {ECO:0000269|PubMed:12297837}.
FT                                /FTId=VAR_026305.
FT   VARIANT      75     75       F -> S (in ALGS1).
FT                                {ECO:0000269|PubMed:12497640}.
FT                                /FTId=VAR_026306.
FT   VARIANT      78     78       C -> S (in ALGS1).
FT                                {ECO:0000269|PubMed:11180599}.
FT                                /FTId=VAR_026307.
FT   VARIANT      79     79       L -> H (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013187.
FT   VARIANT      92     92       C -> R (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026308.
FT   VARIANT      92     92       C -> Y (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026309.
FT   VARIANT     120    120       I -> N (in ALGS1).
FT                                {ECO:0000269|PubMed:15712272}.
FT                                /FTId=VAR_026310.
FT   VARIANT     123    123       P -> S (in ALGS1).
FT                                {ECO:0000269|PubMed:12497640}.
FT                                /FTId=VAR_026311.
FT   VARIANT     127    127       A -> T (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013188.
FT   VARIANT     129    129       P -> R (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013189.
FT   VARIANT     146    146       V -> I (in dbSNP:rs6040067).
FT                                /FTId=VAR_048985.
FT   VARIANT     152    152       I -> T (in ALGS1).
FT                                {ECO:0000269|PubMed:10533065}.
FT                                /FTId=VAR_013190.
FT   VARIANT     155    155       A -> P (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026312.
FT   VARIANT     163    163       P -> L (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013191.
FT   VARIANT     163    163       P -> R (in ALGS1).
FT                                {ECO:0000269|PubMed:12497640}.
FT                                /FTId=VAR_026313.
FT   VARIANT     181    181       Y -> N (in ALGS1).
FT                                {ECO:0000269|PubMed:11180599}.
FT                                /FTId=VAR_026314.
FT   VARIANT     184    184       R -> C (in ALGS1).
FT                                {ECO:0000269|PubMed:9207788,
FT                                ECO:0000269|PubMed:9585603}.
FT                                /FTId=VAR_013192.
FT   VARIANT     184    184       R -> G (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013193.
FT   VARIANT     184    184       R -> H (in ALGS1).
FT                                {ECO:0000269|PubMed:12442286,
FT                                ECO:0000269|PubMed:9585603}.
FT                                /FTId=VAR_013194.
FT   VARIANT     184    184       R -> L (in ALGS1).
FT                                {ECO:0000269|PubMed:10533065}.
FT                                /FTId=VAR_013195.
FT   VARIANT     187    187       C -> S (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013196.
FT   VARIANT     187    187       C -> Y (in ALGS1).
FT                                {ECO:0000269|PubMed:15712272}.
FT                                /FTId=VAR_026315.
FT   VARIANT     203    203       R -> K (in biliary atresia;
FT                                extrahepatic).
FT                                {ECO:0000269|PubMed:12297837}.
FT                                /FTId=VAR_026316.
FT   VARIANT     220    220       C -> F (in ALGS1).
FT                                {ECO:0000269|PubMed:11139247}.
FT                                /FTId=VAR_013197.
FT   VARIANT     224    224       W -> C (in ALGS1).
FT                                {ECO:0000269|PubMed:12497640}.
FT                                /FTId=VAR_026317.
FT   VARIANT     229    229       C -> G (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013198.
FT   VARIANT     229    229       C -> Y (in ALGS1).
FT                                {ECO:0000269|PubMed:11058898}.
FT                                /FTId=VAR_013199.
FT   VARIANT     234    234       C -> Y (in deafness; with congenital
FT                                heart defects and posterior embryotoxon).
FT                                {ECO:0000269|PubMed:12022040}.
FT                                /FTId=VAR_026318.
FT   VARIANT     252    252       R -> G (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026319.
FT   VARIANT     256    256       G -> S (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026320.
FT   VARIANT     269    269       P -> L (in ALGS1).
FT                                {ECO:0000269|PubMed:12497640}.
FT                                /FTId=VAR_026321.
FT   VARIANT     271    271       C -> R (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026322.
FT   VARIANT     274    274       G -> D (in TOF; temperature sensitive
FT                                mutation; the protein is abnormally
FT                                glycosylated and retained
FT                                intracellularly; dbSNP:rs28939668).
FT                                {ECO:0000269|PubMed:11152664,
FT                                ECO:0000269|PubMed:12649809}.
FT                                /FTId=VAR_013200.
FT   VARIANT     284    284       C -> F (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013201.
FT   VARIANT     288    288       W -> C (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013202.
FT   VARIANT     386    386       G -> R (in ALGS1).
FT                                {ECO:0000269|PubMed:11058898}.
FT                                /FTId=VAR_013203.
FT   VARIANT     436    436       C -> W (in ALGS1).
FT                                {ECO:0000269|PubMed:23801938}.
FT                                /FTId=VAR_071513.
FT   VARIANT     438    438       C -> F (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013204.
FT   VARIANT     504    504       N -> S (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026323.
FT   VARIANT     690    690       Y -> D (in biliary atresia;
FT                                extrahepatic).
FT                                {ECO:0000269|PubMed:12297837}.
FT                                /FTId=VAR_026324.
FT   VARIANT     693    693       C -> Y (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026325.
FT   VARIANT     714    714       C -> Y (in ALGS1).
FT                                {ECO:0000269|PubMed:11180599}.
FT                                /FTId=VAR_026326.
FT   VARIANT     731    731       C -> S (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013205.
FT   VARIANT     740    740       C -> R (in ALGS1).
FT                                {ECO:0000269|PubMed:10220506}.
FT                                /FTId=VAR_013206.
FT   VARIANT     753    753       C -> R (in ALGS1).
FT                                {ECO:0000269|PubMed:11139247}.
FT                                /FTId=VAR_013207.
FT   VARIANT     818    818       R -> K. {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026327.
FT   VARIANT     871    871       P -> R (in biliary atresia; extrahepatic;
FT                                dbSNP:rs35761929).
FT                                {ECO:0000269|PubMed:12297837}.
FT                                /FTId=VAR_026328.
FT   VARIANT     889    889       R -> Q (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026329.
FT   VARIANT     902    902       C -> S (in ALGS1).
FT                                {ECO:0000269|PubMed:11180599}.
FT                                /FTId=VAR_026330.
FT   VARIANT     908    908       H -> Q (in biliary atresia;
FT                                extrahepatic).
FT                                {ECO:0000269|PubMed:12297837}.
FT                                /FTId=VAR_026331.
FT   VARIANT     911    911       C -> Y (in ALGS1).
FT                                {ECO:0000269|PubMed:16575836}.
FT                                /FTId=VAR_026332.
FT   VARIANT     913    913       S -> R (in ALGS1).
FT                                {ECO:0000269|PubMed:12442286}.
FT                                /FTId=VAR_026333.
FT   VARIANT     921    921       L -> P (in biliary atresia;
FT                                extrahepatic).
FT                                {ECO:0000269|PubMed:12297837}.
FT                                /FTId=VAR_026334.
FT   VARIANT     937    937       R -> Q (in ALGS1; dbSNP:rs145895196).
FT                                {ECO:0000269|PubMed:12497640}.
FT                                /FTId=VAR_026335.
FT   VARIANT    1055   1056       VR -> G (in ALGS1).
FT                                /FTId=VAR_026336.
FT   VARIANT    1213   1213       R -> Q (in biliary atresia;
FT                                extrahepatic).
FT                                {ECO:0000269|PubMed:12297837}.
FT                                /FTId=VAR_026337.
FT   MUTAGEN     207    207       F->A: Strongly reduced NOTCH1 binding.
FT                                {ECO:0000269|PubMed:18660822}.
FT   CONFLICT    117    117       R -> P (in Ref. 5; AAB39007).
FT                                {ECO:0000305}.
FT   CONFLICT    227    227       P -> R (in Ref. 1; AAC51731).
FT                                {ECO:0000305}.
FT   CONFLICT    498    498       N -> D (in Ref. 1; AAC51731).
FT                                {ECO:0000305}.
FT   STRAND       33     43       {ECO:0000244|PDB:4CC0}.
FT   STRAND       52     57       {ECO:0000244|PDB:4CC0}.
FT   TURN         61     63       {ECO:0000244|PDB:4CC0}.
FT   STRAND       73     81       {ECO:0000244|PDB:4CC0}.
FT   STRAND       88     90       {ECO:0000244|PDB:4CC0}.
FT   STRAND       95     98       {ECO:0000244|PDB:4CC0}.
FT   STRAND      103    105       {ECO:0000244|PDB:4CC0}.
FT   STRAND      118    124       {ECO:0000244|PDB:4CC0}.
FT   STRAND      130    140       {ECO:0000244|PDB:4CC0}.
FT   STRAND      143    147       {ECO:0000244|PDB:4CC0}.
FT   STRAND      150    160       {ECO:0000244|PDB:4CC0}.
FT   STRAND      163    172       {ECO:0000244|PDB:4CC0}.
FT   STRAND      174    187       {ECO:0000244|PDB:4CC0}.
FT   TURN        193    196       {ECO:0000244|PDB:4CC0}.
FT   STRAND      203    205       {ECO:0000244|PDB:4CC0}.
FT   STRAND      208    212       {ECO:0000244|PDB:4CC0}.
FT   STRAND      218    220       {ECO:0000244|PDB:4CC0}.
FT   TURN        226    229       {ECO:0000244|PDB:4CC0}.
FT   TURN        240    242       {ECO:0000244|PDB:4CC0}.
FT   STRAND      257    259       {ECO:0000244|PDB:4CC0}.
FT   TURN        268    270       {ECO:0000244|PDB:2KB9}.
FT   STRAND      273    275       {ECO:0000244|PDB:4CC0}.
FT   STRAND      277    280       {ECO:0000244|PDB:2KB9}.
FT   STRAND      286    289       {ECO:0000244|PDB:2KB9}.
FT   TURN        290    293       {ECO:0000244|PDB:4CC0}.
FT   STRAND      295    297       {ECO:0000244|PDB:4CC0}.
FT   HELIX       299    303       {ECO:0000244|PDB:4CC0}.
FT   STRAND      311    316       {ECO:0000244|PDB:4CC0}.
FT   STRAND      319    323       {ECO:0000244|PDB:4CC0}.
FT   STRAND      328    330       {ECO:0000244|PDB:4CC0}.
SQ   SEQUENCE   1218 AA;  133799 MW;  F36EE9FBF64DF162 CRC64;
     MRSPRTRGRS GRPLSLLLAL LCALRAKVCG ASGQFELEIL SMQNVNGELQ NGNCCGGARN
     PGDRKCTRDE CDTYFKVCLK EYQSRVTAGG PCSFGSGSTP VIGGNTFNLK ASRGNDRNRI
     VLPFSFAWPR SYTLLVEAWD SSNDTVQPDS IIEKASHSGM INPSRQWQTL KQNTGVAHFE
     YQIRVTCDDY YYGFGCNKFC RPRDDFFGHY ACDQNGNKTC MEGWMGPECN RAICRQGCSP
     KHGSCKLPGD CRCQYGWQGL YCDKCIPHPG CVHGICNEPW QCLCETNWGG QLCDKDLNYC
     GTHQPCLNGG TCSNTGPDKY QCSCPEGYSG PNCEIAEHAC LSDPCHNRGS CKETSLGFEC
     ECSPGWTGPT CSTNIDDCSP NNCSHGGTCQ DLVNGFKCVC PPQWTGKTCQ LDANECEAKP
     CVNAKSCKNL IASYYCDCLP GWMGQNCDIN INDCLGQCQN DASCRDLVNG YRCICPPGYA
     GDHCERDIDE CASNPCLNGG HCQNEINRFQ CLCPTGFSGN LCQLDIDYCE PNPCQNGAQC
     YNRASDYFCK CPEDYEGKNC SHLKDHCRTT PCEVIDSCTV AMASNDTPEG VRYISSNVCG
     PHGKCKSQSG GKFTCDCNKG FTGTYCHENI NDCESNPCRN GGTCIDGVNS YKCICSDGWE
     GAYCETNIND CSQNPCHNGG TCRDLVNDFY CDCKNGWKGK TCHSRDSQCD EATCNNGGTC
     YDEGDAFKCM CPGGWEGTTC NIARNSSCLP NPCHNGGTCV VNGESFTCVC KEGWEGPICA
     QNTNDCSPHP CYNSGTCVDG DNWYRCECAP GFAGPDCRIN INECQSSPCA FGATCVDEIN
     GYRCVCPPGH SGAKCQEVSG RPCITMGSVI PDGAKWDDDC NTCQCLNGRI ACSKVWCGPR
     PCLLHKGHSE CPSGQSCIPI LDDQCFVHPC TGVGECRSSS LQPVKTKCTS DSYYQDNCAN
     ITFTFNKEMM SPGLTTEHIC SELRNLNILK NVSAEYSIYI ACEPSPSANN EIHVAISAED
     IRDDGNPIKE ITDKIIDLVS KRDGNSSLIA AVAEVRVQRR PLKNRTDFLV PLLSSVLTVA
     WICCLVTAFY WCLRKRRKPG SHTHSASEDN TTNNVREQLN QIKNPIEKHG ANTVPIKDYE
     NKNSKMSKIR THNSEVEEDD MDKHQQKARF AKQPAYTLVD REEKPPNGTP TKHPNWTNKQ
     DNRDLESAQS LNRMEYIV
//
ID   DDR1_HUMAN              Reviewed;         913 AA.
AC   Q08345; B5A975; B5A976; B7Z2K0; Q14196; Q16562; Q2L6H3; Q4LE50;
AC   Q5ST11; Q5ST12; Q6NSK4; Q9UD35; Q9UD36; Q9UD37; Q9UD86; Q9UDL2;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   17-FEB-2016, entry version 182.
DE   RecName: Full=Epithelial discoidin domain-containing receptor 1;
DE            Short=Epithelial discoidin domain receptor 1;
DE            EC=2.7.10.1;
DE   AltName: Full=CD167 antigen-like family member A;
DE   AltName: Full=Cell adhesion kinase;
DE   AltName: Full=Discoidin receptor tyrosine kinase;
DE   AltName: Full=HGK2;
DE   AltName: Full=Mammary carcinoma kinase 10;
DE            Short=MCK-10;
DE   AltName: Full=Protein-tyrosine kinase 3A;
DE   AltName: Full=Protein-tyrosine kinase RTK-6;
DE   AltName: Full=TRK E;
DE   AltName: Full=Tyrosine kinase DDR;
DE   AltName: Full=Tyrosine-protein kinase CAK;
DE   AltName: CD_antigen=CD167a;
DE   Flags: Precursor;
GN   Name=DDR1; Synonyms=CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRKE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Keratinocyte;
RX   PubMed=8226977;
RA   di Marco E., Cutuli N., Guerra L., Cancedda R., de Luca M.;
RT   "Molecular cloning of trkE, a novel trk-related putative tyrosine
RT   kinase receptor isolated from normal human keratinocytes and widely
RT   expressed by normal human tissues.";
RL   J. Biol. Chem. 268:24290-24295(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-833.
RC   TISSUE=Placenta;
RX   PubMed=8390675; DOI=10.1073/pnas.90.12.5677;
RA   Johnson J.D., Edman J.C., Rutter W.J.;
RT   "A receptor tyrosine kinase found in breast carcinoma cells has an
RT   extracellular discoidin I-like domain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5677-5681(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Ovary;
RX   PubMed=7848919;
RA   Laval S., Butler R., Shelling A.N., Hanby A.M., Poulsom R.,
RA   Ganesan T.S.;
RT   "Isolation and characterization of an epithelial-specific receptor
RT   tyrosine kinase from an ovarian cancer cell line.";
RL   Cell Growth Differ. 5:1173-1183(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal liver;
RX   PubMed=8302582;
RA   Perez J.L., Shen X., Finkernagel S., Sciorra L., Jenkins N.A.,
RA   Gilbert D.J., Copeland N.G., Wong T.W.;
RT   "Identification and chromosomal mapping of a receptor tyrosine kinase
RT   with a putative phospholipid binding sequence in its ectodomain.";
RL   Oncogene 9:211-219(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-833.
RX   PubMed=8977099; DOI=10.1016/S0014-5793(96)01234-3;
RA   Sakuma S., Tada M., Saya H., Sawamura Y., Shinohe Y., Abe H.;
RT   "Receptor protein tyrosine kinase DDR is up-regulated by p53
RT   protein.";
RL   FEBS Lett. 398:165-169(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8796349; DOI=10.1101/gr.6.7.620;
RA   Playford M.P., Butler R.J., Wang X.C., Katso R.M., Cooke I.E.,
RA   Ganesan T.S.;
RT   "The genomic structure of discoidin receptor tyrosine kinase.";
RL   Genome Res. 6:620-627(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Lung;
RX   PubMed=8622863;
RA   Perez J.L., Jing S.Q., Wong T.W.;
RT   "Identification of two isoforms of the Cak receptor kinase that are
RT   coexpressed in breast tumor cell lines.";
RL   Oncogene 12:1469-1477(1996).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND NUCLEOTIDE SEQUENCE [MRNA]
RP   OF 1-286 (ISOFORMS 1/2/4).
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 5).
RC   TISSUE=Brain, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M.,
RA   Ohara R., Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long
RT   cDNAs encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=16702430; DOI=10.1534/genetics.106.057034;
RA   Shiina T., Ota M., Shimizu S., Katsuyama Y., Hashimoto N., Takasu M.,
RA   Anzai T., Kulski J.K., Kikkawa E., Naruse T., Kimura N., Yanagiya K.,
RA   Watanabe A., Hosomichi K., Kohara S., Iwamoto C., Umehara Y.,
RA   Meyer A., Wanner V., Sano K., Macquin C., Ikeo K., Tokunaga K.,
RA   Gojobori T., Inoko H., Bahram S.;
RT   "Rapid evolution of major histocompatibility complex class I genes in
RT   primates generates new disease alleles in humans via hitchhiking
RT   diversity.";
RL   Genetics 173:1555-1570(2006).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   PROTEIN SEQUENCE OF 480-490; 515-525 AND 790-798, IDENTIFICATION BY
RP   MASS SPECTROMETRY, SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   TYR-484; TYR-513; TYR-520; TYR-792; TYR-796 AND TYR-797, GLYCOSYLATION
RP   AT ASN-211 AND ASN-260, AND MUTAGENESIS OF ARG-105; ASN-211; SER-213;
RP   ASN-260; ASN-371; THR-379; THR-393; ASN-394 AND LYS-655.
RX   PubMed=24509848; DOI=10.1074/jbc.M113.541102;
RA   Fu H.L., Valiathan R.R., Payne L., Kumarasiri M., Mahasenan K.V.,
RA   Mobashery S., Huang P., Fridman R.;
RT   "Glycosylation at Asn211 regulates the activation state of the
RT   discoidin domain receptor 1 (DDR1).";
RL   J. Biol. Chem. 289:9275-9287(2014).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 501-550 (ISOFORMS 1/4), NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 501-550 AND 651-694 (ISOFORM 2), NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 651-694 (ISOFORM 4), ALTERNATIVE SPLICING, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=7845687;
RA   Alves F., Vogel W., Mossie K., Millauer B., Hoefler H., Ullrich A.;
RT   "Distinct structural characteristics of discoidin I subfamily receptor
RT   tyrosine kinases and complementary expression in human cancer.";
RL   Oncogene 10:609-618(1995).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 771-824 (ISOFORMS 1/2/4).
RX   PubMed=7834423; DOI=10.1007/BF02303537;
RA   Weiner T.M., Liu E.T., Craven R.J., Cance W.G.;
RT   "Expression of growth factor receptors, the focal adhesion kinase, and
RT   other tyrosine kinases in human soft tissue tumors.";
RL   Ann. Surg. Oncol. 1:18-27(1994).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 772-823 (ISOFORMS 1/2/4), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Melanocyte;
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [19]
RP   FUNCTION AS COLLAGEN RECEPTOR, PHOSPHORYLATION AT TYR-513, INTERACTION
RP   WITH SHC1, AUTOPHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=9659899; DOI=10.1016/S1097-2765(00)80003-9;
RA   Vogel W., Gish G.D., Alves F., Pawson T.;
RT   "The discoidin domain receptor tyrosine kinases are activated by
RT   collagen.";
RL   Mol. Cell 1:13-23(1997).
RN   [20]
RP   FUNCTION.
RX   PubMed=12065315; DOI=10.1161/01.RES.0000022166.74073.F8;
RA   Hou G., Vogel W.F., Bendeck M.P.;
RT   "Tyrosine kinase activity of discoidin domain receptor 1 is necessary
RT   for smooth muscle cell migration and matrix metalloproteinase
RT   expression.";
RL   Circ. Res. 90:1147-1149(2002).
RN   [21]
RP   FUNCTION, INTERACTION WITH PTPN11 AND NCK2, PHOSPHORYLATION AT
RP   TYR-740, AND MUTAGENESIS OF TYR-740.
RX   PubMed=16337946; DOI=10.1016/j.febslet.2005.11.035;
RA   Koo D.H., McFadden C., Huang Y., Abdulhussein R., Friese-Hamim M.,
RA   Vogel W.F.;
RT   "Pinpointing phosphotyrosine-dependent interactions downstream of the
RT   collagen receptor DDR1.";
RL   FEBS Lett. 580:15-22(2006).
RN   [22]
RP   FUNCTION.
RX   PubMed=16234985; DOI=10.1007/s11060-005-6874-1;
RA   Ram R., Lorente G., Nikolich K., Urfer R., Foehr E., Nagavarapu U.;
RT   "Discoidin domain receptor-1a (DDR1a) promotes glioma cell invasion
RT   and adhesion in association with matrix metalloproteinase-2.";
RL   J. Neurooncol. 76:239-248(2006).
RN   [23]
RP   INTERACTION WITH WWC1 AND PRKCZ.
RX   PubMed=18190796; DOI=10.1016/j.bbamcr.2007.12.007;
RA   Hilton H.N., Stanford P.M., Harris J., Oakes S.R., Kaplan W.,
RA   Daly R.J., Ormandy C.J.;
RT   "KIBRA interacts with discoidin domain receptor 1 to modulate
RT   collagen-induced signalling.";
RL   Biochim. Biophys. Acta 1783:383-393(2008).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND INTERACTION
RP   WITH MYH9.
RX   PubMed=19401332; DOI=10.1242/jcs.046219;
RA   Huang Y., Arora P., McCulloch C.A., Vogel W.F.;
RT   "The collagen receptor DDR1 regulates cell spreading and motility by
RT   associating with myosin IIA.";
RL   J. Cell Sci. 122:1637-1646(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH CDH1.
RX   PubMed=20432435; DOI=10.1002/jcp.22134;
RA   Eswaramoorthy R., Wang C.K., Chen W.C., Tang M.J., Ho M.L.,
RA   Hwang C.C., Wang H.M., Wang C.Z.;
RT   "DDR1 regulates the stabilization of cell surface E-cadherin and E-
RT   cadherin-mediated cell aggregation.";
RL   J. Cell. Physiol. 224:387-397(2010).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH SRC.
RX   PubMed=20093046; DOI=10.1016/j.carpath.2009.12.006;
RA   Lu K.K., Trcka D., Bendeck M.P.;
RT   "Collagen stimulates discoidin domain receptor 1-mediated migration of
RT   smooth muscle cells through Src.";
RL   Cardiovasc. Pathol. 20:71-76(2011).
RN   [28]
RP   FUNCTION.
RX   PubMed=20884741; DOI=10.1183/09031936.00039710;
RA   Roberts M.E., Magowan L., Hall I.P., Johnson S.R.;
RT   "Discoidin domain receptor 1 regulates bronchial epithelial repair and
RT   matrix metalloproteinase production.";
RL   Eur. Respir. J. 37:1482-1493(2011).
RN   [29]
RP   FUNCTION AS COLLAGEN RECEPTOR, AND AUTOPHOSPHORYLATION.
RX   PubMed=21044884; DOI=10.1016/j.matbio.2010.10.004;
RA   Xu H., Raynal N., Stathopoulos S., Myllyharju J., Farndale R.W.,
RA   Leitinger B.;
RT   "Collagen binding specificity of the discoidin domain receptors:
RT   binding sites on collagens II and III and molecular determinants for
RT   collagen IV recognition by DDR1.";
RL   Matrix Biol. 30:16-26(2011).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 29-367 IN COMPLEX WITH
RP   INHIBITORY ANTIBODY, SUBUNIT, CALCIUM-BINDING SITES, GLYCOSYLATION AT
RP   ASN-211 AND ASN-260, AND DISULFIDE BONDS.
RX   PubMed=22483115; DOI=10.1016/j.str.2012.02.011;
RA   Carafoli F., Mayer M.C., Shiraishi K., Pecheva M.A., Chan L.Y.,
RA   Nan R., Leitinger B., Hohenester E.;
RT   "Structure of the discoidin domain receptor 1 extracellular region
RT   bound to an inhibitory Fab fragment reveals features important for
RT   signaling.";
RL   Structure 20:688-697(2012).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 601-913 IN COMPLEX WITH
RP   INHIBITOR, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF GLY-707.
RX   PubMed=23899692; DOI=10.1021/cb400430t;
RA   Kim H.G., Tan L., Weisberg E.L., Liu F., Canning P., Choi H.G.,
RA   Ezell S.A., Wu H., Zhao Z., Wang J., Mandinova A., Griffin J.D.,
RA   Bullock A.N., Liu Q., Lee S.W., Gray N.S.;
RT   "Discovery of a potent and selective DDR1 receptor tyrosine kinase
RT   inhibitor.";
RL   ACS Chem. Biol. 8:2145-2150(2013).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 601-913 IN COMPLEXES WITH
RP   INHIBITORS IMATINIB AND PONATINIB, ENZYME REGULATION, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=24768818; DOI=10.1016/j.jmb.2014.04.014;
RA   Canning P., Tan L., Chu K., Lee S.W., Gray N.S., Bullock A.N.;
RT   "Structural mechanisms determining inhibition of the collagen receptor
RT   DDR1 by selective and multi-targeted type II kinase inhibitors.";
RL   J. Mol. Biol. 426:2457-2470(2014).
RN   [33]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-17; ALA-100; GLN-169; ASP-170;
RP   TRP-306 AND ALA-496.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine kinase that functions as cell surface receptor
CC       for fibrillar collagen and regulates cell attachment to the
CC       extracellular matrix, remodeling of the extracellular matrix, cell
CC       migration, differentiation, survival and cell proliferation.
CC       Collagen binding triggers a signaling pathway that involves SRC
CC       and leads to the activation of MAP kinases. Regulates remodeling
CC       of the extracellular matrix by up-regulation of the matrix
CC       metalloproteinases MMP2, MMP7 and MMP9, and thereby facilitates
CC       cell migration and wound healing. Required for normal blastocyst
CC       implantation during pregnancy, for normal mammary gland
CC       differentiation and normal lactation. Required for normal ear
CC       morphology and normal hearing (By similarity). Promotes smooth
CC       muscle cell migration, and thereby contributes to arterial wound
CC       healing. Also plays a role in tumor cell invasion. Phosphorylates
CC       PTPN11. {ECO:0000250, ECO:0000269|PubMed:12065315,
CC       ECO:0000269|PubMed:16234985, ECO:0000269|PubMed:16337946,
CC       ECO:0000269|PubMed:19401332, ECO:0000269|PubMed:20093046,
CC       ECO:0000269|PubMed:20432435, ECO:0000269|PubMed:20884741,
CC       ECO:0000269|PubMed:21044884, ECO:0000269|PubMed:9659899}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Inhibited by the multi-targeted cancer drugs
CC       imatinib and ponatinib. {ECO:0000269|PubMed:24768818}.
CC   -!- SUBUNIT: Homodimer. Interacts (via PPxY motif) with WWC1 (via WW
CC       domains) in a collagen-regulated manner. Forms a tripartite
CC       complex with WWC1 and PRKCZ, but predominantly in the absence of
CC       collagen. Interacts (tyrosine phosphorylated) with SHC1. Interacts
CC       with SRC. Interacts with MYH9. Interacts with CDH1. Interacts with
CC       PTPN11. Interacts with NCK2. {ECO:0000269|PubMed:16337946,
CC       ECO:0000269|PubMed:18190796, ECO:0000269|PubMed:19401332,
CC       ECO:0000269|PubMed:20093046, ECO:0000269|PubMed:20432435,
CC       ECO:0000269|PubMed:22483115, ECO:0000269|PubMed:23899692,
CC       ECO:0000269|PubMed:24509848, ECO:0000269|PubMed:9659899}.
CC   -!- INTERACTION:
CC       O43639:NCK2; NbExp=3; IntAct=EBI-711879, EBI-713635;
CC       Q06124:PTPN11; NbExp=4; IntAct=EBI-711879, EBI-297779;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=CAK I, DDR1b;
CC         IsoId=Q08345-1; Sequence=Displayed;
CC       Name=2; Synonyms=CAK II, DDR1a, Short;
CC         IsoId=Q08345-2; Sequence=VSP_002953;
CC       Name=3; Synonyms=DDR1d;
CC         IsoId=Q08345-4; Sequence=VSP_036916, VSP_036917;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=4;
CC         IsoId=Q08345-5; Sequence=VSP_038057;
CC       Name=5;
CC         IsoId=Q08345-6; Sequence=VSP_043582, VSP_002953;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in T-47D, MDA-MB-175 and HBL-100
CC       breast carcinoma cells, A-431 epidermoid carcinoma cells, SW48 and
CC       SNU-C2B colon carcinoma cells and Hs 294T melanoma cells (at
CC       protein level). Expressed at low levels in most adult tissues and
CC       is highest in the brain, lung, placenta and kidney. Lower levels
CC       of expression are detected in melanocytes, heart, liver, skeletal
CC       muscle and pancreas. Abundant in breast carcinoma cell lines. In
CC       the colonic mucosa, expressed in epithelia but not in the
CC       connective tissue of the lamina propria. In the thyroid gland,
CC       expressed in the epithelium of the thyroid follicles. In pancreas,
CC       expressed in the islets of Langerhans cells, but not in the
CC       surrounding epithelial cells of the exocrine pancreas. In kidney,
CC       expressed in the epithelia of the distal tubules. Not expressed in
CC       connective tissue, endothelial cells, adipose tissue, muscle cells
CC       or cells of hematopoietic origin. {ECO:0000269|PubMed:7845687,
CC       ECO:0000269|PubMed:7848919, ECO:0000269|PubMed:8247543}.
CC   -!- DOMAIN: The Gly/Pro-rich domains may be required for an unusual
CC       geometry of interaction with ligand or substrates.
CC   -!- PTM: Autophosphorylated in response to fibrillar collagen binding.
CC   -!- PTM: Glycosylation of Asn-211, but apparently not of Asn-260, Asn-
CC       371, or Asn-394, prevents autophosphorylation from occurring in
CC       the absence of collagen. {ECO:0000269|PubMed:22483115,
CC       ECO:0000269|PubMed:24509848}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 F5/8 type C domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00081}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- CAUTION: The mutant Gln-371 studied is still likely to be
CC       glycosylated at Asn-370, but study did not include mutagenesis of
CC       Asn-370. {ECO:0000305|PubMed:24509848}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=ACF47649.1; Type=Erroneous termination; Positions=287; Note=Translated as Cys.; Evidence={ECO:0000305};
CC       Sequence=BAE06103.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DDR1ID40280ch6p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X74979; CAA52915.1; -; mRNA.
DR   EMBL; L11315; AAA02866.1; -; mRNA.
DR   EMBL; Z29093; CAA82335.1; -; mRNA.
DR   EMBL; L20817; AAA18019.1; -; mRNA.
DR   EMBL; U48705; AAC50917.1; -; Genomic_DNA.
DR   EMBL; X98208; CAA66871.1; -; Genomic_DNA.
DR   EMBL; X99023; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99024; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99025; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99026; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99027; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99028; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99029; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99030; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99031; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99032; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99033; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99034; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; L57508; AAB05208.1; -; mRNA.
DR   EMBL; EU826613; ACF47649.1; ALT_SEQ; mRNA.
DR   EMBL; EU826614; ACF47650.1; -; mRNA.
DR   EMBL; AK291621; BAF84310.1; -; mRNA.
DR   EMBL; AK294793; BAH11886.1; -; mRNA.
DR   EMBL; AB210021; BAE06103.1; ALT_INIT; mRNA.
DR   EMBL; BA000025; BAB63318.1; -; Genomic_DNA.
DR   EMBL; CR759747; CAQ06757.1; -; Genomic_DNA.
DR   EMBL; CR759747; CAQ06756.1; -; Genomic_DNA.
DR   EMBL; AB088102; BAC54935.1; -; Genomic_DNA.
DR   EMBL; AB103608; BAF31270.1; -; Genomic_DNA.
DR   EMBL; AL662854; CAI17434.1; -; Genomic_DNA.
DR   EMBL; AL662870; CAI18441.1; -; Genomic_DNA.
DR   EMBL; AL773541; CAI18450.1; -; Genomic_DNA.
DR   EMBL; AL773589; CAI18450.1; JOINED; Genomic_DNA.
DR   EMBL; AL773589; CAI18534.1; -; Genomic_DNA.
DR   EMBL; AL773541; CAI18534.1; JOINED; Genomic_DNA.
DR   EMBL; AL662854; CAI17433.1; -; Genomic_DNA.
DR   EMBL; AL662870; CAI18442.1; -; Genomic_DNA.
DR   EMBL; AL773541; CAI18451.1; -; Genomic_DNA.
DR   EMBL; AL773589; CAI18451.1; JOINED; Genomic_DNA.
DR   EMBL; AL773589; CAI18533.1; -; Genomic_DNA.
DR   EMBL; AL773541; CAI18533.1; JOINED; Genomic_DNA.
DR   EMBL; AB202100; BAE78621.1; -; Genomic_DNA.
DR   EMBL; BX927194; CAQ09768.1; -; Genomic_DNA.
DR   EMBL; BX927194; CAQ09767.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03335.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03338.1; -; Genomic_DNA.
DR   EMBL; BC008716; AAH08716.1; -; mRNA.
DR   EMBL; BC013400; AAH13400.1; -; mRNA.
DR   EMBL; BC070070; AAH70070.1; -; mRNA.
DR   CCDS; CCDS34385.1; -. [Q08345-1]
DR   CCDS; CCDS4690.1; -. [Q08345-2]
DR   CCDS; CCDS47396.1; -. [Q08345-5]
DR   CCDS; CCDS56411.1; -. [Q08345-6]
DR   PIR; A48280; A48280.
DR   PIR; A49508; A49508.
DR   RefSeq; NP_001189450.1; NM_001202521.1.
DR   RefSeq; NP_001189451.1; NM_001202522.1.
DR   RefSeq; NP_001189452.1; NM_001202523.1. [Q08345-6]
DR   RefSeq; NP_001284581.1; NM_001297652.1. [Q08345-2]
DR   RefSeq; NP_001284582.1; NM_001297653.1. [Q08345-2]
DR   RefSeq; NP_001284583.1; NM_001297654.1. [Q08345-1]
DR   RefSeq; NP_001945.3; NM_001954.4. [Q08345-2]
DR   RefSeq; NP_054699.2; NM_013993.2. [Q08345-1]
DR   RefSeq; NP_054700.2; NM_013994.2. [Q08345-5]
DR   UniGene; Hs.631988; -.
DR   PDB; 3ZOS; X-ray; 1.92 A; A/B=601-913.
DR   PDB; 4AG4; X-ray; 2.80 A; A=29-367.
DR   PDB; 4BKJ; X-ray; 1.70 A; A/B=601-913.
DR   PDB; 4CKR; X-ray; 2.20 A; A=601-913.
DR   PDB; 5BVK; X-ray; 2.29 A; A=595-913.
DR   PDB; 5BVN; X-ray; 2.21 A; A=595-913.
DR   PDB; 5BVO; X-ray; 1.98 A; A=595-913.
DR   PDB; 5BVW; X-ray; 1.94 A; A=595-913.
DR   PDBsum; 3ZOS; -.
DR   PDBsum; 4AG4; -.
DR   PDBsum; 4BKJ; -.
DR   PDBsum; 4CKR; -.
DR   PDBsum; 5BVK; -.
DR   PDBsum; 5BVN; -.
DR   PDBsum; 5BVO; -.
DR   PDBsum; 5BVW; -.
DR   ProteinModelPortal; Q08345; -.
DR   SMR; Q08345; 30-367, 602-913.
DR   BioGrid; 107234; 14.
DR   DIP; DIP-39698N; -.
DR   IntAct; Q08345; 12.
DR   MINT; MINT-1383336; -.
DR   STRING; 9606.ENSP00000365759; -.
DR   BindingDB; Q08345; -.
DR   ChEMBL; CHEMBL5319; -.
DR   DrugBank; DB00619; Imatinib.
DR   GuidetoPHARMACOLOGY; 1843; -.
DR   iPTMnet; Q08345; -.
DR   PhosphoSite; Q08345; -.
DR   BioMuta; DDR1; -.
DR   DMDM; 729008; -.
DR   MaxQB; Q08345; -.
DR   PaxDb; Q08345; -.
DR   PRIDE; Q08345; -.
DR   DNASU; 780; -.
DR   Ensembl; ENST00000259875; ENSP00000259875; ENSG00000137332. [Q08345-2]
DR   Ensembl; ENST00000324771; ENSP00000318217; ENSG00000204580. [Q08345-1]
DR   Ensembl; ENST00000376567; ENSP00000365751; ENSG00000204580. [Q08345-2]
DR   Ensembl; ENST00000376568; ENSP00000365752; ENSG00000204580. [Q08345-1]
DR   Ensembl; ENST00000376569; ENSP00000365753; ENSG00000204580. [Q08345-2]
DR   Ensembl; ENST00000376570; ENSP00000365754; ENSG00000204580. [Q08345-2]
DR   Ensembl; ENST00000376575; ENSP00000365759; ENSG00000204580. [Q08345-4]
DR   Ensembl; ENST00000383377; ENSP00000372868; ENSG00000137332. [Q08345-1]
DR   Ensembl; ENST00000400410; ENSP00000383261; ENSG00000137332. [Q08345-2]
DR   Ensembl; ENST00000400411; ENSP00000383262; ENSG00000137332. [Q08345-2]
DR   Ensembl; ENST00000400414; ENSP00000383265; ENSG00000137332. [Q08345-1]
DR   Ensembl; ENST00000400486; ENSP00000383334; ENSG00000215522. [Q08345-2]
DR   Ensembl; ENST00000400488; ENSP00000383336; ENSG00000215522. [Q08345-2]
DR   Ensembl; ENST00000400489; ENSP00000383337; ENSG00000215522. [Q08345-2]
DR   Ensembl; ENST00000400491; ENSP00000383338; ENSG00000215522. [Q08345-1]
DR   Ensembl; ENST00000400492; ENSP00000383339; ENSG00000215522. [Q08345-1]
DR   Ensembl; ENST00000412329; ENSP00000391805; ENSG00000230456. [Q08345-1]
DR   Ensembl; ENST00000415092; ENSP00000405540; ENSG00000230456. [Q08345-2]
DR   Ensembl; ENST00000418800; ENSP00000407699; ENSG00000204580. [Q08345-2]
DR   Ensembl; ENST00000419412; ENSP00000416183; ENSG00000234078. [Q08345-2]
DR   Ensembl; ENST00000421229; ENSP00000415730; ENSG00000234078. [Q08345-2]
DR   Ensembl; ENST00000427053; ENSP00000416145; ENSG00000230456. [Q08345-2]
DR   Ensembl; ENST00000429699; ENSP00000401397; ENSG00000234078. [Q08345-1]
DR   Ensembl; ENST00000430933; ENSP00000397769; ENSG00000234078. [Q08345-1]
DR   Ensembl; ENST00000449518; ENSP00000414285; ENSG00000230456. [Q08345-1]
DR   Ensembl; ENST00000452441; ENSP00000405039; ENSG00000204580. [Q08345-1]
DR   Ensembl; ENST00000453510; ENSP00000401208; ENSG00000230456. [Q08345-2]
DR   Ensembl; ENST00000454612; ENSP00000406091; ENSG00000204580. [Q08345-2]
DR   Ensembl; ENST00000454774; ENSP00000400393; ENSG00000234078. [Q08345-2]
DR   Ensembl; ENST00000482873; ENSP00000421978; ENSG00000204580. [Q08345-4]
DR   Ensembl; ENST00000508312; ENSP00000422442; ENSG00000204580. [Q08345-6]
DR   Ensembl; ENST00000513240; ENSP00000427552; ENSG00000204580. [Q08345-5]
DR   Ensembl; ENST00000548133; ENSP00000449611; ENSG00000230456. [Q08345-1]
DR   Ensembl; ENST00000548962; ENSP00000448115; ENSG00000230456. [Q08345-6]
DR   Ensembl; ENST00000549026; ENSP00000449238; ENSG00000215522. [Q08345-6]
DR   Ensembl; ENST00000550384; ENSP00000447474; ENSG00000234078. [Q08345-6]
DR   Ensembl; ENST00000550395; ENSP00000449255; ENSG00000215522. [Q08345-1]
DR   Ensembl; ENST00000552068; ENSP00000449190; ENSG00000234078. [Q08345-1]
DR   Ensembl; ENST00000552721; ENSP00000449307; ENSG00000137332. [Q08345-6]
DR   Ensembl; ENST00000553015; ENSP00000448377; ENSG00000137332. [Q08345-1]
DR   Ensembl; ENST00000617572; ENSP00000479195; ENSG00000215522. [Q08345-4]
DR   Ensembl; ENST00000618059; ENSP00000479204; ENSG00000234078. [Q08345-4]
DR   Ensembl; ENST00000620318; ENSP00000484588; ENSG00000137332. [Q08345-4]
DR   Ensembl; ENST00000621544; ENSP00000484013; ENSG00000230456. [Q08345-4]
DR   GeneID; 780; -.
DR   KEGG; hsa:780; -.
DR   UCSC; uc003nrq.3; human. [Q08345-2]
DR   UCSC; uc003nrr.3; human. [Q08345-1]
DR   UCSC; uc003nrv.3; human. [Q08345-5]
DR   UCSC; uc011dms.2; human. [Q08345-6]
DR   UCSC; uc011dmu.1; human. [Q08345-4]
DR   CTD; 780; -.
DR   GeneCards; DDR1; -.
DR   HGNC; HGNC:2730; DDR1.
DR   HPA; CAB010162; -.
DR   HPA; CAB025656; -.
DR   HPA; HPA057194; -.
DR   MIM; 600408; gene.
DR   neXtProt; NX_Q08345; -.
DR   PharmGKB; PA24348; -.
DR   eggNOG; KOG1094; Eukaryota.
DR   eggNOG; ENOG410XQAI; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000043102; -.
DR   HOVERGEN; HBG005461; -.
DR   InParanoid; Q08345; -.
DR   KO; K05124; -.
DR   OMA; CEVENPQ; -.
DR   PhylomeDB; Q08345; -.
DR   TreeFam; TF317840; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   SignaLink; Q08345; -.
DR   ChiTaRS; DDR1; human.
DR   GeneWiki; DDR1; -.
DR   GenomeRNAi; 780; -.
DR   NextBio; 3152; -.
DR   PMAP-CutDB; Q2L6H3; -.
DR   PRO; PR:Q08345; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; Q08345; -.
DR   CleanEx; HS_DDR1; -.
DR   ExpressionAtlas; Q08345; baseline and differential.
DR   Genevisible; Q08345; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005518; F:collagen binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0038062; F:protein tyrosine kinase collagen receptor activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0038063; P:collagen-activated tyrosine kinase receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043583; P:ear development; IEA:Ensembl.
DR   GO; GO:0007566; P:embryo implantation; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007595; P:lactation; IEA:UniProtKB-KW.
DR   GO; GO:0060749; P:mammary gland alveolus development; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0001952; P:regulation of cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0010715; P:regulation of extracellular matrix disassembly; IMP:UniProtKB.
DR   GO; GO:0043588; P:skin development; IEA:Ensembl.
DR   GO; GO:0014909; P:smooth muscle cell migration; IMP:UniProtKB.
DR   GO; GO:0061302; P:smooth muscle cell-matrix adhesion; IMP:UniProtKB.
DR   GO; GO:0044319; P:wound healing, spreading of cells; IMP:UniProtKB.
DR   Gene3D; 2.60.120.260; -; 1.
DR   InterPro; IPR029553; DDR1/DDR2.
DR   InterPro; IPR000421; FA58C.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   PANTHER; PTHR24416:SF295; PTHR24416:SF295; 5.
DR   Pfam; PF00754; F5_F8_type_C; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00231; FA58C; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01285; FA58C_1; 1.
DR   PROSITE; PS01286; FA58C_2; 1.
DR   PROSITE; PS50022; FA58C_3; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calcium;
KW   Cell membrane; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Kinase; Lactation; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Pregnancy; Receptor; Reference proteome; Secreted; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    913       Epithelial discoidin domain-containing
FT                                receptor 1.
FT                                /FTId=PRO_0000016742.
FT   TOPO_DOM     21    417       Extracellular. {ECO:0000255}.
FT   TRANSMEM    418    438       Helical. {ECO:0000255}.
FT   TOPO_DOM    439    913       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       31    185       F5/8 type C. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00081}.
FT   DOMAIN      610    905       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     616    624       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      192    367       DS-like domain.
FT   MOTIF       481    484       PPxY motif.
FT   COMPBIAS    377    415       Gly/Pro-rich.
FT   COMPBIAS    476    601       Gly/Pro-rich.
FT   ACT_SITE    766    766       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   METAL       211    211       Calcium 1; via carbonyl oxygen.
FT   METAL       230    230       Calcium 1.
FT   METAL       230    230       Calcium 2; via carbonyl oxygen.
FT   METAL       233    233       Calcium 2.
FT   METAL       235    235       Calcium 2; via carbonyl oxygen.
FT   METAL       253    253       Calcium 1; via carbonyl oxygen.
FT   METAL       255    255       Calcium 1; via carbonyl oxygen.
FT   METAL       360    360       Calcium 2; via carbonyl oxygen.
FT   METAL       361    361       Calcium 2.
FT   BINDING     655    655       ATP.
FT   MOD_RES     484    484       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MOD_RES     513    513       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848,
FT                                ECO:0000269|PubMed:9659899}.
FT   MOD_RES     520    520       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MOD_RES     631    631       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     740    740       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:16337946}.
FT   MOD_RES     792    792       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MOD_RES     796    796       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MOD_RES     797    797       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848}.
FT   CARBOHYD    211    211       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:22483115,
FT                                ECO:0000269|PubMed:24509848}.
FT   CARBOHYD    260    260       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:22483115,
FT                                ECO:0000269|PubMed:24509848}.
FT   CARBOHYD    370    370       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    371    371       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    394    394       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     31    185       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:22483115}.
FT   DISULFID     74    177       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:22483115}.
FT   DISULFID    303    348       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:22483115}.
FT   VAR_SEQ       1      1       M -> MSLPRCCPHPLRPEGSGAM (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043582.
FT   VAR_SEQ     190    243       GLLSYTAPVGQTMYLSEAVYLNDSTYDGHTVGGLQYGGLGQ
FT                                LADGVVGLDDFRK -> CSMGVWASWQMVWWGWMTLGRVRS
FT                                CGSGQAMTMWDGATTASPVAMWRWSLSLTG (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_036916.
FT   VAR_SEQ     244    913       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_036917.
FT   VAR_SEQ     506    542       Missing (in isoform 2 and isoform 5).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7845687,
FT                                ECO:0000303|PubMed:7848919,
FT                                ECO:0000303|PubMed:8226977,
FT                                ECO:0000303|PubMed:8622863,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_002953.
FT   VAR_SEQ     665    665       A -> ASFSLFS (in isoform 4).
FT                                {ECO:0000303|PubMed:7845687}.
FT                                /FTId=VSP_038057.
FT   VARIANT      17     17       S -> G (in dbSNP:rs55901302).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041492.
FT   VARIANT     100    100       V -> A (in dbSNP:rs34544756).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041493.
FT   VARIANT     169    169       R -> Q (in dbSNP:rs55980643).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041494.
FT   VARIANT     170    170       A -> D (in dbSNP:rs56231803).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041495.
FT   VARIANT     306    306       R -> W (in dbSNP:rs56024191).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041496.
FT   VARIANT     496    496       S -> A (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041497.
FT   VARIANT     833    833       L -> V (in dbSNP:rs2524235).
FT                                {ECO:0000269|PubMed:8390675,
FT                                ECO:0000269|PubMed:8977099}.
FT                                /FTId=VAR_049716.
FT   MUTAGEN     105    105       R->A: Inhibits collagen-induced
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     211    211       N->A: Phosphorylates regardless of
FT                                collagen presence, collagen addition does
FT                                not alter significantly the levels of
FT                                constitutive phosphorylation.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     211    211       N->Q: Sustained phosphorylation
FT                                regardless of collagen presence, collagen
FT                                addition does not alter significantly the
FT                                levels of constitutive phosphorylation.
FT                                Located intracellularly and at the cell
FT                                surface. Displays a reduced rate of
FT                                receptor internalization, which is not
FT                                altered in the presence of collagen. Able
FT                                to bind collagen as wild-type. Exhibits
FT                                enhanced collagen-independent receptor
FT                                dimerization. Complete loss of the
FT                                collagen-independent constitutive
FT                                activation; when associated with A-655.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     213    213       S->A: Phosphorylates regardless of
FT                                collagen presence, collagen addition does
FT                                not alter significantly the levels of
FT                                constitutive phosphorylation.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     260    260       N->Q: Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type. No activation in the absence
FT                                of collagen.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     371    371       N->Q: Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type. No activation in the absence
FT                                of collagen.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     379    379       T->A: Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type. Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type; when associated with A-393.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     393    393       T->A: Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type. Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type; when associated with A-379.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     394    394       N->Q: Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type. No activation in the absence
FT                                of collagen.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     655    655       K->A: Loss of kinase activity. Complete
FT                                loss of the collagen-independent
FT                                constitutive activation; when associated
FT                                with Q-211.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     707    707       G->A: Confers over 20-fold resistance to
FT                                the ability of an inhibitor to inhibit
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:23899692}.
FT   MUTAGEN     740    740       Y->F: Abolishes interaction with PTPN11.
FT                                {ECO:0000269|PubMed:16337946}.
FT   CONFLICT     94     94       L -> V (in Ref. 2; AAA02866 and 5;
FT                                AAC50917). {ECO:0000305}.
FT   CONFLICT    165    165       R -> H (in Ref. 14; AAH70070).
FT                                {ECO:0000305}.
FT   CONFLICT    285    286       VH -> MW (in Ref. 8; ACF47649).
FT                                {ECO:0000305}.
FT   CONFLICT    741    741       P -> Q (in Ref. 14; AAH70070).
FT                                {ECO:0000305}.
FT   CONFLICT    847    867       QLTDEQVIENAGEFFRDQGRQ -> SAHRRAGHRERGGVLP
FT                                GPGPA (in Ref. 6; CAA66871).
FT                                {ECO:0000305}.
FT   TURN         37     39       {ECO:0000244|PDB:4AG4}.
FT   HELIX        44     46       {ECO:0000244|PDB:4AG4}.
FT   STRAND       47     50       {ECO:0000244|PDB:4AG4}.
FT   HELIX        55     57       {ECO:0000244|PDB:4AG4}.
FT   HELIX        59     61       {ECO:0000244|PDB:4AG4}.
FT   TURN         68     70       {ECO:0000244|PDB:4AG4}.
FT   STRAND       71     73       {ECO:0000244|PDB:4AG4}.
FT   STRAND       87    103       {ECO:0000244|PDB:4AG4}.
FT   HELIX       107    109       {ECO:0000244|PDB:4AG4}.
FT   STRAND      116    127       {ECO:0000244|PDB:4AG4}.
FT   STRAND      129    131       {ECO:0000244|PDB:4AG4}.
FT   STRAND      145    148       {ECO:0000244|PDB:4AG4}.
FT   STRAND      151    169       {ECO:0000244|PDB:4AG4}.
FT   STRAND      171    173       {ECO:0000244|PDB:4AG4}.
FT   STRAND      178    186       {ECO:0000244|PDB:4AG4}.
FT   STRAND      191    197       {ECO:0000244|PDB:4AG4}.
FT   STRAND      204    206       {ECO:0000244|PDB:4AG4}.
FT   STRAND      217    220       {ECO:0000244|PDB:4AG4}.
FT   STRAND      223    226       {ECO:0000244|PDB:4AG4}.
FT   HELIX       230    232       {ECO:0000244|PDB:4AG4}.
FT   STRAND      245    248       {ECO:0000244|PDB:4AG4}.
FT   TURN        251    254       {ECO:0000244|PDB:4AG4}.
FT   STRAND      256    259       {ECO:0000244|PDB:4AG4}.
FT   HELIX       260    262       {ECO:0000244|PDB:4AG4}.
FT   STRAND      266    287       {ECO:0000244|PDB:4AG4}.
FT   HELIX       291    293       {ECO:0000244|PDB:4AG4}.
FT   STRAND      299    306       {ECO:0000244|PDB:4AG4}.
FT   STRAND      308    312       {ECO:0000244|PDB:4AG4}.
FT   STRAND      314    316       {ECO:0000244|PDB:4AG4}.
FT   STRAND      318    321       {ECO:0000244|PDB:4AG4}.
FT   STRAND      332    351       {ECO:0000244|PDB:4AG4}.
FT   STRAND      353    367       {ECO:0000244|PDB:4AG4}.
FT   HELIX       607    609       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      610    619       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      622    631       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       632    634       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      637    639       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      651    657       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       663    678       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      687    691       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      693    696       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      698    702       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       709    714       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       740    759       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       769    771       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      772    774       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       776    778       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      780    782       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       790    795       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      797    800       {ECO:0000244|PDB:3ZOS}.
FT   STRAND      803    805       {ECO:0000244|PDB:3ZOS}.
FT   HELIX       807    809       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       812    817       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       822    837       {ECO:0000244|PDB:4BKJ}.
FT   TURN        838    840       {ECO:0000244|PDB:4BKJ}.
FT   TURN        844    847       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       850    862       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       878    887       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       892    894       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       898    906       {ECO:0000244|PDB:4BKJ}.
FT   TURN        907    909       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       910    912       {ECO:0000244|PDB:4BKJ}.
SQ   SEQUENCE   913 AA;  101128 MW;  C96913EA906C481E CRC64;
     MGPEALSSLL LLLLVASGDA DMKGHFDPAK CRYALGMQDR TIPDSDISAS SSWSDSTAAR
     HSRLESSDGD GAWCPAGSVF PKEEEYLQVD LQRLHLVALV GTQGRHAGGL GKEFSRSYRL
     RYSRDGRRWM GWKDRWGQEV ISGNEDPEGV VLKDLGPPMV ARLVRFYPRA DRVMSVCLRV
     ELYGCLWRDG LLSYTAPVGQ TMYLSEAVYL NDSTYDGHTV GGLQYGGLGQ LADGVVGLDD
     FRKSQELRVW PGYDYVGWSN HSFSSGYVEM EFEFDRLRAF QAMQVHCNNM HTLGARLPGG
     VECRFRRGPA MAWEGEPMRH NLGGNLGDPR ARAVSVPLGG RVARFLQCRF LFAGPWLLFS
     EISFISDVVN NSSPALGGTF PPAPWWPPGP PPTNFSSLEL EPRGQQPVAK AEGSPTAILI
     GCLVAIILLL LLIIALMLWR LHWRRLLSKA ERRVLEEELT VHLSVPGDTI LINNRPGPRE
     PPPYQEPRPR GNPPHSAPCV PNGSALLLSN PAYRLLLATY ARPPRGPGPP TPAWAKPTNT
     QAYSGDYMEP EKPGAPLLPP PPQNSVPHYA EADIVTLQGV TGGNTYAVPA LPPGAVGDGP
     PRVDFPRSRL RFKEKLGEGQ FGEVHLCEVD SPQDLVSLDF PLNVRKGHPL LVAVKILRPD
     ATKNARNDFL KEVKIMSRLK DPNIIRLLGV CVQDDPLCMI TDYMENGDLN QFLSAHQLED
     KAAEGAPGDG QAAQGPTISY PMLLHVAAQI ASGMRYLATL NFVHRDLATR NCLVGENFTI
     KIADFGMSRN LYAGDYYRVQ GRAVLPIRWM AWECILMGKF TTASDVWAFG VTLWEVLMLC
     RAQPFGQLTD EQVIENAGEF FRDQGRQVYL SRPPACPQGL YELMLRCWSR ESEQRPPFSQ
     LHRFLAEDAL NTV
//
ID   TTHY_HUMAN              Reviewed;         147 AA.
AC   P02766; Q549C7; Q6IB96; Q9UBZ6; Q9UCM9;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   20-MAR-1987, sequence version 1.
DT   17-FEB-2016, entry version 202.
DE   RecName: Full=Transthyretin;
DE   AltName: Full=ATTR;
DE   AltName: Full=Prealbumin;
DE   AltName: Full=TBPA;
DE   Flags: Precursor;
GN   Name=TTR; Synonyms=PALB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=6093805; DOI=10.1016/0006-291X(84)91590-0;
RA   Mita S., Maeda S., Shimada K., Araki S.;
RT   "Cloning and sequence analysis of cDNA for human prealbumin.";
RL   Biochem. Biophys. Res. Commun. 124:558-564(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2990465; DOI=10.1016/0006-291X(85)91956-4;
RA   Wallace M.R., Naylor S.L., Kluve-Beckerman B., Long G.L., McDonald L.,
RA   Shows T.B., Benson M.D.;
RT   "Localization of the human prealbumin gene to chromosome 18.";
RL   Biochem. Biophys. Res. Commun. 129:753-758(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=4054629; DOI=10.1016/0378-1119(85)90272-0;
RA   Sasaki H., Yoshioka N., Takagi Y., Sakaki Y.;
RT   "Structure of the chromosomal gene for human serum prealbumin.";
RL   Gene 37:191-197(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2995367;
RA   Tsuzuki T., Mita S., Maeda S., Araki S., Shimada K.;
RT   "Structure of the human prealbumin gene.";
RL   J. Biol. Chem. 260:12224-12227(1985).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT AMYL-TTR MET-50.
RX   PubMed=3818577;
RA   Mita S., Maeda S., Shimada K., Araki S.;
RT   "Analyses of prealbumin mRNAs in individuals with familial amyloidotic
RT   polyneuropathy.";
RL   J. Biochem. 100:1215-1222(1986).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT AMYL-TTR MET-50.
RC   TISSUE=Liver;
RX   PubMed=3022108;
RA   Maeda S., Mita S., Araki S., Shimada K.;
RT   "Structure and expression of the mutant prealbumin gene associated
RT   with familial amyloidotic polyneuropathy.";
RL   Mol. Biol. Med. 3:329-338(1986).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 22-28.
RC   TISSUE=Liver;
RX   PubMed=2015890; DOI=10.1016/0014-5793(91)80387-I;
RA   Christmanson L., Betsholtz C., Gustavsson A., Johansson B.,
RA   Sletten K., Westermark P.;
RT   "The transthyretin cDNA sequence is normal in transthyretin-derived
RT   senile systemic amyloidosis.";
RL   FEBS Lett. 281:177-180(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=1666289;
RA   Gu J.R., Jiang H.Q., He L.P., Li D.Z., Zhou X.M., Dai W.L., Qian L.F.,
RA   Chen Y.Q., Schweinfest C., Papas T.;
RT   "Transthyretin (prealbumin) gene in human primary hepatic cancer.";
RL   Sci. China, Ser. B, Chem. Life Sci. Earth Sci. 34:1312-1318(1991).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RC   TISSUE=Retina;
RX   PubMed=10328977; DOI=10.1006/exer.1998.0646;
RA   Getz R.K., Kennedy B.G., Mangini N.J.;
RT   "Transthyretin localization in cultured and native human retinal
RT   pigment epithelium.";
RL   Exp. Eye Res. 68:629-636(1999).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Corpus callosum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   PROTEIN SEQUENCE OF 21-147.
RX   PubMed=4607556;
RA   Kanda Y., Goodman D.S., Canfield R.E., Morgan F.J.;
RT   "The amino acid sequence of human plasma prealbumin.";
RL   J. Biol. Chem. 249:6796-6805(1974).
RN   [16]
RP   PRELIMINARY PROTEIN SEQUENCE OF 21-147, AND VARIANT SER-26.
RX   PubMed=6300852; DOI=10.1073/pnas.80.2.539;
RA   Pras M., Prelli F., Franklin E.C., Frangione B.;
RT   "Primary structure of an amyloid prealbumin variant in familial
RT   polyneuropathy of Jewish origin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:539-542(1983).
RN   [17]
RP   PROTEIN SEQUENCE OF 21-147, AND VARIANT AMYL-TTR MET-50.
RX   PubMed=6651852; DOI=10.1016/S0006-291X(83)80224-1;
RA   Tawara S., Nakazato M., Kangawa K., Matsuo H., Araki S.;
RT   "Identification of amyloid prealbumin variant in familial amyloidotic
RT   polyneuropathy (Japanese type).";
RL   Biochem. Biophys. Res. Commun. 116:880-888(1983).
RN   [18]
RP   PROTEIN SEQUENCE OF 21-147, AND VARIANT AMYL-TTR MET-50.
RX   PubMed=6583672; DOI=10.1073/pnas.81.3.694;
RA   Dwulet F.E., Benson M.D.;
RT   "Primary structure of an amyloid prealbumin and its plasma precursor
RT   in a heredofamilial polyneuropathy of Swedish origin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:694-698(1984).
RN   [19]
RP   PROTEIN SEQUENCE OF 21-147, AND VARIANT AMYL-TTR ILE-142.
RX   PubMed=3135807; DOI=10.1016/0006-291X(88)90188-X;
RA   Cornwell G.G. III, Sletten K., Johansson B., Westermark P.;
RT   "Evidence that the amyloid fibril protein in senile systemic
RT   amyloidosis is derived from normal prealbumin.";
RL   Biochem. Biophys. Res. Commun. 154:648-653(1988).
RN   [20]
RP   PROTEIN SEQUENCE OF 21-147, AND VARIANT AMYL-TTR MET-50.
RX   PubMed=1517749; DOI=10.1016/0022-510X(92)90048-P;
RA   Kametani F., Ikeda S., Yanagisawa N., Ishi T., Hanyu N.;
RT   "Characterization of a transthyretin-related amyloid fibril protein
RT   from cerebral amyloid angiopathy in type I familial amyloid
RT   polyneuropathy.";
RL   J. Neurol. Sci. 108:178-183(1992).
RN   [21]
RP   PROTEIN SEQUENCE OF 21-41.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 24-67, AND VARIANT AMYL-TTR
RP   LEU-53.
RX   PubMed=1932142; DOI=10.1016/0925-4439(91)90033-6;
RA   Harding J., Skare J., Skinner M.;
RT   "A second transthyretin mutation at position 33 (Leu/Phe) associated
RT   with familial amyloidotic polyneuropathy.";
RL   Biochim. Biophys. Acta 1097:183-186(1991).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 24-67, VARIANT AMYL-TTR GLY-62,
RP   AND VARIANT ASN-110.
RX   PubMed=7923855;
RA   Skare J.C., Jones L.A., Myles N., Kane K., Milunsky A., Cohen A.S.,
RA   Skinner M.;
RT   "Two transthyretin mutations (Glu42Gly, His90Asn) in an Italian family
RT   with amyloidosis.";
RL   Clin. Genet. 45:281-284(1994).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 31-147.
RX   PubMed=4044580;
RA   Soprano D.R., Herbert J., Soprano K.J., Schon E.A., Goodman D.S.;
RT   "Demonstration of transthyretin mRNA in the brain and other
RT   extrahepatic tissues in the rat.";
RL   J. Biol. Chem. 260:11793-11798(1985).
RN   [25]
RP   PROTEIN SEQUENCE OF 42-68; 101-123 AND 125-146, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [26]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 113-129, AND VARIANT DTTRH
RP   THR-129.
RX   PubMed=1979335; DOI=10.1172/JCI114938;
RA   Moses A.C., Rosen H.N., Moller D.E., Tsuzaki S., Haddow J.E.,
RA   Lawlor J., Liepnieks J.J., Nichols W.C., Benson M.D.;
RT   "A point mutation in transthyretin increases affinity for thyroxine
RT   and produces euthyroid hyperthyroxinemia.";
RL   J. Clin. Invest. 86:2025-2033(1990).
RN   [27]
RP   PARTIAL PROTEIN SEQUENCE.
RX   PubMed=7474944;
RA   Gustavsson A., Jahr H., Tobiassen R., Jacobson D.R., Sletten K.,
RA   Westermark P.;
RT   "Amyloid fibril composition and transthyretin gene structure in senile
RT   systemic amyloidosis.";
RL   Lab. Invest. 73:703-708(1995).
RN   [28]
RP   BINDING SITES FOR THYROID HORMONES.
RX   PubMed=201845; DOI=10.1038/268115a0;
RA   Blake C.C.F., Oatley S.J.;
RT   "Protein-DNA and protein-hormone interactions in prealbumin: a model
RT   of the thyroid hormone nuclear receptor?";
RL   Nature 268:115-120(1977).
RN   [29]
RP   FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=3714052; DOI=10.1212/WNL.36.7.900;
RA   Herbert J., Wilcox J.N., Pham K.T., Fremeau R.T. Jr., Zeviani M.,
RA   Dwork A., Soprano D.R., Makover A., Goodman D.S., Zimmerman E.A.,
RA   Roberts J.L., Schon E.A.;
RT   "Transthyretin: a choroid plexus-specific transport protein in human
RT   brain. The 1986 S. Weir Mitchell award.";
RL   Neurology 36:900-911(1986).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [31]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-118.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [32]
RP   GAMMA-CARBOXYGLUTAMATION AT GLU-62, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=18221012; DOI=10.2174/092986608783330297;
RA   Rueggeberg S., Horn P., Li X., Vajkoczy P., Franz T.;
RT   "Detection of a gamma-carboxy-glutamate as novel post-translational
RT   modification of human transthyretin.";
RL   Protein Pept. Lett. 15:43-46(2008).
RN   [33]
RP   GLYCOSYLATION AT ASN-118, AND CHARACTERIZATION OF VARIANT AMYL-TTR
RP   GLY-38.
RX   PubMed=19167329; DOI=10.1016/j.cell.2008.11.047;
RA   Ruiz-Canada C., Kelleher D.J., Gilmore R.;
RT   "Cotranslational and posttranslational N-glycosylation of polypeptides
RT   by distinct mammalian OST isoforms.";
RL   Cell 136:272-283(2009).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   PubMed=4216640; DOI=10.1016/0022-2836(74)90291-5;
RA   Blake C.C.F., Geisow M.J., Swan I.D.A., Rerat C., Rerat B.;
RT   "Structure of human plasma prealbumin at 2.5-A resolution. A
RT   preliminary report on the polypeptide chain conformation, quaternary
RT   structure and thyroxine binding.";
RL   J. Mol. Biol. 88:1-12(1974).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX   PubMed=671542; DOI=10.1016/0022-2836(78)90368-6;
RA   Blake C.C.F., Geisow M.J., Oatley S.J., Rerat B., Rerat C.;
RT   "Structure of prealbumin: secondary, tertiary and quaternary
RT   interactions determined by Fourier refinement at 1.8 A.";
RL   J. Mol. Biol. 121:339-356(1978).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF VARIANT AMYL-TTR MET-50.
RX   PubMed=8382610;
RA   Terry C.J., Damas A.M., Oliveira P., Saraiva M.J.M., Alves I.L.,
RA   Costa P.P., Matias P.M., Sakaki Y., Blake C.C.F.;
RT   "Structure of Met30 variant of transthyretin and its amyloidogenic
RT   implications.";
RL   EMBO J. 12:735-741(1993).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF VARIANT AMYL-TTR MET-50.
RX   PubMed=8428915;
RA   Hamilton J.A., Steinrauf L.K., Braden B.C., Liepnieks J., Benson M.D.,
RA   Holmgren G., Sandgren O., Steen L.;
RT   "The X-ray crystal structure refinements of normal human transthyretin
RT   and the amyloidogenic Val-30-->Met variant to 1.7-A resolution.";
RL   J. Biol. Chem. 268:2416-2424(1993).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF COMPLEX WITH RBP.
RX   PubMed=7754382; DOI=10.1126/science.7754382;
RA   Monaco H.L., Rizzi M., Coda A.;
RT   "Structure of a complex of two plasma proteins: transthyretin and
RT   retinol-binding protein.";
RL   Science 268:1039-1041(1995).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF VARIANTS.
RX   PubMed=9818054; DOI=10.3109/13506129809003843;
RA   Schormann N., Murrell J.R., Benson M.D.;
RT   "Tertiary structures of amyloidogenic and non-amyloidogenic
RT   transthyretin variants: new model for amyloid fibril formation.";
RL   Amyloid 5:175-187(1998).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 21-147 OF VARIANT AMYL-TTR
RP   PRO-75.
RX   PubMed=9733771; DOI=10.1074/jbc.273.38.24715;
RA   Sebastiao M.P., Saraiva M.J., Damas A.M.;
RT   "The crystal structure of amyloidogenic Leu55 --> Pro transthyretin
RT   variant reveals a possible pathway for transthyretin polymerization
RT   into amyloid fibrils.";
RL   J. Biol. Chem. 273:24715-24722(1998).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=9789022; DOI=10.1073/pnas.95.22.12956;
RA   Peterson S.A., Klabunde T., Lashuel H.A., Purkey H., Sacchettini J.C.,
RA   Kelly J.W.;
RT   "Inhibiting transthyretin conformational changes that lead to amyloid
RT   fibril formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:12956-12960(1998).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF COMPLEX WITH RBP4, AND
RP   SUBUNIT.
RX   PubMed=10052934; DOI=10.1021/bi982291i;
RA   Naylor H.M., Newcomer M.E.;
RT   "The structure of human retinol-binding protein (RBP) with its carrier
RT   protein transthyretin reveals an interaction with the carboxy terminus
RT   of RBP.";
RL   Biochemistry 38:2647-2653(1999).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 21-147.
RX   PubMed=10986125; DOI=10.1006/jmbi.2000.4078;
RA   Hoernberg A., Eneqvist T., Olofsson A., Lundgren E.,
RA   Sauer-Eriksson A.E.;
RT   "A comparative analysis of 23 structures of the amyloidogenic protein
RT   transthyretin.";
RL   J. Mol. Biol. 302:649-669(2000).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=10742177; DOI=10.1038/74082;
RA   Klabunde T., Petrassi H.M., Oza V.B., Raman P., Kelly J.W.,
RA   Sacchettini J.C.;
RT   "Rational design of potent human transthyretin amyloid disease
RT   inhibitors.";
RL   Nat. Struct. Biol. 7:312-321(2000).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 21-147, MUTAGENESIS OF
RP   PHE-107 AND LEU-130, IDENTIFICATION BY MASS SPECTROMETRY, FORMATION OF
RP   AMYLOID FIBERS AT ACIDIC PH, AND SUBUNIT.
RX   PubMed=11560492; DOI=10.1021/bi011194d;
RA   Jiang X., Smith C.S., Petrassi H.M., Hammarstroem P., White J.T.,
RA   Sacchettini J.C., Kelly J.W.;
RT   "An engineered transthyretin monomer that is nonamyloidogenic, unless
RT   it is partially denatured.";
RL   Biochemistry 40:11442-11452(2001).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (1.1 ANGSTROMS) OF 30-144 OF VARIANT AMYL-TTR
RP   MET-50 AND VARIANT CHICAGO MET-139 IN COMPLEX WITH L-THYROXINE, AND
RP   SUBUNIT.
RX   PubMed=11243784; DOI=10.1006/jmbi.2000.4415;
RA   Sebastiao M.P., Lamzin V., Saraiva M.J., Damas A.M.;
RT   "Transthyretin stability as a key factor in amyloidogenesis: X-ray
RT   analysis at atomic resolution.";
RL   J. Mol. Biol. 306:733-744(2001).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 21-147 OF VARIANT AMYL-TTR
RP   CYS-134.
RX   PubMed=12403615; DOI=10.1021/bi025800w;
RA   Eneqvist T., Olofsson A., Ando Y., Miyakawa T., Katsuragi S., Jass J.,
RA   Lundgren E., Sauer-Eriksson A.E.;
RT   "Disulfide-bond formation in the transthyretin mutant Y114C prevents
RT   amyloid fibril formation in vivo and in vitro.";
RL   Biochemistry 41:13143-13151(2002).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 21-147IN COMPLEX WITH
RP   AMYLOIDOGENESIS INHIBITORS.
RX   PubMed=12820260; DOI=10.1002/anie.200351179;
RA   Razavi H., Palaninathan S.K., Powers E.T., Wiseman R.L., Purkey H.E.,
RA   Mohamedmohaideen N.N., Deechongkit S., Chiang K.P., Dendle M.T.A.,
RA   Sacchettini J.C., Kelly J.W.;
RT   "Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis,
RT   evaluation, and mechanism of action.";
RL   Angew. Chem. Int. Ed. 42:2758-2761(2003).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.46 ANGSTROMS) OF 21-147 IN COMPLEX WITH
RP   AMYLOIDOGENESIS INHIBITORS, AND FIBRIL FORMATION.
RX   PubMed=14583036; DOI=10.1021/ja030294z;
RA   Green N.S., Palaninathan S.K., Sacchettini J.C., Kelly J.W.;
RT   "Synthesis and characterization of potent bivalent amyloidosis
RT   inhibitors that bind prior to transthyretin tetramerization.";
RL   J. Am. Chem. Soc. 125:13404-13414(2003).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 21-147 IN COMPLEX WITH
RP   DIFLUNISAL ANALOGS, AND INHIBITION OF AMYLOID FORMATION.
RX   PubMed=14711308; DOI=10.1021/jm030347n;
RA   Adamski-Werner S.L., Palaninathan S.K., Sacchettini J.C., Kelly J.W.;
RT   "Diflunisal analogues stabilize the native state of transthyretin.
RT   Potent inhibition of amyloidogenesis.";
RL   J. Med. Chem. 47:355-374(2004).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 21-147 OF VARIANT AMYL-TTR
RP   PHE-98 AND VARIANT HIS-124, AND SUBUNIT.
RX   PubMed=15735344; DOI=10.1107/S0907444904034316;
RA   Neto-Silva R.M., Macedo-Ribeiro S., Pereira P.J.B., Coll M.,
RA   Saraiva M.J., Damas A.M.;
RT   "X-ray crystallographic studies of two transthyretin variants: further
RT   insights into amyloidogenesis.";
RL   Acta Crystallogr. D 61:333-339(2005).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-147 IN COMPLEXES WITH
RP   CHLORIDE AND IODIDE IONS.
RX   PubMed=15981995; DOI=10.1021/bi050249z;
RA   Hoernberg A., Hultdin U.W., Olofsson A., Sauer-Eriksson A.E.;
RT   "The effect of iodide and chloride on transthyretin structure and
RT   stability.";
RL   Biochemistry 44:9290-9299(2005).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 21-147 OF VARIANT AMYL-TTR
RP   CYS-134.
RX   PubMed=16185074; DOI=10.1021/bi050795s;
RA   Karlsson A., Olofsson A., Eneqvist T., Sauer-Eriksson A.E.;
RT   "Cys114-linked dimers of transthyretin are compatible with amyloid
RT   formation.";
RL   Biochemistry 44:13063-13070(2005).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (1.69 ANGSTROMS) OF 21-147 IN COMPLEX WITH
RP   THYROID HORMONE ANALOG, AND SUBUNIT.
RX   PubMed=15826192; DOI=10.1021/ja042929f;
RA   Wiseman R.L., Johnson S.M., Kelker M.S., Foss T., Wilson I.A.,
RA   Kelly J.W.;
RT   "Kinetic stabilization of an oligomeric protein by a single ligand
RT   binding event.";
RL   J. Am. Chem. Soc. 127:5540-5551(2005).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.36 ANGSTROMS) OF 31-147, AND SUBUNIT.
RX   PubMed=15769474; DOI=10.1016/j.jmb.2005.01.050;
RA   Foss T.R., Kelker M.S., Wiseman R.L., Wilson I.A., Kelly J.W.;
RT   "Kinetic stabilization of the native state by protein engineering:
RT   implications for inhibition of transthyretin amyloidogenesis.";
RL   J. Mol. Biol. 347:841-854(2005).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 21-147 OF WILD-TYPE AND
RP   VARIANTS AMYL-TTR PRO-75 AND PHE-98.
RX   PubMed=16627944; DOI=10.1107/S0907444906006962;
RA   Morais-de-Sa E., Neto-Silva R.M., Pereira P.J.B., Saraiva M.J.,
RA   Damas A.M.;
RT   "The binding of 2,4-dinitrophenol to wild-type and amyloidogenic
RT   transthyretin.";
RL   Acta Crystallogr. D 62:512-519(2006).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 21-147.
RX   PubMed=17175208; DOI=10.1016/j.bbapap.2006.10.015;
RA   Gales L., Saraiva M.J., Damas A.M.;
RT   "Structural basis for the protective role of sulfite against
RT   transthyretin amyloid formation.";
RL   Biochim. Biophys. Acta 1774:59-64(2007).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-147.
RX   PubMed=17196219; DOI=10.1016/j.jmb.2006.11.076;
RA   Pasquato N., Berni R., Folli C., Alfieri B., Cendron L., Zanotti G.;
RT   "Acidic pH-induced conformational changes in amyloidogenic mutant
RT   transthyretin.";
RL   J. Mol. Biol. 366:711-719(2007).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 21-147 IN COMPLEX WITH
RP   3,5-DIIODOSALICYLIC ACID, AND THYROXINE BINDING.
RX   PubMed=18155178; DOI=10.1016/j.bbapap.2007.11.014;
RA   Gales L., Almeida M.R., Arsequell G., Valencia G., Saraiva M.J.,
RA   Damas A.M.;
RT   "Iodination of salicylic acid improves its binding to transthyretin.";
RL   Biochim. Biophys. Acta 1784:512-517(2008).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (3.38 ANGSTROMS) OF 21-147 IN COMPLEX WITH RBP4.
RX   PubMed=19021760; DOI=10.1111/j.1742-4658.2008.06705.x;
RA   Zanotti G., Folli C., Cendron L., Alfieri B., Nishida S.K.,
RA   Gliubich F., Pasquato N., Negro A., Berni R.;
RT   "Structural and mutational analyses of protein-protein interactions
RT   between transthyretin and retinol-binding protein.";
RL   FEBS J. 275:5841-5854(2008).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 21-147 IN COMPLEX WITH
RP   2-ARYLBENZOXAZOLE-BASED TRANSTHYRETIN AMYLOIDOGENESIS INHIBITORS.
RX   PubMed=18095641; DOI=10.1021/jm0708735;
RA   Johnson S.M., Connelly S., Wilson I.A., Kelly J.W.;
RT   "Biochemical and structural evaluation of highly selective 2-
RT   arylbenzoxazole-based transthyretin amyloidogenesis inhibitors.";
RL   J. Med. Chem. 51:260-270(2008).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 21-147 IN COMPLEX WITH
RP   BISARYL AMYLOIDOGENESIS INHIBITORS.
RX   PubMed=18811132; DOI=10.1021/jm800435s;
RA   Johnson S.M., Connelly S., Wilson I.A., Kelly J.W.;
RT   "Toward optimization of the linker substructure common to
RT   transthyretin amyloidogenesis inhibitors using biochemical and
RT   structural studies.";
RL   J. Med. Chem. 51:6348-6358(2008).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 21-147 AT PH 3.5 AND 4.5.
RX   PubMed=18662699; DOI=10.1016/j.jmb.2008.07.029;
RA   Palaninathan S.K., Mohamedmohaideen N.N., Snee W.C., Kelly J.W.,
RA   Sacchettini J.C.;
RT   "Structural insight into pH-induced conformational changes within the
RT   native human transthyretin tetramer.";
RL   J. Mol. Biol. 382:1157-1167(2008).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (1.38 ANGSTROMS) OF 21-147.
RG   Mycobacterium tuberculosis structural genomics consortium (TB);
RT   "Crystal structure of the F87M/L110M mutant of human transthyretin at
RT   pH 4.6 soaked.";
RL   Submitted (JUL-2008) to the PDB data bank.
RN   [66]
RP   REVIEW ON VARIANTS.
RX   PubMed=7599630; DOI=10.1002/humu.1380050302;
RA   Saraiva M.J.M.;
RT   "Transthyretin mutations in health and disease.";
RL   Hum. Mutat. 5:191-196(1995).
RN   [67]
RP   VARIANT AMYL-TTR ILE-53.
RX   PubMed=6487335; DOI=10.1016/S0006-291X(84)80222-3;
RA   Nakazato M., Kangawa K., Minamino N., Tawara S., Matsuo H., Araki S.;
RT   "Revised analysis of amino acid replacement in a prealbumin variant
RT   (SKO-III) associated with familial amyloidotic polyneuropathy of
RT   Jewish origin.";
RL   Biochem. Biophys. Res. Commun. 123:921-928(1984).
RN   [68]
RP   VARIANT AMYL-TTR SER-104.
RX   PubMed=3722385; DOI=10.1172/JCI112573;
RA   Wallace M.R., Dwulet F.E., Conneally P.M., Benson M.D.;
RT   "Biochemical and molecular genetic characterization of a new variant
RT   prealbumin associated with hereditary amyloidosis.";
RL   J. Clin. Invest. 78:6-12(1986).
RN   [69]
RP   VARIANT VAL-136.
RX   PubMed=3675594; DOI=10.1016/0006-291X(87)91135-1;
RA   Strahler J.R., Rosenblum B.B., Hanash S.M.;
RT   "Identification and characterization of a human transthyretin
RT   variant.";
RL   Biochem. Biophys. Res. Commun. 148:471-477(1987).
RN   [70]
RP   VARIANT AMYL-TTR TYR-97.
RX   PubMed=2891727; DOI=10.1172/JCI113293;
RA   Wallace M.R., Dwulet F.E., Williams E.C., Conneally P.M., Benson M.D.;
RT   "Identification of a new hereditary amyloidosis prealbumin variant,
RT   Tyr-77, and detection of the gene by DNA analysis.";
RL   J. Clin. Invest. 81:189-193(1988).
RN   [71]
RP   VARIANT AMYL-TTR CYS-134.
RX   PubMed=2161654; DOI=10.1016/0006-291X(90)91445-X;
RA   Ueno S., Uemichi T., Yorifuji S., Tarui S.;
RT   "A novel variant of transthyretin (Tyr114 to Cys) deduced from the
RT   nucleotide sequences of gene fragments from familial amyloidotic
RT   polyneuropathy in Japanese sibling cases.";
RL   Biochem. Biophys. Res. Commun. 169:143-147(1990).
RN   [72]
RP   VARIANTS AMYL-TTR GLY-62 AND ARG-70.
RX   PubMed=2363717; DOI=10.1016/0006-291X(90)92011-N;
RA   Ueno S., Uemichi T., Takahashi N., Soga F., Yorifuji S., Tarui S.;
RT   "Two novel variants of transthyretin identified in Japanese cases with
RT   familial amyloidotic polyneuropathy: transthyretin (Glu42 to Gly) and
RT   transthyretin (Ser50 to Arg).";
RL   Biochem. Biophys. Res. Commun. 169:1117-1121(1990).
RN   [73]
RP   VARIANT CHICAGO MET-139.
RX   PubMed=1877623; DOI=10.1002/ajmg.1320390415;
RA   Harrison H.H., Gordon E.D., Nichols W.C., Benson M.D.;
RT   "Biochemical and clinical characterization of prealbuminCHICAGO: an
RT   apparently benign variant of serum prealbumin (transthyretin)
RT   discovered with high-resolution two-dimensional electrophoresis.";
RL   Am. J. Med. Genet. 39:442-452(1991).
RN   [74]
RP   VARIANT AMYL-TTR ARG-78.
RX   PubMed=1656975; DOI=10.1016/S0006-291X(05)81304-X;
RA   Saeki Y., Ueno S., Yorifuji S., Sugiyama Y., Ide Y., Matsuzawa Y.;
RT   "New mutant gene (transthyretin Arg 58) in cases with hereditary
RT   polyneuropathy detected by non-isotope method of single-strand
RT   conformation polymorphism analysis.";
RL   Biochem. Biophys. Res. Commun. 180:380-385(1991).
RN   [75]
RP   VARIANT ASN-110.
RX   PubMed=1997217;
RA   Skare J.C., Milunsky J.M., Milunsky A., Skare I.B., Cohen A.S.,
RA   Skinner M.;
RT   "A new transthyretin variant from a patient with familial amyloidotic
RT   polyneuropathy has asparagine substituted for histidine at position
RT   90.";
RL   Clin. Genet. 39:6-12(1991).
RN   [76]
RP   VARIANTS AMYL-TTR LEU-53 AND LEU-84.
RX   PubMed=2046936; DOI=10.1212/WNL.41.6.893;
RA   Li S., Minnerath S., Li K., Dyck P.J., Sommer S.S.;
RT   "Two-tiered DNA-based diagnosis of transthyretin amyloidosis reveals
RT   two novel point mutations.";
RL   Neurology 41:893-898(1991).
RN   [77]
RP   VARIANT AMYL-TTR THR-65.
RX   PubMed=1570831;
RA   Saraiva M.J.M., Almeida M.R., Sherman W., Gawinowicz M., Costa P.,
RA   Costa P.P., Goodman D.S.;
RT   "A new transthyretin mutation associated with amyloid
RT   cardiomyopathy.";
RL   Am. J. Hum. Genet. 50:1027-1030(1992).
RN   [78]
RP   VARIANT AMYL-TTR ARG-67.
RX   PubMed=1734866; DOI=10.1016/0006-291X(92)91763-G;
RA   Murakami T., Maeda S., Yi S., Ikegawa S., Kawashima E., Onodera S.,
RA   Shimada K., Araki S.;
RT   "A novel transthyretin mutation associated with familial amyloidotic
RT   polyneuropathy.";
RL   Biochem. Biophys. Res. Commun. 182:520-526(1992).
RN   [79]
RP   VARIANT AMYL-TTR LEU-50.
RX   PubMed=1520326; DOI=10.1016/S0006-291X(05)81506-2;
RA   Murakami T., Atsumi T., Maeda S., Tanase S., Ishikawa K., Mita S.,
RA   Kumamoto T., Araki S., Ando M.;
RT   "A novel transthyretin mutation at position 30 (Leu for Val)
RT   associated with familial amyloidotic polyneuropathy.";
RL   Biochem. Biophys. Res. Commun. 187:397-403(1992).
RN   [80]
RP   VARIANT AMYL-TTR ILE-70.
RX   PubMed=1520336; DOI=10.1016/S0006-291X(05)81516-5;
RA   Nishi H., Kimura A., Harada H., Hayashi Y., Nakamura M., Sasazuki T.;
RT   "Novel variant transthyretin gene (Ser50 to Ile) in familial cardiac
RT   amyloidosis.";
RL   Biochem. Biophys. Res. Commun. 187:460-466(1992).
RN   [81]
RP   VARIANT AMYL-TTR ALA-50.
RX   PubMed=1544214;
RA   Jones L.A., Skare J.C., Cohen A.S., Harding J.A., Milunsky A.,
RA   Skinner M.;
RT   "Familial amyloidotic polyneuropathy: a new transthyretin position 30
RT   mutation (alanine for valine) in a family of German descent.";
RL   Clin. Genet. 41:70-73(1992).
RN   [82]
RP   VARIANT AMYL-TTR PRO-75.
RX   PubMed=1351039; DOI=10.1007/BF00220559;
RA   Jacobson D.R., McFarlin D.E., Kane I., Buxbaum J.N.;
RT   "Transthyretin Pro55, a variant associated with early-onset,
RT   aggressive, diffuse amyloidosis with cardiac and neurologic
RT   involvement.";
RL   Hum. Genet. 89:353-356(1992).
RN   [83]
RP   VARIANTS AMYL-TTR ALA-69 AND GLN-109.
RX   PubMed=1301926; DOI=10.1002/humu.1380010306;
RA   Almeida M.R., Ferlini A., Forabosco A., Gawinowicz M.A., Costa P.P.,
RA   Salvi F., Plasmati R., Tassinari C.A., Altland K., Saraiva M.J.;
RT   "Two transthyretin variants (TTR Ala-49 and TTR Gln-89) in two
RT   Sicilian kindreds with hereditary amyloidosis.";
RL   Hum. Mutat. 1:211-215(1992).
RN   [84]
RP   VARIANT AMYL-TTR ARG-30.
RX   PubMed=1362222; DOI=10.1136/jmg.29.12.888;
RA   Uemichi T., Murrel J.R., Zeldenrust S., Benson M.D.;
RT   "A new mutant transthyretin (Arg 10) associated with familial amyloid
RT   polyneuropathy.";
RL   J. Med. Genet. 29:888-891(1992).
RN   [85]
RP   VARIANT AMYL-TTR ASN-90.
RX   PubMed=1436517; DOI=10.1212/WNL.42.11.2094;
RA   Izumoto S., Younger D., Hays A.P., Martone R.L., Smith R.T.,
RA   Herbert J.;
RT   "Familial amyloidotic polyneuropathy presenting with carpal tunnel
RT   syndrome and a new transthyretin mutation, asparagine 70.";
RL   Neurology 42:2094-2102(1992).
RN   [86]
RP   VARIANT AMYL-TTR LYS-81.
RX   PubMed=8352764; DOI=10.1006/bbrc.1993.1933;
RA   Shiomi K., Nakazato M., Matsukura S., Ohnishi A., Hatanaka H.,
RA   Tsuji S., Murai Y., Kojima M., Kangawa K., Matsuo H.;
RT   "A basic transthyretin variant (Glu61-->Lys) causes familial
RT   amyloidotic polyneuropathy: protein and DNA sequencing and PCR-induced
RT   mutation restriction analysis.";
RL   Biochem. Biophys. Res. Commun. 194:1090-1096(1993).
RN   [87]
RP   VARIANT AMYL-TTR LEU-88.
RX   PubMed=8038017; DOI=10.1136/hrt.70.2.111;
RA   Hesse A., Altland K., Linke R.P., Almeida M.R., Saraiva M.J.M.,
RA   Steinmetz A., Maisch B.;
RT   "Cardiac amyloidosis: a review and report of a new transthyretin
RT   (prealbumin) variant.";
RL   Br. Heart J. 70:111-115(1993).
RN   [88]
RP   VARIANT AMYL-TTR ALA-91.
RX   PubMed=8257997; DOI=10.1002/humu.1380020516;
RA   Almeida M.R., Lopez-Andreu F., Munar-Ques M., Costa P.P.,
RA   Saraiva M.J.;
RT   "Transthyretin Ala-71: a new transthyretin variant in a Spanish family
RT   with familial amyloidotic polyneuropathy.";
RL   Hum. Mutat. 2:420-421(1993).
RN   [89]
RP   VARIANT AMYL-TTR ALA-91.
RX   PubMed=8095302; DOI=10.1136/jmg.30.2.120;
RA   Benson M.D. II, Turpin J.C., Lucotte G., Zeldenrust S.,
RA   Lechevalier B., Benson M.D.;
RT   "A transthyretin variant (alanine 71) associated with familial
RT   amyloidotic polyneuropathy in a French family.";
RL   J. Med. Genet. 30:120-122(1993).
RN   [90]
RP   VARIANT AMYL-TTR ALA-67.
RA   Ferlini A., Salvi F., Patrosso C., Fini S., Vezzoni P., Forbasco A.;
RT   "Gly47Ala: a new transthyretin gene mutation in hereditary amyloidosis
RT   TTR-related.";
RL   J. Rheumatol. 20:187-187(1993).
RN   [91]
RP   VARIANT SER-26, AND VARIANT AMYL-TTR ILE-53.
RX   PubMed=8019560; DOI=10.1002/humu.1380030313;
RA   Jacobson D.R., Buxbaum J.N.;
RT   "A double-variant transthyretin allele (Ser 6, Ile 33) in the Israeli
RT   patient 'SKO' with familial amyloidotic polyneuropathy.";
RL   Hum. Mutat. 3:254-260(1994).
RN   [92]
RP   VARIANT AMYL-TTR VAL-127.
RX   PubMed=8081397; DOI=10.1002/humu.1380030414;
RA   Jacobson D., Gertz M.A., Buxbaum J.N.;
RT   "Transthyretin VAL107, a new variant associated with familial cardiac
RT   and neuropathic amyloidosis.";
RL   Hum. Mutat. 3:399-401(1994).
RN   [93]
RP   VARIANT SER-104, AND RBP BINDING STUDIES.
RX   PubMed=8089102;
RA   Berni R., Malpeli G., Folli C., Murrell J.R., Liepnieks J.J.,
RA   Benson M.D.;
RT   "The Ile-84-->Ser amino acid substitution in transthyretin interferes
RT   with the interaction with plasma retinol-binding protein.";
RL   J. Biol. Chem. 269:23395-23398(1994).
RN   [94]
RP   VARIANT AMYL-TTR VAL-127.
RX   PubMed=7914929; DOI=10.1136/jmg.31.5.416;
RA   Uemichi T., Gertz M.A., Benson M.D.;
RT   "Amyloid polyneuropathy in two German-American families: a new
RT   transthyretin variant (Val 107).";
RL   J. Med. Genet. 31:416-417(1994).
RN   [95]
RP   VARIANT AMYL-TTR GLY-117.
RX   PubMed=8133316; DOI=10.1016/0022-510X(94)90162-7;
RA   Yasuda T., Sobue G., Doyu M., Nakazato M., Shiomi K., Yanagi T.,
RA   Mitsuma T.;
RT   "Familial amyloidotic polyneuropathy with late-onset and well-
RT   preserved autonomic function: a Japanese kindred with novel mutant
RT   transthyretin (Ala97 to Gly).";
RL   J. Neurol. Sci. 121:97-102(1994).
RN   [96]
RP   VARIANT AMYL-TTR PRO-75.
RX   PubMed=7910950; DOI=10.1002/mus.880170611;
RA   Yamamoto K., Hsu S.P., Yoshida K., Ikeda S., Nakazato M., Shiomi K.,
RA   Cheng S.Y., Furihata K., Ueno I., Yanagisawa N.;
RT   "Familial amyloid polyneuropathy in Taiwan: identification of
RT   transthyretin variant (Leu55-->Pro).";
RL   Muscle Nerve 17:637-641(1994).
RN   [97]
RP   VARIANT CTS1 HIS-134.
RX   PubMed=8309582; DOI=10.1212/WNL.44.2.315;
RA   Murakami T., Tachibana S., Endo Y., Kawai R., Hara M., Tanase S.,
RA   Ando M.;
RT   "Familial carpal tunnel syndrome due to amyloidogenic transthyretin
RT   His 114 variant.";
RL   Neurology 44:315-318(1994).
RN   [98]
RP   VARIANTS AMYL-TTR MET-50; ASN-55; ALA-69; ARG-70; ALA-80; TYR-97 AND
RP   GLN-109.
RX   PubMed=7655883; DOI=10.1093/brain/118.4.849;
RA   Reilly M.M., Adams D., Booth D.R., Davis M.B., Said G.,
RA   Laubriat-Bianchin M., Pepys M.B., Thomas P.K., Harding A.E.;
RT   "Transthyretin gene analysis in European patients with suspected
RT   familial amyloid polyneuropathy.";
RL   Brain 118:849-856(1995).
RN   [99]
RP   VARIANT AMYL-TTR LYS-79.
RX   PubMed=7850982; DOI=10.1161/01.CIR.91.4.962;
RA   Booth D.R., Tan S.Y., Hawkins P.N., Pepys M.B., Frustaci A.;
RT   "A novel variant of transthyretin, 59Thr-->Lys, associated with
RT   autosomal dominant cardiac amyloidosis in an Italian family.";
RL   Circulation 91:962-967(1995).
RN   [100]
RP   VARIANT AMYL-TTR GLY-38.
RX   PubMed=8579098;
RA   Vidal R., Garzuly F., Budka H., Lalowski M., Linke R.P., Brittig F.,
RA   Frangione B., Wisniewski T.;
RT   "Meningocerebrovascular amyloidosis associated with a novel
RT   transthyretin mis-sense mutation at codon 18 (TTRD 18G).";
RL   Am. J. Pathol. 148:361-366(1996).
RN   [101]
RP   VARIANT AMYL-TTR GLY-50.
RX   PubMed=9066351; DOI=10.1002/ana.410410305;
RA   Petersen R.B., Goren H., Cohen M., Richardson S.L., Tresser N.,
RA   Lynn A., Gali M., Estes M., Gambetti P.;
RT   "Transthyretin amyloidosis: a new mutation associated with dementia.";
RL   Ann. Neurol. 41:307-313(1997).
RN   [102]
RP   VARIANT AMYL-TTR ILE-40.
RX   PubMed=8990019;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:1<83::AID-HUMU19>3.0.CO;2-L;
RA   Jacobson D.R., Pan T., Kyle R.A., Buxbaum J.N.;
RT   "Transthyretin ILE20, a new variant associated with late-onset cardiac
RT   amyloidosis.";
RL   Hum. Mutat. 9:83-85(1997).
RN   [103]
RP   VARIANT AMYL-TTR THR-54.
RX   PubMed=9605286;
RX   DOI=10.1002/(SICI)1096-8628(19980501)77:2<135::AID-AJMG5>3.0.CO;2-R;
RA   Patrosso M.C., Salvi F., De Grandis D., Vezzoni P., Jacobson D.R.,
RA   Ferlini A.;
RT   "Novel transthyretin missense mutation (Thr34) in an Italian family
RT   with hereditary amyloidosis.";
RL   Am. J. Med. Genet. 77:135-138(1998).
RN   [104]
RP   VARIANT AMYL-TTR ASP-62.
RX   PubMed=10036587; DOI=10.3109/13506129809007302;
RA   Dupuy O., Bletry O., Blanc A.S., Droz D., Viemont M., Delpech M.,
RA   Grateau G.;
RT   "A novel variant of transthyretin (Glu42Asp) associated with sporadic
RT   late-onset cardiac amyloidosis.";
RL   Amyloid 5:285-287(1998).
RN   [105]
RP   VARIANTS AMYL-TTR SER-111 AND SER-136.
RX   PubMed=10627135;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:1<71::AID-HUMU15>3.0.CO;2-7;
RA   Misrahi A.M., Plante V., Lalu T., Serre I., Adams D., Lacroix D.C.,
RA   Said G.;
RT   "New transthyretin variants Ser 91 and Ser 116 associated with
RT   familial amyloidotic polyneuropathy.";
RL   Hum. Mutat. 12:71-71(1998).
RN   [106]
RP   VARIANT AMYL-TTR VAL-93.
RX   PubMed=10694917;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:2<135::AID-HUMU9>3.0.CO;2-K;
RA   Booth D.R., Gillmore J.D., Persey M.R., Booth S.E., Cafferty K.D.,
RA   Tennent G.A., Madhoo S., Cochrane S.W., Whitehead T.C., Pasvol G.,
RA   Hawkins P.N.;
RT   "Transthyretin Ile73Val is associated with familial amyloidotic
RT   polyneuropathy in a Bangladeshi family.";
RL   Hum. Mutat. 12:135-135(1998).
RN   [107]
RP   VARIANT SER-121, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10671063;
RA   Kishikawa M., Nakanishi T., Miyazaki A., Hatanaka M., Shimizu A.,
RA   Tamoto S., Ohsawa N., Hayashi H., Kanai M.;
RT   "A new nonamyloid transthyretin variant, G101S, detected by
RT   electrospray ionization/mass spectrometry.";
RL   Hum. Mutat. 12:363-363(1998).
RN   [108]
RP   VARIANT SER-64.
RX   PubMed=9818883; DOI=10.1212/WNL.51.5.1462;
RA   Klein C.J., Nakumura M., Jacobson D.R., Lacy M.Q., Benson M.D.,
RA   Petersen R.C.;
RT   "Transthyretin amyloidosis (serine 44) with headache, hearing loss,
RT   and peripheral neuropathy.";
RL   Neurology 51:1462-1464(1998).
RN   [109]
RP   VARIANT AMYL-TTR ALA-142, VARIANT SER-26, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=10211412; DOI=10.3109/13506129908993288;
RA   Theberge R., Connors L., Skare J., Skinner M., Falk R.H.,
RA   Costello C.E.;
RT   "A new amyloidogenic transthyretin variant (Val122Ala) found in a
RT   compound heterozygous patient.";
RL   Amyloid 6:54-58(1999).
RN   [110]
RP   VARIANT AMYL-TTR ASN-43, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10439117; DOI=10.3109/13506129909007311;
RA   Connors L.H., Theberge R., Skare J., Costello C.E., Falk R.H.,
RA   Skinner M.;
RT   "A new transthyretin variant (Ser23Asn) associated with familial
RT   amyloidosis in a Portuguese patient.";
RL   Amyloid 6:114-118(1999).
RN   [111]
RP   VARIANTS AMYL-TTR LEU-50; VAL-53; ALA-58; ARG-70; GLY-117 AND SER-117,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10611950; DOI=10.3109/13506129909007341;
RA   Tachibana N., Tokuda T., Yoshida K., Taketomi T., Nakazato M.,
RA   Li Y.F., Masuda Y., Ikeda S.;
RT   "Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum
RT   variant transthyretin in the diagnosis of familial amyloid
RT   polyneuropathy.";
RL   Amyloid 6:282-288(1999).
RN   [112]
RP   VARIANT HIS-124, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10529370; DOI=10.1006/bbrc.1999.1514;
RA   Terazaki H., Ando Y., Misumi S., Nakamura M., Ando E., Matsunaga N.,
RA   Shoji S., Okuyama M., Ideta H., Nakagawa K., Ishizaki T., Ando M.,
RA   Saraiva M.J.;
RT   "A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with
RT   high serum transthyretin (TTR) and retinol binding protein (RBP)
RT   levels.";
RL   Biochem. Biophys. Res. Commun. 264:365-370(1999).
RN   [113]
RP   VARIANT AMYL-TTR PRO-32.
RX   PubMed=10071047; DOI=10.1093/brain/122.2.183;
RA   Brett M., Persey M.R., Reilly M.M., Revesz T., Booth D.R., Booth S.E.,
RA   Hawkins P.N., Pepys M.B., Morgan-Hughes J.A.;
RT   "Transthyretin Leu12Pro is associated with systemic, neuropathic and
RT   leptomeningeal amyloidosis.";
RL   Brain 122:183-190(1999).
RN   [114]
RP   VARIANT AMYL-TTR ILE-69, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10436378; DOI=10.1159/000022872;
RA   Nakamura M., Yamashita T., Ando Y., Hamidi Asl K., Tashima K.,
RA   Ohlsson P., Kususe Y., Benson M.D.;
RT   "Identification of a new transthyretin variant (Ile49) in familial
RT   amyloidotic polyneuropathy using electrospray ionization mass
RT   spectrometry and nonisotopic RNase cleavage assay.";
RL   Hum. Hered. 49:186-189(1999).
RN   [115]
RP   VARIANT AMYL-TTR LYS-109.
RX   PubMed=10842705; DOI=10.3109/13506120009146824;
RA   Nakamura M., Hamidi Asl K., Benson M.D.;
RT   "A novel variant of transthyretin (Glu89Lys) associated with familial
RT   amyloidotic polyneuropathy.";
RL   Amyloid 7:46-50(2000).
RN   [116]
RP   VARIANT AMYL-TTR SER-65, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10842718; DOI=10.3109/13506120009146252;
RA   Janunger T., Anan I., Holmgren G., Lovheim O., Ohlsson P.I.,
RA   Suhr O.B., Tashima K.;
RT   "Heart failure caused by a novel amyloidogenic mutation of the
RT   transthyretin gene: ATTR Ala45Ser.";
RL   Amyloid 7:137-140(2000).
RN   [117]
RP   VARIANT AMYL-TTR MET-48.
RX   PubMed=10882995;
RX   DOI=10.1002/1097-4598(200007)23:7<1016::AID-MUS3>3.0.CO;2-W;
RA   de Carvalho M., Moreira P., Evangelista T., Ducla-Soares J.L.,
RA   Bento M., Fernandes R., Saraiva M.J.;
RT   "New transthyretin mutation V28M in a Portuguese kindred with amyloid
RT   polyneuropathy.";
RL   Muscle Nerve 23:1016-1021(2000).
RN   [118]
RP   VARIANT AMYL-TTR GLU-73.
RX   PubMed=11445644; DOI=10.1212/WNL.57.1.135;
RA   Ellie E., Camou F., Vital A., Rummens C., Grateau G., Delpech M.,
RA   Valleix S.;
RT   "Recurrent subarachnoid hemorrhage associated with a new transthyretin
RT   variant (Gly53Glu).";
RL   Neurology 57:135-137(2001).
RN   [119]
RP   VARIANT AMYL-TTR GLN-75.
RX   PubMed=12557757; DOI=10.3109/13506120209114105;
RA   Yazaki M., Varga J., Dyck P.J., Benson M.D.;
RT   "A new transthyretin variant Leu55Gln in a patient with systemic
RT   amyloidosis.";
RL   Amyloid 9:268-271(2002).
RN   [120]
RP   VARIANTS SER-26 AND MET-139, VARIANTS AMYL-TTR ALA-58; LEU-61; SER-64
RP   AND LEU-84, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=11866053; DOI=10.1021/ac010780+;
RA   Lim A., Prokaeva T., McComb M.E., O'Connor P.B., Theberge R.,
RA   Connors L.H., Skinner M., Costello C.E.;
RT   "Characterization of transthyretin variants in familial transthyretin
RT   amyloidosis by mass spectrometric peptide mapping and DNA sequence
RT   analysis.";
RL   Anal. Chem. 74:741-751(2002).
RN   [121]
RP   VARIANTS AMYL-TTR MET-50; LEU-53; VAL-53; VAL-58; GLU-67; ALA-80;
RP   SER-140 AND ILE-142.
RX   PubMed=12050338; DOI=10.1056/NEJMoa013354;
RA   Lachmann H.J., Booth D.R., Booth S.E., Bybee A., Gilbertson J.A.,
RA   Gillmore J.D., Pepys M.B., Hawkins P.N.;
RT   "Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.";
RL   N. Engl. J. Med. 346:1786-1791(2002).
RN   [122]
RP   VARIANT AMYL-TTR HIS-89.
RX   PubMed=12771253; DOI=10.1212/01.WNL.0000065901.18353.AB;
RA   Blevins G., Macaulay R., Harder S., Fladeland D., Yamashita T.,
RA   Yazaki M., Hamidi Asl K., Benson M.D., Donat J.R.;
RT   "Oculoleptomeningeal amyloidosis in a large kindred with a new
RT   transthyretin variant Tyr69His.";
RL   Neurology 60:1625-1630(2003).
RN   [123]
RP   VARIANT CYS-53, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12876326; DOI=10.1110/ps.0349703;
RA   Lim A., Prokaeva T., McComb M.E., Connors L.H., Skinner M.,
RA   Costello C.E.;
RT   "Identification of S-sulfonation and S-thiolation of a novel
RT   transthyretin Phe33Cys variant from a patient diagnosed with familial
RT   transthyretin amyloidosis.";
RL   Protein Sci. 12:1775-1785(2003).
RN   [124]
RP   VARIANT AMYL-TTR LYS-74.
RX   PubMed=15214015; DOI=10.1002/ajmg.a.30007;
RA   Busse A., Sanchez M.A., Monterroso V., Alvarado M.V., Leon P.;
RT   "A severe form of amyloidotic polyneuropathy in a Costa Rican family
RT   with a rare transthyretin mutation (Glu54Lys).";
RL   Am. J. Med. Genet. A 128:190-194(2004).
RN   [125]
RP   VARIANT AMYL-TTR VAL-53.
RX   PubMed=15478468; DOI=10.1080/13506120410001727767;
RA   Frigerio R., Fabrizi G.M., Ferrarini M., Cavallaro T., Brighina L.,
RA   Santoro P., Agostoni E., Cavaletti G., Rizzuto N., Ferrarese C.;
RT   "An unusual transthyretin gene missense mutation (TTR Phe33Val) linked
RT   to familial amyloidotic polyneuropathy.";
RL   Amyloid 11:121-124(2004).
RN   [126]
RP   VARIANTS SER-26; CYS-53 AND ALA-114, VARIANTS AMYL-TTR GLU-67; HIS-78;
RP   ALA-80 AND TYR-97, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15217993; DOI=10.1373/clinchem.2004.033266;
RA   Bergen H.R. III, Zeldenrust S.R., Butz M.L., Snow D.S., Dyck P.J.,
RA   Dyck P.J.B., Klein C.J., O'Brien J.F., Thibodeau S.N., Muddiman D.C.;
RT   "Identification of transthyretin variants by sequential proteomic and
RT   genomic analysis.";
RL   Clin. Chem. 50:1544-1552(2004).
RN   [127]
RP   VARIANT AMYL-TTR GLY-81.
RX   PubMed=17453626; DOI=10.1080/13506120601116625;
RA   Rosenzweig M., Skinner M., Prokaeva T., Theberge R., Costello C.,
RA   Drachman B.M., Connors L.H.;
RT   "A new transthyretin variant (Glu61Gly) associated with
RT   cardiomyopathy.";
RL   Amyloid 14:65-71(2007).
RN   [128]
RP   VARIANT AMYL-TTR SER-144.
RX   PubMed=17577687; DOI=10.1080/13506120701259895;
RA   Bergstroem J., Patrosso M.C., Colussi G., Salvadore M., Penco S.,
RA   Lando G., Marocchi A., Ueda A., Nakamura M., Ando Y.;
RT   "A novel type of familial transthyretin amyloidosis, ATTR Asn124Ser,
RT   with co-localization of kappa light chains.";
RL   Amyloid 14:141-145(2007).
RN   [129]
RP   VARIANTS AMYL-TTR PRO-32; ILE-40; SER-44; ALA-50; MET-50; LEU-53;
RP   VAL-53; PRO-56; THR-65; ALA-67; ALA-69; ILE-69; ALA-80; LEU-84;
RP   LEU-88; ALA-91; TYR-97; PHE-98; SER-104; ASN-104; THR-104; ALA-114;
RP   GLY-117; ASN-126; MET-127; VAL-127; MET-131 AND ILE-142, VARIANTS
RP   ILE-33; SER-121 AND THR-129, AND VARIANT CHICAGO MET-139.
RX   PubMed=17503405; DOI=10.1002/elps.200600840;
RA   Altland K., Benson M.D., Costello C.E., Ferlini A., Hazenberg B.P.C.,
RA   Hund E., Kristen A.V., Linke R.P., Merlini G., Salvi F., Saraiva M.J.,
RA   Singer R., Skinner M., Winter P.;
RT   "Genetic microheterogeneity of human transthyretin detected by IEF.";
RL   Electrophoresis 28:2053-2064(2007).
RN   [130]
RP   VARIANT AMYL-TTR VAL-58.
RX   PubMed=17635579; DOI=10.1111/j.1365-2362.2007.01836.x;
RA   Augustin S., Llige D., Andreu A., Gonzalez A., Genesca J.;
RT   "Familial amyloidosis in a large Spanish kindred resulting from a D38V
RT   mutation in the transthyretin gene.";
RL   Eur. J. Clin. Invest. 37:673-678(2007).
RN   [131]
RP   VARIANT AMYL-TTR ARG-70.
RX   PubMed=23317988; DOI=10.1016/j.jaad.2012.07.026;
RA   Dekmezian M.S., Tschen J.A., Cho-Vega J.H.;
RT   "Delayed diagnosis of transthyretin amyloidosis with a novel mutation
RT   (c.210T>A) in the transthyretin gene.";
RL   J. Am. Acad. Dermatol. 68:E49-E51(2013).
CC   -!- FUNCTION: Thyroid hormone-binding protein. Probably transports
CC       thyroxine from the bloodstream to the brain.
CC       {ECO:0000269|PubMed:3714052}.
CC   -!- SUBUNIT: Homotetramer. Dimer of dimers. In the homotetramer,
CC       subunits assemble around a central channel that can accommodate
CC       two ligand molecules. Interacts with RBP4.
CC       {ECO:0000269|PubMed:10052934, ECO:0000269|PubMed:11243784,
CC       ECO:0000269|PubMed:11560492, ECO:0000269|PubMed:12820260,
CC       ECO:0000269|PubMed:14583036, ECO:0000269|PubMed:14711308,
CC       ECO:0000269|PubMed:15735344, ECO:0000269|PubMed:15769474,
CC       ECO:0000269|PubMed:15826192, ECO:0000269|PubMed:18095641,
CC       ECO:0000269|PubMed:18155178, ECO:0000269|PubMed:18811132,
CC       ECO:0000269|PubMed:19021760}.
CC   -!- INTERACTION:
CC       Self; NbExp=6; IntAct=EBI-711909, EBI-711909;
CC       Q15109:AGER; NbExp=2; IntAct=EBI-711909, EBI-1646426;
CC       Q01850:CDR2; NbExp=3; IntAct=EBI-711909, EBI-1181367;
CC       P25713:MT3; NbExp=3; IntAct=EBI-711909, EBI-8084264;
CC       H3BTW2:NECAB2; NbExp=3; IntAct=EBI-711909, EBI-10172876;
CC   -!- SUBCELLULAR LOCATION: Secreted. Cytoplasm.
CC   -!- TISSUE SPECIFICITY: Detected in serum and cerebrospinal fluid (at
CC       protein level). Highly expressed in choroid plexus epithelial
CC       cells. Detected in retina pigment epithelium and liver.
CC       {ECO:0000269|PubMed:10328977, ECO:0000269|PubMed:3714052}.
CC   -!- DOMAIN: Each monomer has two 4-stranded beta sheets and the shape
CC       of a prolate ellipsoid. Antiparallel beta-sheet interactions link
CC       monomers into dimers. A short loop from each monomer forms the
CC       main dimer-dimer interaction. These two pairs of loops separate
CC       the opposed, convex beta-sheets of the dimers to form an internal
CC       channel.
CC   -!- PTM: Not glycosylated under normal conditions. Following
CC       unfolding, caused for example by variant AMYL-TTR 'Gly-38', the
CC       cryptic Asn-118 site is exposed and glycosylated by STT3B-
CC       containing OST complex, leading to its degradation by the ER-
CC       associated degradation (ERAD) pathway.
CC       {ECO:0000269|PubMed:14760718, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19167329}.
CC   -!- DISEASE: Amyloidosis, transthyretin-related (AMYL-TTR)
CC       [MIM:105210]: A hereditary generalized amyloidosis due to
CC       transthyretin amyloid deposition. Protein fibrils can form in
CC       different tissues leading to amyloid polyneuropathies, amyloidotic
CC       cardiomyopathy, carpal tunnel syndrome, systemic senile
CC       amyloidosis. The disease includes leptomeningeal amyloidosis that
CC       is characterized by primary involvement of the central nervous
CC       system. Neuropathologic examination shows amyloid in the walls of
CC       leptomeningeal vessels, in pia arachnoid, and subpial deposits.
CC       Some patients also develop vitreous amyloid deposition that leads
CC       to visual impairment (oculoleptomeningeal amyloidosis). Clinical
CC       features include seizures, stroke-like episodes, dementia,
CC       psychomotor deterioration, variable amyloid deposition in the
CC       vitreous humor. {ECO:0000269|PubMed:10036587,
CC       ECO:0000269|PubMed:10071047, ECO:0000269|PubMed:10211412,
CC       ECO:0000269|PubMed:10436378, ECO:0000269|PubMed:10439117,
CC       ECO:0000269|PubMed:10611950, ECO:0000269|PubMed:10627135,
CC       ECO:0000269|PubMed:10694917, ECO:0000269|PubMed:10842705,
CC       ECO:0000269|PubMed:10842718, ECO:0000269|PubMed:10882995,
CC       ECO:0000269|PubMed:11445644, ECO:0000269|PubMed:11866053,
CC       ECO:0000269|PubMed:12050338, ECO:0000269|PubMed:12557757,
CC       ECO:0000269|PubMed:12771253, ECO:0000269|PubMed:1301926,
CC       ECO:0000269|PubMed:1351039, ECO:0000269|PubMed:1362222,
CC       ECO:0000269|PubMed:1436517, ECO:0000269|PubMed:1517749,
CC       ECO:0000269|PubMed:1520326, ECO:0000269|PubMed:1520336,
CC       ECO:0000269|PubMed:15214015, ECO:0000269|PubMed:15217993,
CC       ECO:0000269|PubMed:1544214, ECO:0000269|PubMed:15478468,
CC       ECO:0000269|PubMed:1570831, ECO:0000269|PubMed:1656975,
CC       ECO:0000269|PubMed:1734866, ECO:0000269|PubMed:17453626,
CC       ECO:0000269|PubMed:17503405, ECO:0000269|PubMed:17577687,
CC       ECO:0000269|PubMed:17635579, ECO:0000269|PubMed:1932142,
CC       ECO:0000269|PubMed:2046936, ECO:0000269|PubMed:2161654,
CC       ECO:0000269|PubMed:23317988, ECO:0000269|PubMed:2363717,
CC       ECO:0000269|PubMed:2891727, ECO:0000269|PubMed:3022108,
CC       ECO:0000269|PubMed:3135807, ECO:0000269|PubMed:3722385,
CC       ECO:0000269|PubMed:3818577, ECO:0000269|PubMed:6487335,
CC       ECO:0000269|PubMed:6583672, ECO:0000269|PubMed:6651852,
CC       ECO:0000269|PubMed:7655883, ECO:0000269|PubMed:7850982,
CC       ECO:0000269|PubMed:7910950, ECO:0000269|PubMed:7914929,
CC       ECO:0000269|PubMed:7923855, ECO:0000269|PubMed:8019560,
CC       ECO:0000269|PubMed:8038017, ECO:0000269|PubMed:8081397,
CC       ECO:0000269|PubMed:8095302, ECO:0000269|PubMed:8133316,
CC       ECO:0000269|PubMed:8257997, ECO:0000269|PubMed:8352764,
CC       ECO:0000269|PubMed:8579098, ECO:0000269|PubMed:8990019,
CC       ECO:0000269|PubMed:9066351, ECO:0000269|PubMed:9605286,
CC       ECO:0000269|Ref.90}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Hyperthyroxinemia, dystransthyretinemic (DTTRH)
CC       [MIM:145680]: A condition characterized by elevation of total and
CC       free thyroxine in healthy, euthyroid persons without detectable
CC       binding protein abnormalities. {ECO:0000269|PubMed:1979335}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Carpal tunnel syndrome 1 (CTS1) [MIM:115430]: A condition
CC       characterized by entrapment of the median nerve within the carpal
CC       tunnel. Symptoms include burning pain and paresthesias involving
CC       the ventral surface of the hand and fingers which may radiate
CC       proximally. Impairment of sensation in the distribution of the
CC       median nerve and thenar muscle atrophy may occur. This condition
CC       may be associated with repetitive occupational trauma, wrist
CC       injuries, amyloid neuropathies, rheumatoid arthritis.
CC       {ECO:0000269|PubMed:8309582}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Tetramer dissociation and partial unfolding leads
CC       to the formation of aggregates and amyloid fibrils. Small
CC       molecules that occupy at least one of the thyroid hormone binding
CC       sites stabilize the tetramer, and thereby stabilize the native
CC       state and protect against misfolding and the formation of amyloid
CC       fibrils.
CC   -!- MISCELLANEOUS: Two binding sites for thyroxine are located in the
CC       channel. Less than 1% of plasma prealbumin molecules are normally
CC       involved in thyroxine transport. L-thyroxine binds to the
CC       transthyretin by an order of magnitude stronger than does the
CC       triiodo-L-thyronine. Thyroxine-binding globulin is the major
CC       carrier protein for thyroid hormones in man.
CC   -!- MISCELLANEOUS: About 40% of plasma transthyretin circulates in a
CC       tight protein-protein complex with the plasma retinol-binding
CC       protein (RBP). The formation of the complex with RBP stabilizes
CC       the binding of retinol to RBP and decreases the glomerular
CC       filtration and renal catabolism of the relatively small RBP
CC       molecule. There is evidence for 2 binding sites for RBP, one
CC       possibly being a region that includes Ile-104, located on the
CC       outer surface of the transthyretin molecule.
CC   -!- SIMILARITY: Belongs to the transthyretin family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Transthyretin entry;
CC       URL="https://en.wikipedia.org/wiki/Transthyretin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K02091; AAA60011.1; -; mRNA.
DR   EMBL; M10605; AAA60012.1; -; mRNA.
DR   EMBL; M11518; AAA98771.1; -; Genomic_DNA.
DR   EMBL; M11844; AAA60013.1; -; Genomic_DNA.
DR   EMBL; X59498; CAA42087.1; -; mRNA.
DR   EMBL; D00096; BAA00059.1; -; mRNA.
DR   EMBL; M15517; AAA60018.1; -; Genomic_DNA.
DR   EMBL; M15515; AAA60018.1; JOINED; Genomic_DNA.
DR   EMBL; M15516; AAA60018.1; JOINED; Genomic_DNA.
DR   EMBL; U19780; AAA73473.1; -; mRNA.
DR   EMBL; AF162690; AAD45014.1; -; mRNA.
DR   EMBL; AK312051; BAG34987.1; -; mRNA.
DR   EMBL; BT007189; AAP35853.1; -; mRNA.
DR   EMBL; CR456908; CAG33189.1; -; mRNA.
DR   EMBL; CH471088; EAX01264.1; -; Genomic_DNA.
DR   EMBL; BC005310; AAH05310.1; -; mRNA.
DR   EMBL; BC020791; AAH20791.1; -; mRNA.
DR   EMBL; S63185; AAD14937.2; -; Genomic_DNA.
DR   EMBL; S72385; AAD14098.1; -; Genomic_DNA.
DR   EMBL; M11714; AAA61181.1; -; mRNA.
DR   EMBL; M63285; AAA36784.1; -; Genomic_DNA.
DR   CCDS; CCDS11899.1; -.
DR   PIR; A91532; VBHU.
DR   RefSeq; NP_000362.1; NM_000371.3.
DR   UniGene; Hs.427202; -.
DR   PDB; 1BM7; X-ray; 2.00 A; A/B=21-147.
DR   PDB; 1BMZ; X-ray; 2.00 A; A/B=21-143.
DR   PDB; 1BZ8; X-ray; 2.00 A; A/B=21-147.
DR   PDB; 1BZD; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 1BZE; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 1DVQ; X-ray; 2.00 A; A/B=21-144.
DR   PDB; 1DVS; X-ray; 2.00 A; A/B=21-144.
DR   PDB; 1DVT; X-ray; 1.90 A; A/B=21-144.
DR   PDB; 1DVU; X-ray; 1.90 A; A/B=21-144.
DR   PDB; 1DVX; X-ray; 2.00 A; A/B=21-144.
DR   PDB; 1DVY; X-ray; 1.90 A; A/B=21-144.
DR   PDB; 1DVZ; X-ray; 1.90 A; A/B=21-144.
DR   PDB; 1E3F; X-ray; 1.90 A; A/B=21-145.
DR   PDB; 1E4H; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 1E5A; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 1ETA; X-ray; 1.70 A; 1/2=21-147.
DR   PDB; 1ETB; X-ray; 1.70 A; 1/2=21-147.
DR   PDB; 1F41; X-ray; 1.30 A; A/B=21-147.
DR   PDB; 1F64; Model; -; A=21-147.
DR   PDB; 1F86; X-ray; 1.10 A; A/B=30-144.
DR   PDB; 1FH2; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 1FHN; X-ray; 1.75 A; A/B=21-147.
DR   PDB; 1G1O; X-ray; 2.30 A; A/B/C/D=21-147.
DR   PDB; 1GKO; X-ray; 2.10 A; A/B/C/D=21-147.
DR   PDB; 1ICT; X-ray; 3.00 A; A/B/C/D/E/F/G/H=21-147.
DR   PDB; 1III; X-ray; 2.00 A; A/B=21-147.
DR   PDB; 1IIK; X-ray; 2.00 A; A/B=21-147.
DR   PDB; 1IJN; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 1QAB; X-ray; 3.20 A; A/B/C/D=21-147.
DR   PDB; 1QWH; X-ray; 1.36 A; A/B=31-147.
DR   PDB; 1RLB; X-ray; 3.10 A; A/B/C/D=21-147.
DR   PDB; 1SOK; X-ray; 1.60 A; A/B=21-147.
DR   PDB; 1SOQ; X-ray; 2.10 A; A/B/C/D=21-147.
DR   PDB; 1THA; X-ray; 2.00 A; A/B=21-147.
DR   PDB; 1THC; X-ray; 2.30 A; A/B=21-147.
DR   PDB; 1TLM; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 1TSH; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 1TT6; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 1TTA; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 1TTB; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 1TTC; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 1TTR; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 1TYR; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 1TZ8; X-ray; 1.85 A; A/B/C/D=21-147.
DR   PDB; 1U21; X-ray; 1.69 A; A/B=21-147.
DR   PDB; 1X7S; X-ray; 1.55 A; A/B=21-147.
DR   PDB; 1X7T; X-ray; 1.60 A; A/B=21-147.
DR   PDB; 1Y1D; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 1Z7J; X-ray; 2.20 A; A/B=21-147.
DR   PDB; 1ZCR; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 1ZD6; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 2B14; X-ray; 2.00 A; A/B=21-147.
DR   PDB; 2B15; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 2B16; X-ray; 1.75 A; A/B=21-147.
DR   PDB; 2B77; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 2B9A; X-ray; 1.54 A; A/B=21-147.
DR   PDB; 2F7I; X-ray; 1.60 A; A/B=21-147.
DR   PDB; 2F8I; X-ray; 1.54 A; A/B=21-147.
DR   PDB; 2FBR; X-ray; 1.46 A; A/B=21-147.
DR   PDB; 2FLM; X-ray; 1.65 A; A/B=21-147.
DR   PDB; 2G3X; X-ray; 1.58 A; A/B=21-147.
DR   PDB; 2G3Z; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 2G4E; X-ray; 2.17 A; A/B=21-147.
DR   PDB; 2G4G; X-ray; 1.85 A; A/B=21-147.
DR   PDB; 2G5U; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 2G9K; X-ray; 1.85 A; A/B=21-147.
DR   PDB; 2GAB; X-ray; 1.85 A; A/B=21-147.
DR   PDB; 2H4E; X-ray; 1.45 A; A/B=21-147.
DR   PDB; 2M5N; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=125-135.
DR   PDB; 2NOY; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 2PAB; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 2QEL; X-ray; 2.29 A; A/B/C/D=21-147.
DR   PDB; 2QGB; X-ray; 1.40 A; A/B=21-147.
DR   PDB; 2QGC; X-ray; 1.30 A; A/B=21-147.
DR   PDB; 2QGD; X-ray; 1.50 A; A/B=21-147.
DR   PDB; 2QGE; X-ray; 1.45 A; A/B=21-147.
DR   PDB; 2ROX; X-ray; 2.00 A; A/B=21-147.
DR   PDB; 2ROY; X-ray; 2.20 A; A/B=21-147.
DR   PDB; 2TRH; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 2TRY; X-ray; 2.00 A; A/B=21-147.
DR   PDB; 2WQA; X-ray; 2.85 A; A/B/C/D=21-147.
DR   PDB; 3A4D; X-ray; 2.00 A; A/B=21-147.
DR   PDB; 3A4E; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 3A4F; X-ray; 1.99 A; A/B=21-147.
DR   PDB; 3B56; X-ray; 1.55 A; A/B=21-147.
DR   PDB; 3BSZ; X-ray; 3.38 A; A/B/C/D=21-147.
DR   PDB; 3BT0; X-ray; 1.59 A; A/B=21-147.
DR   PDB; 3CBR; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 3CFM; X-ray; 1.60 A; A/B=30-147.
DR   PDB; 3CFN; X-ray; 1.87 A; A/B=30-147.
DR   PDB; 3CFQ; X-ray; 2.09 A; A/B=30-147.
DR   PDB; 3CFT; X-ray; 1.87 A; A/B=30-147.
DR   PDB; 3CN0; X-ray; 1.52 A; A/B=21-147.
DR   PDB; 3CN1; X-ray; 1.52 A; A/B=21-147.
DR   PDB; 3CN2; X-ray; 1.52 A; A/B=21-147.
DR   PDB; 3CN3; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 3CN4; X-ray; 1.40 A; A/B=21-147.
DR   PDB; 3CXF; X-ray; 2.30 A; A/B=21-147.
DR   PDB; 3D2T; X-ray; 1.85 A; A/B=21-147.
DR   PDB; 3D7P; X-ray; 1.72 A; A/B=21-147.
DR   PDB; 3DGD; X-ray; 1.38 A; A/B/C/D=21-147.
DR   PDB; 3DID; X-ray; 1.78 A; A/B/C/D=21-147.
DR   PDB; 3DJR; X-ray; 2.02 A; A/B=21-147.
DR   PDB; 3DJS; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 3DJT; X-ray; 2.30 A; A/B=21-147.
DR   PDB; 3DJZ; X-ray; 1.82 A; A/B=21-147.
DR   PDB; 3DK0; X-ray; 1.87 A; A/B=21-147.
DR   PDB; 3DK2; X-ray; 2.35 A; A/B=21-147.
DR   PDB; 3DO4; X-ray; 2.40 A; A/B/C/D/E/F/G/H=21-147.
DR   PDB; 3ESN; X-ray; 1.35 A; A/B=21-147.
DR   PDB; 3ESO; X-ray; 1.31 A; A/B=21-147.
DR   PDB; 3ESP; X-ray; 1.31 A; A/B=21-147.
DR   PDB; 3FC8; X-ray; 1.85 A; A/B=21-144.
DR   PDB; 3FCB; X-ray; 1.80 A; A/B=21-144.
DR   PDB; 3GLZ; X-ray; 1.78 A; A/B=21-147.
DR   PDB; 3GPS; X-ray; 1.78 A; A/B/C/D=21-147.
DR   PDB; 3GRB; X-ray; 1.75 A; A/B/C/D=21-147.
DR   PDB; 3GRG; X-ray; 1.90 A; A/B/C/D=21-147.
DR   PDB; 3GS0; X-ray; 1.85 A; A/B=21-147.
DR   PDB; 3GS4; X-ray; 1.78 A; A/B=21-147.
DR   PDB; 3GS7; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 3HJ0; X-ray; 1.34 A; A/B=21-147.
DR   PDB; 3I9A; X-ray; 1.65 A; A/B=21-147.
DR   PDB; 3I9I; X-ray; 1.80 A; A/B=30-145.
DR   PDB; 3I9P; X-ray; 1.90 A; A/B=30-145.
DR   PDB; 3IMR; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 3IMS; X-ray; 1.40 A; A/B=21-147.
DR   PDB; 3IMT; X-ray; 1.40 A; A/B=21-147.
DR   PDB; 3IMU; X-ray; 1.40 A; A/B=21-147.
DR   PDB; 3IMV; X-ray; 1.47 A; A/B=21-147.
DR   PDB; 3IMW; X-ray; 1.31 A; A/B=21-147.
DR   PDB; 3IPB; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 3IPE; X-ray; 1.40 A; A/B=21-147.
DR   PDB; 3KGS; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 3KGT; X-ray; 1.95 A; A/B=21-147.
DR   PDB; 3KGU; X-ray; 1.85 A; A/B=21-147.
DR   PDB; 3M1O; X-ray; 1.20 A; A/B=21-147.
DR   PDB; 3NEE; X-ray; 1.55 A; A/B=30-145.
DR   PDB; 3NEO; X-ray; 2.00 A; A/B=30-145.
DR   PDB; 3NES; X-ray; 1.75 A; A/B=30-145.
DR   PDB; 3NEX; X-ray; 1.70 A; A/B=30-145.
DR   PDB; 3NG5; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 3OZK; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 3OZL; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 3P3R; X-ray; 1.25 A; A/B=21-147.
DR   PDB; 3P3S; X-ray; 1.60 A; A/B=21-147.
DR   PDB; 3P3T; X-ray; 1.45 A; A/B=21-147.
DR   PDB; 3P3U; X-ray; 1.50 A; A/B=21-147.
DR   PDB; 3SSG; X-ray; 2.00 A; A=21-147.
DR   PDB; 3TCT; X-ray; 1.30 A; A/B=21-147.
DR   PDB; 3TFB; X-ray; 2.03 A; A/B=30-145.
DR   PDB; 3U2I; X-ray; 1.70 A; A/B=32-147.
DR   PDB; 3U2J; Neutron; 2.00 A; A/B=32-147.
DR   PDB; 3W3B; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 4ABQ; X-ray; 1.70 A; A/B=21-144.
DR   PDB; 4ABU; X-ray; 1.86 A; A/B=21-144.
DR   PDB; 4ABV; X-ray; 1.80 A; A/B=21-144.
DR   PDB; 4ABW; X-ray; 1.70 A; A/B=21-144.
DR   PDB; 4AC2; X-ray; 1.81 A; A/B=21-144.
DR   PDB; 4AC4; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 4ACT; X-ray; 1.80 A; A/B=21-147.
DR   PDB; 4ANK; X-ray; 1.70 A; A/B=1-147.
DR   PDB; 4DER; X-ray; 1.90 A; A/B=30-145.
DR   PDB; 4DES; X-ray; 1.75 A; A/B=30-145.
DR   PDB; 4DET; X-ray; 2.05 A; A/B=30-145.
DR   PDB; 4DEU; X-ray; 1.60 A; A/B=30-145.
DR   PDB; 4DEW; X-ray; 1.90 A; A/B=1-147.
DR   PDB; 4FI6; X-ray; 1.46 A; A/B=21-147.
DR   PDB; 4FI7; X-ray; 1.40 A; A/B=21-147.
DR   PDB; 4FI8; X-ray; 1.22 A; A/B=21-147.
DR   PDB; 4HIQ; X-ray; 1.18 A; A/B=21-147.
DR   PDB; 4HIS; X-ray; 1.20 A; A/B=21-147.
DR   PDB; 4HJS; X-ray; 1.22 A; A/B=30-145.
DR   PDB; 4HJT; X-ray; 1.45 A; A/B=21-147.
DR   PDB; 4HJU; X-ray; 1.35 A; A/B=21-147.
DR   PDB; 4I85; X-ray; 1.67 A; A/B=21-147.
DR   PDB; 4I87; X-ray; 1.69 A; A/B=21-147.
DR   PDB; 4I89; X-ray; 1.69 A; A/B=21-147.
DR   PDB; 4IIZ; X-ray; 2.10 A; A/B=21-147.
DR   PDB; 4IK6; X-ray; 2.00 A; A/B=21-147.
DR   PDB; 4IK7; X-ray; 2.10 A; A/B=21-147.
DR   PDB; 4IKI; X-ray; 2.00 A; A/B=21-147.
DR   PDB; 4IKJ; X-ray; 2.10 A; A/B=21-147.
DR   PDB; 4IKK; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 4IKL; X-ray; 1.90 A; A/B=21-147.
DR   PDB; 4KY2; X-ray; 1.13 A; A/B=21-147.
DR   PDB; 4L1S; X-ray; 1.50 A; A/B=21-147.
DR   PDB; 4L1T; X-ray; 1.16 A; A/B=21-147.
DR   PDB; 4MAS; X-ray; 1.22 A; A/B=21-147.
DR   PDB; 4MRB; X-ray; 1.27 A; A/B=21-147.
DR   PDB; 4MRC; X-ray; 1.54 A; A/B=22-147.
DR   PDB; 4N85; X-ray; 1.60 A; A/B=1-147.
DR   PDB; 4N86; X-ray; 2.00 A; A/B=1-147.
DR   PDB; 4N87; X-ray; 1.79 A; A/B=1-147.
DR   PDB; 4PM1; X-ray; 1.23 A; A/B=21-147.
DR   PDB; 4PME; X-ray; 1.26 A; A/B=29-146.
DR   PDB; 4PMF; X-ray; 1.35 A; A/B=29-145.
DR   PDB; 4PVL; X-ray; 1.85 A; A/B=21-147.
DR   PDB; 4PVM; Other; 2.00 A; A/B=21-147.
DR   PDB; 4PVN; Other; 2.30 A; A/B=21-147.
DR   PDB; 4PWE; X-ray; 1.40 A; A/B=1-147.
DR   PDB; 4PWF; X-ray; 1.60 A; A/B=1-147.
DR   PDB; 4PWG; X-ray; 1.80 A; A/B=1-147.
DR   PDB; 4PWH; X-ray; 1.80 A; A/B=1-147.
DR   PDB; 4PWI; X-ray; 1.49 A; A/B=1-147.
DR   PDB; 4PWJ; X-ray; 1.55 A; A/B=1-147.
DR   PDB; 4PWK; X-ray; 1.59 A; A/B=1-147.
DR   PDB; 4QRF; X-ray; 1.80 A; A/B=1-147.
DR   PDB; 4QXV; X-ray; 1.12 A; A/B=21-147.
DR   PDB; 4QYA; X-ray; 1.70 A; A/B=21-147.
DR   PDB; 4TKW; X-ray; 1.80 A; A/B=29-147.
DR   PDB; 4TL4; X-ray; 1.75 A; A/B=29-147.
DR   PDB; 4TL5; X-ray; 1.44 A; A/B=29-147.
DR   PDB; 4TLK; X-ray; 1.44 A; A/B=29-147.
DR   PDB; 4TLS; X-ray; 1.35 A; A/B=29-147.
DR   PDB; 4TLT; X-ray; 1.70 A; A/B=29-147.
DR   PDB; 4TLU; X-ray; 1.75 A; A/B=29-147.
DR   PDB; 4TM9; X-ray; 1.70 A; A/B=29-147.
DR   PDB; 4TNE; X-ray; 1.55 A; A/B=29-147.
DR   PDB; 4TNF; X-ray; 1.60 A; A/B=29-147.
DR   PDB; 4TNG; X-ray; 1.60 A; A/B=29-147.
DR   PDB; 4TQ8; X-ray; 1.52 A; A/B=21-147.
DR   PDB; 4TQH; X-ray; 1.51 A; A/B=21-147.
DR   PDB; 4TQI; X-ray; 1.25 A; A/B=21-147.
DR   PDB; 4TQP; X-ray; 1.58 A; A/B=21-147.
DR   PDB; 4WNJ; X-ray; 1.40 A; A/B=21-147.
DR   PDB; 4WNS; X-ray; 1.40 A; A/B=21-147.
DR   PDB; 4WO0; X-ray; 1.34 A; A/B=21-147.
DR   PDB; 4Y9B; X-ray; 1.40 A; A/B=1-147.
DR   PDB; 4Y9C; X-ray; 1.49 A; A/B=1-147.
DR   PDB; 4Y9E; X-ray; 1.49 A; A/B=1-147.
DR   PDB; 4Y9F; X-ray; 1.50 A; A/B=1-147.
DR   PDB; 4Y9G; X-ray; 1.89 A; A/B=1-147.
DR   PDB; 4YDM; X-ray; 1.25 A; A/B=21-147.
DR   PDB; 4YDN; X-ray; 1.35 A; A/B=21-147.
DR   PDB; 5AKS; X-ray; 1.25 A; A/B=21-147.
DR   PDB; 5AKT; X-ray; 1.35 A; A/B=21-147.
DR   PDB; 5AKV; X-ray; 1.52 A; A/B=21-147.
DR   PDB; 5AL0; X-ray; 1.39 A; A/B=21-147.
DR   PDB; 5AL8; X-ray; 1.50 A; A/B=21-147.
DR   PDB; 5BOJ; X-ray; 1.75 A; A/B=21-147.
DR   PDB; 5CR1; X-ray; 1.54 A; A/B=30-145.
DR   PDB; 5TTR; X-ray; 2.70 A; A/B/C/D/E/F/G/H=21-147.
DR   PDBsum; 1BM7; -.
DR   PDBsum; 1BMZ; -.
DR   PDBsum; 1BZ8; -.
DR   PDBsum; 1BZD; -.
DR   PDBsum; 1BZE; -.
DR   PDBsum; 1DVQ; -.
DR   PDBsum; 1DVS; -.
DR   PDBsum; 1DVT; -.
DR   PDBsum; 1DVU; -.
DR   PDBsum; 1DVX; -.
DR   PDBsum; 1DVY; -.
DR   PDBsum; 1DVZ; -.
DR   PDBsum; 1E3F; -.
DR   PDBsum; 1E4H; -.
DR   PDBsum; 1E5A; -.
DR   PDBsum; 1ETA; -.
DR   PDBsum; 1ETB; -.
DR   PDBsum; 1F41; -.
DR   PDBsum; 1F64; -.
DR   PDBsum; 1F86; -.
DR   PDBsum; 1FH2; -.
DR   PDBsum; 1FHN; -.
DR   PDBsum; 1G1O; -.
DR   PDBsum; 1GKO; -.
DR   PDBsum; 1ICT; -.
DR   PDBsum; 1III; -.
DR   PDBsum; 1IIK; -.
DR   PDBsum; 1IJN; -.
DR   PDBsum; 1QAB; -.
DR   PDBsum; 1QWH; -.
DR   PDBsum; 1RLB; -.
DR   PDBsum; 1SOK; -.
DR   PDBsum; 1SOQ; -.
DR   PDBsum; 1THA; -.
DR   PDBsum; 1THC; -.
DR   PDBsum; 1TLM; -.
DR   PDBsum; 1TSH; -.
DR   PDBsum; 1TT6; -.
DR   PDBsum; 1TTA; -.
DR   PDBsum; 1TTB; -.
DR   PDBsum; 1TTC; -.
DR   PDBsum; 1TTR; -.
DR   PDBsum; 1TYR; -.
DR   PDBsum; 1TZ8; -.
DR   PDBsum; 1U21; -.
DR   PDBsum; 1X7S; -.
DR   PDBsum; 1X7T; -.
DR   PDBsum; 1Y1D; -.
DR   PDBsum; 1Z7J; -.
DR   PDBsum; 1ZCR; -.
DR   PDBsum; 1ZD6; -.
DR   PDBsum; 2B14; -.
DR   PDBsum; 2B15; -.
DR   PDBsum; 2B16; -.
DR   PDBsum; 2B77; -.
DR   PDBsum; 2B9A; -.
DR   PDBsum; 2F7I; -.
DR   PDBsum; 2F8I; -.
DR   PDBsum; 2FBR; -.
DR   PDBsum; 2FLM; -.
DR   PDBsum; 2G3X; -.
DR   PDBsum; 2G3Z; -.
DR   PDBsum; 2G4E; -.
DR   PDBsum; 2G4G; -.
DR   PDBsum; 2G5U; -.
DR   PDBsum; 2G9K; -.
DR   PDBsum; 2GAB; -.
DR   PDBsum; 2H4E; -.
DR   PDBsum; 2M5N; -.
DR   PDBsum; 2NOY; -.
DR   PDBsum; 2PAB; -.
DR   PDBsum; 2QEL; -.
DR   PDBsum; 2QGB; -.
DR   PDBsum; 2QGC; -.
DR   PDBsum; 2QGD; -.
DR   PDBsum; 2QGE; -.
DR   PDBsum; 2ROX; -.
DR   PDBsum; 2ROY; -.
DR   PDBsum; 2TRH; -.
DR   PDBsum; 2TRY; -.
DR   PDBsum; 2WQA; -.
DR   PDBsum; 3A4D; -.
DR   PDBsum; 3A4E; -.
DR   PDBsum; 3A4F; -.
DR   PDBsum; 3B56; -.
DR   PDBsum; 3BSZ; -.
DR   PDBsum; 3BT0; -.
DR   PDBsum; 3CBR; -.
DR   PDBsum; 3CFM; -.
DR   PDBsum; 3CFN; -.
DR   PDBsum; 3CFQ; -.
DR   PDBsum; 3CFT; -.
DR   PDBsum; 3CN0; -.
DR   PDBsum; 3CN1; -.
DR   PDBsum; 3CN2; -.
DR   PDBsum; 3CN3; -.
DR   PDBsum; 3CN4; -.
DR   PDBsum; 3CXF; -.
DR   PDBsum; 3D2T; -.
DR   PDBsum; 3D7P; -.
DR   PDBsum; 3DGD; -.
DR   PDBsum; 3DID; -.
DR   PDBsum; 3DJR; -.
DR   PDBsum; 3DJS; -.
DR   PDBsum; 3DJT; -.
DR   PDBsum; 3DJZ; -.
DR   PDBsum; 3DK0; -.
DR   PDBsum; 3DK2; -.
DR   PDBsum; 3DO4; -.
DR   PDBsum; 3ESN; -.
DR   PDBsum; 3ESO; -.
DR   PDBsum; 3ESP; -.
DR   PDBsum; 3FC8; -.
DR   PDBsum; 3FCB; -.
DR   PDBsum; 3GLZ; -.
DR   PDBsum; 3GPS; -.
DR   PDBsum; 3GRB; -.
DR   PDBsum; 3GRG; -.
DR   PDBsum; 3GS0; -.
DR   PDBsum; 3GS4; -.
DR   PDBsum; 3GS7; -.
DR   PDBsum; 3HJ0; -.
DR   PDBsum; 3I9A; -.
DR   PDBsum; 3I9I; -.
DR   PDBsum; 3I9P; -.
DR   PDBsum; 3IMR; -.
DR   PDBsum; 3IMS; -.
DR   PDBsum; 3IMT; -.
DR   PDBsum; 3IMU; -.
DR   PDBsum; 3IMV; -.
DR   PDBsum; 3IMW; -.
DR   PDBsum; 3IPB; -.
DR   PDBsum; 3IPE; -.
DR   PDBsum; 3KGS; -.
DR   PDBsum; 3KGT; -.
DR   PDBsum; 3KGU; -.
DR   PDBsum; 3M1O; -.
DR   PDBsum; 3NEE; -.
DR   PDBsum; 3NEO; -.
DR   PDBsum; 3NES; -.
DR   PDBsum; 3NEX; -.
DR   PDBsum; 3NG5; -.
DR   PDBsum; 3OZK; -.
DR   PDBsum; 3OZL; -.
DR   PDBsum; 3P3R; -.
DR   PDBsum; 3P3S; -.
DR   PDBsum; 3P3T; -.
DR   PDBsum; 3P3U; -.
DR   PDBsum; 3SSG; -.
DR   PDBsum; 3TCT; -.
DR   PDBsum; 3TFB; -.
DR   PDBsum; 3U2I; -.
DR   PDBsum; 3U2J; -.
DR   PDBsum; 3W3B; -.
DR   PDBsum; 4ABQ; -.
DR   PDBsum; 4ABU; -.
DR   PDBsum; 4ABV; -.
DR   PDBsum; 4ABW; -.
DR   PDBsum; 4AC2; -.
DR   PDBsum; 4AC4; -.
DR   PDBsum; 4ACT; -.
DR   PDBsum; 4ANK; -.
DR   PDBsum; 4DER; -.
DR   PDBsum; 4DES; -.
DR   PDBsum; 4DET; -.
DR   PDBsum; 4DEU; -.
DR   PDBsum; 4DEW; -.
DR   PDBsum; 4FI6; -.
DR   PDBsum; 4FI7; -.
DR   PDBsum; 4FI8; -.
DR   PDBsum; 4HIQ; -.
DR   PDBsum; 4HIS; -.
DR   PDBsum; 4HJS; -.
DR   PDBsum; 4HJT; -.
DR   PDBsum; 4HJU; -.
DR   PDBsum; 4I85; -.
DR   PDBsum; 4I87; -.
DR   PDBsum; 4I89; -.
DR   PDBsum; 4IIZ; -.
DR   PDBsum; 4IK6; -.
DR   PDBsum; 4IK7; -.
DR   PDBsum; 4IKI; -.
DR   PDBsum; 4IKJ; -.
DR   PDBsum; 4IKK; -.
DR   PDBsum; 4IKL; -.
DR   PDBsum; 4KY2; -.
DR   PDBsum; 4L1S; -.
DR   PDBsum; 4L1T; -.
DR   PDBsum; 4MAS; -.
DR   PDBsum; 4MRB; -.
DR   PDBsum; 4MRC; -.
DR   PDBsum; 4N85; -.
DR   PDBsum; 4N86; -.
DR   PDBsum; 4N87; -.
DR   PDBsum; 4PM1; -.
DR   PDBsum; 4PME; -.
DR   PDBsum; 4PMF; -.
DR   PDBsum; 4PVL; -.
DR   PDBsum; 4PVM; -.
DR   PDBsum; 4PVN; -.
DR   PDBsum; 4PWE; -.
DR   PDBsum; 4PWF; -.
DR   PDBsum; 4PWG; -.
DR   PDBsum; 4PWH; -.
DR   PDBsum; 4PWI; -.
DR   PDBsum; 4PWJ; -.
DR   PDBsum; 4PWK; -.
DR   PDBsum; 4QRF; -.
DR   PDBsum; 4QXV; -.
DR   PDBsum; 4QYA; -.
DR   PDBsum; 4TKW; -.
DR   PDBsum; 4TL4; -.
DR   PDBsum; 4TL5; -.
DR   PDBsum; 4TLK; -.
DR   PDBsum; 4TLS; -.
DR   PDBsum; 4TLT; -.
DR   PDBsum; 4TLU; -.
DR   PDBsum; 4TM9; -.
DR   PDBsum; 4TNE; -.
DR   PDBsum; 4TNF; -.
DR   PDBsum; 4TNG; -.
DR   PDBsum; 4TQ8; -.
DR   PDBsum; 4TQH; -.
DR   PDBsum; 4TQI; -.
DR   PDBsum; 4TQP; -.
DR   PDBsum; 4WNJ; -.
DR   PDBsum; 4WNS; -.
DR   PDBsum; 4WO0; -.
DR   PDBsum; 4Y9B; -.
DR   PDBsum; 4Y9C; -.
DR   PDBsum; 4Y9E; -.
DR   PDBsum; 4Y9F; -.
DR   PDBsum; 4Y9G; -.
DR   PDBsum; 4YDM; -.
DR   PDBsum; 4YDN; -.
DR   PDBsum; 5AKS; -.
DR   PDBsum; 5AKT; -.
DR   PDBsum; 5AKV; -.
DR   PDBsum; 5AL0; -.
DR   PDBsum; 5AL8; -.
DR   PDBsum; 5BOJ; -.
DR   PDBsum; 5CR1; -.
DR   PDBsum; 5TTR; -.
DR   ProteinModelPortal; P02766; -.
DR   SMR; P02766; 30-145.
DR   BioGrid; 113127; 48.
DR   DIP; DIP-1083N; -.
DR   IntAct; P02766; 47.
DR   MINT; MINT-1374623; -.
DR   STRING; 9606.ENSP00000237014; -.
DR   BindingDB; P02766; -.
DR   ChEMBL; CHEMBL3194; -.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB00255; Diethylstilbestrol.
DR   DrugBank; DB00861; Diflunisal.
DR   DrugBank; DB01093; Dimethyl sulfoxide.
DR   DrugBank; DB00451; Levothyroxine.
DR   DrugBank; DB00279; Liothyronine.
DR   DrugBank; DB01583; Liotrix.
DR   GuidetoPHARMACOLOGY; 2851; -.
DR   PhosphoSite; P02766; -.
DR   BioMuta; TTR; -.
DR   DMDM; 136464; -.
DR   DOSAC-COBS-2DPAGE; P02766; -.
DR   REPRODUCTION-2DPAGE; P02766; -.
DR   SWISS-2DPAGE; P02766; -.
DR   UCD-2DPAGE; P02766; -.
DR   MaxQB; P02766; -.
DR   PaxDb; P02766; -.
DR   PeptideAtlas; P02766; -.
DR   PRIDE; P02766; -.
DR   DNASU; 7276; -.
DR   Ensembl; ENST00000237014; ENSP00000237014; ENSG00000118271.
DR   GeneID; 7276; -.
DR   KEGG; hsa:7276; -.
DR   UCSC; uc002kwx.4; human.
DR   CTD; 7276; -.
DR   GeneCards; TTR; -.
DR   GeneReviews; TTR; -.
DR   HGNC; HGNC:12405; TTR.
DR   HPA; CAB002517; -.
DR   HPA; CAB062567; -.
DR   HPA; CAB073406; -.
DR   HPA; HPA002550; -.
DR   MalaCards; TTR; -.
DR   MIM; 105210; phenotype.
DR   MIM; 115430; phenotype.
DR   MIM; 145680; phenotype.
DR   MIM; 176300; gene.
DR   neXtProt; NX_P02766; -.
DR   Orphanet; 85447; Familial amyloid polyneuropathy.
DR   Orphanet; 85451; Transthyretin-related familial amyloid cardiomyopathy.
DR   PharmGKB; PA37069; -.
DR   eggNOG; KOG3006; Eukaryota.
DR   eggNOG; COG2351; LUCA.
DR   GeneTree; ENSGT00390000005321; -.
DR   HOGENOM; HOG000251776; -.
DR   HOVERGEN; HBG000285; -.
DR   InParanoid; P02766; -.
DR   OrthoDB; EOG7S4X7V; -.
DR   PhylomeDB; P02766; -.
DR   TreeFam; TF300210; -.
DR   Reactome; R-HSA-2453864; Retinoid cycle disease events.
DR   Reactome; R-HSA-2453902; The canonical retinoid cycle in rods (twilight vision).
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   ChiTaRS; TTR; human.
DR   EvolutionaryTrace; P02766; -.
DR   GeneWiki; Transthyretin; -.
DR   GenomeRNAi; 7276; -.
DR   NextBio; 28455; -.
DR   PMAP-CutDB; P02766; -.
DR   PRO; PR:P02766; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   Bgee; P02766; -.
DR   CleanEx; HS_TTR; -.
DR   ExpressionAtlas; P02766; baseline and differential.
DR   Genevisible; P02766; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0042562; F:hormone binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0042572; P:retinol metabolic process; IEA:Ensembl.
DR   GO; GO:0006810; P:transport; NAS:ProtInc.
DR   Gene3D; 2.60.40.180; -; 1.
DR   InterPro; IPR023418; Thyroxine_BS.
DR   InterPro; IPR000895; Transthyretin/HIU_hydrolase.
DR   InterPro; IPR023416; Transthyretin/HIU_hydrolase_SF.
DR   InterPro; IPR023419; Transthyretin_CS.
DR   Pfam; PF00576; Transthyretin; 1.
DR   PRINTS; PR00189; TRNSTHYRETIN.
DR   SMART; SM00095; TR_THY; 1.
DR   SUPFAM; SSF49472; SSF49472; 1.
DR   PROSITE; PS00768; TRANSTHYRETIN_1; 1.
DR   PROSITE; PS00769; TRANSTHYRETIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amyloid; Amyloidosis; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation;
KW   Gamma-carboxyglutamic acid; Glycoprotein; Hormone; Neuropathy;
KW   Phosphoprotein; Polymorphism; Reference proteome; Secreted; Signal;
KW   Thyroid hormone; Transport.
FT   SIGNAL        1     20       {ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|PubMed:1517749,
FT                                ECO:0000269|PubMed:3135807,
FT                                ECO:0000269|PubMed:4607556,
FT                                ECO:0000269|PubMed:6583672,
FT                                ECO:0000269|PubMed:6651852}.
FT   CHAIN        21    147       Transthyretin.
FT                                /FTId=PRO_0000035755.
FT   REGION      135    139       Thyroid hormone binding.
FT   BINDING      35     35       Thyroid hormones.
FT   BINDING      74     74       Thyroid hormones.
FT   MOD_RES      62     62       4-carboxyglutamate; in a patient with
FT                                Moyamoya disease.
FT                                {ECO:0000269|PubMed:18221012}.
FT   MOD_RES      72     72       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P02767}.
FT   CARBOHYD    118    118       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19167329}.
FT   VARIANT      26     26       G -> S (common polymorphism;
FT                                dbSNP:rs1800458).
FT                                {ECO:0000269|PubMed:10211412,
FT                                ECO:0000269|PubMed:11866053,
FT                                ECO:0000269|PubMed:15217993,
FT                                ECO:0000269|PubMed:6300852,
FT                                ECO:0000269|PubMed:8019560}.
FT                                /FTId=VAR_007546.
FT   VARIANT      30     30       C -> R (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:1362222}.
FT                                /FTId=VAR_007547.
FT   VARIANT      32     32       L -> P (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:10071047,
FT                                ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_038959.
FT   VARIANT      33     33       M -> I. {ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_038960.
FT   VARIANT      38     38       D -> E (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                /FTId=VAR_007548.
FT   VARIANT      38     38       D -> G (in AMYL-TTR; leptomeningeal
FT                                amyloidosis; leads to unfolding and
FT                                exposure of N-118 to glycosylation by
FT                                STT3B and subsequent degradation by the
FT                                ERAD pathway).
FT                                {ECO:0000269|PubMed:19167329,
FT                                ECO:0000269|PubMed:8579098}.
FT                                /FTId=VAR_007549.
FT   VARIANT      40     40       V -> I (in AMYL-TTR; late-onset amyloid
FT                                polyneuropathy with carpal tunnel
FT                                syndrome). {ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:8990019}.
FT                                /FTId=VAR_007550.
FT   VARIANT      43     43       S -> N (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:10439117}.
FT                                /FTId=VAR_038961.
FT   VARIANT      44     44       P -> S (in AMYL-TTR; amyloid
FT                                polyneuropathy; dbSNP:rs11541790).
FT                                {ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_007551.
FT   VARIANT      48     48       V -> M (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:10882995}.
FT                                /FTId=VAR_010658.
FT   VARIANT      50     50       V -> A (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:1544214,
FT                                ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_007552.
FT   VARIANT      50     50       V -> G (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:9066351}.
FT                                /FTId=VAR_038962.
FT   VARIANT      50     50       V -> L (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:10611950,
FT                                ECO:0000269|PubMed:1520326}.
FT                                /FTId=VAR_007553.
FT   VARIANT      50     50       V -> M (in AMYL-TTR; amyloid
FT                                polyneuropathy; by far the most frequent
FT                                mutation; dbSNP:rs28933979).
FT                                {ECO:0000269|PubMed:12050338,
FT                                ECO:0000269|PubMed:1517749,
FT                                ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:3022108,
FT                                ECO:0000269|PubMed:3818577,
FT                                ECO:0000269|PubMed:6583672,
FT                                ECO:0000269|PubMed:6651852,
FT                                ECO:0000269|PubMed:7655883,
FT                                ECO:0000269|PubMed:8382610,
FT                                ECO:0000269|PubMed:8428915}.
FT                                /FTId=VAR_007554.
FT   VARIANT      53     53       F -> C (in a patient with amyloidosis).
FT                                {ECO:0000269|PubMed:12876326,
FT                                ECO:0000269|PubMed:15217993}.
FT                                /FTId=VAR_038963.
FT   VARIANT      53     53       F -> I (in AMYL-TTR; Jewish 'SKO' amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:6487335,
FT                                ECO:0000269|PubMed:8019560}.
FT                                /FTId=VAR_007555.
FT   VARIANT      53     53       F -> L (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:12050338,
FT                                ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:1932142,
FT                                ECO:0000269|PubMed:2046936}.
FT                                /FTId=VAR_007556.
FT   VARIANT      53     53       F -> V (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:10611950,
FT                                ECO:0000269|PubMed:12050338,
FT                                ECO:0000269|PubMed:15478468,
FT                                ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_038964.
FT   VARIANT      54     54       R -> T (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:9605286}.
FT                                /FTId=VAR_038965.
FT   VARIANT      55     55       K -> N (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:7655883}.
FT                                /FTId=VAR_038966.
FT   VARIANT      56     56       A -> P (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_007557.
FT   VARIANT      58     58       D -> A (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:10611950,
FT                                ECO:0000269|PubMed:11866053}.
FT                                /FTId=VAR_038967.
FT   VARIANT      58     58       D -> V (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:12050338,
FT                                ECO:0000269|PubMed:17635579}.
FT                                /FTId=VAR_038968.
FT   VARIANT      61     61       W -> L (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:11866053}.
FT                                /FTId=VAR_038969.
FT   VARIANT      62     62       E -> D (in AMYL-TTR; dbSNP:rs11541796).
FT                                {ECO:0000269|PubMed:10036587}.
FT                                /FTId=VAR_038970.
FT   VARIANT      62     62       E -> G (in AMYL-TTR; amyloid
FT                                polyneuropathy; dbSNP:rs11541796).
FT                                {ECO:0000269|PubMed:2363717,
FT                                ECO:0000269|PubMed:7923855}.
FT                                /FTId=VAR_007558.
FT   VARIANT      64     64       F -> S (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:11866053,
FT                                ECO:0000269|PubMed:9818883}.
FT                                /FTId=VAR_038971.
FT   VARIANT      65     65       A -> D (in AMYL-TTR; amyloid
FT                                cardiomyopathy).
FT                                /FTId=VAR_007559.
FT   VARIANT      65     65       A -> S (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:10842718}.
FT                                /FTId=VAR_038972.
FT   VARIANT      65     65       A -> T (in AMYL-TTR; amyloid
FT                                cardiomyopathy).
FT                                {ECO:0000269|PubMed:1570831,
FT                                ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_007560.
FT   VARIANT      67     67       G -> A (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|Ref.90}.
FT                                /FTId=VAR_007561.
FT   VARIANT      67     67       G -> E (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:12050338,
FT                                ECO:0000269|PubMed:15217993}.
FT                                /FTId=VAR_038973.
FT   VARIANT      67     67       G -> R (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:1734866}.
FT                                /FTId=VAR_007562.
FT   VARIANT      67     67       G -> V (in AMYL-TTR; amyloid
FT                                polyneuropathy with carpal tunnel
FT                                syndrome).
FT                                /FTId=VAR_007563.
FT   VARIANT      69     69       T -> A (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:1301926,
FT                                ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:7655883}.
FT                                /FTId=VAR_007564.
FT   VARIANT      69     69       T -> I (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:10436378,
FT                                ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_038974.
FT   VARIANT      70     70       S -> I (in AMYL-TTR; amyloid
FT                                cardiomyopathy).
FT                                {ECO:0000269|PubMed:1520336}.
FT                                /FTId=VAR_007565.
FT   VARIANT      70     70       S -> R (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:10611950,
FT                                ECO:0000269|PubMed:23317988,
FT                                ECO:0000269|PubMed:2363717,
FT                                ECO:0000269|PubMed:7655883}.
FT                                /FTId=VAR_007566.
FT   VARIANT      72     72       S -> P (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                /FTId=VAR_007567.
FT   VARIANT      73     73       G -> E (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:11445644}.
FT                                /FTId=VAR_038975.
FT   VARIANT      74     74       E -> G (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                /FTId=VAR_007568.
FT   VARIANT      74     74       E -> K (in AMYL-TTR; early-onset amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:15214015}.
FT                                /FTId=VAR_038976.
FT   VARIANT      75     75       L -> P (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:1351039,
FT                                ECO:0000269|PubMed:16627944,
FT                                ECO:0000269|PubMed:7910950,
FT                                ECO:0000269|PubMed:9733771}.
FT                                /FTId=VAR_007569.
FT   VARIANT      75     75       L -> Q (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:12557757}.
FT                                /FTId=VAR_038977.
FT   VARIANT      78     78       L -> H (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:15217993}.
FT                                /FTId=VAR_007570.
FT   VARIANT      78     78       L -> R (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:1656975}.
FT                                /FTId=VAR_007571.
FT   VARIANT      79     79       T -> K (in AMYL-TTR; amyloid
FT                                cardiomyopathy).
FT                                {ECO:0000269|PubMed:7850982}.
FT                                /FTId=VAR_007572.
FT   VARIANT      80     80       T -> A (in AMYL-TTR; amyloid
FT                                polyneuropathy and cardiomyopathy).
FT                                {ECO:0000269|PubMed:12050338,
FT                                ECO:0000269|PubMed:15217993,
FT                                ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:7655883}.
FT                                /FTId=VAR_007573.
FT   VARIANT      81     81       E -> G (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:17453626}.
FT                                /FTId=VAR_038978.
FT   VARIANT      81     81       E -> K (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:8352764}.
FT                                /FTId=VAR_007574.
FT   VARIANT      84     84       F -> L (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:11866053,
FT                                ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:2046936}.
FT                                /FTId=VAR_007575.
FT   VARIANT      88     88       I -> L (in AMYL-TTR; amyloid
FT                                cardiomyopathy).
FT                                {ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:8038017}.
FT                                /FTId=VAR_007576.
FT   VARIANT      89     89       Y -> H (in AMYL-TTR; leptomeningeal
FT                                amyloidosis; vitreous amyloid in some
FT                                patients). {ECO:0000269|PubMed:12771253}.
FT                                /FTId=VAR_007577.
FT   VARIANT      90     90       K -> N (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:1436517}.
FT                                /FTId=VAR_007578.
FT   VARIANT      91     91       V -> A (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:8095302,
FT                                ECO:0000269|PubMed:8257997}.
FT                                /FTId=VAR_007579.
FT   VARIANT      93     93       I -> V (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:10694917}.
FT                                /FTId=VAR_007580.
FT   VARIANT      94     94       D -> H.
FT                                /FTId=VAR_007581.
FT   VARIANT      97     97       S -> Y (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:15217993,
FT                                ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:2891727,
FT                                ECO:0000269|PubMed:7655883}.
FT                                /FTId=VAR_007582.
FT   VARIANT      98     98       Y -> F (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:16627944,
FT                                ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_038979.
FT   VARIANT     104    104       I -> N (in AMYL-TTR; vitrous amyloid).
FT                                {ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_007583.
FT   VARIANT     104    104       I -> S (in AMYL-TTR; amyloid
FT                                polyneuropathy; almost no RBP binding).
FT                                {ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:3722385,
FT                                ECO:0000269|PubMed:8089102}.
FT                                /FTId=VAR_007584.
FT   VARIANT     104    104       I -> T (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_038980.
FT   VARIANT     109    109       E -> K (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:10842705}.
FT                                /FTId=VAR_010659.
FT   VARIANT     109    109       E -> Q (in AMYL-TTR; amyloid
FT                                polyneuropathy and cardiomyopathy).
FT                                {ECO:0000269|PubMed:1301926,
FT                                ECO:0000269|PubMed:7655883}.
FT                                /FTId=VAR_007585.
FT   VARIANT     110    110       H -> N. {ECO:0000269|PubMed:1997217,
FT                                ECO:0000269|PubMed:7923855}.
FT                                /FTId=VAR_007586.
FT   VARIANT     111    111       A -> S (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:10627135}.
FT                                /FTId=VAR_007587.
FT   VARIANT     114    114       V -> A (in a patient with amyloidosis).
FT                                {ECO:0000269|PubMed:15217993,
FT                                ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_038981.
FT   VARIANT     117    117       A -> G (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:10611950,
FT                                ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:8133316}.
FT                                /FTId=VAR_007588.
FT   VARIANT     117    117       A -> S (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:10611950}.
FT                                /FTId=VAR_038982.
FT   VARIANT     121    121       G -> S. {ECO:0000269|PubMed:10671063,
FT                                ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_007589.
FT   VARIANT     122    122       P -> R.
FT                                /FTId=VAR_007590.
FT   VARIANT     124    124       R -> C.
FT                                /FTId=VAR_007591.
FT   VARIANT     124    124       R -> H (in dbSNP:rs121918095).
FT                                {ECO:0000269|PubMed:10529370,
FT                                ECO:0000269|PubMed:15735344}.
FT                                /FTId=VAR_038983.
FT   VARIANT     126    126       T -> N (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_038984.
FT   VARIANT     127    127       I -> M (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_038985.
FT   VARIANT     127    127       I -> V (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:7914929,
FT                                ECO:0000269|PubMed:8081397}.
FT                                /FTId=VAR_007592.
FT   VARIANT     129    129       A -> T (in DTTRH; increased affinity for
FT                                thyroxine). {ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:1979335}.
FT                                /FTId=VAR_007593.
FT   VARIANT     131    131       L -> M (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:17503405}.
FT                                /FTId=VAR_007594.
FT   VARIANT     134    134       Y -> C (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:12403615,
FT                                ECO:0000269|PubMed:16185074,
FT                                ECO:0000269|PubMed:2161654}.
FT                                /FTId=VAR_007595.
FT   VARIANT     134    134       Y -> H (in CTS1; amyloid deposit on
FT                                carpal tunnel; patients show no other
FT                                abnormalities).
FT                                {ECO:0000269|PubMed:8309582}.
FT                                /FTId=VAR_007598.
FT   VARIANT     136    136       Y -> S (in AMYL-TTR; amyloid
FT                                polyneuropathy).
FT                                {ECO:0000269|PubMed:10627135}.
FT                                /FTId=VAR_007596.
FT   VARIANT     136    136       Y -> V (requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:3675594}.
FT                                /FTId=VAR_007597.
FT   VARIANT     139    139       T -> M (in Chicago variant;
FT                                dbSNP:rs28933981).
FT                                {ECO:0000269|PubMed:11866053,
FT                                ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:1877623}.
FT                                /FTId=VAR_007599.
FT   VARIANT     140    140       A -> S (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:12050338}.
FT                                /FTId=VAR_038986.
FT   VARIANT     142    142       V -> A (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:10211412}.
FT                                /FTId=VAR_038987.
FT   VARIANT     142    142       V -> I (in AMYL-TTR; dbSNP:rs28933980).
FT                                {ECO:0000269|PubMed:12050338,
FT                                ECO:0000269|PubMed:17503405,
FT                                ECO:0000269|PubMed:3135807}.
FT                                /FTId=VAR_007600.
FT   VARIANT     144    144       N -> S (in AMYL-TTR).
FT                                {ECO:0000269|PubMed:17577687}.
FT                                /FTId=VAR_038988.
FT   MUTAGEN     107    107       F->M: Loss of tetramerization; when
FT                                associated with M-130.
FT                                {ECO:0000269|PubMed:11560492}.
FT   MUTAGEN     130    130       L->M: Loss of tetramerization; when
FT                                associated with M-107.
FT                                {ECO:0000269|PubMed:11560492}.
FT   CONFLICT     41     41       R -> P (in Ref. 3; AAA98771).
FT                                {ECO:0000305}.
FT   CONFLICT    147    147       E -> D (in Ref. 12; CAG33189).
FT                                {ECO:0000305}.
FT   TURN         23     26       {ECO:0000244|PDB:1TSH}.
FT   STRAND       32     38       {ECO:0000244|PDB:1F86}.
FT   TURN         39     42       {ECO:0000244|PDB:1F86}.
FT   STRAND       49     55       {ECO:0000244|PDB:1F86}.
FT   STRAND       57     59       {ECO:0000244|PDB:2B77}.
FT   STRAND       61     68       {ECO:0000244|PDB:1F86}.
FT   STRAND       73     75       {ECO:0000244|PDB:1F86}.
FT   STRAND       77     80       {ECO:0000244|PDB:2QEL}.
FT   TURN         81     83       {ECO:0000244|PDB:1F86}.
FT   STRAND       86     93       {ECO:0000244|PDB:1F86}.
FT   HELIX        95    101       {ECO:0000244|PDB:1F86}.
FT   STRAND      107    118       {ECO:0000244|PDB:1F86}.
FT   STRAND      120    122       {ECO:0000244|PDB:4TLS}.
FT   STRAND      124    132       {ECO:0000244|PDB:1F86}.
FT   STRAND      135    143       {ECO:0000244|PDB:1F86}.
SQ   SEQUENCE   147 AA;  15887 MW;  3A6AEBCBBA56BC44 CRC64;
     MASHRLLLLC LAGLVFVSEA GPTGTGESKC PLMVKVLDAV RGSPAINVAV HVFRKAADDT
     WEPFASGKTS ESGELHGLTT EEEFVEGIYK VEIDTKSYWK ALGISPFHEH AEVVFTANDS
     GPRRYTIAAL LSPYSYSTTA VVTNPKE
//